<SEC-DOCUMENT>0000721371-23-000007.txt : 20230202
<SEC-HEADER>0000721371-23-000007.hdr.sgml : 20230202
<ACCEPTANCE-DATETIME>20230202161917
ACCESSION NUMBER:		0000721371-23-000007
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230202
DATE AS OF CHANGE:		20230202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		23581173

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20221231.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:de10429f-68bb-4228-9960-cf0499f5ed93,g:6028fbd5-3398-4741-87cc-7f6715aa56e4,d:495abb9913e04abfaa8f722b6757199b--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cah="http://www.cardinal.com/20221231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF8yLTEtMS0xLTIzOTQxMQ_4f8b79bc-876e-4268-bf3b-9e6481cacd57">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF8zLTEtMS0xLTIzOTQxMQ_8dec146e-6854-4b93-bff8-c82fef128376">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF80LTEtMS0xLTIzOTQxMQ_6fc42454-3d2e-4526-9951-ab52c9d3facd">2023</ix:nonNumeric><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF81LTEtMS0xLTIzOTQxMQ_1ee6458b-80c4-473b-b5f0-ba3e777c52b9">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF82LTEtMS0xLTIzOTQxMQ_bdd3fc42-3a37-4401-9e54-7b7d17547b2b">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26cee45dd43e48b793c8a55a46959a04_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i44235a75341c4ea98c8f81b1b8a2af14_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9e78550aaf464e52892c197636bb7e4a_D20221001-20230113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d2749e174ce4d1bb8fced961a9f1965_D20230113-20230113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-13</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if015bf8d31b6432ca4059c2c62023d4c_D20220701-20221223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie003cab2aff1438eb31ba142971e023f_D20221223-20221223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc75351148f9471193785633b036daec_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9510233b4906437c8abfc1fb414285bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67172f4a4b5744899699d8c0d3f2b040_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5a82fe562e42b39cc9abc7d652bc3c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57e003e2a274fa58ba3f147eeb46425_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff7bd5cf42946baaf7c655557855e9f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1962adcbf7e4dca9fc9c391d95086d1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15d3c9cb56e4df894c78cded2673b0b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a5991ceefb4f3fbff0ab7d3de1ef49_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab04bb69e4454253801b552864097c8c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0636a7a560a2446ba350112f3a92e561_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531ccc08069542d18a4f2d161e0a3e9a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6584a57799974cfa81733b8b698b8d05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48a58960ee9049118daac30e86acf249_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72445fba2919453fa695e519ad37f80e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if794396f282949418bba779489671b20_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f87392b0f554ebfb1ebc1230d3bbc35_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefcb599bfb564cea80fb52a730ed571e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d958e455d54a82a0e4478e00b8b8de_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f1feb614846497fa32aba331d135eea_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8489c786a1d4bc293b8f36039b77688_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0abdbbfe31344e1b16e538d6c48989c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51c712703e684f4c8ecedda666ab1ff4_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0898bf4c17d140df80b1c69577258376_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c55ac1fb684d339bdf22e8c63911cc_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8599c52e33e549f7b725ed2b5877dbdd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b5ad5a75b004348981b5e5040141950_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d05ecda04046a0a137a84d7cd3374b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290a19fe2fb547e8a22f900e6d3bb92e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe7e1aca3cfc4021b299e214f352264b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic822fa03c99e4574898c49c9633bb752_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9496405ff84f17a05b819da2c1e8d2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i006190cd738a483b88b832cd1d821736_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d689a44b524fc58839dd5a0774a595_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6f8055536e4c23bbf6a5b4bdbdbaf3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81592179f9943bf99db0592e3bb0576_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie27044717449459ca17f71dcb4f3d3bd_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aca8e52a290406d97f8faa6c40af51d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463c8d26a5be4bfc91079e8414077be1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c599c6881bc4d589dd4c8d5eaa44ae3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d1f9c79031447df9e15b07019606fd2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf15831fa01e491d9d2f254aaf0e9bf8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i528f1cd91f784a078a7c3e4ef16b3444_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib39a861394a24af5ae49b541f0fd87ca_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fe3b2f7fe3245da8a78eda539a6ac00_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia13be735cc2443ad8517d5f01b6bfd7e_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i523d8d0b53df49998cdfaddd4b8eb78d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b132521391641bc9c8d883b436c870b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7e08834e134ea488b1bea977bd6b14_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475290592e5849d28bf81c8748343a28_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia274dc691f4f4bcb857dc93d297598ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c22619f98045b1971e6621d17e9cfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836db9f721d446698908e590540d9d99_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a10ebe6fcd4445a59847a469e7153a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a9117e94ff40d2bd8130cb4f715ba9_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6d35fed34747f8a4556dea55894e83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79455390cc9409c9303f326b67ebbc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a29845f22449af9631745d9999727d_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8beab44640464040a492325d59503158_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide09dd2c95024e149104c6f4bcda4a02_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifccdd71418e045be8ce53738fb5ba2d9_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad984dddf58244a2a17c059113ad4369_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6147059e6e0467e9b1f3c9a0643b5d0_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c55cf57cc3e400ba40a7f5c2c90d462_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e03b79450bc414da77871d9a0b3342a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853d1ecaadc74fa8866bcbc54f79d535_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f6c43c451644d383f95dc9f5e104b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec642004b7b430895d25f293ecb4289_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1971f99a0cc54e75a27067d61f454662_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77c92c96b759468d918e57bbb8cd0fa2_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7840a9e9f47f44cf9155eef621b95d6e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08bfa4932993472cbbd06d16e11a6bc3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff33151f7630485aa41a66d9a893641d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eaa1547e5534d768ea3ed534ba2e362_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d33ee800e348859d151250d6109ee0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0293a455c0be418f9e6ccdf022c16c57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f7465ce88c1440a986aade3262014dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b17012c22f40f393b25ec61b1315d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3712b011c34b738780dc9362b76df4_D20140731-20140731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-31</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66c1d6e3cbf4381a0bd67de03e24ce5_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6c3fc3e6e2445aa4d9200c41eef841_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf33963c011d47cea39c41f3cb3e98cf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c45c8e827040f492eecfcaf9019804_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i993e4902e3144a5bb0fd1d2340dcc042_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b5f38455cd438ea15b1ba793e7d1e9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5158c69b2f141aba7524064bfe8f0df_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic809c76f51ee4ec1a6f716add527ca16_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="states"><xbrli:measure>cah:states</xbrli:measure></xbrli:unit><xbrli:unit id="numberofusterritories"><xbrli:measure>cah:numberOfUSTerritories</xbrli:measure></xbrli:unit><xbrli:context id="i18fb106b5e6f449d8ae9790879d1da5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i139081ab99184a1f8b7e1b9c76f62c72_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b411ebb5184bb1a9dfd35919f25b3e_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361a1cbfafd442128bda3c3659c07e1c_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:NativeAmericanTribesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e839715483343b29b2118fba97d1b13_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ia8e0dc33321a4c17baac9c92c4b2a3cb_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68386e21f9e742fb969736106a1cbf00_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i962de220c39d41c99fd21cc23e3bda11_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd7dc7bfc674ee0ae21b5962987f975_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8168246fc242c59a3f7bb52d90228b_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a59fc36d30d420c8aa97be0a9b2a640_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525578e0fcdf4038a90e4f5d3e79ded2_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9944beac48f4f9980659c2177de1820_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581bdde63b994b5da0099ea58092e0c5_D20210701-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5c5c45933b48ec82b48e22389cf840_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i527029a879204a469f1592c5d337a7a1_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c141cd1d64f4c09ad35c5e008a7f485_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf7ff2e260e4c10b571e6c980ad3111_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ShareholderDerivativeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0539d106574706b4942868128b486d_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350fbf1a37334d5289dc88528245bdb4_D20220701-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95fe2ba8ed3a44abadfb859ec9e251e4_D20230101-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd31a13676b345b183f5ced501f7ae50_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9b861e2d5ac4b82a144a3b79ab22e81_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3459c970df844cf2a1ee3095599f0255_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ced27bfe4894fc6803e626c517f05b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac76a749b153465ab4af13b1df78d72a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c199cfd03a3434fb2252f5f91cf4519_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9bf45fc47f34b519bcb944cf300f764_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28968af686284bf28e66c81f371858ae_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3e9a1753b947c98746cbb0141dc97f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f983f7d518449f5badd677106e20d44_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic401427aa03a473ea0f233823ee9d726_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98f9a1c857544358cc749c370824d31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i419db69ec18d45b5973c1365d849e94d_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62912f01f9244e47ae336b38973b6b79_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a13dfbd6e0e47b49bff1d69a1465152_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80c83599bf12444b8d0eaf98c4ced505_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af00a4f8742447cba317049f64150b3_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c17db4a988b439d8092bcb59165e33a_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfe8b32e9774993b62940687e315b97_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1537e0b026743748253259f1422c1d7_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1336136219d3457ba4c78496738f3cfa_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850b0b51db214c4c979fd9e1de993132_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5688d1966bc4586b43f1bd3b0319696_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8508310d7f6f400da86433e5bf10f0c7_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic296f663b9444e33b5f5d47197bb2a3a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc93964635640fe8eb7402e598ad33e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9ecab01856488cb08eb92f6ceefb4f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67242a94677a43a29bdc3644189fb216_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib025910e07224dc6bc0dd03aba8e140d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35bfa7c5d2e64b76a42e9f20bacb3144_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0a6ac4d1f041e7a3c39bd92acde20c_D20211001-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aa6850535854b1a86ffcec853e058c2_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e0f4813dc547caa13b2dd18cb5794a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96adc00f02ea4124a797b7def5d4b482_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab163bd44f34212a39494050f17884b_D20210701-20211004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51514bc1c1804e3e8e046c79f210825c_D20211004-20211004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3ff1d4324243c5b9dab7c4b4e6aaac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i927dad673ba5420a852bc6b2ae6b2c64_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d24c5647c19422b8430fcfe245a94f7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1f2ad28443449a3918666f8d0ca9088_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89a2915b7ed4a078a678477329b0507_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib230b5c311ef47d68a27beaea8522ed6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59555a0f0c174b9491efe42bf0cc4203_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafbe269331e44497b6736f5de1e2161b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i234657f026ec4322af8ba2a7554081dc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0098e44a8448c6988637fda4f53d74_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f837aa398974931b78133ce25f15c52_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea96e756f1646cdbbb7691cf0597a61_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4260860fbed64ec0a99b94ee41089695_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079ed1cf2c02433cb1306b1192fe722a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3668ad01dd604937a1f5a2dbff8c26ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="i5de1192dba4d40dea7d63dad70307f94_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d191632a75148da81cbf62a95aacda0_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac761a14f9bd4458a4a199cf1a930ab0_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id14071c1bf65402a88b667c00185bad9_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb7ebd0dccf4880b310bb4ffe79ba9c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i372f1adca9c14668a399c6ffc8407155_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9327356d31264aeda31dc4ff0d2c87fc_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071f8fbaf46941a48f5d41fde9668d9b_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a7a93a200d473ab5c358f7df672a72_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74408378be5a448e98f4a8a12fb3666f_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4c69b8bfea43cc82c3f371ef88ebf8_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6df290f36db4d3d90865e0e99c3d0b8_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia39b5639f5fa48fc97157c8446d8e414_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib59cd6366c894bc7b2baebc2cd23823b_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e7f4cacb374f3c9209b0378d7b463c_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c827171183b49d9b5eac5515ab8dc44_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847b85afccb1427c9843ef38bfb3b4ef_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0e3bfc4cf14a36a1e7f71d2910082d_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5840a89e1f24c089cf3dc78fab83e52_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i991f809891464521b1f29e8e3fa6c4db_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7759d1263204160a70574351e4794da_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2cadd91b2c54bc6b8874b00950fde1d_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0748902d2bc42b1aa2187c657d51169_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc20395d8d04d49bb7875d92c1c581f_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f31a92ecac49d98787199739713426_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2a6bafa71e46f6bff513c85997576c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b72d75aa77747f688bde3fedede66d3_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d8fab8a7154b2ca8fca6ab14961db8_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea3c4ca236646ceaff7d1d7d0910e14_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20401e15a48a4142ab492d9ed551560b_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd024933b8a4c7dbd94a2ee45b24ed2_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf4d295eb2c84b83a1b9930b69ca5b06_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07757b56850843c5b966cdae4070ece5_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb971d5ee0074937ab22b8a564419c1a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f93e137bed843d5bbce9e33653971d9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314103e38f99480eb96ce0c421f83746_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie88445aacaa14c91a809313e59ddaf22_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16af340395d846e2827ed3fc620c2fad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6f162e7cb341e5a022eee6d2ce58ad_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724588d9b5744663ab373f331e1884cc_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d56087f747e42769e4b2bcea6e62a75_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd307c58e2c24994829573b1f3f8a6a7_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc2a7c414ff419388ee2bf7c1a9ffdf_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78decb5962f2469ba0f935238a752f02_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a85160188a49a1a63acb55c053b255_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503ea8a68f26416685bd1508d35865c3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2f86523a374ec7bcf6bf98d477b026_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5143d217945b451bb550ec1284ff9356_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52092b4628a84f24953a6d6e5f6106ee_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbae0f89cc2e464880a6f49f34d3015f_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8077e88c3a2248e0b130f3f465521df1_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf7d991e3e1433e91f8172e38de1cf0_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9a8d5ad3844888a89cd82186360d79_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i495abb9913e04abfaa8f722b6757199b_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF84NA_00ad24d5-31ff-4713-b788-aacca9b4259a">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MGU0NmZlZTU4NTc5NGIxN2I4ZWM3MTk5MjYzYzgzODYvdGFibGVyYW5nZTowZTQ2ZmVlNTg1Nzk0YjE3YjhlYzcxOTkyNjNjODM4Nl8wLTAtMS0xLTIzOTQxMQ_a8851a5c-f486-41cd-8f78-a5bbb35ead21">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xMjE_361f7030-5c29-46eb-81a9-d9501b078348">December 31, 2022</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6ZjNkYjQyM2QwOGU3NDY5OWIxMTcxYWNmM2M5Y2Y0NWEvdGFibGVyYW5nZTpmM2RiNDIzZDA4ZTc0Njk5YjExNzFhY2YzYzljZjQ1YV8wLTAtMS0xLTIzOTQxMQ_8879a580-40d3-416c-b13d-9f3cdd4850b6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTc5_f23147a2-30b5-4df4-87bc-4524436c8d92">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgw_e007117d-ad74-4719-a803-cfcd35951e38">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.867%"><tr><td style="width:1.0%"></td><td style="width:24.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8wLTAtMS0xLTIzOTQxMQ_97f4fae4-b587-482a-ac88-7a62c13ca613">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8wLTYtMS0xLTIzOTQxMQ_ded43e8b-44df-4c1e-a74a-4f83f252e7cb">31-0958666</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTAtMS0xLTIzOTQxMQ_1c7fce77-b4dd-4ccb-b231-b38ad92bbf35">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTItMS0xLTIzOTQxMQ_e7ffc3a6-ada1-4948-aeb9-e4717f159c00">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTQtMS0xLTIzOTQxMQ_f84e0079-3299-4661-b785-ca020cc17631">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTYtMS0xLTIzOTQxMQ_f83dffff-0356-40b7-9073-7c052aa0e4c2">43017</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF80Mzk4MDQ2NTEyOTA2_8cf2ffe5-0222-4f46-8d24-44562d97ae75">614</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF80Mzk4MDQ2NTEyOTE5_05136091-80e6-4c76-8e6b-6f9bb031b8c8">757-5000</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.370%"><tr><td style="width:1.0%"></td><td style="width:35.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MjczNzQwNzNjYTcyNDgzY2FiYWMzYzVhMDAwNmIwY2UvdGFibGVyYW5nZToyNzM3NDA3M2NhNzI0ODNjYWJhYzNjNWEwMDA2YjBjZV8yLTAtMS0xLTIzOTQxMQ_0bd98d40-f32a-4016-8f9f-ae4520056039">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MjczNzQwNzNjYTcyNDgzY2FiYWMzYzVhMDAwNmIwY2UvdGFibGVyYW5nZToyNzM3NDA3M2NhNzI0ODNjYWJhYzNjNWEwMDA2YjBjZV8yLTEtMS0xLTIzOTQxMQ_380ceb30-e723-4da8-a735-f2ad48b0f31e">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MjczNzQwNzNjYTcyNDgzY2FiYWMzYzVhMDAwNmIwY2UvdGFibGVyYW5nZToyNzM3NDA3M2NhNzI0ODNjYWJhYzNjNWEwMDA2YjBjZV8yLTItMS0xLTIzOTQxMQ_0508553d-f48e-4c67-90d6-cd13aed4957d">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgx_dc642529-77c1-436a-94e8-5ab2fabbaa36">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgy_6f888a12-7c70-4586-8026-4c75d26bb6d7">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6OTdiODk1MTc2OWY0NDJkOTlhZmFhMzlmNTQ1YTc3ZmIvdGFibGVyYW5nZTo5N2I4OTUxNzY5ZjQ0MmQ5OWFmYWEzOWY1NDVhNzdmYl8wLTAtMS0xLTIzOTQxMQ_2660f9fb-c4ad-44f2-ac69-5dc85f552da1">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6OTdiODk1MTc2OWY0NDJkOTlhZmFhMzlmNTQ1YTc3ZmIvdGFibGVyYW5nZTo5N2I4OTUxNzY5ZjQ0MmQ5OWFmYWEzOWY1NDVhNzdmYl8xLTQtMS0xLTIzOTQxMQ_5e1af5e3-0e1c-471a-96c4-de790d6ca05a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6OTdiODk1MTc2OWY0NDJkOTlhZmFhMzlmNTQ1YTc3ZmIvdGFibGVyYW5nZTo5N2I4OTUxNzY5ZjQ0MmQ5OWFmYWEzOWY1NDVhNzdmYl8yLTQtMS0xLTIzOTQxMQ_94a3f31c-95ae-42dc-8343-319dfb6bfca6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgz_9517dcd5-f751-4be9-b78d-08dc8c1b51b2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of January&#160;31, 2023, was the following: <ix:nonFraction unitRef="shares" contextRef="i26cee45dd43e48b793c8a55a46959a04_I20230131" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTc3_4698ce8e-dd5a-4a6d-b235-81d3dc27d8a9">257,639,059</ix:nonFraction>.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q2 Fiscal 2023 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_34">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_34">16</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_43">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_43">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_46">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_49">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_52">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_58">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_58">25</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_64">Financial Statemen</a>ts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_64">26</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_127">44</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_130">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_130">45</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_133">46</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc., an Ohio corporation formed in 1979, is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to fiscal 2023 and fiscal 2022 and to FY23 and FY22 are to the fiscal years ending or ended June&#160;30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2022 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our &#8220;2022 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at December&#160;31, 2022 and June&#160;30, 2022, and in our condensed consolidated statements of earnings/(loss) for the three and six months ended December&#160;31, 2022 and 2021. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2022 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2022, revenue increased 13 percent to $51.5 billion and $101.1 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth from existing and net new customers.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">710</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">863</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">891</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a GAAP operating loss of $119 million and GAAP operating earnings of $18 million during the three and six months ended December&#160;31, 2022, respectively, which included the impact of pre-tax non-cash goodwill impairment charges related to the Medical segment of $709&#160;million and $863 million, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating losses of $950 million and $535 million during the three and six months ended December 31, 2021, respectively, which included the impact of a pre-tax non-cash goodwill impairment charge related to the Medical segment of $1.3 billion. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to goodwill impairment. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating earnings during the three months ended December&#160;31, 2022 was flat primarily due to an increase in Pharmaceutical segment profit largely driven by an increased contribution from branded pharmaceutical and specialty pharmaceutical products, mostly offset by a decrease in Medical segment profit largely resulting from lower volumes in products and distribution.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating earnings during six months ended December&#160;31, 2022 decreased 10 percent primarily due to a decrease in Medical segment profit largely resulting from lower volumes in products and distribution and net inflationary impacts, which primarily related to increased transportation and commodities costs, partially offset by price increases. This decrease was partially offset by an increase in Pharmaceutical segment profit primarily driven by the performance of our generics program.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.50)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.05</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.06</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.48)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.39)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.52</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS").</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">For the three and six months ended December 31, 2022, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 261&#160;million and 266&#160;million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the periods. For the three and six months ended December 31, 2022, non-GAAP diluted EPS is calculated using a weighted average of 263&#160;million and 268&#160;million common shares, which includes potentially dilutive shares.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Impairments and (gain)/loss on disposal of assets, net included pre-tax impairment charges related to the Medical segment of $709 million and $863 million recorded during the three and six months ended December 31, 2022, respectively. For fiscal 2023, the estimated net tax benefit related to the impairments is $68 million and is included in the annual effective tax rate. As a result, the amount of tax benefit increased approximately by an incremental $118 million and $140 million for the three and six months ended December 31, 2022, respectively, and is expected to increase the provision for income taxes during the remainder of the fiscal year. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the three and six months ended December 31, 2021, impairments and (gain)/loss on disposal of assets, net included a pre-tax impairment charge of $1.3 billion related to the Medical segment. For fiscal 2022, the estimated net tax benefit related to the impairment was $92 million and was included in the annual effective tax rate. As a result, the amount of tax benefit in the second quarter increased by approximately an incremental $1.0 billion and significantly increased the provision for income taxes during the remainder of fiscal 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP diluted EPS was adversely impacted by the goodwill impairment charges related to the Medical segment, which had a $(2.05) and $(2.46) per share after-tax impact during the three and six months ended December&#160;31, 2022, respectively, and a $(0.77) and $(0.76) per share after tax impact during the three and six months ended December&#160;31, 2021, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A, and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. GAAP EPS during the three and six months ended December&#160;31, 2022 also includes the favorable impact of litigation recoveries as described further in the "Results of Operations" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2022, non-GAAP diluted EPS increased 4 percent to $1.32 per share, due to a lower share count as a result of share repurchases, partially offset by unfavorable changes in discrete tax items.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2022, non-GAAP diluted EPS decreased 2 percent to $2.52 per share due to the factors impacting non-GAAP operating earnings discussed above, partially offset by a lower share count as a result of share repurchases and net favorable changes in discrete tax items.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.7 billion at December&#160;31, 2022 compared to $4.7 billion at June&#160;30, 2022. During the six months ended December&#160;31, 2022, net cash provided by operating activities was $620 million, which includes the impact of our second annual payment of $372&#160;million related to the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "Settlement Agreement"). In addition, during the six months ended December&#160;31, 2022, we deployed $1.3 billion for share repurchases and $271 million for cash dividends.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2023 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inflationary Impacts </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was negatively affected by inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities and labor during the three and six months ended December&#160;31, 2022 and on a year-over-year basis.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these inflationary impacts to continue to adversely affect Medical segment profit in fiscal 2023 and beyond. In order to mitigate this impact, we have implemented certain price increases and are also evolving our pricing and commercial contracting processes to provide us with greater pricing flexibility. These inflationary costs are difficult to predict and may be greater than we expect or continue longer than our current expectations. In the event these costs decrease, the benefit to Medical segment profit will be delayed until the higher-cost inventory has moved through our supply chain. Our plans to continue to increase prices and evolve our contracting strategies are subject to contingencies and uncertainties and it is possible that our results of operations will be adversely impacted to a greater extent than we currently anticipate or that we may not be able to mitigate the negative impact to the extent or on the timeline we anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To a lesser extent, inflationary impacts, primarily related to increased transportation and labor costs, also adversely affected Pharmaceutical segment profit during the three and six months ended December&#160;31, 2022 and on a year-over-year basis. We expect these inflationary supply chain costs to continue to adversely impact Pharmaceutical segment profit during the remainder of fiscal 2023 on a year-over-year basis, but to a lesser extent than during the six months ended December&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PPE Demand and Pricing</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal protective equipment ("PPE") refers to protective clothing, medical gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPE adversely impacted Medical segment revenue during the three and six months ended December&#160;31, 2022 and on a year-over-year basis, primarily due to declines in pricing and volumes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was favorably impacted during the three and six months ended December&#160;31, 2022 and on a year-over-year basis by a net positive contribution from PPE, primarily driven by decreased costs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The demand and pricing for PPE is subject to risks and uncertainties, which may continue to impact Medical segment revenue, Medical segment profit and consolidated operating earnings/(loss) during the remainder of fiscal 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Medical Goodwill</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to certain reductions in our long-term financial plan assumptions made during the three months ended December&#160;31, 2022, including those related to Cardinal Health branded medical products sales growth, we performed interim goodwill impairment testing for the Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (the &#8220;Medical Unit&#8221;) at December&#160;31, 2022. This testing resulted in a pre-tax goodwill impairment charge of $709&#160;million. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we performed interim goodwill impairment testing for the Medical Unit, which resulted in a pre-tax goodwill impairment charge of $154 million, primarily due to an increase in the risk-free interest rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for the six months ended December&#160;31, 2022. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in key assumptions or a significant change in industry or economic trends during the remainder of fiscal 2023 could result in additional goodwill impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Shareholder Cooperation Agreement</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors (the "Board"), among other things, (1) appointed four new </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent directors, including a representative from Elliott, and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The evaluation and implementation of any actions recommended by the Business Review Committee and the Board may impact our financial position and results of operations during the remainder of fiscal 2023 and beyond. In addition, during the three and six months ended December&#160;31, 2022, we incurred $2 million and $8 million, respectively, of expenses related to the negotiation and finalization of the Cooperation Agreement and other consulting expenses. We expect to incur additional legal, consulting and other expenses related to the Cooperation Agreement and the activities of the Business Review Committee during the remainder of fiscal 2023. See "Risk Factors" section for additional detail related to risks associated with the Cooperation Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Pharmaceutical Segment Generics Program</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of our Pharmaceutical segment generics program positively impacted the year-over-year comparison of Pharmaceutical segment profit during the three and six months ended December&#160;31, 2022. The Pharmaceutical segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health") and generic pharmaceutical contract manufacturing and sourcing costs. During the three and six months ended December 31, 2022, generic pharmaceutical contract manufacturing inventory-related charges adversely impacted the performance of our generics program. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharmaceutical segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharmaceutical segment profit and consolidated operating earnings/(loss) during the remainder of fiscal 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20221231_g1.jpg" alt="cah-20221231_g1.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20221231_g2.jpg" alt="cah-20221231_g2.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,375&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">93,501</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,197&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,797</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,575</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,470</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,460&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,431&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,469</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,457&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,072</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,425&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment revenue increased during the three and six months ended December&#160;31, 2022 primarily due to branded and specialty pharmaceutical sales growth from existing and net new customers, which together increased revenue by $6.2&#160;billion and $12.2&#160;billion, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue decreased during the three and six months ended December&#160;31, 2022 primarily due to lower sales within products and distribution, which includes an adverse impact from PPE pricing and volumes, and was partially offset by sales growth in at-Home Solutions.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold for the three and six months ended December&#160;31, 2022 increased 14 percent to $49.8 billion and 13 percent to $97.8 billion, respectively, compared to the prior-year periods due to the factors affecting the changes in revenue and gross margin. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20221231_g3.jpg" alt="cah-20221231_g3.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20221231_g4.jpg" alt="cah-20221231_g4.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,663</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,616&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,277</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,258&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased during the three and six months ended December&#160;31, 2022 primarily due to the Pharmaceutical segment, which included the performance of our generics program and a higher contribution from branded and specialty pharmaceutical products. During the six months ended December&#160;31, 2022, the increase in gross margin due to the Pharmaceutical segment was partially offset by the adverse impact of lower volumes within products and distribution in the Medical segment. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate declined 33 basis points and 40 basis points during the three and six months ended&#160;December&#160;31, 2022, respectively, mainly due to changes in overall product mix, primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,191</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2022, SG&amp;A expenses increased largely due to inflationary impacts, primarily related to increased transportation and labor costs, and higher operating expenses, partially offset by the beneficial impact of enterprise-wide cost-savings measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2022, we incurred $2 million and $8 million of expenses primarily related to the finalization of the Cooperation Agreement. See the Significant Developments in Fiscal 2023 and Trends section in this MD&amp;A for additional detail related to the Cooperation Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2022, we recorded $6 million of income to reduce our accrual for the assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2018 to the amount invoiced. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_121">Note 12</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">464</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">895</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">481</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">904</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit increased during the three and six months ended December&#160;31, 2022 primarily due to increased contribution from branded and specialty pharmaceutical products and the performance of our generics program, partially offset by inflationary impacts, primarily related to increased transportation and labor costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December 31, 2021, Pharmaceutical segment profit was positively impacted by a $16 million judgme</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt for lost profits related to an ordinary course intellectual property rights claim.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit decreased during the three and six months ended December&#160;31, 2022 largely due to the lower volumes in products and distribution and net inflationary impacts, which primarily related to increased transportation and commodities costs, partially offset by price increases. Medical segment profit during the three months ended December&#160;31, 2022 was favorably impacted by a net positive contribution from PPE, primarily driven by decreased costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three and six months ended&#160;December&#160;31, 2022&#160;were due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">710</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">863</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(207)</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(180)</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and six months ended December&#160;31, 2022 were primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months and six months ended December 31, 2021, restructuring also included costs related to the divestiture of the Cordis business. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $71 million and $79 million for the three months ended December 31, 2022 and 2021, respectively, and $142 million and $157 million for the six months ended December&#160;31, 2022 and 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairments and (Gain)/Loss on Disposal of Assets, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $709&#160;million and $863 million of pre-tax non-cash goodwill impairment charges related to our Medical segment during the three and six months ended December&#160;31, 2022, respectively, and $1.3 billion during the three and six months ended December&#160;31, 2021, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $93 million due to net proceeds from the settlement of a shareholder derivative litigation matter as described further in the Legal Proceedings section during the three and six months ended December&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $66 million during the three and six months ended December&#160;31, 2022, and of $17&#160;million during the six months ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized net income of $46 million and $25 million during the three and six months ended December&#160;31, 2022, respectively, to reduce the reserve for the estimated settlement and defense costs for the Cordis OptEase and TrapEase inferior vena cava ("IVC") product liability due to certain claim settlements and to reflect insurance recoveries received. During the three and six months ended December&#160;31, 2021, we recognized estimated losses and legal defense costs associated with the IVC filter product liability claims of $13 million and $39 million, respectively. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings/(Loss) Before Income Taxes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended&#160;December&#160;31, 2022, interest expense decreased by 32 percent and 35 percent, respectively, primarily due to increased interest income from cash and equivalents.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Early Extinguishment of Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended&#160;December 31, 2021, we recognized a $10 million loss in connection with the debt redemption as described further in</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was&#160;5.4 percent and&#160;105.0 percent during the three months ended&#160;December&#160;31, 2022 and 2021, respectively, and 30.0 percent and 153.1 percent during the six months ended&#160;December&#160;31, 2022 and 2021, respectively. These tax rates reflect the impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December&#160;31, 2022 and 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2022, we recognized cumulative pre-tax goodwill impairment charges of $863 million related to the Medical Unit. The net tax benefit related to this charge is $68 million for fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges recorded during the six months ended December 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax loss for the six months ended December&#160;31, 2022 resulted in recognizing an incremental interim tax benefit of approximately $140 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the six months ended December&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at December&#160;31, 2022. This incremental interim tax benefit will reverse in the future quarters of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations and cash requirements; tax payments; current and projected debt service requirements, upcoming debt maturities, dividends and share repurchases; and known opioid litigation settlement payments. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.7 billion at December&#160;31, 2022 compared to $4.7 billion at June&#160;30, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2022, net cash provided by operating activities was $620 million, which includes the impact of our second annual payment of $372&#160;million related to the Settlement Agreement. For additional information, see Opioid Litigation Settlement Agreement section below. In addition, we deployed cash of $1.3 billion for share repurchases and $271 million for cash dividends.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at December&#160;31, 2022 includes $605 million of cash held by subsidiaries outside of the United States. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at December&#160;31, 2022 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC ("CHF") through September 30, 2025.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2022, we were in compliance with this financial covenant. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both&#160;December&#160;31, 2022 and June&#160;30, 2022, we had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$5.3 billion. We plan to repay our outstanding 3.2% Notes due 2023 at maturity in March 2023 with $550 million of available cash.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Litigation Settlement Agreement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $5.89&#160;billion accrued at December&#160;31, 2022 related to certain opioid litigation, as further described within </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the remaining payment amounts to be spread over the next 17 years. The effective date of the Settlement Agreement was April 2, 2022. During the six months ended December&#160;31, 2022, we made our second annual payment of $372&#160;million under the Settlement Agreement. We expect to make subsequent annual payments under the Settlement Agreement every July for the 18-year term of the Settlement Agreement. The amounts of these future payments may differ from the payments that we have already made.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the six months ended December&#160;31, 2022 and 2021 were $155 million and $141 million, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 10, 2022, August 10, 2022, and November 8, 2022, our Board of Directors approved a quarterly dividend of $0.4957 per share, or $1.98 per share on an annualized basis, which were paid on July 15, 2022, October 17, 2022 and January 15, 2023 to shareholders of record on July 1, 2022, October 3, 2022 and January 3, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2022, we repurchased $1.3&#160;billion of our common shares, in the aggregate, under accelerated share repurchase ("ASR") programs. We funded the ASR programs with available cash. The ASR program initiated in the second quarter of fiscal 2023 concluded in the third quarter of fiscal 2023, which reduced the amount remaining under our existing share repurchase authorization to approximately $1.5 billion. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2022 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2022. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_31"></div></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June&#160;30, 2022. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2022 Form 10-K and our Form 10-Q for the quarter ended September 30, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K and our other filings with the SEC since June 30, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (&#8220;Medical Unit&#8221;); and Cardinal Health at-Home Solutions division. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Unit Goodwill </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to certain reductions in our long-term financial plan assumptions made during the three months ended December&#160;31, 2022, including those related to Cardinal Health branded medical products sales growth, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in a pre-tax goodwill impairment charge of $709 million. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit, which resulted in a pre-tax goodwill impairment charge of $154 million driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for six months ended December&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determinations of the estimated fair value of the Medical Unit at December 31, 2022 and at September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approaches. For the income-based approach, we used discount rates of 10.5 percent for both periods. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim testing performed at December 31, 2022, we updated our long-term financial plan assumptions, including reductions related to the timing and magnitude of the impact of key initiatives related to optimizing and growing sales of Cardinal Health branded medical products. The impairment charge recognized during the three months ended December 31, 2022 </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was driven primarily by the impact of the reductions in our long-term financial plan assumptions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Medical Unit at December 31, 2022 after recognizing the impairment charge was $6.2 billion, of which $1.1 billion was goodwill. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for further discussion. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider these assumptions to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2023 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, including the execution of key initiatives related to optimizing and growing sales of Cardinal Health branded medical products, increasing growth in certain strategic divisions within our Medical segment, and driving simplification efforts and cost optimization projects, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; manufacturing cost inefficiencies resulting from lower than anticipated sales volume; estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates; or a significant change in industry or economic trends. Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent to 11 percent or decrease the terminal growth rate by a hypothetical 1.75 percent to 0.25 percent, the fair value for the Medical Unit would have further decreased by approximately $250 million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in a pre-tax impairment charge of $1.3 billion recorded during the three months ended December 31, 2021.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Surgical gown recall costs or income</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Shareholder cooperation agreement costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health, including costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the new Business Review Committee of the Board of Directors, which was formed under this Cooperation Agreement. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2022, we incurred a one-time contingent attorneys' fee of $18 million related to the finalization of the settlement agreement (the &#8220;Settlement Agreement&#8221;) resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this fee was included in litigation recoveries or charges, net. Additionally, during fiscal 2022 our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits. This judgment was the result of an ordinary course intellectual property rights claim and, therefore, is not adjusted in calculating the litigation recoveries or charges, net adjustment. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">(Gain)/Loss on sale of equity interest in naviHealth</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: operating earnings excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, and (8) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: earnings before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: ne</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth, each net of tax.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth divided by (earnings before income taxes adjusted for the ten items above). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliation</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/<br/>(Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(87)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(137)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(130)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.50)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.48)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">450</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,022)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">891</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">846</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">675</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.52</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(604)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(925)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">934</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">728</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three and six months ended December&#160;31, 2022, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 261&#160;million and 266&#160;million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the periods. For the three and six months ended December&#160;31, 2022, non-GAAP diluted EPS is calculated using a weighted average of 263&#160;million and 268&#160;million common shares, which includes potentially dilutive shares.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairments and (gain)/loss on disposal of assets, net included pre-tax impairment charges related to the Medical segment of $709 million and $863 million recorded during the three and six months ended December 31, 2022, respectively. For fiscal 2023, the estimated net tax benefit related to the impairments is $68 million and is included in the annual effective tax rate. As a result, the amount of tax benefit increased approximately by an incremental $118 million and $140 million for the three and six months ended December 31, 2022, respectively, and is expected to increase the provision for income taxes during the remainder of the fiscal year. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three and six months ended December 31, 2021, impairments and (gain)/loss on disposal of assets, net included a pre-tax impairment charge of $1.3 billion related to the Medical segment.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net for the three months ended December 31, 2021 does not include a $16 million judgement for lost profits related to an ordinary course intellectual property claim, which positively impacted Pharmaceutical segment profit in the quarter.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_43"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2022&#160;Form 10-K since the end of fiscal&#160;2022&#160;through&#160;December&#160;31, 2022.</span></div><div id="i495abb9913e04abfaa8f722b6757199b_46"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of December&#160;31, 2022. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of December&#160;31, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January, 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the parties reached an agreement in principle to settle this matter and in October 2022, the court entered an order approving the settlement and dismissing the case. This settlement does not include any admission of liability. Under the settlement, in December 2022, Cardinal's director and officer's liability insurance carriers, on behalf of the defendants, paid Cardinal Health $124 million, less approximately $31 million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q, including the Risk Factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K, our Form 10-Q for the quarter ended September 30, 2022, and our other filings with the SEC since June&#160;30, 2022. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business could be affected by activist shareholders.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors, among other things, (1) appointed four new independent directors, including a representative from Elliott , and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cooperation Agreement may create unintended consequences, such as creating uncertainty about our management or future strategic direction, which could result in the loss of future business opportunities or negatively impact our ability to attract and retain qualified talent. Additionally, implementing any actions recommended by the Business Review Committee and Board may be costly and time-consuming, may be disruptive to our ongoing business operations and may ultimately be unsuccessful. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that activist shareholders may, among other things, attempt to effect additional changes and exert influence over our Board of Directors and management or initiate a proxy contest, which may disrupt our operations by diverting the attention of management and the Board and be costly and time-consuming. Any such proxy contests, actions or requests, or the mere public presence of activist shareholders, may cause the market price for our shares to experience volatility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We could be subject to adverse changes in the tax laws or additional challenges to our tax positions</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, proposals are made in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include possible increases in U.S. or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission&#8217;s investigation into illegal state aid. In August 2022, the U.S. federal government enacted the Inflation Reduction Act, which imposed a 15 percent corporate minimum tax on certain large corporations and a 1 </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percent tax on share repurchases after December 31, 2022. These provisions may adversely impact our financial position and results of operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the accruals taken in connection with opioid-related lawsuits in fiscal years 2021 and 2020, we recorded net tax benefits of $228 million and $488 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment, and it is possible that they could be subject to challenges by the U.S. Internal Revenue Service ("IRS").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. tax law governing deductibility was changed by the Tax Act. The taxing authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits, or tax law could change again. We also regularly review these estimates and assumptions from time to time and adjust our accruals based on our review, resulting in changes in our tax provision/(benefit). The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2021, our provision for income taxes reflected a $424 million benefit from the tax benefits of a self-insurance pre-tax net operating loss carryback under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. Also, as a result of this net operating loss carryback, we received a U.S. federal income tax refund of $966 million. In connection with this net operating loss carryback, certain industry participants, including us, received a letter from the U.S. House of Representatives&#8217; Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including our use of the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act. We responded to the letter. It is possible that the IRS could challenge our tax position with respect to this self-insurance loss. If these initiatives are successful, our effective tax rate could be adversely impacted. Additionally, laws governing insurance coverage vary by state and some state courts have interpreted laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position. </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. Tax laws are complex and subject to varying interpretations. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. Proposed adjustments in ongoing audits may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share (2,3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3,4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(4)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.72&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,611,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,611,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,645,191&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.36&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,645,010&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,257,740</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">75.33</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,256,658</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,543</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects 713, 188, and 181 common shares purchased in October, November, and December 2022, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 17, 2022, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i44235a75341c4ea98c8f81b1b8a2af14_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNDkyOA_bfc188f9-5879-4f22-84d9-1974bab924c2">250</ix:nonFraction> million and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNDk2OA_51c17e3b-a699-4252-b9f8-212ccea03e55">2.6</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNTAxMw_7431b749-07c1-4321-9a86-7ace13f8ee40">76.58</ix:nonFraction>. The program concluded on January&#160;13, 2023 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e78550aaf464e52892c197636bb7e4a_D20221001-20230113" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNTEwNw_49279dc6-3103-4367-9388-54d07bbfc60b">77.50</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i4d2749e174ce4d1bb8fced961a9f1965_D20230113-20230113" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNTE0Ng_379d2bb8-9c15-4d93-99b8-4bc0167ab8d1">0.6</ix:nonFraction> million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On September 14, 2022, we entered into an ASR program to purchase common shares for an aggregate purchase price of $1.0 billion and received an initial delivery of 12.0 million common shares using a reference price of $66.74. The ASR program concluded on December 23, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if015bf8d31b6432ca4059c2c62023d4c_D20220701-20221223" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNTYy_05239456-5c6e-400b-8a39-5cec4a54e92a">73.36</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="ie003cab2aff1438eb31ba142971e023f_D20221223-20221223" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNTk4_9450f794-8d5a-4f6f-8ad6-c208fb6c0b6e">1.6</ix:nonFraction> million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 4, 2021, our Board of Directors approved a new $3.0&#160;billion share repurchase program, which will expire on December 31, 2024. As of December 31, 2022, we have $1.5 billion authorized for share repurchases remaining under this program.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_64"></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi0xLTEtMS0yMzk0MTE_883c756d-eab7-4758-8394-c148e6b1981c">51,469</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi0zLTEtMS0yMzk0MTE_bb4cbd5e-8c6f-453d-a8d5-dbb31e3140aa">45,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi01LTEtMS0yMzk0MTE_2c2f102a-29ac-45c2-b927-28e14f4ba082">101,072</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi03LTEtMS0yMzk0MTE_08e553e0-4f12-4773-84ed-adf774a4f426">89,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy0xLTEtMS0yMzk0MTE_9cde92cc-a890-47a8-abf3-44cd45df1b7a">49,806</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy0zLTEtMS0yMzk0MTE_5ece7ed4-d009-4479-bf24-5f67ace48e4b">43,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy01LTEtMS0yMzk0MTE_c2ca6671-6512-43db-a0de-a734f828a789">97,795</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy03LTEtMS0yMzk0MTE_4430943b-ca38-462d-82bf-9f3444f8ff74">86,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC0xLTEtMS0yMzk0MTE_89bef088-3c76-4da6-aeb1-3c6a6eb14a3a">1,663</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC0zLTEtMS0yMzk0MTE_19234ba4-15c1-448e-b9ce-55f7b24e5d34">1,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC01LTEtMS0yMzk0MTE_bce79429-ddb7-4a19-b340-4b02457efb15">3,277</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC03LTEtMS0yMzk0MTE_e7058982-2b6c-4957-942f-4f8c4db12efc">3,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy0xLTEtMS0yMzk0MTE_cfb972a7-a996-4aa7-9a5d-691b07cb51fd">1,191</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy0zLTEtMS0yMzk0MTE_46bc280a-b57e-4521-a0d0-c7aaf66bff0d">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy01LTEtMS0yMzk0MTE_0d9c7d48-4c82-4034-8dec-a15b99c66429">2,388</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy03LTEtMS0yMzk0MTE_a0004409-bdf5-4785-98ae-b4e9f102c228">2,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC0xLTEtMS0yMzk0MTE_03bcd50c-b501-41ba-a5e5-3b65f6f197cf">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC0zLTEtMS0yMzk0MTE_df43ccad-2cfb-4cbc-b20e-78715cd49daf">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC01LTEtMS0yMzk0MTE_8934c038-c3c0-45a4-adb0-e21ec2ea7d95">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC03LTEtMS0yMzk0MTE_58588610-77d0-4dba-a37c-35935a79010f">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS0xLTEtMS0yMzk0MTE_1245948f-8b1e-492a-9954-c3271aeda9d2">71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS0zLTEtMS0yMzk0MTE_e9469cd7-e06c-4af3-8867-69a05ac5c909">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS01LTEtMS0yMzk0MTE_c0d346e0-ca90-44d8-bdf1-c7b6f4842cc5">142</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS03LTEtMS0yMzk0MTE_9272e093-6fab-4ccb-855a-35cae155f0e8">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtMS0xLTEtMjM5NDEx_90fa973c-a043-40ff-ad01-75a9f2be960b">710</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtMy0xLTEtMjM5NDEx_24dc9a5d-74b2-40d9-8dc1-f20e2b5f1e31">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtNS0xLTEtMjM5NDEx_d4c6e041-e14b-438e-8506-2568fb228803">863</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtNy0xLTEtMjM5NDEx_b1969d46-866f-4a32-a097-b52b5b938066">1,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtMS0xLTEtMjM5NDEx_354e0f5e-a4dc-45f0-bf65-43725e3e3b46">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtMy0xLTEtMjM5NDEx_706d61d2-9626-4116-9c1a-7169b71a4916">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtNS0xLTEtMjM5NDEx_508d4932-ae36-4ae9-b434-593b16a64f69">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtNy0xLTEtMjM5NDEx_f57c090f-2737-4ac0-ac6c-352e91458c0b">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItMS0xLTEtMjM5NDEx_3043d277-2ab2-4fc4-9f14-fbaa09465d74">119</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItMy0xLTEtMjM5NDEx_be842ca6-edc9-432f-a39b-01f89ae25444">950</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItNS0xLTEtMjM5NDEx_8db023ec-42f9-48fc-a7e0-44c380eaca60">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItNy0xLTEtMjM5NDEx_8c8bd688-6102-4cdd-ae58-024e3f92b7b9">535</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtMS0xLTEtMjM5NDEx_1952066c-b1cb-4179-a2db-88d474c2f4bd">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtMy0xLTEtMjM5NDEx_ce0a0eac-e8ce-434e-b70f-f38dd55eb154">13</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtNS0xLTEtMjM5NDEx_35c5df0a-2669-42b6-ab9f-870869c916bf">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtNy0xLTEtMjM5NDEx_0f04fca0-6911-4545-b5c3-7cc5ec7152e0">17</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtMS0xLTEtMjM5NDEx_2e537abe-3cdd-4af1-93a9-b29c702bc4d3">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtMy0xLTEtMjM5NDEx_74dc7c9f-8bb5-4666-a8eb-50388d50ab4e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtNS0xLTEtMjM5NDEx_c6ebea60-1443-4f06-a897-378aeaf545da">50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtNy0xLTEtMjM5NDEx_dd7b9107-e665-4e5f-bc16-756a0b404af7">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtMS0xLTEtMjM5NDEx_d4ac1cd2-8e2d-4135-b1d1-7f74d20afd3a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtMy0xLTEtMjM5NDEx_0158fe3e-ff54-4774-befa-3c86ab13b06b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtNS0xLTEtMjM5NDEx_24964dbe-cc25-408b-8631-a6adf5eeb81e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtNy0xLTEtMjM5NDEx_09796c5f-5c32-4f27-b2f8-5f6c5bf0f4ad">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctMS0xLTEtMjM5NDEx_7f8aa163-8034-4f7a-be25-5bbf463c62fd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctMy0xLTEtMjM5NDEx_6b68ec87-9be5-4103-ac18-cf105e018565">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctNS0xLTEtMjM5NDEx_92fb9866-b9cc-4234-bd7a-5a6aad624e70">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctNy0xLTEtMjM5NDEx_60a9b82b-f5b7-4128-8dc4-da0456e5886d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtMS0xLTEtMjM5NDEx_2a91c09b-0673-4f7b-a636-d5760581110c">137</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtMy0xLTEtMjM5NDEx_37a09f78-110e-469e-ac68-38ed529aa0ed">973</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtNS0xLTEtMjM5NDEx_434b228f-5033-418c-b2a5-8df2cf194d0e">27</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtNy0xLTEtMjM5NDEx_403c7894-63b9-4685-9608-e375b8375d90">604</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtMS0xLTEtMjM5NDEx_376a92d0-fd93-41e5-aae4-2068e797cdf0">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtMy0xLTEtMjM5NDEx_31f442bc-fb52-450b-8e79-d9d557db9df3">1,022</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtNS0xLTEtMjM5NDEx_a5a7ca00-2cf9-43a7-bda2-e9df831db4fd">8</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtNy0xLTEtMjM5NDEx_2c057418-8cbb-48a3-bd06-0a1eb46e5ee5">925</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtMS0xLTEtMjM5NDEx_15840d4b-f436-4ade-8d08-16cbd7e2397a">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtMy0xLTEtMjM5NDEx_33f62356-cc05-4366-98f8-3cf2b5be6d61">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtNS0xLTEtMjM5NDEx_d26d3cd8-2cfe-47d7-9f13-b9c75637234a">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtNy0xLTEtMjM5NDEx_408bdd0b-174a-4469-91bf-2c8025af8536">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtMS0xLTEtMjM5NDEx_67fc7fb2-6e1a-46f8-aa98-671a2ff81f8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtMy0xLTEtMjM5NDEx_8c961b58-9ca1-4700-93bd-c8bcab11aa69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtNS0xLTEtMjM5NDEx_d0cf71ef-e7c6-43c5-aace-2daccdc79e60">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtNy0xLTEtMjM5NDEx_fc5f73f7-8ca0-46d7-a0e5-def9185ae254">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctMS0xLTEtMjM5NDEx_ffc7fe1f-f059-4d58-a4dd-8fb4279cb427">130</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctMy0xLTEtMjM5NDEx_49641edb-6fce-49ec-bb44-461d261c19e1">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctNS0xLTEtMjM5NDEx_6d05b0ea-80e2-4712-abf8-6dfaaaefe203">20</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctNy0xLTEtMjM5NDEx_88f567d3-32d3-40ec-a078-3494124612b4">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtMS0xLTEtMjM5NDEx_3aa31a9a-72d1-4838-a601-f9ac5c1dcba3">0.50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtMy0xLTEtMjM5NDEx_a9f83936-bc1f-400b-a2a2-951d12163bd2">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtNS0xLTEtMjM5NDEx_6186d689-6b32-4691-92ca-c1924ad4662f">0.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtNy0xLTEtMjM5NDEx_3c4544d3-eb2c-4049-8d8e-9c84813f2569">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtMS0xLTEtMjM5NDEx_9ae43613-922a-42ba-933e-f79c023a3caa">0.50</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtMy0xLTEtMjM5NDEx_e906532a-1e66-46eb-b61c-481683cd19dd">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtNS0xLTEtMjM5NDEx_6ba2d681-7a25-4eda-8cf5-0f390f56faf3">0.08</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtNy0xLTEtMjM5NDEx_11de53ba-c440-4870-8f75-f615d7fef3d9">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtMS0xLTEtMjM5NDEx_b9d064da-dba7-4351-a334-bbc84761b667">261</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtMy0xLTEtMjM5NDEx_3e5b1bb7-dfbd-482b-a1de-09ed5ca63999">279</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtNS0xLTEtMjM5NDEx_90fa3b22-649d-4121-8f95-f8b1f5f91e0e">266</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtNy0xLTEtMjM5NDEx_7d10deb3-5172-476f-98bf-2a1f32105a5d">283</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtMS0xLTEtMjM5NDEx_4cbcfb8a-9e60-4c40-b4db-5270a0fd5050">261</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtMy0xLTEtMjM5NDEx_721c11f3-8127-413b-a2bb-f3af6b415ad7">281</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtNS0xLTEtMjM5NDEx_dacc90a2-1403-4d48-97f3-03a3a980ab87">266</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtNy0xLTEtMjM5NDEx_de54de64-0a1e-48a4-8a78-0cd4075695f0">285</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctMS0xLTEtMjM5NDEx_1f8423e0-19c9-4ec7-88e5-39047442a432">0.4957</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctMy0xLTEtMjM5NDEx_57c22d42-3dfa-41d3-972b-88230d7f16fe">0.4908</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctNS0xLTEtMjM5NDEx_58bd0641-b5a9-4849-94d2-e055f63a8563">0.9914</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctNy0xLTEtMjM5NDEx_ee549839-dff9-4771-b330-c11bd6cc7356">0.9816</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi0xLTEtMS0yMzk0MTE_7a06683f-3407-44f3-9d1b-c0c48bc0be37">130</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi0zLTEtMS0yMzk0MTE_13d9c307-a82a-4ee1-921d-fc5466ce7839">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi01LTEtMS0yMzk0MTE_93c53d98-7247-46fd-88bc-677bd3194e40">19</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi03LTEtMS0yMzk0MTE_77340c3a-551c-4513-808e-e27ba9ad8ae1">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS0xLTEtMS0yMzk0MTE_f0edebf7-a8df-466f-a0f2-dc54ed518100">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS0zLTEtMS0yMzk0MTE_5cf1e64c-c754-486f-99b4-e6424588e4f3">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS01LTEtMS0yMzk0MTE_7f721eaf-3500-4275-a382-68678659956d">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS03LTEtMS0yMzk0MTE_19245f29-5f66-442a-ad25-5ca783d39f01">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy0xLTEtMS0yMzk0MTE_c260702e-fd8a-41de-b3e2-2bc23b9ba129">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy0zLTEtMS0yMzk0MTE_92e1e245-7e2e-4612-bd6a-4cb1f0a4f3b4">6</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy01LTEtMS0yMzk0MTE_6da9bf68-95fb-4351-a3f6-f82639d3505c">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy03LTEtMS0yMzk0MTE_2e65ba4a-c32a-4d4a-8279-38e873c88040">8</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC0xLTEtMS0yMzk0MTE_b79a1620-1c50-4947-bdb7-846f04c939c1">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC0zLTEtMS0yMzk0MTE_024df5ad-ff79-410d-a088-bf4277fcc4f5">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC01LTEtMS0yMzk0MTE_3c40c532-ecba-4adc-8b0d-72431c085049">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC03LTEtMS0yMzk0MTE_0fce96be-5309-4b2e-b03f-1b1ffefc19c6">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtMS0xLTEtMjM5NDEx_4e62531d-fbce-4d75-bc01-4a9a78008bc5">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtMy0xLTEtMjM5NDEx_81654414-4357-4542-80ca-3675da6b2942">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtNS0xLTEtMjM5NDEx_83c5c920-42d0-491b-b84a-4583966bd429">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtNy0xLTEtMjM5NDEx_1e60ded8-7c2c-4c80-9ff2-aa01d368b8ef">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItMS0xLTEtMjM5NDEx_9063a8ce-2a8a-4f93-91b3-b7b5713fd3da">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItMy0xLTEtMjM5NDEx_6f37713a-34fd-4ded-9594-2c311709c7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItNS0xLTEtMjM5NDEx_56fc51ff-b2cd-47e4-b631-4d3a82f06943">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItNy0xLTEtMjM5NDEx_cc511ebc-c3e7-4ddc-a167-90227c63a9a3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtMS0xLTEtMjM5NDEx_f1fe2cd2-bc0f-4908-9d87-0f543c232f7b">100</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtMy0xLTEtMjM5NDEx_bdecbcb8-7495-4dd6-b5dc-90f70cca82b7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtNS0xLTEtMjM5NDEx_9edb521d-ff3d-40d1-adcd-fec119452b14">52</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtNy0xLTEtMjM5NDEx_75b21f27-c7f1-4bcb-90db-6f8140dc0cd0">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNC0xLTEtMS0yMzk0MTE_ac6907f5-bea5-431a-a3b3-ef522760e7ce">3,654</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNC0zLTEtMS0yMzk0MTE_88dd4514-3743-40a1-b3f7-5cd717b79c6f">4,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNS0xLTEtMS0yMzk0MTE_a0d5b00f-2126-4737-a7e5-59377366222f">11,421</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNS0zLTEtMS0yMzk0MTE_61084ef1-00b8-4cdb-a368-4fe6301b14e6">10,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNi0xLTEtMS0yMzk0MTE_25454dc1-d25e-436d-8675-122cd82f39e2">17,263</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNi0zLTEtMS0yMzk0MTE_6a4c373b-1347-450c-bf51-3956e09f3167">15,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNy0xLTEtMS0yMzk0MTE_2c2cf7b4-d1d1-4fe9-92c6-4f6cf62feb2f">2,258</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNy0zLTEtMS0yMzk0MTE_edabe776-100b-47a5-a756-830b79205ded">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfOS0xLTEtMS0yMzk0MTE_cb5dd8b3-72b0-42ba-bf84-5862259af146">34,596</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfOS0zLTEtMS0yMzk0MTE_ba9995ef-47b3-4adb-9d14-c4b4c95a1d1c">32,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTEtMS0xLTEtMjM5NDEx_58718e51-1361-4008-a0b8-e1abae8e0bca">2,341</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTEtMy0xLTEtMjM5NDEx_849e4acf-2d28-430b-a017-ceaa4d5ee9ad">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTItMS0xLTEtMjM5NDEx_76086cfb-8543-465d-9be6-6c4e32b66710">6,618</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTItMy0xLTEtMjM5NDEx_6f04f447-6b5a-48e0-9533-e9d6ace9be98">7,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTQtMS0xLTEtMjM5NDEx_b80071d3-4b9e-41d9-b510-bec83d0113ea">927</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTQtMy0xLTEtMjM5NDEx_baace5ee-9a34-4fd1-aa29-506d24a70c34">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTUtMS0xLTEtMjM5NDEx_496e4172-8a84-491c-8cbc-1ec5907a068d">44,482</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTUtMy0xLTEtMjM5NDEx_daefb799-3691-4f9a-909f-ab78c56558bd">43,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTktMS0xLTEtMjM5NDEx_b5a3fd22-60d8-46f7-9bac-4a67df26e463">30,083</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTktMy0xLTEtMjM5NDEx_417c6f1f-7ba6-49c1-b6e4-d81f408f75ef">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjAtMS0xLTEtMjM5NDEx_e0cce98d-dddd-4ee4-ba35-480b395e0460">577</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjAtMy0xLTEtMjM5NDEx_df339b5d-c22b-4f5b-b389-da0aa9fc8b08">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjEtMS0xLTEtMjM5NDEx_cf1d8847-78e9-4c49-829d-0f309cf60957">2,552</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjEtMy0xLTEtMjM5NDEx_2a563014-d7f7-4fdc-b584-432197dcfb06">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjMtMS0xLTEtMjM5NDEx_b073cf17-1804-427e-94d3-4737d684c0cc">33,212</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjMtMy0xLTEtMjM5NDEx_01850a6a-c976-4517-a951-cbb818fee11d">30,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjUtMS0xLTEtMjM5NDEx_8fc8fdcd-7a09-4648-bed8-715ebe748b3c">4,685</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjUtMy0xLTEtMjM5NDEx_35718a28-4857-4803-a220-5f34e9787f9b">4,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjYtMS0xLTEtMjM5NDEx_74188e33-818f-4b6b-962d-599ef25b1ebf">8,797</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjYtMy0xLTEtMjM5NDEx_5a3ce4eb-d70c-4c85-9210-54b5c8948bf8">9,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMTU_3f4d9dcd-7028-48f3-9ee4-8301c6dd8443"><ix:nonFraction unitRef="shares" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMTU_caa8a9c3-9510-484b-a723-6141b582b599">500</ix:nonFraction></ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMzM_67ce9899-d8a8-4919-aee3-1c32ab40beee"><ix:nonFraction unitRef="shares" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMzM_7ce08dd5-5e4e-4140-8c2b-ab921186f649">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMS0xLTEtMjM5NDEx_078da3ad-cd0a-4c31-8612-e37afed50df9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMy0xLTEtMjM5NDEx_bc8485e4-e8fc-41e4-b06c-e147c3524695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMTY_1a143ecc-0ad4-4353-85e4-6d25ff4db2f5"><ix:nonFraction unitRef="shares" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMTY_c9257334-d6dc-4dd2-a41d-c4d6e81c840a">755</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMzQ_52a60f2e-4dff-4422-a119-708921863631"><ix:nonFraction unitRef="shares" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMzQ_94be8f21-ab01-48b4-94c4-40c566e5100d">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMS0xLTEtMjM5NDEx_2db9cb1c-6f50-4c86-bc97-c8b46ab80228">2,747</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMy0xLTEtMjM5NDEx_d4764a11-6d32-4de7-8646-47dc11e965da">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzMtMS0xLTEtMjM5NDEx_70d545fa-a480-4219-ab8b-7bd5e218ef58">560</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzMtMy0xLTEtMjM5NDEx_cd7062b1-bf5d-40dc-b0f0-6a0d3ca0ab3e">280</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common shares in treasury, at cost: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMC0xLTEtMjM5NDExL3RleHRyZWdpb246MTNkMjY3Njc0YmExNDcyZGFkZjdiYzMxMjM4NWYzNWJfNDE_7f32bba9-45ee-48a0-a503-32891b6f8ed1">68</ix:nonFraction> million </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">shares and <ix:nonFraction unitRef="shares" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMC0xLTEtMjM5NDExL3RleHRyZWdpb246MTNkMjY3Njc0YmExNDcyZGFkZjdiYzMxMjM4NWYzNWJfNTU_fc863265-ad06-4007-aa11-1d6f0bc76194">54</ix:nonFraction> million shares at</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> December&#160;31, 2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMS0xLTEtMjM5NDEx_ac3b26e4-1464-4615-9056-4a193d1ecf8e">4,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMy0xLTEtMjM5NDEx_3cacfcf4-3579-4ffa-9151-67ce701c2845">3,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzUtMS0xLTEtMjM5NDEx_147465c4-0926-4448-9405-50590e242a3f">146</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzUtMy0xLTEtMjM5NDEx_bb74ebe0-e0fc-4835-a47f-bcae2f4ba111">114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzYtMS0xLTEtMjM5NDEx_8d6f3b6a-1d29-4f07-8b2b-6e2bde0bb149">2,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzYtMy0xLTEtMjM5NDEx_3711ac21-b3e3-4118-8e74-b6e5c6ab1025">709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzctMS0xLTEtMjM5NDEx_a6a7ccbc-0911-4fa3-8549-be7cabb5db03">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzctMy0xLTEtMjM5NDEx_ba8374ba-fd6b-4a09-bd46-783ef7dd5d5b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzgtMS0xLTEtMjM5NDEx_5c07e824-8a86-4729-9799-b7a4b249761b">2,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzgtMy0xLTEtMjM5NDEx_f3c605cd-8dc1-4e26-8e49-759e7606ab59">706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; deficit</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzktMS0xLTEtMjM5NDEx_08a68918-7221-4c36-8570-12354970c9d6">44,482</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzktMy0xLTEtMjM5NDEx_27a78049-a10c-44de-b4ac-cd0aa262fde8">43,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' </span></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Equity/(Deficit)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity/ (Deficit)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings/ (Accumulated Deficit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee5a82fe562e42b39cc9abc7d652bc3c_I20220930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xLTEtMS0yMzk0MTE_a5d40b87-2620-4799-8942-8f25bb9304ea">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5a82fe562e42b39cc9abc7d652bc3c_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0zLTEtMS0yMzk0MTE_d42b5708-3f02-4b88-b5a2-1cfecdd676a8">2,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57e003e2a274fa58ba3f147eeb46425_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy01LTEtMS0yMzk0MTE_e6907e62-ff11-4296-87b4-152e5ef3c8f9">301</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3ff7bd5cf42946baaf7c655557855e9f_I20220930" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy03LTEtMS0yMzk0MTE_6e597749-fe9a-4aec-b6be-6b76bd6eabfd">65</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ff7bd5cf42946baaf7c655557855e9f_I20220930" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy05LTEtMS0yMzk0MTE_dbd2406d-a362-47c4-885a-bb56a136599b">3,880</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1962adcbf7e4dca9fc9c391d95086d1_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xMS0xLTEtMjM5NDEx_ab845261-219e-4fb3-8589-46e201d7835f">176</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15d3c9cb56e4df894c78cded2673b0b_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xMy0xLTEtMjM5NDEx_b8a074d9-ef46-4ad3-9899-780f793f927d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62a5991ceefb4f3fbff0ab7d3de1ef49_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xNS0xLTEtMjM5NDEx_db6df438-cc89-47a3-9df7-e8ab69747a79">1,780</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNC01LTEtMS0yMzk0MTE_ffc7fe1f-f059-4d58-a4dd-8fb4279cb427">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab04bb69e4454253801b552864097c8c_D20221001-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNC0xMy0xLTEtMjM5NDEx_38216441-1c80-4a7c-9242-9ad435bd13d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNC0xNS0xLTEtMjM5NDEx_8137f5e4-b928-4f6b-9992-6509638ddd72">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNS0xMS0xLTEtMjM5NDEx_b79a1620-1c50-4947-bdb7-846f04c939c1">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNS0xNS0xLTEtMjM5NDEx_014ecca6-1e6c-42b1-aa4a-eacd590910dc">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy0xLTEtMS0yMzk0MTE_89f6e588-f347-4537-84c9-6c0a867ce753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy0zLTEtMS0yMzk0MTE_4c4436a6-7714-4655-97e8-53bdd1dfe78d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy03LTEtMS0yMzk0MTE_a9b7e6cc-18d1-4719-93b8-e73faf5b9e88">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy05LTEtMS0yMzk0MTE_350b014d-dfe0-4135-8522-2ed91d11572c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy0xNS0xLTEtMjM5NDEx_aa5f0ce6-3edd-43ae-81f5-04cf93fbe3d2">47</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC0zLTEtMS0yMzk0MTE_ab889ba8-f83e-4858-885a-09aa65794f0d">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC03LTEtMS0yMzk0MTE_158e6880-c281-45f6-9adc-61461c1b8772">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC05LTEtMS0yMzk0MTE_80750b1e-413d-4f58-875c-fab979ddbd1f">400</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC0xNS0xLTEtMjM5NDEx_77df0bc7-f672-4257-b5e7-be902674c4ca">250</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0636a7a560a2446ba350112f3a92e561_D20221001-20221231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOS01LTEtMS0yMzk0MTE_760ecbf3-82b3-430d-9637-b2b54955b4a3">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOS0xNS0xLTEtMjM5NDEx_6099972d-8bb1-418d-8771-bf0bd90ec1fe">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMS0xLTEtMjM5NDEx_ca656ce4-5445-45f1-8aaf-d8a6d5a0c80e">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMy0xLTEtMjM5NDEx_f6fadac8-17cb-440c-baaa-293fe8862f4c">2,747</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6584a57799974cfa81733b8b698b8d05_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItNS0xLTEtMjM5NDEx_e9545708-295a-4209-b7aa-c16666e2bfbb">560</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItNy0xLTEtMjM5NDEx_b937526c-8623-4697-b517-29fdbe64b5e7">68</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItOS0xLTEtMjM5NDEx_1d443a3d-6399-4f51-a5b2-5b5982fbc06a">4,254</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a58960ee9049118daac30e86acf249_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMTEtMS0xLTIzOTQxMQ_1f3b4d2a-432b-4443-80fe-8d993e89a3a3">146</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72445fba2919453fa695e519ad37f80e_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMTMtMS0xLTIzOTQxMQ_782b34de-392e-42b1-8704-62c4110a7b21">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMTUtMS0xLTIzOTQxMQ_a3d59478-2483-40e0-ba68-cef618fea5b3">2,212</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if794396f282949418bba779489671b20_I20210930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xLTEtMS0yMzk0MTE_57fe718a-b2b0-4def-9e75-14ad63e45b7a">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if794396f282949418bba779489671b20_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0zLTEtMS0yMzk0MTE_ea6b3a05-a12d-4623-b7a4-d2cd5398a5c6">2,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f87392b0f554ebfb1ebc1230d3bbc35_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS01LTEtMS0yMzk0MTE_7002b825-3ac3-4f1b-b28c-c57afb4a9da6">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iefcb599bfb564cea80fb52a730ed571e_I20210930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS03LTEtMS0yMzk0MTE_2b299acc-8b2c-4a7f-a839-3a42b402750b">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefcb599bfb564cea80fb52a730ed571e_I20210930" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS05LTEtMS0yMzk0MTE_b4e377a0-a6bf-4960-a8a7-2989ca43080d">2,547</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16d958e455d54a82a0e4478e00b8b8de_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xMS0xLTEtMjM5NDEx_b0ee1f7d-9c04-48c2-b9be-22e3bf901ffb">61</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1feb614846497fa32aba331d135eea_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xMy0xLTEtMjM5NDEx_4db14ed9-c90b-4094-8ef5-2c007e920274">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8489c786a1d4bc293b8f36039b77688_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xNS0xLTEtMjM5NDEx_af80d945-8be9-4f9d-b13b-8a4edc8d0253">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMi01LTEtMS0yMzk0MTE_3d270d9e-3a7f-46e5-a8ed-37917edb8e56">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0abdbbfe31344e1b16e538d6c48989c_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMi0xMy0xLTEtMjM5NDEx_07afa748-76f1-4b32-b8b1-e6ae0c451a6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMi0xNS0xLTEtMjM5NDEx_ff396bc6-22af-431f-9444-ddbed21937eb">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c712703e684f4c8ecedda666ab1ff4_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMy0xMS0xLTEtMjM5NDEx_39a30411-c0e7-45da-93d1-50da9a7f27d0">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMy0xNS0xLTEtMjM5NDEx_3e3043d1-9a2c-4e24-8328-58ce0fb9c955">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS0xLTEtMS0yMzk0MTE_505dbc6a-ef82-4f80-b22b-c91c5aad61f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS0zLTEtMS0yMzk0MTE_8d11785e-8f1c-4085-adbb-5233c08e1783">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS03LTEtMS0yMzk0MTE_3346b43b-554e-4fd9-8f2a-9ac799279c1d"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS05LTEtMS0yMzk0MTE_4fd6e900-d58b-48ef-981e-4b3bd06a7ead">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS0xNS0xLTEtMjM5NDEx_aaa158fa-e187-41b8-899f-3f48f94d3702">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi0zLTEtMS0yMzk0MTE_97feaa16-4a85-4614-8f36-4897e6ffc183">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi03LTEtMS0yMzk0MTE_710d6996-23c6-4d4a-81a9-bdd6f3f95f01">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi05LTEtMS0yMzk0MTE_2c9eb553-1e08-425e-a035-4e4f07957737">340</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi0xNS0xLTEtMjM5NDEx_d38d593e-ba28-41a0-838f-6347c781d120">300</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4c55ac1fb684d339bdf22e8c63911cc_D20211001-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNy01LTEtMS0yMzk0MTE_3f5b97f0-7dc0-47c8-aade-b85e15953f0b">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNy0xNS0xLTEtMjM5NDEx_b4574ba0-8fcd-4bec-9a14-48cfe4149607">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC0zLTEtMS0yMzk0MTE_55f40ef1-da76-4a3d-9d58-16d0b4c38bba"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c55ac1fb684d339bdf22e8c63911cc_D20211001-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC01LTEtMS0yMzk0MTE_3800c6af-d8f4-4f6c-a29b-25dbb0d2a3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC03LTEtMS0yMzk0MTE_f572599f-e026-48df-9cbf-7cffb58a38a1"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0abdbbfe31344e1b16e538d6c48989c_D20211001-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC0xMy0xLTEtMjM5NDEx_a51f8242-8405-452c-8207-59df6aa7868a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC0xNS0xLTEtMjM5NDEx_ece51669-d133-4191-9962-ee5ae74059b9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMS0xLTEtMjM5NDEx_0e3a7ae8-c69d-49a8-81a6-20abf09f2935">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMy0xLTEtMjM5NDEx_02dd35c0-ef15-4d92-b506-5c469dcb57f0">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b5ad5a75b004348981b5e5040141950_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtNS0xLTEtMjM5NDEx_b9b65d15-6634-4dd0-ac54-31a61d0df133">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtNy0xLTEtMjM5NDEx_2c35c379-7392-4759-aa88-43586c16b095">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtOS0xLTEtMjM5NDEx_22b9aedf-9eb1-4088-91d9-1671746ad1a7">2,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290a19fe2fb547e8a22f900e6d3bb92e_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMTEtMS0xLTIzOTQxMQ_b0a2f659-9cf0-4051-8f56-1eff6c34f554">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe7e1aca3cfc4021b299e214f352264b_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMTMtMS0xLTIzOTQxMQ_55494e6c-32bc-4552-ad07-a01acf08cbe8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic822fa03c99e4574898c49c9633bb752_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMTUtMS0xLTIzOTQxMQ_b9c8f654-b604-46b2-8d10-3e1eb772d5ff">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9496405ff84f17a05b819da2c1e8d2_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xLTEtMS0yMzk0MTE_b223c758-d28c-4796-93a5-7491e0f218ac">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9496405ff84f17a05b819da2c1e8d2_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0zLTEtMS0yMzk0MTE_6fabce01-146d-4209-817e-ac65feaf4b74">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i006190cd738a483b88b832cd1d821736_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy01LTEtMS0yMzk0MTE_46dec70a-cba2-48e9-bee1-cc32746ac24f">280</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9d689a44b524fc58839dd5a0774a595_I20220630" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy03LTEtMS0yMzk0MTE_dd87f5f0-3c6f-4fc7-b556-5ecc5112bb1d">54</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9d689a44b524fc58839dd5a0774a595_I20220630" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy05LTEtMS0yMzk0MTE_cdb05a0a-ab57-482f-a062-afc656e2fdb2">3,128</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc6f8055536e4c23bbf6a5b4bdbdbaf3_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xMS0xLTEtMjM5NDEx_9d43ee83-9f04-4621-abc2-6393b6c8bebd">114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81592179f9943bf99db0592e3bb0576_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xMy0xLTEtMjM5NDEx_3366d2b2-e485-45c9-b938-d9d1c1d506ea">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xNS0xLTEtMjM5NDEx_40a90472-0c83-4602-8462-198c923423b8">706</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNC01LTEtMS0yMzk0MTE_19073beb-f12d-4940-840e-628e46b4a3e1">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNC0xMy0xLTEtMjM5NDEx_7a9a8f92-463b-45ed-abc1-7e9915f8f1fa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNC0xNS0xLTEtMjM5NDEx_39e6b3c2-5247-45c0-8195-2f16c59e15ed">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNS0xMS0xLTEtMjM5NDEx_5514b173-c6d3-4ae7-8714-24c9d00d2755">32</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNS0xNS0xLTEtMjM5NDEx_4b391298-a2fa-4f67-b378-8949797eb1c0">32</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNi0xMy0xLTEtMjM5NDEx_9354eb83-3be6-4afb-bb08-59b611d7cb53">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNi0xNS0xLTEtMjM5NDEx_911353e7-6879-4780-8bd5-9f7df17f65a3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy0xLTEtMS0yMzk0MTE_4c3f0159-ae5f-4969-b586-4447c6899178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy0zLTEtMS0yMzk0MTE_383207dd-d399-49e0-aa8d-b395492066ed">16</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy03LTEtMS0yMzk0MTE_478b5cb9-5bc8-4fde-a11a-1c5584371fd5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy05LTEtMS0yMzk0MTE_69b94011-a416-46ee-a0cb-4dde219308b0">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy0xNS0xLTEtMjM5NDEx_6f8be2f1-a4a7-4dfe-990e-654ff4052e7e">58</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC0zLTEtMS0yMzk0MTE_b5df22da-e95e-436f-99b9-a7ac4d0757f8">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC03LTEtMS0yMzk0MTE_684a1cd1-2a5a-4111-bf87-df6630949cf1">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC05LTEtMS0yMzk0MTE_85b2126a-5eea-4e1f-a4e5-756b5e18788b">1,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC0xNS0xLTEtMjM5NDEx_16522cdf-68bf-4354-b952-ef01f203eb0f">1,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie27044717449459ca17f71dcb4f3d3bd_D20220701-20221231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOS01LTEtMS0yMzk0MTE_f9abc74d-8efb-4d5e-b6ff-d1ee2de0e03f">260</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOS0xNS0xLTEtMjM5NDEx_2d35f807-3b37-46a3-869e-3a663298136f">260</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie27044717449459ca17f71dcb4f3d3bd_D20220701-20221231" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtNS0xLTEtMjM5NDEx_f3a93d02-c156-456b-8366-365dbc03e77f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtNy0xLTEtMjM5NDEx_e9ea0d27-6127-44f4-b370-2062333c1ca6"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtMTMtMS0xLTIzOTQxMQ_80c25113-dd37-4744-ba00-acd599625df2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtMTUtMS0xLTIzOTQxMQ_c42c4238-2d7e-49b5-b3c3-3e0a088f8a7a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMS0xLTEtMjM5NDEx_7e6e53ae-8c9f-4be3-99cd-7e927d37eae7">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMy0xLTEtMjM5NDEx_bb18da73-f76b-4e1c-9946-37c6df6a6af6">2,747</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6584a57799974cfa81733b8b698b8d05_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItNS0xLTEtMjM5NDEx_82b4b3f3-3d1a-4728-8c77-231d413fae28">560</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItNy0xLTEtMjM5NDEx_5b1fa6e6-cf9e-46ed-b4a1-3fcd2bbcdf8e">68</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItOS0xLTEtMjM5NDEx_e74c777e-b189-4bcd-944e-2fd8e128433a">4,254</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a58960ee9049118daac30e86acf249_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMTEtMS0xLTIzOTQxMQ_65f8c249-f810-4141-a6db-198b97a047ee">146</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72445fba2919453fa695e519ad37f80e_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMTMtMS0xLTIzOTQxMQ_44e40a28-5da9-4377-887d-85a6055ebcf7">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMTUtMS0xLTIzOTQxMQ_4bf68597-a4aa-4cf5-851b-577c6a6f3543">2,212</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2aca8e52a290406d97f8faa6c40af51d_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xLTEtMS0yMzk0MTE_d8522959-ca50-4fab-9653-3b3af085aec2">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aca8e52a290406d97f8faa6c40af51d_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0zLTEtMS0yMzk0MTE_707fbfb5-224e-4a00-bbfe-0659747fdbfe">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463c8d26a5be4bfc91079e8414077be1_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS01LTEtMS0yMzk0MTE_2bbc5758-f963-46c3-8c44-a21bab0366e2">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5c599c6881bc4d589dd4c8d5eaa44ae3_I20210630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS03LTEtMS0yMzk0MTE_00194d3c-938f-4ac5-806c-0b7c01d1811e">36</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c599c6881bc4d589dd4c8d5eaa44ae3_I20210630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS05LTEtMS0yMzk0MTE_aeb1c326-0288-4038-80bd-930f4fece31f">2,186</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d1f9c79031447df9e15b07019606fd2_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xMS0xLTEtMjM5NDEx_c03e88ef-1c25-4a35-b92e-794456ce8a15">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf15831fa01e491d9d2f254aaf0e9bf8_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xMy0xLTEtMjM5NDEx_0ca6c464-67cf-40c4-be39-cff5d99c0c65">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528f1cd91f784a078a7c3e4ef16b3444_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xNS0xLTEtMjM5NDEx_55985940-f4ce-4553-9ac3-a3410b8645cd">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMi01LTEtMS0yMzk0MTE_adae4367-c321-48b6-bfc4-a627b0296ed4">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39a861394a24af5ae49b541f0fd87ca_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMi0xMy0xLTEtMjM5NDEx_a9eb0feb-6b99-483b-a78f-177fc9637966">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMi0xNS0xLTEtMjM5NDEx_de2907e5-b20c-47cd-aa0e-53488f403fa1">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMy0xMS0xLTEtMjM5NDEx_0e6f9199-6ee5-47d9-81e5-f637d88a0bc6">51</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMy0xNS0xLTEtMjM5NDEx_5a148634-3ef5-4dab-ba82-e52ba1abb528">51</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS0xLTEtMS0yMzk0MTE_40907161-bfe6-4129-b598-a14d95486f9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS0zLTEtMS0yMzk0MTE_876c9805-670f-4b81-9ae0-9388c48ff03e">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS03LTEtMS0yMzk0MTE_4e099819-a136-4af7-974e-7b68a9433b68">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS05LTEtMS0yMzk0MTE_627ed8ac-4b26-476f-8ba7-ed3a9ce6bcbe">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS0xNS0xLTEtMjM5NDEx_66ad9e3d-b5d6-4363-bdb6-5c0047632939">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi0zLTEtMS0yMzk0MTE_ea46f8aa-93d0-41d7-8a9d-b61e2c0ec0b0">60</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi03LTEtMS0yMzk0MTE_e5a59196-257b-4544-ad9a-9cfa2706f316">15</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi05LTEtMS0yMzk0MTE_446d3854-17cb-42f3-be28-76ec78bd52e4">740</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi0xNS0xLTEtMjM5NDEx_9ce02fc8-75fe-4b31-8a78-01273fb0a8ce">800</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe3b2f7fe3245da8a78eda539a6ac00_D20210701-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNy01LTEtMS0yMzk0MTE_67591953-90c7-4813-a24b-6b216b343163">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNy0xNS0xLTEtMjM5NDEx_fce3ab6e-fa84-4d12-8c34-1c29885f2574">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xLTEtMS0yMzk0MTE_089b0317-2d6e-4056-a925-0fc490626f8e">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0zLTEtMS0yMzk0MTE_0b27a40b-dd31-42d7-b4d1-c0fd44a174bf">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b5ad5a75b004348981b5e5040141950_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS01LTEtMS0yMzk0MTE_01d6ed64-44ba-4b80-aaea-9c874eadf2fe">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS03LTEtMS0yMzk0MTE_4966af04-bb0d-4b3c-b984-7117d247a46f">50</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS05LTEtMS0yMzk0MTE_c2f29a9a-60a0-4d70-ace7-3e179e0695f1">2,883</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290a19fe2fb547e8a22f900e6d3bb92e_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xMS0xLTEtMjM5NDEx_ea037516-d6be-4a9e-b017-9728e9b1e596">85</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe7e1aca3cfc4021b299e214f352264b_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xMy0xLTEtMjM5NDEx_8cee1871-b87f-4e1e-abc5-19ae4fd1b03b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic822fa03c99e4574898c49c9633bb752_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xNS0xLTEtMjM5NDEx_e08e6287-64fa-4280-a25a-8f075ad0849f">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMy0xLTEtMS0yMzk0MTE_95ae66c4-8c39-421a-b22a-661e5514b53d">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMy0zLTEtMS0yMzk0MTE_2164d0b5-7f28-47fc-9284-3fb191b1463d">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNi0xLTEtMS0yMzk0MTE_33dac650-fcd9-40d8-8b91-9797106c614c">341</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNi0zLTEtMS0yMzk0MTE_81ca056f-5f1c-4269-9c0c-9ff4672658f8">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOC0xLTEtMS0yMzk0MTE_a89552eb-d1ec-4ffd-8486-27e36fceedd8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOC0zLTEtMS0yMzk0MTE_b0991ac2-74b6-49e0-aa80-b6edbb9e8014">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOS0xLTEtMS0yMzk0MTE_ff106faf-bbcb-4077-a6cf-130357db93c0">863</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOS0zLTEtMS0yMzk0MTE_f0678b65-6e1e-4a6f-ba26-113324221b4f">1,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTAtMS0xLTEtMjM5NDEx_3bd48227-6d62-463c-aba7-b3bf096e329e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTAtMy0xLTEtMjM5NDEx_dc88ccf3-10c9-4866-a8d7-ab923845b935">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTEtMS0xLTEtMjM5NDEx_94a7dca4-cb47-4ada-a848-6303f1001f7e">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTEtMy0xLTEtMjM5NDEx_aa007112-854b-46fe-86ed-53b0ed116b62">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTMtMS0xLTEtMjM5NDEx_94e9b3a9-5f5d-4f63-a49f-1b564e607f51">59</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTMtMy0xLTEtMjM5NDEx_e30ca497-be88-404c-a2b8-ad9982f61fc2">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTUtMS0xLTEtMjM5NDEx_80750ba1-b521-4726-b341-9ca986daa2f2">919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTUtMy0xLTEtMjM5NDEx_f540c22b-4424-495d-ae66-dc772b2822f0">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTYtMS0xLTEtMjM5NDEx_63c50ce2-5b27-49ab-824a-c1beb725ae14">1,643</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTYtMy0xLTEtMjM5NDEx_a594b69b-b0b1-4a1f-9e2b-e21b8419940b">361</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTctMS0xLTEtMjM5NDEx_10eae775-a050-4e84-bc1a-de4a8e21d70c">2,954</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTctMy0xLTEtMjM5NDEx_531f62cd-854e-41ae-802a-5cb8c94aa8a0">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTgtMS0xLTEtMjM5NDEx_7019c340-cb4b-46b3-a15b-cdc4fadaa929">1,064</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTgtMy0xLTEtMjM5NDEx_73a3ee3a-270e-4600-8166-225c81becbf0">1,842</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTktMS0xLTEtMjM5NDEx_1a0fb993-386b-4659-9c09-a14fe1aa28b8">620</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTktMy0xLTEtMjM5NDEx_e367d5ce-6648-4db4-a2f6-c5caa52024df">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divestitures, net of cash sold</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjItMS0xLTEtMjM5NDEx_e4eaac40-408f-4d14-a0ed-a3e44566b101">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjItMy0xLTEtMjM5NDEx_11a977c4-a347-4f4d-ac18-39a4f0d2ed58">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjQtMS0xLTEtMjM5NDEx_e36e2f6b-9a22-43b7-8f62-28e4e752c4c6">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjQtMy0xLTEtMjM5NDEx_b81f3255-fea7-4188-b685-52171c981b5f">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMS0xLTEtMjU1ODEw_a92b97e1-da1d-47e5-a38c-8d845e43da1d">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMy0xLTEtMjU1ODE4_0f9d72ce-c8bd-487f-a5d7-05834796a17c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMS0xLTEtMjM5NDEx_e2468368-a058-46b6-a589-9a3232f6f633">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMy0xLTEtMjM5NDEx_b5a28a60-73b5-4d9e-baff-6a1683b2c37a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjYtMS0xLTEtMjM5NDEx_884d033a-c372-4e9d-9afc-b21fad3b407e">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjYtMy0xLTEtMjM5NDEx_07b5a812-9743-492c-8e32-bfa430180259">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjgtMS0xLTEtMjM5NDEx_93848862-7579-46de-be87-2369ae26031c">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjgtMy0xLTEtMjM5NDEx_de0212bd-74cd-414e-ae7c-336a90f7fe5e">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzMtMS0xLTEtMjM5NDEx_6df6a2d3-412c-4115-9151-8d975aa6e13a">13</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzMtMy0xLTEtMjM5NDEx_b80196b8-f5c6-46f9-b8ba-afcf0fec063d">592</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax proceeds/(withholdings) from share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzQtMS0xLTEtMjM5NDEx_5879a336-0606-4623-bb8a-ea7cfb08fc47">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzQtMy0xLTEtMjM5NDEx_e610aba1-33da-43b4-8433-ab0f59c03572">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzYtMS0xLTEtMjM5NDEx_9a1ffc1a-fab8-4583-af89-0178fabdd0b9">271</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzYtMy0xLTEtMjM5NDEx_3af0d2ba-fa7e-4073-8863-68d1edad33f6">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzctMS0xLTEtMjM5NDEx_faaf6ed1-6bf0-4c93-b403-8f36c6acaea7">1,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzctMy0xLTEtMjM5NDEx_6e4e0cfc-8c87-4d66-bb4b-3f56b28b41a5">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzgtMS0xLTEtMjM5NDEx_3d2368c4-4d2e-44dc-a26f-35159d43d750">1,525</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzgtMy0xLTEtMjM5NDEx_e70dcf46-e25c-4fd1-8e8b-3b13cef37103">1,708</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDAtMS0xLTEtMjM5NDEx_6a88bd2f-c563-44f9-9fb1-9a0960b4bfe0">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDAtMy0xLTEtMjM5NDEx_2a8a64b8-f9fd-41f3-bb96-e5ec650f2c88">11</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents reclassified from assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:CashReclassifiedToAssetHeldForSale" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDEtMS0xLTEtMjM5NDEx_863d58ec-76ec-4a50-af2a-b5c374740ef1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="cah:CashReclassifiedToAssetHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDEtMy0xLTEtMjM5NDEx_7c8c217c-9567-43ff-ab29-f3d463760a69">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDMtMS0xLTEtMjM5NDEx_00b63499-b0ac-4ef3-be54-a5a2b3fab731">1,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDMtMy0xLTEtMjM5NDEx_62435c5f-6afc-4e08-aeed-780ab11b9f14">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDQtMS0xLTEtMjM5NDEx_d6da3f72-f528-4421-b17d-a38e52a0d16f">4,717</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528f1cd91f784a078a7c3e4ef16b3444_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDQtMy0xLTEtMjM5NDEx_973cfdf1-a5b5-4b33-a06d-4280a6142b74">3,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDUtMS0xLTEtMjM5NDEx_e773934c-36e2-4141-a1be-7c897832d7b6">3,654</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic822fa03c99e4574898c49c9633bb752_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDUtMy0xLTEtMjM5NDEx_00858eab-0d38-4912-be7a-dfc6a9be9c24">3,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="i495abb9913e04abfaa8f722b6757199b_82"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84Mi9mcmFnOmU4NTc2ZjRjZTQwNjQ0ZmRiM2I1MWE2NjFhNDA2Mzg3L3RleHRyZWdpb246ZTg1NzZmNGNlNDA2NDRmZGIzYjUxYTY2MWE0MDYzODdfMzEwNA_94ce6e40-a404-413d-9fc0-01f216bb4258" continuedAt="ie1a5c325b1ec4bec9c548f9b83771173" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84Mi9mcmFnOmU4NTc2ZjRjZTQwNjQ0ZmRiM2I1MWE2NjFhNDA2Mzg3L3RleHRyZWdpb246ZTg1NzZmNGNlNDA2NDRmZGIzYjUxYTY2MWE0MDYzODdfMzEwNQ_33752bb8-aa42-4b04-a9f7-ecf296b84901" continuedAt="if8a7bb986fdf451d803e5d15581f8d2b" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").</span></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ie1a5c325b1ec4bec9c548f9b83771173"><ix:continuation id="if8a7bb986fdf451d803e5d15581f8d2b"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84Mi9mcmFnOmU4NTc2ZjRjZTQwNjQ0ZmRiM2I1MWE2NjFhNDA2Mzg3L3RleHRyZWdpb246ZTg1NzZmNGNlNDA2NDRmZGIzYjUxYTY2MWE0MDYzODdfMzExNA_5ee03f48-7c2c-4fd5-8f5f-6c248f2cf98a" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the six months ended December 31, 2022.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_85"></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84NS9mcmFnOmI3NmQxMTFkMzZlMTQyNTI4N2EzNTYzZGMxMDNlNzBjL3RleHRyZWdpb246Yjc2ZDExMWQzNmUxNDI1Mjg3YTM1NjNkYzEwM2U3MGNfNTc3_0d32b6cc-44ab-4cab-aa3a-6b716c8f0d97" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia13be735cc2443ad8517d5f01b6bfd7e_D20210701-20220630" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84NS9mcmFnOmI3NmQxMTFkMzZlMTQyNTI4N2EzNTYzZGMxMDNlNzBjL3RleHRyZWdpb246Yjc2ZDExMWQzNmUxNDI1Mjg3YTM1NjNkYzEwM2U3MGNfOTA_c77e36c3-4fa5-4fdc-9c51-242843a0ca12">923</ix:nonFraction> million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RleHRyZWdpb246YTdhN2Q4NWFjYjJlNDliODg1YTUxMzY3ZWM3ZjZhMWVfMTAyOQ_a5893e16-b8cc-49d4-a63b-38ab5c182f12" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RleHRyZWdpb246YTdhN2Q4NWFjYjJlNDliODg1YTUxMzY3ZWM3ZjZhMWVfMTAyNA_e4eded95-2aa4-4413-b218-d9741c31e783" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMi0xLTEtMS0yMzk0MTE_d01a1855-d009-418d-b71f-e39a240eb178">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMi0zLTEtMS0yMzk0MTE_56c5146f-23dc-45e0-a629-058692098251">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMy0xLTEtMS0yMzk0MTE_23de6889-a9c2-4127-892a-6ac81534f75b">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMy0zLTEtMS0yMzk0MTE_e423cefe-e07f-48a3-8c85-1a408ab1bcd7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfNC0xLTEtMS0yMzk0MTE_a220e1d6-8a36-40e9-b4c4-4cefab2e9f37">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfNC0zLTEtMS0yMzk0MTE_82c3232a-1514-4065-98fe-3430d36c254c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMi0xLTEtMS0yMzk0MTE_dc135264-4542-433e-a741-ae50037b33e8">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMi0zLTEtMS0yMzk0MTE_ca2cab2b-5365-442b-9ef0-444e0e3a4a65">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMy0xLTEtMS0yMzk0MTE_be6ae57d-3703-467d-aeed-670721e8757a">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMy0zLTEtMS0yMzk0MTE_403b7d34-89da-4a30-9fe0-dc91f6376758">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfNC0xLTEtMS0yMzk0MTE_3f39bcae-5562-46a4-ab8c-4ee0b8b5d721">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfNC0zLTEtMS0yMzk0MTE_6d39e7cf-fd84-4778-8790-1157102b17e7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and six months ended December&#160;31, 2022 and December 31, 2021 were primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months and six months ended December 31, 2021, restructuring also included costs related to the divestiture of the Cordis business. </span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RleHRyZWdpb246YTdhN2Q4NWFjYjJlNDliODg1YTUxMzY3ZWM3ZjZhMWVfOTk5_8d423e95-2c88-4251-b02a-8c039d51722d" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523d8d0b53df49998cdfaddd4b8eb78d_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMS0xLTEtMS0yMzk0MTE_b3410712-40ef-41cb-b280-88529452cddf">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b132521391641bc9c8d883b436c870b_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMS0zLTEtMS0yMzk0MTE_6c508c5c-c98b-47b9-9903-b413e21bc454">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMS01LTEtMS0yMzk0MTE_1c69736f-a181-45e5-ab03-9dd27fe20c9e">66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7e08834e134ea488b1bea977bd6b14_D20220701-20221231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMi0xLTEtMS0yMzk0MTE_3faf2aa8-a75d-4bb0-a6cd-8b99d67f1a28">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475290592e5849d28bf81c8748343a28_D20220701-20221231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMi0zLTEtMS0yMzk0MTE_4626aefe-0868-4bf1-8e36-182c1139d942">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMi01LTEtMS0yMzk0MTE_ebe7e617-9cb5-4953-8afe-9dcbe0d86f55">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e7e08834e134ea488b1bea977bd6b14_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMy0xLTEtMS0yMzk0MTE_8aa943f2-2c40-4090-8c72-d083ba34acfd">20</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475290592e5849d28bf81c8748343a28_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMy0zLTEtMS0yMzk0MTE_60ffa7e4-0202-40c9-b97a-d0c7c6127018">13</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMy01LTEtMS0yMzk0MTE_c8467fc3-7ce7-4c2a-a7c6-5a1f0527fdb3">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia274dc691f4f4bcb857dc93d297598ae_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfNC0xLTEtMS0yMzk0MTE_2ab7b697-1117-4842-bed1-3017673a2543">61</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c22619f98045b1971e6621d17e9cfb_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfNC0zLTEtMS0yMzk0MTE_7d7cca85-37c3-426a-ac94-9a09fc658968">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfNC01LTEtMS0yMzk0MTE_95c0b35a-6128-49b4-9a90-02cbaf1af108">63</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="i495abb9913e04abfaa8f722b6757199b_91"></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI1OA_de4d68db-3e76-4585-8092-68436655ca67" continuedAt="i93a6cf3f9cdc4c089774fb2abb24fd65" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI1Mw_9c913480-4653-4a88-b297-9e00267c215d" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836db9f721d446698908e590540d9d99_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMS0xLTEtMS0yMzk0MTE_ebcc70c5-39a5-447b-bb47-7a5986ec30e1">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a10ebe6fcd4445a59847a469e7153a_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMS0zLTEtMS0yMzk0MTE_026e4ffb-76c9-4218-bb4b-b486b21b76aa">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMS01LTEtMS0yMzk0MTE_d54d3efb-2c35-451f-8ba7-db58c233e4c4">5,855</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a9117e94ff40d2bd8130cb4f715ba9_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMy0xLTEtMS0yMzk0MTE_8254f815-016e-481b-8257-45cfabcbd2e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMy0zLTEtMS0yMzk0MTE_6a9d46a7-a962-4978-8dc9-3c8202a7ae2c">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMy01LTEtMS0yMzk0MTE_7b6b974a-a509-4135-b9e3-bbcc836c3506">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a9117e94ff40d2bd8130cb4f715ba9_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNC0xLTEtMS0yMzk0MTE_c4d3ec98-9aa4-4aca-9000-3251ba416713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNC0zLTEtMS0yMzk0MTE_ad68f552-efab-4e10-94e1-8e98bbb4ed24">863</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNC01LTEtMS0yMzk0MTE_9860b10d-af68-4d1b-b5c8-44ec1a7e374e">863</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6d35fed34747f8a4556dea55894e83_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNS0xLTEtMS0yMzk0MTE_0dd54616-d05a-4c50-8a7e-86f290bb7a66">2,673</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79455390cc9409c9303f326b67ebbc3_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNS0zLTEtMS0yMzk0MTE_7137286f-2fe7-4373-920d-d92a8bb67ff8">2,313</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNS01LTEtMS0yMzk0MTE_19150c8b-d3b7-45da-bf8f-11a5d126182a">4,986</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2022 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $<ix:nonFraction unitRef="usd" contextRef="ie79455390cc9409c9303f326b67ebbc3_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMzI5ODUzNDg5ODA0OA_7bdc2808-8240-4599-a5e0-110ecaed554a">4.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia1a10ebe6fcd4445a59847a469e7153a_I20220630" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMzM4_37c4c6b7-40ae-46ea-a892-f7cf9302c328">3.5</ix:nonFraction>&#160;billion, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to certain reductions in our long-term financial plan assumptions made during the three months ended December&#160;31, 2022, including those related to Cardinal Health branded medical products sales growth, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in a pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="id0a29845f22449af9631745d9999727d_D20221001-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg1Mw_ee3267cb-d58b-4062-989b-16c20725d338">709</ix:nonFraction> million. The impairment charge recognized during the three months ended December&#160;31, 2022 was driven primarily by the impact of the reductions in our long-term financial plan assumptions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit, which resulted in a pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i8beab44640464040a492325d59503158_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg3MA_005372ac-ce8a-48b7-963e-1e9bef1fbdbc">154</ix:nonFraction> million driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjE1Mg_ad68f552-efab-4e10-94e1-8e98bbb4ed24">863</ix:nonFraction> million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for six months ended December&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determinations of the estimated fair value of the Medical Unit at December 31, 2022 and at September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of <ix:nonFraction unitRef="number" contextRef="ide09dd2c95024e149104c6f4bcda4a02_D20220701-20220930" decimals="3" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg4MQ_1b24d02a-4734-4d69-8995-c984d721705d"><ix:nonFraction unitRef="number" contextRef="ifccdd71418e045be8ce53738fb5ba2d9_D20221001-20221231" decimals="3" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg4MQ_c939d8e5-f481-4a70-8296-45874c16306c">2</ix:nonFraction></ix:nonFraction> percent), and the market-based approaches. For the income-based approach, we used discount rates of <ix:nonFraction unitRef="number" contextRef="ifccdd71418e045be8ce53738fb5ba2d9_D20221001-20221231" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjc0ODc3OTA5MDY1OQ_73ee467f-aaec-43a2-b7a0-cb338acd3e55"><ix:nonFraction unitRef="number" contextRef="ide09dd2c95024e149104c6f4bcda4a02_D20220701-20220930" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjc0ODc3OTA5MDY1OQ_f9c3e149-d32b-4f26-a5b1-246371c54805">10.5</ix:nonFraction></ix:nonFraction> percent for both periods. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Medical Unit at December&#160;31, 2022 after recognizing the impairment charges was $<ix:nonFraction unitRef="usd" contextRef="iad984dddf58244a2a17c059113ad4369_I20221231" decimals="-6" name="us-gaap:AssetsNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNTQ5NzU1ODIyOTQ5_a894f7b6-bcba-4d1d-9474-8e805ec956bb">6.2</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="iad984dddf58244a2a17c059113ad4369_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNTQ5NzU1ODIyOTYw_9e36c2e5-d69f-4689-9687-8b7a71ff2cb6">1.1</ix:nonFraction>&#160;billion was goodwill.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i93a6cf3f9cdc4c089774fb2abb24fd65" continuedAt="ia158530deffc41ff8b1b4c24dd63919b"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unit exceeding the fair value, resulting in a pre-tax impairment charge of $<ix:nonFraction unitRef="usd" contextRef="id6147059e6e0467e9b1f3c9a0643b5d0_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjc0ODc3OTA4NDA3MQ_2e8374fb-6a52-4e7c-bfce-d1e8a1a51824">1.3</ix:nonFraction> billion recorded during the three months ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI3OQ_cb3a8143-a0c6-4bb3-b257-12fb9addaad7" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c55cf57cc3e400ba40a7f5c2c90d462_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMy0xLTEtMS0yMzk0MTE_9ca6ef26-c597-4b06-9762-d5cabbd9b704">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c55cf57cc3e400ba40a7f5c2c90d462_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMy01LTEtMS0yMzk0MTE_5f60d205-e9af-447a-ad66-f2bee7f46f84">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNC0xLTEtMS0yMzk0MTE_36a4a21e-61df-42ae-8cf5-e6370184f993">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNC01LTEtMS0yMzk0MTE_84278d84-7444-4d31-bc97-f3c294b449af">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e03b79450bc414da77871d9a0b3342a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy0xLTEtMS0yMzk0MTE_10a0913c-2e28-4987-b850-8eebfc4a45a6">3,234</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e03b79450bc414da77871d9a0b3342a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy0zLTEtMS0yMzk0MTE_c3d23d64-62c0-4bfe-88b4-6ee5d64393b3">2,220</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e03b79450bc414da77871d9a0b3342a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy01LTEtMS0yMzk0MTE_32765eb5-adb2-4751-b228-9862398914e5">1,014</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i853d1ecaadc74fa8866bcbc54f79d535_D20220701-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy03LTEtMS0yMzk0MTE_7280f25e-2731-4dcb-807e-95a141e827e2">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f6c43c451644d383f95dc9f5e104b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC0xLTEtMS0yMzk0MTE_b24b624b-cb4d-4e59-afd2-104285333208">547</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f6c43c451644d383f95dc9f5e104b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC0zLTEtMS0yMzk0MTE_4486dfaf-41fe-4ebb-be05-64fe026e7311">369</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f6c43c451644d383f95dc9f5e104b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC01LTEtMS0yMzk0MTE_89c4d58f-e218-443d-8e57-fcd7cdbded17">178</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icec642004b7b430895d25f293ecb4289_D20220701-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC03LTEtMS0yMzk0MTE_3f6443bc-c503-4981-b486-ca927071a373">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1971f99a0cc54e75a27067d61f454662_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS0xLTEtMS0yMzk0MTE_34bf560c-3126-4d57-88cf-5acdf730c3be">1,036</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1971f99a0cc54e75a27067d61f454662_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS0zLTEtMS0yMzk0MTE_918e3e94-5b9d-452c-ad92-3793a3e3b4b1">607</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1971f99a0cc54e75a27067d61f454662_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS01LTEtMS0yMzk0MTE_75516f76-f15a-436c-9551-5dcbbd52a45f">429</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i77c92c96b759468d918e57bbb8cd0fa2_D20220701-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS03LTEtMS0yMzk0MTE_e84205c1-60b6-4295-b462-1e6e5602464d">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtMS0xLTEtMjM5NDEx_605e26a3-58ff-4a07-9eb5-b7ae0874c10c">4,817</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtMy0xLTEtMjM5NDEx_3392a25a-d783-4bae-b502-75aedc0e2ba1">3,196</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtNS0xLTEtMjM5NDEx_440e104e-1bc7-4942-a159-d46512e5e2de">1,621</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtNy0xLTEtMjM5NDEx_c3719ea1-d3dc-44d5-8357-df644078569f">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTEtMS0xLTEtMjM5NDEx_309f513f-ef10-4177-9a32-8f20dfff6313">4,828</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTEtMy0xLTEtMjM5NDEx_d66afd1e-34f4-418b-b12b-ada94bc9f942">3,196</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTEtNS0xLTEtMjM5NDEx_94bedb0a-e59f-4338-b1f4-51a937f6f2bf">1,632</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7840a9e9f47f44cf9155eef621b95d6e_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMy0xLTEtMS0yMzk0MTE_be56e0c6-29ba-4ccd-9c92-70d69d47d496">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7840a9e9f47f44cf9155eef621b95d6e_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMy01LTEtMS0yMzk0MTE_6cb93e39-57c4-4826-8ec4-a66f027d7835">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNC0xLTEtMS0yMzk0MTE_0b3e88af-6278-421e-aeb2-83fa20f28d79">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNC01LTEtMS0yMzk0MTE_f816f17f-26ad-4071-b903-87e49abe45ad">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNy0xLTEtMS0yMzk0MTE_4a1d8bf4-15cb-4bc9-9110-4811721cbf4a">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNy0zLTEtMS0yMzk0MTE_65ef54d9-41ec-4b18-8e06-b2befa18f8cc">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNy01LTEtMS0yMzk0MTE_0074c2ed-6887-4e73-8872-e6b61acc24a9">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08bfa4932993472cbbd06d16e11a6bc3_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOC0xLTEtMS0yMzk0MTE_f0a16f4d-bc6e-4573-9526-13745ce1d76b">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08bfa4932993472cbbd06d16e11a6bc3_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOC0zLTEtMS0yMzk0MTE_12070f74-6b31-41fa-8c1a-d1cad2181b2d">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08bfa4932993472cbbd06d16e11a6bc3_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOC01LTEtMS0yMzk0MTE_8fc2029f-810c-4843-8459-d1f516b128db">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff33151f7630485aa41a66d9a893641d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOS0xLTEtMS0yMzk0MTE_ea8d00e9-c248-4047-8202-62dad08d91d7">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff33151f7630485aa41a66d9a893641d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOS0zLTEtMS0yMzk0MTE_eac44a41-a4df-40d7-bb2c-82b37c653ef8">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff33151f7630485aa41a66d9a893641d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOS01LTEtMS0yMzk0MTE_ead8b15f-fb9e-4389-974b-af0249e53292">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTAtMS0xLTEtMjM5NDEx_1bfbeb1a-758b-41d9-a19d-4a772d99b637">4,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTAtMy0xLTEtMjM5NDEx_4ff77423-35cf-415c-9c4d-9b0078e4e77c">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTAtNS0xLTEtMjM5NDEx_eea5182e-d73e-4191-ab89-ee78ca416479">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTEtMS0xLTEtMjM5NDEx_05952cf2-22fa-45b0-89fc-2cfffe8258c0">4,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTEtMy0xLTEtMjM5NDEx_619a0329-7a86-4607-b660-9a8563b1e2c8">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTEtNS0xLTEtMjM5NDEx_95012950-0820-4beb-86cc-70865c901cbe">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia158530deffc41ff8b1b4c24dd63919b">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjAxMA_860695c2-b48b-404f-b660-6f0f329262f4">71</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjAxNw_62ef59e7-6820-4743-816d-2476a91335c2">79</ix:nonFraction> million for the three months ended December 31, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjA3Ng_0055c6be-b3a7-49b3-a7cd-fffc131e988d">142</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjA4Mw_4940fc5b-6236-494c-bec6-dafcdffb0581">157</ix:nonFraction> million for the six months ended December&#160;31, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjIzMA_82527b48-5835-43f6-a056-95beb5d7e9af">147</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjIzNA_525f6910-504f-41f3-b5a0-4cd8b61c2b5a">260</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjIzOA_afabacec-db33-4e65-ac4b-c9721bd504f9">235</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI0Mg_9efcd5b7-ae05-4e75-8f31-2534cea72cf5">208</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI1MA_5b535414-0340-4af0-bdfb-69abf7b9301e">176</ix:nonFraction> million.</ix:continuation></span></div><div id="i495abb9913e04abfaa8f722b6757199b_100"></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzI1MDg_7a3aaeee-8b20-4292-a413-e8e119d1d277" continuedAt="i04e2c3a0905149789b491dabae489264" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-8" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1Nw_8fc7d3c1-5e40-4d2a-904a-8245a754801c"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1Nw_9ef417a3-b3a0-46cc-baa6-93c8048e0045">5.3</ix:nonFraction></ix:nonFraction> billion at both December&#160;31, 2022 and June&#160;30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzU1MA_a2d78eba-ba6f-4f27-a908-a03fcfcfa7e9">30.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzU1Nw_aac92ce6-ec9e-4cb2-a60f-d11adf57c7c2">27.1</ix:nonFraction> billion at December&#160;31, 2022 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we redeemed all outstanding $<ix:nonFraction unitRef="usd" contextRef="i9eaa1547e5534d768ea3ed534ba2e362_D20210701-20211231" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzQzOTgwNDY1MTM4ODU_c96d3e43-80e5-46de-ad00-786162e9030a">572</ix:nonFraction>&#160;million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i9eaa1547e5534d768ea3ed534ba2e362_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzg4MA_0e542875-de6d-499f-a577-7abc3a26fea5">10</ix:nonFraction>&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="i04d33ee800e348859d151250d6109ee0_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE0MTU_82352518-5840-4d07-9370-c5bed4131887">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="i0293a455c0be418f9e6ccdf022c16c57_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE0NTU_d8dd7fc7-c384-4c71-bb24-bcea46916122">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="i6f7465ce88c1440a986aade3262014dc_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1MDA_8fab217d-2197-4461-87a4-09f65049e68e">1.0</ix:nonFraction> billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2022, we had <ix:nonFraction unitRef="usd" contextRef="i91b17012c22f40f393b25ec61b1315d5_I20221231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1NTU_d1820557-bd8f-495b-ae2f-761c1d2ab07a">no</ix:nonFraction> amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2025. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i04e2c3a0905149789b491dabae489264">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2022, we were in compliance with this financial covenant.</ix:continuation> </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMjk_c0a88e7f-3a09-4e78-8597-fbf7ba23b5a9" continuedAt="i1aca69df16d14c2eb7c36553dd880acc" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="i4d3712b011c34b738780dc9362b76df4_D20140731-20140731" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI1NA_4ae429d7-e79f-47f7-ab9b-b893ded255b5">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="if66c1d6e3cbf4381a0bd67de03e24ce5_I20180430" decimals="-6" name="cah:AggregateAnnualAssessment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzcwOQ_6521d980-fd53-4efb-99db-55f0a49d31e3">100</ix:nonFraction>&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. In the second quarter of fiscal year 2022, we paid the State of New York $<ix:nonFraction unitRef="usd" contextRef="i4e6c3fc3e6e2445aa4d9200c41eef841_D20211001-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIxMjY_4268e126-2ee6-4138-ab89-606c4e067319">20</ix:nonFraction>&#160;million, our portion of the assessment for calendar year 2017. At June 30, 2022, we had an accrual of $<ix:nonFraction unitRef="usd" contextRef="ibf33963c011d47cea39c41f3cb3e98cf_I20220630" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIyNDA_a65b3cd2-8b9b-49e8-8543-e2fb74966694">20</ix:nonFraction>&#160;million, which represented our estimate of our portion of the assessment for calendar year 2018. Du</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ring the three and six months ended December&#160;31, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="if5c45c8e827040f492eecfcaf9019804_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0MjM_688369ee-e3bb-40f3-8952-add46d009360">6</ix:nonFraction>&#160;million of income to reduce this accrual to the invoiced amount for the calendar year 2018 assessment. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i993e4902e3144a5bb0fd1d2340dcc042_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzU5Mzg_8924e588-482e-42a8-aaa4-604a56666781">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Settlement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i1aca69df16d14c2eb7c36553dd880acc" continuedAt="i5179ad6249124522ace02e0de9877ed6"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims brought by states and political subdivisions. This Settlement Agreement became effective on April 2, 2022. In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="i81b5f38455cd438ea15b1ba793e7d1e9_I20220630" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUxNDU_6d6b13af-fa69-4d99-922a-14c8ca3fe117">160</ix:nonFraction>&#160;million to the State of Washington and its participating subdivisions and approximately $<ix:nonFraction unitRef="usd" contextRef="ib5158c69b2f141aba7524064bfe8f0df_I20220630" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUxNTk_f3f689d6-55f2-4788-95a0-74528bf0a35a">95</ix:nonFraction>&#160;million to the State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. Each of Washington and Oklahoma is now subject to the Settlement Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Distributors, parties to the Settlement Agreement include <ix:nonFraction unitRef="states" contextRef="ic809c76f51ee4ec1a6f716add527ca16_I20230131" decimals="0" name="cah:SettlingStates" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIyMzY5_db63aee8-a9c6-4e5e-a9cb-09259837dc6d">48</ix:nonFraction> states, the District of Columbia and <ix:nonFraction unitRef="numberofusterritories" contextRef="ic809c76f51ee4ec1a6f716add527ca16_I20230131" decimals="0" name="cah:SettlingUSTerritories" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIyMzY1_4f4001c9-7aa6-46ca-9a3b-5e8438c65e45">5</ix:nonFraction> U.S. territories. Over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, we agreed to pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i18fb106b5e6f449d8ae9790879d1da5d_I20221231" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMDI_bf44c349-6dbc-443a-894d-8c6d1a16faf8">6.3</ix:nonFraction>&#160;billion. The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions, including the Attorney General for the State of Alabama, and we intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December 31, 2022, we made our second annual payment of $<ix:nonFraction unitRef="usd" contextRef="i139081ab99184a1f8b7e1b9c76f62c72_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMTY_bcb121ac-3fd8-4bf8-9abb-d85d4cd2d17c">372</ix:nonFraction>&#160;million under the Settlement Agreement. In total, we have $<ix:nonFraction unitRef="usd" contextRef="i18fb106b5e6f449d8ae9790879d1da5d_I20221231" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxMzk3OTY_364b5997-5b11-4a78-b0f9-20ea38ad990f">5.89</ix:nonFraction>&#160;billion accrued at December&#160;31, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="i18fb106b5e6f449d8ae9790879d1da5d_I20221231" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxMzk4MjU_5e74104c-30fc-4a95-8af6-b8500c8ecbf5">480</ix:nonFraction>&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgement in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $<ix:nonFraction unitRef="usd" contextRef="i40b411ebb5184bb1a9dfd35919f25b3e_I20220731" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMzM_c7c69680-b23d-47e8-ae8f-fb9388f5ea8c">124</ix:nonFraction>&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i361a1cbfafd442128bda3c3659c07e1c_I20221031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyNDc_911494e6-3794-4b92-b9a0-0d9b63905ccc">136</ix:nonFraction>&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="i4e839715483343b29b2118fba97d1b13_I20230131" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzQzOTgwNDY1ODMxODU_a08f05c9-92f3-48b2-8a16-eb80e23734ba">468</ix:nonFraction> lawsuits as of January 31, 2023. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="ia8e0dc33321a4c17baac9c92c4b2a3cb_I20230131" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE0OTc3_094516c8-c145-472c-a004-6a2cddfda952">88</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving <ix:nonFraction unitRef="plaintiff" contextRef="i68386e21f9e742fb969736106a1cbf00_D20220701-20220731" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE1MTQw_4fe49892-341e-47fb-b9a3-a4b93c293f98">21</ix:nonFraction> plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial began in January 2023. A trial involving <ix:nonFraction unitRef="plaintiff" contextRef="i962de220c39d41c99fd21cc23e3bda11_D20230131-20230131" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0OTA_01628af8-ebba-45a4-8255-302578640f8c">eight</ix:nonFraction> hospital plaintiffs is scheduled to begin in Alabama in July 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. In the three months ended December 31, 2022, we received approximately $<ix:nonFraction unitRef="usd" contextRef="iabd7dc7bfc674ee0ae21b5962987f975_D20221001-20221231" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0NzY_2927da29-9298-4aa3-b19e-f5cdef54d024">10</ix:nonFraction>&#160;million in insurance recoveries related to these matters; however, we </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i5179ad6249124522ace02e0de9877ed6" continuedAt="i0d0f8267c58241deade6b93b9c4fb0b3"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have not recorded a receivable for any additional recoveries as of</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, we are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="ifd8168246fc242c59a3f7bb52d90228b_I20230131" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2Mzk0_dfa5eaf8-4cc1-4a8d-92cc-a726066a41c1">450</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i0a59fc36d30d420c8aa97be0a9b2a640_D20230131-20230131" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2NTE3_4dae9ea4-3d72-4f9b-990f-0db4b0086757">5,161</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of IVC filter products. Another <ix:nonFraction unitRef="lawsuit" contextRef="i525578e0fcdf4038a90e4f5d3e79ded2_I20230131" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2NjY4_4bdeaf78-98f4-434c-bd3b-8575ded7314b">3</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="ic9944beac48f4f9980659c2177de1820_D20230131-20230131" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2NzIy_f1d07c9f-623f-4471-8c9b-d8967125309f">3</ix:nonFraction> plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits seek a variety of remedies, including unspecified monetary damages. Since July 2021, we have entered into agreements to settle approximately <ix:nonFraction unitRef="lawsuit" contextRef="i581bdde63b994b5da0099ea58092e0c5_D20210701-20230131" decimals="0" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzQzOTgwNDY1ODMwNzc_5ab0898e-69c7-49d9-9f89-db8c899d6f1d">2,885</ix:nonFraction> product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized net income of $<ix:nonFraction unitRef="usd" contextRef="i7b5c5c45933b48ec82b48e22389cf840_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:ProductLiabilityAccrualPeriodExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0NTA_ffbb6e19-2991-4be1-94ac-30b74004fdba">46</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i527029a879204a469f1592c5d337a7a1_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:ProductLiabilityAccrualPeriodExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0NjM_b51d23a7-f6a1-448a-9b7e-53c7b68a2128">25</ix:nonFraction>&#160;million during the three and six months ended December&#160;31, 2022, respectively, to reduce the reserve for the estimated settlement and defense costs for these matters due to certain claim settlements and to reflect insurance recoveries received in the quarter. At December&#160;31, 2022, we had a total of $<ix:nonFraction unitRef="usd" contextRef="i0c141cd1d64f4c09ad35c5e008a7f485_I20221231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE3MDk0_980b462c-7ac3-420d-8203-48b235346f7e">471</ix:nonFraction>&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="icdf7ff2e260e4c10b571e6c980ad3111_I20221231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE3NTUw_4aca3243-37ef-4cff-8c08-e32a096f49c7">826</ix:nonFraction>&#160;million. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the intended complaint. We are vigorously defending ourselves in this matter. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we received net cash proceeds resulting from the settlement of a lawsuit in which we were a class member or plaintiff of $<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="cah:IncomefromSettlementsofClassActionLawsuits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyNjE_e9a36b3d-0832-4f5c-8f68-3462a9de8791">66</ix:nonFraction>&#160;million, which was recognized in litigation (recoveries)/charges, net, during the three months ended December 31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0d0f8267c58241deade6b93b9c4fb0b3">In December 2021, the parties reached an agreement in principle to settle this matter. In October 2022, a court entered an order approving the settlement and dismissing the case. The settlement does not include any admission of liability. Under this settlement, in December 2022, Cardinal's director and officer's liability insurance carriers, on behalf of the defendants, paid Cardinal Health $<ix:nonFraction unitRef="usd" contextRef="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231" decimals="-6" name="cah:GrossInsuranceSettlementBeforeAttorneyFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0MzY_86264aaf-37eb-4a9d-a88c-057f56fede5b">124</ix:nonFraction>&#160;million, less approximately $<ix:nonFraction unitRef="usd" contextRef="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231" decimals="-6" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyNzU_7670cc77-5a3d-4e19-a71e-87effbf14dcf">31</ix:nonFraction>&#160;million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal received net cash proceeds resulting from this settlement of $<ix:nonFraction unitRef="usd" contextRef="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231" decimals="-6" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyODg_904b919e-ccc3-4ec3-8958-4e87731b47cd">93</ix:nonFraction>&#160;million, which was recognized in litigation (recoveries)/charges, net, during the three months ended December 31, 2022.</ix:continuation> </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_106"></div><div style="width:100.000%"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzkwODA_c7ec0864-9470-4e95-ba1b-1c68fa7bf516" continuedAt="id414191c928f47908f882655db4d3d01" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended&#160;December&#160;31, 2022, the effective tax rate was&#160;<ix:nonFraction unitRef="number" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzMzMw_77a09c5d-f82a-4269-9623-ed43fa8e19be">5.4</ix:nonFraction> percent and&#160;<ix:nonFraction unitRef="number" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzM0MA_36b43e92-ab42-4b3b-8a8f-fadf2d61fe2e">30.0</ix:nonFraction> percent, respectively, and reflects the impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December&#160;31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended&#160;December&#160;31, 2021, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzU0OA_0f35be0e-5905-46ce-8b29-4f6ae4968804">105.0</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzU1NQ_317d6d59-1b7d-4bd6-bc17-6bd817635f6e">153.1</ix:nonFraction> percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charge recognized during the three and six months ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2022, we recognized pre-tax goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i2c0539d106574706b4942868128b486d_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzExMTQ_2cfe9942-9863-402b-989d-f480e49dc794">863</ix:nonFraction>&#160;million related to the Medical Unit. The net tax benefit related to this charge is $<ix:nonFraction unitRef="usd" contextRef="i350fbf1a37334d5289dc88528245bdb4_D20220701-20230630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzEyMTk_9070ac86-3be3-4dd6-9765-f10bdeba319f">68</ix:nonFraction>&#160;million for fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the six months ended December 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax loss for the six months ended December&#160;31, 2022 resulted in recognizing an incremental interim tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="i95fe2ba8ed3a44abadfb859ec9e251e4_D20230101-20230630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzIyOTQ_d176074a-17aa-4692-ac2c-d8d650a03a1d">140</ix:nonFraction>&#160;million, which impacted </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the six months ended December&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at December&#160;31, 2022. This incremental interim tax benefit will reverse in the future quarters of fiscal 2023.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYxNjU_552397f6-2fec-4ecb-8f08-136c5c16bcb8">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYxNzI_ba962f52-d079-4391-8727-176f859d580e">943</ix:nonFraction> million of unrecognized tax benefits, at December&#160;31, 2022 and June&#160;30, 2022, respectively. The December&#160;31, 2022 and June&#160;30, 2022 balances include $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYyNjM_b6fe8b24-0fc7-457a-86b9-1c4ae758ce56">889</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYyNzA_2a57434e-ae39-4647-95b2-bb9a55a9c13d">858</ix:nonFraction> million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and June&#160;30, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzY0MDc_283cc47c-b951-41d4-a01a-75547b1b416e">56</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzY0MTQ_8c473609-cf88-4bec-a66f-f8237514fca8">48</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="icd31a13676b345b183f5ced501f7ae50_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzcyNjM_47a81377-f7f2-44d6-ba1d-adefd66e516a">zero</ix:nonFraction> and a net decrease of up to $<ix:nonFraction unitRef="usd" contextRef="id9b861e2d5ac4b82a144a3b79ab22e81_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzcyOTQ_82008ead-e619-48ac-880f-b98e952dcfa0">120</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i3459c970df844cf2a1ee3095599f0255_I20221231" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzg2MDA_6b9b32cb-b753-4b33-b94a-f52dd8b07a49">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4ced27bfe4894fc6803e626c517f05b7_I20220630" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzI3NDg3NzkwODQxMzk_53d10ec0-d93a-4827-b785-55db4f66c8bb">75</ix:nonFraction>&#160;million at </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id414191c928f47908f882655db4d3d01">December&#160;31, 2022 and June&#160;30, 2022, respectively, and is included in other assets in the condensed consolidated balance sheets.</ix:continuation></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_109"></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90ZXh0cmVnaW9uOmM5NjhiYjA0ODAzMDRiYWZhOThkMzg3ZjRlYjEwMzBmXzEyMzA_f02e4cac-9403-412f-a229-d18cc827013b" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90ZXh0cmVnaW9uOmM5NjhiYjA0ODAzMDRiYWZhOThkMzg3ZjRlYjEwMzBmXzEyMjQ_ab050594-01c2-4f9a-bc78-fa34c0fb410f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac76a749b153465ab4af13b1df78d72a_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtMS0xLTEtMjM5NDEx_e1decc22-21b4-411f-a874-86e702a00641">1,146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtMy0xLTEtMjM5NDEx_550ef176-9bc9-447a-b5cb-3a1dc71f0af4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c199cfd03a3434fb2252f5f91cf4519_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtNS0xLTEtMjM5NDEx_13d3c073-2553-4e26-9e69-7f0fa3532a16">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtNy0xLTEtMjM5NDEx_8d098450-ed69-4af7-8d57-681c0a94d3fb">1,146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac76a749b153465ab4af13b1df78d72a_I20221231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtMS0xLTEtMjM5NDEx_4a75e96d-c250-4f13-98e5-b54cb19de3a0">94</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtMy0xLTEtMjM5NDEx_8a8cc1d0-db9a-442d-95de-7f8b2429fb9d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c199cfd03a3434fb2252f5f91cf4519_I20221231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtNS0xLTEtMjM5NDEx_a9a6397f-a85c-4dac-bd97-f57a81c2ec94">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtNy0xLTEtMjM5NDEx_02b2c574-8943-400c-8256-ef4af1a49df7">94</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac76a749b153465ab4af13b1df78d72a_I20221231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtMS0xLTEtMjM5NDEx_ee0ea07c-ae90-422f-ab65-48693dc2a34c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtMy0xLTEtMjM5NDEx_6fb7b9a9-116a-4200-984a-4af0700a0b69">48</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c199cfd03a3434fb2252f5f91cf4519_I20221231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtNS0xLTEtMjM5NDEx_c714a56d-3e65-4346-883f-b2c1d661d352">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtNy0xLTEtMjM5NDEx_3ab779a3-e33d-4264-b613-44b3e4bfcf5d">48</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bf45fc47f34b519bcb944cf300f764_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtMS0xLTEtMjM5NDEx_95bb8cb5-509f-4b7e-82e2-1a46cd05e41d">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28968af686284bf28e66c81f371858ae_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtMy0xLTEtMjM5NDEx_5719a57b-1633-4f11-b0f4-2201b6e8bb32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3e9a1753b947c98746cbb0141dc97f_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtNS0xLTEtMjM5NDEx_9ff26152-ad8d-4d3f-9510-f21d32b1ebc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f983f7d518449f5badd677106e20d44_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtNy0xLTEtMjM5NDEx_42c2db75-32a9-4889-b2aa-39e9c17b5fb8">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bf45fc47f34b519bcb944cf300f764_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtMS0xLTEtMjM5NDEx_f28ece0a-6798-4e57-9833-436e3fc8f2f8">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28968af686284bf28e66c81f371858ae_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtMy0xLTEtMjM5NDEx_600fa85d-a63d-4d09-be5b-2f4710f0d2dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3e9a1753b947c98746cbb0141dc97f_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtNS0xLTEtMjM5NDEx_3905fbbe-1b4a-4fcf-afac-63828c64ecd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f983f7d518449f5badd677106e20d44_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtNy0xLTEtMjM5NDEx_4482ec8e-ba03-4714-80b4-f17013f1e431">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bf45fc47f34b519bcb944cf300f764_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtMS0xLTEtMjM5NDEx_bc379888-c565-45f7-8985-e72b04d176d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28968af686284bf28e66c81f371858ae_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtMy0xLTEtMjM5NDEx_f59d9b71-d6b1-4a44-9039-49a45abfa1b1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3e9a1753b947c98746cbb0141dc97f_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtNS0xLTEtMjM5NDEx_5afcffe6-e5ea-4687-a4fa-9589f449709e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f983f7d518449f5badd677106e20d44_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtNy0xLTEtMjM5NDEx_2ed2eba1-f2ec-414e-ba81-26c69a8019d9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_112"></div><ix:nonNumeric contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzgzNDU_8a81eab7-0df0-49c8-a2d3-855ea1f28503" continuedAt="i1a3fffaad0be4392b6f3cb6269ae27d6" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i1a3fffaad0be4392b6f3cb6269ae27d6" continuedAt="idab6004df5a84360b064c486334cbe04"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December&#160;31, 2022 and 2021, there was <ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_11ae3cd9-4955-4def-9e9f-aa8927573202"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_182dbdc0-54ea-4bb9-a38c-aa523d99968d"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_c1063776-cd52-478e-bb43-25c24dd00da9"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_ec7adbb3-24d8-4b7a-83d2-848b08f7a695">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended December 31, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ic401427aa03a473ea0f233823ee9d726_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzM1Mzc_6003826d-3788-4b5d-a6f8-d6d2298621fe">200</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib98f9a1c857544358cc749c370824d31_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzM1NDQ_54b579c8-777b-429f-9223-072b76da430b">300</ix:nonFraction> million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="idab6004df5a84360b064c486334cbe04" continuedAt="i219c184a23ef4209a70224691d99a08b"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses recognized in other comprehensive income/(loss) were a $<ix:nonFraction unitRef="usd" contextRef="i419db69ec18d45b5973c1365d849e94d_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0MDA_705cb7bf-3bdf-4b82-85ba-fa6e2e226cb3">2</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="i62912f01f9244e47ae336b38973b6b79_D20211001-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0MDc_1dce4b0e-c122-41de-8a81-66d6efaa5764">1</ix:nonFraction>&#160;million gain for the three months ended December&#160;31, 2022 and 2021, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i3a13dfbd6e0e47b49bff1d69a1465152_D20220701-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0Njg_bcbfed9d-0b3b-406a-ab2d-84194f6a1926">2</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="i80c83599bf12444b8d0eaf98c4ced505_D20210701-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0NzU_d5676761-9d60-4a46-9bf4-2645f1c67382">3</ix:nonFraction>&#160;million gain for the six months ended December&#160;31, 2022 and 2021, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="i2af00a4f8742447cba317049f64150b3_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYyMTQ_c8c4b52d-7adb-45de-8515-50ce02a93bea">43</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="i3c17db4a988b439d8092bcb59165e33a_D20211001-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYyMjg_a141f0b3-8ed3-4c72-964c-4e26cc49c9ee">17</ix:nonFraction>&#160;million gain during the three months ended December&#160;31, 2022 and 2021, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i5bfe8b32e9774993b62940687e315b97_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYyOTc_17a8ab4c-9b54-4789-b519-779972436971">21</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="ie1537e0b026743748253259f1422c1d7_D20210701-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYzMTE_c421ef05-0d86-44d4-b3ed-c2691d18c4f0">22</ix:nonFraction>&#160;million gain during the six months ended December&#160;31, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="i2af00a4f8742447cba317049f64150b3_D20221001-20221231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzU0OTc1NTgyMjQxOA_b76bb71f-ec46-433f-a782-a572246fda0f">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3c17db4a988b439d8092bcb59165e33a_D20211001-20211231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzY1NjI_c8a3a5ae-fa1f-4efa-897a-ee4db6e6147d">5</ix:nonFraction>&#160;million during the three months ended December&#160;31, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i5bfe8b32e9774993b62940687e315b97_D20220701-20221231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzY2MTQ_7f3dcfe6-d5e1-4a87-9c60-d12ca99a7e2b">8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie1537e0b026743748253259f1422c1d7_D20210701-20211231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzY2MjE_96924bca-46a4-44a8-b6ba-bb3d21318c3b">11</ix:nonFraction>&#160;million during the six months ended December&#160;31, 2022 and 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i219c184a23ef4209a70224691d99a08b"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $<ix:nonFraction unitRef="usd" contextRef="i1336136219d3457ba4c78496738f3cfa_D20221001-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc0NDI_efabc36d-b545-4264-9f61-6aed4020c0e2">3</ix:nonFraction> million gain and a $<ix:nonFraction unitRef="usd" contextRef="i850b0b51db214c4c979fd9e1de993132_D20211001-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc0NTY_f0a268b7-9625-436e-9e52-e362c5a3dedd">2</ix:nonFraction> million gain during the three months ended December 31, 2022 and 2021, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="ic5688d1966bc4586b43f1bd3b0319696_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc1MjY_387c22e7-c6df-4f77-b184-3bae0bc3c3e2">3</ix:nonFraction> million loss and a $<ix:nonFraction unitRef="usd" contextRef="i8508310d7f6f400da86433e5bf10f0c7_D20210701-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc1Mzg_ca6638e2-0ceb-4fb6-85d0-607b3303da4f">4</ix:nonFraction> million gain during the six months ended December&#160;31, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht..</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at December&#160;31, 2022 and June&#160;30, 2022 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzgzNDY_6ee72a68-be23-4f6b-9261-a5594622e1ea" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic296f663b9444e33b5f5d47197bb2a3a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzEtMS0xLTEtMjM5NDEx_5fdfb07d-159d-4143-a4d6-39f541133555">4,912</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc93964635640fe8eb7402e598ad33e_I20220630" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzEtMy0xLTEtMjM5NDEx_1e4792a3-123a-4af8-930a-cfae229f1d61">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzItMS0xLTEtMjM5NDEx_e6839047-7740-4a57-9098-e76c60455d01">5,262</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzItMy0xLTEtMjM5NDEx_94c8d1e3-b507-46a0-9a78-2b317179df8c">5,315</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="i495abb9913e04abfaa8f722b6757199b_115"></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzE4OTQ_abda4781-eab3-477a-8131-eff2c0e9daa4" continuedAt="ie03c745bbdcb47d3a3d3c4783970280e" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $<ix:nonFraction unitRef="usd" contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzI3NDg3NzkwNzM5MDM_320fe856-1e0b-4e86-821a-bf6516575b9a">1.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODYwODg_f311c78b-0d24-474f-95fc-6b61e4b15130">800</ix:nonFraction> million of our common shares, in the aggregate, through share repurchase programs during the six months ended December&#160;31, 2022 and 2021, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i44235a75341c4ea98c8f81b1b8a2af14_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzQzNg_bfc188f9-5879-4f22-84d9-1974bab924c2">250</ix:nonFraction> million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzQ3NQ_51c17e3b-a699-4252-b9f8-212ccea03e55">2.6</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzUxOQ_7431b749-07c1-4321-9a86-7ace13f8ee40">76.58</ix:nonFraction>. The program concluded on January 13, 2023 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e78550aaf464e52892c197636bb7e4a_D20221001-20230113" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzYwNg_49279dc6-3103-4367-9388-54d07bbfc60b">77.50</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i4d2749e174ce4d1bb8fced961a9f1965_D20230113-20230113" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzY0Mg_379d2bb8-9c15-4d93-99b8-4bc0167ab8d1">0.6</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="iec9ecab01856488cb08eb92f6ceefb4f_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzExNzE_d43bb862-fa06-44e2-9ab2-c9c352f0c482">1.0</ix:nonFraction>&#160;billion. We received an initial </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ie03c745bbdcb47d3a3d3c4783970280e"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery of <ix:nonFraction unitRef="shares" contextRef="i67242a94677a43a29bdc3644189fb216_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzEyMTA_ce2a6b3a-0dac-45d1-a973-2a109b2669e8">12.0</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i67242a94677a43a29bdc3644189fb216_D20220701-20220930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzEyNTQ_528f5831-7109-4954-ab11-5bbffec1e56f">66.74</ix:nonFraction>. The program concluded on December 23, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if015bf8d31b6432ca4059c2c62023d4c_D20220701-20221223" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc4Mjg_05239456-5c6e-400b-8a39-5cec4a54e92a">73.36</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="ie003cab2aff1438eb31ba142971e023f_D20221223-20221223" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc4MzQ_9450f794-8d5a-4f6f-8ad6-c208fb6c0b6e">1.6</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ib025910e07224dc6bc0dd03aba8e140d_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5MjE_e5be466c-a4e0-401e-8552-bfe4f48b27c9">300</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i35bfa7c5d2e64b76a42e9f20bacb3144_D20211001-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5MzU_14bef42b-bdfc-4bc8-aaf3-0f8f488a3df2">4.8</ix:nonFraction>&#160;million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i35bfa7c5d2e64b76a42e9f20bacb3144_D20211001-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5NDg_4120c1e4-9d9d-4d59-a116-fc938cc37fcb">50.30</ix:nonFraction>. The program concluded on January 31, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc0a6ac4d1f041e7a3c39bd92acde20c_D20211001-20220131" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5NTg_e612e633-39bd-4cae-9ab1-37118a9cacb9">49.39</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i0aa6850535854b1a86ffcec853e058c2_D20220131-20220131" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5NjY_af4c606c-dd65-4d8b-a56b-b39ab58d3a63">1.3</ix:nonFraction>&#160;million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="if3e0f4813dc547caa13b2dd18cb5794a_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5Nzk_7bc5a97c-b9ed-4d1a-ad74-a71f57fe7a64">500</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i96adc00f02ea4124a797b7def5d4b482_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5OTM_fc6bbaed-1559-4474-9633-d8642ec998c7">7.8</ix:nonFraction>&#160;million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i96adc00f02ea4124a797b7def5d4b482_D20210701-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODgwMDY_132f0195-cf08-459e-97e9-7c6572ec738a">51.53</ix:nonFraction>. The program concluded on October 4, 2021 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ab163bd44f34212a39494050f17884b_D20210701-20211004" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODgwMTQ_de4aed3a-f13b-4c06-a14f-2cd64acab1c2">51.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i51514bc1c1804e3e8e046c79f210825c_D20211004-20211004" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODgwMjI_3bc9f1b6-e89c-4623-8f66-a84ddd4b5422">2.0</ix:nonFraction>&#160;million common shares.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzE5MDI_c5c926c8-aa44-43c7-9234-e2adf6210086" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb3ff1d4324243c5b9dab7c4b4e6aaac_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzEtMS0xLTEtMjM5NDEx_b2ed1786-ac94-4c3b-b46e-d01c11291d6f">102</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927dad673ba5420a852bc6b2ae6b2c64_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzEtMy0xLTEtMjM5NDEx_63ad23ed-84ed-416f-81fb-93e0f9146359">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d24c5647c19422b8430fcfe245a94f7_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzEtNS0xLTEtMjM5NDEx_5da4e430-5036-4d94-bd1c-10279ab9161f">114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzItMS0xLTEtMjM5NDEx_b0ba47c6-02c9-4026-bbe9-a3f1b75a4f9a">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzItMy0xLTEtMjM5NDEx_86585f7c-d3a7-4968-83f6-d28b0f973a79">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzItNS0xLTEtMjM5NDEx_d19f2c56-58dc-4319-b1bf-f0926672d32f">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzMtMS0xLTEtMjM5NDEx_d9844629-e3dc-4e00-a48d-2ae497737199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzMtMy0xLTEtMjM5NDEx_c3f54754-a6f0-4f44-849c-57d6c677dd96">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzMtNS0xLTEtMjM5NDEx_0214f979-e5ab-4933-9d1d-df5740770ff4">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtMC0xLTEtMjgyNzc1L3RleHRyZWdpb246NDlhZTY4MzkyZTg2NDlmOGJhN2Q0ZTU0NDA5YWMyNDJfNDM5ODA0NjUxMTIwOQ_7134eba6-40b0-41af-9949-7158161a5d08">5</ix:nonFraction>&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtMS0xLTEtMjM5NDEx_53b8a58b-7f82-44f3-bd29-0b9269ac86a8">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtMy0xLTEtMjM5NDEx_93fc0811-9b95-4cc7-a70b-10eddf4e4b38">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1f2ad28443449a3918666f8d0ca9088_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtNS0xLTEtMjM5NDEx_a7e03c03-a8b8-4ec5-a95b-ffbffb2727f9">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if89a2915b7ed4a078a678477329b0507_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzUtMS0xLTEtMjM5NDEx_4c26b312-b7ad-4231-871f-faa4e9bbef02">140</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib230b5c311ef47d68a27beaea8522ed6_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzUtMy0xLTEtMjM5NDEx_c99f135e-e70a-4bc4-9865-cfb8f283c1b7">6</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59555a0f0c174b9491efe42bf0cc4203_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzUtNS0xLTEtMjM5NDEx_e505ffe4-eeb5-435a-8884-c40570dfad69">146</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafbe269331e44497b6736f5de1e2161b_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzEtMS0xLTEtMjUzNDIw_85b6bf2a-daeb-43d2-b620-b400d2c677d6">46</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i234657f026ec4322af8ba2a7554081dc_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzEtMy0xLTEtMjUzNDIw_863e0492-e5ae-48e6-82b8-c56061cb5673">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d0098e44a8448c6988637fda4f53d74_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzEtNS0xLTEtMjUzNDIw_601a404f-9d21-45e3-a424-6ffd55f88116">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f837aa398974931b78133ce25f15c52_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzItMS0xLTEtMjUzNDIw_38ce61f2-c3c7-4919-b5fa-3e6b21540453">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzItMy0xLTEtMjUzNDIw_edad6d51-3a9e-4ec1-91bf-bed16325a402">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzItNS0xLTEtMjUzNDIw_a5623369-c650-4c7f-88cd-fe2612acfc68">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f837aa398974931b78133ce25f15c52_D20210701-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzMtMS0xLTEtMjUzNDIw_f4b7b486-2de9-4f9e-876c-a82ebb1a555e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzMtMy0xLTEtMjUzNDIw_69c545cf-4afc-4eda-90ef-32e7ae6241bd">3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzMtNS0xLTEtMjUzNDIw_9e447b16-4ac2-4355-94f3-db5eabdde0bf">3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax expense of $<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtMC0xLTEtMjgzMzEwL3RleHRyZWdpb246MjQyNDU1Mzc3N2E5NGQ5YmJkZjU2OGUxZjNiNzJiMTlfNDM5ODA0NjUxMTIwOQ_7e311931-3310-4558-b0bb-a27a9a31b3b8">7</ix:nonFraction>&#160;million</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f837aa398974931b78133ce25f15c52_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtMS0xLTEtMjUzNDIw_fec26c97-6055-4c1d-b200-e0e00ce74225">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtMy0xLTEtMjUzNDIw_b37731f8-0f2f-4b2e-bdf2-55e75bd74bd3">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ea96e756f1646cdbbb7691cf0597a61_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtNS0xLTEtMjUzNDIw_779d7105-043f-48b6-a6d6-a2daa4906280">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4260860fbed64ec0a99b94ee41089695_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzUtMS0xLTEtMjUzNDIw_a4fbf289-0903-4d06-b1bd-7405bc80481f">89</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079ed1cf2c02433cb1306b1192fe722a_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzUtMy0xLTEtMjUzNDIw_cd0bd1d0-8fd2-48e2-9604-3882ec4f896e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3668ad01dd604937a1f5a2dbff8c26ed_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzUtNS0xLTEtMjUzNDIw_5ea3b7a8-993c-4129-a70a-e0422fb2fc7a">85</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="i495abb9913e04abfaa8f722b6757199b_118"></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzkyOQ_ad03dcfa-31b9-4a24-90cf-eda980df4bf3" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzkyNA_a938fdbe-a388-4a95-93bb-b9941597ee20" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzItMS0xLTEtMjM5NDEx_16b0d5fc-0c83-49bb-bc77-615554e124b0">261</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzItMy0xLTEtMjM5NDEx_3a53ecb7-5149-405d-84ee-76f38615d511">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzQtMS0xLTEtMjM5NDEx_8af48c26-9574-4079-bbe3-09be571c4a90">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzQtMy0xLTEtMjM5NDEx_7c1a1dec-6ac5-4b76-bc95-c94f8741f407">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzUtMS0xLTEtMjM5NDEx_fe75aef9-281f-4f3d-88c2-b70c7982782e">261</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzUtMy0xLTEtMjM5NDEx_15fff8ab-d0c2-4053-a2e2-14802686cf69">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzItMS0xLTEtMjM5NDEx_b0be3b42-733a-4a72-8c67-5824c25ef9d2">266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzItMy0xLTEtMjM5NDEx_3a922cec-4ec0-4f6a-b026-65611997b365">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzQtMS0xLTEtMjM5NDEx_b449d003-5e3c-4937-9a8f-41261bf524f4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzQtMy0xLTEtMjM5NDEx_59fc93b5-2616-4019-bd16-6787fbd3261f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzUtMS0xLTEtMjM5NDEx_1e3c6c79-bd25-4a8d-990e-bcea25d2b223">266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzUtMy0xLTEtMjM5NDEx_ded199e2-0501-4bb5-a72e-96dbc882091b">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were <ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzI4Nw_23b41238-587a-4881-a88e-2471a5a6dfce"><ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzI4Nw_b49bdd05-af61-4f17-a8ca-8671eacda52b">3</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE2NzQ_1e9d199e-5f36-4bb2-8545-599dd70fe763">5</ix:nonFraction> million for the three and six months ended December&#160;31, 2022, respectively. For both the three and six months ended December 31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE2ODg_88c0d400-1ae6-42dc-8c6e-3171a40eebba"><ix:nonFraction unitRef="shares" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE2ODg_c70b77c5-3af9-4026-8d13-e538dcdf437e">2</ix:nonFraction></ix:nonFraction> million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were <ix:nonFraction unitRef="shares" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzI3NDg3NzkwNzExOTY_4c4d561d-1974-4a00-bd6a-bf320a71992d">5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE3MDI_5a113570-dcd9-42e4-b010-8b40c4277b2f">4</ix:nonFraction> million for the three and six months ended December 31, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_121"></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYxMDI_0a398e73-f908-4ea0-901e-21fce2ace8dc" continuedAt="i140d4619a3ea4580b7954ccdeb2ea3ef" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzEwMQ_7c8ef6da-8d6e-4e86-921d-dfbdd9bfa76b"><ix:nonFraction unitRef="segment" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzEwMQ_d8331263-d2f0-48c2-afa6-a83d969edace">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:continuation id="i140d4619a3ea4580b7954ccdeb2ea3ef" continuedAt="ie19c0b373a514b19bfeddf7e5c07a0fa"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our <ix:nonFraction unitRef="segment" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzE4NDc_7c8ef6da-8d6e-4e86-921d-dfbdd9bfa76b"><ix:nonFraction unitRef="segment" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzE4NDc_d8331263-d2f0-48c2-afa6-a83d969edace">two</ix:nonFraction></ix:nonFraction> reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwOTk_825fe913-102e-4c3b-9e0f-0a8d9f656871" continuedAt="i3ecf517d13d14953a4d13bd4a73757b6" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de1192dba4d40dea7d63dad70307f94_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzItMS0xLTEtMjM5NDEx_a4f9c46d-6924-4a2f-8e09-fbbe3514f4e5">47,391</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d191632a75148da81cbf62a95aacda0_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzItMy0xLTEtMjM5NDEx_f1bfcd19-653d-4e36-8e30-4e17f6671acc">41,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac761a14f9bd4458a4a199cf1a930ab0_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzMtMS0xLTEtMjM5NDEx_c69103d0-61a5-475d-92d4-d4bc3c7de1ee">282</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14071c1bf65402a88b667c00185bad9_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzMtMy0xLTEtMjM5NDEx_ccd26df5-f792-4f16-b48f-b851a781f83f">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb7ebd0dccf4880b310bb4ffe79ba9c_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzQtMS0xLTEtMjM5NDEx_30f8ee65-1417-45b0-b6bb-5e8a857ed090">47,673</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i372f1adca9c14668a399c6ffc8407155_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzQtMy0xLTEtMjM5NDEx_405648a4-2cc6-4135-800f-7e0557b17fc5">41,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9327356d31264aeda31dc4ff0d2c87fc_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzUtMS0xLTEtMjM5NDEx_a8bc9efe-a29b-4b9a-a68c-a088debc9b3a">3,099</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071f8fbaf46941a48f5d41fde9668d9b_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzUtMy0xLTEtMjM5NDEx_f6b4361e-7969-4084-90cb-7c9629f9aa24">3,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a7a93a200d473ab5c358f7df672a72_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzYtMS0xLTEtMjM5NDEx_a7596175-1ce9-4e25-9540-6f9d98c51599">698</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74408378be5a448e98f4a8a12fb3666f_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzYtMy0xLTEtMjM5NDEx_0fe8437f-2da5-492d-967f-b9d6ef6a3b3e">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4c69b8bfea43cc82c3f371ef88ebf8_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzctMS0xLTEtMjM5NDEx_f6f67e03-66b3-4033-8b00-6fb7c787f57a">3,797</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6df290f36db4d3d90865e0e99c3d0b8_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzctMy0xLTEtMjM5NDEx_25772d8d-bea4-4a47-97cd-b782d51b32cd">4,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzgtMS0xLTEtMjM5NDEx_a59e96f2-90f4-491b-a32f-ef04e05a602d">51,470</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzgtMy0xLTEtMjM5NDEx_c06ad083-b566-474f-befb-fc601fdd4b8e">45,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzktMS0xLTEtMjM5NDEx_8994b226-a7a5-40b6-8a5b-7506fa767193">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzktMy0xLTEtMjM5NDEx_180e70c3-a0e2-488a-a629-89e47d077a20">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzEwLTEtMS0xLTIzOTQxMQ_b1610068-b0cd-4b65-b8bf-1b5dca6b6ebe">51,469</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzEwLTMtMS0xLTIzOTQxMQ_c7b38a43-b499-4a65-a530-548b146f8909">45,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i3ecf517d13d14953a4d13bd4a73757b6"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39b5639f5fa48fc97157c8446d8e414_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzItMS0xLTEtMjM5NDEx_7d036b8f-fe2e-449c-a346-96b72e94bf7a">92,938</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59cd6366c894bc7b2baebc2cd23823b_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzItMy0xLTEtMjM5NDEx_84242d33-8ac3-46cf-b81d-6f96e49783e3">80,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7f4cacb374f3c9209b0378d7b463c_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzMtMS0xLTEtMjM5NDEx_d4b708ef-6703-4bc2-9416-be462c1ea28f">563</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c827171183b49d9b5eac5515ab8dc44_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzMtMy0xLTEtMjM5NDEx_21680c6f-f486-455d-82c2-6a6ea20c696e">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847b85afccb1427c9843ef38bfb3b4ef_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzQtMS0xLTEtMjM5NDEx_4656af6e-dc8b-4e2b-a3cd-aee4d7bdab98">93,501</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0e3bfc4cf14a36a1e7f71d2910082d_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzQtMy0xLTEtMjM5NDEx_4831a1dd-5fc6-4bad-8918-2e17dd744c08">81,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5840a89e1f24c089cf3dc78fab83e52_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzUtMS0xLTEtMjM5NDEx_baf58957-8675-4b2e-be02-a45e9410488b">6,239</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991f809891464521b1f29e8e3fa6c4db_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzUtMy0xLTEtMjM5NDEx_4011a520-cec0-47aa-803e-081d75d5f8b9">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7759d1263204160a70574351e4794da_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzYtMS0xLTEtMjM5NDEx_1c369ef0-27e2-49e6-a44f-8be1c563caba">1,336</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2cadd91b2c54bc6b8874b00950fde1d_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzYtMy0xLTEtMjM5NDEx_16b67981-3959-418c-a47f-4a48d04b72f6">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0748902d2bc42b1aa2187c657d51169_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzctMS0xLTEtMjM5NDEx_2ded3584-330d-4183-ae0f-94dc4ff874b1">7,575</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc20395d8d04d49bb7875d92c1c581f_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzctMy0xLTEtMjM5NDEx_5764b6b4-ae0e-4c0d-b531-afa736e1ce08">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzgtMS0xLTEtMjM5NDEx_a6914b68-6efc-4cad-b7b0-501650db7f03">101,076</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzgtMy0xLTEtMjM5NDEx_ecab96e4-a74e-4780-92fe-f15ddfdb41e1">89,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzktMS0xLTEtMjM5NDEx_34546a85-a2e1-4ded-929a-3a6e91e52d7a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8f31a92ecac49d98787199739713426_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzktMy0xLTEtMjM5NDEx_a59253ad-def3-463f-85bd-48c0a66c194a">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzEwLTEtMS0xLTIzOTQxMQ_ce87c657-fd86-48d2-8dee-b4a85ad2de19">101,072</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzEwLTMtMS0xLTIzOTQxMQ_08e553e0-4f12-4773-84ed-adf774a4f426">89,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:continuation><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwOTA_dc5ff445-7d82-4618-9c87-767f6899dfeb" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2a6bafa71e46f6bff513c85997576c_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzItMS0xLTEtMjM5NDEx_db361ed5-db95-4b82-ab05-549f7e62d1fc">50,333</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b72d75aa77747f688bde3fedede66d3_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzItMy0xLTEtMjM5NDEx_917ce6a6-cbcb-4091-8eed-55745be0ba05">44,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d8fab8a7154b2ca8fca6ab14961db8_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzMtMS0xLTEtMjM5NDEx_6b8f3144-1bd2-4504-a858-a72519aec10a">1,137</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea3c4ca236646ceaff7d1d7d0910e14_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzMtMy0xLTEtMjM5NDEx_66e99d25-556d-435d-819c-39e52ab367cb">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzQtMS0xLTEtMjM5NDEx_c3841851-a620-481c-9ec3-ed3fe4c1e571">51,470</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzQtMy0xLTEtMjM5NDEx_b6cb700c-6efe-4eeb-b89d-90157f00ff36">45,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzUtMS0xLTEtMjM5NDEx_f12766b5-2a64-4fd5-ac46-bf8599172f59">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzUtMy0xLTEtMjM5NDEx_40be71e8-c2f6-4e8b-902c-a6153e067687">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzYtMS0xLTEtMjM5NDEx_539dd775-7aa3-45e0-824b-ceec51d3be4d">51,469</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzYtMy0xLTEtMjM5NDEx_65d6c78f-f1a3-4c5f-ba33-3acb1551113c">45,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20401e15a48a4142ab492d9ed551560b_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzItMS0xLTEtMjM5NDEx_c83e35ad-544f-4a4e-8cd0-2baa32dbf928">98,810</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd024933b8a4c7dbd94a2ee45b24ed2_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzItMy0xLTEtMjM5NDEx_9da00331-e11c-4f5b-87f7-8412d3b8ad64">87,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf4d295eb2c84b83a1b9930b69ca5b06_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzMtMS0xLTEtMjM5NDEx_a609191e-3f06-40d5-9d23-8b856a7e8170">2,266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07757b56850843c5b966cdae4070ece5_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzMtMy0xLTEtMjM5NDEx_c7f9aa62-a593-492d-8958-97d71a3581ca">2,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzQtMS0xLTEtMjM5NDEx_1941d61f-feed-438f-8978-a571939e2cb5">101,076</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzQtMy0xLTEtMjM5NDEx_bc9ba292-84d5-4ca8-9eb9-56b2e2da4f1e">89,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzUtMS0xLTEtMjM5NDEx_ab5c7aa2-7fe5-4438-aa9b-2c228a603128">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8f31a92ecac49d98787199739713426_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzUtMy0xLTEtMjM5NDEx_cdf0e334-0e3f-4bbf-8f25-36b99c03a133">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzYtMS0xLTEtMjM5NDEx_ef44c001-3f69-4bca-b65f-24685cddf1cb">101,072</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzYtMy0xLTEtMjM5NDEx_4ec64a86-4697-401e-b534-1ba2149de6b0">89,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ie19c0b373a514b19bfeddf7e5c07a0fa" continuedAt="icd1eaddee6cb4f648000cb02b5e7475b"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="id0a29845f22449af9631745d9999727d_D20221001-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzI3NDg3NzkwODQ0NTA_ee3267cb-d58b-4062-989b-16c20725d338">709</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2c0539d106574706b4942868128b486d_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzI3NDg3NzkwODQ2OTU_2cfe9942-9863-402b-989d-f480e49dc794">863</ix:nonFraction>&#160;million during the three and six months ended December&#160;31, 2022, respectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQzODE_951bb6ea-5e98-4f28-b2cb-22414640762c">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQzODg_5992799d-7865-4405-8029-a57130cd45d9">11</ix:nonFraction> million for the three months ended December&#160;31, 2022 and 2021, and $<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQ0MzM_a4d3e5a4-3b6b-446a-b28b-8322ef14e4c1">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQ0NDA_4e21743f-5542-4485-a470-e5e780defa7a">18</ix:nonFraction> million for the six months ended December&#160;31, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwODg_43a09551-c8fb-4e8f-b75b-808cc1d985cc" continuedAt="ifdb1b98b70604c18b0a09c00b4d1c300" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb7ebd0dccf4880b310bb4ffe79ba9c_D20221001-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzItMS0xLTEtMjM5NDEx_21c79d64-4c4a-494c-8431-651c108f59f6">464</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i372f1adca9c14668a399c6ffc8407155_D20211001-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzItMy0xLTEtMjM5NDEx_f04b6a20-6695-4bbd-b005-aa5ee6664341">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4c69b8bfea43cc82c3f371ef88ebf8_D20221001-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzMtMS0xLTEtMjM5NDEx_92a23c01-1944-4706-af2c-107d3858ba72">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6df290f36db4d3d90865e0e99c3d0b8_D20211001-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzMtMy0xLTEtMjM5NDEx_2c672d17-5acb-4822-8cea-a1759383ba1d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzQtMS0xLTEtMjM5NDEx_de078f8d-f39a-4f24-82df-e9c2078b1a01">481</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzQtMy0xLTEtMjM5NDEx_606577a0-6fb7-49d9-9678-b440f263308a">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzUtMS0xLTEtMjM5NDEx_ec642310-9174-4076-a098-70489987e5a3">600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzUtMy0xLTEtMjM5NDEx_a6edbab9-b3eb-4785-8fdd-094462b210fb">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzYtMS0xLTEtMjM5NDEx_fca83e6b-4c73-4591-85aa-64e9e8332bae">119</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzYtMy0xLTEtMjM5NDEx_8e23c95a-5013-4163-abb8-7809a9e3e8ad">950</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="icd1eaddee6cb4f648000cb02b5e7475b" continuedAt="i9bbe13b6130c4bb89644a75e75b3d9e0"><ix:continuation id="ifdb1b98b70604c18b0a09c00b4d1c300"><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847b85afccb1427c9843ef38bfb3b4ef_D20220701-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzItMS0xLTEtMjM5NDEx_9270dfa9-bc08-474f-9724-00c49aa321cb">895</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0e3bfc4cf14a36a1e7f71d2910082d_D20210701-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzItMy0xLTEtMjM5NDEx_44d7a8e8-c0ac-4919-8f43-ade86b6d894d">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0748902d2bc42b1aa2187c657d51169_D20220701-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzMtMS0xLTEtMjM5NDEx_a827b2b5-6ddc-4061-9500-a69352947d92">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc20395d8d04d49bb7875d92c1c581f_D20210701-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzMtMy0xLTEtMjM5NDEx_05752084-b789-436f-9b5d-c796bfe69d89">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzQtMS0xLTEtMjM5NDEx_ccc9f2d4-3e7e-445a-b2a5-079eae91c203">904</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzQtMy0xLTEtMjM5NDEx_359d455c-9a18-43fc-8b95-5375b59c207e">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzUtMS0xLTEtMjM5NDEx_478394e4-4206-4ebc-8528-849c90e85714">886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8f31a92ecac49d98787199739713426_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzUtMy0xLTEtMjM5NDEx_33dffda4-fb3e-4220-8966-e174b5729f92">1,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzYtMS0xLTEtMjM5NDEx_74837fac-bd35-4f0d-8ba7-2c646976a1f1">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzYtMy0xLTEtMjM5NDEx_000871a0-f380-4339-bea2-54892c0a1401">535</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i993e4902e3144a5bb0fd1d2340dcc042_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzU1OTg_8924e588-482e-42a8-aaa4-604a56666781">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div></ix:continuation><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwODU_9756ae88-ae91-46c3-ab06-4539ded87f1f" continuedAt="i7adb35e67e9d47aeba94e456ad459e12" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb971d5ee0074937ab22b8a564419c1a_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzEtMS0xLTEtMjM5NDEx_af05e903-d452-44dd-9f39-4fe5417a4ba3">28,992</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f93e137bed843d5bbce9e33653971d9_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzEtMy0xLTEtMjM5NDEx_e24602a4-a71b-43dc-beb6-b93ea2cb1833">26,409</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314103e38f99480eb96ce0c421f83746_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzItMS0xLTEtMjM5NDEx_cf04588b-071e-4e81-b18b-6cd3919f1cc9">10,757</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88445aacaa14c91a809313e59ddaf22_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzItMy0xLTEtMjM5NDEx_f786933c-567b-4a2d-9d98-86395631786b">11,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16af340395d846e2827ed3fc620c2fad_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzMtMS0xLTEtMjM5NDEx_bf46d7be-b649-416b-b713-69235db53d79">4,733</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6f162e7cb341e5a022eee6d2ce58ad_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzMtMy0xLTEtMjM5NDEx_6063b5b2-94da-4ab8-a00a-dc1b90a6f582">5,837</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzQtMS0xLTEtMjM5NDEx_c4a1a910-a255-4728-9c37-bc79433a9542">44,482</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzQtMy0xLTEtMjM5NDEx_df37af81-036e-4b77-9494-89c0534209d8">43,878</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i9bbe13b6130c4bb89644a75e75b3d9e0" continuedAt="ide9a956196aa4110b24ee6e53caa253a"><ix:continuation id="i7adb35e67e9d47aeba94e456ad459e12" continuedAt="ibf09db75148443b29638aee0535b6f83">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:continuation id="ide9a956196aa4110b24ee6e53caa253a"><ix:continuation id="ibf09db75148443b29638aee0535b6f83">Medical reflects cumulative $<ix:nonFraction unitRef="usd" contextRef="i2c0539d106574706b4942868128b486d_D20220701-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzI3NDg3NzkwODQxNDY_2cfe9942-9863-402b-989d-f480e49dc794">863</ix:nonFraction>&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the three and six months ended December 31, 2022, respectively.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i495abb9913e04abfaa8f722b6757199b_124"></div><ix:nonNumeric contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0NDk_f8326496-43cc-4f4b-87d4-76604a31d4fe" continuedAt="ic96ad3a6eadd42fc8b4537c1c6d14713" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0NTg_afaba51f-14e1-4f09-8943-31c1fb80e0e7" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724588d9b5744663ab373f331e1884cc_D20221001-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzItMS0xLTEtMjM5NDEx_9d17558a-9784-4cef-9704-27f454be3c4d">15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d56087f747e42769e4b2bcea6e62a75_D20211001-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzItMy0xLTEtMjM5NDEx_c5707031-628d-4f59-ad46-eea71358c60c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd307c58e2c24994829573b1f3f8a6a7_D20221001-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzQtMS0xLTEtMjM5NDEx_94fa52e5-ef55-424a-92b3-f1b61d172cb8">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc2a7c414ff419388ee2bf7c1a9ffdf_D20211001-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzQtMy0xLTEtMjM5NDEx_cef8426c-a515-46f5-846d-e23e63949590">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzUtMS0xLTEtMjM5NDEx_01dbd233-233e-4a63-bfa6-21f73217ee98">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzUtMy0xLTEtMjM5NDEx_73146ec8-1f1d-4187-bba4-0c19447d6c22">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzItMS0xLTEtMjM5NDEx_fc1455ab-11b5-4cf2-9da4-e7f3ed37f92f">32</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78decb5962f2469ba0f935238a752f02_D20210701-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzItMy0xLTEtMjM5NDEx_0f7089b7-e00b-4be0-97bf-da8b19e89ed8">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzQtMS0xLTEtMjM5NDEx_109c5a49-d943-4ae6-83e7-d899b6d8a6f3">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a85160188a49a1a63acb55c053b255_D20210701-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzQtMy0xLTEtMjM5NDEx_0d2189f2-f079-4f1c-804e-e4acab10601d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzUtMS0xLTEtMjM5NDEx_6c0b192f-5f0c-4099-a5ed-b111c4351549">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzUtMy0xLTEtMjM5NDEx_dc02e7ec-8f39-4bf7-9800-7289d8c7ebd3">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI5Mw_85320fbe-5505-437f-bf65-43a951e6a54b">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc75351148f9471193785633b036daec_D20211001-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzMwMA_7dca1607-bd48-4aa5-bdd9-d55a08a2ea59">2</ix:nonFraction> million for the three months ended December&#160;31, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzM1OQ_d0c3b8fb-964d-4e09-bd6e-11cd82afdea8">6</ix:nonFraction> million for both the six months ended December&#160;31, 2022 and 2021.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzUwMQ_0a38b31c-e8ad-4c94-8e10-78aa4153c861">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ic96ad3a6eadd42fc8b4537c1c6d14713"><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0NTk_18a61811-f237-4e69-9237-04f1b2a37689" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i503ea8a68f26416685bd1508d35865c3_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzEtMS0xLTEtMjM5NDEx_d33ace62-f63c-4cfb-b37f-1395af0e7cf5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i503ea8a68f26416685bd1508d35865c3_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzEtMy0xLTEtMjM5NDEx_71a9aa68-b895-4eaa-803d-fbae0407b363">46.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzItMS0xLTEtMjM5NDEx_2fe26a6d-b4e3-4dd2-9ef5-16f96d9ec987">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzItMy0xLTEtMjM5NDEx_80d79e13-2de7-4b25-8b0e-c1613b7f7e82">70.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzMtMS0xLTEtMjM5NDEx_6f20d7e0-4d4c-4ce5-bc6d-ee6cd5d16585">1.3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzMtMy0xLTEtMjM5NDEx_702dffaa-0ef3-4e61-adca-e40d8c023686">49.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzQtMS0xLTEtMjM5NDEx_7e22662c-b0cd-4bbb-928f-9c6fe1b67c3e">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzQtMy0xLTEtMjM5NDEx_aa7f6dec-f554-44f1-b01a-881837d9d130">57.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f2f86523a374ec7bcf6bf98d477b026_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzUtMS0xLTEtMjM5NDEx_8b67d704-cf4e-4ac7-8b79-bace9b9b1d47">2.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f2f86523a374ec7bcf6bf98d477b026_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzUtMy0xLTEtMjM5NDEx_76bcdd35-6a45-4bc9-a813-bea8a2dc3c30">56.86</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i5f2f86523a374ec7bcf6bf98d477b026_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzg0OA_f196bc78-02be-4d9f-88a9-f60d88b46d90">108</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzkyMQ_48bcdc4b-f911-41a2-b26a-efc39849b3c8">two years</ix:nonNumeric>.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE2NDc_a6d848d7-8e3f-4c83-b770-12cc731487e4">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="i5143d217945b451bb550ec1284ff9356_D20200701-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTA_24f91f61-2a9e-4ef0-8791-582c169ea148"><ix:nonFraction unitRef="number" contextRef="i52092b4628a84f24953a6d6e5f6106ee_D20220701-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTA_6ca42b74-79d7-479d-a51e-861534863fb7">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="ifbae0f89cc2e464880a6f49f34d3015f_D20210701-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTY_8c4c987b-cdbe-401a-a260-91aa1fc04586"><ix:nonFraction unitRef="number" contextRef="i8077e88c3a2248e0b130f3f465521df1_D20200701-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTY_97403093-87bb-49d9-9c37-16317776724a">240</ix:nonFraction></ix:nonFraction> percent of the target award amount for the fiscal 2020 and 2021 grants and <ix:nonFraction unitRef="number" contextRef="i52092b4628a84f24953a6d6e5f6106ee_D20220701-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4ODY_44128b11-3123-4ac8-9615-0c8f24607fbf">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i8bf7d991e3e1433e91f8172e38de1cf0_D20220701-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4OTI_1b464551-61c3-4654-a771-82d275778c69">234</ix:nonFraction> percent for the fiscal 2022 and 2023 grants. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0OTE_2f10e63c-8bb2-4db6-bfa6-20dbeee5694a" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzEtMS0xLTEtMjM5NDEx_66f7477f-14f6-4395-937f-2953fe91996b">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzEtMy0xLTEtMjM5NDEx_471fa84a-4d64-4146-8be4-382c924aca1a">54.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzItMS0xLTEtMjM5NDEx_1932c111-54e1-4663-87f9-80ceecfcf7f9">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzItMy0xLTEtMjM5NDEx_0ed8fe6a-25d4-407b-9ce3-f6b502bd92b9">76.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzMtMS0xLTEtMjM5NDEx_51753727-4ee9-41bb-bd0b-8840c8ad198c">0.4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzMtMy0xLTEtMjM5NDEx_c61b7f9e-9390-404b-9bc2-adfbd022d75c">59.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzQtMS0xLTEtMjM5NDEx_983564b4-fb2f-41d3-ae7d-cce2823741b8">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzQtMy0xLTEtMjM5NDEx_d3ba5c72-5e1f-493e-8cbe-e8954dc2ea98">64.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc9a8d5ad3844888a89cd82186360d79_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzUtMS0xLTEtMjM5NDEx_1117bb9e-5cb6-45cf-a0a8-5fd278da4a66">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc9a8d5ad3844888a89cd82186360d79_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzUtMy0xLTEtMjM5NDEx_41dd1b3a-f817-41a1-9fe3-d97514cd65fd">76.49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="idc9a8d5ad3844888a89cd82186360d79_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzIzMDA_66c869a0-3041-47cf-8492-159a75829c86">41</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzIzNzM_83489766-162d-41d9-bf37-4c1b33cfd6da">two years</ix:nonNumeric> if performance goals are achieved.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations, as amended  (incorporated by reference to Exhibit 3.2 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm">Aircraft Time Sharing Agreement, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm">dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm"> as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm">November 7,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm"> 2022, by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm">among</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm"> Cardinal Health, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit101.htm">Jason M. Hollar</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit102.htm">Second</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit102.htm"> Amendment to the Cardinal Health Deferred Compensation Plan, as amended and restated on January 1, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xexhibit102.htm">2020, dated November 4, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000181/altofferletter.htm">Offer Letter (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on December 19, 2022, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000181/altcbpagreement.htm">Confidentiality and Business Protection Agreement (incorporated by reference to Exhibit 10.2 to Cardinal Health's Current Report on Form 8-K filed on December 19, 2022, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xex3111.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xex3121.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xex3211.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q2_10qx123122xex9911.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_64">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_64">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_43">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_43">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_46">21</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_49">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_52">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_58">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_58">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_127">44</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i495abb9913e04abfaa8f722b6757199b_133">46</a></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i495abb9913e04abfaa8f722b6757199b_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.182%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;PATRICIA M. ENGLISH</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patricia M. English</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a23q2_10qx123122xexhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i29e3e9e816934cbba647bfa0dc01f05d_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AIRCRAFT TIME SHARING AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Aircraft Time Sharing Agreement (&#8220;Agreement&#8221;) by and between Cardinal Health, Inc. (&#8220;Operator&#8221;), an Ohio corporation whose address is 7000 Cardinal Place, Dublin, Ohio 43017 and Jason M. Hollar (&#8220;User&#8221;), whose address is 7000 Cardinal Place, Dublin, Ohio 43017 (collectively the &#34;Parties&#34;), is effective November 7, 2022, and shall terminate on December 31, 2025, unless terminated sooner by either party pursuant to Article 1 below.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, Operator has the right of possession of the aircraft (&#8220;Aircraft&#8221;) described in the Leased Aircraft Subject to the Aircraft Time Sharing Agreement attached hereto and made a part hereof, as Exhibit A&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, Operator employs a fully qualified flight crew to operate the Aircraft&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, Operator desires to provide to User, and User desires to have the use of said Aircraft with flight crew on a non-exclusive time sharing basis as defined in Section 91.501(c)(1) of the Federal Aviation Regulations (&#34;FAR&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, this Agreement sets forth the understanding of the Parties as to the terms under which Operator will provide User with the use, on a periodic basis, of the Aircraft as described in Exhibit A hereto, currently operated by Operator&#59; and </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, the use of the Aircraft will at all times be pursuant to and in full compliance with the requirements of Part 91 (General Operating and Flight Rules) of FAR&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the Parties agree as follows&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1. Termination. </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Either party may terminate this Agreement for any reason upon written notice to the other, such termination to become effective thirty (30) days from the date of the notice&#59; provided that this Agreement may be terminated on such shorter notice as may be required to comply with applicable laws, regulations, insurance requirements or in the event the insurance required hereunder is not in full force and effect.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2. Use of Aircraft. </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) User acknowledges that Operator uses the Aircraft primarily for its business and that such business use always has priority.  User may use the Aircraft from time to time, with the permission and approval of Operator's Flight Operations Department, for all lawful purposes allowed by FAR Part 91 (General Operating and Flight Rules) at such times as the Operator does not require the use of the Aircraft for the business purposes of Operator or an affiliate.  User shall be permitted to have guests accompany him on such flights. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) User represents, warrants, and covenants to Operator that&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.         User shall use each Aircraft for and on his own account only and shall not use any Aircraft for the purposes of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;providing transportation of passengers or cargo in air commerce for compensation or hire and shall not accept any reimbursement from a passenger or otherwise for charges under this Agreement&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.             User shall refrain from incurring any mechanics lien or other lien in connection with inspection, preventative maintenance, maintenance or storage of the Aircraft, whether permissible or impermissible under this Agreement, and User shall not attempt to convey, mortgage, assign, lease or any way alienate the Aircraft or create any kind of lien or security interest involving the Aircraft or do anything or take any action that might mature into such a lien&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.           During the term of this Agreement, User will abide by and conform to all such laws, governmental and airport orders, rules and regulations as shall from time to time be in effect relating in any way to the operation and use of the Aircraft by a time-sharing User. </font></div><div style="text-indent:31.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) User shall provide Operator's Flight Operations Department with notice of his desire to use the Aircraft and proposed flight schedules pursuant to and in accordance with Operator&#8217;s Corporate Aircraft Utilization Policy, as amended from time to time.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Operator shall have sole and exclusive authority over the scheduling of the Aircraft, including whether an Aircraft is available and which Aircraft is used for any particular flight. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e) Operator shall not be liable to User or any other person for loss, injury or damage occasioned by the delay or failure to furnish the Aircraft and crew pursuant to this Agreement for any reason.  </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3. Time-Sharing Arrangement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is intended that this Agreement is and will meet the requirements of a &#34;Time Sharing Agreement&#34; as that term is defined in FAR Section 91.501(c)(1). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4. Cost of Use of Aircraft. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) In exchange for use of the Aircraft, User shall pay the following amounts for each flight, pursuant to FAR Section 91.501(d)&#58; </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)        The cost of fuel, oil, lubricants and other additives. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)       Travel expenses of the crew, including food, lodging and ground transportation.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)       Hangar and tie-down costs when the Aircraft is required by the User to be away from the Aircraft's base of &#160;&#160;&#160;&#160;operation. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)        Insurance obtained for the specific flight.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5)        Landing fees, airport taxes and similar assessments. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)        Customs, foreign permit and similar fees directly related to the flight.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(7)        In flight food and beverages. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(8)        Passenger ground transportation. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9)        Flight planning and weather contract services. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)      An additional charge comprised of the allocable share attributable to such flight of the average quarterly cost of trip-related repairs and maintenance and other similar incremental costs, which shall not exceed 100% of the expenses listed in Paragraph 4(a)(1).</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Operator will invoice, and User will pay, for all appropriate charges. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) In addition to the rate referenced in Paragraph 4(a) above, User shall also be assessed the Federal Excise Taxes as imposed under Section 4261 of the Internal Revenue Code and any applicable state and local taxes associated with such flight(s) required by law to be collected and remitted by Operator (&#34;Transportation Taxes&#34;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5. Invoicing and Payment. </font></div><div><font><br></font></div><div style="text-indent:0.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All payments to be made to Operator by User hereunder shall be paid in the manner set forth in this Paragraph 5.  Operator will pay to suppliers, employees, contractors, and government entities all expenses related to the operation and maintenance of the Aircraft hereunder in the ordinary course.  For all flights operated hereunder in each calendar month, Operator shall provide to User an initial invoice for the charges specified in Paragraph 4 of this Agreement (including Transportation Taxes), such invoice to be issued within thirty (30) days after the end of the calendar month in which such flights were completed.  The initial invoice for the costs specified in Paragraph 4(a) above may be based, in whole or in part, on average or estimated costs subject to reconciliation as provided in this Paragraph 5.  User shall pay Operator the full amount of such monthly invoice within thirty (30) days after receipt of the invoice.  After the completion of each calendar quarter, Operator shall also provide to User final invoices for all flights operated hereunder in each calendar month of such calendar quarter.  Such final invoices will be based on the actual costs for such flights, based on the billings received by Operator from third party vendors.  To the extent that User is required to pay Operator any additional amounts under the final invoices, it will do so within thirty (30) days after receipt of the final invoice.  In the event that the final invoice reduces the amounts paid as reimbursement under the initial invoices for such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">flights, the Operator shall return any overage or provide a credit to the User.  All invoices shall separately itemize the expenses in items (1) through (10) of Paragraph 4(a) for the collective flights included in that invoice.  User shall further pay all costs incurred by Operator in collecting any amounts due from User pursuant to the provisions of this Paragraph 5 after delinquency, including court costs and reasonable attorneys' fees.</font></div><div style="text-indent:0.2pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6. Insurance and Limitation of Liability. </font></div><div><font><br></font></div><div style="text-indent:0.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator represents that the flight operations for the Aircraft as contemplated in this Agreement will be covered by the Operator's aircraft all-risk physical damage insurance (hull coverage), aircraft bodily injury and property damage liability insurance, passenger, pilot and crew voluntary settlement insurance and statutory workers compensation and employer's liability insurance. </font></div><div style="text-indent:0.2pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) Insurance. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.         Operator will maintain or cause to be maintained in full force and effect throughout the term of this Agreement aircraft liability insurance in respect of the Aircraft in an amount at least equal to $100 million combined single limit for bodily injury to or death of persons (including passengers) and property damage liability.  Operator will retain all rights and benefits with respect to the proceeds payable under policies of hull insurance that may be payable as a result of any incident or occurrence while an Aircraft is being operated on behalf of User under this Agreement. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.             Operator shall use best efforts to procure such additional insurance coverage as User may request naming User as an additional insured&#59; provided, that the cost of such additional insurance shall be borne by User pursuant to Paragraph 4(a)(4) hereof. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Limitation of Liability.  User agrees that the insurance specified in paragraph 6(a) shall provide its sole recourse for all claims, losses, liabilities, obligations, demands, suits, judgments or causes of action, penalties, fines, costs and expenses of any nature whatsoever, including attorneys' fees and expenses for or on account of or arising out of, or in any way connected with, the use of the Aircraft by User, family members or guests, including injury to or death of any persons, including User, family members and guests which may result from or arise out of the use or operation of the Aircraft during the term of this Agreement (&#34;Claims&#34;).  This Paragraph 6 shall survive termination of this Agreement. </font></div><div><font><br></font></div><div style="text-indent:0.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) User agrees that when, in the reasonable view of Operator's Flight Operations Department or the pilots of the Aircraft, safety may be compromised, Operator or the pilots may terminate a flight, refuse to commence a flight or take other action necessitated by such safety considerations without liability for loss, injury, damage or delay. </font></div><div style="text-indent:0.2pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) In no event shall Operator be liable to User or his family members, employees, agents, representatives, guests or invitees for any claims or liabilities, including property damage or injury and death, and expenses, including attorney's fees, in excess of the amount paid by Operator's insurance carrier in the event of such loss. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e) OPERATOR SHALL IN NO EVENT BE LIABLE TO USER OR HIS FAMILY MEMBERS, EMPLOYEES, AGENTS, REPRESENTATIVES, GUESTS OR INVITEES FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES AND&#47;OR PUNITIVE DAMAGES OF ANY KIND OR NATURE UNDER ANY CIRCUMSTANCES OR FOR ANY REASON INCLUDING ANY DELAY OR FAILURE TO FURNISH THE AIRCRAFT OR CAUSED OR OCCASIONED BY THE PERFORMANCE OR NON-PERFORMANCE OF ANY SERVICES COVERED BY THIS AGREEMENT. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7. Covenants Regarding Aircraft Maintenance. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator shall, at its own expense, inspect, maintain, service, repair, overhaul and test the Aircraft in accordance with FAR Part 91.  Each Aircraft will remain in good operating condition and in a condition consistent with its airworthiness certification, including all FAA-issued airworthiness directives and mandatory service bulletins.  In the event that any non-standard maintenance is required at a time when a flight has been scheduled for User, Operator or Operator's Pilot-In-Command shall immediately notify User of the maintenance required, the effect on the ability to comply with User's dispatch requirements and the manner in which the Parties will proceed with the performance of such maintenance and conduct of the balance of the planned flight(s). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8. No Warranty. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NEITHER OPERATOR (NOR ITS AFFILIATES) MAKES, HAS MADE OR SHALL BE DEEMED TO MAKE OR HAVE MADE ANY WARRANTY OR REPRESENTATION, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, WITH RESPECT TO ANY </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AIRCRAFT TO BE USED HEREUNDER OR ANY ENGINE OR COMPONENT THEREOF, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY AS TO DESIGN, COMPLIANCE WITH SPECIFICATIONS, QUALITY OF MATERIALS OR WORKMANSHIP, MERCHANTABILITY, FITNESS FOR ANY PURPOSE, USE OR OPERATION, AIRWORTHINESS, SAFETY, PATENT, TRADEMARK OR COPYRIGHT INFRINGEMENT OR TITLE. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9. Operational Control. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator shall be responsible for the physical and technical operation of the Aircraft and the safe performance of all flights and shall retain full authority and control, including exclusive operational control, and possession of the Aircraft at all times during the term of this Agreement.  In accordance with applicable FARs, the qualified flight crew provided by Operator will exercise all required and&#47;or appropriate duties and responsibilities regarding the safety of each flight conducted hereunder.  The Pilot-In-Command shall have absolute discretion in all matters concerning the preparation of the Aircraft for flight and the flight itself, the load carried and its distribution, the decision whether or not a flight shall be undertaken, the route to be flown, the place where landings shall be made and all other matters relating to operation of the Aircraft.  User specifically agrees that the flight crew shall have final and complete authority to delay or cancel any flight for any reason or condition which, in sole judgment of the Pilot-In-Command, could compromise the safety of the flight and to take any other action which, in the sole judgment of the Pilot-In-Command, is necessitated by considerations of safety.  No such action of the Pilot-In-Command shall create or support any liability to User or any other person for loss, injury, damages or delay.  The Parties further agree that Operator shall not be liable for delay or failure to furnish the Aircraft and crew pursuant to this Agreement which is caused by government regulation or authority, mechanical difficulty or breakdown, war, civil commotion, strikes or labor disputes, weather conditions, acts of God or other circumstances beyond Operator's reasonable control.  User agrees that Operator's operation of aircraft is within the operation guidelines of the Operator's Flight Operations Department manual and the crews are responsible to operate within the guidelines of FAR 91 and the Operator's Flight Operations Department manual. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">10. Governing Law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Parties hereto acknowledge that this Agreement shall be governed by and construed in all respects in accordance with the laws of the State of Ohio. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11. Counterparts. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Agreement may be executed in one or more counterparts each of which will be deemed an original, all of which together shall constitute one and the same agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12. Notices and Communications.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All notices, requests, demands and other communications required or desired to be given hereunder shall be in writing (except as permitted pursuant to Paragraph 2(c)) and shall be deemed to be given&#58; (i) if personally delivered, upon such delivery&#59; (ii) if mailed by certified mail, return receipt requested, postage pre-paid, addressed as (to the extent applicable for mailing) listed in the preamble hereto, upon the earlier to occur of actual receipt, refusal to accept receipt or three (3) days after such mailing&#59; (iii) if sent by regularly scheduled overnight delivery carrier with delivery fees either prepaid or an arrangement, satisfactory with such carrier, made for the payment of such fees, addressed (to the extent applicable for overnight delivery) as listed in the preamble hereto, upon the earlier to occur of actual receipt or the next &#8220;Business Day&#8221; (as hereafter defined) after being sent by such delivery&#59; or (iv) upon actual receipt when sent by fax.  Notice given by other means shall be deemed to be given only upon actual receipt.  Addresses may be changed by written notice given as provided herein and signed by the party giving the notice. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">13. Further Acts. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator and User shall from time to time perform such other and further acts and execute such other and further instruments as may be required by law or may be reasonably necessary to&#58; (i) carry out the intent and purpose of this Agreement&#59; and (ii) establish, maintain and protect the respective rights and remedies of the other party. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">14. Successors and Assigns. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Neither this Agreement nor any party&#8217;s interest herein shall be assignable to any other party whatsoever, except that Operator may assign its interest to an affiliate without the consent of the User.  This Agreement shall inure to the benefit of and be binding upon the Parties hereto, their heirs, representatives and successors. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">15. Severability. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event that any one or more of the provisions of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable, those provisions shall be replaced by provisions acceptable to both Parties to this Agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">16. Flight Crew. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator is responsible for providing a qualified flight crew for all flight operations under this Agreement.  The Operator will furnish two experienced and competent pilots who shall be under the direction and control of the Operator at all times. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">17. Taxes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Parties acknowledge that reimbursement of all items specified in Paragraph 4, except for subsections (a)(7) and (a)(8) thereof, are subject to the Transportation Taxes.  User shall pay to Operator (for payment to the appropriate governmental agency) any Transportation Taxes applicable to flights of the Aircraft conducted hereunder.  Operator shall indemnify User for any claims related to the Transportation Taxes to the extent that User has paid Operator the amounts necessary to pay such taxes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">18. Right of Possession. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator has the right of possession to each Aircraft in Exhibit A pursuant to an Aircraft Lease Agreement.  Nothing herein shall constitute a transfer of Operator's possessory rights to the Aircraft. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">19. Truth-in-Leasing. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Operator shall mail a copy of this Agreement for and on behalf of both Parties to&#58; Federal Aviation Administration, Aircraft Registration Branch (AFS-750), Attention&#58; Technical Section, P.O. Box 25724, Oklahoma City, Oklahoma 73125, within twenty-four (24) hours of its execution, as provided by FAR 91.23 (c)(1).  Additionally, Operator agrees to comply with the notification requirements of FAR Section 91.23 by notifying by telephone or in person the FAA Flight Standards Office nearest to the originating point of the first flight under this Agreement at least forty-eight (48) hours prior to such flight. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) OPERATOR CERTIFIES THAT EACH AIRCRAFT HAS BEEN INSPECTED AND MAINTAINED WITHIN THE 12-MONTH PERIOD PRECEDING THE DATE OF THIS AGREEMENT IN ACCORDANCE WITH THE PROVISIONS OF PART 91 OF THE FEDERAL AVIATION REGULATIONS AND THAT ALL APPLICABLE REQUIREMENTS FOR EACH AIRCRAFT'S MAINTENANCE AND INSPECTION HEREUNDER WILL BE MET AND ARE VALID FOR THE OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT DURING THE DURATION OF THIS AGREEMENT. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) OPERATOR, WHOSE ADDRESS APPEARS AND AUTHORIZED SIGNATURE APPEARS BELOW, AGREES, CERTIFIES AND ACKNOWLEDGES THAT WHENEVER EACH AIRCRAFT IS OPERATED UNDER THIS AGREEMENT, OPERATOR SHALL BE KNOWN AS, CONSIDERED AND SHALL IN FACT BE THE OPERATOR OF THE AIRCRAFT AND THAT OPERATOR UNDERSTANDS ITS RESPONSIBILITIES FOR COMPLIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) THE PARTIES UNDERSTAND THAT AN EXPLANATION OF FACTORS AND PERTINENT FEDERAL AVIATION REGULATIONS BEARING ON OPERATIONAL CONTROL CAN BE OBTAINED FROM THE RESPONSIBLE FAA FLIGHT STANDARDS OFFICE. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) OPERATOR AGREES TO KEEP A COPY OF THIS AGREEMENT IN THE AIRCRAFT AT ALL TIMES DURING THE TERM OF THIS AGREEMENT.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the Parties hereto have each caused this Agreement to be duly executed on November 7, 2022. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OPERATOR&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Carrie S. Cox</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">_______________________</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;   Carrie S. Cox</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58;    Chair of the Human Resources and Compensation Committee of the Board of Directors</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">USER&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jason M. Hollar </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jason M. Hollar</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">______________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Leased Aircraft Subject to Aircraft Time Sharing Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of the undersigned is a party to the Aircraft Time Sharing Agreement dated November 7, 2022, by and between Cardinal Health, Inc. (&#8220;Operator&#8221;) and Jason M. Hollar (&#8220;User&#8221;) (together the &#8220;Parties&#8221;), and agrees that from and after November 7, 2022, until this Exhibit A shall be superseded and replaced through agreement of the Parties or the Aircraft Time Sharing Agreement shall be terminated pursuant to its terms, the Aircraft described below shall constitute the &#8220;Aircraft&#8221; described in and subject to the terms of the Aircraft Time Sharing Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N600CH 2019 EMB-550 Serial#054</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N200CH 2016 Falcon 2000LXS Serial#319</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OPERATOR&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Carrie S. Cox</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">_______________________</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;   Carrie S. Cox</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58;    Chair of the Human Resources and Compensation Committee of the Board of Directors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">USER&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jason M. Hollar</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jason M. Hollar</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">______________________</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a23q2_10qx123122xexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic1efff44c70444f190e01962067afe9b_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SECOND AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH DEFERRED COMPENSATION PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(As Amended and Restated January 1, 2020)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Background Information</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A.         Cardinal Health, Inc. (&#8220;Cardinal Health&#8221;) previously adopted and currently maintains the Cardinal Health Deferred Compensation Plan (the &#8220;Plan&#8221;) for the benefit of a select group of management and highly compensated employees of Cardinal Health and its subsidiaries and affiliates.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B.         Section 7.1 of the Plan provides that the Plan may be amended at any time through a written resolution adopted or approved by the Financial Benefit Plans Committee (&#8220;FBPC&#8221;), with respect to any amendment that, when aggregated with any other amendment or amendments approved on the same date, is reasonably expected to have an annual financial impact on Cardinal Health of $5 million or less.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C.        The FBPC has concluded that the amendment set forth below, when aggregated with any other amendments set to be approved on the same date, is reasonably expected to have an annual financial impact on Cardinal Health of less than $5 million.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">D.        The FBPC desires to amend the Plan, effective for calendar years commencing on and after January 1, 2023, to&#58; (1) change the &#8220;Eligibility Effective Date&#8221; for individuals who become Eligible Employees on or after January 1, 2023&#59; and (2) provide that deferral election percentages will carry over each year unless changed by the participant.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Amendment of the Cardinal Health Deferred Compensation Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Plan is hereby amended as set forth below, effective as of January 1, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.         Section 2.1 of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">            &#8220;2.1  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General Eligibility Conditions</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To become eligible to participate in the Plan, an individual must be (i) a Director, or (ii) an Eligible Employee.  In order to receive a benefit under the Plan, however, a Participant must also meet the requirements of Sections 2.2 and 2.3.  An Eligible Employee or a Director shall be considered eligible to participate in the Plan effective as of the date he first becomes a Director or an Eligible Employee in accordance with this Plan (the &#8220;Eligibility Effective Date&#8221;). Notwithstanding the foregoing, effective for each individual who becomes an Eligible Employee in a Plan Year commencing on or after January 1, 2023, the immediately preceding sentence shall not apply, and such Eligible Employee shall be considered eligible to participate in the Plan effective as of (and his or her &#8220;Eligibility Effective Date&#8221; shall be)&#58; (1) April 1, if such individual first becomes an Eligible Employee in the preceding November, December, January, February, or March&#59; (2) August 1, if such individual first becomes an Eligible Employee in the preceding April, May, June, or July&#59; or (3) January 1, if such individual first becomes an Eligible Employee in the preceding August, September, or October.  Any Participation Agreement entered with respect to an Eligibility Effective Date of April 1 or August 1 shall not take effect until the end of the 30-day period commencing on the applicable Eligibility Effective Date.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.         Section 3.1 of the Plan is hereby amended to add the following paragraph to the end thereof&#58;</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Effective for Plan Years commencing on or after January 1, 2024, unless otherwise elected by a Participant prior to the beginning of the applicable Plan Year (or at such other time as may be specified under regulations issued under Code Section 409A) in accordance with procedures established by the Administrative Committee, a Participant&#8217;s deferral election percentages for Compensation earned in such Plan Year shall be the same as the deferral election percentages applicable to such Participant&#8217;s Compensation earned in the immediately preceding Plan Year.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.         All other provisions of the Plan shall remain in full force and effect.</font></div><div><font><br></font></div><div style="padding-left:180pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="padding-left:180pt;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH, INC.</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FINANCIAL BENEFIT PLANS COMMITTEE</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Kendell Sherrer ________________</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58;  ________________________________</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">_________November 4, 2022_______</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a23q2_10qx123122xex3111.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i84cefe1c4302427196c84e19ad88ff9c_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;2, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a23q2_10qx123122xex3121.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie34c9ef0e3c44b1c9ddbc97bbae71cea_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Patricia M. English, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;2, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PATRICIA M. ENGLISH</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia M. English</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a23q2_10qx123122xex3211.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iccf9a1d5e02c4d6c8279a1e80cc430f1_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jason M. Hollar, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Patricia M. English, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended December&#160;31, 2022 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;2, 2023 </font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PATRICIA M. ENGLISH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia M. English</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>a23q2_10qx123122xex9911.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i05db2dcfddbc4e9ca971c488abaf5ba1_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2022 (the &#8220;2022 Form 10-K&#8221;), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significantly increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the Department of Justice which we believe concern our anti-diversion program, our anti-diversion policies and procedures and our distribution of certain controlled substances&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the national settlement agreement to resolve the vast majority of opioid-related claims brought by states and other governmental entities, including the risk that the implementation and maintenance of the required changes to distributors' controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility of additional adverse impacts to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with industry reliance on ethylene oxide (&#34;EtO&#34;) to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages&#59; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact our customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties associated with states' proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the risk that we may not effectively implement and maintain data governance structures across businesses to allow us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that our business performance or internal control over financial reporting may be adversely impacted if we are not successful at attracting, retaining and developing talent&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the importation of products or source materials used in products that we manufacture or distribute, including risks associated with our country-of-origin determinations and the possibility that we could experience supply disruptions as a result of the Uyghur Forced Labor Prevention Act&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">certain risks arising from the ongoing COVID-19 pandemic&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2022 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cah-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de10429f-68bb-4228-9960-cf0499f5ed93,g:6028fbd5-3398-4741-87cc-7f6715aa56e4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>0000002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.cardinal.com/role/Divestitures">
        <link:definition>0000009 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>0000010 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>0000011 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>0000014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>0000015 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>0000016 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>0000017 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>0000019 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>0000020 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsTables" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables">
        <link:definition>0000022 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>0000023 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>0000024 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsTables" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables">
        <link:definition>0000025 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>0000026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>0000027 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>0000028 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>0000029 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>0000030 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails">
        <link:definition>0000032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsDetails" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails">
        <link:definition>0000033 - Disclosure - Discontinued Operations and Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>0000034 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>0000035 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails">
        <link:definition>0000036 - Disclosure - Restructuring and Employee Severance Narative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>0000037 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000038 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails">
        <link:definition>0000040 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
        <link:definition>0000041 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails">
        <link:definition>0000042 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000043 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>0000044 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000045 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>0000046 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>0000047 - Disclosure - Shareholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000048 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>0000049 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>0000050 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000051 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>0000052 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>0000053 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
        <link:definition>0000054 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>0000055 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>0000056 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>0000057 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>0000058 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>0000059 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>0000060 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>0000061 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LawsuitTypeDomain" abstract="true" name="LawsuitTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_CordisDivestitureDomain" abstract="true" name="CordisDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeMember" abstract="true" name="CardinalHealthAtHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CARESActDomain" abstract="true" name="CARESActDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CordisDivestitureAxis" abstract="true" name="CordisDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NarativeAbstract" abstract="true" name="NarativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NativeAmericanTribesMember" abstract="true" name="NativeAmericanTribesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" abstract="false" name="SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackAxis" abstract="true" name="NetOperatingLossCarrybackAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_GoodwillImpairmentAxis" abstract="true" name="GoodwillImpairmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MaturityDateAxis" abstract="true" name="MaturityDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthSolutionsMember" abstract="true" name="NuclearPrecisionHealthSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_A300MillionShareRepurchaseProgramMember" abstract="true" name="A300MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMattersAgreementAxis" abstract="true" name="TaxMattersAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MaturityDateDomain" abstract="true" name="MaturityDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IncomefromSettlementsofClassActionLawsuits" abstract="false" name="IncomefromSettlementsofClassActionLawsuits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ShareholderDerivativeLitigationMember" abstract="true" name="ShareholderDerivativeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" abstract="true" name="LongTermObligationsandOtherShortTermBorrowingsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_A500MillionShareRepurchaseProgramMember" abstract="true" name="A500MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_JudgmentForLostProfits" abstract="false" name="JudgmentForLostProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MedicalUnitGoodwillImpairmentMember" abstract="true" name="MedicalUnitGoodwillImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SettlingStates" abstract="false" name="SettlingStates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_TotalLongTermandShortTermObligations" abstract="false" name="TotalLongTermandShortTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_DiscountRateFairValueInput" abstract="false" name="DiscountRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_GoodwillImpairmentDomain" abstract="true" name="GoodwillImpairmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CordisDivestitureMember" abstract="true" name="CordisDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_GrossInsuranceSettlementBeforeAttorneyFees" abstract="false" name="GrossInsuranceSettlementBeforeAttorneyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CashReclassifiedToAssetHeldForSale" abstract="false" name="CashReclassifiedToAssetHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TerminalGrowthRateFairValueInput" abstract="false" name="TerminalGrowthRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_MedicalUnitMember" abstract="true" name="MedicalUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SettlingUSTerritories" abstract="false" name="SettlingUSTerritories" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A250MillionShareRepurchaseProgramMember" abstract="true" name="A250MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TaxMattersAgreementDomain" abstract="true" name="TaxMattersAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A1BillionShareRepurchaseProgramMember" abstract="true" name="A1BillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cah-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de10429f-68bb-4228-9960-cf0499f5ed93,g:6028fbd5-3398-4741-87cc-7f6715aa56e4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_0a473927-b14f-4656-8963-4417739e4448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5539b243-5508-41d6-aa19-3f68b42a6c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0a473927-b14f-4656-8963-4417739e4448" xlink:to="loc_us-gaap_Revenues_5539b243-5508-41d6-aa19-3f68b42a6c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c1865d94-e0f7-4970-965b-722a47d50571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0a473927-b14f-4656-8963-4417739e4448" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c1865d94-e0f7-4970-965b-722a47d50571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a88d4666-95e7-4393-b15a-0b91d36f1f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_54d2ab5e-fe7e-497d-82f0-d0690e1cb127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a88d4666-95e7-4393-b15a-0b91d36f1f52" xlink:to="loc_us-gaap_OperatingIncomeLoss_54d2ab5e-fe7e-497d-82f0-d0690e1cb127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_96437a2c-4db8-4a81-8328-3b3440734de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a88d4666-95e7-4393-b15a-0b91d36f1f52" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_96437a2c-4db8-4a81-8328-3b3440734de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7b6a3409-bb1b-4033-90d3-28b3bef7b6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a88d4666-95e7-4393-b15a-0b91d36f1f52" xlink:to="loc_us-gaap_InterestExpense_7b6a3409-bb1b-4033-90d3-28b3bef7b6e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81e19d25-3172-42fe-a009-08bcbcf4f298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a88d4666-95e7-4393-b15a-0b91d36f1f52" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81e19d25-3172-42fe-a009-08bcbcf4f298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_9932339f-b38f-4348-b168-cbe75f4f08d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a88d4666-95e7-4393-b15a-0b91d36f1f52" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_9932339f-b38f-4348-b168-cbe75f4f08d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f3d9dfa7-aedb-4295-a7d5-ee7d8e7b6791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79a40da4-42a6-48d4-877a-1caa1ca88337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f3d9dfa7-aedb-4295-a7d5-ee7d8e7b6791" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79a40da4-42a6-48d4-877a-1caa1ca88337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9444364d-af02-4cda-af68-9f0bc9ec62a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f3d9dfa7-aedb-4295-a7d5-ee7d8e7b6791" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9444364d-af02-4cda-af68-9f0bc9ec62a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5bb088aa-1fe4-494a-b685-2bcc7f590c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7d2a2a06-36eb-4932-ac0a-7cdee1be7907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5bb088aa-1fe4-494a-b685-2bcc7f590c09" xlink:to="loc_us-gaap_GrossProfit_7d2a2a06-36eb-4932-ac0a-7cdee1be7907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a613632-c3e3-4ce7-b8f9-5298fb3ba47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5bb088aa-1fe4-494a-b685-2bcc7f590c09" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a613632-c3e3-4ce7-b8f9-5298fb3ba47a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a27deac0-8a15-4640-b3ff-f728491fe485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5bb088aa-1fe4-494a-b685-2bcc7f590c09" xlink:to="loc_us-gaap_RestructuringCharges_a27deac0-8a15-4640-b3ff-f728491fe485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_bae0687f-6d62-4bbb-9097-94bd08f00cb5" xlink:href="cah-20221231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5bb088aa-1fe4-494a-b685-2bcc7f590c09" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_bae0687f-6d62-4bbb-9097-94bd08f00cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_3ebed0b0-8ab2-4f6f-b8c6-a7edfa40dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5bb088aa-1fe4-494a-b685-2bcc7f590c09" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_3ebed0b0-8ab2-4f6f-b8c6-a7edfa40dea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c87797e4-ca56-473d-ad00-3c3aa4656b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5bb088aa-1fe4-494a-b685-2bcc7f590c09" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c87797e4-ca56-473d-ad00-3c3aa4656b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f09aefab-1ecc-47ca-adbe-751ee64a25bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b6de12ba-1249-4bf7-b938-7b9b3f20c813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f09aefab-1ecc-47ca-adbe-751ee64a25bf" xlink:to="loc_us-gaap_ProfitLoss_b6de12ba-1249-4bf7-b938-7b9b3f20c813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ba259811-eb15-4502-b06a-aadfbd826128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f09aefab-1ecc-47ca-adbe-751ee64a25bf" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ba259811-eb15-4502-b06a-aadfbd826128" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_032f56c0-2aed-4cb1-a0f2-b3bf2680ad56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d6841072-05a9-4a17-afbc-61a8188a82db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_032f56c0-2aed-4cb1-a0f2-b3bf2680ad56" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d6841072-05a9-4a17-afbc-61a8188a82db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_631c23e2-e303-4b44-9ba8-0a6224f871d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_032f56c0-2aed-4cb1-a0f2-b3bf2680ad56" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_631c23e2-e303-4b44-9ba8-0a6224f871d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_90305be6-1e2e-41c5-8018-ea949692edad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_97d364ff-732a-48b1-836b-806099f1a822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_90305be6-1e2e-41c5-8018-ea949692edad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_97d364ff-732a-48b1-836b-806099f1a822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3ab1a287-934b-4ec6-b8b3-fa25cd2d7eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_90305be6-1e2e-41c5-8018-ea949692edad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3ab1a287-934b-4ec6-b8b3-fa25cd2d7eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_131a1bd0-5566-46e0-9729-dd17b96226f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4d3540cd-14f6-426d-ba9e-8f738cfa8626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_131a1bd0-5566-46e0-9729-dd17b96226f5" xlink:to="loc_us-gaap_ProfitLoss_4d3540cd-14f6-426d-ba9e-8f738cfa8626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_438a4b0c-1e69-4fb6-85f6-a1f20e5690c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_131a1bd0-5566-46e0-9729-dd17b96226f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_438a4b0c-1e69-4fb6-85f6-a1f20e5690c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c7b56589-fead-4588-bec3-19b12e46b2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_010ef532-fd88-4153-b269-3739a84fd9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7b56589-fead-4588-bec3-19b12e46b2a4" xlink:to="loc_us-gaap_AssetsCurrent_010ef532-fd88-4153-b269-3739a84fd9d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f44464a6-d05b-4793-a1f9-0f335fc2665d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7b56589-fead-4588-bec3-19b12e46b2a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f44464a6-d05b-4793-a1f9-0f335fc2665d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_49151ace-71e0-4204-9f4a-0dc4034a10b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7b56589-fead-4588-bec3-19b12e46b2a4" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_49151ace-71e0-4204-9f4a-0dc4034a10b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6ea9c147-4e49-44ed-9c7d-92cdf8c12b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7b56589-fead-4588-bec3-19b12e46b2a4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6ea9c147-4e49-44ed-9c7d-92cdf8c12b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b56ee4bf-a2ec-4c83-a1c3-04148e0b63aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7a1b5051-be40-4d4a-b0bf-48b89d698121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b56ee4bf-a2ec-4c83-a1c3-04148e0b63aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7a1b5051-be40-4d4a-b0bf-48b89d698121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8f1d9405-8870-4c7d-8fab-cec4504bce44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b56ee4bf-a2ec-4c83-a1c3-04148e0b63aa" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8f1d9405-8870-4c7d-8fab-cec4504bce44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_43d4c7f5-4b11-4344-b4ef-a64c4f34286e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b56ee4bf-a2ec-4c83-a1c3-04148e0b63aa" xlink:to="loc_us-gaap_InventoryNet_43d4c7f5-4b11-4344-b4ef-a64c4f34286e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_052ace01-3165-4c01-89b4-276097824a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b56ee4bf-a2ec-4c83-a1c3-04148e0b63aa" xlink:to="loc_us-gaap_OtherAssetsCurrent_052ace01-3165-4c01-89b4-276097824a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c85dccb9-79b4-4e9d-b1e3-334c1ada09ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_901e78f7-b08f-40fc-aada-c514d719d878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c85dccb9-79b4-4e9d-b1e3-334c1ada09ae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_901e78f7-b08f-40fc-aada-c514d719d878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6ba4d06c-3bab-4ac9-b0db-f917ff6caa82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c85dccb9-79b4-4e9d-b1e3-334c1ada09ae" xlink:to="loc_us-gaap_PreferredStockValue_6ba4d06c-3bab-4ac9-b0db-f917ff6caa82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e738b84-ea44-40e2-939c-9a0ecdb9dfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c85dccb9-79b4-4e9d-b1e3-334c1ada09ae" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e738b84-ea44-40e2-939c-9a0ecdb9dfba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_71416998-1db2-4e10-b6ec-4d96c23a57ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c85dccb9-79b4-4e9d-b1e3-334c1ada09ae" xlink:to="loc_us-gaap_CommonStockValue_71416998-1db2-4e10-b6ec-4d96c23a57ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_666d4646-2151-42e0-ac9b-e19b98cce3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c85dccb9-79b4-4e9d-b1e3-334c1ada09ae" xlink:to="loc_us-gaap_TreasuryStockValue_666d4646-2151-42e0-ac9b-e19b98cce3fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2a91da10-5013-4ab6-85c5-3b29c83dcd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_41fe62fa-99ec-421d-a4d7-d40c2244dcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2a91da10-5013-4ab6-85c5-3b29c83dcd33" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_41fe62fa-99ec-421d-a4d7-d40c2244dcf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6a8dd8ce-e01b-4349-af76-fbb5f139ae1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2a91da10-5013-4ab6-85c5-3b29c83dcd33" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6a8dd8ce-e01b-4349-af76-fbb5f139ae1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_68586ed8-d1cc-4432-85dc-8d6fbb916de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2a91da10-5013-4ab6-85c5-3b29c83dcd33" xlink:to="loc_us-gaap_AccountsPayableCurrent_68586ed8-d1cc-4432-85dc-8d6fbb916de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b0a3e3-8a41-405a-84f3-17fcc25ecb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_347af9e1-d6dd-43ab-a58b-13e2a3f8ef03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b0a3e3-8a41-405a-84f3-17fcc25ecb71" xlink:to="loc_us-gaap_CommonStockValue_347af9e1-d6dd-43ab-a58b-13e2a3f8ef03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_420148ef-ede7-4d84-8f38-8da55f4d87c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b0a3e3-8a41-405a-84f3-17fcc25ecb71" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_420148ef-ede7-4d84-8f38-8da55f4d87c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f86af42c-2d9a-46d8-a4db-aa0e2b334653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b0a3e3-8a41-405a-84f3-17fcc25ecb71" xlink:to="loc_us-gaap_TreasuryStockValue_f86af42c-2d9a-46d8-a4db-aa0e2b334653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c5e711b-6c65-4f95-8126-66eb1b88b9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b0a3e3-8a41-405a-84f3-17fcc25ecb71" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c5e711b-6c65-4f95-8126-66eb1b88b9b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_862d643c-bfe3-4f07-8cb4-23eda749db0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b0a3e3-8a41-405a-84f3-17fcc25ecb71" xlink:to="loc_us-gaap_MinorityInterest_862d643c-bfe3-4f07-8cb4-23eda749db0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e0444e0-dd66-4019-9e75-65ecbaeb55de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_69159aaf-6689-487e-8200-8e4119c9ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e0444e0-dd66-4019-9e75-65ecbaeb55de" xlink:to="loc_us-gaap_LiabilitiesCurrent_69159aaf-6689-487e-8200-8e4119c9ab64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_3c75999e-293d-42f7-8dc2-59fccbd2ae35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e0444e0-dd66-4019-9e75-65ecbaeb55de" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_3c75999e-293d-42f7-8dc2-59fccbd2ae35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_7350f5ec-e3bf-4348-813e-88f4c42249a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e0444e0-dd66-4019-9e75-65ecbaeb55de" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_7350f5ec-e3bf-4348-813e-88f4c42249a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_195a2f06-d69a-4343-92dc-a8c12aaef366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e0444e0-dd66-4019-9e75-65ecbaeb55de" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_195a2f06-d69a-4343-92dc-a8c12aaef366" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1707cdf0-9414-4fca-a4f7-7f1f8356e102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3bca8f1a-bfce-4432-ad52-b32a59ec123f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1707cdf0-9414-4fca-a4f7-7f1f8356e102" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3bca8f1a-bfce-4432-ad52-b32a59ec123f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_655855e5-7b68-4c92-ab63-454ca9b962be" xlink:href="cah-20221231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1707cdf0-9414-4fca-a4f7-7f1f8356e102" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_655855e5-7b68-4c92-ab63-454ca9b962be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_6e1f4960-9505-493e-9836-1d3188f69864" xlink:href="cah-20221231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1707cdf0-9414-4fca-a4f7-7f1f8356e102" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_6e1f4960-9505-493e-9836-1d3188f69864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1bd33348-e9de-40bc-96d5-ba9f5a8b3e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1707cdf0-9414-4fca-a4f7-7f1f8356e102" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1bd33348-e9de-40bc-96d5-ba9f5a8b3e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_eae50422-3b7f-4cad-a94d-462d253c6e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1707cdf0-9414-4fca-a4f7-7f1f8356e102" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_eae50422-3b7f-4cad-a94d-462d253c6e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_edefe988-8dd8-4f06-acec-744c8380a3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_ProfitLoss_edefe988-8dd8-4f06-acec-744c8380a3b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0dcfbcae-7c54-4e9a-99b9-097c616d7339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0dcfbcae-7c54-4e9a-99b9-097c616d7339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_b879accc-ad34-48e5-b897-d1144f65e0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_b879accc-ad34-48e5-b897-d1144f65e0e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_7ae6032b-c714-4304-83db-32422a069c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_7ae6032b-c714-4304-83db-32422a069c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6e28814d-80a6-45ee-9e23-8728d3ef39bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6e28814d-80a6-45ee-9e23-8728d3ef39bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_795732f1-c292-4d25-99c1-d0380053761d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_ShareBasedCompensation_795732f1-c292-4d25-99c1-d0380053761d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_d593c7b7-472c-4ed9-b06e-17e62faec198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_d593c7b7-472c-4ed9-b06e-17e62faec198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_485e350d-c7fc-40b1-b79b-4e41b1c48591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_485e350d-c7fc-40b1-b79b-4e41b1c48591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6f6dcb85-a425-4184-8b9c-da4bc4fb76fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6f6dcb85-a425-4184-8b9c-da4bc4fb76fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9a7fd6cc-5fe5-4e9b-9506-dd29c12f3e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9a7fd6cc-5fe5-4e9b-9506-dd29c12f3e5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6d0a47f3-75e4-4804-a91e-ad92977413f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e5902f6-6383-4403-923a-8d2b52abb96c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6d0a47f3-75e4-4804-a91e-ad92977413f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffaf0638-8c85-40a4-8a9d-a9a225f883e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ce421b4-9631-47a7-aa9f-0b80e42dfe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffaf0638-8c85-40a4-8a9d-a9a225f883e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ce421b4-9631-47a7-aa9f-0b80e42dfe9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66e81fb-0bf7-4e67-b9ea-32b36af17d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffaf0638-8c85-40a4-8a9d-a9a225f883e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66e81fb-0bf7-4e67-b9ea-32b36af17d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e310ccd-933f-4ace-a6d6-884bbf7aca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffaf0638-8c85-40a4-8a9d-a9a225f883e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e310ccd-933f-4ace-a6d6-884bbf7aca9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c96f999c-4200-4c13-a635-66fea87e207c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffaf0638-8c85-40a4-8a9d-a9a225f883e9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c96f999c-4200-4c13-a635-66fea87e207c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_05be0509-7def-4932-8446-b2d02b6e229f" xlink:href="cah-20221231.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffaf0638-8c85-40a4-8a9d-a9a225f883e9" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_05be0509-7def-4932-8446-b2d02b6e229f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf88675d-1cc4-40ec-8bb6-db97d510f4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7e00d8fe-261b-4a58-a6a4-c7cc693081e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf88675d-1cc4-40ec-8bb6-db97d510f4ca" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7e00d8fe-261b-4a58-a6a4-c7cc693081e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_60083cc6-51a6-48a4-b96c-41177215f50f" xlink:href="cah-20221231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf88675d-1cc4-40ec-8bb6-db97d510f4ca" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_60083cc6-51a6-48a4-b96c-41177215f50f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_6b44b4e3-0e47-480d-b86b-96fee7792488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf88675d-1cc4-40ec-8bb6-db97d510f4ca" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_6b44b4e3-0e47-480d-b86b-96fee7792488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f2960ffb-2f11-44b8-9272-2e13f823ff42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf88675d-1cc4-40ec-8bb6-db97d510f4ca" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f2960ffb-2f11-44b8-9272-2e13f823ff42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7cb9b9d4-e505-4fe6-a176-e8d17afa0d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_304c2f24-c63d-4bd6-ac55-384984908b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_7cb9b9d4-e505-4fe6-a176-e8d17afa0d66" xlink:to="loc_us-gaap_SeveranceCosts1_304c2f24-c63d-4bd6-ac55-384984908b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_20d6fddc-ab48-4048-bee2-66a94da578bc" xlink:href="cah-20221231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_7cb9b9d4-e505-4fe6-a176-e8d17afa0d66" xlink:to="loc_cah_FacilityExitAndOtherCosts_20d6fddc-ab48-4048-bee2-66a94da578bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_98405931-7f83-41bb-9d7d-9144238dcf48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_293dd7a2-afdb-4517-844b-953cdc28dc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_98405931-7f83-41bb-9d7d-9144238dcf48" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_293dd7a2-afdb-4517-844b-953cdc28dc55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2ee6146b-8d77-4062-8b4c-82a17f2cb434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_98405931-7f83-41bb-9d7d-9144238dcf48" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2ee6146b-8d77-4062-8b4c-82a17f2cb434" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fbba798-8e86-4073-a2d7-cf91be8af3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_78743b83-9090-489c-9d92-c3c13e9b0873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fbba798-8e86-4073-a2d7-cf91be8af3bc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_78743b83-9090-489c-9d92-c3c13e9b0873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ae119514-0e7f-42a7-bea6-db637591c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fbba798-8e86-4073-a2d7-cf91be8af3bc" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ae119514-0e7f-42a7-bea6-db637591c27b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cah-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de10429f-68bb-4228-9960-cf0499f5ed93,g:6028fbd5-3398-4741-87cc-7f6715aa56e4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i27fe8270deb14f148f62d6b56f331b32_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a33ce9f7-c6ba-4167-9685-91c307e89d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_CommonStockSharesIssued_a33ce9f7-c6ba-4167-9685-91c307e89d6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa87f05d-e353-40cb-b067-c22c6a6293c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa87f05d-e353-40cb-b067-c22c6a6293c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a481f15f-cc57-4a8a-b383-7cfda0a2446c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockShares_a481f15f-cc57-4a8a-b383-7cfda0a2446c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e6e7a3fc-6540-4886-96fb-8930aaf3bbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockValue_e6e7a3fc-6540-4886-96fb-8930aaf3bbc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e137c55-8cef-4ae1-a2a5-368421340fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_ProfitLoss_7e137c55-8cef-4ae1-a2a5-368421340fd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc45e12c-915d-4b53-a38b-f0792753a84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_NetIncomeLoss_fc45e12c-915d-4b53-a38b-f0792753a84c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d81c9550-6e48-408f-a40c-6b6dd057dd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d81c9550-6e48-408f-a40c-6b6dd057dd5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6dd04f96-0db6-4fce-985b-e7f44112b9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6dd04f96-0db6-4fce-985b-e7f44112b9cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb6f769f-3ab4-448f-bf60-b911d247ade1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb6f769f-3ab4-448f-bf60-b911d247ade1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3c74e7f5-a5ca-4b13-9d79-c41a83a8c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3c74e7f5-a5ca-4b13-9d79-c41a83a8c3d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04eac8da-f8fb-4e1c-972a-4aec78d2e676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04eac8da-f8fb-4e1c-972a-4aec78d2e676" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9871a2d0-fda9-4d57-8c92-2c7398897969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9871a2d0-fda9-4d57-8c92-2c7398897969" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_d082311e-e9e8-483c-8c33-8d0221de9b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_Dividends_d082311e-e9e8-483c-8c33-8d0221de9b0d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_b1b65128-cb1e-4b15-9fe0-7afc387765f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_b1b65128-cb1e-4b15-9fe0-7afc387765f3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_a248635e-0007-401b-bacb-295f62e8400f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockholdersEquityOther_a248635e-0007-401b-bacb-295f62e8400f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8bae8d57-edad-490a-a58c-dba186bc176d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d7486b2-4a57-44f1-8a63-29d6070baf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_ed70e85a-2dfc-46e7-9594-0b08c09e2932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_2f2ec72c-8b6a-46b7-bdad-4455ed08f6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_94e12cb2-94f8-4976-af90-e0dc4f948d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_94e12cb2-94f8-4976-af90-e0dc4f948d73" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c2dc9ef5-7e7a-4712-9dd9-315c765f1203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c2dc9ef5-7e7a-4712-9dd9-315c765f1203" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6b5c2c2b-1809-4370-b918-4dc06a3834d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StatementTable_6b5c2c2b-1809-4370-b918-4dc06a3834d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6db1446-c954-48b3-99c2-bc1e68545295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6b5c2c2b-1809-4370-b918-4dc06a3834d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6db1446-c954-48b3-99c2-bc1e68545295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6db1446-c954-48b3-99c2-bc1e68545295_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6db1446-c954-48b3-99c2-bc1e68545295" xlink:to="loc_us-gaap_EquityComponentDomain_e6db1446-c954-48b3-99c2-bc1e68545295_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6db1446-c954-48b3-99c2-bc1e68545295" xlink:to="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_247d4cba-af5b-41c6-aee3-82c6a610c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_CommonStockMember_247d4cba-af5b-41c6-aee3-82c6a610c64c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_11a13d05-20be-44d2-834f-d34974f124e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_RetainedEarningsMember_11a13d05-20be-44d2-834f-d34974f124e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_1113f141-505d-4d11-b4cc-a0bd89f9b471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_TreasuryStockMember_1113f141-505d-4d11-b4cc-a0bd89f9b471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_587e6382-9571-452a-8146-c579a290cebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_587e6382-9571-452a-8146-c579a290cebe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_abd6c609-c678-4625-b2e3-5eb6b49cfa37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_NoncontrollingInterestMember_abd6c609-c678-4625-b2e3-5eb6b49cfa37" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended" id="ia77d993c0c6a4104b4dd405225668977_DiscontinuedOperationsandDisposalGroupsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0dcbdd7d-b75e-4c59-b369-83ae2cc392a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_83317c75-194b-4f0f-a451-d59701ff6883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0dcbdd7d-b75e-4c59-b369-83ae2cc392a4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_83317c75-194b-4f0f-a451-d59701ff6883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0dcbdd7d-b75e-4c59-b369-83ae2cc392a4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d7445eb-c966-433f-9dbb-8a3cd13cb620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d7445eb-c966-433f-9dbb-8a3cd13cb620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7445eb-c966-433f-9dbb-8a3cd13cb620_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d7445eb-c966-433f-9dbb-8a3cd13cb620" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7445eb-c966-433f-9dbb-8a3cd13cb620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8c797762-4e35-4253-b224-a42a05d78fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d7445eb-c966-433f-9dbb-8a3cd13cb620" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8c797762-4e35-4253-b224-a42a05d78fab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_4caf218a-8fac-4dc1-8a68-292828e83612" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:to="loc_cah_CordisDivestitureAxis_4caf218a-8fac-4dc1-8a68-292828e83612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_4caf218a-8fac-4dc1-8a68-292828e83612_default" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_4caf218a-8fac-4dc1-8a68-292828e83612" xlink:to="loc_cah_CordisDivestitureDomain_4caf218a-8fac-4dc1-8a68-292828e83612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7016e2c8-91b8-4105-99c2-38e189c0f157" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_4caf218a-8fac-4dc1-8a68-292828e83612" xlink:to="loc_cah_CordisDivestitureDomain_7016e2c8-91b8-4105-99c2-38e189c0f157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_01d9bff4-74ae-445d-8ac9-3cfece846b87" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_7016e2c8-91b8-4105-99c2-38e189c0f157" xlink:to="loc_cah_CordisDivestitureMember_01d9bff4-74ae-445d-8ac9-3cfece846b87" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="i48ccee80a24c4555bb405757af019f14_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_7d475ccb-57e8-418a-93a3-4a61bcbca633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7d475ccb-57e8-418a-93a3-4a61bcbca633" xlink:to="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4facd3fa-a25a-4eb4-aec0-6b595e9bb23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:to="loc_us-gaap_RestructuringReserve_4facd3fa-a25a-4eb4-aec0-6b595e9bb23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_3fe64a67-b7a3-4a13-9066-a47eb64a5911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:to="loc_us-gaap_RestructuringCosts_3fe64a67-b7a3-4a13-9066-a47eb64a5911" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6f912178-e6f4-4f1d-af28-ff133e20d879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:to="loc_us-gaap_PaymentsForRestructuring_6f912178-e6f4-4f1d-af28-ff133e20d879" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_931665fe-fec0-4c45-a2d9-1a5b78afe7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d4432a3c-885f-48e7-928f-78b3235b1200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7d475ccb-57e8-418a-93a3-4a61bcbca633" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d4432a3c-885f-48e7-928f-78b3235b1200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7db71499-cabd-43bb-9443-e230c6d3ead8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d4432a3c-885f-48e7-928f-78b3235b1200" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7db71499-cabd-43bb-9443-e230c6d3ead8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7db71499-cabd-43bb-9443-e230c6d3ead8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7db71499-cabd-43bb-9443-e230c6d3ead8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7db71499-cabd-43bb-9443-e230c6d3ead8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7db71499-cabd-43bb-9443-e230c6d3ead8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_51886312-5c3e-4410-a989-5be4034ad1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:to="loc_us-gaap_EmployeeSeveranceMember_51886312-5c3e-4410-a989-5be4034ad1e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_b9ed843f-868d-4d3b-b027-8bba020696d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:to="loc_us-gaap_FacilityClosingMember_b9ed843f-868d-4d3b-b027-8bba020696d1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended" id="i30a772c8747347d78c5725c5c0d23a9b_RestructuringandEmployeeSeveranceNarativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f4e93cda-e88d-4991-aaf9-b0075230cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:to="loc_us-gaap_SeveranceCosts1_f4e93cda-e88d-4991-aaf9-b0075230cfe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_7488bd37-3f7e-478a-9ffb-0c0e2e8cd528" xlink:href="cah-20221231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:to="loc_cah_FacilityExitAndOtherCosts_7488bd37-3f7e-478a-9ffb-0c0e2e8cd528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b7c2939b-6f65-4ebb-8316-4362177debe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b7c2939b-6f65-4ebb-8316-4362177debe7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_09e06ca1-faab-4def-a10b-399729c716d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b7c2939b-6f65-4ebb-8316-4362177debe7" xlink:to="loc_us-gaap_RestructuringPlanAxis_09e06ca1-faab-4def-a10b-399729c716d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_09e06ca1-faab-4def-a10b-399729c716d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_09e06ca1-faab-4def-a10b-399729c716d5" xlink:to="loc_us-gaap_RestructuringPlanDomain_09e06ca1-faab-4def-a10b-399729c716d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_03b2192d-e5a1-4a35-9ba2-d4bf56366ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_09e06ca1-faab-4def-a10b-399729c716d5" xlink:to="loc_us-gaap_RestructuringPlanDomain_03b2192d-e5a1-4a35-9ba2-d4bf56366ffa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="ic8eec040db68481384771109bd992a06_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:to="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e4441ec5-3856-4027-8a25-e743af9de8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:to="loc_us-gaap_Goodwill_e4441ec5-3856-4027-8a25-e743af9de8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_825b8fa7-86b5-464f-9a5e-9638c248e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_825b8fa7-86b5-464f-9a5e-9638c248e25d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_10307c6a-7158-4428-973a-d3f4e34c1dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_10307c6a-7158-4428-973a-d3f4e34c1dc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_79f9075d-b01a-4de1-a60c-7e13dea80383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc263a6f-49ed-4517-bd0e-f7eb981b8c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc263a6f-49ed-4517-bd0e-f7eb981b8c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e787b2b1-afef-4f33-b34b-5739d6baecac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e787b2b1-afef-4f33-b34b-5739d6baecac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e787b2b1-afef-4f33-b34b-5739d6baecac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e787b2b1-afef-4f33-b34b-5739d6baecac" xlink:to="loc_us-gaap_SegmentDomain_e787b2b1-afef-4f33-b34b-5739d6baecac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e787b2b1-afef-4f33-b34b-5739d6baecac" xlink:to="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_110ca023-6bdc-4963-b318-f1b0b75dcce7" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:to="loc_cah_PharmaceuticalMember_110ca023-6bdc-4963-b318-f1b0b75dcce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_757bc049-d264-4cae-912b-f2c0fe611390" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:to="loc_cah_MedicalMember_757bc049-d264-4cae-912b-f2c0fe611390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_421743b5-d382-4ffa-86d0-99090f61736d" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:to="loc_cah_CordisDivestitureAxis_421743b5-d382-4ffa-86d0-99090f61736d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_421743b5-d382-4ffa-86d0-99090f61736d_default" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_421743b5-d382-4ffa-86d0-99090f61736d" xlink:to="loc_cah_CordisDivestitureDomain_421743b5-d382-4ffa-86d0-99090f61736d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_d59a051c-5270-4b2b-8b9d-e3d57f545ab3" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_421743b5-d382-4ffa-86d0-99090f61736d" xlink:to="loc_cah_CordisDivestitureDomain_d59a051c-5270-4b2b-8b9d-e3d57f545ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_d3cb16ba-9915-4809-95a5-e20a6fc66e4e" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_d59a051c-5270-4b2b-8b9d-e3d57f545ab3" xlink:to="loc_cah_CordisDivestitureMember_d3cb16ba-9915-4809-95a5-e20a6fc66e4e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i1deceb18578241218131083eaaae41a8_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_63375754-542d-4a94-9892-d91d81ace6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7e2ad474-60bb-416c-b358-fc8508f911ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_63375754-542d-4a94-9892-d91d81ace6bc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7e2ad474-60bb-416c-b358-fc8508f911ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d066e93a-fe19-4c3f-9f0b-2a51fd094611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_63375754-542d-4a94-9892-d91d81ace6bc" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d066e93a-fe19-4c3f-9f0b-2a51fd094611" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_61828320-2651-45c8-8006-7457bb84a2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d066e93a-fe19-4c3f-9f0b-2a51fd094611" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_61828320-2651-45c8-8006-7457bb84a2d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_61828320-2651-45c8-8006-7457bb84a2d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_61828320-2651-45c8-8006-7457bb84a2d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_61828320-2651-45c8-8006-7457bb84a2d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7d09c7d-81a2-49c5-9517-c24cb1f8c29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_61828320-2651-45c8-8006-7457bb84a2d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7d09c7d-81a2-49c5-9517-c24cb1f8c29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_0ffea567-8cb5-474a-a3d0-39d56c0407e3" xlink:href="cah-20221231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7d09c7d-81a2-49c5-9517-c24cb1f8c29c" xlink:to="loc_cah_IPRDTrademarksandOtherMember_0ffea567-8cb5-474a-a3d0-39d56c0407e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7614463-05fb-4ecf-a190-97a5458fd14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7614463-05fb-4ecf-a190-97a5458fd14e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_834817b6-4773-4826-9e15-a169f1ed9e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_834817b6-4773-4826-9e15-a169f1ed9e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0e0c2a3d-c8f6-43bf-9463-18f19ed1abef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0e0c2a3d-c8f6-43bf-9463-18f19ed1abef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_24bfe973-77be-4140-bddb-0d061ae241f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_24bfe973-77be-4140-bddb-0d061ae241f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e87e8ff9-4e42-41aa-bee1-25f31d874324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e87e8ff9-4e42-41aa-bee1-25f31d874324" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e55f2774-2d9b-4507-9d79-42503e2539a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e87e8ff9-4e42-41aa-bee1-25f31d874324" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e55f2774-2d9b-4507-9d79-42503e2539a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e55f2774-2d9b-4507-9d79-42503e2539a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e55f2774-2d9b-4507-9d79-42503e2539a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e55f2774-2d9b-4507-9d79-42503e2539a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e55f2774-2d9b-4507-9d79-42503e2539a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_5cd19672-cb2c-44f3-8a7d-c9c7fdac6465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_5cd19672-cb2c-44f3-8a7d-c9c7fdac6465" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_cf548bed-c9e1-46e7-8816-bf530c5a6fa0" xlink:href="cah-20221231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:to="loc_cah_TrademarksAndPatentsMember_cf548bed-c9e1-46e7-8816-bf530c5a6fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7bf99788-3005-46ac-a373-3479f8be6ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7bf99788-3005-46ac-a373-3479f8be6ae4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i1cb8bfbc34b94674b23f47d4396561ad_GoodwillandOtherIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_18d67732-d263-4905-bb1e-00a3a5a5998a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_us-gaap_Goodwill_18d67732-d263-4905-bb1e-00a3a5a5998a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e9dc9ec1-7913-470f-baef-915ae5345368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e9dc9ec1-7913-470f-baef-915ae5345368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_9958c447-de0c-47f6-9240-3663d2d9395c" xlink:href="cah-20221231.xsd#cah_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_cah_DiscountRateFairValueInput_9958c447-de0c-47f6-9240-3663d2d9395c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_9472df53-8aa1-4ba6-bb5e-6814dadec640" xlink:href="cah-20221231.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_9472df53-8aa1-4ba6-bb5e-6814dadec640" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet_079b8516-3aa7-492a-b869-5667e6ef9c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_us-gaap_AssetsNet_079b8516-3aa7-492a-b869-5667e6ef9c5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_578d49d1-6bad-4d09-b7b5-1a8fe989d845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:to="loc_us-gaap_ReportingUnitAxis_578d49d1-6bad-4d09-b7b5-1a8fe989d845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_578d49d1-6bad-4d09-b7b5-1a8fe989d845_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_578d49d1-6bad-4d09-b7b5-1a8fe989d845" xlink:to="loc_us-gaap_ReportingUnitDomain_578d49d1-6bad-4d09-b7b5-1a8fe989d845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_063af77a-a8ed-433c-9698-17c826591227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_578d49d1-6bad-4d09-b7b5-1a8fe989d845" xlink:to="loc_us-gaap_ReportingUnitDomain_063af77a-a8ed-433c-9698-17c826591227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_36add99c-df08-47a9-bc6b-15ff8c570081" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_063af77a-a8ed-433c-9698-17c826591227" xlink:to="loc_cah_MedicalUnitMember_36add99c-df08-47a9-bc6b-15ff8c570081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4049f030-2487-47ae-b798-9ba3627740de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4049f030-2487-47ae-b798-9ba3627740de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4049f030-2487-47ae-b798-9ba3627740de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4049f030-2487-47ae-b798-9ba3627740de" xlink:to="loc_us-gaap_SegmentDomain_4049f030-2487-47ae-b798-9ba3627740de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7d9533b4-81fb-4fb8-8c31-fd973e948962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4049f030-2487-47ae-b798-9ba3627740de" xlink:to="loc_us-gaap_SegmentDomain_7d9533b4-81fb-4fb8-8c31-fd973e948962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_e8d903c3-28ca-4ec5-aee2-33774d343900" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7d9533b4-81fb-4fb8-8c31-fd973e948962" xlink:to="loc_cah_MedicalMember_e8d903c3-28ca-4ec5-aee2-33774d343900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_13109af0-dfcf-4376-ae18-38131ee3e4a0" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:to="loc_cah_GoodwillImpairmentAxis_13109af0-dfcf-4376-ae18-38131ee3e4a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_13109af0-dfcf-4376-ae18-38131ee3e4a0_default" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_13109af0-dfcf-4376-ae18-38131ee3e4a0" xlink:to="loc_cah_GoodwillImpairmentDomain_13109af0-dfcf-4376-ae18-38131ee3e4a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_08ac048b-7db5-4fd9-83f5-a71b838d79b9" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_13109af0-dfcf-4376-ae18-38131ee3e4a0" xlink:to="loc_cah_GoodwillImpairmentDomain_08ac048b-7db5-4fd9-83f5-a71b838d79b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_82f2dbf0-9c16-481f-ad32-5ae426a62bc8" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_08ac048b-7db5-4fd9-83f5-a71b838d79b9" xlink:to="loc_cah_MedicalUnitMember_82f2dbf0-9c16-481f-ad32-5ae426a62bc8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended" id="ia770f9cc401b4910823ab09bdcf20ce6_LongTermObligationsandOtherShortTermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_e129fb56-8ebc-4fbe-848d-a31d4e66d1d4" xlink:href="cah-20221231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_cah_TotalLongTermandShortTermObligations_e129fb56-8ebc-4fbe-848d-a31d4e66d1d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5c60d711-6d68-4ac5-a276-37f78f892999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5c60d711-6d68-4ac5-a276-37f78f892999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9fb99423-eb32-47e1-9c91-d09ebd3ed5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9fb99423-eb32-47e1-9c91-d09ebd3ed5b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_57a1f6b4-7edf-4e47-af50-1d72cefc9ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_57a1f6b4-7edf-4e47-af50-1d72cefc9ce6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1ce17da7-6fe5-4f5e-910e-ae4bb0f4dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1ce17da7-6fe5-4f5e-910e-ae4bb0f4dbea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_39ad4085-1c00-496b-8fa1-93be238c8c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_OtherShortTermBorrowings_39ad4085-1c00-496b-8fa1-93be238c8c4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a99f7821-342b-4b52-9f9a-834bf8870532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:to="loc_us-gaap_DebtInstrumentAxis_a99f7821-342b-4b52-9f9a-834bf8870532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a99f7821-342b-4b52-9f9a-834bf8870532_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a99f7821-342b-4b52-9f9a-834bf8870532" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a99f7821-342b-4b52-9f9a-834bf8870532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a99f7821-342b-4b52-9f9a-834bf8870532" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_4ce73d58-0d3d-4935-b9b8-e7e41d93ada1" xlink:href="cah-20221231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:to="loc_cah_A2.616Notesdue2022Member_4ce73d58-0d3d-4935-b9b8-e7e41d93ada1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_4da113e2-30b0-44ff-b84f-a0fd2661adff" xlink:href="cah-20221231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_4da113e2-30b0-44ff-b84f-a0fd2661adff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_29bcf0e1-4219-4f22-9c67-65e7b5bf387d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:to="loc_us-gaap_CreditFacilityAxis_29bcf0e1-4219-4f22-9c67-65e7b5bf387d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_29bcf0e1-4219-4f22-9c67-65e7b5bf387d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_29bcf0e1-4219-4f22-9c67-65e7b5bf387d" xlink:to="loc_us-gaap_CreditFacilityDomain_29bcf0e1-4219-4f22-9c67-65e7b5bf387d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_29bcf0e1-4219-4f22-9c67-65e7b5bf387d" xlink:to="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c8609616-d481-43d4-beb2-a0b30295090c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_us-gaap_CommercialPaperMember_c8609616-d481-43d4-beb2-a0b30295090c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_29a22129-4e9a-401f-9997-d8645245110c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_29a22129-4e9a-401f-9997-d8645245110c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_e2f41b2c-0dd9-4e36-b5eb-e038fd9559c1" xlink:href="cah-20221231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_e2f41b2c-0dd9-4e36-b5eb-e038fd9559c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3f4e7d2c-4bbd-4a59-8e94-6953153a584e" xlink:href="cah-20221231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3f4e7d2c-4bbd-4a59-8e94-6953153a584e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended" id="i30d6c79b89914fed901f38d95af99918_LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_9df81e80-125a-4b87-b3e8-d3990113646f" xlink:href="cah-20221231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:to="loc_cah_TotalLongTermandShortTermObligations_9df81e80-125a-4b87-b3e8-d3990113646f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f9c6277-77a0-4f0e-8048-3822d92d808a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f9c6277-77a0-4f0e-8048-3822d92d808a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2ca22511-dcb6-4f0d-9748-984a7691be8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2ca22511-dcb6-4f0d-9748-984a7691be8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:to="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ceb12663-bbc0-44a0-b114-85605213b9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ceb12663-bbc0-44a0-b114-85605213b9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ceb12663-bbc0-44a0-b114-85605213b9cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ceb12663-bbc0-44a0-b114-85605213b9cd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ceb12663-bbc0-44a0-b114-85605213b9cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_40c068d6-0cc4-4108-8709-210631fc355d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ceb12663-bbc0-44a0-b114-85605213b9cd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_40c068d6-0cc4-4108-8709-210631fc355d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_64d33c17-ae05-466a-a858-ce06d6a20cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_64d33c17-ae05-466a-a858-ce06d6a20cf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_64d33c17-ae05-466a-a858-ce06d6a20cf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_64d33c17-ae05-466a-a858-ce06d6a20cf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_64d33c17-ae05-466a-a858-ce06d6a20cf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d99214bc-5ab2-482c-8567-452b29cd5bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_64d33c17-ae05-466a-a858-ce06d6a20cf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d99214bc-5ab2-482c-8567-452b29cd5bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_e164653b-5bda-4748-92b2-cf22d9be17ab" xlink:href="cah-20221231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d99214bc-5ab2-482c-8567-452b29cd5bae" xlink:to="loc_cah_A2.616Notesdue2022Member_e164653b-5bda-4748-92b2-cf22d9be17ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended" id="ia0911292b132494d907fbc3a31e66276_CommitmentsContingentLiabilitiesandLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_3789527f-2509-4488-bc16-6253fe5311e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_3789527f-2509-4488-bc16-6253fe5311e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_1a85b841-6e8c-4ec8-ad51-782bf19df613" xlink:href="cah-20221231.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_AggregateAnnualAssessment_1a85b841-6e8c-4ec8-ad51-782bf19df613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_e580c451-0471-4da6-adb3-06a212ff00c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_e580c451-0471-4da6-adb3-06a212ff00c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2b805c87-81ba-4763-98fe-ee98d2b892b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2b805c87-81ba-4763-98fe-ee98d2b892b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_e831488f-65b4-4294-a3f3-c33ef673d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_e831488f-65b4-4294-a3f3-c33ef673d5a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_f2e1bfab-df35-4c46-9f95-bec4f5298626" xlink:href="cah-20221231.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_JudgmentForLostProfits_f2e1bfab-df35-4c46-9f95-bec4f5298626" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d249d0f1-28cb-4248-aff4-3dfe6d95569a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d249d0f1-28cb-4248-aff4-3dfe6d95569a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_0731d05e-b144-46f9-90fd-13b9e51117d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_0731d05e-b144-46f9-90fd-13b9e51117d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_c991189e-9f5b-474c-8d6e-06d02d6ee03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LitigationReserve_c991189e-9f5b-474c-8d6e-06d02d6ee03d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_2b5fdeed-8465-4191-a617-90da63ea79a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LitigationReserveCurrent_2b5fdeed-8465-4191-a617-90da63ea79a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_9a76d98d-8446-4970-8c4a-c5db8534de20" xlink:href="cah-20221231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_LossContingencyLawsuitsNumber_9a76d98d-8446-4970-8c4a-c5db8534de20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_6380a24c-4c00-4e51-91da-b10125267336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_6380a24c-4c00-4e51-91da-b10125267336" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_73bf6bc1-e1d4-41ae-b188-e50f7f0f0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_73bf6bc1-e1d4-41ae-b188-e50f7f0f0f8d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_7065f792-1af8-4bbf-abc9-4b5c12d00a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_7065f792-1af8-4bbf-abc9-4b5c12d00a38" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_44170a3e-42dc-45d5-9684-1c935bcc1ae4" xlink:href="cah-20221231.xsd#cah_SettlingStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_SettlingStates_44170a3e-42dc-45d5-9684-1c935bcc1ae4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_efe7ea2b-c7b6-425a-990d-ed4f9a300fce" xlink:href="cah-20221231.xsd#cah_SettlingUSTerritories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_SettlingUSTerritories_efe7ea2b-c7b6-425a-990d-ed4f9a300fce" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_f1648929-e0b5-41c0-9237-e99c753a9b49" xlink:href="cah-20221231.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_f1648929-e0b5-41c0-9237-e99c753a9b49" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_132bf7ac-e4a2-44c2-a258-35f38f204692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_InsuranceRecoveries_132bf7ac-e4a2-44c2-a258-35f38f204692" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_0b6025d0-b2c6-4611-b7f0-fd6e4ebdf21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualPeriodExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_0b6025d0-b2c6-4611-b7f0-fd6e4ebdf21f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_149efbab-69d9-4e4b-b8a5-0b36995dee3d" xlink:href="cah-20221231.xsd#cah_GrossInsuranceSettlementBeforeAttorneyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_149efbab-69d9-4e4b-b8a5-0b36995dee3d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_a983481c-ce1f-4525-9498-60a56de65550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LegalFees_a983481c-ce1f-4525-9498-60a56de65550" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_f21844bf-6d3b-43f5-bb8c-0b2bc0319832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_f21844bf-6d3b-43f5-bb8c-0b2bc0319832" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_057a765b-080c-4f8b-adfa-b834d2db5135" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_MajorCustomersAxis_057a765b-080c-4f8b-adfa-b834d2db5135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_057a765b-080c-4f8b-adfa-b834d2db5135_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_057a765b-080c-4f8b-adfa-b834d2db5135" xlink:to="loc_srt_NameOfMajorCustomerDomain_057a765b-080c-4f8b-adfa-b834d2db5135_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab838cac-7be5-4c0e-9f77-9ee18f184024" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_057a765b-080c-4f8b-adfa-b834d2db5135" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab838cac-7be5-4c0e-9f77-9ee18f184024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_fd12f444-b8d1-4bc6-bc2d-dee01abf2d77" xlink:href="cah-20221231.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab838cac-7be5-4c0e-9f77-9ee18f184024" xlink:to="loc_cah_CVSHealthMember_fd12f444-b8d1-4bc6-bc2d-dee01abf2d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_db8b4588-c771-4e33-8790-5f6b5daf20bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_LitigationCaseAxis_db8b4588-c771-4e33-8790-5f6b5daf20bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_db8b4588-c771-4e33-8790-5f6b5daf20bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_db8b4588-c771-4e33-8790-5f6b5daf20bf" xlink:to="loc_srt_LitigationCaseTypeDomain_db8b4588-c771-4e33-8790-5f6b5daf20bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_db8b4588-c771-4e33-8790-5f6b5daf20bf" xlink:to="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_ea2d8e54-b982-48ce-a6d2-89f648e2f2c9" xlink:href="cah-20221231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_ea2d8e54-b982-48ce-a6d2-89f648e2f2c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_5575f114-b4c5-462b-af64-65dc539ead52" xlink:href="cah-20221231.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_OpioidLawsuitsMember_5575f114-b4c5-462b-af64-65dc539ead52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_7babf7d3-fa84-4951-abaa-1e702b3abd2c" xlink:href="cah-20221231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_7babf7d3-fa84-4951-abaa-1e702b3abd2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderDerivativeLitigationMember_da39f840-9dba-4caf-aec5-46a22766d58d" xlink:href="cah-20221231.xsd#cah_ShareholderDerivativeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_ShareholderDerivativeLitigationMember_da39f840-9dba-4caf-aec5-46a22766d58d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_25cab309-9206-4cbd-839e-b2cd18d78ae3" xlink:href="cah-20221231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_cah_OpioidLitigationAxis_25cab309-9206-4cbd-839e-b2cd18d78ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_25cab309-9206-4cbd-839e-b2cd18d78ae3_default" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_25cab309-9206-4cbd-839e-b2cd18d78ae3" xlink:to="loc_cah_OpioidLitigationDomain_25cab309-9206-4cbd-839e-b2cd18d78ae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_e8cecabe-f8ae-4658-820d-d43378ef31ab" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_25cab309-9206-4cbd-839e-b2cd18d78ae3" xlink:to="loc_cah_OpioidLitigationDomain_e8cecabe-f8ae-4658-820d-d43378ef31ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_625e1b4c-5db3-4f04-8dc0-57a1ea2bac71" xlink:href="cah-20221231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_e8cecabe-f8ae-4658-820d-d43378ef31ab" xlink:to="loc_cah_TotalOpioidLitigationMember_625e1b4c-5db3-4f04-8dc0-57a1ea2bac71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67" xlink:href="cah-20221231.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_cah_LawsuitTypeAxis_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67_default" xlink:href="cah-20221231.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67" xlink:to="loc_cah_LawsuitTypeDomain_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:href="cah-20221231.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67" xlink:to="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_dbfd4a2a-2079-49bc-98da-a355b3aaa85e" xlink:href="cah-20221231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:to="loc_cah_ClassActionLawsuitsMember_dbfd4a2a-2079-49bc-98da-a355b3aaa85e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_8db2994b-e0d4-40d9-9a54-7a5ca72238d7" xlink:href="cah-20221231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_8db2994b-e0d4-40d9-9a54-7a5ca72238d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_c1f343c0-d96d-4164-a11e-8e344f3c9732" xlink:href="cah-20221231.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_cah_PlaintiffTypeAxis_c1f343c0-d96d-4164-a11e-8e344f3c9732" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_c1f343c0-d96d-4164-a11e-8e344f3c9732_default" xlink:href="cah-20221231.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_c1f343c0-d96d-4164-a11e-8e344f3c9732" xlink:to="loc_cah_PlaintiffTypeDomain_c1f343c0-d96d-4164-a11e-8e344f3c9732_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_b5c7896a-423a-4dfc-91a9-e9f31eeafce3" xlink:href="cah-20221231.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_c1f343c0-d96d-4164-a11e-8e344f3c9732" xlink:to="loc_cah_PlaintiffTypeDomain_b5c7896a-423a-4dfc-91a9-e9f31eeafce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_bbcdfa96-262a-4824-868f-17d4fe202d14" xlink:href="cah-20221231.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_b5c7896a-423a-4dfc-91a9-e9f31eeafce3" xlink:to="loc_cah_PrivatePartiesMember_bbcdfa96-262a-4824-868f-17d4fe202d14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_17f837f8-30e5-4c76-a763-ca545712e205" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_StatementGeographicalAxis_17f837f8-30e5-4c76-a763-ca545712e205" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_17f837f8-30e5-4c76-a763-ca545712e205_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_17f837f8-30e5-4c76-a763-ca545712e205" xlink:to="loc_srt_SegmentGeographicalDomain_17f837f8-30e5-4c76-a763-ca545712e205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_17f837f8-30e5-4c76-a763-ca545712e205" xlink:to="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_d7db31d8-2afa-4828-82ac-96f49ee0f344" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_GA_d7db31d8-2afa-4828-82ac-96f49ee0f344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_409425df-fd1e-4871-86b0-edb340197a00" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_WV_409425df-fd1e-4871-86b0-edb340197a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_b24966c9-69e1-444b-9d86-25e3b5254f34" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_WA_b24966c9-69e1-444b-9d86-25e3b5254f34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_587f69b6-ebfb-4128-a0e0-8aeeabb61c3a" xlink:href="cah-20221231.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_cah_AlamedaCountyMember_587f69b6-ebfb-4128-a0e0-8aeeabb61c3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_13b51656-f098-43c3-a3d0-0b7d1f2b1bc9" xlink:href="cah-20221231.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_cah_OtherJurisdictionsMember_13b51656-f098-43c3-a3d0-0b7d1f2b1bc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_e39244c2-c979-4313-8b48-12bc58ec35bb" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_OK_e39244c2-c979-4313-8b48-12bc58ec35bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL_250a35c6-6f41-4a53-b040-613b2dd2bc8c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_AL_250a35c6-6f41-4a53-b040-613b2dd2bc8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember_fa1fc834-d928-43ee-9123-cf24e4ec4798" xlink:href="cah-20221231.xsd#cah_NativeAmericanTribesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_cah_NativeAmericanTribesMember_fa1fc834-d928-43ee-9123-cf24e4ec4798" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_09d5606b-180f-406a-9758-f757a5517cfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_RangeAxis_09d5606b-180f-406a-9758-f757a5517cfd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09d5606b-180f-406a-9758-f757a5517cfd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_09d5606b-180f-406a-9758-f757a5517cfd" xlink:to="loc_srt_RangeMember_09d5606b-180f-406a-9758-f757a5517cfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_09d5606b-180f-406a-9758-f757a5517cfd" xlink:to="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c70be32a-149a-45ab-a080-e89dd482493d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:to="loc_srt_MinimumMember_c70be32a-149a-45ab-a080-e89dd482493d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74b57a91-3448-46d2-bd88-96c23ed5a0ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:to="loc_srt_MaximumMember_74b57a91-3448-46d2-bd88-96c23ed5a0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_cfce8f4b-a967-427b-80f6-cedb4bca6947" xlink:href="cah-20221231.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:to="loc_cah_OpioidLawsuitsMember_cfce8f4b-a967-427b-80f6-cedb4bca6947" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_0bd6b3b1-10d0-4e8a-9685-893bd6feba86" xlink:href="cah-20221231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_0bd6b3b1-10d0-4e8a-9685-893bd6feba86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c28f1834-21ac-4429-a03b-662865a9576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c28f1834-21ac-4429-a03b-662865a9576b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c28f1834-21ac-4429-a03b-662865a9576b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c28f1834-21ac-4429-a03b-662865a9576b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c28f1834-21ac-4429-a03b-662865a9576b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b3b088b0-dedc-4de0-a395-366bba304eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c28f1834-21ac-4429-a03b-662865a9576b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b3b088b0-dedc-4de0-a395-366bba304eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c7a150df-83ec-4832-aad9-9ad17cc26f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b3b088b0-dedc-4de0-a395-366bba304eee" xlink:to="loc_us-gaap_SubsequentEventMember_c7a150df-83ec-4832-aad9-9ad17cc26f28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f0f4681-792d-4ab9-8da8-cb94e12c11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f0f4681-792d-4ab9-8da8-cb94e12c11e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3f0f4681-792d-4ab9-8da8-cb94e12c11e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f0f4681-792d-4ab9-8da8-cb94e12c11e2" xlink:to="loc_us-gaap_SegmentDomain_3f0f4681-792d-4ab9-8da8-cb94e12c11e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_465cc759-e82f-4bdb-89a9-3baed8b263ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f0f4681-792d-4ab9-8da8-cb94e12c11e2" xlink:to="loc_us-gaap_SegmentDomain_465cc759-e82f-4bdb-89a9-3baed8b263ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_39fb7abb-3ab3-4383-8cd5-d4d5ea4391a9" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_465cc759-e82f-4bdb-89a9-3baed8b263ec" xlink:to="loc_cah_PharmaceuticalMember_39fb7abb-3ab3-4383-8cd5-d4d5ea4391a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i674a50e6c2f149f4a0c95ac0fc54470d_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d79b1d8-911e-4038-8b8a-286094a93ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d79b1d8-911e-4038-8b8a-286094a93ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_570ea4a8-6d2c-490e-9fe8-72bd59de8bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_570ea4a8-6d2c-490e-9fe8-72bd59de8bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_736ef4aa-7527-4c77-b45e-8ee469e612fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_736ef4aa-7527-4c77-b45e-8ee469e612fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d62f69c7-340d-46bc-bc1b-3def812e4916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d62f69c7-340d-46bc-bc1b-3def812e4916" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b4f7facb-f142-4332-b84c-f404a6ad3cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b4f7facb-f142-4332-b84c-f404a6ad3cb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c48e748f-7108-4dfe-9d97-f0a216bea66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c48e748f-7108-4dfe-9d97-f0a216bea66a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0dbf796-0028-4555-a416-ccab8fa7617f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0dbf796-0028-4555-a416-ccab8fa7617f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_a35594bf-0827-4505-a7b3-b955348d0b86" xlink:href="cah-20221231.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_cah_IndemnificationReceivable_a35594bf-0827-4505-a7b3-b955348d0b86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_9d1a2932-3f14-4264-adcd-e026f60e1efd" xlink:href="cah-20221231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_OpioidLitigationAxis_9d1a2932-3f14-4264-adcd-e026f60e1efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_9d1a2932-3f14-4264-adcd-e026f60e1efd_default" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_9d1a2932-3f14-4264-adcd-e026f60e1efd" xlink:to="loc_cah_OpioidLitigationDomain_9d1a2932-3f14-4264-adcd-e026f60e1efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_be525986-e7c8-41ff-8cd3-d41fed884eaf" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_9d1a2932-3f14-4264-adcd-e026f60e1efd" xlink:to="loc_cah_OpioidLitigationDomain_be525986-e7c8-41ff-8cd3-d41fed884eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_d70dd904-8d39-4045-8ac1-f6df0bc5c789" xlink:href="cah-20221231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_be525986-e7c8-41ff-8cd3-d41fed884eaf" xlink:to="loc_cah_TotalOpioidLitigationMember_d70dd904-8d39-4045-8ac1-f6df0bc5c789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_7ddfacd7-191e-4018-ad84-543e43ec32cf" xlink:href="cah-20221231.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_TaxMatterAxis_7ddfacd7-191e-4018-ad84-543e43ec32cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_7ddfacd7-191e-4018-ad84-543e43ec32cf_default" xlink:href="cah-20221231.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_7ddfacd7-191e-4018-ad84-543e43ec32cf" xlink:to="loc_cah_TaxMatterDomain_7ddfacd7-191e-4018-ad84-543e43ec32cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_bb906c94-3a61-487c-a22a-1b4baffe8119" xlink:href="cah-20221231.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_7ddfacd7-191e-4018-ad84-543e43ec32cf" xlink:to="loc_cah_TaxMatterDomain_bb906c94-3a61-487c-a22a-1b4baffe8119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_33f4e7dd-19ce-45e2-a540-6fb4ecaebdb5" xlink:href="cah-20221231.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_bb906c94-3a61-487c-a22a-1b4baffe8119" xlink:to="loc_cah_CareFusionMember_33f4e7dd-19ce-45e2-a540-6fb4ecaebdb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4b1970e-f032-46b4-b498-f45faae6f773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4b1970e-f032-46b4-b498-f45faae6f773" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b1970e-f032-46b4-b498-f45faae6f773_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4b1970e-f032-46b4-b498-f45faae6f773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4b1970e-f032-46b4-b498-f45faae6f773_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46fb12f6-dab7-4497-b61a-e9380d663d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4b1970e-f032-46b4-b498-f45faae6f773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46fb12f6-dab7-4497-b61a-e9380d663d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_67c32821-5c86-43c2-9ac7-11d5e6a268a6" xlink:href="cah-20221231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_TaxMattersAgreementAxis_67c32821-5c86-43c2-9ac7-11d5e6a268a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_67c32821-5c86-43c2-9ac7-11d5e6a268a6_default" xlink:href="cah-20221231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_67c32821-5c86-43c2-9ac7-11d5e6a268a6" xlink:to="loc_cah_TaxMattersAgreementDomain_67c32821-5c86-43c2-9ac7-11d5e6a268a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_0c679f0a-efba-434f-a2aa-2aa5c5da492b" xlink:href="cah-20221231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_67c32821-5c86-43c2-9ac7-11d5e6a268a6" xlink:to="loc_cah_TaxMattersAgreementDomain_0c679f0a-efba-434f-a2aa-2aa5c5da492b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_ad4d3321-5b3e-4df4-99d5-d71c31aedd60" xlink:href="cah-20221231.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_0c679f0a-efba-434f-a2aa-2aa5c5da492b" xlink:to="loc_cah_CareFusionMember_ad4d3321-5b3e-4df4-99d5-d71c31aedd60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0600985f-1a9d-410b-b5d1-3c0f2bd0effa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_srt_RangeAxis_0600985f-1a9d-410b-b5d1-3c0f2bd0effa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0600985f-1a9d-410b-b5d1-3c0f2bd0effa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0600985f-1a9d-410b-b5d1-3c0f2bd0effa" xlink:to="loc_srt_RangeMember_0600985f-1a9d-410b-b5d1-3c0f2bd0effa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0600985f-1a9d-410b-b5d1-3c0f2bd0effa" xlink:to="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5da614a3-dafc-45d8-8be8-d065ff485c17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:to="loc_srt_MinimumMember_5da614a3-dafc-45d8-8be8-d065ff485c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cee44f38-a605-4757-b4b0-cbf1b44cf18c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:to="loc_srt_MaximumMember_cee44f38-a605-4757-b4b0-cbf1b44cf18c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_20053065-15bf-440e-98d4-4b3bccfbcd17" xlink:href="cah-20221231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_20053065-15bf-440e-98d4-4b3bccfbcd17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_20053065-15bf-440e-98d4-4b3bccfbcd17_default" xlink:href="cah-20221231.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_20053065-15bf-440e-98d4-4b3bccfbcd17" xlink:to="loc_cah_CARESActDomain_20053065-15bf-440e-98d4-4b3bccfbcd17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_055fa87b-57da-4da2-b2c2-a97a8d49a5d5" xlink:href="cah-20221231.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_20053065-15bf-440e-98d4-4b3bccfbcd17" xlink:to="loc_cah_CARESActDomain_055fa87b-57da-4da2-b2c2-a97a8d49a5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2d6d421c-5448-4bb2-8297-480612586822" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_srt_StatementScenarioAxis_2d6d421c-5448-4bb2-8297-480612586822" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2d6d421c-5448-4bb2-8297-480612586822_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2d6d421c-5448-4bb2-8297-480612586822" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2d6d421c-5448-4bb2-8297-480612586822_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_14d940ca-7c77-488f-99f8-98b91357df9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2d6d421c-5448-4bb2-8297-480612586822" xlink:to="loc_srt_ScenarioUnspecifiedDomain_14d940ca-7c77-488f-99f8-98b91357df9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4be799a9-9d46-4d5f-9acc-868247973402" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_14d940ca-7c77-488f-99f8-98b91357df9c" xlink:to="loc_srt_ScenarioForecastMember_4be799a9-9d46-4d5f-9acc-868247973402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_07b0c3ed-21bf-4acc-a401-89c72f355026" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_GoodwillImpairmentAxis_07b0c3ed-21bf-4acc-a401-89c72f355026" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_07b0c3ed-21bf-4acc-a401-89c72f355026_default" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_07b0c3ed-21bf-4acc-a401-89c72f355026" xlink:to="loc_cah_GoodwillImpairmentDomain_07b0c3ed-21bf-4acc-a401-89c72f355026_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_07b0c3ed-21bf-4acc-a401-89c72f355026" xlink:to="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_02a8c9c6-a493-4a01-b30e-85cafc3d144d" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:to="loc_cah_MedicalUnitMember_02a8c9c6-a493-4a01-b30e-85cafc3d144d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_79a7b5dd-6dd5-4150-9285-d71781964ace" xlink:href="cah-20221231.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_79a7b5dd-6dd5-4150-9285-d71781964ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_ff87c88b-ab87-4230-8842-cd5a8a0a9f29" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_CordisDivestitureAxis_ff87c88b-ab87-4230-8842-cd5a8a0a9f29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_ff87c88b-ab87-4230-8842-cd5a8a0a9f29_default" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_ff87c88b-ab87-4230-8842-cd5a8a0a9f29" xlink:to="loc_cah_CordisDivestitureDomain_ff87c88b-ab87-4230-8842-cd5a8a0a9f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_b5b85fde-78d4-4150-bd78-4ff4e93e2180" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_ff87c88b-ab87-4230-8842-cd5a8a0a9f29" xlink:to="loc_cah_CordisDivestitureDomain_b5b85fde-78d4-4150-bd78-4ff4e93e2180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_28023ea1-4f3c-4a39-acd7-f906a18bb6dd" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_b5b85fde-78d4-4150-bd78-4ff4e93e2180" xlink:to="loc_cah_CordisDivestitureMember_28023ea1-4f3c-4a39-acd7-f906a18bb6dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df40be26-c5c4-4fcc-90c5-f44f2d21b9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df40be26-c5c4-4fcc-90c5-f44f2d21b9c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c91f3f05-2b3e-4ab4-9a15-f1119536a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df40be26-c5c4-4fcc-90c5-f44f2d21b9c4" xlink:to="loc_us-gaap_SubsequentEventMember_c91f3f05-2b3e-4ab4-9a15-f1119536a3a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_b217124e-de4d-4549-95bf-f090ae856e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_us-gaap_ReportingUnitAxis_b217124e-de4d-4549-95bf-f090ae856e17" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_b217124e-de4d-4549-95bf-f090ae856e17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_b217124e-de4d-4549-95bf-f090ae856e17" xlink:to="loc_us-gaap_ReportingUnitDomain_b217124e-de4d-4549-95bf-f090ae856e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_4f6261f7-2bb4-4b23-b5c3-fdf33ca48d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_b217124e-de4d-4549-95bf-f090ae856e17" xlink:to="loc_us-gaap_ReportingUnitDomain_4f6261f7-2bb4-4b23-b5c3-fdf33ca48d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_c179eafb-badb-41c7-91bb-766ca22c0d62" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_4f6261f7-2bb4-4b23-b5c3-fdf33ca48d86" xlink:to="loc_cah_MedicalUnitMember_c179eafb-badb-41c7-91bb-766ca22c0d62" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="icf1d2eab329b45b8bba9adf37ebc44b6_FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b2a3371-e82e-47d5-ba4c-cdcfddb7758a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b2a3371-e82e-47d5-ba4c-cdcfddb7758a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9d2660d2-045c-427b-b6b0-79126d8ed9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9d2660d2-045c-427b-b6b0-79126d8ed9e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_6324405f-eb33-47be-9680-b3e273b40757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_6324405f-eb33-47be-9680-b3e273b40757" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_b0067975-be69-4e56-8205-11e4abb432f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:to="loc_us-gaap_LiabilitiesAbstract_b0067975-be69-4e56-8205-11e4abb432f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_917aa0e6-4e4c-4957-807a-5865160b151d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cba759c-d41d-4f41-bedf-f6d67a7a3596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cba759c-d41d-4f41-bedf-f6d67a7a3596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cba759c-d41d-4f41-bedf-f6d67a7a3596_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cba759c-d41d-4f41-bedf-f6d67a7a3596" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cba759c-d41d-4f41-bedf-f6d67a7a3596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cba759c-d41d-4f41-bedf-f6d67a7a3596" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_af5cd96c-8ea5-42c4-88cf-35132feec194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_af5cd96c-8ea5-42c4-88cf-35132feec194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b7a7525c-fc8e-45c2-8369-6f8b09032c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b7a7525c-fc8e-45c2-8369-6f8b09032c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d9a824b6-5d2d-48cd-a540-d49073e760c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d9a824b6-5d2d-48cd-a540-d49073e760c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9aa115d7-7425-43da-ac79-53b672ba7900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9aa115d7-7425-43da-ac79-53b672ba7900" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa115d7-7425-43da-ac79-53b672ba7900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9aa115d7-7425-43da-ac79-53b672ba7900" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa115d7-7425-43da-ac79-53b672ba7900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c343d96b-b7e8-4c84-aa62-aa82053d056d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9aa115d7-7425-43da-ac79-53b672ba7900" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c343d96b-b7e8-4c84-aa62-aa82053d056d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1f332bd2-3b69-456c-b29a-c6c831537b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c343d96b-b7e8-4c84-aa62-aa82053d056d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1f332bd2-3b69-456c-b29a-c6c831537b2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i174fea6a069d445fb76c30c707f359c0_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_40e61b83-9826-4341-97bf-8ebbf668e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_40e61b83-9826-4341-97bf-8ebbf668e51f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_3b3e4185-42bc-40c5-90fd-bd652fb8bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_3b3e4185-42bc-40c5-90fd-bd652fb8bc1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_6fd0e5b9-1e38-41f4-91fd-700d5b41e2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_6fd0e5b9-1e38-41f4-91fd-700d5b41e2af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8d347ca1-a030-4999-a497-5d054ca395d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8d347ca1-a030-4999-a497-5d054ca395d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4bca8a1a-13ce-4368-b6b3-9b6bc27c5fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4bca8a1a-13ce-4368-b6b3-9b6bc27c5fbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e60383a8-eb63-4717-acf7-bba40caf9578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e60383a8-eb63-4717-acf7-bba40caf9578" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_de97fa73-50fb-40aa-897c-e53c17bb039b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_de97fa73-50fb-40aa-897c-e53c17bb039b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_de97fa73-50fb-40aa-897c-e53c17bb039b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_de97fa73-50fb-40aa-897c-e53c17bb039b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_de97fa73-50fb-40aa-897c-e53c17bb039b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dea66cf8-33dd-4ecb-9671-b3aa8245b040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_de97fa73-50fb-40aa-897c-e53c17bb039b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dea66cf8-33dd-4ecb-9671-b3aa8245b040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ccb4eeed-c671-49af-b0ee-1397bdf81c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea66cf8-33dd-4ecb-9671-b3aa8245b040" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ccb4eeed-c671-49af-b0ee-1397bdf81c58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_89997f3d-0923-489e-b850-4fee74cdfa78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_89997f3d-0923-489e-b850-4fee74cdfa78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89997f3d-0923-489e-b850-4fee74cdfa78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_89997f3d-0923-489e-b850-4fee74cdfa78" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89997f3d-0923-489e-b850-4fee74cdfa78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84b06825-2269-489f-9ff4-e07df0fb527e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_89997f3d-0923-489e-b850-4fee74cdfa78" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84b06825-2269-489f-9ff4-e07df0fb527e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ae04395a-dde1-4bf1-a04d-461958271b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84b06825-2269-489f-9ff4-e07df0fb527e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ae04395a-dde1-4bf1-a04d-461958271b66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4a79d875-bf9a-4368-818b-d0753166a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_HedgingDesignationAxis_4a79d875-bf9a-4368-818b-d0753166a6e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4a79d875-bf9a-4368-818b-d0753166a6e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4a79d875-bf9a-4368-818b-d0753166a6e5" xlink:to="loc_us-gaap_HedgingDesignationDomain_4a79d875-bf9a-4368-818b-d0753166a6e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4a79d875-bf9a-4368-818b-d0753166a6e5" xlink:to="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9aa21918-00b3-44f6-87f8-4ab39275c900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9aa21918-00b3-44f6-87f8-4ab39275c900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_cb4d0898-0077-41d3-bab9-b23f16eba19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:to="loc_us-gaap_NondesignatedMember_cb4d0898-0077-41d3-bab9-b23f16eba19c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b00628e9-5aca-4e5c-a217-2ad6cca57328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b00628e9-5aca-4e5c-a217-2ad6cca57328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b00628e9-5aca-4e5c-a217-2ad6cca57328_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b00628e9-5aca-4e5c-a217-2ad6cca57328" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b00628e9-5aca-4e5c-a217-2ad6cca57328_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_78fc147c-3ed8-4e20-9156-b36c240a27e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b00628e9-5aca-4e5c-a217-2ad6cca57328" xlink:to="loc_us-gaap_HedgingRelationshipDomain_78fc147c-3ed8-4e20-9156-b36c240a27e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c0887e28-9c37-456e-9160-1506bdeb2b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_78fc147c-3ed8-4e20-9156-b36c240a27e2" xlink:to="loc_us-gaap_FairValueHedgingMember_c0887e28-9c37-456e-9160-1506bdeb2b82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c723f290-5f4d-417a-9bbe-c113a27047f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c723f290-5f4d-417a-9bbe-c113a27047f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c723f290-5f4d-417a-9bbe-c113a27047f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c723f290-5f4d-417a-9bbe-c113a27047f0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c723f290-5f4d-417a-9bbe-c113a27047f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c723f290-5f4d-417a-9bbe-c113a27047f0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2cf6375c-038d-402b-8f95-e06927b6c5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:to="loc_us-gaap_CashFlowHedgingMember_2cf6375c-038d-402b-8f95-e06927b6c5ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_53788fbd-d819-403d-a9fa-d8dfb5b1d5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:to="loc_us-gaap_ForeignExchangeContractMember_53788fbd-d819-403d-a9fa-d8dfb5b1d5a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_46e53e6e-4045-4748-8397-268a183cd41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:to="loc_us-gaap_InterestRateSwapMember_46e53e6e-4045-4748-8397-268a183cd41d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_e11de053-a3e3-4f79-b971-20758b041703" xlink:href="cah-20221231.xsd#cah_MaturityDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_cah_MaturityDateAxis_e11de053-a3e3-4f79-b971-20758b041703" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_e11de053-a3e3-4f79-b971-20758b041703_default" xlink:href="cah-20221231.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_MaturityDateAxis_e11de053-a3e3-4f79-b971-20758b041703" xlink:to="loc_cah_MaturityDateDomain_e11de053-a3e3-4f79-b971-20758b041703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_ce64cefc-5dea-4587-8490-0d3b1156cae5" xlink:href="cah-20221231.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_MaturityDateAxis_e11de053-a3e3-4f79-b971-20758b041703" xlink:to="loc_cah_MaturityDateDomain_ce64cefc-5dea-4587-8490-0d3b1156cae5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="icad71194a9b44b7590ef9f8d470c10d8_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_be189e96-a176-4a86-ae57-767446251560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:to="loc_us-gaap_DebtInstrumentFairValue_be189e96-a176-4a86-ae57-767446251560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_88750f38-2f56-43ba-b98c-c94efc50df0d" xlink:href="cah-20221231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_88750f38-2f56-43ba-b98c-c94efc50df0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec805c9-f150-40f9-b5b5-808d0126c735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec805c9-f150-40f9-b5b5-808d0126c735" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec805c9-f150-40f9-b5b5-808d0126c735" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_afe898a5-e781-4dcf-ae53-a4467b3c7d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_afe898a5-e781-4dcf-ae53-a4467b3c7d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_50a77bde-f3f1-4d1e-8683-0dc782f3918f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_afe898a5-e781-4dcf-ae53-a4467b3c7d39" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_50a77bde-f3f1-4d1e-8683-0dc782f3918f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="iaf50f3c20b544de4a17aa19580b5cf97_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04b29a4b-0a5e-48b6-9d0e-38f4e6e646b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04b29a4b-0a5e-48b6-9d0e-38f4e6e646b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8309ee8b-0e78-4e52-8fc6-2cd1d6b71351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8309ee8b-0e78-4e52-8fc6-2cd1d6b71351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1a3315f4-c8de-4f2d-9a43-856586ba298b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1a3315f4-c8de-4f2d-9a43-856586ba298b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e066b80d-0670-47f8-8f08-f4b7b32a1a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e066b80d-0670-47f8-8f08-f4b7b32a1a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e066b80d-0670-47f8-8f08-f4b7b32a1a5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e066b80d-0670-47f8-8f08-f4b7b32a1a5e" xlink:to="loc_us-gaap_EquityComponentDomain_e066b80d-0670-47f8-8f08-f4b7b32a1a5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d49850fa-9cfa-4f50-99b2-44333b91fecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e066b80d-0670-47f8-8f08-f4b7b32a1a5e" xlink:to="loc_us-gaap_EquityComponentDomain_d49850fa-9cfa-4f50-99b2-44333b91fecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_68629a56-5838-44ab-95c7-4a4cc5107305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d49850fa-9cfa-4f50-99b2-44333b91fecf" xlink:to="loc_us-gaap_TreasuryStockMember_68629a56-5838-44ab-95c7-4a4cc5107305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8ab7849c-2ff8-435e-b2e1-312883013d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8ab7849c-2ff8-435e-b2e1-312883013d94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8ab7849c-2ff8-435e-b2e1-312883013d94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8ab7849c-2ff8-435e-b2e1-312883013d94" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8ab7849c-2ff8-435e-b2e1-312883013d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d84861fa-41c2-46d8-90dd-48aa29fc08dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8ab7849c-2ff8-435e-b2e1-312883013d94" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d84861fa-41c2-46d8-90dd-48aa29fc08dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9dda158a-1800-471a-bd44-9e3c15dcd15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d84861fa-41c2-46d8-90dd-48aa29fc08dc" xlink:to="loc_us-gaap_SubsequentEventMember_9dda158a-1800-471a-bd44-9e3c15dcd15d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_07e1f25e-ac03-4221-85fa-68b0a1b11a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_07e1f25e-ac03-4221-85fa-68b0a1b11a98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_07e1f25e-ac03-4221-85fa-68b0a1b11a98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_07e1f25e-ac03-4221-85fa-68b0a1b11a98" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_07e1f25e-ac03-4221-85fa-68b0a1b11a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_07e1f25e-ac03-4221-85fa-68b0a1b11a98" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A250MillionShareRepurchaseProgramMember_08fa0921-c950-408e-aa29-1a060e0b3611" xlink:href="cah-20221231.xsd#cah_A250MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A250MillionShareRepurchaseProgramMember_08fa0921-c950-408e-aa29-1a060e0b3611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember_58f8fffa-e970-46aa-84d9-47420b4239e2" xlink:href="cah-20221231.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A1BillionShareRepurchaseProgramMember_58f8fffa-e970-46aa-84d9-47420b4239e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_12159f33-309c-4258-a4b1-0ae4d1eb0e06" xlink:href="cah-20221231.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_12159f33-309c-4258-a4b1-0ae4d1eb0e06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_7e43bb17-d87c-4ae8-8d48-934c19cad219" xlink:href="cah-20221231.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_7e43bb17-d87c-4ae8-8d48-934c19cad219" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="id10865262f3947269be5c4c09448af7e_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ff11c298-4f41-4356-ba91-804012d6a664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ff11c298-4f41-4356-ba91-804012d6a664" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3037dac-31c7-4864-89de-eb45b93b8103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3037dac-31c7-4864-89de-eb45b93b8103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a31c2b9f-601a-4290-a448-ac0e628c3037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a31c2b9f-601a-4290-a448-ac0e628c3037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_56b880f4-427c-4619-9888-5bde1dd66958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_56b880f4-427c-4619-9888-5bde1dd66958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d9b3695-1c42-48e8-b4ec-c55895cb5351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d9b3695-1c42-48e8-b4ec-c55895cb5351" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_72ceeaf7-e542-42aa-839e-c7f177be131e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_72ceeaf7-e542-42aa-839e-c7f177be131e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49a6a350-8b02-440b-aeca-bea6842cb4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2c389f0e-a9ec-4a6a-bae5-79595f5f1188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ff11c298-4f41-4356-ba91-804012d6a664" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2c389f0e-a9ec-4a6a-bae5-79595f5f1188" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_27cd5cb7-8921-4809-bb01-94158506b465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2c389f0e-a9ec-4a6a-bae5-79595f5f1188" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_27cd5cb7-8921-4809-bb01-94158506b465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27cd5cb7-8921-4809-bb01-94158506b465_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27cd5cb7-8921-4809-bb01-94158506b465" xlink:to="loc_us-gaap_EquityComponentDomain_27cd5cb7-8921-4809-bb01-94158506b465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27cd5cb7-8921-4809-bb01-94158506b465" xlink:to="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f968394-3f2b-4212-af61-4586ab12d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f968394-3f2b-4212-af61-4586ab12d48c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_e712c142-3139-48e1-aa50-fa0ba1988f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_e712c142-3139-48e1-aa50-fa0ba1988f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_aa7b6af8-18eb-4e2a-9cba-6ba84e6104a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_aa7b6af8-18eb-4e2a-9cba-6ba84e6104a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00a96bb0-e3ca-47c8-b319-8e0d37a497db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00a96bb0-e3ca-47c8-b319-8e0d37a497db" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i554acfc256c640739f54b0c7614b16ab_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_51c0a3ad-5ce9-4841-b4b2-15ba0bd3923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_51c0a3ad-5ce9-4841-b4b2-15ba0bd3923c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_dc550397-cb6f-48a1-99c9-25374ea468ad" xlink:href="cah-20221231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_dc550397-cb6f-48a1-99c9-25374ea468ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_65d96238-7f6a-493a-b3ac-100796627752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_NumberOfReportableSegments_65d96238-7f6a-493a-b3ac-100796627752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c028203f-742e-4d99-b77f-e083650f2d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c028203f-742e-4d99-b77f-e083650f2d0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_27f7525c-73ac-4a11-a41d-4446793d60ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_27f7525c-73ac-4a11-a41d-4446793d60ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_b40269e0-348a-4c1d-9ae3-692ee106193f" xlink:href="cah-20221231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_cah_OpioidLitigationAxis_b40269e0-348a-4c1d-9ae3-692ee106193f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_b40269e0-348a-4c1d-9ae3-692ee106193f_default" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_b40269e0-348a-4c1d-9ae3-692ee106193f" xlink:to="loc_cah_OpioidLitigationDomain_b40269e0-348a-4c1d-9ae3-692ee106193f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_176a8421-b557-4381-8017-f712da8178db" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_b40269e0-348a-4c1d-9ae3-692ee106193f" xlink:to="loc_cah_OpioidLitigationDomain_176a8421-b557-4381-8017-f712da8178db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_df2767fa-e1ab-4c28-ba37-e9cde5dec40b" xlink:href="cah-20221231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_176a8421-b557-4381-8017-f712da8178db" xlink:to="loc_cah_TotalOpioidLitigationMember_df2767fa-e1ab-4c28-ba37-e9cde5dec40b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9fdec747-44f2-4857-9c91-9b550bf0bb54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_srt_LitigationCaseAxis_9fdec747-44f2-4857-9c91-9b550bf0bb54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9fdec747-44f2-4857-9c91-9b550bf0bb54_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9fdec747-44f2-4857-9c91-9b550bf0bb54" xlink:to="loc_srt_LitigationCaseTypeDomain_9fdec747-44f2-4857-9c91-9b550bf0bb54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ad23b1c6-5319-4634-b2ac-1f5c40de1829" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9fdec747-44f2-4857-9c91-9b550bf0bb54" xlink:to="loc_srt_LitigationCaseTypeDomain_ad23b1c6-5319-4634-b2ac-1f5c40de1829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_82b0887d-59d5-49c4-a7d7-050b5b474e76" xlink:href="cah-20221231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ad23b1c6-5319-4634-b2ac-1f5c40de1829" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_82b0887d-59d5-49c4-a7d7-050b5b474e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_0cabd130-6790-4839-9b3a-c070df2453d5" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_cah_CordisDivestitureAxis_0cabd130-6790-4839-9b3a-c070df2453d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_0cabd130-6790-4839-9b3a-c070df2453d5_default" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_0cabd130-6790-4839-9b3a-c070df2453d5" xlink:to="loc_cah_CordisDivestitureDomain_0cabd130-6790-4839-9b3a-c070df2453d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_4d68f573-1471-4f9a-8902-a3294201d35b" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_0cabd130-6790-4839-9b3a-c070df2453d5" xlink:to="loc_cah_CordisDivestitureDomain_4d68f573-1471-4f9a-8902-a3294201d35b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a12e2cad-d00a-49dd-8bd5-e9c094d7166b" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_4d68f573-1471-4f9a-8902-a3294201d35b" xlink:to="loc_cah_CordisDivestitureMember_a12e2cad-d00a-49dd-8bd5-e9c094d7166b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_56a57058-eff3-4a7b-8540-1109acb8277f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_56a57058-eff3-4a7b-8540-1109acb8277f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_56a57058-eff3-4a7b-8540-1109acb8277f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_56a57058-eff3-4a7b-8540-1109acb8277f" xlink:to="loc_us-gaap_SegmentDomain_56a57058-eff3-4a7b-8540-1109acb8277f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_06cde06a-97e6-4827-95ac-af213f533ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_56a57058-eff3-4a7b-8540-1109acb8277f" xlink:to="loc_us-gaap_SegmentDomain_06cde06a-97e6-4827-95ac-af213f533ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_47f502c5-7192-422e-898e-4e69e36c9b7d" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_06cde06a-97e6-4827-95ac-af213f533ddd" xlink:to="loc_cah_MedicalMember_47f502c5-7192-422e-898e-4e69e36c9b7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6f233efc-70b5-4efa-a1d6-3a91a96b563c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_us-gaap_ReportingUnitAxis_6f233efc-70b5-4efa-a1d6-3a91a96b563c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6f233efc-70b5-4efa-a1d6-3a91a96b563c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_6f233efc-70b5-4efa-a1d6-3a91a96b563c" xlink:to="loc_us-gaap_ReportingUnitDomain_6f233efc-70b5-4efa-a1d6-3a91a96b563c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c5aea529-e3c7-4406-9cf0-a2a8fb2f9f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_6f233efc-70b5-4efa-a1d6-3a91a96b563c" xlink:to="loc_us-gaap_ReportingUnitDomain_c5aea529-e3c7-4406-9cf0-a2a8fb2f9f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_62fe9497-7053-4106-a120-695b6ee362c5" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_c5aea529-e3c7-4406-9cf0-a2a8fb2f9f8a" xlink:to="loc_cah_MedicalUnitMember_62fe9497-7053-4106-a120-695b6ee362c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="i6836f3dd3b9f47b9bbcfee9bd49fd48b_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a1af6080-e5ac-4bf6-8977-755c2449795f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f9d3ad3b-7698-4996-bc65-f40bf010f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a1af6080-e5ac-4bf6-8977-755c2449795f" xlink:to="loc_us-gaap_Revenues_f9d3ad3b-7698-4996-bc65-f40bf010f18d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a1af6080-e5ac-4bf6-8977-755c2449795f" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:to="loc_us-gaap_SubsegmentsAxis_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46" xlink:to="loc_us-gaap_SubsegmentsDomain_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46" xlink:to="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_ac8b069d-3028-4b09-82c5-0e7dd2198945" xlink:href="cah-20221231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_ac8b069d-3028-4b09-82c5-0e7dd2198945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember_742687f5-1acf-4e43-9f30-72a33d7646c0" xlink:href="cah-20221231.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_NuclearPrecisionHealthSolutionsMember_742687f5-1acf-4e43-9f30-72a33d7646c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_a9172383-48af-4c53-8a0f-46a4589f319f" xlink:href="cah-20221231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_MedicaldistributionandproductsMember_a9172383-48af-4c53-8a0f-46a4589f319f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_aae52ddd-44aa-450b-a013-20d8ed9dfc11" xlink:href="cah-20221231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_CardinalHealthAtHomeMember_aae52ddd-44aa-450b-a013-20d8ed9dfc11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:to="loc_srt_ConsolidationItemsAxis_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c" xlink:to="loc_srt_ConsolidationItemsDomain_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c" xlink:to="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1d7f9996-835f-48d8-890f-f43dba21e2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:to="loc_us-gaap_OperatingSegmentsMember_1d7f9996-835f-48d8-890f-f43dba21e2c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_958896f4-fcd6-44ec-977b-4d87ee25ef41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_958896f4-fcd6-44ec-977b-4d87ee25ef41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_557273ff-b32f-4ef1-801d-f3b0aba9ce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_557273ff-b32f-4ef1-801d-f3b0aba9ce0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_557273ff-b32f-4ef1-801d-f3b0aba9ce0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_557273ff-b32f-4ef1-801d-f3b0aba9ce0a" xlink:to="loc_us-gaap_SegmentDomain_557273ff-b32f-4ef1-801d-f3b0aba9ce0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_557273ff-b32f-4ef1-801d-f3b0aba9ce0a" xlink:to="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_0fdc3c2c-ce68-420c-9198-0b6b87bb75c9" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:to="loc_cah_PharmaceuticalMember_0fdc3c2c-ce68-420c-9198-0b6b87bb75c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_299397cc-d3c7-4802-a013-e6ae8997754f" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:to="loc_cah_MedicalMember_299397cc-d3c7-4802-a013-e6ae8997754f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="i9cf423426de249eca72916b7b88a7527_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be3a4568-afc6-48da-8b6e-e423abc29472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:to="loc_us-gaap_OperatingIncomeLoss_be3a4568-afc6-48da-8b6e-e423abc29472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_be1a2563-fc8d-45fd-92d4-1a9756493bea" xlink:href="cah-20221231.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:to="loc_cah_JudgmentForLostProfits_be1a2563-fc8d-45fd-92d4-1a9756493bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_944c7be5-cf0b-48bb-85ea-ef0bcc8562af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_944c7be5-cf0b-48bb-85ea-ef0bcc8562af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b9c0e025-c768-45ab-a905-4153f4467a22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:to="loc_srt_ConsolidationItemsAxis_b9c0e025-c768-45ab-a905-4153f4467a22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b9c0e025-c768-45ab-a905-4153f4467a22_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b9c0e025-c768-45ab-a905-4153f4467a22" xlink:to="loc_srt_ConsolidationItemsDomain_b9c0e025-c768-45ab-a905-4153f4467a22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b9c0e025-c768-45ab-a905-4153f4467a22" xlink:to="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2cdc0a17-2a28-4a75-bf54-d5a942db2471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:to="loc_us-gaap_OperatingSegmentsMember_2cdc0a17-2a28-4a75-bf54-d5a942db2471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2deea391-dba3-4784-9327-46d221860489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2deea391-dba3-4784-9327-46d221860489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4a5cfae2-7b37-4576-ace4-8b9af4f45527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4a5cfae2-7b37-4576-ace4-8b9af4f45527" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4a5cfae2-7b37-4576-ace4-8b9af4f45527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a5cfae2-7b37-4576-ace4-8b9af4f45527" xlink:to="loc_us-gaap_SegmentDomain_4a5cfae2-7b37-4576-ace4-8b9af4f45527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a5cfae2-7b37-4576-ace4-8b9af4f45527" xlink:to="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_fedd49b9-4e3e-423b-a318-25eb030f8cc9" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:to="loc_cah_PharmaceuticalMember_fedd49b9-4e3e-423b-a318-25eb030f8cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_4d72332d-ef88-4af6-b4df-399539975a05" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:to="loc_cah_MedicalMember_4d72332d-ef88-4af6-b4df-399539975a05" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended" id="if0d4687faf7e4b1cb400ea635e4658fd_SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a54a9f66-a812-4788-b650-30305555918b" xlink:href="cah-20221231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_339c36b1-607e-4cec-8e02-3e4e86a59c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a54a9f66-a812-4788-b650-30305555918b" xlink:to="loc_us-gaap_Revenues_339c36b1-607e-4cec-8e02-3e4e86a59c30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:href="cah-20221231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a54a9f66-a812-4788-b650-30305555918b" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:to="loc_srt_ConsolidationItemsAxis_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c" xlink:to="loc_srt_ConsolidationItemsDomain_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c" xlink:to="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_48d308d7-e62d-4e47-a589-2ff1be5e272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:to="loc_us-gaap_OperatingSegmentsMember_48d308d7-e62d-4e47-a589-2ff1be5e272b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_cab10ceb-5964-4453-8065-b21ef9416d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_cab10ceb-5964-4453-8065-b21ef9416d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:to="loc_srt_StatementGeographicalAxis_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2" xlink:to="loc_srt_SegmentGeographicalDomain_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2" xlink:to="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1cba9d40-3610-41a5-b9c5-7e4ff888f5c4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:to="loc_country_US_1cba9d40-3610-41a5-b9c5-7e4ff888f5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_193b3693-b71c-40c4-aa32-7830dc76c637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:to="loc_us-gaap_NonUsMember_193b3693-b71c-40c4-aa32-7830dc76c637" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i5dd53964844245549bea096044c7902b_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_02a6c3a7-2328-48b2-994e-d5398456dc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:to="loc_us-gaap_Assets_02a6c3a7-2328-48b2-994e-d5398456dc74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_16e1b8da-c5aa-45f0-ab58-388228f9a947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_16e1b8da-c5aa-45f0-ab58-388228f9a947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e1db7414-094c-4ecc-af04-b79ff20668ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_srt_ConsolidationItemsAxis_e1db7414-094c-4ecc-af04-b79ff20668ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e1db7414-094c-4ecc-af04-b79ff20668ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e1db7414-094c-4ecc-af04-b79ff20668ad" xlink:to="loc_srt_ConsolidationItemsDomain_e1db7414-094c-4ecc-af04-b79ff20668ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e1db7414-094c-4ecc-af04-b79ff20668ad" xlink:to="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4013c639-78d0-4e44-9dab-a14deb6348b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:to="loc_us-gaap_OperatingSegmentsMember_4013c639-78d0-4e44-9dab-a14deb6348b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c10b7a15-61f0-46dd-a669-be5c4b9c0ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c10b7a15-61f0-46dd-a669-be5c4b9c0ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_859535e9-5393-461b-9542-e89156539427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_859535e9-5393-461b-9542-e89156539427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_859535e9-5393-461b-9542-e89156539427_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_859535e9-5393-461b-9542-e89156539427" xlink:to="loc_us-gaap_SegmentDomain_859535e9-5393-461b-9542-e89156539427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_859535e9-5393-461b-9542-e89156539427" xlink:to="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_dfb63a22-39dc-486f-99ea-f8005e23bf36" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:to="loc_cah_PharmaceuticalMember_dfb63a22-39dc-486f-99ea-f8005e23bf36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bb0eb920-9df3-4584-83b9-0b777ce24559" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:to="loc_cah_MedicalMember_bb0eb920-9df3-4584-83b9-0b777ce24559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_edc13744-11fe-4e90-b653-5bf48a99413e" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_cah_CordisDivestitureAxis_edc13744-11fe-4e90-b653-5bf48a99413e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_edc13744-11fe-4e90-b653-5bf48a99413e_default" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_edc13744-11fe-4e90-b653-5bf48a99413e" xlink:to="loc_cah_CordisDivestitureDomain_edc13744-11fe-4e90-b653-5bf48a99413e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_e8f133e9-b148-43bb-8898-9bfc73e6d73e" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_edc13744-11fe-4e90-b653-5bf48a99413e" xlink:to="loc_cah_CordisDivestitureDomain_e8f133e9-b148-43bb-8898-9bfc73e6d73e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_840b8c03-411d-45fa-83f6-c369432e3483" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_e8f133e9-b148-43bb-8898-9bfc73e6d73e" xlink:to="loc_cah_CordisDivestitureMember_840b8c03-411d-45fa-83f6-c369432e3483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2762558e-57bc-41e7-a858-a0da7e9ac633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_us-gaap_ReportingUnitAxis_2762558e-57bc-41e7-a858-a0da7e9ac633" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_2762558e-57bc-41e7-a858-a0da7e9ac633_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2762558e-57bc-41e7-a858-a0da7e9ac633" xlink:to="loc_us-gaap_ReportingUnitDomain_2762558e-57bc-41e7-a858-a0da7e9ac633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_0e7de1d4-bc7b-4033-8991-0087a36189d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2762558e-57bc-41e7-a858-a0da7e9ac633" xlink:to="loc_us-gaap_ReportingUnitDomain_0e7de1d4-bc7b-4033-8991-0087a36189d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_4054c1f8-a8a7-4e53-96f5-ca011ab22d2c" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_0e7de1d4-bc7b-4033-8991-0087a36189d1" xlink:to="loc_cah_MedicalUnitMember_4054c1f8-a8a7-4e53-96f5-ca011ab22d2c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="id5b22770f52d45da8cb1178857a40c17_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_d9c76061-e8af-4732-b483-1481921520bf" xlink:href="cah-20221231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_cah_VestingPeriodinyearsforShares_d9c76061-e8af-4732-b483-1481921520bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_fc94a2cb-0cee-4b51-a138-f7b7ceba2484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_fc94a2cb-0cee-4b51-a138-f7b7ceba2484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7fee6fa9-e2b5-4769-8ad0-355a61016c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7fee6fa9-e2b5-4769-8ad0-355a61016c90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_69d2bb08-1a92-4d07-a264-c583d48f086a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_69d2bb08-1a92-4d07-a264-c583d48f086a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_52764ecf-87f3-4790-b196-fe0adf6987f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_52764ecf-87f3-4790-b196-fe0adf6987f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b133405a-89b9-40f5-a1a0-02ff98006dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b133405a-89b9-40f5-a1a0-02ff98006dfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e801664c-1067-43da-8b4f-c484c6012a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:to="loc_us-gaap_AwardTypeAxis_e801664c-1067-43da-8b4f-c484c6012a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e801664c-1067-43da-8b4f-c484c6012a18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e801664c-1067-43da-8b4f-c484c6012a18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e801664c-1067-43da-8b4f-c484c6012a18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e801664c-1067-43da-8b4f-c484c6012a18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1b869dbd-75e0-4f91-b1a3-25f870ef4d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1b869dbd-75e0-4f91-b1a3-25f870ef4d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_40803652-491a-483a-8c3b-8dfc144a674b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:to="loc_us-gaap_PerformanceSharesMember_40803652-491a-483a-8c3b-8dfc144a674b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99d1094b-cef7-4e8a-92dc-5d72cd589aa8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:to="loc_srt_RangeAxis_99d1094b-cef7-4e8a-92dc-5d72cd589aa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99d1094b-cef7-4e8a-92dc-5d72cd589aa8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99d1094b-cef7-4e8a-92dc-5d72cd589aa8" xlink:to="loc_srt_RangeMember_99d1094b-cef7-4e8a-92dc-5d72cd589aa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99d1094b-cef7-4e8a-92dc-5d72cd589aa8" xlink:to="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbaf796e-e3ff-45d5-9e62-2fb5e6e2b659" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:to="loc_srt_MinimumMember_dbaf796e-e3ff-45d5-9e62-2fb5e6e2b659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3234dc9b-cab8-4b43-8c5f-dd2a808cd451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:to="loc_srt_MaximumMember_3234dc9b-cab8-4b43-8c5f-dd2a808cd451" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="i064e8b5f96414fd49360e8fe6b38ea69_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a88a62b3-2739-4830-bc5b-b993460152bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_85f2ed14-b94a-45d0-a6b8-8480fad7ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a88a62b3-2739-4830-bc5b-b993460152bc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_85f2ed14-b94a-45d0-a6b8-8480fad7ef30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb197251-406d-4180-a30c-78dbcbd86ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a88a62b3-2739-4830-bc5b-b993460152bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb197251-406d-4180-a30c-78dbcbd86ca7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_225ef4c3-98ab-4298-bfc8-f60186ba208f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb197251-406d-4180-a30c-78dbcbd86ca7" xlink:to="loc_us-gaap_AwardTypeAxis_225ef4c3-98ab-4298-bfc8-f60186ba208f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_225ef4c3-98ab-4298-bfc8-f60186ba208f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_225ef4c3-98ab-4298-bfc8-f60186ba208f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_225ef4c3-98ab-4298-bfc8-f60186ba208f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_225ef4c3-98ab-4298-bfc8-f60186ba208f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_457b871e-728c-4f49-a5cb-b91c3ef308de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_457b871e-728c-4f49-a5cb-b91c3ef308de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_46db9a80-8d40-484a-b0bf-88feb0eadb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:to="loc_us-gaap_PerformanceSharesMember_46db9a80-8d40-484a-b0bf-88feb0eadb4b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="i5831e283ab7a4d14badd0c10dd466ce6_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6f58ba6-200d-4210-a641-c2297dfd5380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4030b1f7-7af3-4955-9aaa-a48ac002b3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6f58ba6-200d-4210-a641-c2297dfd5380" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4030b1f7-7af3-4955-9aaa-a48ac002b3f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e43a66d2-284d-42d0-b646-242e09b51694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6f58ba6-200d-4210-a641-c2297dfd5380" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e43a66d2-284d-42d0-b646-242e09b51694" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f9ce70b-0e14-4210-b268-23101b892c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e43a66d2-284d-42d0-b646-242e09b51694" xlink:to="loc_us-gaap_AwardTypeAxis_2f9ce70b-0e14-4210-b268-23101b892c3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f9ce70b-0e14-4210-b268-23101b892c3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2f9ce70b-0e14-4210-b268-23101b892c3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f9ce70b-0e14-4210-b268-23101b892c3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_414fdbac-ca20-4fca-bddd-fea97a5f5691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2f9ce70b-0e14-4210-b268-23101b892c3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_414fdbac-ca20-4fca-bddd-fea97a5f5691" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="i8e5f5afb3b5d4aef9828ac54902741b9_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_323361ac-95d8-4bbd-a0c3-5e7a7ab1ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_323361ac-95d8-4bbd-a0c3-5e7a7ab1ce98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4738410d-e0ce-465d-a94b-996465f4facf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4738410d-e0ce-465d-a94b-996465f4facf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82e51f73-b523-482c-b123-e60b41936fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82e51f73-b523-482c-b123-e60b41936fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec26a809-e7bd-4a63-955c-e08cf1f18a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec26a809-e7bd-4a63-955c-e08cf1f18a31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_41c7884b-69ce-4b53-ba76-fbaa7e4df6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_41c7884b-69ce-4b53-ba76-fbaa7e4df6ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6bd559e1-89c7-4f0f-84bb-4e58b63016da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6bd559e1-89c7-4f0f-84bb-4e58b63016da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114d17cb-f3cc-4480-a4e8-82659c0c77c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2aed594b-f0e2-4624-9c8c-c2c8c2a81e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2aed594b-f0e2-4624-9c8c-c2c8c2a81e3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b817f834-4cd0-414f-86f8-311304e815b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b817f834-4cd0-414f-86f8-311304e815b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f7da902-c601-4b1b-ad34-354d45f35706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f7da902-c601-4b1b-ad34-354d45f35706" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20c15e39-901b-4951-8bfc-a1d8dd499d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20c15e39-901b-4951-8bfc-a1d8dd499d12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_24dce2c2-2244-4c67-b75e-d98855f5f675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6a32a6e-1973-4a76-94a8-f27775176746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6a32a6e-1973-4a76-94a8-f27775176746" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_820504d2-9ef2-4a00-9550-8d96f7dbebbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6a32a6e-1973-4a76-94a8-f27775176746" xlink:to="loc_us-gaap_AwardTypeAxis_820504d2-9ef2-4a00-9550-8d96f7dbebbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_820504d2-9ef2-4a00-9550-8d96f7dbebbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_820504d2-9ef2-4a00-9550-8d96f7dbebbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_820504d2-9ef2-4a00-9550-8d96f7dbebbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c285948-a2af-4f40-a2a3-cf468110c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_820504d2-9ef2-4a00-9550-8d96f7dbebbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c285948-a2af-4f40-a2a3-cf468110c45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0baee733-596c-460f-91f8-c19daef070d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c285948-a2af-4f40-a2a3-cf468110c45b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0baee733-596c-460f-91f8-c19daef070d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="id68aef90347a4cada6f2c7a1480de757_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0a6ab09e-c469-49fe-ad56-e185e63ef688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0a6ab09e-c469-49fe-ad56-e185e63ef688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_afac1820-75bc-4179-b36f-dea50f440880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_afac1820-75bc-4179-b36f-dea50f440880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25653020-ebe8-41d5-abd4-b7ab12945e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25653020-ebe8-41d5-abd4-b7ab12945e79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_654b8a82-856c-44fe-8aee-1acd0f65990c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_654b8a82-856c-44fe-8aee-1acd0f65990c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d97a16e2-6930-46f2-b7a5-8ea1d1fb13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d97a16e2-6930-46f2-b7a5-8ea1d1fb13a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff370c09-e0e7-4b47-a9bb-790b38f18dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48c6ba6f-5c8e-435d-98bf-05bc2869b08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48c6ba6f-5c8e-435d-98bf-05bc2869b08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb86d8a8-84c8-4b72-9b7e-0270ca0bcc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb86d8a8-84c8-4b72-9b7e-0270ca0bcc5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d9741f59-af32-48cf-a4ea-a3f090b559ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d9741f59-af32-48cf-a4ea-a3f090b559ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_449f6f9a-4a2a-429d-bc42-5d1f2a752895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_449f6f9a-4a2a-429d-bc42-5d1f2a752895" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4962e957-fa9e-454c-8148-b21509a9d5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d4d37e7f-16b2-42c7-b1b5-1695ef61c226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d4d37e7f-16b2-42c7-b1b5-1695ef61c226" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_34229b3e-41be-4391-9f03-758db9dd3d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_34229b3e-41be-4391-9f03-758db9dd3d2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_75c5a353-e149-4341-995e-35cb708e808e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_75c5a353-e149-4341-995e-35cb708e808e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c87d779e-5bd5-48d5-bf20-70fe0b37a6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c87d779e-5bd5-48d5-bf20-70fe0b37a6a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_763e6e2b-0736-4f77-bf71-2bb933d60b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c87d779e-5bd5-48d5-bf20-70fe0b37a6a1" xlink:to="loc_us-gaap_AwardTypeAxis_763e6e2b-0736-4f77-bf71-2bb933d60b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_763e6e2b-0736-4f77-bf71-2bb933d60b2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_763e6e2b-0736-4f77-bf71-2bb933d60b2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_763e6e2b-0736-4f77-bf71-2bb933d60b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb380a61-ad07-4472-b9bf-5390e93d8584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_763e6e2b-0736-4f77-bf71-2bb933d60b2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb380a61-ad07-4472-b9bf-5390e93d8584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_18f26208-38b0-4298-9e27-de4d921a24db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb380a61-ad07-4472-b9bf-5390e93d8584" xlink:to="loc_us-gaap_PerformanceSharesMember_18f26208-38b0-4298-9e27-de4d921a24db" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cah-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de10429f-68bb-4228-9960-cf0499f5ed93,g:6028fbd5-3398-4741-87cc-7f6715aa56e4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_82d30f2f-6bd1-40a2-8fcb-a61000d5965a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_0082acc3-238a-4c3d-bd2b-bc7f4ded2989_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_bc66935f-6a42-44f9-91f9-70deb18fe12b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_3123537b-4b03-48e2-89b3-28aa6815edb4_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e2483f85-400e-4901-b07b-ea209ec61387_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ac307049-e76f-48aa-97dd-ae9e0d02a24a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_590db1c0-eb04-478e-8cf6-fd301c3069d4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_531d191a-55f4-4aae-b233-11ea5997bbe8_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d897feec-2188-4aeb-806d-6842c1e16490_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_9fdbfa52-7656-46fb-a73d-ce5c36aaeca2_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_6daa3d9b-ccaf-4f16-b02c-6e74b32f88e9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f2e0506c-59ac-4f41-a8b1-c0f9a6cfbea7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_35f39efd-6272-48a2-9605-63eaa9582284_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_d1211f25-9f77-4bd6-9d78-53159ba5ccc7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_6cfcd88f-0d07-49e3-b41a-2c8ce51f4c3d_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:href="cah-20221231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_30625b75-5b4e-420b-a501-8358030e71a3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_fa00635f-63fc-4734-a5a0-d75155189951_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e46d449e-3f2f-413c-9a30-04fe4124e8ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_85bd8ea5-e81d-405d-ad4a-de1868690ce9_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_bc29f978-1683-432b-95dd-ee3b50b22909_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ac8b8a15-b9d3-4099-8363-292f21605f5b_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_47125efb-a1bb-4749-830e-047f92f0db20_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_23ed6b2a-e979-472d-82ae-0241e9e36649_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_1e9953c1-e935-42dc-acc1-00c741ddcac5_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20221231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_ba226fd3-6e76-4322-9212-049b791d0049_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_3596a134-005b-45b6-a391-e404053f0117_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20221231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2ff960a0-50cd-4d5a-b96d-e1ec435b5161_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7ace6a60-89ef-4714-93e9-0a29868085a2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_1af8c84b-93ae-4293-9926-ba563413c749_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20221231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4f299d4a-57e0-46d9-a0e2-07b66f2c5782_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1b56a6d-d6b7-46b4-8f93-3c565e246394_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureDomain_4b4549f2-2159-487c-9dd5-7b87b04159a7_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_label_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_documentation_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureDomain" xlink:to="lab_cah_CordisDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9e6325be-63f7-4779-bcfb-9fd8c25f5634_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_079c5918-a2dd-4ed3-bb7c-15d83169b0d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss) attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_eaf27103-7df9-49d5-a597-eb9670a397b8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateAxis_83e8aac6-ae47-4f88-a978-509aa6c5af35_terseLabel_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_cah_MaturityDateAxis_label_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Axis]</link:label>
    <link:label id="lab_cah_MaturityDateAxis_documentation_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis" xlink:href="cah-20221231.xsd#cah_MaturityDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateAxis" xlink:to="lab_cah_MaturityDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f19ef672-cfcc-47a3-94a2-bfbd0fdd0b6d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6464cd53-2624-4ea0-b167-f55ea8a70311_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_6f9e2c94-48e1-457b-8964-3ef4f843faef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5b96658f-ad09-4583-a9e9-0c5bc375441b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8233b069-3684-4287-b2e2-9ab888e5fcfd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_f4668807-129e-431f-80a4-3c49c4c65b79_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WV_cb3c0875-c05e-44e1-9555-48572298c872_terseLabel_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:label id="lab_stpr_WV_label_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_5dfc5f85-1b54-49e0-9662-842676b79ffa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_e64c08b0-a1eb-48a5-bc89-923b5b2169af_terseLabel_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents reclassified from/(to) assets held for sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_label_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_documentation_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:href="cah-20221231.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:to="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4cc675d7-7e78-4ba0-a28b-95756e2ddfc7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3c3f4b82-fb63-434d-92dd-025d7dda18b0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_87a89340-4de8-44e4-a4e7-02e8ecc6a90e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_6a6a0f60-075d-46a2-9e58-cbe0844a9d98_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_dd92c032-e746-496c-9845-ed25f455fc51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_211f0714-5095-4550-9d41-8cd8206da38c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f94096f1-5ed2-4c3d-ba89-9feb77ca59b0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_3eb38d05-dabc-4ebf-97c4-a3208de4fcb0_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20221231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_613ea53c-f85e-4de5-ac59-53242ae74f42_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_186afff4-ffb7-41ab-bcf6-034e331a0e8b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7ac7d8d9-b4e9-45e9-96a3-dc1d7ae4ee26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_270e8c2e-b84d-4f51-b90f-5caaaad9724d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_ad8c9ac2-b32c-4e9d-9c19-ac56f68bbff3_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project costs on investment and other spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20221231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_478fa8c9-bd5e-4b25-9b5d-4e0e7b864e88_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_349723e5-a8ae-4140-821a-2be431942ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_14f611a5-e226-46b8-9af6-115ad769dbf1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7968d573-c7d6-4bee-9d19-93cb5fc91e04_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_4a62e41f-8dd7-4ae8-bf52-5d30bb4897cb_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_673e52d7-4a53-449f-af03-0845d5cf66e9_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20221231.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6503bc9c-428b-4ecd-b795-0425243908e0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_34a00c0f-6c21-4137-b41a-fdb2a816f0ef_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_565aa7bf-df14-438d-ae85-83de5b30962d_terseLabel_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program</link:label>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember" xlink:href="cah-20221231.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A1BillionShareRepurchaseProgramMember" xlink:to="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_f0deb8fe-e0d7-4d8f-b769-84c0b0c1b002_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_e529f3a8-9d98-4717-a0e1-e992e78a14ae_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax proceeds/(withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20221231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_6a6e272f-bc90-4bd6-ae17-22329d366f5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures, net of cash sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_bbf6752b-7de9-41ff-99ca-1b0bbc855c40_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20221231.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2ee2e4e-ee7c-4a73-bea2-efe9a2a5dac5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_fcdd5600-1caa-4e20-87de-e1deead0189e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1f303ef0-4cf2-4282-a498-be537acf92d1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1026861a-721e-432f-9201-4dd0c5862bd8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e9295dd-e086-42c4-b17c-b89377192e67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingUSTerritories_d0f8e307-f85c-40e9-a564-8f4ef29eea7e_terseLabel_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_label_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_documentation_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories" xlink:href="cah-20221231.xsd#cah_SettlingUSTerritories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingUSTerritories" xlink:to="lab_cah_SettlingUSTerritories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_7fda002a-7780-456b-b9eb-069020ef8d8a_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f11cbc7e-426f-4128-82aa-28c40cd13032_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1ea911d0-7926-47a9-ab15-acbff2181ba1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_174a6529-bf58-49df-ae75-94e992c7a989_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_839bb7a1-ef09-4f30-b80b-f874e011413f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_27684c14-0271-4bb6-9815-2e1e000858fb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91947b9f-6fa1-4f6f-9fed-5e446f556687_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_5b18c916-0b94-4183-aaeb-be8623af6a85_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_de05af63-f5e9-40b8-be29-e1bc6b0feff5_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c774907c-3eae-46d8-8f10-988af4119dc8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0fc60ea6-d723-4077-a04a-048cf360b3ae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6d93bf63-6217-47ad-9b46-58daa20174f8_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d3f44039-ff4f-4b13-92dc-df3bdb3ceeca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1d9ed08a-b917-4c90-a00e-31bb387ee0ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d8f2f36c-a4cc-4d72-916a-bc3661e60c1a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureMember_5369fe75-1d75-472a-809c-1fb55696870f_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_label_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_documentation_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureMember" xlink:to="lab_cah_CordisDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_c6475f3d-093f-4a09-a3d1-ec5e3927db21_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20221231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_ad8f7b5b-b281-497c-9a3f-592e108a7a50_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20221231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_10fe5b85-d9f1-464b-ab1c-2ae2539b81cd_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_08c1665c-0ab1-4107-ab0a-413a65e0ccb5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_dffa0014-8e3e-423a-8f88-397a1e92885a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_6d6562a3-6e59-4ee7-97a0-82d0affca079_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e9f172e0-eebc-4144-b619-329c5b53dfd5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_23340c88-89ca-44f8-bee2-4be73c938ba7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_5553d5ff-6a12-45c5-a206-9e6d11575c15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain)/loss on sale of equity interest in naviHealth</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_ef1239c7-7d8e-4a8f-a353-35f70eb43188_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20221231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0e080921-b4d4-4663-9255-44967f186dec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c924fd69-f3eb-4dc2-9806-74e55e1c9fde_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_ad6e68d8-a5b2-4ec2-bb5b-26a33eba9088_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_01cad306-204a-413a-b673-6fcd70d8a748_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1774dbc0-c0a1-4f83-96f8-3fc9baae130e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4eb8bb3c-4334-4df3-8b9d-c3fa2218bbb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_31956165-868f-4afb-a8e9-3be8985d9798_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_7c6adb63-f6c9-4b99-b679-d1c261488ef0_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b998a06d-eadf-463d-acf2-b9a990da8485_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56a7eb6a-dcf2-4d88-a108-0de080805c05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3c5b989-a48e-446e-86c0-053de9f24371_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e70ed43b-4af6-4739-9788-46be929b55eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_db9f3e42-ee15-48f2-98b3-d3842d134404_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2537d2ff-b147-498e-96a4-18e7198af29d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b9678d27-1ddb-4749-bb78-e6e1ba9445f6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_f66d8f42-2c68-4eba-a03b-93c9cda8a810_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_93ddacb2-e119-4332-b3e8-5fb8092980c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_509e0e82-4c7b-4bc9-8dfd-8a544256c07c_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5ca6da82-f3f1-4d22-bf0f-1cbf37ae10f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_a2c9c112-e64a-4707-add8-6dd9827080a2_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20221231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_aa6aa12e-a730-4f47-a5c3-71cc28d78be3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentAxis_00f13d02-f1aa-4034-b055-ec9846dca73b_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_label_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentAxis" xlink:to="lab_cah_GoodwillImpairmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fe1982dc-00c0-4ef7-9692-b82018ec69fc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_ce8b060b-ca44-4dc0-bd9f-816d8fc64b31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_c0f6d9b1-6e1a-4a10-9797-02b347c4f61b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_094b1f8f-09e0-4eb9-bf1e-c5180b54ba84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5e40a43f-a8d2-4440-a546-06709111a641_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_AL_5d5c0daf-1009-4981-9670-002711a9bfed_terseLabel_en-US" xlink:label="lab_stpr_AL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALABAMA</link:label>
    <link:label id="lab_stpr_AL_label_en-US" xlink:label="lab_stpr_AL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALABAMA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_AL" xlink:to="lab_stpr_AL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fd1d49e8-55de-4101-9981-7bf99cfa1926_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b9044663-c36b-41f9-9d30-312bd5bd0572_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_578b39ad-10f0-4d9c-9996-a7d51d27cd9b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductLiabilityAccrualPeriodExpense_c2edb670-ce1e-4bfd-90fc-3f225dfe655d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Accrual, Period Expense</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityAccrualPeriodExpense_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Accrual, Period Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualPeriodExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:to="lab_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_2cabd436-2a03-467b-bbd1-345ac27c5a82_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d337f599-4a4f-4667-a2fa-f9ed64cec387_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_19f5104f-c8d0-4127-89b7-f5ba6beeb634_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ec91ee4c-6675-4467-8166-647d2f36dd13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_c0aba342-d51b-4367-be16-84f30da32691_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_746665b9-aa08-44e0-be4d-f74d1775d2a4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_b0565871-0c29-4fd2-92c1-de5e41d4b68f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1c5def5e-5701-4203-94bd-ab8c00b212f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_45b61992-5a63-4a3e-ae53-b23af3f05fd6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0438c4a0-bd8b-4fa6-906d-291f797af310_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_80bbf45e-ba77-4e51-926e-24b6602b8e71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_6b600a73-eb26-411c-a35e-718752ba5138_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_688411b6-1c04-4fe0-9799-7e6503f48f1c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2bf6a0a3-cd15-4ab7-9bce-fbb4df90214b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b4818ce4-fe9e-4bad-947c-def94b3a6e6f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_539656c4-0968-4ce8-aa96-6308121ab267_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_1723de9d-5622-4ad7-96b6-06c823bfc4a3_terseLabel_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_label_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_documentation_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput" xlink:href="cah-20221231.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TerminalGrowthRateFairValueInput" xlink:to="lab_cah_TerminalGrowthRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e1be42c2-f8bc-4047-a7ad-d5ba7096ed21_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c4abaf97-e62d-45eb-89ab-63ef936261a1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c05aa1cb-0520-48cd-bd99-e4f817066622_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_11786467-1fe6-4b26-8bf6-ee6d3c7bfe9c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a19cfc99-85c4-4e1b-8b51-42055f6b6e01_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_89ebb56e-fec1-4a77-a902-9b28a34986af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f3931fbf-03e4-4045-8576-d055a9e63a3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_176a782e-221f-478d-b5de-cbd38ba3c686_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_05ebff05-48e2-4fe8-b7a9-81cc203208b1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5ee4b92f-3c06-4d30-a865-58f21b986f09_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3789c23b-96e5-42e2-a833-0c876811fc9d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_97c608f6-59d5-4a40-ab2e-27e6f78c82bf_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20221231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_674cbc29-d61c-483c-a908-6e6857de99fd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_49ae1238-3c17-43ca-b8e4-4818e7468945_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ac7ca983-0e45-4c04-9b31-e253134a4662_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0355f03c-ad27-4be0-96e5-7a165d5083cb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1adedaa1-18e5-43e9-9c3d-86f3e53ea88f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees_dc14793c-0d9e-441d-95c0-5b8653068865_terseLabel_en-US" xlink:label="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Insurance Settlement Before Attorney Fees</link:label>
    <link:label id="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees_label_en-US" xlink:label="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Insurance Settlement Before Attorney Fees</link:label>
    <link:label id="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees_documentation_en-US" xlink:label="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Insurance Settlement Before Attorney Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:href="cah-20221231.xsd#cah_GrossInsuranceSettlementBeforeAttorneyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:to="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_JudgmentForLostProfits_6b261556-81e6-4263-81fa-f66c93ee6c41_terseLabel_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_label_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_documentation_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits" xlink:href="cah-20221231.xsd#cah_JudgmentForLostProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_JudgmentForLostProfits" xlink:to="lab_cah_JudgmentForLostProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_275c8956-80d8-4a8c-8ebd-6da84e25416a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8f17fe9c-7e61-40ef-9b00-4a37e116bdc7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_6b1d3957-6be1-446d-a5de-34a239888332_terseLabel_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_label_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_documentation_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:href="cah-20221231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:to="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2863830c-446d-4c64-b8f1-3dbce53084d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_396f7872-9c5b-4749-a23c-2919556551b8_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_1ae3720a-e557-4b16-845a-06d7348cded2_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f560fa51-4324-4707-b76a-72033ffc1d90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_479ead54-5f00-414c-aef4-113631666c62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0d73d71f-cb37-48c9-a821-5eb6dfcd0a2a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_402c13cb-c526-4020-ab0a-fe014baa0a79_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20221231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ba810602-381f-4ffa-929f-8f2cd122ae82_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1493f163-72f4-494f-8318-ddf3b8a7922b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_fa910033-0006-42b2-a02d-8a045a5fd079_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_cd063483-2fc2-4d19-824e-ca8b18a27a06_terseLabel_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_label_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_documentation_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations" xlink:href="cah-20221231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalLongTermandShortTermObligations" xlink:to="lab_cah_TotalLongTermandShortTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_b9f072c8-a772-4832-9eb6-d49792e6f499_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CARESActDomain_7c240cc6-1488-4f46-a95d-530a16312200_terseLabel_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_label_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_documentation_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain" xlink:href="cah-20221231.xsd#cah_CARESActDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CARESActDomain" xlink:to="lab_cah_CARESActDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_e566de11-6c61-4e13-a369-1d1dcc429e99_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_9d828377-e69a-4d54-a228-5d3c28feaee6_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_573479d0-0c68-4e11-8275-b3b13cbcfd20_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d8e38a2d-f078-4232-8572-a4d77288cb8a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c5a05c78-a4e1-4860-9f5a-c3367d94b5ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_17d09235-1965-467d-b6f0-bdebc00d19f8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c652ce23-e234-4bf9-bba8-f6e7fad59fa0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_4b6e0ca4-a108-4fdb-9371-b66555d8d92a_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and patents</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20221231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_534f802a-7349-4c8d-8c07-50afe178cc2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bb4fef53-fa52-4e91-8960-9a9d067b7944_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7d11abae-83af-4d2d-a53c-9ad1233d6069_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_c0ee370b-cb44-44a6-9f6f-59bd19cb03ef_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_263e9c10-a552-4bb8-8ccd-526cb44bc790_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_66ffda89-e076-46e4-bba5-ddc5a85d1cd3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_1dd230c0-91c2-432a-8395-168c5b1d9075_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_c31eebb8-a283-4990-a2c2-ac3f13d05acd_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_4bf2d788-2e5e-4e8a-99d6-ff48267de561_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Solutions [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember" xlink:href="cah-20221231.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthSolutionsMember" xlink:to="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9a9fadeb-f1de-4dfa-8990-42d6ce69e55b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b72783f0-da7f-41d8-9e30-a6dc71cdcc0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_43ef3059-312c-4ded-8215-57292445d2d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_d646e8ab-77ee-4497-bc7f-b81f4d91c4a0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4c60ba04-8e7c-4841-a1da-ca0008708093_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7de7ca17-539a-4611-8830-1087cff474ab_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_b90a55bf-61c6-4762-8fdf-5a1945955380_terseLabel_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_label_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_documentation_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:href="cah-20221231.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:to="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c6283ff2-37ad-4ab3-983e-ff4dda6adf34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e9ee38cb-0544-4ae8-bb1d-9b2f93f0245a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_9e6700b8-c078-4442-a10d-48faa20b14ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_492d71e5-67c5-4795-a6f2-2a2a7871f328_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d77867d3-1390-4629-9c3e-df90a66f27d8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_2a76ad12-c7ce-4973-8807-8439e866432d_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20221231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_03caf569-cd2c-496d-85ee-90348823bb17_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20221231.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_57e6f6e2-5797-4cfb-88d5-5d77ed09bcab_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d07532ef-a522-4415-b0e5-c4d8f0960280_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_c816b8d2-1961-455e-8eee-72111d61c180_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ae670ac8-8ba9-46c3-aef0-8695ea0b5de6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_42210c2e-51e9-48e1-a420-11196f7fa128_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_7ee52bd5-422f-4974-b7cc-9d50a05204b7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5dbcf88c-1404-4887-841b-ed90811684ee_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_381b9625-1899-4d63-99e9-007dfc8bb4a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_885d89ab-358b-4081-a73e-be4b22a6da9a_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_7a106ed0-417d-408b-9735-d977e7bb796d_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_label_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:href="cah-20221231.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:to="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingStates_04d9c7ce-0c21-41f1-b685-b007829593f5_terseLabel_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_label_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_documentation_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates" xlink:href="cah-20221231.xsd#cah_SettlingStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingStates" xlink:to="lab_cah_SettlingStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dc7200ad-386d-4852-b937-b6449c2149cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a8e1303b-a410-4f25-91b0-70ebb62868b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_67d5edf3-45be-431f-93f9-3fe8c24431ca_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_be90fcb8-2406-4db1-aeae-827f758520ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_5f34f362-f163-4ef8-9314-6d0e5d49b97e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_addf1518-beb4-41cd-a94b-e43bb0fc1885_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_07ef1f4a-adde-4ed9-8ee4-8f7b7da5fea2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f792e00c-ebad-4740-a3b9-8cf0fde2124b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6c1c0b4f-7d5a-4da8-9a22-6bb5f377d425_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a9ca0228-8fc9-4afd-b09f-0d60ea6587bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59c6bf10-d0b2-41a6-991b-7809d0bc9be8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_caab5884-37a2-4818-97b1-21e9a429cef0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2253e2e6-6dc9-4bc3-97a0-3bc89d190d87_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_6b4ed091-b5c8-4863-94d3-508ef1d7d92c_terseLabel_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:href="cah-20221231.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_441ffde2-eacc-49a6-8d90-b0bfcd0a08f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4a986a3c-652b-4ef9-a50a-523ec4845b87_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5318a78e-42a0-4d80-a11e-8bdd1ddcbdcf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_5c4901ed-da6b-4e59-be1a-0144a0b04864_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e04b8a97-e419-482a-86b0-429c5f6d44e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_877747c3-9e35-410f-8e47-a3cbbdef73a7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_fac43734-1a93-4b6d-9ec7-d2f7537e65f0_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20221231.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_cce6e57e-b8e1-4229-9566-d85a6475a295_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20221231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeDomain_07d00fe3-a6d4-425b-8926-f5e0636b7ac4_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_label_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_documentation_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain" xlink:href="cah-20221231.xsd#cah_LawsuitTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeDomain" xlink:to="lab_cah_LawsuitTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_3d58570e-d04f-4b7c-bb24-1e2c752358c1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c1f80268-0fe4-4128-b9af-e72839e1a00c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f8cad425-4bc3-433e-82eb-d3082a73a9d0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_95917dc0-d47e-4129-af90-3b57dc9f1407_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ea2c23e4-0c1f-4338-b684-88f4f2034d35_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b142bc7b-132e-4c0f-9296-5f7313cbbe38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7aebb665-8349-4664-8b67-03f3bfb6f49b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_07b84316-feaa-4dc5-8bb0-1fa7d6120253_terseLabel_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:href="cah-20221231.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8fd680d6-d8b3-4589-9b51-f9f4bcaf95c2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_4c17d189-45ad-4bfd-90a6-3bdec3bfcfdb_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20221231.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_661c204d-e344-4658-bc25-3d43690d1433_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentDomain_57df6bd1-682d-4e2a-9540-4853c45ec5cb_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_label_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentDomain" xlink:to="lab_cah_GoodwillImpairmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a1c60222-d39e-4a27-bca4-8ffd709d658d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_efa9a5ee-d05b-4624-a827-688fc2d9ef2d_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_a60cfc02-a832-42c7-8994-aa7bd7515142_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_ca904e8f-a0bb-4512-b489-dd5c85f85d97_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_a2d5d0b7-04b0-42df-ad48-b25867959def_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_e1d839cb-3b59-49c7-91ad-2de6379239ef_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_e845899c-58c5-41a5-8e8b-3d1f4fe89114_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7b42b8ef-d26d-4607-833a-d666c9493e6c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d2048730-09fa-4931-b534-9cbf6ed1ca1b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_260b9a1b-88a9-4c31-8123-7415159d2b92_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_48f441e9-732a-43ba-b9a6-29ec43e62ee2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7b385843-1f8d-4d91-847c-b11acdd9c4bc_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_137b4822-98eb-4a7a-ad85-f1b35777f45e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a23f0fd8-4062-4a4e-b880-4bc71a11697e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_7a289f32-9cfc-4fec-ab02-511da2531e78_terseLabel_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_label_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_documentation_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:href="cah-20221231.xsd#cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:to="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_01b587ae-5071-4f93-bc1b-c1c9e163bc69_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_27de5f94-b4ec-42e6-8874-8176c60041e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_819a0296-4650-4e7f-89e8-38b3205a001d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_e0c4922d-3236-40f1-aa3c-e0c617624379_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8afb24d2-ad42-4829-a139-e20bb8aaddee_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f46b91d-f659-46fd-ba71-62f117328879_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_f9546f0d-dc47-45fb-8cb0-e76526d31ecd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_fa8a8e0b-fac7-4b03-86b8-4406dc742bd5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contract</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitMember_3ef6bf48-cd7b-4de3-bd10-8d55304dbe18_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:label id="lab_cah_MedicalUnitMember_label_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitMember" xlink:to="lab_cah_MedicalUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_7aaaeac0-2e15-4535-9838-75fe002130c4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7043913b-823a-471d-8b06-987ba1acaf17_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_3389cc83-c901-489d-b838-71ae554c4941_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20221231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b574a9e1-80b4-4fad-b207-899de6ca29c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at December&#160;31, 2022 and June 30, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3b4520ca-c0ba-4acb-bb8f-944ef29862a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7a0a1697-fe71-4a9b-993d-f7d5cb688652_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_21f9e880-4e28-455e-bd19-29714dbd6a60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateDomain_18c68b33-4a42-4f4c-b799-eaf998a550b6_terseLabel_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_label_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_documentation_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain" xlink:href="cah-20221231.xsd#cah_MaturityDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateDomain" xlink:to="lab_cah_MaturityDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1cbb146b-c47b-42bb-ba77-be10db7595cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_f0e33d50-809f-42e8-b5c6-6e1718f5acf3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_80a0030a-d651-4d12-b93e-e983ef1c24b2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_f1b8a341-6f7c-4503-823f-c42a2c9c88c5_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4b04bdf-ba68-43eb-b857-9a8fbf95a9e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9dca1b39-0898-454f-8243-dce5d27f536f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_33bfdd40-97a3-4a78-9b73-f8569d1ee8c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5c346c1a-6ef3-4e9d-a0dd-080172c690ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2753c8ab-4b31-412f-ae8f-2b1a045acae0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_51b428b6-b3d3-44c4-9078-c4b7820a86bc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3bf5a63a-3863-4008-a9d7-8626e61f3aad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3b0fd0e4-6efb-4889-8364-a7aca85a8991_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_87486278-abc7-43e0-b5f0-da18fea6ce85_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a2c4b438-c869-47bb-b773-e32659faab7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_5da27163-5e1b-4881-bb90-def836942573_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember" xlink:href="cah-20221231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeMember" xlink:to="lab_cah_CardinalHealthAtHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3bc39f3a-854b-4825-bdde-d19c8b6106e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_b10b7ee7-d1d7-4563-b0fa-51333d7e2b7a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c406575b-876d-414a-99b6-e298b44ecbce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_db3dd1e7-d3d5-446b-82a6-f46794fa0e8e_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1c0db5da-0628-4ab7-8ae4-9d8a9f1c87fd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d18169-2f7b-4fd9-963b-c5d237318a99_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_4d0c4059-cafd-47b7-b391-ecd69d154555_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_eb35a146-7dd1-415c-8cb2-76496cdd47b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0adfc86a-2ff9-44d7-82e7-529a0be43a50_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3c0c98df-b5e7-4f82-831e-9fb54a9b4d57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_db5cf59f-9919-4f52-b317-b5f8f09b221a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_9c6ededa-1a90-46ff-9e50-bdfc25702b88_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1fdb0ddd-b762-4128-bee2-f6fc7cfd3fdc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5e7fee20-7bd1-4b74-91ca-30fab7b85b8d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_77dbcca6-33f1-4731-9ad7-a21bb05bab36_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_4b749f3a-1c0c-411b-b64a-8cb2055729da_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a940c8ac-1929-4d16-90f0-e7a24b0a7e49_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_bda8e9ad-5625-4816-b96e-42ff2174fd95_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_92b428f5-3bd4-4c5a-b344-03f6892b8246_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_4fb47342-d150-4257-af3b-e2252cff768e_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20221231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_5e20f22a-41b3-4d6f-8d35-2aace6a799c1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_d98112c0-a1df-4015-8e6f-ce4daf630885_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_11b1c13a-c240-433b-af90-a70fb1f2d5de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_326dc7ed-f623-430e-b335-4d8f677c4a3a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_5aa2b6c7-9296-4d74-82ef-74c650061ac1_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_10a81bc6-7b59-4913-864d-cdeb9044567b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_eebfde14-056f-4fdb-a516-1c517ec8bf51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_036d8a60-7491-4c90-a765-e5d549173937_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20221231.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_97778efc-db3a-4e3b-8868-68f98dfb2102_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5d15c8e9-8726-4b81-bec2-7c7e06ca3276_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26bab487-2061-4e32-b880-82de5e22ba1a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_aa16eaee-48a2-44a8-882f-28df298268fa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_46803366-bcab-4cb1-80b7-98f46a4860a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_629db13e-92e0-42c8-b2bf-f2201ed5966b_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury, at cost: 68 million shares and 54 million shares at December&#160;31, 2022 and June 30, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_c82ff733-6e88-4a45-8fc1-c30c504997db_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_617fccd1-6e39-473f-86fd-83d3b081fb50_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e8bde069-bae3-48ab-bd33-1178347dcf69_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_79d0dab8-59ec-4c6b-a85c-294f6d51a623_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c1aac225-491d-4adb-b197-505e4eff5dd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3b6a94c2-aa02-4d57-8995-287c6fe30a83_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9cad3216-a67a-484d-97ee-ff9cdf387ef2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_09d813b0-79c9-4b8d-ba95-cb76a2119550_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareholderDerivativeLitigationMember_c1083a93-4f2d-4414-a43f-3fa12bd5dba8_terseLabel_en-US" xlink:label="lab_cah_ShareholderDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Derivative Litigation [Member]</link:label>
    <link:label id="lab_cah_ShareholderDerivativeLitigationMember_label_en-US" xlink:label="lab_cah_ShareholderDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Derivative Litigation [Member]</link:label>
    <link:label id="lab_cah_ShareholderDerivativeLitigationMember_documentation_en-US" xlink:label="lab_cah_ShareholderDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Derivative Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderDerivativeLitigationMember" xlink:href="cah-20221231.xsd#cah_ShareholderDerivativeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareholderDerivativeLitigationMember" xlink:to="lab_cah_ShareholderDerivativeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_575bd920-383b-4229-a9ff-fcdf575d6a46_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ffadd758-0be6-4939-bb04-1cc0220d93f1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b90a7f09-ec00-4fa7-ac0d-29a0b0de509c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5230abba-f9e1-44ac-9723-e6756b4e6477_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4cb25b35-06d4-465e-99e7-7058ec61cf99_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_71044f91-3261-41c8-aba3-1f05de6254d1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b5bfeafe-9f15-4432-a433-1c64a45fa575_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_15d92832-46e7-43ab-9eb3-80b1b9378e65_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_284f7053-562b-46f7-9928-26d7dd4404e4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a9ef977a-1b12-4737-9c14-f305cfe23deb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_afbfc420-f177-44b8-a388-be8151f9feba_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_0fcbd9a3-8d9c-44cf-b1ae-0ac5d20220ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3fc49f1e-7fb4-47b8-85b6-acbd8d1c105a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_da0956fd-ecf3-4251-81c9-4b3c04bf2eb0_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureAxis_21fe27e3-d394-4f62-9acc-321781cc3a15_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_label_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_documentation_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureAxis" xlink:to="lab_cah_CordisDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_29a97561-6e30-42b2-8e2d-a183ea361e91_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_917cf251-8172-47fd-9f26-3ec5eca04c02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4d89b270-c68f-4279-bef5-5f8f79749529_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_f1bb5909-44c6-4b64-86d9-e93a75b5f039_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_85cf4027-3232-416d-b304-3148ddf12886_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_cabcfd64-d527-45f4-abb4-03cae0ae36c8_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis" xlink:href="cah-20221231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackAxis" xlink:to="lab_cah_NetOperatingLossCarrybackAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_38eaf7bb-2991-4128-9e0c-c89c74d7b255_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_d2eeb3a7-e79b-4f97-90ab-65f5427e38ce_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_edaf0672-a975-4b66-8812-2de3b5cc1a75_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_4da318a0-75ad-4788-b676-d0465740a693_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20221231.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0074c3ff-4840-40b5-9209-47b843f8ea3c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_0ac7bb86-5ea1-4da7-a1e8-1fe71e83dbbf_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20221231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_74e9fa8e-a652-4692-be7b-768fc58637c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_177a62cf-9c0f-4a32-a683-9a7ed82334a4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5591cb3a-5654-49ec-a44c-803b96fc5d7a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7be6e8a-8a14-498a-80e3-46d0c1a4f162_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_112b9bbf-0050-48af-b4a7-d197cd806875_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9251b346-27a1-41a6-a7e6-21f79f7d1866_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a85acac7-a049-4755-9a31-a44505af4ca6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_de37f0ea-117a-4ecf-8ea2-82ed6be50572_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_77f5a156-07c8-4e78-a018-c87f10967079_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e48aef14-e579-4bcd-8c1e-0e31bbf528b7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_24ba821b-7f87-46bc-8c48-d53932f6faf4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_c1beb60c-652f-4743-a9a6-94008410fb01_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_1a8c0998-ac0d-45ef-902b-66a505a72ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_58f22a0a-8207-4503-ad3a-385c1c14e236_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_4c5201e9-c471-4fc0-ad36-d055b50f806e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_99c35ca0-74c8-41d5-a0c3-31fffbe99e07_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e2daa20b-fd4e-433c-bee5-944c0633e542_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9817aba1-a181-4a31-892d-7db89094f55c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5689d43b-189c-4d41-95de-fa6ec34aa359_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_1d17be8e-5228-4254-b31a-206bfde49f6a_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bb68a2f8-ff92-44d1-b717-fa87411dfc65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Held for Sale [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_750e86a6-8ec0-472d-9b77-e56e0bcd56e7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ae885c91-1e5f-4749-a17b-44016ba67388_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0a4c6857-1ee3-4d75-b1e5-fdba3a4e91c5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNet_39aa6e5a-acf6-4b37-82a9-05096e36a8dd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets</link:label>
    <link:label id="lab_us-gaap_AssetsNet_label_en-US" xlink:label="lab_us-gaap_AssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNet" xlink:to="lab_us-gaap_AssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b29f0576-9fb3-4283-99f2-931d953154eb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;500 thousand shares, Issued&#8212;none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_665be6fd-5680-48a0-8de9-49336f55eca8_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b2d84a9e-eb97-47f8-bd7b-2e8de0ea2037_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2350789f-61a8-4afb-b9b7-1b391291576a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_21f95bc5-ab23-44f9-8a5a-21cd9af494b5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c702ff7d-81a3-4697-82c1-880e30cd4d86_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4eae0cf6-42ee-47f9-80e2-4974f4654803_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_5613eff8-532f-4e59-8cc4-e353e0ec7642_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_37c3cfff-57ff-40fa-a540-7e47ef6c35dd_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20221231.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_bb49a8db-36d8-47b8-b3ea-44dde995375d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_7c0c09db-32c0-45a1-bf10-bcfa5f868abe_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_0e715e27-956d-437f-b355-d7fa7b67e437_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NarativeAbstract_192a1028-1746-4a46-8590-9b7e7cc557d6_terseLabel_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_label_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_documentation_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract" xlink:href="cah-20221231.xsd#cah_NarativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NarativeAbstract" xlink:to="lab_cah_NarativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f40fe293-8ad4-4c14-beaa-592d2f6f83da_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_540f97df-5802-4946-be8d-613b81611e19_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ff5e4742-808f-4ceb-8f70-fe458b00c9d5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_c27d1a43-cb13-400e-9203-ac8d8fe91d13_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_c387b69d-637b-4bef-b071-2358d615007b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_ec521cd2-875a-498e-9dd8-6722c9d6e438_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_3deb6ef3-c4d4-4ee4-87bc-f566088fd893_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_e52c397e-43d2-4edb-8d2b-e3b17a664a90_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NativeAmericanTribesMember_50fd4095-d008-4dd0-b404-666cb5718ae4_terseLabel_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes</link:label>
    <link:label id="lab_cah_NativeAmericanTribesMember_label_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes [Member]</link:label>
    <link:label id="lab_cah_NativeAmericanTribesMember_documentation_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember" xlink:href="cah-20221231.xsd#cah_NativeAmericanTribesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NativeAmericanTribesMember" xlink:to="lab_cah_NativeAmericanTribesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a0ebe61-e01a-4973-a3c4-e590a1039d43_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ea23585b-2f47-4eae-8fdd-d2ec6cea0796_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_844c0694-8cb8-4104-aff9-261627305076_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_3a1d6e73-51f5-4075-8d52-1fe687bb5035_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9de9c836-449c-49f4-96d4-f1b12552f49d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c04a99b1-61e0-4099-aedc-9ea39206a09e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_2dee8f5d-bd6e-4b9b-bdc5-b8a078f1104b_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20221231.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_97023d07-3e3a-412b-8eba-c458f850bcf4_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20221231.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_OK_798b17c1-eef7-441c-813f-7bdcc87b7061_terseLabel_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OKLAHOMA</link:label>
    <link:label id="lab_stpr_OK_label_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OKLAHOMA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_OK" xlink:to="lab_stpr_OK" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_8b70918a-aadc-4231-b647-cd508ab2882c_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20221231.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5de39edd-7a7f-48a1-9acc-17b697af95b0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8452be3-f54e-41e3-9d34-0e0980fb9a74_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_fd4fb392-105a-407c-ae25-6ec80c725c8f_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20221231.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_00c8c8ff-6b3a-48ae-ac65-0026d1d3efd2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_afd0bde9-d066-411e-ab91-0cdd0f56fb9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_98e03dc7-5196-44dc-a0dd-ca34ea75f375_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f1146fe3-06f3-4723-b10a-e46b6b6ca227_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_674e0368-2b8f-41bd-a823-fc4931396a2b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DiscountRateFairValueInput_0b7fcfba-00bb-4aac-962a-3ec4b04ebc38_terseLabel_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_label_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_documentation_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput" xlink:href="cah-20221231.xsd#cah_DiscountRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DiscountRateFairValueInput" xlink:to="lab_cah_DiscountRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_3fa4892b-d336-43ab-9587-038cd50bbe5c_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_68db2436-3eaa-4125-add1-9a5cf7f46c9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_fb1ca57e-0337-4c88-8ff7-3fed87e05193_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4b732920-1a45-4958-bcba-c4e852065f9a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_677f516f-327a-47c4-ada0-9b8aa8b49c50_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ffd15992-950b-43c7-99fb-06b7488766ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_94b138ef-0313-43ab-9923-f1ebee7f1caf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9094d531-f786-4519-b0cb-3aceff2f16ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_e9e0123c-a157-4a6b-aa1a-6de5404e675d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9a173b26-32cd-477f-948e-526d73815c49_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_00cca435-e7f8-49af-939b-61ae30f1abeb_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20221231.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_390c6e37-282a-4650-b182-56976f48144f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_be531299-11b5-46ad-8a20-b25be8924b2c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_700d6510-e43b-46bc-84e2-4770a16ee506_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20221231.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d22fa6e1-8209-4a9c-90f9-76215e39e44f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_6d0ac095-e319-4485-a3cc-ac2a55e9a056_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20221231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_4bb80308-3740-4c77-84d9-6bce6288cc8f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ced1290c-7046-4fa5-bc16-1410159f222c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_0677f0cf-e3d8-4247-802e-5c6162b464db_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_fddb830c-fbd0-402e-9a63-1835a4eff317_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRecoveries_1a51f4b1-1c6e-4d1b-bbc6-e0d7fb329efd_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries" xlink:to="lab_us-gaap_InsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_c8c7cddb-e609-4af8-a2df-1d2243a4bb7b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_2ca42a12-6f42-4442-a4c1-6b7e58b6f880_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_470d9bca-711e-41ce-91c1-749c048465d7_verboseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20221231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_006263ba-f2ba-44c0-8463-717ef16665de_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_254f6fbd-f8d8-4750-97ab-389e969236d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_958faa04-2afe-4f90-8e02-04996995613a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_5bd71394-50eb-46c2-80c3-ba97174473ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_63430769-0b7b-4416-a00e-4ad637d4a156_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:href="cah-20221231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f7c663b7-9faf-4e3d-a33f-a1a1a9bd2e3d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_d285b5b5-f188-43d9-beaf-8b38315fdc25_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_07f9040f-f2e8-4133-9868-166e3db6000a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_cfd49286-b4cc-41f7-a490-cdcea960c748_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_841478ef-c1bf-4c6b-825a-013ac70d7570_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_b8f00f09-ca37-4550-b972-ff43fbc34fb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_08012088-a429-465b-83c3-5f28e97f8b30_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options, restricted share units, and performance share units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_19cebe81-39b5-4c74-b687-5287ce95d085_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8bb461eb-04fe-4005-886a-317cd69f18d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5569f4f3-613e-4ae0-8a85-e4d4c5d7d94c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5ac11697-e393-4918-812c-73c70e5bf95b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45e3d632-6e23-4233-8458-bf992491b781_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_79e4d79d-f850-4261-8d92-466d6785aa58_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5345b889-3747-4e40-85ff-54f6cce535a2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0fba76d-05f9-4d9d-98a2-b449fe6588ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_70f11bbc-ec03-4434-8649-5a4b3fbc02ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_5a0c864f-36f3-49b2-94bf-c8886a59f0b2_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_e664162c-413d-465a-873f-7540bf8305ef_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_cd712cf1-d3b8-4509-b1d6-34edb9ce83d4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bf25ab49-3146-443f-b84f-d68b7494112c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_36130dd5-e3f6-4bbd-988e-4d937f9531a3_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5aee26f0-8642-4042-9fa6-f72e5e5e86fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5a9d89db-4558-4595-956c-c3c27b0ecd1e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_00651291-0287-425e-89ff-308d6462fc7f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c3618325-0d73-4001-b0be-bea2cb307267_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9d1fe0a4-fad3-4643-98ef-a13afa49c73b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A250MillionShareRepurchaseProgramMember_56c66319-18ad-4e74-a758-5d3c2b03a32f_terseLabel_en-US" xlink:label="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$250 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A250MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$250 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A250MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$250 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A250MillionShareRepurchaseProgramMember" xlink:href="cah-20221231.xsd#cah_A250MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A250MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementDomain_5b1b3fa6-756f-410c-aca5-0732c3880496_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_label_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain" xlink:href="cah-20221231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementDomain" xlink:to="lab_cah_TaxMattersAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_519effa0-5807-422a-82cd-05e28dcdd7c7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementAxis_a00f6f32-b9e1-4569-a898-95f7e4f29f5a_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_label_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis" xlink:href="cah-20221231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementAxis" xlink:to="lab_cah_TaxMattersAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c184f190-00a8-4508-b3b8-1c4ca8c25dc9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_fdafb3db-03c5-49a6-998f-d19ac63aa3db_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f21b6031-a63d-44bc-afc1-89955ca5baf7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cah-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de10429f-68bb-4228-9960-cf0499f5ed93,g:6028fbd5-3398-4741-87cc-7f6715aa56e4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_49538020-b3ac-4e10-a0ee-f8c2780ce590" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_DocumentType_49538020-b3ac-4e10-a0ee-f8c2780ce590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_489cb153-5dcb-4b36-9106-cbc9782033d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_DocumentQuarterlyReport_489cb153-5dcb-4b36-9106-cbc9782033d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d9b26395-a4f6-4f96-98e6-eae5442d16ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_DocumentPeriodEndDate_d9b26395-a4f6-4f96-98e6-eae5442d16ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0c8b8f43-70fa-4af1-8dde-2441f9516121" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_DocumentTransitionReport_0c8b8f43-70fa-4af1-8dde-2441f9516121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5de4a5a3-45e3-48e2-a4be-efe50dd55383" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityFileNumber_5de4a5a3-45e3-48e2-a4be-efe50dd55383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_68d2fd1b-6fdf-4e6f-8c2e-43357035ca00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityRegistrantName_68d2fd1b-6fdf-4e6f-8c2e-43357035ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b005e6c9-3de2-4f00-800e-17622d713924" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityCentralIndexKey_b005e6c9-3de2-4f00-800e-17622d713924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_02a7c924-3f39-41c8-b3ce-68359e9eaba8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_CurrentFiscalYearEndDate_02a7c924-3f39-41c8-b3ce-68359e9eaba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f2a3faaf-c114-4bac-a346-e22806032245" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_DocumentFiscalYearFocus_f2a3faaf-c114-4bac-a346-e22806032245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c2c3ef6e-f429-48d5-848e-f497f03d1e02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c2c3ef6e-f429-48d5-848e-f497f03d1e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9c4beaca-f34a-4528-8fbc-bfb45519dbac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_AmendmentFlag_9c4beaca-f34a-4528-8fbc-bfb45519dbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1e92356c-a054-4768-a679-0dfc00f4e769" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1e92356c-a054-4768-a679-0dfc00f4e769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6a6524ee-67bc-4d5d-9769-54429f586751" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityTaxIdentificationNumber_6a6524ee-67bc-4d5d-9769-54429f586751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e83d8c76-b310-4c96-8a03-c597f5500192" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityAddressAddressLine1_e83d8c76-b310-4c96-8a03-c597f5500192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0c7cec3a-4e25-4ae7-846f-1128d779176e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityAddressCityOrTown_0c7cec3a-4e25-4ae7-846f-1128d779176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5da0b3c7-7809-43fe-a4d7-59b935855b07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityAddressStateOrProvince_5da0b3c7-7809-43fe-a4d7-59b935855b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f87cfc74-0752-4309-a5ce-dba338ba8134" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityAddressPostalZipCode_f87cfc74-0752-4309-a5ce-dba338ba8134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_815ba9db-15a5-445b-9547-1b7a3b50e369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_CityAreaCode_815ba9db-15a5-445b-9547-1b7a3b50e369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9149d53e-d2d7-4b54-b83f-d9527f200b1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_LocalPhoneNumber_9149d53e-d2d7-4b54-b83f-d9527f200b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_db5be81f-a9f5-4289-a531-2c73500d9d24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_Security12bTitle_db5be81f-a9f5-4289-a531-2c73500d9d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8058c4d3-a22e-4364-9901-6280465a48de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_TradingSymbol_8058c4d3-a22e-4364-9901-6280465a48de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_50bfe616-18ff-43a8-98e6-be413c3d03bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_SecurityExchangeName_50bfe616-18ff-43a8-98e6-be413c3d03bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5dd09e52-0452-4444-8d8b-697ab5a89bd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityCurrentReportingStatus_5dd09e52-0452-4444-8d8b-697ab5a89bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fe97d4ae-23f0-4537-821c-f86aea01838a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityInteractiveDataCurrent_fe97d4ae-23f0-4537-821c-f86aea01838a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cc877f19-99be-463f-b33f-43085666fe26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityFilerCategory_cc877f19-99be-463f-b33f-43085666fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_93a8f55c-8b4e-4f2d-82c7-241b050fefe1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntitySmallBusiness_93a8f55c-8b4e-4f2d-82c7-241b050fefe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cbef6f31-99de-4050-ac27-d9562897dad2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityEmergingGrowthCompany_cbef6f31-99de-4050-ac27-d9562897dad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6da1bac4-2149-48a2-bab9-54a5074eb04b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityShellCompany_6da1bac4-2149-48a2-bab9-54a5074eb04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e2366867-e6e0-48c2-8e72-d579ec4904fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3ee0870-d767-4f2f-a93f-32965a98ec36" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e2366867-e6e0-48c2-8e72-d579ec4904fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b2783eae-19a8-452f-afbf-f0a35ec94f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_Revenues_b2783eae-19a8-452f-afbf-f0a35ec94f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b05e6456-501e-4d77-afe1-39700067fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b05e6456-501e-4d77-afe1-39700067fff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_27369130-ff5b-49a2-bc2c-085ddbdd54be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_GrossProfit_27369130-ff5b-49a2-bc2c-085ddbdd54be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ef21dce1-433e-45a8-841d-c5f80d0f9de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ef21dce1-433e-45a8-841d-c5f80d0f9de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0689fa56-2111-477c-98a9-7cae5a34b98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ef21dce1-433e-45a8-841d-c5f80d0f9de2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0689fa56-2111-477c-98a9-7cae5a34b98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d7abf67f-1c88-4190-8135-8118586ca687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ef21dce1-433e-45a8-841d-c5f80d0f9de2" xlink:to="loc_us-gaap_RestructuringCharges_d7abf67f-1c88-4190-8135-8118586ca687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_568bf3fa-e4da-4430-a7c7-35fad3bb9710" xlink:href="cah-20221231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ef21dce1-433e-45a8-841d-c5f80d0f9de2" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_568bf3fa-e4da-4430-a7c7-35fad3bb9710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e26dfef9-ab2f-4309-a145-8450c1c418b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ef21dce1-433e-45a8-841d-c5f80d0f9de2" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e26dfef9-ab2f-4309-a145-8450c1c418b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ecdbde4a-f629-4490-b8d5-6df0c7252b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ef21dce1-433e-45a8-841d-c5f80d0f9de2" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ecdbde4a-f629-4490-b8d5-6df0c7252b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_94db072b-f956-413b-a22d-89a14a15a87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_OperatingIncomeLoss_94db072b-f956-413b-a22d-89a14a15a87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9e28256a-7e9c-4926-a480-3bf343880ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9e28256a-7e9c-4926-a480-3bf343880ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b0c79f45-a391-424d-af1f-27e77537252e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_InterestExpense_b0c79f45-a391-424d-af1f-27e77537252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c93443ee-dea4-4a24-b2b6-0152136aaa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c93443ee-dea4-4a24-b2b6-0152136aaa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_c7941d48-50e8-49ff-b78b-f09dbf2c5141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_c7941d48-50e8-49ff-b78b-f09dbf2c5141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f831c47f-7a84-4985-9c24-63c2a71d4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f831c47f-7a84-4985-9c24-63c2a71d4f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3286bb62-76a8-4346-82b5-d13c9f53384b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3286bb62-76a8-4346-82b5-d13c9f53384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_987f4ec7-d02f-4d9e-ba01-49fed2219c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_ProfitLoss_987f4ec7-d02f-4d9e-ba01-49fed2219c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9c4e3a33-7ae2-4e7b-8021-5fb7eb3e8d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9c4e3a33-7ae2-4e7b-8021-5fb7eb3e8d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9630aa25-87f1-4a15-979a-e5d22d87cef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_NetIncomeLoss_9630aa25-87f1-4a15-979a-e5d22d87cef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_e97c2714-3f12-4c45-b4be-f91323ff13ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_e97c2714-3f12-4c45-b4be-f91323ff13ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c636bb1f-caa5-4148-bb18-2a0549ca73ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e97c2714-3f12-4c45-b4be-f91323ff13ce" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c636bb1f-caa5-4148-bb18-2a0549ca73ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4b2ce086-35b2-4a71-b165-81a95c8af280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e97c2714-3f12-4c45-b4be-f91323ff13ce" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4b2ce086-35b2-4a71-b165-81a95c8af280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c77cecc8-a7af-478c-a0e1-cf694b2653e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c77cecc8-a7af-478c-a0e1-cf694b2653e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8708750f-7719-4db5-9e07-021b981ec1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8708750f-7719-4db5-9e07-021b981ec1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18df8204-0400-4a34-8a5d-ce8831f497c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8708750f-7719-4db5-9e07-021b981ec1ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18df8204-0400-4a34-8a5d-ce8831f497c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80582825-71cb-4511-9f13-4690384df7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8708750f-7719-4db5-9e07-021b981ec1ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80582825-71cb-4511-9f13-4690384df7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_4b3644de-640f-47cf-acad-d757bd264027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed945eba-953b-4454-bf2d-b5259d3fe3ff" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_4b3644de-640f-47cf-acad-d757bd264027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81486295-d30b-44b5-ad38-1d723ba3cf25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a857eb1c-1a8e-4786-9dae-f6d1877a6dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81486295-d30b-44b5-ad38-1d723ba3cf25" xlink:to="loc_us-gaap_ProfitLoss_a857eb1c-1a8e-4786-9dae-f6d1877a6dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5f443915-a28f-4e4e-9693-586f1a9ffd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81486295-d30b-44b5-ad38-1d723ba3cf25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5f443915-a28f-4e4e-9693-586f1a9ffd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a62c8ad9-af9a-4e90-a5a1-294ebbfaba98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5f443915-a28f-4e4e-9693-586f1a9ffd60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a62c8ad9-af9a-4e90-a5a1-294ebbfaba98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_261665cf-c5e0-4e94-8022-1d6374bd36b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5f443915-a28f-4e4e-9693-586f1a9ffd60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_261665cf-c5e0-4e94-8022-1d6374bd36b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5997c8f6-8fd8-4f89-972f-5a20196a1224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5f443915-a28f-4e4e-9693-586f1a9ffd60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5997c8f6-8fd8-4f89-972f-5a20196a1224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b0dffc99-bd1d-4d66-aaf2-437e36b39969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81486295-d30b-44b5-ad38-1d723ba3cf25" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b0dffc99-bd1d-4d66-aaf2-437e36b39969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63ff498e-01c0-44dc-a93b-a680f40e72ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81486295-d30b-44b5-ad38-1d723ba3cf25" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63ff498e-01c0-44dc-a93b-a680f40e72ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e2c65921-763c-480a-b072-8c570a41686b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81486295-d30b-44b5-ad38-1d723ba3cf25" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e2c65921-763c-480a-b072-8c570a41686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_af51e3ec-c146-4c73-a319-774f13654ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_AssetsAbstract_af51e3ec-c146-4c73-a319-774f13654ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b2ab1e29-6835-47a3-aaf3-64ba5b360dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af51e3ec-c146-4c73-a319-774f13654ba1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b2ab1e29-6835-47a3-aaf3-64ba5b360dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2bab4a0-5922-401c-abc2-4b8db2772541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2ab1e29-6835-47a3-aaf3-64ba5b360dfe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2bab4a0-5922-401c-abc2-4b8db2772541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_39eb02f2-ca62-4c7b-9feb-458564efb0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2ab1e29-6835-47a3-aaf3-64ba5b360dfe" xlink:to="loc_us-gaap_ReceivablesNetCurrent_39eb02f2-ca62-4c7b-9feb-458564efb0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_111b8abb-4f74-4cee-8190-1052b22caf58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2ab1e29-6835-47a3-aaf3-64ba5b360dfe" xlink:to="loc_us-gaap_InventoryNet_111b8abb-4f74-4cee-8190-1052b22caf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ed014a85-b25d-4d91-94ef-4c0bb62571ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2ab1e29-6835-47a3-aaf3-64ba5b360dfe" xlink:to="loc_us-gaap_OtherAssetsCurrent_ed014a85-b25d-4d91-94ef-4c0bb62571ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_12980d42-7d71-4db9-84c7-2782645e7039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2ab1e29-6835-47a3-aaf3-64ba5b360dfe" xlink:to="loc_us-gaap_AssetsCurrent_12980d42-7d71-4db9-84c7-2782645e7039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_59d2bd39-0706-4a17-bd17-69b4d6654064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af51e3ec-c146-4c73-a319-774f13654ba1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_59d2bd39-0706-4a17-bd17-69b4d6654064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_80ffecc4-e0a8-4b63-86ad-d766f65d430e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af51e3ec-c146-4c73-a319-774f13654ba1" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_80ffecc4-e0a8-4b63-86ad-d766f65d430e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a7759528-47cb-4870-a996-d643b7380146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af51e3ec-c146-4c73-a319-774f13654ba1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a7759528-47cb-4870-a996-d643b7380146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4ca122ed-aead-47d7-9cc3-a7e4ea3866a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af51e3ec-c146-4c73-a319-774f13654ba1" xlink:to="loc_us-gaap_Assets_4ca122ed-aead-47d7-9cc3-a7e4ea3866a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28eb5890-fb52-4bbd-863a-eae612312445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28eb5890-fb52-4bbd-863a-eae612312445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5b149614-2ea9-4776-926c-f7d19446aadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28eb5890-fb52-4bbd-863a-eae612312445" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5b149614-2ea9-4776-926c-f7d19446aadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4923ed33-0150-4334-a3f4-8f7896347ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5b149614-2ea9-4776-926c-f7d19446aadb" xlink:to="loc_us-gaap_AccountsPayableCurrent_4923ed33-0150-4334-a3f4-8f7896347ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_bcd32428-1af1-4d54-b2a0-37a68348fd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5b149614-2ea9-4776-926c-f7d19446aadb" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_bcd32428-1af1-4d54-b2a0-37a68348fd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_201b81d9-d72f-4a12-8047-1244f6dec38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5b149614-2ea9-4776-926c-f7d19446aadb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_201b81d9-d72f-4a12-8047-1244f6dec38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a1d3be75-e5b6-4662-b770-5eeee1891518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5b149614-2ea9-4776-926c-f7d19446aadb" xlink:to="loc_us-gaap_LiabilitiesCurrent_a1d3be75-e5b6-4662-b770-5eeee1891518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_34188a0e-cffb-4dbf-a67f-b1452ffb04f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28eb5890-fb52-4bbd-863a-eae612312445" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_34188a0e-cffb-4dbf-a67f-b1452ffb04f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_6e72c2dd-c27c-49c7-9b55-e2221b2280fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28eb5890-fb52-4bbd-863a-eae612312445" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_6e72c2dd-c27c-49c7-9b55-e2221b2280fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28eb5890-fb52-4bbd-863a-eae612312445" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8534e043-e5a6-4b56-a0fb-8d550cd8f223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8534e043-e5a6-4b56-a0fb-8d550cd8f223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b5555c1a-df21-414e-9eb1-c21b5192f5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8534e043-e5a6-4b56-a0fb-8d550cd8f223" xlink:to="loc_us-gaap_PreferredStockValue_b5555c1a-df21-414e-9eb1-c21b5192f5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ae4e2c8-de52-41f1-815e-b7587faf0a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ae4e2c8-de52-41f1-815e-b7587faf0a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ab17e5b4-7370-4d6a-8acb-d065d3a1c175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ae4e2c8-de52-41f1-815e-b7587faf0a00" xlink:to="loc_us-gaap_CommonStockValue_ab17e5b4-7370-4d6a-8acb-d065d3a1c175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2aee9a98-eee6-4fdc-bc27-a886997b7391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2aee9a98-eee6-4fdc-bc27-a886997b7391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_cc0d97f3-7ae9-4653-b14f-16d5b334f744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_TreasuryStockValue_cc0d97f3-7ae9-4653-b14f-16d5b334f744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88ccd4a6-5295-4b59-8a94-55f33933d6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88ccd4a6-5295-4b59-8a94-55f33933d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e5a0fff-4d31-4c3e-8291-c2c7eb13fe48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_StockholdersEquity_7e5a0fff-4d31-4c3e-8291-c2c7eb13fe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ba2f8cad-e89b-4eb2-9876-49161e47aa7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_MinorityInterest_ba2f8cad-e89b-4eb2-9876-49161e47aa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ed67e080-960c-4604-983c-233a07eaac96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ddc54f1-3e3a-4441-99b0-a4dc1ece2413" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ed67e080-960c-4604-983c-233a07eaac96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35ad236a-8537-43bc-9b60-14c6f8b2e42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28eb5890-fb52-4bbd-863a-eae612312445" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_35ad236a-8537-43bc-9b60-14c6f8b2e42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f3188ad2-cffb-418c-98ca-f7cc373a8d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f3188ad2-cffb-418c-98ca-f7cc373a8d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a6209267-6c6c-47ab-ab6c-a2c568324831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a6209267-6c6c-47ab-ab6c-a2c568324831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fab92b39-2829-4dc0-bf79-062c44f3b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fab92b39-2829-4dc0-bf79-062c44f3b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_007a1b3b-88b2-4131-b2e7-b46aa60a20f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_CommonStockSharesIssued_007a1b3b-88b2-4131-b2e7-b46aa60a20f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_c55831a5-ffef-4f8d-a3ce-03002afe315a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_TreasuryStockShares_c55831a5-ffef-4f8d-a3ce-03002afe315a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_540aa15b-381a-49c6-99b4-d48997908bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ca1a1840-05d6-4300-ac05-fe4866a66880" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_540aa15b-381a-49c6-99b4-d48997908bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_537c5d68-176f-4401-bb62-fb415a1d30f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_be43afa9-0b52-4cbf-8204-ad4ad59d8907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_537c5d68-176f-4401-bb62-fb415a1d30f9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_be43afa9-0b52-4cbf-8204-ad4ad59d8907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6eb20474-5861-4cfe-ab45-b724dc481ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_537c5d68-176f-4401-bb62-fb415a1d30f9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6eb20474-5861-4cfe-ab45-b724dc481ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2027d4f3-8d86-4da3-9585-74cbe26eb0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_537c5d68-176f-4401-bb62-fb415a1d30f9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2027d4f3-8d86-4da3-9585-74cbe26eb0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ec3f9e3b-f3f3-46d3-9cc8-2ee17d292adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_537c5d68-176f-4401-bb62-fb415a1d30f9" xlink:to="loc_us-gaap_CommonStockSharesIssued_ec3f9e3b-f3f3-46d3-9cc8-2ee17d292adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_6b1ae56f-3211-439a-ad82-f355edcc80dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_537c5d68-176f-4401-bb62-fb415a1d30f9" xlink:to="loc_us-gaap_TreasuryStockShares_6b1ae56f-3211-439a-ad82-f355edcc80dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4f41bf3b-7885-4295-9f49-cb55087a5bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6b5c2c2b-1809-4370-b918-4dc06a3834d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4f41bf3b-7885-4295-9f49-cb55087a5bb1" xlink:to="loc_us-gaap_StatementTable_6b5c2c2b-1809-4370-b918-4dc06a3834d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6db1446-c954-48b3-99c2-bc1e68545295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6b5c2c2b-1809-4370-b918-4dc06a3834d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6db1446-c954-48b3-99c2-bc1e68545295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6db1446-c954-48b3-99c2-bc1e68545295" xlink:to="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_247d4cba-af5b-41c6-aee3-82c6a610c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_CommonStockMember_247d4cba-af5b-41c6-aee3-82c6a610c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_11a13d05-20be-44d2-834f-d34974f124e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_RetainedEarningsMember_11a13d05-20be-44d2-834f-d34974f124e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_1113f141-505d-4d11-b4cc-a0bd89f9b471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_TreasuryStockMember_1113f141-505d-4d11-b4cc-a0bd89f9b471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_587e6382-9571-452a-8146-c579a290cebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_587e6382-9571-452a-8146-c579a290cebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_abd6c609-c678-4625-b2e3-5eb6b49cfa37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_418e5d6a-d6ec-46de-ba35-900a72cb9d62" xlink:to="loc_us-gaap_NoncontrollingInterestMember_abd6c609-c678-4625-b2e3-5eb6b49cfa37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6b5c2c2b-1809-4370-b918-4dc06a3834d2" xlink:to="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a33ce9f7-c6ba-4167-9685-91c307e89d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_CommonStockSharesIssued_a33ce9f7-c6ba-4167-9685-91c307e89d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa87f05d-e353-40cb-b067-c22c6a6293c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa87f05d-e353-40cb-b067-c22c6a6293c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a481f15f-cc57-4a8a-b383-7cfda0a2446c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockShares_a481f15f-cc57-4a8a-b383-7cfda0a2446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e6e7a3fc-6540-4886-96fb-8930aaf3bbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockValue_e6e7a3fc-6540-4886-96fb-8930aaf3bbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e137c55-8cef-4ae1-a2a5-368421340fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_ProfitLoss_7e137c55-8cef-4ae1-a2a5-368421340fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc45e12c-915d-4b53-a38b-f0792753a84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_NetIncomeLoss_fc45e12c-915d-4b53-a38b-f0792753a84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d81c9550-6e48-408f-a40c-6b6dd057dd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d81c9550-6e48-408f-a40c-6b6dd057dd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6dd04f96-0db6-4fce-985b-e7f44112b9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6dd04f96-0db6-4fce-985b-e7f44112b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb6f769f-3ab4-448f-bf60-b911d247ade1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb6f769f-3ab4-448f-bf60-b911d247ade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3c74e7f5-a5ca-4b13-9d79-c41a83a8c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3c74e7f5-a5ca-4b13-9d79-c41a83a8c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04eac8da-f8fb-4e1c-972a-4aec78d2e676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04eac8da-f8fb-4e1c-972a-4aec78d2e676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9871a2d0-fda9-4d57-8c92-2c7398897969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9871a2d0-fda9-4d57-8c92-2c7398897969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_d082311e-e9e8-483c-8c33-8d0221de9b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_Dividends_d082311e-e9e8-483c-8c33-8d0221de9b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_b1b65128-cb1e-4b15-9fe0-7afc387765f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_b1b65128-cb1e-4b15-9fe0-7afc387765f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_a248635e-0007-401b-bacb-295f62e8400f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockholdersEquityOther_a248635e-0007-401b-bacb-295f62e8400f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8bae8d57-edad-490a-a58c-dba186bc176d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_CommonStockSharesIssued_8bae8d57-edad-490a-a58c-dba186bc176d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d7486b2-4a57-44f1-8a63-29d6070baf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d7486b2-4a57-44f1-8a63-29d6070baf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_ed70e85a-2dfc-46e7-9594-0b08c09e2932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockShares_ed70e85a-2dfc-46e7-9594-0b08c09e2932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_2f2ec72c-8b6a-46b7-bdad-4455ed08f6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockValue_2f2ec72c-8b6a-46b7-bdad-4455ed08f6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_94e12cb2-94f8-4976-af90-e0dc4f948d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_94e12cb2-94f8-4976-af90-e0dc4f948d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c2dc9ef5-7e7a-4712-9dd9-315c765f1203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_383f2afa-79d2-4349-b375-a3811efed3aa" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c2dc9ef5-7e7a-4712-9dd9-315c765f1203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20221231.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c7d7c3f-ce4c-41ad-ac82-15edc4bb835e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c7d7c3f-ce4c-41ad-ac82-15edc4bb835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_864cbeda-8244-4bec-a3e0-d0989860894b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c7d7c3f-ce4c-41ad-ac82-15edc4bb835e" xlink:to="loc_us-gaap_ProfitLoss_864cbeda-8244-4bec-a3e0-d0989860894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c7d7c3f-ce4c-41ad-ac82-15edc4bb835e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_01c210e1-c9f6-49f5-80f9-56ccf0f33a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_01c210e1-c9f6-49f5-80f9-56ccf0f33a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_fa00985d-e002-419d-859e-50f8bcc54ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_fa00985d-e002-419d-859e-50f8bcc54ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8adad895-417c-4fc1-b73c-2976bf877233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8adad895-417c-4fc1-b73c-2976bf877233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ad1bdbc4-763a-495b-97b3-7e1871fef239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ad1bdbc4-763a-495b-97b3-7e1871fef239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_80f52405-2206-45bf-bc95-6ad75f90d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:to="loc_us-gaap_ShareBasedCompensation_80f52405-2206-45bf-bc95-6ad75f90d4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_a27260d2-ca3a-43d0-881d-e8e5990a4b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_a27260d2-ca3a-43d0-881d-e8e5990a4b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1351270-2db3-48b1-bf76-ca90dad0f73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e6bb0b0-674c-4b8f-a14f-865229e01da1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1351270-2db3-48b1-bf76-ca90dad0f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_51b48784-ea99-461b-ac1a-e2ffa0d6f2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1351270-2db3-48b1-bf76-ca90dad0f73f" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_51b48784-ea99-461b-ac1a-e2ffa0d6f2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3c3f5114-a62c-4ed9-9147-852b8264ed39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1351270-2db3-48b1-bf76-ca90dad0f73f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3c3f5114-a62c-4ed9-9147-852b8264ed39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b374f71a-f2ec-4cbb-b7d6-666f462eb165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1351270-2db3-48b1-bf76-ca90dad0f73f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b374f71a-f2ec-4cbb-b7d6-666f462eb165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_aa128b1c-6832-4456-b39e-1ae9396a9b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1351270-2db3-48b1-bf76-ca90dad0f73f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_aa128b1c-6832-4456-b39e-1ae9396a9b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e1d7b16a-c9f9-43e3-a1bf-73a68547c208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c7d7c3f-ce4c-41ad-ac82-15edc4bb835e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e1d7b16a-c9f9-43e3-a1bf-73a68547c208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_82a2181b-ea49-4376-a83f-52ea9acf8560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_82a2181b-ea49-4376-a83f-52ea9acf8560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_62a31f10-159e-4d5f-aeb1-717abc8984b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_62a31f10-159e-4d5f-aeb1-717abc8984b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c9697495-5ace-4a46-9be5-4ad3b6ac4c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c9697495-5ace-4a46-9be5-4ad3b6ac4c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_17c4fabf-f9df-4ddd-8678-5369a6f5b64e" xlink:href="cah-20221231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_17c4fabf-f9df-4ddd-8678-5369a6f5b64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_e3d6a2e8-881d-4d7f-b74a-606ac1498df3" xlink:href="cah-20221231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_e3d6a2e8-881d-4d7f-b74a-606ac1498df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f6be9d77-2c4c-4139-b194-f18fb084e06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cde4f7c3-73b9-4d06-adf4-bca938fb793c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f6be9d77-2c4c-4139-b194-f18fb084e06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e6547898-0177-4485-bdca-6a80b692a8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e6547898-0177-4485-bdca-6a80b692a8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_1dc96611-b604-4ba3-a297-7ee69c804ef2" xlink:href="cah-20221231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_1dc96611-b604-4ba3-a297-7ee69c804ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_d92126d6-441d-4534-b80b-66bffe9c649d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_d92126d6-441d-4534-b80b-66bffe9c649d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7ca0836a-a837-48b0-9f44-e0e04af85027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7ca0836a-a837-48b0-9f44-e0e04af85027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd3ef46a-bf86-447e-bdf4-53462c7abc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd3ef46a-bf86-447e-bdf4-53462c7abc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75e63e89-8b82-4cf5-be05-da24cd0e2d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e8a20d27-600a-4b83-a551-44dea21559fb" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75e63e89-8b82-4cf5-be05-da24cd0e2d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_795e31fc-4eb0-4664-b011-499e21721dad" xlink:href="cah-20221231.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_795e31fc-4eb0-4664-b011-499e21721dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfabf475-6c38-4f89-8d87-b71c41a8bfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfabf475-6c38-4f89-8d87-b71c41a8bfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_409dee99-d34a-4b2e-8f87-c4ae1f0d54a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_409dee99-d34a-4b2e-8f87-c4ae1f0d54a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f899c0b-479c-4ae0-a713-4ec17372f00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a50913ac-c16a-4e0b-9457-b243c6535ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f899c0b-479c-4ae0-a713-4ec17372f00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fc7c460a-9c0b-4ec8-8532-af4ab5d96f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ac21c346-3525-4761-8ce0-bb6f7b62d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc7c460a-9c0b-4ec8-8532-af4ab5d96f8f" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ac21c346-3525-4761-8ce0-bb6f7b62d0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Divestitures" xlink:type="simple" xlink:href="cah-20221231.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_73a6ede5-9a31-441d-9aa7-28a3e3bae4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_0294346c-7a95-47cf-90fd-4b05e5e0e087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_73a6ede5-9a31-441d-9aa7-28a3e3bae4fc" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_0294346c-7a95-47cf-90fd-4b05e5e0e087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_6b3389c3-3260-46d9-9ba4-391256174f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b70c0ad1-4214-412c-8000-a7a42ad19f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_6b3389c3-3260-46d9-9ba4-391256174f32" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b70c0ad1-4214-412c-8000-a7a42ad19f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26c6e20a-e9f6-45f8-8223-a24d49455b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5d518bbb-d334-43cf-9e26-8840e741ef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26c6e20a-e9f6-45f8-8223-a24d49455b4f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5d518bbb-d334-43cf-9e26-8840e741ef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20221231.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_26d64fe7-9e35-4e4d-939b-a3a928d92a35" xlink:href="cah-20221231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2ebdb18e-8af3-40ff-9d59-f5bce6cbb5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_26d64fe7-9e35-4e4d-939b-a3a928d92a35" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2ebdb18e-8af3-40ff-9d59-f5bce6cbb5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20221231.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_611918ee-196d-4161-86d1-3b6df3971d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7111b5aa-8b70-495a-bde3-ac05052d1e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_611918ee-196d-4161-86d1-3b6df3971d07" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7111b5aa-8b70-495a-bde3-ac05052d1e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f70f351e-0ac5-4b67-88d0-866760fe9aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f8771105-3ac6-4daa-89bc-65d1e9bef38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f70f351e-0ac5-4b67-88d0-866760fe9aac" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f8771105-3ac6-4daa-89bc-65d1e9bef38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f1eafd4f-93c4-48f8-aed6-e8882c917621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a7178a53-1385-4485-a4ae-315f5fc8973e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f1eafd4f-93c4-48f8-aed6-e8882c917621" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a7178a53-1385-4485-a4ae-315f5fc8973e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20221231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c30317c-adf3-4640-97ea-2e6f24e5b74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_e84ba9ba-d066-4948-b153-45704bdde2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c30317c-adf3-4640-97ea-2e6f24e5b74d" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_e84ba9ba-d066-4948-b153-45704bdde2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6babe0b3-55d4-4c69-b5be-8d1e61a89496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_477069e2-41c4-4a88-9485-80cb35e98ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6babe0b3-55d4-4c69-b5be-8d1e61a89496" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_477069e2-41c4-4a88-9485-80cb35e98ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20221231.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4d7ed7fd-a3fb-46df-bfd1-ad079e44a9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1b82ef98-f4eb-4f96-9c7b-6b709dcf44cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4d7ed7fd-a3fb-46df-bfd1-ad079e44a9ac" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1b82ef98-f4eb-4f96-9c7b-6b709dcf44cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eaae53a2-9ee2-4e72-8217-3236455acfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b31b0445-a736-446a-9467-a64aba5df555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eaae53a2-9ee2-4e72-8217-3236455acfb7" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b31b0445-a736-446a-9467-a64aba5df555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3360541-740b-41be-b1a5-b5230da8c422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4f0f86cd-9e99-42ae-9eaa-85d76f1c6b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3360541-740b-41be-b1a5-b5230da8c422" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4f0f86cd-9e99-42ae-9eaa-85d76f1c6b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5ed2fcdb-7a86-4c3c-99a9-fd2030e62a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0500b0a4-4a3a-4425-bcda-8fcca6deaff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5ed2fcdb-7a86-4c3c-99a9-fd2030e62a6d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0500b0a4-4a3a-4425-bcda-8fcca6deaff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_23b711ff-ae67-40ed-a333-a692294e7acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5ed2fcdb-7a86-4c3c-99a9-fd2030e62a6d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_23b711ff-ae67-40ed-a333-a692294e7acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cah-20221231.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_59ad8d5f-ef78-4cdf-a237-7544009c25ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_9952e201-07fd-4f32-80d4-15dcff873843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fbf87d89-a8d8-4f43-8194-838e17582e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_9952e201-07fd-4f32-80d4-15dcff873843" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fbf87d89-a8d8-4f43-8194-838e17582e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_809a0553-c516-4b2b-9a79-86976fa2e5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_9952e201-07fd-4f32-80d4-15dcff873843" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_809a0553-c516-4b2b-9a79-86976fa2e5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_168da85f-e10b-43a6-bf7d-fd73efebb7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_ea386373-871b-40dd-a4d1-7456285d9d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_168da85f-e10b-43a6-bf7d-fd73efebb7a9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_ea386373-871b-40dd-a4d1-7456285d9d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4b420f06-d088-4cab-98ad-17e7f8423f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_168da85f-e10b-43a6-bf7d-fd73efebb7a9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4b420f06-d088-4cab-98ad-17e7f8423f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20221231.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_39f986cb-8bae-4c81-bb2d-21cd7d8dc888" xlink:href="cah-20221231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_86891eb4-ae71-4135-bc82-2339b9c5e18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_37bff633-547a-46c6-a2b7-4e34eb29a945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86891eb4-ae71-4135-bc82-2339b9c5e18c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_37bff633-547a-46c6-a2b7-4e34eb29a945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20221231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0bff9d0c-bf1b-4dfc-ae63-0b6df3320431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_aa405829-4419-4dc9-b1a4-59db6bbfcd00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0bff9d0c-bf1b-4dfc-ae63-0b6df3320431" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_aa405829-4419-4dc9-b1a4-59db6bbfcd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d0a3e752-105f-4698-be0f-045d30495d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e027b374-8c0d-4b72-b702-a3a5857f4dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d0a3e752-105f-4698-be0f-045d30495d3d" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e027b374-8c0d-4b72-b702-a3a5857f4dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20221231.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9967a55f-8557-46b5-b7a0-2a7cdc7e2057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_0fad5a7f-b6f8-4b4b-90df-813614b710c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9967a55f-8557-46b5-b7a0-2a7cdc7e2057" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_0fad5a7f-b6f8-4b4b-90df-813614b710c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e372a7a6-636a-4347-b182-c9912d4ab60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_06b109e2-76ed-4977-88ed-30821b520fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e372a7a6-636a-4347-b182-c9912d4ab60d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_06b109e2-76ed-4977-88ed-30821b520fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_018774fc-1a9f-4c2b-af00-a986972044c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e372a7a6-636a-4347-b182-c9912d4ab60d" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_018774fc-1a9f-4c2b-af00-a986972044c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_9f9b1e7e-fa5f-4407-b0cd-b84defc7531f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e372a7a6-636a-4347-b182-c9912d4ab60d" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_9f9b1e7e-fa5f-4407-b0cd-b84defc7531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_e219e2b2-2a40-4cf2-8deb-6d754ee21d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e372a7a6-636a-4347-b182-c9912d4ab60d" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_e219e2b2-2a40-4cf2-8deb-6d754ee21d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28fb9de4-5573-434a-aff2-2c340bd7b1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b227742d-6602-4200-acb9-da79cacea98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28fb9de4-5573-434a-aff2-2c340bd7b1b2" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b227742d-6602-4200-acb9-da79cacea98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ed3b892e-939a-4400-a294-1140047986bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28fb9de4-5573-434a-aff2-2c340bd7b1b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ed3b892e-939a-4400-a294-1140047986bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_5e794ded-fc80-4130-b96c-b9766e237206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28fb9de4-5573-434a-aff2-2c340bd7b1b2" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_5e794ded-fc80-4130-b96c-b9766e237206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e96c3bc3-8a43-411f-ae16-e8bc17894cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a925d11d-edb2-42a9-8e5b-5ccb46decb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a925d11d-edb2-42a9-8e5b-5ccb46decb40" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d7445eb-c966-433f-9dbb-8a3cd13cb620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d7445eb-c966-433f-9dbb-8a3cd13cb620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8c797762-4e35-4253-b224-a42a05d78fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d7445eb-c966-433f-9dbb-8a3cd13cb620" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8c797762-4e35-4253-b224-a42a05d78fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_4caf218a-8fac-4dc1-8a68-292828e83612" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:to="loc_cah_CordisDivestitureAxis_4caf218a-8fac-4dc1-8a68-292828e83612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7016e2c8-91b8-4105-99c2-38e189c0f157" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_4caf218a-8fac-4dc1-8a68-292828e83612" xlink:to="loc_cah_CordisDivestitureDomain_7016e2c8-91b8-4105-99c2-38e189c0f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_01d9bff4-74ae-445d-8ac9-3cfece846b87" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_7016e2c8-91b8-4105-99c2-38e189c0f157" xlink:to="loc_cah_CordisDivestitureMember_01d9bff4-74ae-445d-8ac9-3cfece846b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0dcbdd7d-b75e-4c59-b369-83ae2cc392a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b7174ecf-c525-4949-9327-d5daa819fbaa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0dcbdd7d-b75e-4c59-b369-83ae2cc392a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_83317c75-194b-4f0f-a451-d59701ff6883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0dcbdd7d-b75e-4c59-b369-83ae2cc392a4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_83317c75-194b-4f0f-a451-d59701ff6883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_e6406540-e7ea-4d8d-912b-8ae4c21a5f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_6b713f1e-206f-414f-889c-332224574131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_e6406540-e7ea-4d8d-912b-8ae4c21a5f9b" xlink:to="loc_us-gaap_SeveranceCosts1_6b713f1e-206f-414f-889c-332224574131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_8a066840-deec-4fb4-b285-2f6318fdc915" xlink:href="cah-20221231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_e6406540-e7ea-4d8d-912b-8ae4c21a5f9b" xlink:to="loc_cah_FacilityExitAndOtherCosts_8a066840-deec-4fb4-b285-2f6318fdc915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6deaad2d-f3df-46d4-9b8b-0156756ff36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_e6406540-e7ea-4d8d-912b-8ae4c21a5f9b" xlink:to="loc_us-gaap_RestructuringCharges_6deaad2d-f3df-46d4-9b8b-0156756ff36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_66b8e0f3-ae5b-4e69-a746-dd1e4f36192c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d4432a3c-885f-48e7-928f-78b3235b1200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_66b8e0f3-ae5b-4e69-a746-dd1e4f36192c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d4432a3c-885f-48e7-928f-78b3235b1200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7db71499-cabd-43bb-9443-e230c6d3ead8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d4432a3c-885f-48e7-928f-78b3235b1200" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7db71499-cabd-43bb-9443-e230c6d3ead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7db71499-cabd-43bb-9443-e230c6d3ead8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_51886312-5c3e-4410-a989-5be4034ad1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:to="loc_us-gaap_EmployeeSeveranceMember_51886312-5c3e-4410-a989-5be4034ad1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_b9ed843f-868d-4d3b-b027-8bba020696d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cb3feb49-d847-44ce-a7e0-465eb9f82d6f" xlink:to="loc_us-gaap_FacilityClosingMember_b9ed843f-868d-4d3b-b027-8bba020696d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_7d475ccb-57e8-418a-93a3-4a61bcbca633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d4432a3c-885f-48e7-928f-78b3235b1200" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_7d475ccb-57e8-418a-93a3-4a61bcbca633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7d475ccb-57e8-418a-93a3-4a61bcbca633" xlink:to="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4facd3fa-a25a-4eb4-aec0-6b595e9bb23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:to="loc_us-gaap_RestructuringReserve_4facd3fa-a25a-4eb4-aec0-6b595e9bb23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_3fe64a67-b7a3-4a13-9066-a47eb64a5911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:to="loc_us-gaap_RestructuringCosts_3fe64a67-b7a3-4a13-9066-a47eb64a5911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6f912178-e6f4-4f1d-af28-ff133e20d879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:to="loc_us-gaap_PaymentsForRestructuring_6f912178-e6f4-4f1d-af28-ff133e20d879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_931665fe-fec0-4c45-a2d9-1a5b78afe7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31c257a4-ede2-46e0-afe4-e40df1cea8d0" xlink:to="loc_us-gaap_RestructuringReserve_931665fe-fec0-4c45-a2d9-1a5b78afe7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract_3f4a6b51-f2e4-46a7-b4fc-a6e473130655" xlink:href="cah-20221231.xsd#cah_NarativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b7c2939b-6f65-4ebb-8316-4362177debe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NarativeAbstract_3f4a6b51-f2e4-46a7-b4fc-a6e473130655" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b7c2939b-6f65-4ebb-8316-4362177debe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_09e06ca1-faab-4def-a10b-399729c716d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b7c2939b-6f65-4ebb-8316-4362177debe7" xlink:to="loc_us-gaap_RestructuringPlanAxis_09e06ca1-faab-4def-a10b-399729c716d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_03b2192d-e5a1-4a35-9ba2-d4bf56366ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_09e06ca1-faab-4def-a10b-399729c716d5" xlink:to="loc_us-gaap_RestructuringPlanDomain_03b2192d-e5a1-4a35-9ba2-d4bf56366ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b7c2939b-6f65-4ebb-8316-4362177debe7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f4e93cda-e88d-4991-aaf9-b0075230cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:to="loc_us-gaap_SeveranceCosts1_f4e93cda-e88d-4991-aaf9-b0075230cfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_7488bd37-3f7e-478a-9ffb-0c0e2e8cd528" xlink:href="cah-20221231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_abeb35d0-b5ee-48c3-819a-1ee03ceb509a" xlink:to="loc_cah_FacilityExitAndOtherCosts_7488bd37-3f7e-478a-9ffb-0c0e2e8cd528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43e5c331-f80f-41f3-8ef9-09080b66ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43e5c331-f80f-41f3-8ef9-09080b66ec25" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e787b2b1-afef-4f33-b34b-5739d6baecac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e787b2b1-afef-4f33-b34b-5739d6baecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e787b2b1-afef-4f33-b34b-5739d6baecac" xlink:to="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_110ca023-6bdc-4963-b318-f1b0b75dcce7" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:to="loc_cah_PharmaceuticalMember_110ca023-6bdc-4963-b318-f1b0b75dcce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_757bc049-d264-4cae-912b-f2c0fe611390" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f93200a6-212a-475a-96a8-a9630830e426" xlink:to="loc_cah_MedicalMember_757bc049-d264-4cae-912b-f2c0fe611390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_421743b5-d382-4ffa-86d0-99090f61736d" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:to="loc_cah_CordisDivestitureAxis_421743b5-d382-4ffa-86d0-99090f61736d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_d59a051c-5270-4b2b-8b9d-e3d57f545ab3" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_421743b5-d382-4ffa-86d0-99090f61736d" xlink:to="loc_cah_CordisDivestitureDomain_d59a051c-5270-4b2b-8b9d-e3d57f545ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_d3cb16ba-9915-4809-95a5-e20a6fc66e4e" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_d59a051c-5270-4b2b-8b9d-e3d57f545ab3" xlink:to="loc_cah_CordisDivestitureMember_d3cb16ba-9915-4809-95a5-e20a6fc66e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b1eb780b-2f56-40eb-bc6f-a9ef57de16f2" xlink:to="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:to="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e4441ec5-3856-4027-8a25-e743af9de8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:to="loc_us-gaap_Goodwill_e4441ec5-3856-4027-8a25-e743af9de8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_825b8fa7-86b5-464f-9a5e-9638c248e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_825b8fa7-86b5-464f-9a5e-9638c248e25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_10307c6a-7158-4428-973a-d3f4e34c1dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_10307c6a-7158-4428-973a-d3f4e34c1dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_79f9075d-b01a-4de1-a60c-7e13dea80383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1ce6c97f-86cb-4c5f-839f-4df5eacadfdb" xlink:to="loc_us-gaap_Goodwill_79f9075d-b01a-4de1-a60c-7e13dea80383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc263a6f-49ed-4517-bd0e-f7eb981b8c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_9673a76b-d3ac-484f-aabc-9393ed417291" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc263a6f-49ed-4517-bd0e-f7eb981b8c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b2728cb-5b4f-47d6-b937-3e8a72b686d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d066e93a-fe19-4c3f-9f0b-2a51fd094611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b2728cb-5b4f-47d6-b937-3e8a72b686d1" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d066e93a-fe19-4c3f-9f0b-2a51fd094611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_61828320-2651-45c8-8006-7457bb84a2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d066e93a-fe19-4c3f-9f0b-2a51fd094611" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_61828320-2651-45c8-8006-7457bb84a2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7d09c7d-81a2-49c5-9517-c24cb1f8c29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_61828320-2651-45c8-8006-7457bb84a2d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7d09c7d-81a2-49c5-9517-c24cb1f8c29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_0ffea567-8cb5-474a-a3d0-39d56c0407e3" xlink:href="cah-20221231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7d09c7d-81a2-49c5-9517-c24cb1f8c29c" xlink:to="loc_cah_IPRDTrademarksandOtherMember_0ffea567-8cb5-474a-a3d0-39d56c0407e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_63375754-542d-4a94-9892-d91d81ace6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d066e93a-fe19-4c3f-9f0b-2a51fd094611" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_63375754-542d-4a94-9892-d91d81ace6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7e2ad474-60bb-416c-b358-fc8508f911ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_63375754-542d-4a94-9892-d91d81ace6bc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7e2ad474-60bb-416c-b358-fc8508f911ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e87e8ff9-4e42-41aa-bee1-25f31d874324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b2728cb-5b4f-47d6-b937-3e8a72b686d1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e87e8ff9-4e42-41aa-bee1-25f31d874324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e55f2774-2d9b-4507-9d79-42503e2539a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e87e8ff9-4e42-41aa-bee1-25f31d874324" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e55f2774-2d9b-4507-9d79-42503e2539a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e55f2774-2d9b-4507-9d79-42503e2539a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_5cd19672-cb2c-44f3-8a7d-c9c7fdac6465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_5cd19672-cb2c-44f3-8a7d-c9c7fdac6465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_cf548bed-c9e1-46e7-8816-bf530c5a6fa0" xlink:href="cah-20221231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:to="loc_cah_TrademarksAndPatentsMember_cf548bed-c9e1-46e7-8816-bf530c5a6fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7bf99788-3005-46ac-a373-3479f8be6ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5fe40a7f-0f4a-4984-a0e2-5502a287d20c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7bf99788-3005-46ac-a373-3479f8be6ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e87e8ff9-4e42-41aa-bee1-25f31d874324" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7614463-05fb-4ecf-a190-97a5458fd14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7614463-05fb-4ecf-a190-97a5458fd14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_834817b6-4773-4826-9e15-a169f1ed9e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_834817b6-4773-4826-9e15-a169f1ed9e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0e0c2a3d-c8f6-43bf-9463-18f19ed1abef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0e0c2a3d-c8f6-43bf-9463-18f19ed1abef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_24bfe973-77be-4140-bddb-0d061ae241f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d4439426-892b-4b31-b537-27b2ecf446d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_24bfe973-77be-4140-bddb-0d061ae241f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6b5ce0a1-c7e5-4729-9bf7-b4cd4243973c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b2728cb-5b4f-47d6-b937-3e8a72b686d1" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6b5ce0a1-c7e5-4729-9bf7-b4cd4243973c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ceb8851b-d6db-4bbf-bc4c-f9f47db598d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b2728cb-5b4f-47d6-b937-3e8a72b686d1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ceb8851b-d6db-4bbf-bc4c-f9f47db598d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_128dcfdb-3f48-45d5-a0c5-2270fa95aafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_128dcfdb-3f48-45d5-a0c5-2270fa95aafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e77bec3b-a7e7-4b91-8eb3-f02d384eacce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e77bec3b-a7e7-4b91-8eb3-f02d384eacce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e4da3746-8023-4dbf-8a24-ffe7c8089fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e4da3746-8023-4dbf-8a24-ffe7c8089fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4aeb77aa-8f3e-42e2-a27e-f9c3446ace4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4aeb77aa-8f3e-42e2-a27e-f9c3446ace4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8570238b-2d46-4afc-b87e-91aba3987229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8570238b-2d46-4afc-b87e-91aba3987229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8dd8b6cf-3bce-48e1-8041-8248733e326c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8dd8b6cf-3bce-48e1-8041-8248733e326c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_295d3fab-5f40-4a8e-8339-75ae8ebc5cd5" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_578d49d1-6bad-4d09-b7b5-1a8fe989d845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:to="loc_us-gaap_ReportingUnitAxis_578d49d1-6bad-4d09-b7b5-1a8fe989d845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_063af77a-a8ed-433c-9698-17c826591227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_578d49d1-6bad-4d09-b7b5-1a8fe989d845" xlink:to="loc_us-gaap_ReportingUnitDomain_063af77a-a8ed-433c-9698-17c826591227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_36add99c-df08-47a9-bc6b-15ff8c570081" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_063af77a-a8ed-433c-9698-17c826591227" xlink:to="loc_cah_MedicalUnitMember_36add99c-df08-47a9-bc6b-15ff8c570081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4049f030-2487-47ae-b798-9ba3627740de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4049f030-2487-47ae-b798-9ba3627740de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7d9533b4-81fb-4fb8-8c31-fd973e948962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4049f030-2487-47ae-b798-9ba3627740de" xlink:to="loc_us-gaap_SegmentDomain_7d9533b4-81fb-4fb8-8c31-fd973e948962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_e8d903c3-28ca-4ec5-aee2-33774d343900" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7d9533b4-81fb-4fb8-8c31-fd973e948962" xlink:to="loc_cah_MedicalMember_e8d903c3-28ca-4ec5-aee2-33774d343900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_13109af0-dfcf-4376-ae18-38131ee3e4a0" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:to="loc_cah_GoodwillImpairmentAxis_13109af0-dfcf-4376-ae18-38131ee3e4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_08ac048b-7db5-4fd9-83f5-a71b838d79b9" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_13109af0-dfcf-4376-ae18-38131ee3e4a0" xlink:to="loc_cah_GoodwillImpairmentDomain_08ac048b-7db5-4fd9-83f5-a71b838d79b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_82f2dbf0-9c16-481f-ad32-5ae426a62bc8" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_08ac048b-7db5-4fd9-83f5-a71b838d79b9" xlink:to="loc_cah_MedicalUnitMember_82f2dbf0-9c16-481f-ad32-5ae426a62bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_715d3817-5e00-4e38-bb0a-8f34f951adf5" xlink:to="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_18d67732-d263-4905-bb1e-00a3a5a5998a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_us-gaap_Goodwill_18d67732-d263-4905-bb1e-00a3a5a5998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e9dc9ec1-7913-470f-baef-915ae5345368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e9dc9ec1-7913-470f-baef-915ae5345368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_9958c447-de0c-47f6-9240-3663d2d9395c" xlink:href="cah-20221231.xsd#cah_DiscountRateFairValueInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_cah_DiscountRateFairValueInput_9958c447-de0c-47f6-9240-3663d2d9395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_9472df53-8aa1-4ba6-bb5e-6814dadec640" xlink:href="cah-20221231.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_9472df53-8aa1-4ba6-bb5e-6814dadec640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet_079b8516-3aa7-492a-b869-5667e6ef9c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_768a2e2c-6171-47df-b965-fef5f3b90a82" xlink:to="loc_us-gaap_AssetsNet_079b8516-3aa7-492a-b869-5667e6ef9c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_7d309a8a-387c-43da-b4a2-4f5d8c333459" xlink:href="cah-20221231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_7d309a8a-387c-43da-b4a2-4f5d8c333459" xlink:to="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a99f7821-342b-4b52-9f9a-834bf8870532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:to="loc_us-gaap_DebtInstrumentAxis_a99f7821-342b-4b52-9f9a-834bf8870532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a99f7821-342b-4b52-9f9a-834bf8870532" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_4ce73d58-0d3d-4935-b9b8-e7e41d93ada1" xlink:href="cah-20221231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:to="loc_cah_A2.616Notesdue2022Member_4ce73d58-0d3d-4935-b9b8-e7e41d93ada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_4da113e2-30b0-44ff-b84f-a0fd2661adff" xlink:href="cah-20221231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70babf19-a5fb-47e9-ab9d-46165a178943" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_4da113e2-30b0-44ff-b84f-a0fd2661adff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_29bcf0e1-4219-4f22-9c67-65e7b5bf387d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:to="loc_us-gaap_CreditFacilityAxis_29bcf0e1-4219-4f22-9c67-65e7b5bf387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_29bcf0e1-4219-4f22-9c67-65e7b5bf387d" xlink:to="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c8609616-d481-43d4-beb2-a0b30295090c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_us-gaap_CommercialPaperMember_c8609616-d481-43d4-beb2-a0b30295090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_29a22129-4e9a-401f-9997-d8645245110c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_29a22129-4e9a-401f-9997-d8645245110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_e2f41b2c-0dd9-4e36-b5eb-e038fd9559c1" xlink:href="cah-20221231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_e2f41b2c-0dd9-4e36-b5eb-e038fd9559c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3f4e7d2c-4bbd-4a59-8e94-6953153a584e" xlink:href="cah-20221231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c665b112-3277-4e9c-88e2-f4e946371e8f" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3f4e7d2c-4bbd-4a59-8e94-6953153a584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1821888-e8b1-4bb2-9aeb-f73c49a00d32" xlink:to="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_e129fb56-8ebc-4fbe-848d-a31d4e66d1d4" xlink:href="cah-20221231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_cah_TotalLongTermandShortTermObligations_e129fb56-8ebc-4fbe-848d-a31d4e66d1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5c60d711-6d68-4ac5-a276-37f78f892999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5c60d711-6d68-4ac5-a276-37f78f892999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9fb99423-eb32-47e1-9c91-d09ebd3ed5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9fb99423-eb32-47e1-9c91-d09ebd3ed5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_57a1f6b4-7edf-4e47-af50-1d72cefc9ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_57a1f6b4-7edf-4e47-af50-1d72cefc9ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1ce17da7-6fe5-4f5e-910e-ae4bb0f4dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1ce17da7-6fe5-4f5e-910e-ae4bb0f4dbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_39ad4085-1c00-496b-8fa1-93be238c8c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_df0a89f1-7ef9-476b-8b14-c56c4cc4e4a8" xlink:to="loc_us-gaap_OtherShortTermBorrowings_39ad4085-1c00-496b-8fa1-93be238c8c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d556cf2-9dd5-4d4c-b18e-503ab70a4526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d556cf2-9dd5-4d4c-b18e-503ab70a4526" xlink:to="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ceb12663-bbc0-44a0-b114-85605213b9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ceb12663-bbc0-44a0-b114-85605213b9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_40c068d6-0cc4-4108-8709-210631fc355d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ceb12663-bbc0-44a0-b114-85605213b9cd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_40c068d6-0cc4-4108-8709-210631fc355d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_64d33c17-ae05-466a-a858-ce06d6a20cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_64d33c17-ae05-466a-a858-ce06d6a20cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d99214bc-5ab2-482c-8567-452b29cd5bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_64d33c17-ae05-466a-a858-ce06d6a20cf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d99214bc-5ab2-482c-8567-452b29cd5bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_e164653b-5bda-4748-92b2-cf22d9be17ab" xlink:href="cah-20221231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d99214bc-5ab2-482c-8567-452b29cd5bae" xlink:to="loc_cah_A2.616Notesdue2022Member_e164653b-5bda-4748-92b2-cf22d9be17ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_daed2daa-1c85-4d0b-9f4a-4c21918254c0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_9df81e80-125a-4b87-b3e8-d3990113646f" xlink:href="cah-20221231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:to="loc_cah_TotalLongTermandShortTermObligations_9df81e80-125a-4b87-b3e8-d3990113646f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f9c6277-77a0-4f0e-8048-3822d92d808a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f9c6277-77a0-4f0e-8048-3822d92d808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2ca22511-dcb6-4f0d-9748-984a7691be8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ae883b3-e863-44cf-9b59-69723562f4bf" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2ca22511-dcb6-4f0d-9748-984a7691be8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8e5d0f31-8f82-4019-ab6a-5558d0241b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8e5d0f31-8f82-4019-ab6a-5558d0241b51" xlink:to="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_057a765b-080c-4f8b-adfa-b834d2db5135" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_MajorCustomersAxis_057a765b-080c-4f8b-adfa-b834d2db5135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab838cac-7be5-4c0e-9f77-9ee18f184024" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_057a765b-080c-4f8b-adfa-b834d2db5135" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab838cac-7be5-4c0e-9f77-9ee18f184024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_fd12f444-b8d1-4bc6-bc2d-dee01abf2d77" xlink:href="cah-20221231.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab838cac-7be5-4c0e-9f77-9ee18f184024" xlink:to="loc_cah_CVSHealthMember_fd12f444-b8d1-4bc6-bc2d-dee01abf2d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_db8b4588-c771-4e33-8790-5f6b5daf20bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_LitigationCaseAxis_db8b4588-c771-4e33-8790-5f6b5daf20bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_db8b4588-c771-4e33-8790-5f6b5daf20bf" xlink:to="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_ea2d8e54-b982-48ce-a6d2-89f648e2f2c9" xlink:href="cah-20221231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_ea2d8e54-b982-48ce-a6d2-89f648e2f2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_5575f114-b4c5-462b-af64-65dc539ead52" xlink:href="cah-20221231.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_OpioidLawsuitsMember_5575f114-b4c5-462b-af64-65dc539ead52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_7babf7d3-fa84-4951-abaa-1e702b3abd2c" xlink:href="cah-20221231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_7babf7d3-fa84-4951-abaa-1e702b3abd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderDerivativeLitigationMember_da39f840-9dba-4caf-aec5-46a22766d58d" xlink:href="cah-20221231.xsd#cah_ShareholderDerivativeLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6e08908c-56b6-4476-84ba-79e04a28bc5c" xlink:to="loc_cah_ShareholderDerivativeLitigationMember_da39f840-9dba-4caf-aec5-46a22766d58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_25cab309-9206-4cbd-839e-b2cd18d78ae3" xlink:href="cah-20221231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_cah_OpioidLitigationAxis_25cab309-9206-4cbd-839e-b2cd18d78ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_e8cecabe-f8ae-4658-820d-d43378ef31ab" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_25cab309-9206-4cbd-839e-b2cd18d78ae3" xlink:to="loc_cah_OpioidLitigationDomain_e8cecabe-f8ae-4658-820d-d43378ef31ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_625e1b4c-5db3-4f04-8dc0-57a1ea2bac71" xlink:href="cah-20221231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_e8cecabe-f8ae-4658-820d-d43378ef31ab" xlink:to="loc_cah_TotalOpioidLitigationMember_625e1b4c-5db3-4f04-8dc0-57a1ea2bac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67" xlink:href="cah-20221231.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_cah_LawsuitTypeAxis_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:href="cah-20221231.xsd#cah_LawsuitTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_f9a74935-67a2-4fe2-9ee2-ea5ece1f5d67" xlink:to="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_dbfd4a2a-2079-49bc-98da-a355b3aaa85e" xlink:href="cah-20221231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:to="loc_cah_ClassActionLawsuitsMember_dbfd4a2a-2079-49bc-98da-a355b3aaa85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_8db2994b-e0d4-40d9-9a54-7a5ca72238d7" xlink:href="cah-20221231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_dff01761-3faa-42ef-b7d6-28a315f7981d" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_8db2994b-e0d4-40d9-9a54-7a5ca72238d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_c1f343c0-d96d-4164-a11e-8e344f3c9732" xlink:href="cah-20221231.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_cah_PlaintiffTypeAxis_c1f343c0-d96d-4164-a11e-8e344f3c9732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_b5c7896a-423a-4dfc-91a9-e9f31eeafce3" xlink:href="cah-20221231.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_c1f343c0-d96d-4164-a11e-8e344f3c9732" xlink:to="loc_cah_PlaintiffTypeDomain_b5c7896a-423a-4dfc-91a9-e9f31eeafce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_bbcdfa96-262a-4824-868f-17d4fe202d14" xlink:href="cah-20221231.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_b5c7896a-423a-4dfc-91a9-e9f31eeafce3" xlink:to="loc_cah_PrivatePartiesMember_bbcdfa96-262a-4824-868f-17d4fe202d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_17f837f8-30e5-4c76-a763-ca545712e205" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_StatementGeographicalAxis_17f837f8-30e5-4c76-a763-ca545712e205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_17f837f8-30e5-4c76-a763-ca545712e205" xlink:to="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_d7db31d8-2afa-4828-82ac-96f49ee0f344" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_GA_d7db31d8-2afa-4828-82ac-96f49ee0f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_409425df-fd1e-4871-86b0-edb340197a00" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_WV_409425df-fd1e-4871-86b0-edb340197a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_b24966c9-69e1-444b-9d86-25e3b5254f34" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_WA_b24966c9-69e1-444b-9d86-25e3b5254f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_587f69b6-ebfb-4128-a0e0-8aeeabb61c3a" xlink:href="cah-20221231.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_cah_AlamedaCountyMember_587f69b6-ebfb-4128-a0e0-8aeeabb61c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_13b51656-f098-43c3-a3d0-0b7d1f2b1bc9" xlink:href="cah-20221231.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_cah_OtherJurisdictionsMember_13b51656-f098-43c3-a3d0-0b7d1f2b1bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_e39244c2-c979-4313-8b48-12bc58ec35bb" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_OK_e39244c2-c979-4313-8b48-12bc58ec35bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL_250a35c6-6f41-4a53-b040-613b2dd2bc8c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AL"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_stpr_AL_250a35c6-6f41-4a53-b040-613b2dd2bc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember_fa1fc834-d928-43ee-9123-cf24e4ec4798" xlink:href="cah-20221231.xsd#cah_NativeAmericanTribesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2236edc7-2f2e-4e2d-8827-d11935564e58" xlink:to="loc_cah_NativeAmericanTribesMember_fa1fc834-d928-43ee-9123-cf24e4ec4798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_09d5606b-180f-406a-9758-f757a5517cfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_srt_RangeAxis_09d5606b-180f-406a-9758-f757a5517cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_09d5606b-180f-406a-9758-f757a5517cfd" xlink:to="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c70be32a-149a-45ab-a080-e89dd482493d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:to="loc_srt_MinimumMember_c70be32a-149a-45ab-a080-e89dd482493d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74b57a91-3448-46d2-bd88-96c23ed5a0ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_442ab10d-bdb4-439f-829f-3a548db62037" xlink:to="loc_srt_MaximumMember_74b57a91-3448-46d2-bd88-96c23ed5a0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9e7fcd6-f6d0-4a86-8d6f-e8e3aa1aadb0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_cfce8f4b-a967-427b-80f6-cedb4bca6947" xlink:href="cah-20221231.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:to="loc_cah_OpioidLawsuitsMember_cfce8f4b-a967-427b-80f6-cedb4bca6947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_0bd6b3b1-10d0-4e8a-9685-893bd6feba86" xlink:href="cah-20221231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5e51a1bc-9ed9-4e1f-b646-64d6cfcf49a7" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_0bd6b3b1-10d0-4e8a-9685-893bd6feba86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c28f1834-21ac-4429-a03b-662865a9576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c28f1834-21ac-4429-a03b-662865a9576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b3b088b0-dedc-4de0-a395-366bba304eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c28f1834-21ac-4429-a03b-662865a9576b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b3b088b0-dedc-4de0-a395-366bba304eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c7a150df-83ec-4832-aad9-9ad17cc26f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b3b088b0-dedc-4de0-a395-366bba304eee" xlink:to="loc_us-gaap_SubsequentEventMember_c7a150df-83ec-4832-aad9-9ad17cc26f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f0f4681-792d-4ab9-8da8-cb94e12c11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f0f4681-792d-4ab9-8da8-cb94e12c11e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_465cc759-e82f-4bdb-89a9-3baed8b263ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f0f4681-792d-4ab9-8da8-cb94e12c11e2" xlink:to="loc_us-gaap_SegmentDomain_465cc759-e82f-4bdb-89a9-3baed8b263ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_39fb7abb-3ab3-4383-8cd5-d4d5ea4391a9" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_465cc759-e82f-4bdb-89a9-3baed8b263ec" xlink:to="loc_cah_PharmaceuticalMember_39fb7abb-3ab3-4383-8cd5-d4d5ea4391a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_81ee4bce-198a-4a31-871d-0e3df0472c30" xlink:to="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_3789527f-2509-4488-bc16-6253fe5311e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_3789527f-2509-4488-bc16-6253fe5311e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_1a85b841-6e8c-4ec8-ad51-782bf19df613" xlink:href="cah-20221231.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_AggregateAnnualAssessment_1a85b841-6e8c-4ec8-ad51-782bf19df613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_e580c451-0471-4da6-adb3-06a212ff00c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_e580c451-0471-4da6-adb3-06a212ff00c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2b805c87-81ba-4763-98fe-ee98d2b892b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2b805c87-81ba-4763-98fe-ee98d2b892b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_e831488f-65b4-4294-a3f3-c33ef673d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_e831488f-65b4-4294-a3f3-c33ef673d5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_f2e1bfab-df35-4c46-9f95-bec4f5298626" xlink:href="cah-20221231.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_JudgmentForLostProfits_f2e1bfab-df35-4c46-9f95-bec4f5298626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d249d0f1-28cb-4248-aff4-3dfe6d95569a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d249d0f1-28cb-4248-aff4-3dfe6d95569a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_0731d05e-b144-46f9-90fd-13b9e51117d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_0731d05e-b144-46f9-90fd-13b9e51117d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_c991189e-9f5b-474c-8d6e-06d02d6ee03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LitigationReserve_c991189e-9f5b-474c-8d6e-06d02d6ee03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_2b5fdeed-8465-4191-a617-90da63ea79a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LitigationReserveCurrent_2b5fdeed-8465-4191-a617-90da63ea79a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_9a76d98d-8446-4970-8c4a-c5db8534de20" xlink:href="cah-20221231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_LossContingencyLawsuitsNumber_9a76d98d-8446-4970-8c4a-c5db8534de20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_6380a24c-4c00-4e51-91da-b10125267336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_6380a24c-4c00-4e51-91da-b10125267336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_73bf6bc1-e1d4-41ae-b188-e50f7f0f0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_73bf6bc1-e1d4-41ae-b188-e50f7f0f0f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_7065f792-1af8-4bbf-abc9-4b5c12d00a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_7065f792-1af8-4bbf-abc9-4b5c12d00a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_44170a3e-42dc-45d5-9684-1c935bcc1ae4" xlink:href="cah-20221231.xsd#cah_SettlingStates"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_SettlingStates_44170a3e-42dc-45d5-9684-1c935bcc1ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_efe7ea2b-c7b6-425a-990d-ed4f9a300fce" xlink:href="cah-20221231.xsd#cah_SettlingUSTerritories"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_SettlingUSTerritories_efe7ea2b-c7b6-425a-990d-ed4f9a300fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_f1648929-e0b5-41c0-9237-e99c753a9b49" xlink:href="cah-20221231.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_f1648929-e0b5-41c0-9237-e99c753a9b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_132bf7ac-e4a2-44c2-a258-35f38f204692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_InsuranceRecoveries_132bf7ac-e4a2-44c2-a258-35f38f204692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_0b6025d0-b2c6-4611-b7f0-fd6e4ebdf21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualPeriodExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_0b6025d0-b2c6-4611-b7f0-fd6e4ebdf21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_149efbab-69d9-4e4b-b8a5-0b36995dee3d" xlink:href="cah-20221231.xsd#cah_GrossInsuranceSettlementBeforeAttorneyFees"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_149efbab-69d9-4e4b-b8a5-0b36995dee3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_a983481c-ce1f-4525-9498-60a56de65550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_LegalFees_a983481c-ce1f-4525-9498-60a56de65550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_f21844bf-6d3b-43f5-bb8c-0b2bc0319832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa8feb45-8bba-483b-bf3d-0221989287ea" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_f21844bf-6d3b-43f5-bb8c-0b2bc0319832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_96c21c1f-2809-4e0d-95f2-79d2ff0b9142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96c21c1f-2809-4e0d-95f2-79d2ff0b9142" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_9d1a2932-3f14-4264-adcd-e026f60e1efd" xlink:href="cah-20221231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_OpioidLitigationAxis_9d1a2932-3f14-4264-adcd-e026f60e1efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_be525986-e7c8-41ff-8cd3-d41fed884eaf" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_9d1a2932-3f14-4264-adcd-e026f60e1efd" xlink:to="loc_cah_OpioidLitigationDomain_be525986-e7c8-41ff-8cd3-d41fed884eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_d70dd904-8d39-4045-8ac1-f6df0bc5c789" xlink:href="cah-20221231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_be525986-e7c8-41ff-8cd3-d41fed884eaf" xlink:to="loc_cah_TotalOpioidLitigationMember_d70dd904-8d39-4045-8ac1-f6df0bc5c789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_7ddfacd7-191e-4018-ad84-543e43ec32cf" xlink:href="cah-20221231.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_TaxMatterAxis_7ddfacd7-191e-4018-ad84-543e43ec32cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_bb906c94-3a61-487c-a22a-1b4baffe8119" xlink:href="cah-20221231.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_7ddfacd7-191e-4018-ad84-543e43ec32cf" xlink:to="loc_cah_TaxMatterDomain_bb906c94-3a61-487c-a22a-1b4baffe8119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_33f4e7dd-19ce-45e2-a540-6fb4ecaebdb5" xlink:href="cah-20221231.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_bb906c94-3a61-487c-a22a-1b4baffe8119" xlink:to="loc_cah_CareFusionMember_33f4e7dd-19ce-45e2-a540-6fb4ecaebdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4b1970e-f032-46b4-b498-f45faae6f773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4b1970e-f032-46b4-b498-f45faae6f773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46fb12f6-dab7-4497-b61a-e9380d663d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4b1970e-f032-46b4-b498-f45faae6f773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46fb12f6-dab7-4497-b61a-e9380d663d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_67c32821-5c86-43c2-9ac7-11d5e6a268a6" xlink:href="cah-20221231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_TaxMattersAgreementAxis_67c32821-5c86-43c2-9ac7-11d5e6a268a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_0c679f0a-efba-434f-a2aa-2aa5c5da492b" xlink:href="cah-20221231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_67c32821-5c86-43c2-9ac7-11d5e6a268a6" xlink:to="loc_cah_TaxMattersAgreementDomain_0c679f0a-efba-434f-a2aa-2aa5c5da492b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_ad4d3321-5b3e-4df4-99d5-d71c31aedd60" xlink:href="cah-20221231.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_0c679f0a-efba-434f-a2aa-2aa5c5da492b" xlink:to="loc_cah_CareFusionMember_ad4d3321-5b3e-4df4-99d5-d71c31aedd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0600985f-1a9d-410b-b5d1-3c0f2bd0effa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_srt_RangeAxis_0600985f-1a9d-410b-b5d1-3c0f2bd0effa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0600985f-1a9d-410b-b5d1-3c0f2bd0effa" xlink:to="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5da614a3-dafc-45d8-8be8-d065ff485c17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:to="loc_srt_MinimumMember_5da614a3-dafc-45d8-8be8-d065ff485c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cee44f38-a605-4757-b4b0-cbf1b44cf18c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c33d8f61-59a1-4b0f-9355-028043b0efd9" xlink:to="loc_srt_MaximumMember_cee44f38-a605-4757-b4b0-cbf1b44cf18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_20053065-15bf-440e-98d4-4b3bccfbcd17" xlink:href="cah-20221231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_20053065-15bf-440e-98d4-4b3bccfbcd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_055fa87b-57da-4da2-b2c2-a97a8d49a5d5" xlink:href="cah-20221231.xsd#cah_CARESActDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_20053065-15bf-440e-98d4-4b3bccfbcd17" xlink:to="loc_cah_CARESActDomain_055fa87b-57da-4da2-b2c2-a97a8d49a5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2d6d421c-5448-4bb2-8297-480612586822" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_srt_StatementScenarioAxis_2d6d421c-5448-4bb2-8297-480612586822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_14d940ca-7c77-488f-99f8-98b91357df9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2d6d421c-5448-4bb2-8297-480612586822" xlink:to="loc_srt_ScenarioUnspecifiedDomain_14d940ca-7c77-488f-99f8-98b91357df9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4be799a9-9d46-4d5f-9acc-868247973402" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_14d940ca-7c77-488f-99f8-98b91357df9c" xlink:to="loc_srt_ScenarioForecastMember_4be799a9-9d46-4d5f-9acc-868247973402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_07b0c3ed-21bf-4acc-a401-89c72f355026" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_GoodwillImpairmentAxis_07b0c3ed-21bf-4acc-a401-89c72f355026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:href="cah-20221231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_07b0c3ed-21bf-4acc-a401-89c72f355026" xlink:to="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_02a8c9c6-a493-4a01-b30e-85cafc3d144d" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:to="loc_cah_MedicalUnitMember_02a8c9c6-a493-4a01-b30e-85cafc3d144d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_79a7b5dd-6dd5-4150-9285-d71781964ace" xlink:href="cah-20221231.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_894629fb-fdd8-45e0-ae5b-9b5f861439a3" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_79a7b5dd-6dd5-4150-9285-d71781964ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_ff87c88b-ab87-4230-8842-cd5a8a0a9f29" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_cah_CordisDivestitureAxis_ff87c88b-ab87-4230-8842-cd5a8a0a9f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_b5b85fde-78d4-4150-bd78-4ff4e93e2180" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_ff87c88b-ab87-4230-8842-cd5a8a0a9f29" xlink:to="loc_cah_CordisDivestitureDomain_b5b85fde-78d4-4150-bd78-4ff4e93e2180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_28023ea1-4f3c-4a39-acd7-f906a18bb6dd" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_b5b85fde-78d4-4150-bd78-4ff4e93e2180" xlink:to="loc_cah_CordisDivestitureMember_28023ea1-4f3c-4a39-acd7-f906a18bb6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df40be26-c5c4-4fcc-90c5-f44f2d21b9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a22f52ae-7f5e-4db7-86c7-cad4e3b735a4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df40be26-c5c4-4fcc-90c5-f44f2d21b9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c91f3f05-2b3e-4ab4-9a15-f1119536a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df40be26-c5c4-4fcc-90c5-f44f2d21b9c4" xlink:to="loc_us-gaap_SubsequentEventMember_c91f3f05-2b3e-4ab4-9a15-f1119536a3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_b217124e-de4d-4549-95bf-f090ae856e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_us-gaap_ReportingUnitAxis_b217124e-de4d-4549-95bf-f090ae856e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_4f6261f7-2bb4-4b23-b5c3-fdf33ca48d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_b217124e-de4d-4549-95bf-f090ae856e17" xlink:to="loc_us-gaap_ReportingUnitDomain_4f6261f7-2bb4-4b23-b5c3-fdf33ca48d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_c179eafb-badb-41c7-91bb-766ca22c0d62" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_4f6261f7-2bb4-4b23-b5c3-fdf33ca48d86" xlink:to="loc_cah_MedicalUnitMember_c179eafb-badb-41c7-91bb-766ca22c0d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0fbe0a1-9107-4e4e-beec-f5862b023129" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d79b1d8-911e-4038-8b8a-286094a93ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d79b1d8-911e-4038-8b8a-286094a93ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_570ea4a8-6d2c-490e-9fe8-72bd59de8bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_570ea4a8-6d2c-490e-9fe8-72bd59de8bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_736ef4aa-7527-4c77-b45e-8ee469e612fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_736ef4aa-7527-4c77-b45e-8ee469e612fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d62f69c7-340d-46bc-bc1b-3def812e4916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d62f69c7-340d-46bc-bc1b-3def812e4916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b4f7facb-f142-4332-b84c-f404a6ad3cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b4f7facb-f142-4332-b84c-f404a6ad3cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c48e748f-7108-4dfe-9d97-f0a216bea66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c48e748f-7108-4dfe-9d97-f0a216bea66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0dbf796-0028-4555-a416-ccab8fa7617f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0dbf796-0028-4555-a416-ccab8fa7617f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_a35594bf-0827-4505-a7b3-b955348d0b86" xlink:href="cah-20221231.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ffcaf48b-823e-44b8-bd27-9644b2bd1781" xlink:to="loc_cah_IndemnificationReceivable_a35594bf-0827-4505-a7b3-b955348d0b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1105a8e6-8149-4cee-865c-acfdef4e7aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1105a8e6-8149-4cee-865c-acfdef4e7aad" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cba759c-d41d-4f41-bedf-f6d67a7a3596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cba759c-d41d-4f41-bedf-f6d67a7a3596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cba759c-d41d-4f41-bedf-f6d67a7a3596" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_af5cd96c-8ea5-42c4-88cf-35132feec194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_af5cd96c-8ea5-42c4-88cf-35132feec194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b7a7525c-fc8e-45c2-8369-6f8b09032c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b7a7525c-fc8e-45c2-8369-6f8b09032c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d9a824b6-5d2d-48cd-a540-d49073e760c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ee6cd36-01ea-4113-bf4e-b9575814b34d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d9a824b6-5d2d-48cd-a540-d49073e760c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9aa115d7-7425-43da-ac79-53b672ba7900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9aa115d7-7425-43da-ac79-53b672ba7900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c343d96b-b7e8-4c84-aa62-aa82053d056d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9aa115d7-7425-43da-ac79-53b672ba7900" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c343d96b-b7e8-4c84-aa62-aa82053d056d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1f332bd2-3b69-456c-b29a-c6c831537b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c343d96b-b7e8-4c84-aa62-aa82053d056d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1f332bd2-3b69-456c-b29a-c6c831537b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ebb2905-2918-4108-9cec-5ed530e6af91" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b2a3371-e82e-47d5-ba4c-cdcfddb7758a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b2a3371-e82e-47d5-ba4c-cdcfddb7758a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9d2660d2-045c-427b-b6b0-79126d8ed9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9d2660d2-045c-427b-b6b0-79126d8ed9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_6324405f-eb33-47be-9680-b3e273b40757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d5cfd289-de4e-46b4-a511-53d87c4faade" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_6324405f-eb33-47be-9680-b3e273b40757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_b0067975-be69-4e56-8205-11e4abb432f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5793ae9b-8582-4ec7-82eb-d0f8032079da" xlink:to="loc_us-gaap_LiabilitiesAbstract_b0067975-be69-4e56-8205-11e4abb432f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_917aa0e6-4e4c-4957-807a-5865160b151d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_b0067975-be69-4e56-8205-11e4abb432f8" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_917aa0e6-4e4c-4957-807a-5865160b151d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_316adf02-1abe-4f4a-900b-875807e03b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_316adf02-1abe-4f4a-900b-875807e03b3b" xlink:to="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_de97fa73-50fb-40aa-897c-e53c17bb039b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_de97fa73-50fb-40aa-897c-e53c17bb039b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dea66cf8-33dd-4ecb-9671-b3aa8245b040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_de97fa73-50fb-40aa-897c-e53c17bb039b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dea66cf8-33dd-4ecb-9671-b3aa8245b040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ccb4eeed-c671-49af-b0ee-1397bdf81c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dea66cf8-33dd-4ecb-9671-b3aa8245b040" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ccb4eeed-c671-49af-b0ee-1397bdf81c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_89997f3d-0923-489e-b850-4fee74cdfa78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_89997f3d-0923-489e-b850-4fee74cdfa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84b06825-2269-489f-9ff4-e07df0fb527e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_89997f3d-0923-489e-b850-4fee74cdfa78" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84b06825-2269-489f-9ff4-e07df0fb527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ae04395a-dde1-4bf1-a04d-461958271b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84b06825-2269-489f-9ff4-e07df0fb527e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ae04395a-dde1-4bf1-a04d-461958271b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4a79d875-bf9a-4368-818b-d0753166a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_HedgingDesignationAxis_4a79d875-bf9a-4368-818b-d0753166a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4a79d875-bf9a-4368-818b-d0753166a6e5" xlink:to="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9aa21918-00b3-44f6-87f8-4ab39275c900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9aa21918-00b3-44f6-87f8-4ab39275c900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_cb4d0898-0077-41d3-bab9-b23f16eba19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c1abb828-c3ab-4bad-bf2d-2d8fd1efe29c" xlink:to="loc_us-gaap_NondesignatedMember_cb4d0898-0077-41d3-bab9-b23f16eba19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b00628e9-5aca-4e5c-a217-2ad6cca57328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b00628e9-5aca-4e5c-a217-2ad6cca57328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_78fc147c-3ed8-4e20-9156-b36c240a27e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b00628e9-5aca-4e5c-a217-2ad6cca57328" xlink:to="loc_us-gaap_HedgingRelationshipDomain_78fc147c-3ed8-4e20-9156-b36c240a27e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c0887e28-9c37-456e-9160-1506bdeb2b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_78fc147c-3ed8-4e20-9156-b36c240a27e2" xlink:to="loc_us-gaap_FairValueHedgingMember_c0887e28-9c37-456e-9160-1506bdeb2b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c723f290-5f4d-417a-9bbe-c113a27047f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c723f290-5f4d-417a-9bbe-c113a27047f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c723f290-5f4d-417a-9bbe-c113a27047f0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2cf6375c-038d-402b-8f95-e06927b6c5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:to="loc_us-gaap_CashFlowHedgingMember_2cf6375c-038d-402b-8f95-e06927b6c5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_53788fbd-d819-403d-a9fa-d8dfb5b1d5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:to="loc_us-gaap_ForeignExchangeContractMember_53788fbd-d819-403d-a9fa-d8dfb5b1d5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_46e53e6e-4045-4748-8397-268a183cd41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0513d5d5-a99e-4013-af1a-0cbe88d1b8af" xlink:to="loc_us-gaap_InterestRateSwapMember_46e53e6e-4045-4748-8397-268a183cd41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_e11de053-a3e3-4f79-b971-20758b041703" xlink:href="cah-20221231.xsd#cah_MaturityDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_cah_MaturityDateAxis_e11de053-a3e3-4f79-b971-20758b041703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_ce64cefc-5dea-4587-8490-0d3b1156cae5" xlink:href="cah-20221231.xsd#cah_MaturityDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateAxis_e11de053-a3e3-4f79-b971-20758b041703" xlink:to="loc_cah_MaturityDateDomain_ce64cefc-5dea-4587-8490-0d3b1156cae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_60b024f0-d4d2-4f0c-8e65-f0ce1119a08f" xlink:to="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_40e61b83-9826-4341-97bf-8ebbf668e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_40e61b83-9826-4341-97bf-8ebbf668e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_3b3e4185-42bc-40c5-90fd-bd652fb8bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_3b3e4185-42bc-40c5-90fd-bd652fb8bc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_6fd0e5b9-1e38-41f4-91fd-700d5b41e2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_6fd0e5b9-1e38-41f4-91fd-700d5b41e2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8d347ca1-a030-4999-a497-5d054ca395d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8d347ca1-a030-4999-a497-5d054ca395d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4bca8a1a-13ce-4368-b6b3-9b6bc27c5fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4bca8a1a-13ce-4368-b6b3-9b6bc27c5fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e60383a8-eb63-4717-acf7-bba40caf9578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_35fe2237-3a0d-4e53-aff5-9a216d90ffe5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e60383a8-eb63-4717-acf7-bba40caf9578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b8463d4b-617a-4313-8ae7-82772f97b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec805c9-f150-40f9-b5b5-808d0126c735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b8463d4b-617a-4313-8ae7-82772f97b81b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec805c9-f150-40f9-b5b5-808d0126c735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec805c9-f150-40f9-b5b5-808d0126c735" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_afe898a5-e781-4dcf-ae53-a4467b3c7d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d93ff58c-eb7b-4a4c-86c1-f7bb2b642ae3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_afe898a5-e781-4dcf-ae53-a4467b3c7d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_50a77bde-f3f1-4d1e-8683-0dc782f3918f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_afe898a5-e781-4dcf-ae53-a4467b3c7d39" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_50a77bde-f3f1-4d1e-8683-0dc782f3918f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec805c9-f150-40f9-b5b5-808d0126c735" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_be189e96-a176-4a86-ae57-767446251560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:to="loc_us-gaap_DebtInstrumentFairValue_be189e96-a176-4a86-ae57-767446251560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_88750f38-2f56-43ba-b98c-c94efc50df0d" xlink:href="cah-20221231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a9f33ea7-08dc-41a2-a771-718f98b7d6ea" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_88750f38-2f56-43ba-b98c-c94efc50df0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ade15967-89bf-4294-ba0d-9002038e480d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ade15967-89bf-4294-ba0d-9002038e480d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e066b80d-0670-47f8-8f08-f4b7b32a1a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e066b80d-0670-47f8-8f08-f4b7b32a1a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d49850fa-9cfa-4f50-99b2-44333b91fecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e066b80d-0670-47f8-8f08-f4b7b32a1a5e" xlink:to="loc_us-gaap_EquityComponentDomain_d49850fa-9cfa-4f50-99b2-44333b91fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_68629a56-5838-44ab-95c7-4a4cc5107305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d49850fa-9cfa-4f50-99b2-44333b91fecf" xlink:to="loc_us-gaap_TreasuryStockMember_68629a56-5838-44ab-95c7-4a4cc5107305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8ab7849c-2ff8-435e-b2e1-312883013d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8ab7849c-2ff8-435e-b2e1-312883013d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d84861fa-41c2-46d8-90dd-48aa29fc08dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8ab7849c-2ff8-435e-b2e1-312883013d94" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d84861fa-41c2-46d8-90dd-48aa29fc08dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9dda158a-1800-471a-bd44-9e3c15dcd15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d84861fa-41c2-46d8-90dd-48aa29fc08dc" xlink:to="loc_us-gaap_SubsequentEventMember_9dda158a-1800-471a-bd44-9e3c15dcd15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_07e1f25e-ac03-4221-85fa-68b0a1b11a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_07e1f25e-ac03-4221-85fa-68b0a1b11a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_07e1f25e-ac03-4221-85fa-68b0a1b11a98" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A250MillionShareRepurchaseProgramMember_08fa0921-c950-408e-aa29-1a060e0b3611" xlink:href="cah-20221231.xsd#cah_A250MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A250MillionShareRepurchaseProgramMember_08fa0921-c950-408e-aa29-1a060e0b3611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember_58f8fffa-e970-46aa-84d9-47420b4239e2" xlink:href="cah-20221231.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A1BillionShareRepurchaseProgramMember_58f8fffa-e970-46aa-84d9-47420b4239e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_12159f33-309c-4258-a4b1-0ae4d1eb0e06" xlink:href="cah-20221231.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_12159f33-309c-4258-a4b1-0ae4d1eb0e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_7e43bb17-d87c-4ae8-8d48-934c19cad219" xlink:href="cah-20221231.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b9e87833-18d8-44f2-9f96-8a54937407f0" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_7e43bb17-d87c-4ae8-8d48-934c19cad219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14cc2a8f-e7b8-49d5-b6f9-5ca9f29829d9" xlink:to="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04b29a4b-0a5e-48b6-9d0e-38f4e6e646b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04b29a4b-0a5e-48b6-9d0e-38f4e6e646b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8309ee8b-0e78-4e52-8fc6-2cd1d6b71351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8309ee8b-0e78-4e52-8fc6-2cd1d6b71351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1a3315f4-c8de-4f2d-9a43-856586ba298b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c424462d-a262-4c2b-b172-318d4440ab9f" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1a3315f4-c8de-4f2d-9a43-856586ba298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c1376bc9-201f-4b12-92cc-087e9609eb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2c389f0e-a9ec-4a6a-bae5-79595f5f1188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1376bc9-201f-4b12-92cc-087e9609eb63" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2c389f0e-a9ec-4a6a-bae5-79595f5f1188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_27cd5cb7-8921-4809-bb01-94158506b465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2c389f0e-a9ec-4a6a-bae5-79595f5f1188" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_27cd5cb7-8921-4809-bb01-94158506b465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27cd5cb7-8921-4809-bb01-94158506b465" xlink:to="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f968394-3f2b-4212-af61-4586ab12d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f968394-3f2b-4212-af61-4586ab12d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_e712c142-3139-48e1-aa50-fa0ba1988f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_e712c142-3139-48e1-aa50-fa0ba1988f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_aa7b6af8-18eb-4e2a-9cba-6ba84e6104a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_aa7b6af8-18eb-4e2a-9cba-6ba84e6104a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00a96bb0-e3ca-47c8-b319-8e0d37a497db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9ae68c9e-c57a-4ac0-b97a-f9f232a213a2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00a96bb0-e3ca-47c8-b319-8e0d37a497db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ff11c298-4f41-4356-ba91-804012d6a664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2c389f0e-a9ec-4a6a-bae5-79595f5f1188" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ff11c298-4f41-4356-ba91-804012d6a664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ff11c298-4f41-4356-ba91-804012d6a664" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3037dac-31c7-4864-89de-eb45b93b8103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3037dac-31c7-4864-89de-eb45b93b8103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a31c2b9f-601a-4290-a448-ac0e628c3037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a31c2b9f-601a-4290-a448-ac0e628c3037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_56b880f4-427c-4619-9888-5bde1dd66958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_56b880f4-427c-4619-9888-5bde1dd66958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d9b3695-1c42-48e8-b4ec-c55895cb5351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_1d9b3695-1c42-48e8-b4ec-c55895cb5351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_72ceeaf7-e542-42aa-839e-c7f177be131e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_72ceeaf7-e542-42aa-839e-c7f177be131e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49a6a350-8b02-440b-aeca-bea6842cb4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_53b3fcb9-a71d-406c-916a-49676f9f0223" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49a6a350-8b02-440b-aeca-bea6842cb4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_776f79a3-4072-43e9-aa69-4c7b51389a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1e93367-da3a-4a5a-a944-80bf7fc316a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_776f79a3-4072-43e9-aa69-4c7b51389a55" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1e93367-da3a-4a5a-a944-80bf7fc316a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_b51cc550-bfe3-4aaf-bfa1-24953d5e30c5" xlink:href="cah-20221231.xsd#cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_776f79a3-4072-43e9-aa69-4c7b51389a55" xlink:to="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_b51cc550-bfe3-4aaf-bfa1-24953d5e30c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2731863e-b33d-4929-bf75-bc784512be03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e4a78c4-3f14-4691-ae27-fe0d53fbd8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2731863e-b33d-4929-bf75-bc784512be03" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e4a78c4-3f14-4691-ae27-fe0d53fbd8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_859f85e2-7d3a-4976-bdb6-c2b1526ce680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2731863e-b33d-4929-bf75-bc784512be03" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_859f85e2-7d3a-4976-bdb6-c2b1526ce680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2ec2f99d-b831-4c55-9cc9-e637cd662b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_859f85e2-7d3a-4976-bdb6-c2b1526ce680" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2ec2f99d-b831-4c55-9cc9-e637cd662b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ee2fd111-6b5e-4d6c-84d7-6eed9471caa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2731863e-b33d-4929-bf75-bc784512be03" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ee2fd111-6b5e-4d6c-84d7-6eed9471caa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cc512202-92e7-48be-9e4e-e287731f2ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cc512202-92e7-48be-9e4e-e287731f2ecc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_b40269e0-348a-4c1d-9ae3-692ee106193f" xlink:href="cah-20221231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_cah_OpioidLitigationAxis_b40269e0-348a-4c1d-9ae3-692ee106193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_176a8421-b557-4381-8017-f712da8178db" xlink:href="cah-20221231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_b40269e0-348a-4c1d-9ae3-692ee106193f" xlink:to="loc_cah_OpioidLitigationDomain_176a8421-b557-4381-8017-f712da8178db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_df2767fa-e1ab-4c28-ba37-e9cde5dec40b" xlink:href="cah-20221231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_176a8421-b557-4381-8017-f712da8178db" xlink:to="loc_cah_TotalOpioidLitigationMember_df2767fa-e1ab-4c28-ba37-e9cde5dec40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9fdec747-44f2-4857-9c91-9b550bf0bb54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_srt_LitigationCaseAxis_9fdec747-44f2-4857-9c91-9b550bf0bb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ad23b1c6-5319-4634-b2ac-1f5c40de1829" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9fdec747-44f2-4857-9c91-9b550bf0bb54" xlink:to="loc_srt_LitigationCaseTypeDomain_ad23b1c6-5319-4634-b2ac-1f5c40de1829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_82b0887d-59d5-49c4-a7d7-050b5b474e76" xlink:href="cah-20221231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ad23b1c6-5319-4634-b2ac-1f5c40de1829" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_82b0887d-59d5-49c4-a7d7-050b5b474e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_0cabd130-6790-4839-9b3a-c070df2453d5" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_cah_CordisDivestitureAxis_0cabd130-6790-4839-9b3a-c070df2453d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_4d68f573-1471-4f9a-8902-a3294201d35b" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_0cabd130-6790-4839-9b3a-c070df2453d5" xlink:to="loc_cah_CordisDivestitureDomain_4d68f573-1471-4f9a-8902-a3294201d35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a12e2cad-d00a-49dd-8bd5-e9c094d7166b" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_4d68f573-1471-4f9a-8902-a3294201d35b" xlink:to="loc_cah_CordisDivestitureMember_a12e2cad-d00a-49dd-8bd5-e9c094d7166b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_56a57058-eff3-4a7b-8540-1109acb8277f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_56a57058-eff3-4a7b-8540-1109acb8277f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_06cde06a-97e6-4827-95ac-af213f533ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_56a57058-eff3-4a7b-8540-1109acb8277f" xlink:to="loc_us-gaap_SegmentDomain_06cde06a-97e6-4827-95ac-af213f533ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_47f502c5-7192-422e-898e-4e69e36c9b7d" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_06cde06a-97e6-4827-95ac-af213f533ddd" xlink:to="loc_cah_MedicalMember_47f502c5-7192-422e-898e-4e69e36c9b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6f233efc-70b5-4efa-a1d6-3a91a96b563c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_us-gaap_ReportingUnitAxis_6f233efc-70b5-4efa-a1d6-3a91a96b563c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c5aea529-e3c7-4406-9cf0-a2a8fb2f9f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_6f233efc-70b5-4efa-a1d6-3a91a96b563c" xlink:to="loc_us-gaap_ReportingUnitDomain_c5aea529-e3c7-4406-9cf0-a2a8fb2f9f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_62fe9497-7053-4106-a120-695b6ee362c5" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_c5aea529-e3c7-4406-9cf0-a2a8fb2f9f8a" xlink:to="loc_cah_MedicalUnitMember_62fe9497-7053-4106-a120-695b6ee362c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5f58ac57-93d6-4d45-883a-0814d2cacc6d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_51c0a3ad-5ce9-4841-b4b2-15ba0bd3923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_51c0a3ad-5ce9-4841-b4b2-15ba0bd3923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_dc550397-cb6f-48a1-99c9-25374ea468ad" xlink:href="cah-20221231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_dc550397-cb6f-48a1-99c9-25374ea468ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_65d96238-7f6a-493a-b3ac-100796627752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_NumberOfReportableSegments_65d96238-7f6a-493a-b3ac-100796627752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c028203f-742e-4d99-b77f-e083650f2d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c028203f-742e-4d99-b77f-e083650f2d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_27f7525c-73ac-4a11-a41d-4446793d60ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd126387-5948-403e-968c-a62567b49459" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_27f7525c-73ac-4a11-a41d-4446793d60ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_54231c66-3c81-4e5d-a53b-b20a994b0b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cc512202-92e7-48be-9e4e-e287731f2ecc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_54231c66-3c81-4e5d-a53b-b20a994b0b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ecc8720d-1cb4-4009-95ea-f8dc9562cae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cc512202-92e7-48be-9e4e-e287731f2ecc" xlink:to="loc_us-gaap_NumberOfReportableSegments_ecc8720d-1cb4-4009-95ea-f8dc9562cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_a5a2057b-d54f-4421-95ec-a89c7d846809" xlink:href="cah-20221231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cc512202-92e7-48be-9e4e-e287731f2ecc" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_a5a2057b-d54f-4421-95ec-a89c7d846809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b50bd153-e4f5-438b-aba7-fe35188135e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b50bd153-e4f5-438b-aba7-fe35188135e0" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:to="loc_us-gaap_SubsegmentsAxis_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_87bb82ba-f07b-4bca-82fa-2db5dd4f4b46" xlink:to="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_ac8b069d-3028-4b09-82c5-0e7dd2198945" xlink:href="cah-20221231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_ac8b069d-3028-4b09-82c5-0e7dd2198945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember_742687f5-1acf-4e43-9f30-72a33d7646c0" xlink:href="cah-20221231.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_NuclearPrecisionHealthSolutionsMember_742687f5-1acf-4e43-9f30-72a33d7646c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_a9172383-48af-4c53-8a0f-46a4589f319f" xlink:href="cah-20221231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_MedicaldistributionandproductsMember_a9172383-48af-4c53-8a0f-46a4589f319f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_aae52ddd-44aa-450b-a013-20d8ed9dfc11" xlink:href="cah-20221231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f0afd7f0-98f0-4f26-8935-b0535b98f3f3" xlink:to="loc_cah_CardinalHealthAtHomeMember_aae52ddd-44aa-450b-a013-20d8ed9dfc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:to="loc_srt_ConsolidationItemsAxis_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_25978c9f-ef9e-4aef-9dfb-30dfa9a9c34c" xlink:to="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1d7f9996-835f-48d8-890f-f43dba21e2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:to="loc_us-gaap_OperatingSegmentsMember_1d7f9996-835f-48d8-890f-f43dba21e2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_958896f4-fcd6-44ec-977b-4d87ee25ef41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_49ea44ee-8f29-46ce-b671-014c0015ab7b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_958896f4-fcd6-44ec-977b-4d87ee25ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_557273ff-b32f-4ef1-801d-f3b0aba9ce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_557273ff-b32f-4ef1-801d-f3b0aba9ce0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_557273ff-b32f-4ef1-801d-f3b0aba9ce0a" xlink:to="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_0fdc3c2c-ce68-420c-9198-0b6b87bb75c9" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:to="loc_cah_PharmaceuticalMember_0fdc3c2c-ce68-420c-9198-0b6b87bb75c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_299397cc-d3c7-4802-a013-e6ae8997754f" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_db90bc45-c41c-4860-a2b9-eacdb094699a" xlink:to="loc_cah_MedicalMember_299397cc-d3c7-4802-a013-e6ae8997754f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a1af6080-e5ac-4bf6-8977-755c2449795f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d456c6c7-bc13-41a8-a5b2-7c245e8e93e6" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a1af6080-e5ac-4bf6-8977-755c2449795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f9d3ad3b-7698-4996-bc65-f40bf010f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a1af6080-e5ac-4bf6-8977-755c2449795f" xlink:to="loc_us-gaap_Revenues_f9d3ad3b-7698-4996-bc65-f40bf010f18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f994eaeb-fd41-440e-b2b7-23ea3f80e989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f994eaeb-fd41-440e-b2b7-23ea3f80e989" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_944c7be5-cf0b-48bb-85ea-ef0bcc8562af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fad56ef3-4c0c-4fd9-b5d8-99dc707017ac" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_944c7be5-cf0b-48bb-85ea-ef0bcc8562af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b9c0e025-c768-45ab-a905-4153f4467a22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:to="loc_srt_ConsolidationItemsAxis_b9c0e025-c768-45ab-a905-4153f4467a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b9c0e025-c768-45ab-a905-4153f4467a22" xlink:to="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2cdc0a17-2a28-4a75-bf54-d5a942db2471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:to="loc_us-gaap_OperatingSegmentsMember_2cdc0a17-2a28-4a75-bf54-d5a942db2471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2deea391-dba3-4784-9327-46d221860489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8abc0fd5-dae2-4853-aff8-438f3f03ae95" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2deea391-dba3-4784-9327-46d221860489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4a5cfae2-7b37-4576-ace4-8b9af4f45527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4a5cfae2-7b37-4576-ace4-8b9af4f45527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a5cfae2-7b37-4576-ace4-8b9af4f45527" xlink:to="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_fedd49b9-4e3e-423b-a318-25eb030f8cc9" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:to="loc_cah_PharmaceuticalMember_fedd49b9-4e3e-423b-a318-25eb030f8cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_4d72332d-ef88-4af6-b4df-399539975a05" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3335ae69-76e8-40a7-be1d-e0f537af76eb" xlink:to="loc_cah_MedicalMember_4d72332d-ef88-4af6-b4df-399539975a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd4b8afe-95ab-4c90-98a0-0d77eb753116" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be3a4568-afc6-48da-8b6e-e423abc29472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:to="loc_us-gaap_OperatingIncomeLoss_be3a4568-afc6-48da-8b6e-e423abc29472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_be1a2563-fc8d-45fd-92d4-1a9756493bea" xlink:href="cah-20221231.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f5579315-1ddb-4e80-a1f2-49af1bf6994e" xlink:to="loc_cah_JudgmentForLostProfits_be1a2563-fc8d-45fd-92d4-1a9756493bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c9f14e8b-30b4-4348-b1a3-8344fdcdcdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:href="cah-20221231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c9f14e8b-30b4-4348-b1a3-8344fdcdcdd6" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:to="loc_srt_ConsolidationItemsAxis_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_ee22c1c3-a5d4-4cec-92b0-770d8172dd5c" xlink:to="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_48d308d7-e62d-4e47-a589-2ff1be5e272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:to="loc_us-gaap_OperatingSegmentsMember_48d308d7-e62d-4e47-a589-2ff1be5e272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_cab10ceb-5964-4453-8065-b21ef9416d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_bc1eb8b3-0fff-43bf-9b68-f8c062e6c30d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_cab10ceb-5964-4453-8065-b21ef9416d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:to="loc_srt_StatementGeographicalAxis_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b7486eed-4b11-42d2-b1d7-92ee46a8c0a2" xlink:to="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1cba9d40-3610-41a5-b9c5-7e4ff888f5c4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:to="loc_country_US_1cba9d40-3610-41a5-b9c5-7e4ff888f5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_193b3693-b71c-40c4-aa32-7830dc76c637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_227620ff-098f-43d2-ae5c-4052c0289a9d" xlink:to="loc_us-gaap_NonUsMember_193b3693-b71c-40c4-aa32-7830dc76c637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a54a9f66-a812-4788-b650-30305555918b" xlink:href="cah-20221231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_504f3bfd-8d5a-4132-95fb-c0598149bbeb" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a54a9f66-a812-4788-b650-30305555918b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_339c36b1-607e-4cec-8e02-3e4e86a59c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a54a9f66-a812-4788-b650-30305555918b" xlink:to="loc_us-gaap_Revenues_339c36b1-607e-4cec-8e02-3e4e86a59c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d003111f-50d4-4f4a-bc9c-ebd4797d2897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d003111f-50d4-4f4a-bc9c-ebd4797d2897" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e1db7414-094c-4ecc-af04-b79ff20668ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_srt_ConsolidationItemsAxis_e1db7414-094c-4ecc-af04-b79ff20668ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e1db7414-094c-4ecc-af04-b79ff20668ad" xlink:to="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4013c639-78d0-4e44-9dab-a14deb6348b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:to="loc_us-gaap_OperatingSegmentsMember_4013c639-78d0-4e44-9dab-a14deb6348b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c10b7a15-61f0-46dd-a669-be5c4b9c0ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7949595b-55c9-4df1-82ef-6344734ab934" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c10b7a15-61f0-46dd-a669-be5c4b9c0ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_859535e9-5393-461b-9542-e89156539427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_859535e9-5393-461b-9542-e89156539427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_859535e9-5393-461b-9542-e89156539427" xlink:to="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_dfb63a22-39dc-486f-99ea-f8005e23bf36" xlink:href="cah-20221231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:to="loc_cah_PharmaceuticalMember_dfb63a22-39dc-486f-99ea-f8005e23bf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bb0eb920-9df3-4584-83b9-0b777ce24559" xlink:href="cah-20221231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f1b66243-caa9-4625-9d2a-912d935a7683" xlink:to="loc_cah_MedicalMember_bb0eb920-9df3-4584-83b9-0b777ce24559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_edc13744-11fe-4e90-b653-5bf48a99413e" xlink:href="cah-20221231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_cah_CordisDivestitureAxis_edc13744-11fe-4e90-b653-5bf48a99413e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_e8f133e9-b148-43bb-8898-9bfc73e6d73e" xlink:href="cah-20221231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_edc13744-11fe-4e90-b653-5bf48a99413e" xlink:to="loc_cah_CordisDivestitureDomain_e8f133e9-b148-43bb-8898-9bfc73e6d73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_840b8c03-411d-45fa-83f6-c369432e3483" xlink:href="cah-20221231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_e8f133e9-b148-43bb-8898-9bfc73e6d73e" xlink:to="loc_cah_CordisDivestitureMember_840b8c03-411d-45fa-83f6-c369432e3483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2762558e-57bc-41e7-a858-a0da7e9ac633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_us-gaap_ReportingUnitAxis_2762558e-57bc-41e7-a858-a0da7e9ac633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_0e7de1d4-bc7b-4033-8991-0087a36189d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2762558e-57bc-41e7-a858-a0da7e9ac633" xlink:to="loc_us-gaap_ReportingUnitDomain_0e7de1d4-bc7b-4033-8991-0087a36189d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_4054c1f8-a8a7-4e53-96f5-ca011ab22d2c" xlink:href="cah-20221231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_0e7de1d4-bc7b-4033-8991-0087a36189d1" xlink:to="loc_cah_MedicalUnitMember_4054c1f8-a8a7-4e53-96f5-ca011ab22d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be12d2e4-0344-492f-a9bf-0decb4faf839" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_02a6c3a7-2328-48b2-994e-d5398456dc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:to="loc_us-gaap_Assets_02a6c3a7-2328-48b2-994e-d5398456dc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_16e1b8da-c5aa-45f0-ab58-388228f9a947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_580b2d80-a350-4dc3-9990-28416727adfd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_16e1b8da-c5aa-45f0-ab58-388228f9a947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdf41ac4-c01b-4983-8c22-4da4203170a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdf41ac4-c01b-4983-8c22-4da4203170a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e801664c-1067-43da-8b4f-c484c6012a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:to="loc_us-gaap_AwardTypeAxis_e801664c-1067-43da-8b4f-c484c6012a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e801664c-1067-43da-8b4f-c484c6012a18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1b869dbd-75e0-4f91-b1a3-25f870ef4d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1b869dbd-75e0-4f91-b1a3-25f870ef4d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_40803652-491a-483a-8c3b-8dfc144a674b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5177d534-494a-4eb6-875a-70212ecbe3d7" xlink:to="loc_us-gaap_PerformanceSharesMember_40803652-491a-483a-8c3b-8dfc144a674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99d1094b-cef7-4e8a-92dc-5d72cd589aa8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:to="loc_srt_RangeAxis_99d1094b-cef7-4e8a-92dc-5d72cd589aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99d1094b-cef7-4e8a-92dc-5d72cd589aa8" xlink:to="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbaf796e-e3ff-45d5-9e62-2fb5e6e2b659" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:to="loc_srt_MinimumMember_dbaf796e-e3ff-45d5-9e62-2fb5e6e2b659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3234dc9b-cab8-4b43-8c5f-dd2a808cd451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c1a2750-1fd9-4302-a341-5c130b0f592b" xlink:to="loc_srt_MaximumMember_3234dc9b-cab8-4b43-8c5f-dd2a808cd451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ca12d7d-08f7-4ed3-b586-f33335beb073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_d9c76061-e8af-4732-b483-1481921520bf" xlink:href="cah-20221231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_cah_VestingPeriodinyearsforShares_d9c76061-e8af-4732-b483-1481921520bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_fc94a2cb-0cee-4b51-a138-f7b7ceba2484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_fc94a2cb-0cee-4b51-a138-f7b7ceba2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7fee6fa9-e2b5-4769-8ad0-355a61016c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7fee6fa9-e2b5-4769-8ad0-355a61016c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_69d2bb08-1a92-4d07-a264-c583d48f086a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_69d2bb08-1a92-4d07-a264-c583d48f086a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_52764ecf-87f3-4790-b196-fe0adf6987f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_52764ecf-87f3-4790-b196-fe0adf6987f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b133405a-89b9-40f5-a1a0-02ff98006dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84a12e1e-c8e7-47c0-aca6-ca3860ea7da3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b133405a-89b9-40f5-a1a0-02ff98006dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbd5d968-f758-47ff-b867-1c4c434fd665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb197251-406d-4180-a30c-78dbcbd86ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbd5d968-f758-47ff-b867-1c4c434fd665" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb197251-406d-4180-a30c-78dbcbd86ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_225ef4c3-98ab-4298-bfc8-f60186ba208f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb197251-406d-4180-a30c-78dbcbd86ca7" xlink:to="loc_us-gaap_AwardTypeAxis_225ef4c3-98ab-4298-bfc8-f60186ba208f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_225ef4c3-98ab-4298-bfc8-f60186ba208f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_457b871e-728c-4f49-a5cb-b91c3ef308de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_457b871e-728c-4f49-a5cb-b91c3ef308de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_46db9a80-8d40-484a-b0bf-88feb0eadb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe5159c-e8dd-41d6-a9ba-8b4e3290e8e9" xlink:to="loc_us-gaap_PerformanceSharesMember_46db9a80-8d40-484a-b0bf-88feb0eadb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a88a62b3-2739-4830-bc5b-b993460152bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb197251-406d-4180-a30c-78dbcbd86ca7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a88a62b3-2739-4830-bc5b-b993460152bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_85f2ed14-b94a-45d0-a6b8-8480fad7ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a88a62b3-2739-4830-bc5b-b993460152bc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_85f2ed14-b94a-45d0-a6b8-8480fad7ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a466e121-ae4c-487b-b6b5-69828624a4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9864a8ca-55f4-4fb7-bdf6-c98ddd816f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e43a66d2-284d-42d0-b646-242e09b51694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9864a8ca-55f4-4fb7-bdf6-c98ddd816f24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e43a66d2-284d-42d0-b646-242e09b51694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f9ce70b-0e14-4210-b268-23101b892c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e43a66d2-284d-42d0-b646-242e09b51694" xlink:to="loc_us-gaap_AwardTypeAxis_2f9ce70b-0e14-4210-b268-23101b892c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_414fdbac-ca20-4fca-bddd-fea97a5f5691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2f9ce70b-0e14-4210-b268-23101b892c3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_414fdbac-ca20-4fca-bddd-fea97a5f5691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6f58ba6-200d-4210-a641-c2297dfd5380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e43a66d2-284d-42d0-b646-242e09b51694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6f58ba6-200d-4210-a641-c2297dfd5380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4030b1f7-7af3-4955-9aaa-a48ac002b3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6f58ba6-200d-4210-a641-c2297dfd5380" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4030b1f7-7af3-4955-9aaa-a48ac002b3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e10fdd5-aa0f-44ac-a10e-87bfd57a587b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6a32a6e-1973-4a76-94a8-f27775176746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e10fdd5-aa0f-44ac-a10e-87bfd57a587b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6a32a6e-1973-4a76-94a8-f27775176746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_820504d2-9ef2-4a00-9550-8d96f7dbebbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6a32a6e-1973-4a76-94a8-f27775176746" xlink:to="loc_us-gaap_AwardTypeAxis_820504d2-9ef2-4a00-9550-8d96f7dbebbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c285948-a2af-4f40-a2a3-cf468110c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_820504d2-9ef2-4a00-9550-8d96f7dbebbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c285948-a2af-4f40-a2a3-cf468110c45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0baee733-596c-460f-91f8-c19daef070d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c285948-a2af-4f40-a2a3-cf468110c45b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0baee733-596c-460f-91f8-c19daef070d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6a32a6e-1973-4a76-94a8-f27775176746" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_323361ac-95d8-4bbd-a0c3-5e7a7ab1ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_323361ac-95d8-4bbd-a0c3-5e7a7ab1ce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4738410d-e0ce-465d-a94b-996465f4facf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4738410d-e0ce-465d-a94b-996465f4facf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82e51f73-b523-482c-b123-e60b41936fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82e51f73-b523-482c-b123-e60b41936fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec26a809-e7bd-4a63-955c-e08cf1f18a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec26a809-e7bd-4a63-955c-e08cf1f18a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_41c7884b-69ce-4b53-ba76-fbaa7e4df6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_41c7884b-69ce-4b53-ba76-fbaa7e4df6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6bd559e1-89c7-4f0f-84bb-4e58b63016da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6bd559e1-89c7-4f0f-84bb-4e58b63016da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114d17cb-f3cc-4480-a4e8-82659c0c77c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_95124c4d-1d1d-48a7-a3f9-44a3f00582b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114d17cb-f3cc-4480-a4e8-82659c0c77c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52240a16-455f-4605-aa03-b8b6baf045d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2aed594b-f0e2-4624-9c8c-c2c8c2a81e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2aed594b-f0e2-4624-9c8c-c2c8c2a81e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b817f834-4cd0-414f-86f8-311304e815b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b817f834-4cd0-414f-86f8-311304e815b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f7da902-c601-4b1b-ad34-354d45f35706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f7da902-c601-4b1b-ad34-354d45f35706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20c15e39-901b-4951-8bfc-a1d8dd499d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20c15e39-901b-4951-8bfc-a1d8dd499d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_24dce2c2-2244-4c67-b75e-d98855f5f675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f99d95f-df24-4c9b-82a0-26b7112f2ff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_24dce2c2-2244-4c67-b75e-d98855f5f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20221231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e2c5bea-9800-47dd-be7a-61494abef7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c87d779e-5bd5-48d5-bf20-70fe0b37a6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e2c5bea-9800-47dd-be7a-61494abef7fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c87d779e-5bd5-48d5-bf20-70fe0b37a6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_763e6e2b-0736-4f77-bf71-2bb933d60b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c87d779e-5bd5-48d5-bf20-70fe0b37a6a1" xlink:to="loc_us-gaap_AwardTypeAxis_763e6e2b-0736-4f77-bf71-2bb933d60b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb380a61-ad07-4472-b9bf-5390e93d8584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_763e6e2b-0736-4f77-bf71-2bb933d60b2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb380a61-ad07-4472-b9bf-5390e93d8584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_18f26208-38b0-4298-9e27-de4d921a24db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb380a61-ad07-4472-b9bf-5390e93d8584" xlink:to="loc_us-gaap_PerformanceSharesMember_18f26208-38b0-4298-9e27-de4d921a24db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c87d779e-5bd5-48d5-bf20-70fe0b37a6a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0a6ab09e-c469-49fe-ad56-e185e63ef688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0a6ab09e-c469-49fe-ad56-e185e63ef688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_afac1820-75bc-4179-b36f-dea50f440880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_afac1820-75bc-4179-b36f-dea50f440880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25653020-ebe8-41d5-abd4-b7ab12945e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25653020-ebe8-41d5-abd4-b7ab12945e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_654b8a82-856c-44fe-8aee-1acd0f65990c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_654b8a82-856c-44fe-8aee-1acd0f65990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d97a16e2-6930-46f2-b7a5-8ea1d1fb13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d97a16e2-6930-46f2-b7a5-8ea1d1fb13a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff370c09-e0e7-4b47-a9bb-790b38f18dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baa412b8-8b58-46ba-bfdb-3d1c43017e33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff370c09-e0e7-4b47-a9bb-790b38f18dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48c6ba6f-5c8e-435d-98bf-05bc2869b08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48c6ba6f-5c8e-435d-98bf-05bc2869b08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb86d8a8-84c8-4b72-9b7e-0270ca0bcc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb86d8a8-84c8-4b72-9b7e-0270ca0bcc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d9741f59-af32-48cf-a4ea-a3f090b559ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d9741f59-af32-48cf-a4ea-a3f090b559ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_449f6f9a-4a2a-429d-bc42-5d1f2a752895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_449f6f9a-4a2a-429d-bc42-5d1f2a752895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4962e957-fa9e-454c-8148-b21509a9d5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8aea9d0e-deec-49a0-bd14-e0386384e0f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4962e957-fa9e-454c-8148-b21509a9d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d4d37e7f-16b2-42c7-b1b5-1695ef61c226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d4d37e7f-16b2-42c7-b1b5-1695ef61c226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_34229b3e-41be-4391-9f03-758db9dd3d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_34229b3e-41be-4391-9f03-758db9dd3d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_75c5a353-e149-4341-995e-35cb708e808e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ba3e2e-c344-4f5c-957b-f271c6e9d188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_75c5a353-e149-4341-995e-35cb708e808e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20221231_g1.jpg
<TEXT>
begin 644 cah-20221231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ(W@F74'AU.2&W6:,3"X2,;46$[60@;LG(-?HW_P;E_\$AOVX/@;^U!\2_\
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MVF/"OCF?2$#ZI8:/?_Z7:QD[5DDMY LJQD\!RNTG@'-?E?\ \$T/'GCC5?\
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M?\&9/QO\'^/-9GOI_ACXVTSPMI4]U(7D_LY=<T&\MT+'DK']L>)!_"D2*,
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MAXM\-:#XF\!^*+3PUXVU#P[=06$UQ-J^CF%X+ET$<K81Y%",21&Q'0U^V5%
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M&OB[X0WF?'UKX%T-\,US9P+<W]K9Q@L+=+FU!V*"8TF#'Y4=A^SM% '\T/\
MP5Z_;4_X*=_\%O/V'/"5]X;_ ."8/C7P=X'\"^*;2[UZ]@L;W4+CQ!KTEK/
MAL8!:I)]FAC:Z9V D"F:-7=6VA_IK_@Y>_91^/WQ9_X(R?LU>(/AS\*-?UF?
MX?0:/_PENEZ=I4LUWIL,NB)$9I854NJ)+&L;DCY&D7..<?N)10!^!'_!7G]H
M?]JK_@KS_P $ O _Q1T_]ACQOX:\36G[0UE9_P#"&:9H]_J=S-8VVB7ZG4E
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MWCG_ ()3Z[KWQ0L-3U*#X7^-(O#+WL5O)=NQ\U(_L<R:I''.[S1-&Y23>(V
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M1>H:SJOB'Q()'\/^#/"EI%/J-U%&0KW#"62..&%6(7>[@L<A%<JP&'_P2O\
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MR_''C7PK\-?!6L?$7QWKD&F:'H&EW&HZSJ5TV(K2U@C:669SV545F/L*^,M
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MC**6D3R+]NZ72/$'_!X_\!;3X$/#)K]CH>D+XZ.G$&19DMM2DN1-M_B_LHP
MY_@VCIBKO_!*;1].U/\ X.Y_VL+V]M4DET_PMXBN+-V4$Q2'4M&B+#T.R5US
MZ,?6@#W[_@CO_P ' /[1'[8O[;WB;_@G1^W[^RMI_P ,/B;IEC=76EPZ3%=6
MZ[[=5DEL[BVNGD=9/(;SDE5RCHA^494MR_[1/_!P%_P44^+_ .V3\2_V5/\
M@CU_P3YTSXIVGP>U.73?&OB;Q%+-(LEU%+)#)Y4<5Q;+$GG0SI'F21YA"SJH
M' \NN+>&U_X/?()((PC7'A$O,5&-Y'@EER?7A5'X"O.OVE_^"1O[6<?[>/Q<
M_:\_X-[_ /@HOX3\2:M?Z_)J_CSP!X)^)MO;:KHMW?3SSM9SE)#9W-NTZ7#)
M'<O&4V["C;"Y /TI_P""(/\ P6.US_@JIX+\<^&?B]\ ;OX<?$OX8ZNFG^+M
M#Q,;25G:1-T1F4/%)')#)'+;N6:,A"6._"_*'_!"K7Y/V0?^"YO[:/\ P3.M
MI#;^&]2UB;QQX4TTG$=D/M$4@BC'JUKJEL#ZK9KZ5U__  ;L?\%??VV_VK/C
M]\3_ /@G5_P42\'V:?$OX8:;/J$NN6^EPV5R[07L=I>6UY%;8MVE$UQ$RRPJ
MJN"Y(;ACYO\ !:*6[_X/6OBS-H.3'!\-8&U8Q],?\(UHZ\_\#:(?6@#]M***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"[6[Z:;J\L+G>;LW+B;;]B*X\I,^9G(VX/W;10!\)7'_  1BU.?_ (+E0?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7F?[97_)K/CK_ +%Z?^0KTRO,_P!LK_DU
MGQU_V+T_\A0!^2]%%% !1110 4444 %?I-_P2T_Y-93_ +&&\_E'7YLU^DW_
M  2T_P"364_[&&\_E'0!]'4444 %%%% !17"?%_QGXE\+7UE#H6I>0LT3M(/
M)1LD$8^\#7'?\+<^(?\ T,'_ )*0_P#Q% 'ME%>)_P#"W/B'_P!#!_Y*0_\
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M110 4444 %%%% !7Z3?\$M/^364_[&&\_E'7YLU^DW_!+3_DUE/^QAO/Y1T
M?1U%%% !1110!YA\?_\ D):=_P!<)/\ T(5Y]7H/Q_\ ^0EIW_7"3_T(5Y]0
M 4444 %%%% !4^E_\A*W_P"NZ?\ H0J"I]+_ .0E;_\ 7=/_ $(4 ?1-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y
MG^V5_P FL^.O^Q>G_D*],KS/]LK_ )-9\=?]B]/_ "% 'Y+T444 %%%% !11
M10 5^DW_  2T_P"364_[&&\_E'7YLU^DW_!+3_DUE/\ L8;S^4= 'T=1110
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M3R,N)V'W74A26"U]VZ7SJ5OC_GNG\Q0!]$T444 %%%% !1110 4444 %%%%
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MR:SXZ_[%Z?\ D*],KS/]LK_DUGQU_P!B]/\ R% '\WO_  5E_9Z^.^I:;?\
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M_P"P_P ?_P#D):=_UPD_]"%?CU\=/A;_ ,%+?V2/VJ?#7@WX%^#O"_Q)\/\
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M44 >8?'_ /Y"6G?]<)/_ $(5Y]7H/Q__ .0EIW_7"3_T(5Y]0 4444 %%%%
M!4^E_P#(2M_^NZ?^A"H*GTO_ )"5O_UW3_T(4 ?1-%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !17B6J?M2_&6PU.YL+;]BWQO=1P
M3O''<Q7-MMF4,0'&6Z$#(^M0?\-8?&S_ *,?\=_^!5M_\50!YU_P5Y_Y)3X4
M_P"QAD_]$-7P)7W'^U[<_&S]JOPII/AC_AEKQWH/]EZBUUY_V6VNO-S&4V[?
M.CV]<YR?I7@7_#$GQL_Z)5X[_P#";MO_ )-H \9HKV;_ (8D^-G_ $2KQW_X
M3=M_\FT?\,2?&S_HE7CO_P )NV_^3: /&:*]F_X8D^-G_1*O'?\ X3=M_P#)
MM'_#$GQL_P"B5>.__";MO_DV@#QFBO9O^&)/C9_T2KQW_P"$W;?_ ";1_P ,
M2?&S_HE7CO\ \)NV_P#DV@#]+?A'_P DI\,?]B]9?^B$KH:^>O"/[27QL\*^
M%-,\,?\ #%7CN?\ LW3H;7S_ #[9?,\N-4W;=YQG&<9./6M'_AK#XV?]&/\
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MEN&+8*+L)Y YYKT&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+2ZU:WMK"\2ZD,TA#WUU-<01^?/-+N9WY))X"J% ^Q: "BBB@ HHHH ****
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20221231_g2.jpg
<TEXT>
begin 644 cah-20221231_g2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M] (4 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K"^*4DD/PR\1RQ2,KKH-X593@@B%\$&MVL#XK?\ )+O$O_8 O/\
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M6:+1-0U O=I$WW9)(HE=H4;G:\@56P<$X-?FY_P;^_\ !;;]L_XF_'SX@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X0_\
M!\7_ ,DM_9U_[&#Q)_Z(T^OB#_@LS_P1W_;%_P""7&E^"?'?Q_\ VL_&'QE^
M#?B?68]/UW4M.U"ZLKBRG&)3:O#=37,4;21)(T,I+J6A8,JX7=^MO_!S]_P2
MI_;%_P""HG@7X/:%^R+X2TC5;CP=JVLW&N+JNO06(C2YBM%B*F4C?DPOG'3
M]:^\?VZ/V./AM^WO^R)XT_9)^+$*C3/%VB-;0WPB#OIMXF)+:\C!_CAG2.0#
MHVS:>&(H _.OX_:'^R-^RO\ \&IWC_Q+_P $O9[\>!?%/@**>+6+ZX#ZGJ$F
MIWUKI^HR7SH /M0C>6"55 6/R?+4!445\&?L'?$W]IW6O^")-Y^Q)\*_^#?K
MQ%\3O#WQ$T76_,^,^FZ^JC4]2FN+A+?5%A_LV0F2R=88T'G];(?,N3C[B_X(
MP_\ !(;]OGX*?L:?'3_@EQ_P47\'Z4OPD^(.EW3^$]>T'Q1;WLNF7DZ^1<>7
M%G>H8B"ZBRH5)()"PS+BOG#PA_P35_X.EOV2/V=_$G_!+#]G$^$=8^#NM:A=
M0:=\1++Q1IUK+IMC=2E[A;=IKB.\M4E+.\B+!*RM+)Y;?,6(!V'PX_X)S?M5
M?$__ (-2O'O[+7[4?P9\0>&?'?PG\0ZKXH\ :+XBLBETEM9,NHDQ(<DB6*XU
M.! .\F!TQ7RK^TK^W3XT_P""E/\ P2>_87_X)@?#S7#<^-O$GC8>'?%4:MN:
M Z9,FE:49><LCV]XL[D]#;[B>,U_0M_P3G_9+\??L?\ [%7A']F[XY?&_6OB
MAXFT_3I?^$I\4>)=6N;\WMQ.[/)#$UTS.+6,,(8T./W<8)4%F%?EA_P23_X-
ML?CW^Q7_ ,%D-7_:=^*N@Z-_PJ/P1>Z]=_"JYBUJ*YN+QYW:VL/-MP=T3):3
MR2$M]V6%,9X- 'D__!T!HW_"K_VTOV)_V-O WP:NO''@;P1H&FP>'/AA;W7D
M_P#"1G^TK:R&EAPCA7FALH+</L;;YQ(4Y(.!_P %//\ AZ-_P4 ^+OP6^.WP
MB_X($>/?@QXP^#>MQW=AK^C7HOY+VWBFMYK:V*QV%KL6"2 M'RP7S7 "[CG]
M)_\ @X-_X(^_%?\ X*4?#_P%\:?V3/&%IH/QH^#^KR7_ (1FO;LVT>H0N\4K
M0"< ^3.DUO#+"[?(&#JQ42;T^9/@M^P__P ')G[?'[9OPN^)O_!2OXE'X+>!
M/A;*LEZOP[\:6UE=^(H_,BDGC":-=RYDN3#$DCRM&D<88QQY^1@#S[_@M'\(
MO GQW_X.K_V8/A5\3?#MKJ^@:GX3\-MJFE7T0D@O(H=5U><PRH>'C8QA64Y#
M*2""":M_\'*?PZ\$?#G_ (+)_L/_ !"\">%M/T?5=0\4:5!>7>FV:0-*MGKU
MB;?=L SL\YPI/0$#H!7U)^W#_P $M_VO?CE_P<)_ ;_@H=\/?"FDW'PQ\ ^&
M],L_$>I7&NPQ7,4L-SJDD@2W8[Y %NH>0.<GT-)_P7'_ ."6W[7O[<_[>O[+
M/Q]_9Z\)Z3?^&_A5XCBO/&-Q?Z[#:R01+JEC<DQQR$-*?+@D.%[@#O0!\[_\
M%,76/_@[[_9:9S@'P;HPY]3<:V!^M)_P<V7$3?\ !8C]A"U5QO3QC8.RYY ;
MQ#IX!_\ '3^5>L_\' 7_  23_P""@/Q\_;/^$?\ P4V_X)E1Z=JGQ%^'6G6N
MGSZ!=ZI:6<H:TO9KNUNHS>NEO,A-S-'+'(ZY4( '#,%\&^,/_!&G_@NY^V1^
MV7^SW^WW^V5J_@K5_$?A[QMIL_B;PAH>K6MK:>#M#L-1L[F*.+#%;F>5FOI)
M!&TN-D8\QMP5 #R[_@HS\;/BS9?\'8NK>*-%_8PO_P!H?4/AEH>EQ>#?A;!J
M MS*@\.PW@N%9K>X&(+F]GN@/+/S@-P1FO0O@[X(_P""C7QU_P"#@SX1?\%&
M++_@D#XX_9_T&41:-\2(S/\ ;;2\$L-W;3ZC<3+:VP7,$\"%2C?-:J^XD_+]
M,_\ !9__ ()$?MV^)/V[O!7_  5T_P""2^N:4OQ;\-V$=CX@\+ZI>P6W]J"*
M*2!)HWN2L$@>VE:VFBE>,&-8RC;LTG_!+G]A3_@MO\2_^"B-[_P49_X*O?%Z
MZ\"V=CI;6>E_"#P=XR!T_4I/(:"(7%M87,MK]EB#O, \DDCS;6; 7D _62BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBC12KM8Y29#P20 #WBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3V@'/;R3'CVQ0!]/?\'-'_*8S]@[_L<[#_U(=.H_X*A_\K>7[*7_ &)FA_\
MI;KE'_!S1_RF,_8._P"QSL/_ %(=.H_X*A_\K>7[*7_8F:'_ .ENN4 ?0-K^
MV?\ "1_^#GVY_8W'[#?PW7Q8GAH7!^-PM3_PD;)_PC277E%]N-OEG[/U_P!6
M,5C_ /!4?_@XP^+WP(_;'E_X)V_\$R?V3&^-'Q4TH >)9'M+N]MK.X$8E>TA
MM;(K+</'&0TLGF(D1RI#%7V^+6/_ "N[WO\ V)@_]0R.L?\ X-M9]#T7_@NG
M^VQX?^+$T*_$6?7=;^Q&](%Q+"OB&<W^S/)!<VC''4!3T&: /K#_ ((U?\'
M>N_M[?'SQ!^PO^V;^SN_PA^..@033PZ$R7$,&IK  UQ (+H>=:W,2$2>4Q??
M&'<,-I%>6_&O_@YC_:"^'7_!0/XQ?\$^_AA^PFWQ$\7>&-5FT;X6Z5X7N;F2
M[UN_1XV:2\ 5A#;QV_GRN4&?W:C**6D3R+]NZ72/$'_!X_\  6T^!#PR:_8Z
M'I"^.CIQ!D69+;4I+D3;?XO[*, .?X-HZ8J[_P $IM'T[4_^#N?]K"]O;5))
M=/\ "WB*XLW903%(=2T:(L/0[)77/HQ]: /?O^"._P#P< _M$?MB_MO>)O\
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MU@;5C'TQ_P (UHZ\_P# VB'UH _;2BBB@ HHHH **** "BBB@ HHHH ****
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M^"(=M_P5<^&GPH^%_@?XXV'PPT[X6WUS)8VZ>$CJ$4MO)#!#'!&BW, A6-8
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M/+J:X\5^'].AN5@,L\GFS^1-:W$3"%I,R"W='5'.495"JOZX44 ?#'_!&_\
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MWA+3];AL)GW/:BYMTF\IFP-Q0N5R.#MR.M=]I?\ R$K?_KNG_H0H ^B:***
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MF]% 'KW@OXN?\)?KR:)_PC_V??&S>;]KWXP,]-@_G795XU\&/^1[@_ZX2?\
MH->RT %%%% !7F?[97_)K/CK_L7I_P"0KTRO,_VRO^36?'7_ &+T_P#(4 ?D
MO7Y-?M :9\/?@K^W9XGT3]LOX97,GA;Q9X\O=77Q;]C:8S:1<:=>P1PPD*6_
M<R7,#9C.Y&@S@E$K]9:_,_\ ;/\ V@OCEIWQ\?X(_M.? 2[\7Z58^*]3NO <
M>DZ'NBUBQN=*O;:WA  /F2))/ [,NYT*28&44$ ^L]4_9H_88\<?L\^&O$?B
M7PEIWB7P/X-\+27'AW5;[4)YQ;Z:(Q*[!]X9AMC'#<C9C QBO+?^"1/P \(6
M?A[Q-^V!8^!+?09/'NI7,'A;28 VW3-$CFPD0W$DEY(P6)SN\E&'4UC>//AW
M\7OV>/\ @BC_ ,*FU+1+^7Q5/I"VMSIUK$TTT"7VIF62$JF3E()F1@,@$'M7
MU'\.M,B_9_\ V4-'T_2M DNSX0\!1%-.ARKW,EO9AB@X)#NRGG!.6S@T ?,7
M_!;#QUI^D>'/A1\/O%8O9/#.M^.!=>);33P3-=6MMY0:-0"-Q*W#$+D98*>H
M!&I^PAK/[,'B#]J[Q3?^$/V?_$GPA^(47A>**[\$:E;I:6=SII:$BXCMTC4"
M3(A+9 ^]N&[+D<[^V/<_%']K7]D[X6?MH>#/@AJ5MK/@OQ?)J]]X(F9YKI;.
M*[:)S_JT9\M:PN0$R$D8\A<G0_9=\6>)OVS/^"ADG[8/AWX6>(/#'@WPWX &
MAQW'B&T$,E_>-([% %)5MOFOG#' B3=M+A: /N"OTF_X):?\FLI_V,-Y_*.O
MS9K])O\ @EI_R:RG_8PWG\HZ /HZBBB@ HHHH \P^/\ _P A+3O^N$G_ *$*
M^3_V\?AK^R=\>OA5I7[./[6/B(:;:>.O$MK8>#YK:_:UOUUQ TUL]E,H)CN4
M\MV4]" RL&5BI^L/C_\ \A+3O^N$G_H0KYB_;2_8\\!_ML?!^'X7^,?$FL>'
M[_2==M->\)>*_#MP(M0T'5[5BUO>V[,"-R[G4@CE78 J<, #X3_X)W?%+]IC
M]B'XT^!?V>/B/\;KKXD_"OXK:_\ $^'PPFM:?'_;GA_4_#^KZC+<RRW28-ZM
MXD4DSLXR)IB!L _>>7:%^P_\0/VC/^":_C+_ (*36_QTO-"@\57>I?%9OV?K
M.1SX N8[.:2Z^Q7MGO#SR3+:AI9!)&AE8$QG9FOL'_@G%_P3&\?_  ,\91_M
M$_M;_&?7_'/CO1M0\4V/@ZQU2WLK>QT.RU#6[NYGOH8;/*&XOU9+AV+;HUN/
M(VJ(P%JZG_P1;D30]6_9^\#_ +;_ ,1?#G[/VOZI/>:K\%--L[+RECGF,T]A
M;:DT?VJVL9'9PUNIP5=P6)8M0!]8_L[?%:W^/'[/W@7XXV>C-IT7C/P=IFNQ
M:>[9-JMW:17 B)P,E1)MZ=J^4/VV?C#\0/V\OBIK?_!+/]D74IK73UA2W_:%
M^*%NNZW\,:5,/WFCVS?=EU&ZCW1E>1$C/N&=YB^D+_\ 9LN8OC7X ^)7@KXN
M>(O#GAOP%X;O-'C^'.DW;QZ-J<<L21P27$(8*[6ZH/*RIVY."*^0OAG_ ,$,
M/C+\&;35K#X3_P#!6KXS>'H-=UVYUK68M*M+2(7FH7#!IKF3'+R.0,L<G  Z
M 4 ?>OP[\ ^%/A3X T/X7^ ])2PT/PYH]MI>C6,9)6WM;>)8HHP3R0J(HY]*
MW]+_ .0E;_\ 7=/_ $(5RGP>\#Z[\,_A9X?^'WB?XA:GXMU'1M)@L[WQ-K6/
MM>J2(@5KB;;QO<C<<=S75Z7_ ,A*W_Z[I_Z$* /HFBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^1O\ @KS_ ,DI\*?]C#)_
MZ(:OSH^)WC>U^&7PU\0_$B^LWN(/#VAW>I36\;8:5((7E*@]B0F/QK]%_P#@
MKS_R2GPI_P!C#)_Z(:OSK^(VH>"=*\ :UJ'Q)N;:'P]%I<YUR6\SY*VGED2E
M\?P[-V?:@#\^?V9/VFO^"D7Q'^.-M\8K.VT[Q7X?UVWT:?7?!>FLJQZ;I5U<
M:A''-!O($<D?V:4NV\LQ>%7W8^3VS]JWXN_\%"-5^-FM_#S]E7PKIWAWPYX.
M\-#5=0\4^*-*<P:W+L$C6UM*\;1L0"%P,897W.HVU\F21^+?^"?WQ-UWXX_L
M;?&9?$7PTM+3P_?:EIFHD/\ VCI]_<WRQ6ZDK\WEO#*-X\MU,V<'#Y^^/VF_
M"G@_]L+PAX@_9<\#?M%OX;\0V'E3^((-#N=]S% \;A8+F-74^5)O0LA/S  8
MYS0!I?L-_M'ZC^U;^S/X>^,VN:+%I^I7HFM]3MK8'R?M$,K1,\>XD[&VA@"2
M5W;<G&3Y/^U#^T)^UYXM_:WMOV/?V/\ 4?#>A7]CX1_M_6M=\2P>8LBF38(D
M!20 ?-&,A"27/*A"3J_\$B?BH?B5^QU9:,?"^G:6?!NM7/A\C24*P77E+%-]
MH ))W/\ :,NV?F<,W&[ \I_:=^&NN?MF?\%++CX)>"O'4OP\O? 7P]-Q>>,-
M%64:E?I.8B+?*2QYA7[4O&>,RC)W@  ^@O\ @GI^TUXR_:H_9_;QI\1M&M;/
MQ#HVO76B:W]A7$$\\ C;S4&3@%95! )&X-C P![G7R=_P2 \4D_L]Z]\&KCP
M_IUK<_#SQG>Z+<7^EHPCU-@0YN6+$DR,Q8$]-JI@#H/K&@#]D_A'_P DI\,?
M]B]9?^B$KH:Y[X1_\DI\,?\ 8O67_HA*Z&@ HHHH *\,^)G_ "/>I?\ 7<?^
M@BO<Z\,^)G_(]ZE_UW'_ *"* /R#_P""\=S\,O%?[2%Y\-_VK?$#VG@NR_9A
M\0ZW\(]/U'49+73=2\=)<21L"594GNHK40&&-\C,IV@LX#?;W[$W[)N@?L"^
M ?''AK0?C&+OX6W/B&?Q!X(T74&8P^#M,>!7FM$NI9G\RV#J\JY"A S9+%BU
M>'_\%>/CU^S]XV\'_%?]A;XV?"?3KG6H/V?]5\=^!=;\106\L%S=P+<0E+'S
M 62\@V>:2A#A"2.,FOG71_V<_C_XH\)_M4?\$[O^";NM:?K7PI\/?%#PM:Z=
MI'B3Q7<"SM;"XL9;KQ%H5M?#?(B>?':P.@)*)<SJ3O9F(!Z;^PQ\=/C-^TK_
M ,%H[S]H#QG?7EEX(\;?LVZI?_"GPU.'C-OX?B\1Z=;VU]+&>!->%);KID17
M$2Y(  _1[Q9JVI:!X5U/7=&T";5;RRT^:>TTNWD"27DJ(66%6/ 9R H)X!-?
MEY\)/$?_  4WL_\ @M5X&TWXD_L]_"#0M0@^ 7]G:GI7AOQ%=/9V7A >(K,7
M%S;Y49NXW")'#@(5^E?IQX;^)?PY\9^(M;\(>#_'^B:KJWAFYCM_$FEZ;JL,
M]QI4TB;XX[F-&+0.R?,JN%)7D<4 ?!7[!_B+]M77?^"O/CK4_P!M>;3-*UG6
MOV?]/U?1O 6@Z@;FS\*6,FM3116)E^[<7 \EI)9UX9Y2%^15 _1"OD+PQ_RG
M?\7?]FK:-_ZD-]7U[0!U?P8_Y'N#_KA)_P"@U[+7C7P8_P"1[@_ZX2?^@U[+
M0 4444 %>9_ME?\ )K/CK_L7I_Y"O3*\S_;*_P"36?'7_8O3_P A0!^2]8_B
M+P%X2\5Z]H?B;Q!HZW%]X;OI+S1)S*Z_9IY()+=W 4@-F*61<,"/FSC(!&Q1
M0 4444 %%%% !7Z3?\$M/^364_[&&\_E'7YLU^DW_!+3_DUE/^QAO/Y1T ?1
MU%%% !1110!YA\?_ /D):=_UPD_]"%>?5Z#\?_\ D):=_P!<)/\ T(5Y]0 4
M444 %%%% !4^E_\ (2M_^NZ?^A"H*GTO_D)6_P#UW3_T(4 ?1-%%% !1110
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M -!KV6OECP7\5?C9X0UY-;_X8_\ '=QLC9?*Q;)G(QU\P_RKL_\ AK#XV?\
M1C_CO_P*MO\ XJ@#W2BO"_\ AK#XV?\ 1C_CO_P*MO\ XJC_ (:P^-G_ $8_
MX[_\"K;_ .*H ]TKS/\ ;*_Y-9\=?]B]/_(5R_\ PUA\;/\ HQ_QW_X%6W_Q
M5<S\9?C7\;/BW\+-=^&G_#&_CO3_ .VM.>U^V[K:7R=W\6SS%W?3(^M 'YRT
M5[-_PQ)\;/\ HE7CO_PF[;_Y-H_X8D^-G_1*O'?_ (3=M_\ )M 'C-%>S?\
M#$GQL_Z)5X[_ /";MO\ Y-H_X8D^-G_1*O'?_A-VW_R;0!XS17LW_#$GQL_Z
M)5X[_P#";MO_ )-H_P"&)/C9_P!$J\=_^$W;?_)M 'C-?I-_P2T_Y-93_L8;
MS^4=?'__  Q)\;/^B5>._P#PF[;_ .3:^D_V6?&'QL_9I^%B_#3_ (9,\=ZU
MMU&:Z^V^5;6W^LV_+L\U^FWKGG/2@#Z[HKPO_AK#XV?]&/\ CO\ \"K;_P"*
MH_X:P^-G_1C_ ([_ / JV_\ BJ /=**\+_X:P^-G_1C_ ([_ / JV_\ BJ/^
M&L/C9_T8_P"._P#P*MO_ (J@#I?C_P#\A+3O^N$G_H0KSZJ?C_XT_&SQS<VU
MQ_PQQX[M?L\;+C=;/NR0?^>@QTKG_P#A+OC9_P!&F^._^_5M_P#': .LHKD_
M^$N^-G_1IOCO_OU;?_':/^$N^-G_ $:;X[_[]6W_ ,=H ZRBN3_X2[XV?]&F
M^._^_5M_\=H_X2[XV?\ 1IOCO_OU;?\ QV@#K*GTO_D)6_\ UW3_ -"%<9_P
MEWQL_P"C3?'?_?JV_P#CM/M?&GQLMKF.X_X9+\=MY<@;'E6PS@Y_YZT ?7-%
M>%_\-8?&S_HQ_P =_P#@5;?_ !5'_#6'QL_Z,?\ '?\ X%6W_P 50![I17GW
MP9^,?CWXFZG>V/B_X ^(?!T=K LD-SK4T3+<,6P4783R!SS7H- !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7PA^U5^U'^W3^U#^W#K?_!.+
M_@FI\0O#GPZ;X=>'[#5OC1\:/$/AQ-:?09K]6DL-+L+"4B*:YDA4SL9?DV'
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M3PYJL-WY=EH4-X^L M"S;3"LL:2H>5+88 BNR_X*-_M9?&+X[?%2Y_X)*?\
M!/B[!^)_B71E;XJ_$,1E['X7>';E=KW4K C=J4\3,+6V!#_,)244*Q />?\
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M)X=^#GCR/POXMO=$N8O#/B*:PCNH].OS&WD320RJRRQK)M+(1RN0,'!'R/\
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MC^#=+LM2#G)%Q%:11R9/<[E-=E0 4444 %%%% !1110 4444 %%%% !1110
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M&J1EC!<7,,\MP[3(BK,5CE=3(6-?H]10!\<_LE?\$ROVG_V<?CQI'Q=^)/\
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MX?N;F+RKBXT30K>T>5,YVLT2*6&0#@\9H _)+P;^V!\7_P#@C#X,^+__  2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20221231_g3.jpg
<TEXT>
begin 644 cah-20221231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /,OVSOVHO!/[%/[*GC[]JSXAP//I7@7PU<:I+9QR!'
MO)47$-LC$$*\LS1Q*3P#(,\5_/9^RI_P3*_X*8_\'/1\1?MR?M;?MES>!? -
MQKMQ9^$;*729]2M0\3?/#I^FBY@BAM8B1$9C)O>17W>8X=Z_57_@Z?@UZ?\
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M;I^'FL>*;N[^RV&FP:VJ+?3YP(K>9PL5P['A5C=BW\.:_)7_ (.-_@?\-/\
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M%&OV&?VY+K4-._9._:@\)^-[[2H?.U'2])U#%Y;Q;@OFM;R!91'N(7S-NW)
MSDU^,7_!UMI'C#X0?\%./@7^V'^T'^S=>?%;X :)X0BL+GPQ-J%Q::;/J*WE
MX]S:RW$*M]GED26SD4L,3" )AUC<#7_X(T^+?^" O[3'_!3[PG^T9^Q[J'Q*
M_9^^*EII4D&D?!JZN;>+0M<N#;SQW7ESD7'GAX''^C^9;DM#YB(2&H _?"OY
M"O\ @J_^T9^T9\'_ /@MI\;/B;\/?B+XE%K\/?B^NL+80ZY<+;PI#>6YC!C#
M[0AE,:8QCYQQS7]>M?RT?M3_  (_X:#_ ."E?_!3[PO;V7FW>A_"K7/$UFRK
MEHCI?B+P_?R,OU@@F4^SF@#])O\ @ZZ_:TUFV_X)D?#/P5\ /%-_%JGQM\?:
M3_8DFE7;03W6FK;/=C8R,#\TSV(P#@[ZX/\ X,L?''CGQK^SG\<9O'/C+5=9
MFM?'.F1PR:KJ,MPT8^QR9"F1B0"?2OCOX#?M"?\ #TO]J[_@EQ^RD;[^TH_A
M=X42]\3VA;=Y<FEW\XDBF]WL?#EM(<]4N5YRQKZ!_P"#13PCI7C_ /X)\_M7
M^!M>^)=]X,L-8U1;*_\ %^F7D5M<:+!+I=PDEY'-,K1Q/$A:02,"%*[CTH _
M4?Q[_P %O_\ @DI\,OB3=?"3QM^WQ\/;/7K&\-I?6Z:J9H;:<-M:.2XB5H49
M6!#!G&T@AL8->U?%;]JK]F_X'_!1/VD/BO\ &WPWHO@&6*UEA\876J1G3I8[
MDJMNZ3J2CK(73:RDAMPP>:_F5_:/T/\ X-PO@%^QEX^_9D_9FT7XA?M"?&@6
MNH7.C_&#2M(O+6VTB5&+122;IHH3:0(H#O'!*LN7?< RE/<=:\4Z[XF_X,G+
M*+7-0EN?[+\=)8V;3.6*0+XJ9D3)[+O( [  #@"@#]P/"O\ P4__ ."?'CCX
MU^&_V=/"'[77@K4O&WB_1K75?#?AZSU8/-?VMS;"ZMV0@;=TENRS)&2'9&5@
MI# F#XQ?\%4_^"<O[/OQN@_9Q^-/[97@/PWXUGDCC?0=3UM$DM7D *+<.,QV
MK,"I F9"0P/0@U^:O_!%C_@D]^RM^RM_P3I\"_\ !9?4=+US6_C3H/PKU[Q=
M9W]_K#O9)&=-NXK>V6V(VA([0(@(.[<6.[;M1?!_^#:O_@D+^R'_ ,%2_P!G
M'XP_MF_M_P#A.^^(OBCQ%\1[W0H;J_UZ[@DM)1:6U[<WX:WD0M<2RWX^9]VW
MR1@#<V0#]UOA/^V1^RS\=?BOXJ^!GP>^._ASQ'XO\#S/%XN\/:5J EN=*=)3
M"RS*/ND2 K]17P/_ ,&[OP?^$7[)/PE^./BBR_X*:^%?CQHZZG9ZEKFMZ->7
M#0^&(;>"Z=UF,\LFT,FY^,#$1KY&_P"#47X4W/P&_P""KW[7GP*N_$=SK#^"
M%NO#QU6\DWRW8LM<EM1*Q[EA$#^-<U_P;!?\HU/V\_\ L7)__3-JM '['^)/
M^"P?_!,'PC\'+'X_Z_\ MP?#^+PAJFJSZ;I>L1ZR)1>W4(1IHH8XPTDIC$D9
M<JI">8NXC<*]E^!_QX^#/[2WPSTWXR_ #XG:+XO\+:NC-I^N:#?)<6\NTE67
M<I^5U8%61L,K A@""*_G\_X-C?\ @B]^Q;_P48_8;^(WQK_;#\&:AXJNX_&5
MYX0\)0OKMU;Q^'HH[&TNI+NV2&15\YY;T'+AE'D#Y?F?=[?_ ,&2GB;Q(OP#
M^/WPNO\ 5))=-T+QWI=U9VQ<[(Y[BUGBF=1VW"TAS_N"@#]P:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_P#:M_9P
M\ _M?_LV^-_V8?BA$YT+QSX;NM)OY80#);^:A"3QYX\R)]DB9XW(M?SW?LX_
MM'?\%I?^#9+7?%7[)GC/]CRY^*OPLO==EO\ PUJ\.GWKZ;),P"&YLKZV200B
M5%1I+29=ZL =J%G,G]*-% '\V7PZ^$W_  68_P"#A#_@I/\ "O\ ;"^-W[-*
M?#7X>?#7Q!IUU9:EJFA7&F:=9Z=;7R7<D=NUSFXU*YE*;=R9C#8SY*YKZM_:
MO^ _QPUK_@[L^"GQKTCX,^*[OP98>$;>.^\6VWAVYDTRV<:9JJE9+I4,2$,Z
M#!8'+J.XK]H** /S;_X.<O\ @EW\6/\ @I'^Q+I&K?LZ:.=4^(?PNUZ36=&T
M..15EU:REB\N[M822!Y_R02H"?F\@H,LZU^;O[3'_!6;_@L?_P %8OV4;+_@
MDSH7_!,_Q3H_C_Q UAIGQ'\726-[$;Z.WFCD+203VT4>DJ\L4;322S.FW>HV
M!\#^D:B@#\E/VO\ ]GC_ (*R?\$C?^"3OP,^%W_!*358?$DOPOM98_C!H.E>
M$8-5O-9:YE^V3W-I%-$\A@^U27:ND2^=Y=Q&PV^6[#\W?VX;C5O^"\/Q'^'_
M ,(OV'/^"(U_\(/B*^N^;\0_'Z:*;2U1'79(+R6*U@C\E')D,\_[XF-4126V
MM_4;10!^3G_!8;]H7_@KG_P3O^-?PR\?_"#X7S?&[]ERT\-VNG?$GP)9>#[:
M\N+J:*%[>=;Z;[//<0Q2*8IXYA^[$J&.0%<+)\,_LP_L_P"M_P#!5?\ X+7_
M  =_:Q_8I_X)?:E^S=\+?AGKNEZYXXU9])-A8W\]A>F\;"QPQ6XFFVQVPA@5
MF(+22';G;_2310 5^)?_  3T_9+^*/B;_@XT_;9N?BO\%_%6F^ ?B!\.O$VC
M6_B/4O#MS#I^HQ7>I:2A2&XD013%HA*0%8Y",>@-?MI10!_./_P:@_\ !-K]
MHOX-_P#!4'QO\4?VB/@1XJ\,VGP^\#ZC8:3J6O\ ARZLX+K4KB[AMMUO)-&J
MRK]G2[Y0GAU/0UL_\$3_ -A/]LCQ7_P15_;7_9SM?@YXL\(^-O&JQ1^%M-\3
M:+<:5+JVVT=GMXOM*)N$RJT&?NYE 8@9K^A^B@#^9#]C;]IG]M73/^"1WCS_
M ((S?L_?\$BO&J_$[4=-URV\=>/9]#ELD_LZ62:XGEO5DMT=KQ8&:SAC>3G;
M$$W-B)O3="^!?[1&N?\ !H)K7[/<7[.?CZ+QOHWQ42*7PE-X-ODU*5&UN"\\
MZ.V,7FO'Y4X.]5*_*W/RG']$5% 'RA_P2H^#=SJ/_!&WX.? 7XP>$M1TM[_X
M,VFB^(]%U*T>VNH%FM#%-%)'(H:-]KL"&&0>HK\<OV&=4_X+H?\ ! WXL_$G
M_@GW\$_^"?.K?&#1_&/B5KOP1XCCT*];2&NRBV\>IK=P#R5BD@2W,\,TD9B\
MI=SQ8;=_1IJVF6FM:5<Z-?JQ@N[=X9@CE24=2IP1R#@]17X.^!_V%_\ @ZI_
MX)?_ !.\9_#_ /8B\=6WQM\ :Y,L>@ZKXS\;V-XMC;QM)Y$J6VKWD+6=P$DQ
M*L0>)RJY\P(A !D_\&F_ASXJ>%/^"J'[77AKXX:S#J?C/2UN;/QCJ=J^Z*ZU
M5-<F2ZE1L+E7F61@<#(/0=*T_P#@V]_9Q_:%^%G_  3P_;<\,?$[X#^,_#FI
M>(- F30=.U[PO=V<^I,=)U- MO'+&K3'<Z+A >6 ZD5]C_\ !O-_P2)_:$_X
M)XZ)\4/VBOVU/%NGZI\8/C/K45]X@MM.NEN$TZ))+B=O,F0!))YI[F623R\Q
M@)&%8_-7Z34 ?E9_P:"_![XN?!+_ ()D^+O"?QG^%GB/PCJL_P ;-4NH=,\3
MZ'<6%Q) VE:0BRK'.BL4+(ZA@,$HPSP:\P_X,\?@/\<?@?X4_:,A^-7P9\5^
M#WU3Q9HLFF)XH\.W.GF[18[_ '-$)T7S -RY*Y W#U%?M%10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V66
M*")IYY%1$4L[N<!0.I)["O$O#/\ P4F_81\7?L\ZA^UGHW[47A0?#32];;2+
M[QO>WIM=.CO0Z)Y0FG5%;YY$4,N5); )(-?/?_!RC^V)JW[&G_!)#XA^(/"6
MJM9>(?'30>"] N8WVM&]_O%RRD<AQ917C*1R&"GM7@WQI_9E_8H_9#_X-AO
M/P0_;ML/'UOX!M?#_AS4O&2?#%;0:S_;%_>Q7S[#=_NBHO+@JQ;GRUP,8 H
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M/H=L\>N78ECB6TTW;=%YI6,F_P#>+$BI&[,RA: /T%HKX7_X)6?\' _[$O\
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MZMD@'[%4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW@C2_!7PMT2PE\):-X*O]+O+;38TF6]N3;175R9 -QDF^T3&1B<N7).:Z?\
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MY YR?0T ?.]C_P KN][_ -B8/_4,CKDO^""'PJ^'O[8O_!>']L#]H?\ :?\
M"NG>)O%?A'Q)J?\ PCMEK]JERFGM+J\]MYD<<@(#006T5NC8RB2$#&0:^M;7
M_@EO^U[%_P '.%S_ ,%/7\)Z3_PJ27PV+--5_MV'[5YO_"-K88^S9\S'V@%<
MXZ<]*\8_;Z_X(T_\%3OV3_\ @I+XC_X*?_\ !$'Q'I5WJ/Q">XF\9^![^_L;
M9Q<W+K)> K?LEM<VTTR"X^:1)(Y2=HX5@ >:_M+?#CP/^Q!_P=]?!3_AE7P[
M9^'[;XCZ-877B_0M"MU@M3)?KJ-E=YACPBAH[>*Y8  >9^\^\<U'_P $Z/@G
M\-?C)_P=W?M(ZA\2/"%AK/\ PAEIK^OZ'%J-LLT=O?K=Z9:).%8$;U2[EVG&
M58AA@@$?0/\ P1Z_X(S_ +>2_M[:O_P5V_X+#^,-/OOBM):2V_A/PM9WMM<G
M3I)+<VIN)6M,VL2QVQ>&&&%G'[QG9@RC=VG[ 7_!+?\ :]_9^_X. _VA?^"@
MWQ*\*:3;_#3XB>&]7L_#&HVVNPS7,TMQJ&ESQA[=3OC!2UF))'! '<4 ?,/@
M_P %>%_A;_P>T7&B_#[0[71['6?#MQ>WUEIT"PQ233>#S-,^Q0!EYE\UC_$[
M,QY)->6_'WX4?\%I?^""'_!1CXX?M=_LI_LX0?$WX:_%KQ3>ZQ?:T?"DNMV\
MEE/>3WBPW9M&6[L)(6N'1G)2*1@&_> *%^[[O_@EM^U[+_P<XVW_  4^3PGI
M/_"I(O#ALWU7^W8?M7F_\(T^GX^S9\S'V@A<XZ<]*\7^(G["/_!Q)_P39_;?
M^)7QP_X)E>(M,^.O@'XFW9G70OB5XOCGGTJ,2RRP02KJ5];,&MS/+'')#.P>
M-@9$!^50#T;_ (-IO^"@7_!/O]KWQ!\3- ^ O[#NA? [XON@UKQ[8Z'*;BWU
MZW>Y?=<02N%>*..XGP;4J$A\]!&6!.WS'X%R3>%O^#U/XNZ?X?RD&L?#6$:G
M''TP?#NC3'/UEBC;ZFO;O^""O_!(C]K?]E7]H;XN?\%'O^"A>M:'%\7?C UQ
M%/X:\.2Q20Z;#<WBWMV\SP?N?,DGCA"QQ%E1(LEV+D)Y7_P2"T"3]J?_ (.3
M?VT_VWK5/M.B>"%;P58WH&8Y+L36]BC(W1L0Z+,./X95/<4 ?LU1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!R7Q\^"?@+]I+X(^+?V?_ (I:9]L\.^,_#UWHVLP+@,;>XB:)RA(.UP&W
M*W56 (Y%>,_\$F/V*_BI_P $\?V(O#?['_Q4^,-AXY?P??7T>@Z[8Z;):G^S
MIKA[B*&1'=SOC:6100<! @'2OI.B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH S?&-OXIN_".JVO@;4+2TUN739TT>[OX3)!#=&-A$\B*060/M+ ')
M(KYC_P"".W_!,C3?^"67[*EQ\%]3\>Q^,/&'B/Q1>^(?'7C%;1H?[5OIV"J0
MKLS*B0I$N"QR_F/QO(KZNHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N&_:7\8^(_A]\ _%GC7PAJ/V34],T:6>RN?)23RY!T.UP5/T((
MKN:\S_;*_P"36?'7_8O3_P A0!\"?\/%_P!LG_HL7_EO:=_\CT?\/%_VR?\
MHL7_ );VG?\ R/7B5% 'MO\ P\7_ &R?^BQ?^6]IW_R/1_P\7_;)_P"BQ?\
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M^*_%>H?&K4-3U+4?'.NZ.+C3]-U74;X$:KK&J)$L=JMO)*K0DJ7VVZ 9.YZ
M/TPJ?2_^0E;_ /7=/_0A7*?!K39=&^$'A32)_%\7B%[3PU8POK\,PD34BMNB
MFY5P3N$F-X;)R&S75Z7_ ,A*W_Z[I_Z$* /HFBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^1O\ @KS_ ,DI\*?]C#)_Z(:O
MSX\0Z_I'A70+[Q1X@ODMK#3;.6ZOKF3.V*&-"[N<=@H)_"OT'_X*\_\ )*?"
MG_8PR?\ HAJ_.KXD>";#XE_#O7_ASJMP\5KX@T6ZTVYEC'S)'/"T3,/<!B:
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M3_Z&WQW_ .%E<_XT?\.]_@G_ -#;X[_\+*Y_QH ]THKPO_AWO\$_^AM\=_\
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MZ_XEUBUTK0]-BT+5%:[O+B5888@SVH4%I'5<L0!GD@4 ?8]%?'OQ!_X+\?\
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MTI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?!#X7?"SQ?%XA\1ZBMKI,NJ_!:]L;=)L%@7GEMPD0^4_,2!G%>9_M^>.K/\
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M?H%7Q!_P0*\+>)_"/['GC73?%GAR_P!+N9?C_P".+B*WU&S>!WADU>5DD"N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>)]=O_VX_P!NCPW\6]+O+"*/0=/T/X96V@MI]P')>5I(78RAEPNT],9KZ.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20221231_g4.jpg
<TEXT>
begin 644 cah-20221231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /._VM?V:O /[8W[,_CC]ESXGJXT/QSX<N=*O)X5
M!DMC(G[NXC!X\R*0)*N>-T:YK^?+]F[]IG_@M-_P;+ZMXH_9%\=?L<7/Q3^%
M]UKLU]X9U:&PO7TUYGPIN+&_MDD6)955'DM)5WH_.V,LY?\ I1HH _FU^%7P
MA_X++?\ !P-_P4S^%7[:7QT_9K3X:_#WX9^(M,N[+4=4T*XTS3K33K2_2\>&
MV-SFXU&XE*E=ZYC#$9,*U]4_M+_ ?XX:M_P=\_![XVZ7\&?%=SX+L?",4=[X
MNM_#MR^EV[C1=53:]T$\I#O=%P6!RRCJ17[0T4 ?FM_P<[_\$N_B[_P4=_8O
MT/Q'^S?HSZK\1/A5KLNL:/H<,@6;5;&:()=VT!) \_,=O*@R-WD,@!9UK\X_
MVG_^"L'_  6-_P""NG[+-C_P2=\/_P#!,_Q/HGCO7Y;#3_B3XL>RO81?);31
MREI()[:*/24::*-YGEF=<!E&T-@?TBT4 ?DK^V7\ ?\ @K'_ ,$C?^"5GP)^
M&7_!*34HO$\?PMLW@^,'A_2O",&JWFM-/*+N>ZM8IHGE-N;I[Q9$B'G".XC8
M8\MV'YN?MN+JG_!>7XI?#[X2_L,?\$2[_P"#GC]];,GQ%\?KHIM+1$D79)]L
MEAM8(O)C8M(9YQYS%%1%RVUOZC:* /R<_P""QG[1W_!7'_@GK\??AS\1/A7\
M*9_CA^RQ#X=M[#XB^ [/P?;7EQ<S1PO;SK?3_9YYXHW!BN(YA^Z\U3'("N%D
M^'?V4OV>]>_X*G_\%M?A%^UU^Q=_P3"U+]F[X4_#76--UKQKJCZ2;"QO[BQN
MWNF*JD,5N)I_W=MY$"LVW,DAVYV_TBT4 %?B/_P3M_9%^*7BS_@X5_;D7XL?
M!GQ5I?@/XB> O%&BVWB/4_#ES#I^HQ7FIZ<A6&XD013%HO,8!6.0K'H#7[<4
M4 ?SD_\ !IS_ ,$X/VB_@[_P4J\>_%C]HGX#>*_#%MX#\!7^G:3?>(/#ES9P
MW.I7-W#!NMY)HU64>1%=<H3Q(IZ'G3_X(K?L(?ME>+?^"&7[9O[-]G\&_%OA
M+QQXRDA7PQI7B71;C2YM6$=HKR6\7VE$W"94>#/W<RX8@9K^B.B@#^8_]D/]
MIK]M2#_@D'XY_P""-'[/7_!(KQK'\2KO2];@\>^/9M#ELHSISS374\MXDENC
MM>B M911/)EML03<V(3Z=:_ O]HC7_\ @T$N/V>[?]G/Q\GC?1/BH(9_"<O@
MV^74I$;6UO/.2V,7FO'Y5PIWA2ORMS\IQ_1%10!\I_\ !+[X+SZW_P $;/@]
M^S_\8/"NHZ6VI?!"QT/Q)H^HVCVUU;K-8>3/%)'(H:-P'8$,,@]17XW_ +"6
MM?\ !=?_ ((+_$WXC_\ !/#X+?\ !/?5?BYI?B_Q.]YX(\2IH5ZVC_;&C2W3
M5%NX!Y AD@CMS-#-)&8C$NYX\-N_HRUS2+/Q#HMYH&H[_L]]:R6\_EN5;8ZE
M6PPY!P3R.E?@]X#_ &&_^#K#_@F%\1_&?PY_8J\<VOQL\!:W,L>A:SXQ\;6-
MX+&WC:3R)H[;6+R%K.XV28E2(/$[*N?,"(0 9O\ P:4>&_B=X4_X*:_M=>&O
MC1K,.I^+]+,EGXNU.V?=%=:HFM7*7,JMM7*O,LC X&0>@Z59_P"#<']G#]H?
MX6_\$OOVU_"/Q.^ OC3PYJVO^&;J/0M+U[PM=V=QJ+G1-00+!'+&K3$NRKA
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXC\4^ OB'J5C:>%=0\"Z=#=272W=C/>P3[;B> +$T,#'.=P+*"O7'GO[&/\
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M>!O@QX6\*Z[\/O%FDV'A.ZT#1H+)ULYRT$M@/*5=T.TB79V: $8YSXK_ ,%
M_P!B[_@I)^VS^P[^PU_P5,_9,\/S>-?B+\,?A?HUWKFA2PPW-[/<1I:W5OJD
M5M<92]+R1,TL0#.V^,JCC=MJ>*?^"4G_  <E_P#!6KQ'X&_9W_X*M^.M*\(?
M"+P9JL5YJ6K0:KHLUQJA13$UPD.F/(UQ>&)G1'N!'&GFNV,EE;[&_P""R?\
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MP4H_X)/^ /!WQ T[XJ6<\6KV/BG6+2!-.2Z^SM=6]U%<W5L[H+BVCGC>W<L
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M_BY8>.+KP6]W;:3X@L-.DM?,T][AYH(G1W<AHQ(8Q@XV(@[&OC/P7_P>+_\
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M,?@K_@RB_8!T;Q';:GXV_:=^*^MZ?#('FTR"33K3[0 <[&D%L[!3T.W#8/#
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M-^'_ !_)&FA>+8M&U+2OL*2.$6XF@U!G\^!6=!*Z.C1 EBC8VUQG_!9N?0]
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MW9P<8H_X+B?\$8=3_P""Q/A?X;>'--_:'@^'Y^'^LWU^\T_A9M3^W"X2!=@
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M;"ZD5 TEI(<-#=1YX\V&98YD)XWQKGBO2J* /SE_X)F_\$$;[]C#]C?XL_L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ+I]\6:X,0)D$$A CN2H5F(B9\*I/0$T ?7'_#0?_4H_^3__ -KH_P"&@_\
MJ4?_ "?_ /M=?+/B#]O3]D7PK^T?:_LD^(/C9IUM\0+R:""+0WM;@HEQ/&98
M+62Z$9MXKB6,%XX'D6612"J$$9[B_P#C%\.--^+VF_ :Z\1_\5;JV@76MV>D
M16DTC?V?;RPPRW$DB(8X5\R>)%\QE+DL$#;&V@'T)X+^+G_"7Z\FB?\ "/\
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MB#!3,BR*IEB#%09(]R LHS\PR ?17_"W/B'_ -#!_P"2D/\ \11_PMSXA_\
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M_P $C'E^)W[-'C+P7XOMW\1> ;;QK>:?X1M_$D'VE)=,"QL(2DP(>)20=I&
MS..V  ><_#+XK:OX)_91^*/P5^!FNR7MIXE^-5[X&^#D@OGN(X;:Z\M6,$I+
M$P0PF619 2 Q!SSFOO'X3_#?P]\'OAGH/PL\*0[-.\/Z5!8VN5P76- N]O5F
M(+$]RQ-?'OQDU6VM?BE\1?B+\%_"^FZ7X<_9K^'M_;>%++2].BBLXO$M[ SS
MSI$BB,B"'"LN.')/<UN?\$_?B!\6-/\ CU=?"#QA\9M>\;Z7K'PDT3QC]L\0
MW@N)+"_NA'YL,3@ K"WF%EC.=JJN.<D@']+/PC_Y)3X8_P"Q>LO_ $0E=#7/
M?"/_ ))3X8_[%ZR_]$)70T %%%% !7PO^VC\(_@I\./VG+__ (*-?$#PSXO\
M3Z]X#\&RZ#HOA[0-+.J&".YNHGDN+.RCC,K7KDK$9$?_ %.01C)K[HK\Y_V_
MOVY_'/[$W[;UIJ7QV\(7?_#/OB#PI)%)XT\/^%KW4KG0O$L<X(CO5M1*ZVLU
ML5$;+%GS0P)(R5 /)_\ @ASKWA[X@_#GXU?&CPA:6V@Z5XV^/&M:K8_#T,J7
MGA5?*MX3!?6Z\6EW*T1G> 9"B1>3DXQO^"K.N?$:;]N/]FC1O /[(VM_&5="
MM_%NMS^$;1;>&QN;M[&&SM#=7=Y_HUM&GG7$FZ3)W*@"DD4G[%OQ)U/PMXG_
M &M/^"JFL?!3QGIGP[\;W&D7W@WPL- ,6M:U9Z+IDD$^HQ64K1D-=NX,8<HS
MB,%NH8^C?M$?\%"?'_[.7CSX6_'#QI\*]7'[//CKP6\WB;7+3PG=WFL^$=7E
M6*XM'OX;5I2EN\3-$P2)RLP.7QM# 'SI^T[^WKX3U+_@F+^TYX<\.?LXO\ ?
MBQX*T[3=!^('@UX;42V,.K74-G!>PW5HJI=P-#<S%)E (()'#(S:7A'XX?LF
M>-/%?[.7P8^(7["?Q(^%?P[T3QEIK_LX?%.^@MK.WU'4H8F^RV\Z1DSVL=^F
M6\N8!KDE6=0<E>;^(W[.7Q _X*P^'/VMOVA?A?\ #_6=%\-_$#X<:)X4^$8\
M2Z;)IMQXIGTF=M1:],,X5XH9+E8H(I) ,KN)V[64=)\7/VM-*_X*;Z7\$?V2
MO@W\$O'6D>-]+^*'ASQ#\5=/U[P5>Z=!X M=)E%Q=++<3Q)$TK.GDP+$S;]_
M)0D*0!/BK\'_ (Z#XI?$G]D>R_9[\9WFJ?$3]JOP]\2/#_Q/M=#9]!L="@DT
MBXGFFU#.R"XMETVXMQ;L1(YDCV!E?->W?L<?&?X/^+OBSXO_ &T/BQ\5_#6B
M7OQF\1CPS\&-/U[7;>UGU#PSI$LEO;?8XYG#RFZNY+R\VQ@EDN8..!7>_P#!
M2/X@^+-,^!-I\ ?A7JSVGCCXSZ]#X(\+W,',EBEVCM?Z@ .0+73X[NXW </'
M&.K"OA__ (*%> /V=O@3X_\ C;\$OBE\.HYKGQ'^S%X>\)?LJV+:%)>2M?6G
M]I0?8--=8VV727LFF3,JD/MV2'Y1F@#]CO@Q_P CW!_UPD_]!KV6O /V3[/Q
M1IUMX:T_QO<^=K4'AZ&/5YM^[S+I;=1*V>^7#'->_P! !1110 5YG^V5_P F
ML^.O^Q>G_D*],KS/]LK_ )-9\=?]B]/_ "% '\PW_!03]GOQKX=F^(O[4O[0
M?[5]UH>H6]PO_"E= \.:^\0Q&?EA:%T5C*1L+>0?E9FD9B.!]J_LNZ_\1?%/
M[.?@CQ'\6[62'Q+>^&;.;64GBV2&=HE)9UXV.W#,N!AB1@8Q7R[^UK^TU^Q3
M^T5X(^*GPP^/&E?V!XH^&,>H6_AV'Q!>K;W=Q?>6RQ7%@L<G[W=)'$0.3M92
MP"L:] _8I_:=T_P;^Q]\'#^T_P".Y[;Q+XW=],\/R:C;3S3:FQNWCM SHC8+
M0M;G>Y 8,&)Y)H \\_:=_8K^,/QS^)/Q1^.'[1?QOUCPOX1\,:,UQ\-K?P]K
M:K! L,4C/-<1LOR<QJ[ 8=C+@. @%==^R9^V!K'@W_@F%IW[37[06J3WUSHV
MGWD4=U=2GS]6,5S)!;)N/+2.P2,N<DD%SW->._\ !1+]K#PE\=OVC(/V']5^
M,%OX)^'NC7*2_$;Q'(6+WTJ;7-E$$5L[257!&/,R6!$0W='^U-X&^(_Q[\!_
M!U?^">OPZT7Q[\,/!5[)<OI,NIPVUC/=VA2.W2=;B>"295_>YP?F+-N)W4 <
MM_P3G\<_M!:A+^U)XP\<W%Z?'?\ 8-KJ45H[,S6M]);:C-%$D9)V;28U"#[N
MT+VK/_8)^)OPZ^#'Q3LO'7@_QO/>Z'-^SU)XF^+0&KR78&M17C%Y)0[MLN<8
M0)P2'''S9.Q_P35\8?M7ZA^WO\61XX^%&BV*:MJ,#_% V]XC?V+<I#=FT2WQ
M<-Y@DD+*Q7S< <E>M>S_ +6_PS^&VO>._!O[&_PH^'NAZ')\3-?&L_$:;0M)
MAM7GT2P<3R^>T2J2TTVR-7;/.X=S0!W'_!/OP'XAT;X(2_%[X@VNSQ5\3]7F
M\5Z\&R3"+G!MK<9Y"QVXB 4_=)88K]FO^"6G_)K*?]C#>?RCK^=#X?\ Q^^.
M[_M ^'_BM-\8=;EM==_:"U+P%<?#]IT_LNTTF%$6(I;A?DFCW!FD!R?ES_%N
M_HO_ ."6G_)K*?\ 8PWG\HZ /HZBBB@ HHHH ^9?^"D/[*7PO_:]T7P=X#^,
M$FHRZ+H/BRQ\2/I5G/&L&J364OF16MXDD;B:U9R"\7!;8OS#'/Y__LV?&_P'
M^U%_P6RU?X@^!/!>J_#\^#O@;+HFH:9XST9M'U?Q@9=3BDCNH+.0!YK&V6+
MN&YW2JH&TYK[7_X*^_&S]HG]G/X;^$_C1\ _ALWBZRT/Q99R_$?0K+3)+O4I
M/#)=EO9;")'4O<QYC< A@463@8R/C+P?\:?#/_!27_@I[\%OC[^RSX3\1R^
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MQ3_9F_9"\,^"/A7^WC\:/$?A[3?B'X<L]-\%F.W>TL5FU:+=>)'#%D/"\C7
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MB821J0/W<B$#!% 'Z6T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#'_(]P?]<)/_ $&O9:\+_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\
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M !H PZ;-!#<Q&"XA61&^\CJ"#^!K>_X=[_!/_H;?'?\ X65S_C1_P[W^"?\
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MU\:7^ .L_MZ^#X_$4=]]CE=(+R33(YMVTJVII ;%<'@DS@#!R17T[\2_C/\
M"7X-?"[4?C;\5?B1HOA_PAI-@+W4?$FJZC'#900'&V0RL=I#%E"X)+%E"Y)
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M'XI? ?Q#X"UD7FH#8(Y)-$U"SAFMV3S3YJ2RAE>'HN2I/D'PI_;L\>?L9_\
M!#2X^)G[.6OWGB;X[_'/XXZU+\4-0\->$[N]N/AYXBU.9KC5)+K3VC$JW-E:
MI!&L4@ >9XW7S(B-P!]A>++[P?\ '3_@X3^'2_LVZ1:M=? WX2:_;_'KQ/I,
M(6(QZHMNFCZ%<2IP\\<D,EVL)SM0D\%2!J?\'-5S!9_\$2?C)=W*DQQ7GA1Y
M J[B5'BK2">._':N&_X(P?MJ_P#!/KP4?#_[!_[+'P3^.MIKWB&:^U;Q%X[^
M)/PXN;23Q%JP@>YN]1U*^E<[IYO*8#.0/DC7  KTW_@XV\+>)_&G_!''XL^&
MO!WAR_U;4;C4/"IM]/TRS>>>4)XHTEV*H@+-A59C@<!23P* */[/7_!8[_@F
M%^T=\:_#GP0^%WPL\7Q>(?$>HK:Z3+JOP6O;&W2;!8%YY;<)$/E/S$@9Q7F?
M[?GCJS_X(L?\%!_^'HT.B7\WP6^-NAMX<^.FDZ/;&1K/Q)96TLNC:JD:_P <
MZQO9L3A07+,2T@K].*^(/^#B'PKXF\9_\$N?$N@^$/#=_JU\_CCPA(EEIMF\
M\K(GB+3W=@B DA5!8G' !)X% '-_L8?\$U_'GQD_8.^+OB;]KGQ+J_A?XP_M
M?V\^J_%+5M&*B^\.Z=<PF*QT* RJ0L=I8OY!1@2&EF7)PIKFO^"HGPY^#&@^
M(_V//^"<G[+O@K3(_B7H?Q>\.:]X,MM&LT2?PCX7T>3?J6J2-& 8('BC\DJV
M!<.S ;V0X^R_V]OVG-1_8U_8[^('[3.A_#Z_\5ZGX4T!Y]&\-Z;:R32ZC?2.
MD%M"5B!?8T\L>]E!*IN;M7Y=_P#!)K_@I%^R?\&_%,GQ-_: ^%W[0/C/]I3X
MV:I9Q?$?XB:I\'KN.TM99I$2'2;)F;%II=J650  &$?F, %1(P#[[UOX#?L?
M?\$];#]HW]O3]HCQ7#J%E\1;HZU\0=;\7VEO,8=,ALXK2WT6$; 9K<!-D5N=
MS2/.$^8E16!_P0-^%OQ+^$7_  2I^&7AOXH^&+O0+J^_M76=(\,WS,9M%TJ_
MU2ZO+"S;=\P*6T\7RM@IG80-N*^$_P!L?_@HC\'_ (W?\%4/$'AS]O+X+?&;
M5O@I^S_XC6V^''P\\)?#*\U#3?%GB6W9TN=;U-OE2>*WD5H[:'YT8?O#@,Z2
M?K'^R%^U;X _;3^!NG_'_P"&?A;Q3HVD:E=7-O!8>,M!?3;]&AE:)B\#DLJD
MJ2I[C!H ].HHHH **** (=1T[3]8T^?2=6L8;JUNH6AN;:XB#QS1L"K(RGAE
M()!!X(-?C!J7Q3_:=_X);ZG\3/\ @A)^SUI>J7.O_%/Q#'/^QWXA*2/#HF@Z
MU-,=5$THSY2Z.4NYU8Y8E@Y&TJ*_:6OB#]KKPKXFU'_@N1^Q[XKT_P -W\^E
MZ;X'^(T>HZE#9NUO:O)960C620#:A8@A0Q&<'&: /H+]E3]B?X#?LD_LQ>!_
MV5_ G@RPO="\#:*ME9SZEI\<DMS,QWW-V^X$"6>8O,^."SGL *^6O^#?#P+X
M(NOV/_&>K7/@[2I+JW_:'\<BWN9-.B,D0369=FUBN5VX&,=,<5^@5?$'_! K
MPMXG\(_L>>-=-\6>'+_2[F7X_P#CBXBM]1LW@=X9-7E9) K@$JP.0W0CD4 <
MM_P1%^&WPZ\<>$?VJSXU\ Z+K&_]MOXCQO\ VII4-QN07D!"GS%.1DGCWJ+_
M ()U>!O#7['G_!8;]I[]B7X.:5#I'PX\0^%/#OQ+T#PI8(([+0M0NO-L]06V
MB7Y8DG>*.38H"J(U50%4"OG_ /8/_P""JWPD_P""=OC?]I?X%?'#]G+XY:IK
MFL_M;>/?$&DMX-^%MUJ%M=V5S?*D+1R@J&+&%B,<8*G.#7U%_P $I?AM\>/C
M-^TU\</^"J'[1GP6USX<3?%O^R-!^&O@'Q7 (=6TGPSI<+JL]Y%DF":ZGD:4
MPMS'L[JRL0#[KHHHH **** "BBB@ KX<_P""VG[/7Q)7X?>#O^"DG[+VBFX^
M+O[,VK2>)=,LH,J_B'P\R;=9T=RHRRRVH=U !;,;*@#29K[CK+\<1O-X*UB*
M*,LS:7<!549))C;C% 'Y_?\ !/36K7_@K+^VYJ7_  5UU32KY?A5\/\ 2IO!
MW[->FZO:F)III57^W-?,;?=D>3-C&P.#'!(" 5!J_P#\%9/AW\/]/_;)_8=M
MK#P+HT$=U^T'-'=1PZ9$JS)_8]V=K +\PSS@UW?_  ;W^&?$?@[_ ((V? KP
MSXN\/WNE:E:>&[M;K3]2M'@GA8ZE=D!XW 93@@\CH167_P %6/"WB?Q!^V'^
MQ)J6@^'+^^MM+^/\UQJ=Q9V;RI:0_P!D72^9*R@B-<D#<V!D@4 <_P#\%L?!
M_A+2]:_8ST/3/"VG6]E=?MO^#_M-G!8QI%+FSU,'<@&&R  <CH*=_P %]_V3
M/@[??\$Y_''[3'@/P'HOAKXE_!R&W\;?#_QSHNEPVVHZ7?V%Q%-\DT:ABCQH
MR%"2I)5L;D4BK_P<(>,)_A;X+_9?^-T_@?Q)K^E> OVMO#/B'Q#:>%-$EU"\
MCL+:QU1Y9%AC&3C@#.!E@,C->2_ME?\ !03Q?_P6>^!EU_P3H_8,_9+^-.FO
M\3M0L]-\=_$WQ]X ET;1?"F@K<QRWL[32N?.G>*-HT@ !<.V"6 4@'Z=_!7Q
M[+\5?@YX2^*$UHMN_B3PS8:H\"YQ$;BWCF*C/IOQ^%=-6?X3\,:-X)\*Z9X,
M\.VWD:?I&GPV5C#G/EPQ((T7/LJ@5H4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!4UC0=#\0P16NOZ-:7T4%W#=01WENL
MJQSQ.)(I5# X='575ARK*"""*MT44 %%%% !1110 4444 %%%% !1110 54T
MS0=#T6>]NM'T:TM)=1N_M6H26UNL;74^Q(_-D*@;WV1QIN;)VHHS@"K=% !1
M110 4444 %%%% !1110 4444 %%%% !17QA_P5$_;1_;B^ G[0_[/O[+'[!W
M@OX7:KXL^-M]XG@,_P 53J"V-J-)T^*^R'L9%="T?GCE'RP0?*,FF_!K6/\
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MYJ_B>TM9= ;5-07Q[I.B7>HII]OK-P&'V-LR212FT1=X211O^\Z@'Z;T444
M%%%% !1110 445^6'[&W[<7_  <1_MY_L\:-^U/\!?A1^Q]:>$_$=]J<&D0>
M)[SQ-!?*++4+FQD,J0O(@)DMG(VN<J5/!)  /U/HKX<\4_M[_MM?LA_M"_L\
M?#S]O[P-\,;7PA\9H+CPQX@\6> %U#[/X?\ &YED>PMO.NY3NL[N )&@:,2"
M82DOL4 ^@?M4_MO_ !2\(_MQ_!W]@3]EOPMH.M^+_&#3>)?B7?:]#/-;^%?!
MEL3'+=E(98V%Q<3D06Y8E-ZMO4@@T ?4=%?G3KO_  47_P""J/Q^/Q5^/?[
M/[.GP=U/X/\ PF\4ZMH4=O\ $#6M2C\0>.IM)8KJ$FFM:_Z/:1F1)(H3.'WL
MF3M!('4?$;_@K)\6/C?X4_9[\&?\$W/A5X:UOXA_M$>#;CQ;I\GQ*OIX=(\(
M:+:Q0M=3WXM/WT\@GF6V2.$C=(K'< !N /NZBOE']@#]M3]I'XI_&_XF_L5_
MMQ?#7PCX>^+7PPM],U234/A]>7,NA>(]&U!9?L][:+=9GA*20R1212$D-M()
M!./JZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^V^!]KXPANM DTYI)-7_ +;T^WM%*2AP(?*,!8Y5MV[ VXS7GG_!83_@G/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899540368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,639,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666900003744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 51,469<span></span>
</td>
<td class="nump">$ 45,457<span></span>
</td>
<td class="nump">$ 101,072<span></span>
</td>
<td class="nump">$ 89,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">49,806<span></span>
</td>
<td class="nump">43,841<span></span>
</td>
<td class="nump">97,795<span></span>
</td>
<td class="nump">86,167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
<td class="nump">3,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="nump">2,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="num">(207)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain)/loss on sale of equity interest in naviHealth</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings/(loss) before income taxes</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(973)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(1,022)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(925)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">(130)<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss) attributable to Cardinal Health, Inc.</a></td>
<td class="num">$ (130)<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in shares)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted (in shares)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4957<span></span>
</td>
<td class="nump">$ 0.4908<span></span>
</td>
<td class="nump">$ 0.9914<span></span>
</td>
<td class="nump">$ 0.9816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666995444816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">$ (130)<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">30<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899894672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 3,654<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">10,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">17,263<span></span>
</td>
<td class="nump">15,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">34,596<span></span>
</td>
<td class="nump">32,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,341<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">6,618<span></span>
</td>
<td class="nump">7,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">44,482<span></span>
</td>
<td class="nump">43,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">30,083<span></span>
</td>
<td class="nump">27,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,552<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,212<span></span>
</td>
<td class="nump">30,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">4,685<span></span>
</td>
<td class="nump">4,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">8,797<span></span>
</td>
<td class="nump">9,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized&#8212;500 thousand shares, Issued&#8212;none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at December&#160;31, 2022 and June 30, 2022</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common shares in treasury, at cost: 68 million shares and 54 million shares at December&#160;31, 2022 and June 30, 2022, respectively</a></td>
<td class="num">(4,254)<span></span>
</td>
<td class="num">(3,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' equity</a></td>
<td class="num">(2,213)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; deficit</a></td>
<td class="num">(2,212)<span></span>
</td>
<td class="num">(706)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; deficit</a></td>
<td class="nump">$ 44,482<span></span>
</td>
<td class="nump">$ 43,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899879824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666894205584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2021</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">$ 2,666<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(800)<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Sep. 30, 2021</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">$ 2,666<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (706)<span></span>
</td>
<td class="nump">$ 2,813<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (3,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2022</a></td>
<td class="num">$ (1,780)<span></span>
</td>
<td class="nump">$ 2,576<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (706)<span></span>
</td>
<td class="nump">$ 2,813<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (3,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="num">$ (2,212)<span></span>
</td>
<td class="nump">$ 2,747<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="num">(68,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2022</a></td>
<td class="num">$ (4,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Sep. 30, 2022</a></td>
<td class="num">(1,780)<span></span>
</td>
<td class="nump">$ 2,576<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">$ (129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="num">$ (2,212)<span></span>
</td>
<td class="nump">$ 2,747<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (146)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="num">(68,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2022</a></td>
<td class="num">$ (4,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666901237984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">$ (130)<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain)/loss on sale of equity interest in naviHealth</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(919)<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,643)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,954<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(1,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net tax proceeds/(withholdings) from share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,525)<span></span>
</td>
<td class="num">(1,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CashReclassifiedToAssetHeldForSale', window );">Cash and equivalents reclassified from/(to) assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,063)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
<td class="nump">3,407<span></span>
</td>
<td class="nump">$ 3,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 3,654<span></span>
</td>
<td class="nump">$ 3,161<span></span>
</td>
<td class="nump">$ 3,654<span></span>
</td>
<td class="nump">$ 3,161<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CashReclassifiedToAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Reclassified to Asset Held for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CashReclassifiedToAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666985949296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the six months ended December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666985911360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i495abb9913e04abfaa8f722b6757199b_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903488144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and six months ended December&#160;31, 2022 and December 31, 2021 were primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months and six months ended December 31, 2021, restructuring also included costs related to the divestiture of the Cordis business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903370192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(863)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(863)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,313</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,986</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2022 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to certain reductions in our long-term financial plan assumptions made during the three months ended December&#160;31, 2022, including those related to Cardinal Health branded medical products sales growth, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in a pre-tax goodwill impairment charge of $709 million. The impairment charge recognized during the three months ended December&#160;31, 2022 was driven primarily by the impact of the reductions in our long-term financial plan assumptions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit, which resulted in a pre-tax goodwill impairment charge of $154 million driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for six months ended December&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determinations of the estimated fair value of the Medical Unit at December 31, 2022 and at September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approaches. For the income-based approach, we used discount rates of 10.5 percent for both periods. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Medical Unit at December&#160;31, 2022 after recognizing the impairment charges was $6.2&#160;billion, of which $1.1&#160;billion was goodwill.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unit exceeding the fair value, resulting in a pre-tax impairment charge of $1.3 billion recorded during the three months ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,220</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,014</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">547</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">369</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">607</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">429</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,817</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,621</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,828</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,632</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Total amortization of intangible assets was $71 million and $79 million for the three months ended December 31, 2022 and 2021, respectively, and $142 million and $157 million for the six months ended December&#160;31, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $147 million, $260 million, $235 million, $208 million, and $176 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899495648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract', window );"><strong>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both December&#160;31, 2022 and June&#160;30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $30.1 billion and $27.1 billion at December&#160;31, 2022 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we redeemed all outstanding $572&#160;million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2025. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2022, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LongTermObligationsandOtherShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903488144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. In the second quarter of fiscal year 2022, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. At June 30, 2022, we had an accrual of $20&#160;million, which represented our estimate of our portion of the assessment for calendar year 2018. Du</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ring the three and six months ended December&#160;31, 2022, we recorded $6&#160;million of income to reduce this accrual to the invoiced amount for the calendar year 2018 assessment. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Settlement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims brought by states and political subdivisions. This Settlement Agreement became effective on April 2, 2022. In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160&#160;million to the State of Washington and its participating subdivisions and approximately $95&#160;million to the State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. Each of Washington and Oklahoma is now subject to the Settlement Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Distributors, parties to the Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, we agreed to pay up to approximately $6.3&#160;billion. The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions, including the Attorney General for the State of Alabama, and we intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December 31, 2022, we made our second annual payment of $372&#160;million under the Settlement Agreement. In total, we have $5.89&#160;billion accrued at December&#160;31, 2022, of which $480&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgement in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 468 lawsuits as of January 31, 2023. Of these, 88 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial began in January 2023. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. In the three months ended December 31, 2022, we received approximately $10&#160;million in insurance recoveries related to these matters; however, we </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have not recorded a receivable for any additional recoveries as of</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, we are named as a defendant in approximately 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,161 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 3 lawsuits involving similar claims by approximately 3 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits seek a variety of remedies, including unspecified monetary damages. Since July 2021, we have entered into agreements to settle approximately 2,885 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized net income of $46&#160;million and $25&#160;million during the three and six months ended December&#160;31, 2022, respectively, to reduce the reserve for the estimated settlement and defense costs for these matters due to certain claim settlements and to reflect insurance recoveries received in the quarter. At December&#160;31, 2022, we had a total of $471&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $826&#160;million. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the intended complaint. We are vigorously defending ourselves in this matter. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we received net cash proceeds resulting from the settlement of a lawsuit in which we were a class member or plaintiff of $66&#160;million, which was recognized in litigation (recoveries)/charges, net, during the three months ended December 31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. </span></div></div>In December 2021, the parties reached an agreement in principle to settle this matter. In October 2022, a court entered an order approving the settlement and dismissing the case. The settlement does not include any admission of liability. Under this settlement, in December 2022, Cardinal's director and officer's liability insurance carriers, on behalf of the defendants, paid Cardinal Health $124&#160;million, less approximately $31&#160;million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal received net cash proceeds resulting from this settlement of $93&#160;million, which was recognized in litigation (recoveries)/charges, net, during the three months ended December 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903402080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended&#160;December&#160;31, 2022, the effective tax rate was&#160;5.4 percent and&#160;30.0 percent, respectively, and reflects the impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December&#160;31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended&#160;December&#160;31, 2021, the effective tax rate was 105.0 percent and 153.1 percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charge recognized during the three and six months ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2022, we recognized pre-tax goodwill impairment charges of $863&#160;million related to the Medical Unit. The net tax benefit related to this charge is $68&#160;million for fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the six months ended December 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax loss for the six months ended December&#160;31, 2022 resulted in recognizing an incremental interim tax benefit of approximately $140&#160;million, which impacted </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the six months ended December&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at December&#160;31, 2022. This incremental interim tax benefit will reverse in the future quarters of fiscal 2023.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $1.0 billion and $943 million of unrecognized tax benefits, at December&#160;31, 2022 and June&#160;30, 2022, respectively. The December&#160;31, 2022 and June&#160;30, 2022 balances include $889 million and $858 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and June&#160;30, 2022, we had $56 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $120 million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $78 million and $75&#160;million at </span></div></div>December&#160;31, 2022 and June&#160;30, 2022, respectively, and is included in other assets in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903251584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,146</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,146</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666904319104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December&#160;31, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended December 31, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $300 million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses recognized in other comprehensive income/(loss) were a $2&#160;million loss and a $1&#160;million gain for the three months ended December&#160;31, 2022 and 2021, respectively, and a $2&#160;million gain and a $3&#160;million gain for the six months ended December&#160;31, 2022 and 2021, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $43&#160;million loss and a $17&#160;million gain during the three months ended December&#160;31, 2022 and 2021, respectively, and a $21&#160;million loss and a $22&#160;million gain during the six months ended December&#160;31, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4&#160;million and $5&#160;million during the three months ended December&#160;31, 2022 and 2021, respectively, and $8&#160;million and $11&#160;million during the six months ended December&#160;31, 2022 and 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $3 million gain and a $2 million gain during the three months ended December 31, 2022 and 2021, respectively, and a $3 million loss and a $4 million gain during the six months ended December&#160;31, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht..</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at December&#160;31, 2022 and June&#160;30, 2022 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,912</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,262</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903490624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $1.3&#160;billion and $800 million of our common shares, in the aggregate, through share repurchase programs during the six months ended December&#160;31, 2022 and 2021, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0&#160;billion. We received an initial </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8&#160;million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3&#160;million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8&#160;million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(140)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax expense of $7&#160;million</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903372192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 3 million and 5 million for the three and six months ended December&#160;31, 2022, respectively. For both the three and six months ended December 31, 2022, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903388560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,391</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,164&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,375&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,099</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,797</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,470</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,460&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,469</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,457&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92,938</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,778&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">93,501</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,197&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,239</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,575</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,431&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,072</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,425&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,333</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,382&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,470</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,460&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,469</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,457&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98,810</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,223&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,431&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,072</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,425&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i495abb9913e04abfaa8f722b6757199b_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized goodwill impairment charges of $709 million and $863&#160;million during the three and six months ended December&#160;31, 2022, respectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $5 million and $11 million for the three months ended December&#160;31, 2022 and 2021, and $11 million and $18 million for the six months ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">464</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">481</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">895</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">904</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,992</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,757</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,733</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,482</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the three and six months ended December 31, 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903373776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $3 million and $2 million for the three months ended December&#160;31, 2022 and 2021, respectively, and $6 million for both the six months ended December&#160;31, 2022 and 2021.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.95&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56.86</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $108 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76.49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $41 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903331392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the six months ended December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the six months ended December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903519328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666985727632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(863)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(863)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,313</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,986</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2022 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,220</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,014</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">547</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">369</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">607</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">429</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,817</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,621</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,828</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,632</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666904401136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,146</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,146</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899474464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,912</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,262</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899495648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(140)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax expense of $7&#160;million</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666903370192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666904327936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,391</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,164&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,375&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,099</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,797</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,470</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,460&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,469</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,457&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92,938</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,778&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">93,501</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,197&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,239</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,575</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,431&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,072</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,425&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,333</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,382&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,470</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,460&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,469</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,457&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98,810</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,223&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,431&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,072</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,425&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">464</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">481</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">895</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">904</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,992</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,757</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,733</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,482</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the three and six months ended December 31, 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899891904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.95&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56.86</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76.49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666900155120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899701904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666901127424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666900030400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899612032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 4,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892244608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">4,817<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,196<span></span>
</td>
<td class="nump">3,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,621<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 4,828<span></span>
</td>
<td class="nump">4,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">Trademarks and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,234<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,014<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666897702096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization of intangible assets - Year One</a></td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization of intangible assets - Year Two</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization of intangible assets - Year Three</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization of intangible assets - Year Four</a></td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TerminalGrowthRateFairValueInput', window );">Terminal Growth Rate, Fair Value Input</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net Assets</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TerminalGrowthRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminal Growth Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TerminalGrowthRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686385-199418<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=118262037&amp;loc=d3e9915-115836<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604008-122996<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892229760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other Short-term Borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember', window );">Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666904472096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Long-term Debt and Lease Obligation, Current</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 4,685<span></span>
</td>
<td class="nump">$ 4,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892972064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">19 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>numberOfUSTerritories </div>
<div>states </div>
<div>lawsuit </div>
<div>plaintiff</div>
</th>
<th class="th"><div>Jul. 31, 2014</div></th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>numberOfUSTerritories </div>
<div>states </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IncomefromSettlementsofClassActionLawsuits', window );">Income from Settlements of Class Action Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number | lawsuit</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Estimated Litigation Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingStates', window );">Settling States | states</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingUSTerritories', window );">Settling U.S Territories | numberOfUSTerritories</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Loss Contingency Accrual, Period Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | WEST VIRGINIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | WASHINGTON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | OKLAHOMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Native American tribes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | GEORGIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | ALABAMA | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityAccrualPeriodExpense', window );">Product Liability Accrual, Period Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Alameda County [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">5,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Other Jurisdictions [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number | lawsuit</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ShareholderDerivativeLitigationMember', window );">Shareholder Derivative Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_GrossInsuranceSettlementBeforeAttorneyFees', window );">Gross Insurance Settlement Before Attorney Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from Insurance Settlement, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GrossInsuranceSettlementBeforeAttorneyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Insurance Settlement Before Attorney Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GrossInsuranceSettlementBeforeAttorneyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IncomefromSettlementsofClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from Settlements of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IncomefromSettlementsofClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingUSTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling U.S Territories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingUSTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityAccrualPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss reported during the period pertaining to product liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityAccrualPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_NativeAmericanTribesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_NativeAmericanTribesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_AL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_AL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ShareholderDerivativeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ShareholderDerivativeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892878704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">153.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (1,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">$ (925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Medical Unit Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Medical Unit Goodwill Impairment [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666897492096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666901145936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666905041184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 5,262<span></span>
</td>
<td class="nump">$ 5,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 4,912<span></span>
</td>
<td class="nump">$ 5,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666894637968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 13, 2023</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Oct. 04, 2021</div></th>
<th class="th"><div>Jan. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 04, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A250MillionShareRepurchaseProgramMember', window );">$250 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A1BillionShareRepurchaseProgramMember', window );">$1 billion share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A300MillionShareRepurchaseProgramMember', window );">$300 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember', window );">$500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $250 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $1 billion share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $300 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.10<span></span>
</td>
<td class="nump">$ 51.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | Subsequent Event | $250 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A250MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A250MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A1BillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A1BillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A300MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A300MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892830032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">$ (1,780)<span></span>
</td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="num">$ (706)<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">30<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(2,212)<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="num">(2,212)<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (146)<span></span>
</td>
<td class="num">$ (85)<span></span>
</td>
<td class="num">$ (146)<span></span>
</td>
<td class="num">$ (85)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666904993312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss', window );">Shares that would be antidilutive as a result of net loss</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares that would be antidilutive as a result of net loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892852944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Employee stock options, restricted share units, and performance share units (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666899562608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="num">$ (207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">$ (180)<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892511104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 51,469<span></span>
</td>
<td class="nump">$ 45,457<span></span>
</td>
<td class="nump">$ 101,072<span></span>
</td>
<td class="nump">$ 89,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">51,470<span></span>
</td>
<td class="nump">45,460<span></span>
</td>
<td class="nump">101,076<span></span>
</td>
<td class="nump">89,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">47,673<span></span>
</td>
<td class="nump">41,375<span></span>
</td>
<td class="nump">93,501<span></span>
</td>
<td class="nump">81,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,797<span></span>
</td>
<td class="nump">4,085<span></span>
</td>
<td class="nump">7,575<span></span>
</td>
<td class="nump">8,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">47,391<span></span>
</td>
<td class="nump">41,164<span></span>
</td>
<td class="nump">92,938<span></span>
</td>
<td class="nump">80,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">3,446<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember', window );">Cardinal Health At Home [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 1,336<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892793696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (119)<span></span>
</td>
<td class="num">$ (950)<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (535)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="nump">895<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (600)<span></span>
</td>
<td class="num">$ (1,426)<span></span>
</td>
<td class="num">$ (886)<span></span>
</td>
<td class="num">$ (1,540)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666897682176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 51,469<span></span>
</td>
<td class="nump">$ 45,457<span></span>
</td>
<td class="nump">$ 101,072<span></span>
</td>
<td class="nump">$ 89,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">50,333<span></span>
</td>
<td class="nump">44,382<span></span>
</td>
<td class="nump">98,810<span></span>
</td>
<td class="nump">87,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">51,470<span></span>
</td>
<td class="nump">45,460<span></span>
</td>
<td class="nump">101,076<span></span>
</td>
<td class="nump">89,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892512800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 44,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,482<span></span>
</td>
<td class="nump">$ 43,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,992<span></span>
</td>
<td class="nump">26,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
<td class="nump">11,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 4,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,733<span></span>
</td>
<td class="nump">$ 5,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666894586128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666897642128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892483136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 46.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">70.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">49.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">57.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 56.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139666892388704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">76.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">59.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">64.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 76.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>cah-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cah-20221231.xsd" xlink:type="simple"/>
    <context id="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26cee45dd43e48b793c8a55a46959a04_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i44235a75341c4ea98c8f81b1b8a2af14_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e78550aaf464e52892c197636bb7e4a_D20221001-20230113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <context id="i4d2749e174ce4d1bb8fced961a9f1965_D20230113-20230113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-13</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <context id="if015bf8d31b6432ca4059c2c62023d4c_D20220701-20221223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="ie003cab2aff1438eb31ba142971e023f_D20221223-20221223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc75351148f9471193785633b036daec_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9510233b4906437c8abfc1fb414285bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67172f4a4b5744899699d8c0d3f2b040_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iee5a82fe562e42b39cc9abc7d652bc3c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib57e003e2a274fa58ba3f147eeb46425_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3ff7bd5cf42946baaf7c655557855e9f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic1962adcbf7e4dca9fc9c391d95086d1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if15d3c9cb56e4df894c78cded2673b0b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i62a5991ceefb4f3fbff0ab7d3de1ef49_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iab04bb69e4454253801b552864097c8c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0636a7a560a2446ba350112f3a92e561_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i531ccc08069542d18a4f2d161e0a3e9a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6584a57799974cfa81733b8b698b8d05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48a58960ee9049118daac30e86acf249_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72445fba2919453fa695e519ad37f80e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if794396f282949418bba779489671b20_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8f87392b0f554ebfb1ebc1230d3bbc35_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iefcb599bfb564cea80fb52a730ed571e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i16d958e455d54a82a0e4478e00b8b8de_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9f1feb614846497fa32aba331d135eea_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic8489c786a1d4bc293b8f36039b77688_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie0abdbbfe31344e1b16e538d6c48989c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i51c712703e684f4c8ecedda666ab1ff4_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0898bf4c17d140df80b1c69577258376_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4c55ac1fb684d339bdf22e8c63911cc_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8599c52e33e549f7b725ed2b5877dbdd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b5ad5a75b004348981b5e5040141950_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7d05ecda04046a0a137a84d7cd3374b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i290a19fe2fb547e8a22f900e6d3bb92e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe7e1aca3cfc4021b299e214f352264b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic822fa03c99e4574898c49c9633bb752_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd9496405ff84f17a05b819da2c1e8d2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i006190cd738a483b88b832cd1d821736_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie9d689a44b524fc58839dd5a0774a595_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idc6f8055536e4c23bbf6a5b4bdbdbaf3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic81592179f9943bf99db0592e3bb0576_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie27044717449459ca17f71dcb4f3d3bd_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2aca8e52a290406d97f8faa6c40af51d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i463c8d26a5be4bfc91079e8414077be1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5c599c6881bc4d589dd4c8d5eaa44ae3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1d1f9c79031447df9e15b07019606fd2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icf15831fa01e491d9d2f254aaf0e9bf8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i528f1cd91f784a078a7c3e4ef16b3444_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib39a861394a24af5ae49b541f0fd87ca_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fe3b2f7fe3245da8a78eda539a6ac00_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia13be735cc2443ad8517d5f01b6bfd7e_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i523d8d0b53df49998cdfaddd4b8eb78d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6b132521391641bc9c8d883b436c870b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8e7e08834e134ea488b1bea977bd6b14_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i475290592e5849d28bf81c8748343a28_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia274dc691f4f4bcb857dc93d297598ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13c22619f98045b1971e6621d17e9cfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i836db9f721d446698908e590540d9d99_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia1a10ebe6fcd4445a59847a469e7153a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i81a9117e94ff40d2bd8130cb4f715ba9_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f6d35fed34747f8a4556dea55894e83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie79455390cc9409c9303f326b67ebbc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0a29845f22449af9631745d9999727d_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8beab44640464040a492325d59503158_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide09dd2c95024e149104c6f4bcda4a02_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifccdd71418e045be8ce53738fb5ba2d9_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad984dddf58244a2a17c059113ad4369_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6147059e6e0467e9b1f3c9a0643b5d0_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c55cf57cc3e400ba40a7f5c2c90d462_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e03b79450bc414da77871d9a0b3342a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i853d1ecaadc74fa8866bcbc54f79d535_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99f6c43c451644d383f95dc9f5e104b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icec642004b7b430895d25f293ecb4289_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1971f99a0cc54e75a27067d61f454662_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77c92c96b759468d918e57bbb8cd0fa2_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7840a9e9f47f44cf9155eef621b95d6e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i08bfa4932993472cbbd06d16e11a6bc3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iff33151f7630485aa41a66d9a893641d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9eaa1547e5534d768ea3ed534ba2e362_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04d33ee800e348859d151250d6109ee0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0293a455c0be418f9e6ccdf022c16c57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f7465ce88c1440a986aade3262014dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i91b17012c22f40f393b25ec61b1315d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d3712b011c34b738780dc9362b76df4_D20140731-20140731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-31</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="if66c1d6e3cbf4381a0bd67de03e24ce5_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i4e6c3fc3e6e2445aa4d9200c41eef841_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf33963c011d47cea39c41f3cb3e98cf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if5c45c8e827040f492eecfcaf9019804_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i993e4902e3144a5bb0fd1d2340dcc042_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81b5f38455cd438ea15b1ba793e7d1e9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib5158c69b2f141aba7524064bfe8f0df_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic809c76f51ee4ec1a6f716add527ca16_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i18fb106b5e6f449d8ae9790879d1da5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i139081ab99184a1f8b7e1b9c76f62c72_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40b411ebb5184bb1a9dfd35919f25b3e_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i361a1cbfafd442128bda3c3659c07e1c_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:NativeAmericanTribesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i4e839715483343b29b2118fba97d1b13_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="ia8e0dc33321a4c17baac9c92c4b2a3cb_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i68386e21f9e742fb969736106a1cbf00_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i962de220c39d41c99fd21cc23e3bda11_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="iabd7dc7bfc674ee0ae21b5962987f975_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd8168246fc242c59a3f7bb52d90228b_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i0a59fc36d30d420c8aa97be0a9b2a640_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i525578e0fcdf4038a90e4f5d3e79ded2_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="ic9944beac48f4f9980659c2177de1820_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i581bdde63b994b5da0099ea58092e0c5_D20210701-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i7b5c5c45933b48ec82b48e22389cf840_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i527029a879204a469f1592c5d337a7a1_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c141cd1d64f4c09ad35c5e008a7f485_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdf7ff2e260e4c10b571e6c980ad3111_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ShareholderDerivativeLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2c0539d106574706b4942868128b486d_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i350fbf1a37334d5289dc88528245bdb4_D20220701-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i95fe2ba8ed3a44abadfb859ec9e251e4_D20230101-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="icd31a13676b345b183f5ced501f7ae50_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9b861e2d5ac4b82a144a3b79ab22e81_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3459c970df844cf2a1ee3095599f0255_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ced27bfe4894fc6803e626c517f05b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iac76a749b153465ab4af13b1df78d72a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c199cfd03a3434fb2252f5f91cf4519_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9bf45fc47f34b519bcb944cf300f764_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i28968af686284bf28e66c81f371858ae_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7e3e9a1753b947c98746cbb0141dc97f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1f983f7d518449f5badd677106e20d44_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic401427aa03a473ea0f233823ee9d726_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib98f9a1c857544358cc749c370824d31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i419db69ec18d45b5973c1365d849e94d_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i62912f01f9244e47ae336b38973b6b79_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a13dfbd6e0e47b49bff1d69a1465152_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80c83599bf12444b8d0eaf98c4ced505_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2af00a4f8742447cba317049f64150b3_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3c17db4a988b439d8092bcb59165e33a_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5bfe8b32e9774993b62940687e315b97_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1537e0b026743748253259f1422c1d7_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1336136219d3457ba4c78496738f3cfa_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i850b0b51db214c4c979fd9e1de993132_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5688d1966bc4586b43f1bd3b0319696_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8508310d7f6f400da86433e5bf10f0c7_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic296f663b9444e33b5f5d47197bb2a3a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fc93964635640fe8eb7402e598ad33e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iec9ecab01856488cb08eb92f6ceefb4f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67242a94677a43a29bdc3644189fb216_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib025910e07224dc6bc0dd03aba8e140d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35bfa7c5d2e64b76a42e9f20bacb3144_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc0a6ac4d1f041e7a3c39bd92acde20c_D20211001-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i0aa6850535854b1a86ffcec853e058c2_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="if3e0f4813dc547caa13b2dd18cb5794a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i96adc00f02ea4124a797b7def5d4b482_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ab163bd44f34212a39494050f17884b_D20210701-20211004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="i51514bc1c1804e3e8e046c79f210825c_D20211004-20211004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="ibb3ff1d4324243c5b9dab7c4b4e6aaac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i927dad673ba5420a852bc6b2ae6b2c64_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6d24c5647c19422b8430fcfe245a94f7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1f2ad28443449a3918666f8d0ca9088_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if89a2915b7ed4a078a678477329b0507_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib230b5c311ef47d68a27beaea8522ed6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59555a0f0c174b9491efe42bf0cc4203_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iafbe269331e44497b6736f5de1e2161b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i234657f026ec4322af8ba2a7554081dc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5d0098e44a8448c6988637fda4f53d74_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9f837aa398974931b78133ce25f15c52_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ea96e756f1646cdbbb7691cf0597a61_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4260860fbed64ec0a99b94ee41089695_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i079ed1cf2c02433cb1306b1192fe722a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3668ad01dd604937a1f5a2dbff8c26ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5de1192dba4d40dea7d63dad70307f94_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d191632a75148da81cbf62a95aacda0_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac761a14f9bd4458a4a199cf1a930ab0_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id14071c1bf65402a88b667c00185bad9_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ideb7ebd0dccf4880b310bb4ffe79ba9c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i372f1adca9c14668a399c6ffc8407155_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9327356d31264aeda31dc4ff0d2c87fc_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i071f8fbaf46941a48f5d41fde9668d9b_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9a7a93a200d473ab5c358f7df672a72_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74408378be5a448e98f4a8a12fb3666f_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd4c69b8bfea43cc82c3f371ef88ebf8_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia6df290f36db4d3d90865e0e99c3d0b8_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia39b5639f5fa48fc97157c8446d8e414_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib59cd6366c894bc7b2baebc2cd23823b_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38e7f4cacb374f3c9209b0378d7b463c_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8c827171183b49d9b5eac5515ab8dc44_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i847b85afccb1427c9843ef38bfb3b4ef_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e0e3bfc4cf14a36a1e7f71d2910082d_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5840a89e1f24c089cf3dc78fab83e52_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i991f809891464521b1f29e8e3fa6c4db_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7759d1263204160a70574351e4794da_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic2cadd91b2c54bc6b8874b00950fde1d_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0748902d2bc42b1aa2187c657d51169_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idcc20395d8d04d49bb7875d92c1c581f_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8f31a92ecac49d98787199739713426_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf2a6bafa71e46f6bff513c85997576c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6b72d75aa77747f688bde3fedede66d3_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29d8fab8a7154b2ca8fca6ab14961db8_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ea3c4ca236646ceaff7d1d7d0910e14_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20401e15a48a4142ab492d9ed551560b_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5fd024933b8a4c7dbd94a2ee45b24ed2_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf4d295eb2c84b83a1b9930b69ca5b06_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i07757b56850843c5b966cdae4070ece5_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb971d5ee0074937ab22b8a564419c1a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f93e137bed843d5bbce9e33653971d9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i314103e38f99480eb96ce0c421f83746_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie88445aacaa14c91a809313e59ddaf22_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i16af340395d846e2827ed3fc620c2fad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba6f162e7cb341e5a022eee6d2ce58ad_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i724588d9b5744663ab373f331e1884cc_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6d56087f747e42769e4b2bcea6e62a75_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd307c58e2c24994829573b1f3f8a6a7_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iebc2a7c414ff419388ee2bf7c1a9ffdf_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i78decb5962f2469ba0f935238a752f02_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i38a85160188a49a1a63acb55c053b255_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i503ea8a68f26416685bd1508d35865c3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5f2f86523a374ec7bcf6bf98d477b026_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5143d217945b451bb550ec1284ff9356_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52092b4628a84f24953a6d6e5f6106ee_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifbae0f89cc2e464880a6f49f34d3015f_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8077e88c3a2248e0b130f3f465521df1_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bf7d991e3e1433e91f8172e38de1cf0_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idc9a8d5ad3844888a89cd82186360d79_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="states">
        <measure>cah:states</measure>
    </unit>
    <unit id="numberofusterritories">
        <measure>cah:numberOfUSTerritories</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF8yLTEtMS0xLTIzOTQxMQ_4f8b79bc-876e-4268-bf3b-9e6481cacd57">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF8zLTEtMS0xLTIzOTQxMQ_8dec146e-6854-4b93-bff8-c82fef128376">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF80LTEtMS0xLTIzOTQxMQ_6fc42454-3d2e-4526-9951-ab52c9d3facd">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF81LTEtMS0xLTIzOTQxMQ_1ee6458b-80c4-473b-b5f0-ba3e777c52b9">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl80L2ZyYWc6ZGZkMDQ3ZDI1Mzc3NGJkMWI3ZDkxZWRlZDg5ZmNjYWQvdGFibGU6NzQ2MGViZjVmNjJkNDFmNDk1Mzg3NDM0ODc3ZmYwNTQvdGFibGVyYW5nZTo3NDYwZWJmNWY2MmQ0MWY0OTUzODc0MzQ4NzdmZjA1NF82LTEtMS0xLTIzOTQxMQ_bdd3fc42-3a37-4401-9e54-7b7d17547b2b">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF84NA_00ad24d5-31ff-4713-b788-aacca9b4259a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MGU0NmZlZTU4NTc5NGIxN2I4ZWM3MTk5MjYzYzgzODYvdGFibGVyYW5nZTowZTQ2ZmVlNTg1Nzk0YjE3YjhlYzcxOTkyNjNjODM4Nl8wLTAtMS0xLTIzOTQxMQ_a8851a5c-f486-41cd-8f78-a5bbb35ead21">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xMjE_361f7030-5c29-46eb-81a9-d9501b078348">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6ZjNkYjQyM2QwOGU3NDY5OWIxMTcxYWNmM2M5Y2Y0NWEvdGFibGVyYW5nZTpmM2RiNDIzZDA4ZTc0Njk5YjExNzFhY2YzYzljZjQ1YV8wLTAtMS0xLTIzOTQxMQ_8879a580-40d3-416c-b13d-9f3cdd4850b6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTc5_f23147a2-30b5-4df4-87bc-4524436c8d92">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgw_e007117d-ad74-4719-a803-cfcd35951e38">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8wLTAtMS0xLTIzOTQxMQ_97f4fae4-b587-482a-ac88-7a62c13ca613">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8wLTYtMS0xLTIzOTQxMQ_ded43e8b-44df-4c1e-a74a-4f83f252e7cb">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTAtMS0xLTIzOTQxMQ_1c7fce77-b4dd-4ccb-b231-b38ad92bbf35">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTItMS0xLTIzOTQxMQ_e7ffc3a6-ada1-4948-aeb9-e4717f159c00">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTQtMS0xLTIzOTQxMQ_f84e0079-3299-4661-b785-ca020cc17631">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6NTQ2N2QyYmI5NzZjNDdmNzk4MDdmNjc3YmUwY2Q1ODIvdGFibGVyYW5nZTo1NDY3ZDJiYjk3NmM0N2Y3OTgwN2Y2NzdiZTBjZDU4Ml8zLTYtMS0xLTIzOTQxMQ_f83dffff-0356-40b7-9073-7c052aa0e4c2">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF80Mzk4MDQ2NTEyOTA2_8cf2ffe5-0222-4f46-8d24-44562d97ae75">614</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF80Mzk4MDQ2NTEyOTE5_05136091-80e6-4c76-8e6b-6f9bb031b8c8">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MjczNzQwNzNjYTcyNDgzY2FiYWMzYzVhMDAwNmIwY2UvdGFibGVyYW5nZToyNzM3NDA3M2NhNzI0ODNjYWJhYzNjNWEwMDA2YjBjZV8yLTAtMS0xLTIzOTQxMQ_0bd98d40-f32a-4016-8f9f-ae4520056039">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MjczNzQwNzNjYTcyNDgzY2FiYWMzYzVhMDAwNmIwY2UvdGFibGVyYW5nZToyNzM3NDA3M2NhNzI0ODNjYWJhYzNjNWEwMDA2YjBjZV8yLTEtMS0xLTIzOTQxMQ_380ceb30-e723-4da8-a735-f2ad48b0f31e">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6MjczNzQwNzNjYTcyNDgzY2FiYWMzYzVhMDAwNmIwY2UvdGFibGVyYW5nZToyNzM3NDA3M2NhNzI0ODNjYWJhYzNjNWEwMDA2YjBjZV8yLTItMS0xLTIzOTQxMQ_0508553d-f48e-4c67-90d6-cd13aed4957d">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgx_dc642529-77c1-436a-94e8-5ab2fabbaa36">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgy_6f888a12-7c70-4586-8026-4c75d26bb6d7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6OTdiODk1MTc2OWY0NDJkOTlhZmFhMzlmNTQ1YTc3ZmIvdGFibGVyYW5nZTo5N2I4OTUxNzY5ZjQ0MmQ5OWFmYWEzOWY1NDVhNzdmYl8wLTAtMS0xLTIzOTQxMQ_2660f9fb-c4ad-44f2-ac69-5dc85f552da1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6OTdiODk1MTc2OWY0NDJkOTlhZmFhMzlmNTQ1YTc3ZmIvdGFibGVyYW5nZTo5N2I4OTUxNzY5ZjQ0MmQ5OWFmYWEzOWY1NDVhNzdmYl8xLTQtMS0xLTIzOTQxMQ_5e1af5e3-0e1c-471a-96c4-de790d6ca05a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGFibGU6OTdiODk1MTc2OWY0NDJkOTlhZmFhMzlmNTQ1YTc3ZmIvdGFibGVyYW5nZTo5N2I4OTUxNzY5ZjQ0MmQ5OWFmYWEzOWY1NDVhNzdmYl8yLTQtMS0xLTIzOTQxMQ_94a3f31c-95ae-42dc-8343-319dfb6bfca6">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTgz_9517dcd5-f751-4be9-b78d-08dc8c1b51b2">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i26cee45dd43e48b793c8a55a46959a04_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xL2ZyYWc6MzZjMDdjNmVmMTFhNGQ3ZmI1M2I1ZGE3YzYzZDE1NjgvdGV4dHJlZ2lvbjozNmMwN2M2ZWYxMWE0ZDdmYjUzYjVkYTdjNjNkMTU2OF8xNTc3_4698ce8e-dd5a-4a6d-b235-81d3dc27d8a9"
      unitRef="shares">257639059</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i44235a75341c4ea98c8f81b1b8a2af14_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNDkyOA_bfc188f9-5879-4f22-84d9-1974bab924c2"
      unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNDk2OA_51c17e3b-a699-4252-b9f8-212ccea03e55"
      unitRef="shares">2600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNTAxMw_7431b749-07c1-4321-9a86-7ace13f8ee40"
      unitRef="usdPerShare">76.58</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i9e78550aaf464e52892c197636bb7e4a_D20221001-20230113"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNTEwNw_49279dc6-3103-4367-9388-54d07bbfc60b"
      unitRef="usdPerShare">77.50</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4d2749e174ce4d1bb8fced961a9f1965_D20230113-20230113"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNDM5ODA0NjUxNTE0Ng_379d2bb8-9c15-4d93-99b8-4bc0167ab8d1"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if015bf8d31b6432ca4059c2c62023d4c_D20220701-20221223"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNTYy_05239456-5c6e-400b-8a39-5cec4a54e92a"
      unitRef="usdPerShare">73.36</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie003cab2aff1438eb31ba142971e023f_D20221223-20221223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl81OC9mcmFnOmM2Y2I1ZWRjNzY0YzQwODFhNzE4NzhhY2E3ZTY4MjgzL3RleHRyZWdpb246YzZjYjVlZGM3NjRjNDA4MWE3MTg3OGFjYTdlNjgyODNfNTk4_9450f794-8d5a-4f6f-8ad6-c208fb6c0b6e"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:Revenues
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi0xLTEtMS0yMzk0MTE_883c756d-eab7-4758-8394-c148e6b1981c"
      unitRef="usd">51469000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi0zLTEtMS0yMzk0MTE_bb4cbd5e-8c6f-453d-a8d5-dbb31e3140aa"
      unitRef="usd">45457000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi01LTEtMS0yMzk0MTE_2c2f102a-29ac-45c2-b927-28e14f4ba082"
      unitRef="usd">101072000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMi03LTEtMS0yMzk0MTE_08e553e0-4f12-4773-84ed-adf774a4f426"
      unitRef="usd">89425000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy0xLTEtMS0yMzk0MTE_9cde92cc-a890-47a8-abf3-44cd45df1b7a"
      unitRef="usd">49806000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy0zLTEtMS0yMzk0MTE_5ece7ed4-d009-4479-bf24-5f67ace48e4b"
      unitRef="usd">43841000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy01LTEtMS0yMzk0MTE_c2ca6671-6512-43db-a0de-a734f828a789"
      unitRef="usd">97795000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMy03LTEtMS0yMzk0MTE_4430943b-ca38-462d-82bf-9f3444f8ff74"
      unitRef="usd">86167000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC0xLTEtMS0yMzk0MTE_89bef088-3c76-4da6-aeb1-3c6a6eb14a3a"
      unitRef="usd">1663000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC0zLTEtMS0yMzk0MTE_19234ba4-15c1-448e-b9ce-55f7b24e5d34"
      unitRef="usd">1616000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC01LTEtMS0yMzk0MTE_bce79429-ddb7-4a19-b340-4b02457efb15"
      unitRef="usd">3277000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNC03LTEtMS0yMzk0MTE_e7058982-2b6c-4957-942f-4f8c4db12efc"
      unitRef="usd">3258000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy0xLTEtMS0yMzk0MTE_cfb972a7-a996-4aa7-9a5d-691b07cb51fd"
      unitRef="usd">1191000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy0zLTEtMS0yMzk0MTE_46bc280a-b57e-4521-a0d0-c7aaf66bff0d"
      unitRef="usd">1151000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy01LTEtMS0yMzk0MTE_0d9c7d48-4c82-4034-8dec-a15b99c66429"
      unitRef="usd">2388000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfNy03LTEtMS0yMzk0MTE_a0004409-bdf5-4785-98ae-b4e9f102c228"
      unitRef="usd">2265000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC0xLTEtMS0yMzk0MTE_03bcd50c-b501-41ba-a5e5-3b65f6f197cf"
      unitRef="usd">17000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC0zLTEtMS0yMzk0MTE_df43ccad-2cfb-4cbc-b20e-78715cd49daf"
      unitRef="usd">7000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC01LTEtMS0yMzk0MTE_8934c038-c3c0-45a4-adb0-e21ec2ea7d95"
      unitRef="usd">46000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOC03LTEtMS0yMzk0MTE_58588610-77d0-4dba-a37c-35935a79010f"
      unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS0xLTEtMS0yMzk0MTE_1245948f-8b1e-492a-9954-c3271aeda9d2"
      unitRef="usd">71000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS0zLTEtMS0yMzk0MTE_e9469cd7-e06c-4af3-8867-69a05ac5c909"
      unitRef="usd">79000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS01LTEtMS0yMzk0MTE_c0d346e0-ca90-44d8-bdf1-c7b6f4842cc5"
      unitRef="usd">142000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfOS03LTEtMS0yMzk0MTE_9272e093-6fab-4ccb-855a-35cae155f0e8"
      unitRef="usd">158000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtMS0xLTEtMjM5NDEx_90fa973c-a043-40ff-ad01-75a9f2be960b"
      unitRef="usd">-710000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtMy0xLTEtMjM5NDEx_24dc9a5d-74b2-40d9-8dc1-f20e2b5f1e31"
      unitRef="usd">-1295000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtNS0xLTEtMjM5NDEx_d4c6e041-e14b-438e-8506-2568fb228803"
      unitRef="usd">-863000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTAtNy0xLTEtMjM5NDEx_b1969d46-866f-4a32-a097-b52b5b938066"
      unitRef="usd">-1293000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtMS0xLTEtMjM5NDEx_354e0f5e-a4dc-45f0-bf65-43725e3e3b46"
      unitRef="usd">207000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtMy0xLTEtMjM5NDEx_706d61d2-9626-4116-9c1a-7169b71a4916"
      unitRef="usd">-34000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtNS0xLTEtMjM5NDEx_508d4932-ae36-4ae9-b434-593b16a64f69"
      unitRef="usd">180000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTEtNy0xLTEtMjM5NDEx_f57c090f-2737-4ac0-ac6c-352e91458c0b"
      unitRef="usd">-52000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItMS0xLTEtMjM5NDEx_3043d277-2ab2-4fc4-9f14-fbaa09465d74"
      unitRef="usd">-119000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItMy0xLTEtMjM5NDEx_be842ca6-edc9-432f-a39b-01f89ae25444"
      unitRef="usd">-950000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItNS0xLTEtMjM5NDEx_8db023ec-42f9-48fc-a7e0-44c380eaca60"
      unitRef="usd">18000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTItNy0xLTEtMjM5NDEx_8c8bd688-6102-4cdd-ae58-024e3f92b7b9"
      unitRef="usd">-535000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtMS0xLTEtMjM5NDEx_1952066c-b1cb-4179-a2db-88d474c2f4bd"
      unitRef="usd">7000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtMy0xLTEtMjM5NDEx_ce0a0eac-e8ce-434e-b70f-f38dd55eb154"
      unitRef="usd">13000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtNS0xLTEtMjM5NDEx_35c5df0a-2669-42b6-ab9f-870869c916bf"
      unitRef="usd">5000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTQtNy0xLTEtMjM5NDEx_0f04fca0-6911-4545-b5c3-7cc5ec7152e0"
      unitRef="usd">17000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtMS0xLTEtMjM5NDEx_2e537abe-3cdd-4af1-93a9-b29c702bc4d3"
      unitRef="usd">25000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtMy0xLTEtMjM5NDEx_74dc7c9f-8bb5-4666-a8eb-50388d50ab4e"
      unitRef="usd">37000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtNS0xLTEtMjM5NDEx_c6ebea60-1443-4f06-a897-378aeaf545da"
      unitRef="usd">50000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTUtNy0xLTEtMjM5NDEx_dd7b9107-e665-4e5f-bc16-756a0b404af7"
      unitRef="usd">77000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtMS0xLTEtMjM5NDEx_d4ac1cd2-8e2d-4135-b1d1-7f74d20afd3a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtMy0xLTEtMjM5NDEx_0158fe3e-ff54-4774-befa-3c86ab13b06b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtNS0xLTEtMjM5NDEx_24964dbe-cc25-408b-8631-a6adf5eeb81e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTYtNy0xLTEtMjM5NDEx_09796c5f-5c32-4f27-b2f8-5f6c5bf0f4ad"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctMS0xLTEtMjM5NDEx_7f8aa163-8034-4f7a-be25-5bbf463c62fd"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctMy0xLTEtMjM5NDEx_6b68ec87-9be5-4103-ac18-cf105e018565"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctNS0xLTEtMjM5NDEx_92fb9866-b9cc-4234-bd7a-5a6aad624e70"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTctNy0xLTEtMjM5NDEx_60a9b82b-f5b7-4128-8dc4-da0456e5886d"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtMS0xLTEtMjM5NDEx_2a91c09b-0673-4f7b-a636-d5760581110c"
      unitRef="usd">-137000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtMy0xLTEtMjM5NDEx_37a09f78-110e-469e-ac68-38ed529aa0ed"
      unitRef="usd">-973000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtNS0xLTEtMjM5NDEx_434b228f-5033-418c-b2a5-8df2cf194d0e"
      unitRef="usd">-27000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMTgtNy0xLTEtMjM5NDEx_403c7894-63b9-4685-9608-e375b8375d90"
      unitRef="usd">-604000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtMS0xLTEtMjM5NDEx_376a92d0-fd93-41e5-aae4-2068e797cdf0"
      unitRef="usd">-7000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtMy0xLTEtMjM5NDEx_31f442bc-fb52-450b-8e79-d9d557db9df3"
      unitRef="usd">-1022000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtNS0xLTEtMjM5NDEx_a5a7ca00-2cf9-43a7-bda2-e9df831db4fd"
      unitRef="usd">-8000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjAtNy0xLTEtMjM5NDEx_2c057418-8cbb-48a3-bd06-0a1eb46e5ee5"
      unitRef="usd">-925000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtMS0xLTEtMjM5NDEx_15840d4b-f436-4ade-8d08-16cbd7e2397a"
      unitRef="usd">-130000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtMy0xLTEtMjM5NDEx_33f62356-cc05-4366-98f8-3cf2b5be6d61"
      unitRef="usd">49000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtNS0xLTEtMjM5NDEx_d26d3cd8-2cfe-47d7-9f13-b9c75637234a"
      unitRef="usd">-19000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjEtNy0xLTEtMjM5NDEx_408bdd0b-174a-4469-91bf-2c8025af8536"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtMS0xLTEtMjM5NDEx_67fc7fb2-6e1a-46f8-aa98-671a2ff81f8e"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtMy0xLTEtMjM5NDEx_8c961b58-9ca1-4700-93bd-c8bcab11aa69"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtNS0xLTEtMjM5NDEx_d0cf71ef-e7c6-43c5-aace-2daccdc79e60"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjYtNy0xLTEtMjM5NDEx_fc5f73f7-8ca0-46d7-a0e5-def9185ae254"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctMS0xLTEtMjM5NDEx_ffc7fe1f-f059-4d58-a4dd-8fb4279cb427"
      unitRef="usd">-130000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctMy0xLTEtMjM5NDEx_49641edb-6fce-49ec-bb44-461d261c19e1"
      unitRef="usd">49000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctNS0xLTEtMjM5NDEx_6d05b0ea-80e2-4712-abf8-6dfaaaefe203"
      unitRef="usd">-20000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMjctNy0xLTEtMjM5NDEx_88f567d3-32d3-40ec-a078-3494124612b4"
      unitRef="usd">320000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtMS0xLTEtMjM5NDEx_3aa31a9a-72d1-4838-a601-f9ac5c1dcba3"
      unitRef="usdPerShare">-0.50</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtMy0xLTEtMjM5NDEx_a9f83936-bc1f-400b-a2a2-951d12163bd2"
      unitRef="usdPerShare">0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtNS0xLTEtMjM5NDEx_6186d689-6b32-4691-92ca-c1924ad4662f"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzAtNy0xLTEtMjM5NDEx_3c4544d3-eb2c-4049-8d8e-9c84813f2569"
      unitRef="usdPerShare">1.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtMS0xLTEtMjM5NDEx_9ae43613-922a-42ba-933e-f79c023a3caa"
      unitRef="usdPerShare">-0.50</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtMy0xLTEtMjM5NDEx_e906532a-1e66-46eb-b61c-481683cd19dd"
      unitRef="usdPerShare">0.17</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtNS0xLTEtMjM5NDEx_6ba2d681-7a25-4eda-8cf5-0f390f56faf3"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzEtNy0xLTEtMjM5NDEx_11de53ba-c440-4870-8f75-f615d7fef3d9"
      unitRef="usdPerShare">1.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtMS0xLTEtMjM5NDEx_b9d064da-dba7-4351-a334-bbc84761b667"
      unitRef="shares">261000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtMy0xLTEtMjM5NDEx_3e5b1bb7-dfbd-482b-a1de-09ed5ca63999"
      unitRef="shares">279000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtNS0xLTEtMjM5NDEx_90fa3b22-649d-4121-8f95-f8b1f5f91e0e"
      unitRef="shares">266000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzQtNy0xLTEtMjM5NDEx_7d10deb3-5172-476f-98bf-2a1f32105a5d"
      unitRef="shares">283000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtMS0xLTEtMjM5NDEx_4cbcfb8a-9e60-4c40-b4db-5270a0fd5050"
      unitRef="shares">261000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtMy0xLTEtMjM5NDEx_721c11f3-8127-413b-a2bb-f3af6b415ad7"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtNS0xLTEtMjM5NDEx_dacc90a2-1403-4d48-97f3-03a3a980ab87"
      unitRef="shares">266000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzUtNy0xLTEtMjM5NDEx_de54de64-0a1e-48a4-8a78-0cd4075695f0"
      unitRef="shares">285000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctMS0xLTEtMjM5NDEx_1f8423e0-19c9-4ec7-88e5-39047442a432"
      unitRef="usdPerShare">0.4957</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctMy0xLTEtMjM5NDEx_57c22d42-3dfa-41d3-972b-88230d7f16fe"
      unitRef="usdPerShare">0.4908</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctNS0xLTEtMjM5NDEx_58bd0641-b5a9-4849-94d2-e055f63a8563"
      unitRef="usdPerShare">0.9914</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82NC9mcmFnOjhhY2QxMTk3Nzc2MTRhN2Q4YzFlY2NkMDkxYThlZDZlL3RhYmxlOmFiNTYyMzg0MjNmMjQ2MmQ5ZjA2OTAzZjdkZGEzOWRiL3RhYmxlcmFuZ2U6YWI1NjIzODQyM2YyNDYyZDlmMDY5MDNmN2RkYTM5ZGJfMzctNy0xLTEtMjM5NDEx_ee549839-dff9-4771-b330-c11bd6cc7356"
      unitRef="usdPerShare">0.9816</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi0xLTEtMS0yMzk0MTE_7a06683f-3407-44f3-9d1b-c0c48bc0be37"
      unitRef="usd">-130000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi0zLTEtMS0yMzk0MTE_13d9c307-a82a-4ee1-921d-fc5466ce7839"
      unitRef="usd">49000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi01LTEtMS0yMzk0MTE_93c53d98-7247-46fd-88bc-677bd3194e40"
      unitRef="usd">-19000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMi03LTEtMS0yMzk0MTE_77340c3a-551c-4513-808e-e27ba9ad8ae1"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS0xLTEtMS0yMzk0MTE_f0edebf7-a8df-466f-a0f2-dc54ed518100"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS0zLTEtMS0yMzk0MTE_5cf1e64c-c754-486f-99b4-e6424588e4f3"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS01LTEtMS0yMzk0MTE_7f721eaf-3500-4275-a382-68678659956d"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNS03LTEtMS0yMzk0MTE_19245f29-5f66-442a-ad25-5ca783d39f01"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy0xLTEtMS0yMzk0MTE_c260702e-fd8a-41de-b3e2-2bc23b9ba129"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy0zLTEtMS0yMzk0MTE_92e1e245-7e2e-4612-bd6a-4cb1f0a4f3b4"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy01LTEtMS0yMzk0MTE_6da9bf68-95fb-4351-a3f6-f82639d3505c"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfNy03LTEtMS0yMzk0MTE_2e65ba4a-c32a-4d4a-8279-38e873c88040"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC0xLTEtMS0yMzk0MTE_b79a1620-1c50-4947-bdb7-846f04c939c1"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC0zLTEtMS0yMzk0MTE_024df5ad-ff79-410d-a088-bf4277fcc4f5"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC01LTEtMS0yMzk0MTE_3c40c532-ecba-4adc-8b0d-72431c085049"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfOC03LTEtMS0yMzk0MTE_0fce96be-5309-4b2e-b03f-1b1ffefc19c6"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtMS0xLTEtMjM5NDEx_4e62531d-fbce-4d75-bc01-4a9a78008bc5"
      unitRef="usd">-100000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtMy0xLTEtMjM5NDEx_81654414-4357-4542-80ca-3675da6b2942"
      unitRef="usd">25000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtNS0xLTEtMjM5NDEx_83c5c920-42d0-491b-b84a-4583966bd429"
      unitRef="usd">-51000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTAtNy0xLTEtMjM5NDEx_1e60ded8-7c2c-4c80-9ff2-aa01d368b8ef"
      unitRef="usd">270000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItMS0xLTEtMjM5NDEx_9063a8ce-2a8a-4f93-91b3-b7b5713fd3da"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItMy0xLTEtMjM5NDEx_6f37713a-34fd-4ded-9594-2c311709c7cb"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItNS0xLTEtMjM5NDEx_56fc51ff-b2cd-47e4-b631-4d3a82f06943"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTItNy0xLTEtMjM5NDEx_cc511ebc-c3e7-4ddc-a167-90227c63a9a3"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtMS0xLTEtMjM5NDEx_f1fe2cd2-bc0f-4908-9d87-0f543c232f7b"
      unitRef="usd">-100000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtMy0xLTEtMjM5NDEx_bdecbcb8-7495-4dd6-b5dc-90f70cca82b7"
      unitRef="usd">25000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtNS0xLTEtMjM5NDEx_9edb521d-ff3d-40d1-adcd-fec119452b14"
      unitRef="usd">-52000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl82Ny9mcmFnOjUxZTQ4NDY2OTQ1YTRjNzU5YzU3NTVhOWRlMmUyNGQ3L3RhYmxlOjg4MmE0MTg0NDgzZTRjMDRiMjkxM2NmMTU0OWFkNjFmL3RhYmxlcmFuZ2U6ODgyYTQxODQ0ODNlNGMwNGIyOTEzY2YxNTQ5YWQ2MWZfMTQtNy0xLTEtMjM5NDEx_75b21f27-c7f1-4bcb-90db-6f8140dc0cd0"
      unitRef="usd">269000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNC0xLTEtMS0yMzk0MTE_ac6907f5-bea5-431a-a3b3-ef522760e7ce"
      unitRef="usd">3654000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNC0zLTEtMS0yMzk0MTE_88dd4514-3743-40a1-b3f7-5cd717b79c6f"
      unitRef="usd">4717000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNS0xLTEtMS0yMzk0MTE_a0d5b00f-2126-4737-a7e5-59377366222f"
      unitRef="usd">11421000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNS0zLTEtMS0yMzk0MTE_61084ef1-00b8-4cdb-a368-4fe6301b14e6"
      unitRef="usd">10561000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNi0xLTEtMS0yMzk0MTE_25454dc1-d25e-436d-8675-122cd82f39e2"
      unitRef="usd">17263000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNi0zLTEtMS0yMzk0MTE_6a4c373b-1347-450c-bf51-3956e09f3167"
      unitRef="usd">15636000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNy0xLTEtMS0yMzk0MTE_2c2cf7b4-d1d1-4fe9-92c6-4f6cf62feb2f"
      unitRef="usd">2258000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfNy0zLTEtMS0yMzk0MTE_edabe776-100b-47a5-a756-830b79205ded"
      unitRef="usd">2021000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfOS0xLTEtMS0yMzk0MTE_cb5dd8b3-72b0-42ba-bf84-5862259af146"
      unitRef="usd">34596000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfOS0zLTEtMS0yMzk0MTE_ba9995ef-47b3-4adb-9d14-c4b4c95a1d1c"
      unitRef="usd">32935000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTEtMS0xLTEtMjM5NDEx_58718e51-1361-4008-a0b8-e1abae8e0bca"
      unitRef="usd">2341000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTEtMy0xLTEtMjM5NDEx_849e4acf-2d28-430b-a017-ceaa4d5ee9ad"
      unitRef="usd">2361000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTItMS0xLTEtMjM5NDEx_76086cfb-8543-465d-9be6-6c4e32b66710"
      unitRef="usd">6618000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTItMy0xLTEtMjM5NDEx_6f04f447-6b5a-48e0-9533-e9d6ace9be98"
      unitRef="usd">7629000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTQtMS0xLTEtMjM5NDEx_b80071d3-4b9e-41d9-b510-bec83d0113ea"
      unitRef="usd">927000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTQtMy0xLTEtMjM5NDEx_baace5ee-9a34-4fd1-aa29-506d24a70c34"
      unitRef="usd">953000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTUtMS0xLTEtMjM5NDEx_496e4172-8a84-491c-8cbc-1ec5907a068d"
      unitRef="usd">44482000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTUtMy0xLTEtMjM5NDEx_daefb799-3691-4f9a-909f-ab78c56558bd"
      unitRef="usd">43878000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTktMS0xLTEtMjM5NDEx_b5a3fd22-60d8-46f7-9bac-4a67df26e463"
      unitRef="usd">30083000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMTktMy0xLTEtMjM5NDEx_417c6f1f-7ba6-49c1-b6e4-d81f408f75ef"
      unitRef="usd">27128000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjAtMS0xLTEtMjM5NDEx_e0cce98d-dddd-4ee4-ba35-480b395e0460"
      unitRef="usd">577000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjAtMy0xLTEtMjM5NDEx_df339b5d-c22b-4f5b-b389-da0aa9fc8b08"
      unitRef="usd">580000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjEtMS0xLTEtMjM5NDEx_cf1d8847-78e9-4c49-829d-0f309cf60957"
      unitRef="usd">2552000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjEtMy0xLTEtMjM5NDEx_2a563014-d7f7-4fdc-b584-432197dcfb06"
      unitRef="usd">2842000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjMtMS0xLTEtMjM5NDEx_b073cf17-1804-427e-94d3-4737d684c0cc"
      unitRef="usd">33212000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjMtMy0xLTEtMjM5NDEx_01850a6a-c976-4517-a951-cbb818fee11d"
      unitRef="usd">30550000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjUtMS0xLTEtMjM5NDEx_8fc8fdcd-7a09-4648-bed8-715ebe748b3c"
      unitRef="usd">4685000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjUtMy0xLTEtMjM5NDEx_35718a28-4857-4803-a220-5f34e9787f9b"
      unitRef="usd">4735000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjYtMS0xLTEtMjM5NDEx_74188e33-818f-4b6b-962d-599ef25b1ebf"
      unitRef="usd">8797000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMjYtMy0xLTEtMjM5NDEx_5a3ce4eb-d70c-4c85-9210-54b5c8948bf8"
      unitRef="usd">9299000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMTU_3f4d9dcd-7028-48f3-9ee4-8301c6dd8443"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMTU_caa8a9c3-9510-484b-a723-6141b582b599"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMzM_67ce9899-d8a8-4919-aee3-1c32ab40beee"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMC0xLTEtMjM5NDExL3RleHRyZWdpb246ZGU3ODk5NDUxZGRiNDJhYWE2ODI4MTkxNmU3OTdkZjlfMzM_7ce08dd5-5e4e-4140-8c2b-ab921186f649"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMS0xLTEtMjM5NDEx_078da3ad-cd0a-4c31-8612-e37afed50df9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzAtMy0xLTEtMjM5NDEx_bc8485e4-e8fc-41e4-b06c-e147c3524695"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMTY_1a143ecc-0ad4-4353-85e4-6d25ff4db2f5"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMTY_c9257334-d6dc-4dd2-a41d-c4d6e81c840a"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMzQ_52a60f2e-4dff-4422-a119-708921863631"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMC0xLTEtMjM5NDExL3RleHRyZWdpb246YmYzMzNkMGIzMWY1NDY4OWJmNDVjM2E3YjcyODA1YjJfMzQ_94be8f21-ab01-48b4-94c4-40c566e5100d"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMS0xLTEtMjM5NDEx_2db9cb1c-6f50-4c86-bc97-c8b46ab80228"
      unitRef="usd">2747000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzItMy0xLTEtMjM5NDEx_d4764a11-6d32-4de7-8646-47dc11e965da"
      unitRef="usd">2813000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzMtMS0xLTEtMjM5NDEx_70d545fa-a480-4219-ab8b-7bd5e218ef58"
      unitRef="usd">-560000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzMtMy0xLTEtMjM5NDEx_cd7062b1-bf5d-40dc-b0f0-6a0d3ca0ab3e"
      unitRef="usd">-280000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMC0xLTEtMjM5NDExL3RleHRyZWdpb246MTNkMjY3Njc0YmExNDcyZGFkZjdiYzMxMjM4NWYzNWJfNDE_7f32bba9-45ee-48a0-a503-32891b6f8ed1"
      unitRef="shares">68000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMC0xLTEtMjM5NDExL3RleHRyZWdpb246MTNkMjY3Njc0YmExNDcyZGFkZjdiYzMxMjM4NWYzNWJfNTU_fc863265-ad06-4007-aa11-1d6f0bc76194"
      unitRef="shares">54000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMS0xLTEtMjM5NDEx_ac3b26e4-1464-4615-9056-4a193d1ecf8e"
      unitRef="usd">4254000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzQtMy0xLTEtMjM5NDEx_3cacfcf4-3579-4ffa-9151-67ce701c2845"
      unitRef="usd">3128000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzUtMS0xLTEtMjM5NDEx_147465c4-0926-4448-9405-50590e242a3f"
      unitRef="usd">-146000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzUtMy0xLTEtMjM5NDEx_bb74ebe0-e0fc-4835-a47f-bcae2f4ba111"
      unitRef="usd">-114000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzYtMS0xLTEtMjM5NDEx_8d6f3b6a-1d29-4f07-8b2b-6e2bde0bb149"
      unitRef="usd">-2213000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzYtMy0xLTEtMjM5NDEx_3711ac21-b3e3-4118-8e74-b6e5c6ab1025"
      unitRef="usd">-709000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzctMS0xLTEtMjM5NDEx_a6a7ccbc-0911-4fa3-8549-be7cabb5db03"
      unitRef="usd">1000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzctMy0xLTEtMjM5NDEx_ba8374ba-fd6b-4a09-bd46-783ef7dd5d5b"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzgtMS0xLTEtMjM5NDEx_5c07e824-8a86-4729-9799-b7a4b249761b"
      unitRef="usd">-2212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzgtMy0xLTEtMjM5NDEx_f3c605cd-8dc1-4e26-8e49-759e7606ab59"
      unitRef="usd">-706000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzktMS0xLTEtMjM5NDEx_08a68918-7221-4c36-8570-12354970c9d6"
      unitRef="usd">44482000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83MC9mcmFnOjdmN2FhNDQ3MTVmNDQ5YTlhYjNmNjQ3OTdlYjAzYzk5L3RhYmxlOjk1MmEzOWExNmNmZTRjMjI5MzNlZWM3ZjJjODc4YzZhL3RhYmxlcmFuZ2U6OTUyYTM5YTE2Y2ZlNGMyMjkzM2VlYzdmMmM4NzhjNmFfMzktMy0xLTEtMjM5NDEx_27a78049-a10c-44de-b4ac-cd0aa262fde8"
      unitRef="usd">43878000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="iee5a82fe562e42b39cc9abc7d652bc3c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xLTEtMS0yMzk0MTE_a5d40b87-2620-4799-8942-8f25bb9304ea"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee5a82fe562e42b39cc9abc7d652bc3c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0zLTEtMS0yMzk0MTE_d42b5708-3f02-4b88-b5a2-1cfecdd676a8"
      unitRef="usd">2576000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib57e003e2a274fa58ba3f147eeb46425_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy01LTEtMS0yMzk0MTE_e6907e62-ff11-4296-87b4-152e5ef3c8f9"
      unitRef="usd">-301000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i3ff7bd5cf42946baaf7c655557855e9f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy03LTEtMS0yMzk0MTE_6e597749-fe9a-4aec-b6be-6b76bd6eabfd"
      unitRef="shares">-65000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i3ff7bd5cf42946baaf7c655557855e9f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy05LTEtMS0yMzk0MTE_dbd2406d-a362-47c4-885a-bb56a136599b"
      unitRef="usd">-3880000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1962adcbf7e4dca9fc9c391d95086d1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xMS0xLTEtMjM5NDEx_ab845261-219e-4fb3-8589-46e201d7835f"
      unitRef="usd">-176000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if15d3c9cb56e4df894c78cded2673b0b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xMy0xLTEtMjM5NDEx_b8a074d9-ef46-4ad3-9899-780f793f927d"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62a5991ceefb4f3fbff0ab7d3de1ef49_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMy0xNS0xLTEtMjM5NDEx_db6df438-cc89-47a3-9df7-e8ab69747a79"
      unitRef="usd">-1780000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNC01LTEtMS0yMzk0MTE_ffc7fe1f-f059-4d58-a4dd-8fb4279cb427"
      unitRef="usd">-130000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="iab04bb69e4454253801b552864097c8c_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNC0xMy0xLTEtMjM5NDEx_38216441-1c80-4a7c-9242-9ad435bd13d5"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNC0xNS0xLTEtMjM5NDEx_8137f5e4-b928-4f6b-9992-6509638ddd72"
      unitRef="usd">-130000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNS0xMS0xLTEtMjM5NDEx_b79a1620-1c50-4947-bdb7-846f04c939c1"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNS0xNS0xLTEtMjM5NDEx_014ecca6-1e6c-42b1-aa4a-eacd590910dc"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy0xLTEtMS0yMzk0MTE_89f6e588-f347-4537-84c9-6c0a867ce753"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy0zLTEtMS0yMzk0MTE_4c4436a6-7714-4655-97e8-53bdd1dfe78d"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy03LTEtMS0yMzk0MTE_a9b7e6cc-18d1-4719-93b8-e73faf5b9e88"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy05LTEtMS0yMzk0MTE_350b014d-dfe0-4135-8522-2ed91d11572c"
      unitRef="usd">26000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfNy0xNS0xLTEtMjM5NDEx_aa5f0ce6-3edd-43ae-81f5-04cf93fbe3d2"
      unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibea241b239234f768c3f121ed5fe6fd9_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC0zLTEtMS0yMzk0MTE_ab889ba8-f83e-4858-885a-09aa65794f0d"
      unitRef="usd">150000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC03LTEtMS0yMzk0MTE_158e6880-c281-45f6-9adc-61461c1b8772"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib17bc63d890c4bcca30763101a1e41b0_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC05LTEtMS0yMzk0MTE_80750b1e-413d-4f58-875c-fab979ddbd1f"
      unitRef="usd">400000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOC0xNS0xLTEtMjM5NDEx_77df0bc7-f672-4257-b5e7-be902674c4ca"
      unitRef="usd">250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i0636a7a560a2446ba350112f3a92e561_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOS01LTEtMS0yMzk0MTE_760ecbf3-82b3-430d-9637-b2b54955b4a3"
      unitRef="usd">129000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfOS0xNS0xLTEtMjM5NDEx_6099972d-8bb1-418d-8771-bf0bd90ec1fe"
      unitRef="usd">129000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesIssued
      contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMS0xLTEtMjM5NDEx_ca656ce4-5445-45f1-8aaf-d8a6d5a0c80e"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMy0xLTEtMjM5NDEx_f6fadac8-17cb-440c-baaa-293fe8862f4c"
      unitRef="usd">2747000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6584a57799974cfa81733b8b698b8d05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItNS0xLTEtMjM5NDEx_e9545708-295a-4209-b7aa-c16666e2bfbb"
      unitRef="usd">-560000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItNy0xLTEtMjM5NDEx_b937526c-8623-4697-b517-29fdbe64b5e7"
      unitRef="shares">68000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItOS0xLTEtMjM5NDEx_1d443a3d-6399-4f51-a5b2-5b5982fbc06a"
      unitRef="usd">4254000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48a58960ee9049118daac30e86acf249_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMTEtMS0xLTIzOTQxMQ_1f3b4d2a-432b-4443-80fe-8d993e89a3a3"
      unitRef="usd">-146000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72445fba2919453fa695e519ad37f80e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMTMtMS0xLTIzOTQxMQ_782b34de-392e-42b1-8704-62c4110a7b21"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjkxMzEyNzk1MmJjNzQwMWM5ZDFiYTdjNTlhZmIxNmIyL3RhYmxlcmFuZ2U6OTEzMTI3OTUyYmM3NDAxYzlkMWJhN2M1OWFmYjE2YjJfMTItMTUtMS0xLTIzOTQxMQ_a3d59478-2483-40e0-ba68-cef618fea5b3"
      unitRef="usd">-2212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="if794396f282949418bba779489671b20_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xLTEtMS0yMzk0MTE_57fe718a-b2b0-4def-9e75-14ad63e45b7a"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if794396f282949418bba779489671b20_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0zLTEtMS0yMzk0MTE_ea6b3a05-a12d-4623-b7a4-d2cd5398a5c6"
      unitRef="usd">2666000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f87392b0f554ebfb1ebc1230d3bbc35_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS01LTEtMS0yMzk0MTE_7002b825-3ac3-4f1b-b28c-c57afb4a9da6"
      unitRef="usd">1335000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="iefcb599bfb564cea80fb52a730ed571e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS03LTEtMS0yMzk0MTE_2b299acc-8b2c-4a7f-a839-3a42b402750b"
      unitRef="shares">43000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="iefcb599bfb564cea80fb52a730ed571e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS05LTEtMS0yMzk0MTE_b4e377a0-a6bf-4960-a8a7-2989ca43080d"
      unitRef="usd">2547000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16d958e455d54a82a0e4478e00b8b8de_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xMS0xLTEtMjM5NDEx_b0ee1f7d-9c04-48c2-b9be-22e3bf901ffb"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f1feb614846497fa32aba331d135eea_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xMy0xLTEtMjM5NDEx_4db14ed9-c90b-4094-8ef5-2c007e920274"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8489c786a1d4bc293b8f36039b77688_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMS0xNS0xLTEtMjM5NDEx_af80d945-8be9-4f9d-b13b-8a4edc8d0253"
      unitRef="usd">1396000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMi01LTEtMS0yMzk0MTE_3d270d9e-3a7f-46e5-a8ed-37917edb8e56"
      unitRef="usd">49000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ie0abdbbfe31344e1b16e538d6c48989c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMi0xMy0xLTEtMjM5NDEx_07afa748-76f1-4b32-b8b1-e6ae0c451a6e"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMi0xNS0xLTEtMjM5NDEx_ff396bc6-22af-431f-9444-ddbed21937eb"
      unitRef="usd">49000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i51c712703e684f4c8ecedda666ab1ff4_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMy0xMS0xLTEtMjM5NDEx_39a30411-c0e7-45da-93d1-50da9a7f27d0"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMy0xNS0xLTEtMjM5NDEx_3e3043d1-9a2c-4e24-8328-58ce0fb9c955"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS0xLTEtMS0yMzk0MTE_505dbc6a-ef82-4f80-b22b-c91c5aad61f6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS0zLTEtMS0yMzk0MTE_8d11785e-8f1c-4085-adbb-5233c08e1783"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS03LTEtMS0yMzk0MTE_3346b43b-554e-4fd9-8f2a-9ac799279c1d"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS05LTEtMS0yMzk0MTE_4fd6e900-d58b-48ef-981e-4b3bd06a7ead"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNS0xNS0xLTEtMjM5NDEx_aaa158fa-e187-41b8-899f-3f48f94d3702"
      unitRef="usd">19000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi0zLTEtMS0yMzk0MTE_97feaa16-4a85-4614-8f36-4897e6ffc183"
      unitRef="usd">40000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi03LTEtMS0yMzk0MTE_710d6996-23c6-4d4a-81a9-bdd6f3f95f01"
      unitRef="shares">7000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi05LTEtMS0yMzk0MTE_2c9eb553-1e08-425e-a035-4e4f07957737"
      unitRef="usd">340000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNi0xNS0xLTEtMjM5NDEx_d38d593e-ba28-41a0-838f-6347c781d120"
      unitRef="usd">300000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="ie4c55ac1fb684d339bdf22e8c63911cc_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNy01LTEtMS0yMzk0MTE_3f5b97f0-7dc0-47c8-aade-b85e15953f0b"
      unitRef="usd">139000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfNy0xNS0xLTEtMjM5NDEx_b4574ba0-8fcd-4bec-9a14-48cfe4149607"
      unitRef="usd">139000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i3dd96b4e6d6f4d669770ccecbcacacd6_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC0zLTEtMS0yMzk0MTE_55f40ef1-da76-4a3d-9d58-16d0b4c38bba"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="ie4c55ac1fb684d339bdf22e8c63911cc_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC01LTEtMS0yMzk0MTE_3800c6af-d8f4-4f6c-a29b-25dbb0d2a3b1"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i0898bf4c17d140df80b1c69577258376_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC03LTEtMS0yMzk0MTE_f572599f-e026-48df-9cbf-7cffb58a38a1"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="ie0abdbbfe31344e1b16e538d6c48989c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC0xMy0xLTEtMjM5NDEx_a51f8242-8405-452c-8207-59df6aa7868a"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfOC0xNS0xLTEtMjM5NDEx_ece51669-d133-4191-9962-ee5ae74059b9"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMS0xLTEtMjM5NDEx_0e3a7ae8-c69d-49a8-81a6-20abf09f2935"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMy0xLTEtMjM5NDEx_02dd35c0-ef15-4d92-b506-5c469dcb57f0"
      unitRef="usd">2721000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b5ad5a75b004348981b5e5040141950_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtNS0xLTEtMjM5NDEx_b9b65d15-6634-4dd0-ac54-31a61d0df133"
      unitRef="usd">1245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtNy0xLTEtMjM5NDEx_2c35c379-7392-4759-aa88-43586c16b095"
      unitRef="shares">50000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtOS0xLTEtMjM5NDEx_22b9aedf-9eb1-4088-91d9-1671746ad1a7"
      unitRef="usd">2883000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i290a19fe2fb547e8a22f900e6d3bb92e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMTEtMS0xLTIzOTQxMQ_b0a2f659-9cf0-4051-8f56-1eff6c34f554"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe7e1aca3cfc4021b299e214f352264b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMTMtMS0xLTIzOTQxMQ_55494e6c-32bc-4552-ad07-a01acf08cbe8"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic822fa03c99e4574898c49c9633bb752_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjk4OGI0ZTQ3ZTkzZjRiY2JiZWZmZmQ0OThhMWY3NjhjL3RhYmxlcmFuZ2U6OTg4YjRlNDdlOTNmNGJjYmJlZmZmZDQ5OGExZjc2OGNfMTAtMTUtMS0xLTIzOTQxMQ_b9c8f654-b604-46b2-8d10-3e1eb772d5ff"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="icd9496405ff84f17a05b819da2c1e8d2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xLTEtMS0yMzk0MTE_b223c758-d28c-4796-93a5-7491e0f218ac"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd9496405ff84f17a05b819da2c1e8d2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0zLTEtMS0yMzk0MTE_6fabce01-146d-4209-817e-ac65feaf4b74"
      unitRef="usd">2813000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i006190cd738a483b88b832cd1d821736_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy01LTEtMS0yMzk0MTE_46dec70a-cba2-48e9-bee1-cc32746ac24f"
      unitRef="usd">-280000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ie9d689a44b524fc58839dd5a0774a595_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy03LTEtMS0yMzk0MTE_dd87f5f0-3c6f-4fc7-b556-5ecc5112bb1d"
      unitRef="shares">-54000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ie9d689a44b524fc58839dd5a0774a595_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy05LTEtMS0yMzk0MTE_cdb05a0a-ab57-482f-a062-afc656e2fdb2"
      unitRef="usd">-3128000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc6f8055536e4c23bbf6a5b4bdbdbaf3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xMS0xLTEtMjM5NDEx_9d43ee83-9f04-4621-abc2-6393b6c8bebd"
      unitRef="usd">-114000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic81592179f9943bf99db0592e3bb0576_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xMy0xLTEtMjM5NDEx_3366d2b2-e485-45c9-b938-d9d1c1d506ea"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMy0xNS0xLTEtMjM5NDEx_40a90472-0c83-4602-8462-198c923423b8"
      unitRef="usd">-706000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNC01LTEtMS0yMzk0MTE_19073beb-f12d-4940-840e-628e46b4a3e1"
      unitRef="usd">-20000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNC0xMy0xLTEtMjM5NDEx_7a9a8f92-463b-45ed-abc1-7e9915f8f1fa"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNC0xNS0xLTEtMjM5NDEx_39e6b3c2-5247-45c0-8195-2f16c59e15ed"
      unitRef="usd">-19000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNS0xMS0xLTEtMjM5NDEx_5514b173-c6d3-4ae7-8714-24c9d00d2755"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNS0xNS0xLTEtMjM5NDEx_4b391298-a2fa-4f67-b378-8949797eb1c0"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNi0xMy0xLTEtMjM5NDEx_9354eb83-3be6-4afb-bb08-59b611d7cb53"
      unitRef="usd">-2000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNi0xNS0xLTEtMjM5NDEx_911353e7-6879-4780-8bd5-9f7df17f65a3"
      unitRef="usd">-2000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy0xLTEtMS0yMzk0MTE_4c3f0159-ae5f-4969-b586-4447c6899178"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy0zLTEtMS0yMzk0MTE_383207dd-d399-49e0-aa8d-b395492066ed"
      unitRef="usd">-16000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy03LTEtMS0yMzk0MTE_478b5cb9-5bc8-4fde-a11a-1c5584371fd5"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy05LTEtMS0yMzk0MTE_69b94011-a416-46ee-a0cb-4dde219308b0"
      unitRef="usd">74000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfNy0xNS0xLTEtMjM5NDEx_6f8be2f1-a4a7-4dfe-990e-654ff4052e7e"
      unitRef="usd">58000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9b29373dfccf4e97843fe905da6107a0_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC0zLTEtMS0yMzk0MTE_b5df22da-e95e-436f-99b9-a7ac4d0757f8"
      unitRef="usd">-50000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC03LTEtMS0yMzk0MTE_684a1cd1-2a5a-4111-bf87-df6630949cf1"
      unitRef="shares">16000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC05LTEtMS0yMzk0MTE_85b2126a-5eea-4e1f-a4e5-756b5e18788b"
      unitRef="usd">1200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOC0xNS0xLTEtMjM5NDEx_16522cdf-68bf-4354-b952-ef01f203eb0f"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="ie27044717449459ca17f71dcb4f3d3bd_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOS01LTEtMS0yMzk0MTE_f9abc74d-8efb-4d5e-b6ff-d1ee2de0e03f"
      unitRef="usd">260000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfOS0xNS0xLTEtMjM5NDEx_2d35f807-3b37-46a3-869e-3a663298136f"
      unitRef="usd">260000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="ie27044717449459ca17f71dcb4f3d3bd_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtNS0xLTEtMjM5NDEx_f3a93d02-c156-456b-8366-365dbc03e77f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtNy0xLTEtMjM5NDEx_e9ea0d27-6127-44f4-b370-2062333c1ca6"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="ice04a57075274d8498b1aa8c429f9760_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtMTMtMS0xLTIzOTQxMQ_80c25113-dd37-4744-ba00-acd599625df2"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTAtMTUtMS0xLTIzOTQxMQ_c42c4238-2d7e-49b5-b3c3-3e0a088f8a7a"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMS0xLTEtMjM5NDEx_7e6e53ae-8c9f-4be3-99cd-7e927d37eae7"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i531ccc08069542d18a4f2d161e0a3e9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMy0xLTEtMjM5NDEx_bb18da73-f76b-4e1c-9946-37c6df6a6af6"
      unitRef="usd">2747000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6584a57799974cfa81733b8b698b8d05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItNS0xLTEtMjM5NDEx_82b4b3f3-3d1a-4728-8c77-231d413fae28"
      unitRef="usd">-560000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItNy0xLTEtMjM5NDEx_5b1fa6e6-cf9e-46ed-b4a1-3fcd2bbcdf8e"
      unitRef="shares">68000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ied56ae01e84c4ea9b1ea8936d12a3d80_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItOS0xLTEtMjM5NDEx_e74c777e-b189-4bcd-944e-2fd8e128433a"
      unitRef="usd">4254000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48a58960ee9049118daac30e86acf249_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMTEtMS0xLTIzOTQxMQ_65f8c249-f810-4141-a6db-198b97a047ee"
      unitRef="usd">-146000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72445fba2919453fa695e519ad37f80e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMTMtMS0xLTIzOTQxMQ_44e40a28-5da9-4377-887d-85a6055ebcf7"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOjgyOWQzYTAzZGU5YzQ0ZDJiNjM3MWY0MGQ3ZWMyYTA3L3RhYmxlcmFuZ2U6ODI5ZDNhMDNkZTljNDRkMmI2MzcxZjQwZDdlYzJhMDdfMTItMTUtMS0xLTIzOTQxMQ_4bf68597-a4aa-4cf5-851b-577c6a6f3543"
      unitRef="usd">-2212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2aca8e52a290406d97f8faa6c40af51d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xLTEtMS0yMzk0MTE_d8522959-ca50-4fab-9653-3b3af085aec2"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2aca8e52a290406d97f8faa6c40af51d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0zLTEtMS0yMzk0MTE_707fbfb5-224e-4a00-bbfe-0659747fdbfe"
      unitRef="usd">2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i463c8d26a5be4bfc91079e8414077be1_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS01LTEtMS0yMzk0MTE_2bbc5758-f963-46c3-8c44-a21bab0366e2"
      unitRef="usd">1205000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i5c599c6881bc4d589dd4c8d5eaa44ae3_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS03LTEtMS0yMzk0MTE_00194d3c-938f-4ac5-806c-0b7c01d1811e"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i5c599c6881bc4d589dd4c8d5eaa44ae3_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS05LTEtMS0yMzk0MTE_aeb1c326-0288-4038-80bd-930f4fece31f"
      unitRef="usd">2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d1f9c79031447df9e15b07019606fd2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xMS0xLTEtMjM5NDEx_c03e88ef-1c25-4a35-b92e-794456ce8a15"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf15831fa01e491d9d2f254aaf0e9bf8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xMy0xLTEtMjM5NDEx_0ca6c464-67cf-40c4-be39-cff5d99c0c65"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i528f1cd91f784a078a7c3e4ef16b3444_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMS0xNS0xLTEtMjM5NDEx_55985940-f4ce-4553-9ac3-a3410b8645cd"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMi01LTEtMS0yMzk0MTE_adae4367-c321-48b6-bfc4-a627b0296ed4"
      unitRef="usd">320000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ib39a861394a24af5ae49b541f0fd87ca_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMi0xMy0xLTEtMjM5NDEx_a9eb0feb-6b99-483b-a78f-177fc9637966"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMi0xNS0xLTEtMjM5NDEx_de2907e5-b20c-47cd-aa0e-53488f403fa1"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMy0xMS0xLTEtMjM5NDEx_0e6f9199-6ee5-47d9-81e5-f637d88a0bc6"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfMy0xNS0xLTEtMjM5NDEx_5a148634-3ef5-4dab-ba82-e52ba1abb528"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS0xLTEtMS0yMzk0MTE_40907161-bfe6-4129-b598-a14d95486f9f"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS0zLTEtMS0yMzk0MTE_876c9805-670f-4b81-9ae0-9388c48ff03e"
      unitRef="usd">-25000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS03LTEtMS0yMzk0MTE_4e099819-a136-4af7-974e-7b68a9433b68"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS05LTEtMS0yMzk0MTE_627ed8ac-4b26-476f-8ba7-ed3a9ce6bcbe"
      unitRef="usd">43000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNS0xNS0xLTEtMjM5NDEx_66ad9e3d-b5d6-4363-bdb6-5c0047632939"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i259bb9c1afa447dea7842af296bc2ad3_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi0zLTEtMS0yMzk0MTE_ea46f8aa-93d0-41d7-8a9d-b61e2c0ec0b0"
      unitRef="usd">-60000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi03LTEtMS0yMzk0MTE_e5a59196-257b-4544-ad9a-9cfa2706f316"
      unitRef="shares">15000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi05LTEtMS0yMzk0MTE_446d3854-17cb-42f3-be28-76ec78bd52e4"
      unitRef="usd">740000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNi0xNS0xLTEtMjM5NDEx_9ce02fc8-75fe-4b31-8a78-01273fb0a8ce"
      unitRef="usd">800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i8fe3b2f7fe3245da8a78eda539a6ac00_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNy01LTEtMS0yMzk0MTE_67591953-90c7-4813-a24b-6b216b343163"
      unitRef="usd">280000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfNy0xNS0xLTEtMjM5NDEx_fce3ab6e-fa84-4d12-8c34-1c29885f2574"
      unitRef="usd">280000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xLTEtMS0yMzk0MTE_089b0317-2d6e-4056-a925-0fc490626f8e"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8599c52e33e549f7b725ed2b5877dbdd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0zLTEtMS0yMzk0MTE_0b27a40b-dd31-42d7-b4d1-c0fd44a174bf"
      unitRef="usd">2721000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b5ad5a75b004348981b5e5040141950_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS01LTEtMS0yMzk0MTE_01d6ed64-44ba-4b80-aaea-9c874eadf2fe"
      unitRef="usd">1245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS03LTEtMS0yMzk0MTE_4966af04-bb0d-4b3c-b984-7117d247a46f"
      unitRef="shares">50000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="id7d05ecda04046a0a137a84d7cd3374b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS05LTEtMS0yMzk0MTE_c2f29a9a-60a0-4d70-ace7-3e179e0695f1"
      unitRef="usd">2883000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i290a19fe2fb547e8a22f900e6d3bb92e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xMS0xLTEtMjM5NDEx_ea037516-d6be-4a9e-b017-9728e9b1e596"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe7e1aca3cfc4021b299e214f352264b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xMy0xLTEtMjM5NDEx_8cee1871-b87f-4e1e-abc5-19ae4fd1b03b"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic822fa03c99e4574898c49c9633bb752_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83My9mcmFnOjU4MTJmZmFlZTU3ZDQ0NWNiZjRmMThhNDdlMjkwMDZiL3RhYmxlOmRkZjg2MmExNjkwYzRmYjg4NzhiMDUwN2M0NjAzMDNiL3RhYmxlcmFuZ2U6ZGRmODYyYTE2OTBjNGZiODg3OGIwNTA3YzQ2MDMwM2JfOS0xNS0xLTEtMjM5NDEx_e08e6287-64fa-4280-a25a-8f075ad0849f"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMy0xLTEtMS0yMzk0MTE_95ae66c4-8c39-421a-b22a-661e5514b53d"
      unitRef="usd">-19000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMy0zLTEtMS0yMzk0MTE_2164d0b5-7f28-47fc-9284-3fb191b1463d"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNi0xLTEtMS0yMzk0MTE_33dac650-fcd9-40d8-8b91-9797106c614c"
      unitRef="usd">341000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNi0zLTEtMS0yMzk0MTE_81ca056f-5f1c-4269-9c0c-9ff4672658f8"
      unitRef="usd">332000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOC0xLTEtMS0yMzk0MTE_a89552eb-d1ec-4ffd-8486-27e36fceedd8"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOC0zLTEtMS0yMzk0MTE_b0991ac2-74b6-49e0-aa80-b6edbb9e8014"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOS0xLTEtMS0yMzk0MTE_ff106faf-bbcb-4077-a6cf-130357db93c0"
      unitRef="usd">-863000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfOS0zLTEtMS0yMzk0MTE_f0678b65-6e1e-4a6f-ba26-113324221b4f"
      unitRef="usd">-1293000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTAtMS0xLTEtMjM5NDEx_3bd48227-6d62-463c-aba7-b3bf096e329e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTAtMy0xLTEtMjM5NDEx_dc88ccf3-10c9-4866-a8d7-ab923845b935"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTEtMS0xLTEtMjM5NDEx_94a7dca4-cb47-4ada-a848-6303f1001f7e"
      unitRef="usd">48000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTEtMy0xLTEtMjM5NDEx_aa007112-854b-46fe-86ed-53b0ed116b62"
      unitRef="usd">42000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTMtMS0xLTEtMjM5NDEx_94e9b3a9-5f5d-4f63-a49f-1b564e607f51"
      unitRef="usd">59000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTMtMy0xLTEtMjM5NDEx_e30ca497-be88-404c-a2b8-ad9982f61fc2"
      unitRef="usd">25000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTUtMS0xLTEtMjM5NDEx_80750ba1-b521-4726-b341-9ca986daa2f2"
      unitRef="usd">919000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTUtMy0xLTEtMjM5NDEx_f540c22b-4424-495d-ae66-dc772b2822f0"
      unitRef="usd">329000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTYtMS0xLTEtMjM5NDEx_63c50ce2-5b27-49ab-824a-c1beb725ae14"
      unitRef="usd">1643000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTYtMy0xLTEtMjM5NDEx_a594b69b-b0b1-4a1f-9e2b-e21b8419940b"
      unitRef="usd">361000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTctMS0xLTEtMjM5NDEx_10eae775-a050-4e84-bc1a-de4a8e21d70c"
      unitRef="usd">2954000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTctMy0xLTEtMjM5NDEx_531f62cd-854e-41ae-802a-5cb8c94aa8a0"
      unitRef="usd">1059000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTgtMS0xLTEtMjM5NDEx_7019c340-cb4b-46b3-a15b-cdc4fadaa929"
      unitRef="usd">1064000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTgtMy0xLTEtMjM5NDEx_73a3ee3a-270e-4600-8166-225c81becbf0"
      unitRef="usd">1842000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTktMS0xLTEtMjM5NDEx_1a0fb993-386b-4659-9c09-a14fe1aa28b8"
      unitRef="usd">620000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMTktMy0xLTEtMjM5NDEx_e367d5ce-6648-4db4-a2f6-c5caa52024df"
      unitRef="usd">549000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjItMS0xLTEtMjM5NDEx_e4eaac40-408f-4d14-a0ed-a3e44566b101"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjItMy0xLTEtMjM5NDEx_11a977c4-a347-4f4d-ac18-39a4f0d2ed58"
      unitRef="usd">938000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjQtMS0xLTEtMjM5NDEx_e36e2f6b-9a22-43b7-8f62-28e4e752c4c6"
      unitRef="usd">155000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjQtMy0xLTEtMjM5NDEx_b81f3255-fea7-4188-b685-52171c981b5f"
      unitRef="usd">141000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMS0xLTEtMjU1ODEw_a92b97e1-da1d-47e5-a38c-8d845e43da1d"
      unitRef="usd">2000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMy0xLTEtMjU1ODE4_0f9d72ce-c8bd-487f-a5d7-05834796a17c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMS0xLTEtMjM5NDEx_e2468368-a058-46b6-a589-9a3232f6f633"
      unitRef="usd">5000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjUtMy0xLTEtMjM5NDEx_b5a28a60-73b5-4d9e-baff-6a1683b2c37a"
      unitRef="usd">4000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjYtMS0xLTEtMjM5NDEx_884d033a-c372-4e9d-9afc-b21fad3b407e"
      unitRef="usd">1000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjYtMy0xLTEtMjM5NDEx_07b5a812-9743-492c-8e32-bfa430180259"
      unitRef="usd">22000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjgtMS0xLTEtMjM5NDEx_93848862-7579-46de-be87-2369ae26031c"
      unitRef="usd">-157000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMjgtMy0xLTEtMjM5NDEx_de0212bd-74cd-414e-ae7c-336a90f7fe5e"
      unitRef="usd">815000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzMtMS0xLTEtMjM5NDEx_6df6a2d3-412c-4115-9151-8d975aa6e13a"
      unitRef="usd">13000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzMtMy0xLTEtMjM5NDEx_b80196b8-f5c6-46f9-b8ba-afcf0fec063d"
      unitRef="usd">592000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzQtMS0xLTEtMjM5NDEx_5879a336-0606-4623-bb8a-ea7cfb08fc47"
      unitRef="usd">9000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzQtMy0xLTEtMjM5NDEx_e610aba1-33da-43b4-8433-ab0f59c03572"
      unitRef="usd">-27000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzYtMS0xLTEtMjM5NDEx_9a1ffc1a-fab8-4583-af89-0178fabdd0b9"
      unitRef="usd">271000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzYtMy0xLTEtMjM5NDEx_3af0d2ba-fa7e-4073-8863-68d1edad33f6"
      unitRef="usd">289000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzctMS0xLTEtMjM5NDEx_faaf6ed1-6bf0-4c93-b403-8f36c6acaea7"
      unitRef="usd">1250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzctMy0xLTEtMjM5NDEx_6e4e0cfc-8c87-4d66-bb4b-3f56b28b41a5"
      unitRef="usd">800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzgtMS0xLTEtMjM5NDEx_3d2368c4-4d2e-44dc-a26f-35159d43d750"
      unitRef="usd">-1525000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfMzgtMy0xLTEtMjM5NDEx_e70dcf46-e25c-4fd1-8e8b-3b13cef37103"
      unitRef="usd">-1708000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDAtMS0xLTEtMjM5NDEx_6a88bd2f-c563-44f9-9fb1-9a0960b4bfe0"
      unitRef="usd">-1000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDAtMy0xLTEtMjM5NDEx_2a8a64b8-f9fd-41f3-bb96-e5ec650f2c88"
      unitRef="usd">-11000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDEtMS0xLTEtMjM5NDEx_863d58ec-76ec-4a50-af2a-b5c374740ef1"
      unitRef="usd">0</cah:CashReclassifiedToAssetHeldForSale>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDEtMy0xLTEtMjM5NDEx_7c8c217c-9567-43ff-ab29-f3d463760a69"
      unitRef="usd">109000000</cah:CashReclassifiedToAssetHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDMtMS0xLTEtMjM5NDEx_00b63499-b0ac-4ef3-be54-a5a2b3fab731"
      unitRef="usd">-1063000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDMtMy0xLTEtMjM5NDEx_62435c5f-6afc-4e08-aeed-780ab11b9f14"
      unitRef="usd">-246000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDQtMS0xLTEtMjM5NDEx_d6da3f72-f528-4421-b17d-a38e52a0d16f"
      unitRef="usd">4717000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i528f1cd91f784a078a7c3e4ef16b3444_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDQtMy0xLTEtMjM5NDEx_973cfdf1-a5b5-4b33-a06d-4280a6142b74"
      unitRef="usd">3407000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDUtMS0xLTEtMjM5NDEx_e773934c-36e2-4141-a1be-7c897832d7b6"
      unitRef="usd">3654000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic822fa03c99e4574898c49c9633bb752_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl83Ni9mcmFnOjMzZGZiMmIzNjg2NDQ1MWI5MmMwMTE1ZDk3NGRlYzliL3RhYmxlOjZmMzZiODEwYzEzNDQzNTFhYTc0MzA1ZmRiNDJmZjBlL3RhYmxlcmFuZ2U6NmYzNmI4MTBjMTM0NDM1MWFhNzQzMDVmZGI0MmZmMGVfNDUtMy0xLTEtMjM5NDEx_00858eab-0d38-4912-be7a-dfc6a9be9c24"
      unitRef="usd">3161000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84Mi9mcmFnOmU4NTc2ZjRjZTQwNjQ0ZmRiM2I1MWE2NjFhNDA2Mzg3L3RleHRyZWdpb246ZTg1NzZmNGNlNDA2NDRmZGIzYjUxYTY2MWE0MDYzODdfMzEwNA_94ce6e40-a404-413d-9fc0-01f216bb4258">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted during the six months ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84Mi9mcmFnOmU4NTc2ZjRjZTQwNjQ0ZmRiM2I1MWE2NjFhNDA2Mzg3L3RleHRyZWdpb246ZTg1NzZmNGNlNDA2NDRmZGIzYjUxYTY2MWE0MDYzODdfMzEwNQ_33752bb8-aa42-4b04-a9f7-ecf296b84901">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2022 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted during the six months ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84Mi9mcmFnOmU4NTc2ZjRjZTQwNjQ0ZmRiM2I1MWE2NjFhNDA2Mzg3L3RleHRyZWdpb246ZTg1NzZmNGNlNDA2NDRmZGIzYjUxYTY2MWE0MDYzODdfMzExNA_5ee03f48-7c2c-4fd5-8f5f-6c248f2cf98a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted during the six months ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84NS9mcmFnOmI3NmQxMTFkMzZlMTQyNTI4N2EzNTYzZGMxMDNlNzBjL3RleHRyZWdpb246Yjc2ZDExMWQzNmUxNDI1Mjg3YTM1NjNkYzEwM2U3MGNfNTc3_0d32b6cc-44ab-4cab-aa3a-6b716c8f0d97">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we sold the Cordis business to Hellman &amp;amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i495abb9913e04abfaa8f722b6757199b_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Cordis business operated within our Medical segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ia13be735cc2443ad8517d5f01b6bfd7e_D20210701-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84NS9mcmFnOmI3NmQxMTFkMzZlMTQyNTI4N2EzNTYzZGMxMDNlNzBjL3RleHRyZWdpb246Yjc2ZDExMWQzNmUxNDI1Mjg3YTM1NjNkYzEwM2U3MGNfOTA_c77e36c3-4fa5-4fdc-9c51-242843a0ca12"
      unitRef="usd">923000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RleHRyZWdpb246YTdhN2Q4NWFjYjJlNDliODg1YTUxMzY3ZWM3ZjZhMWVfMTAyOQ_a5893e16-b8cc-49d4-a63b-38ab5c182f12">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Restructuring and Employee Severance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring and employee severance costs during the three and six months ended December&#160;31, 2022 and December 31, 2021 were primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months and six months ended December 31, 2021, restructuring also included costs related to the divestiture of the Cordis business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RleHRyZWdpb246YTdhN2Q4NWFjYjJlNDliODg1YTUxMzY3ZWM3ZjZhMWVfMTAyNA_e4eded95-2aa4-4413-b218-d9741c31e783">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMi0xLTEtMS0yMzk0MTE_d01a1855-d009-418d-b71f-e39a240eb178"
      unitRef="usd">10000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMi0zLTEtMS0yMzk0MTE_56c5146f-23dc-45e0-a629-058692098251"
      unitRef="usd">2000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMy0xLTEtMS0yMzk0MTE_23de6889-a9c2-4127-892a-6ac81534f75b"
      unitRef="usd">7000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfMy0zLTEtMS0yMzk0MTE_e423cefe-e07f-48a3-8c85-1a408ab1bcd7"
      unitRef="usd">5000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfNC0xLTEtMS0yMzk0MTE_a220e1d6-8a36-40e9-b4c4-4cefab2e9f37"
      unitRef="usd">17000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOjFiOTMzZmM4ZGM1NjQ0YzM4MWVkMDBlOWNhOWIyMmU1L3RhYmxlcmFuZ2U6MWI5MzNmYzhkYzU2NDRjMzgxZWQwMGU5Y2E5YjIyZTVfNC0zLTEtMS0yMzk0MTE_82c3232a-1514-4065-98fe-3430d36c254c"
      unitRef="usd">7000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMi0xLTEtMS0yMzk0MTE_dc135264-4542-433e-a741-ae50037b33e8"
      unitRef="usd">29000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMi0zLTEtMS0yMzk0MTE_ca2cab2b-5365-442b-9ef0-444e0e3a4a65"
      unitRef="usd">10000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMy0xLTEtMS0yMzk0MTE_be6ae57d-3703-467d-aeed-670721e8757a"
      unitRef="usd">17000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfMy0zLTEtMS0yMzk0MTE_403b7d34-89da-4a30-9fe0-dc91f6376758"
      unitRef="usd">15000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfNC0xLTEtMS0yMzk0MTE_3f39bcae-5562-46a4-ab8c-4ee0b8b5d721"
      unitRef="usd">46000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmMxNGQ4MzgzMzViNzRmOTI4Nzk4YjRmMGJiZDhjMjJjL3RhYmxlcmFuZ2U6YzE0ZDgzODMzNWI3NGY5Mjg3OThiNGYwYmJkOGMyMmNfNC0zLTEtMS0yMzk0MTE_6d39e7cf-fd84-4778-8790-1157102b17e7"
      unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RleHRyZWdpb246YTdhN2Q4NWFjYjJlNDliODg1YTUxMzY3ZWM3ZjZhMWVfOTk5_8d423e95-2c88-4251-b02a-8c039d51722d">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i523d8d0b53df49998cdfaddd4b8eb78d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMS0xLTEtMS0yMzk0MTE_b3410712-40ef-41cb-b280-88529452cddf"
      unitRef="usd">56000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i6b132521391641bc9c8d883b436c870b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMS0zLTEtMS0yMzk0MTE_6c508c5c-c98b-47b9-9903-b413e21bc454"
      unitRef="usd">10000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMS01LTEtMS0yMzk0MTE_1c69736f-a181-45e5-ab03-9dd27fe20c9e"
      unitRef="usd">66000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i8e7e08834e134ea488b1bea977bd6b14_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMi0xLTEtMS0yMzk0MTE_3faf2aa8-a75d-4bb0-a6cd-8b99d67f1a28"
      unitRef="usd">25000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i475290592e5849d28bf81c8748343a28_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMi0zLTEtMS0yMzk0MTE_4626aefe-0868-4bf1-8e36-182c1139d942"
      unitRef="usd">5000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMi01LTEtMS0yMzk0MTE_ebe7e617-9cb5-4953-8afe-9dcbe0d86f55"
      unitRef="usd">30000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8e7e08834e134ea488b1bea977bd6b14_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMy0xLTEtMS0yMzk0MTE_8aa943f2-2c40-4090-8c72-d083ba34acfd"
      unitRef="usd">20000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i475290592e5849d28bf81c8748343a28_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMy0zLTEtMS0yMzk0MTE_60ffa7e4-0202-40c9-b97a-d0c7c6127018"
      unitRef="usd">13000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfMy01LTEtMS0yMzk0MTE_c8467fc3-7ce7-4c2a-a7c6-5a1f0527fdb3"
      unitRef="usd">33000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ia274dc691f4f4bcb857dc93d297598ae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfNC0xLTEtMS0yMzk0MTE_2ab7b697-1117-4842-bed1-3017673a2543"
      unitRef="usd">61000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i13c22619f98045b1971e6621d17e9cfb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfNC0zLTEtMS0yMzk0MTE_7d7cca85-37c3-426a-ac94-9a09fc658968"
      unitRef="usd">2000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl84OC9mcmFnOmE3YTdkODVhY2IyZTQ5Yjg4NWE1MTM2N2VjN2Y2YTFlL3RhYmxlOmViN2ZkMzg0NDNjODQ5NWRiYmVmZjEzYzQ3NzkwYTMwL3RhYmxlcmFuZ2U6ZWI3ZmQzODQ0M2M4NDk1ZGJiZWZmMTNjNDc3OTBhMzBfNC01LTEtMS0yMzk0MTE_95c0b35a-6128-49b4-9a90-02cbaf1af108"
      unitRef="usd">63000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI1OA_de4d68db-3e76-4585-8092-68436655ca67">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At December 31, 2022 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to certain reductions in our long-term financial plan assumptions made during the three months ended December&#160;31, 2022, including those related to Cardinal Health branded medical products sales growth, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in a pre-tax goodwill impairment charge of $709 million. The impairment charge recognized during the three months ended December&#160;31, 2022 was driven primarily by the impact of the reductions in our long-term financial plan assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit, which resulted in a pre-tax goodwill impairment charge of $154 million driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for six months ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our determinations of the estimated fair value of the Medical Unit at December 31, 2022 and at September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approaches. For the income-based approach, we used discount rates of 10.5 percent for both periods. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Medical Unit at December&#160;31, 2022 after recognizing the impairment charges was $6.2&#160;billion, of which $1.1&#160;billion was goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unit exceeding the fair value, resulting in a pre-tax impairment charge of $1.3 billion recorded during the three months ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;429&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,817&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,621&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,828&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Total amortization of intangible assets was $71 million and $79 million for the three months ended December 31, 2022 and 2021, respectively, and $142 million and $157 million for the six months ended December&#160;31, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $147 million, $260 million, $235 million, $208 million, and $176 million.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI1Mw_9c913480-4653-4a88-b297-9e00267c215d">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At December 31, 2022 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i836db9f721d446698908e590540d9d99_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMS0xLTEtMS0yMzk0MTE_ebcc70c5-39a5-447b-bb47-7a5986ec30e1"
      unitRef="usd">2673000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia1a10ebe6fcd4445a59847a469e7153a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMS0zLTEtMS0yMzk0MTE_026e4ffb-76c9-4218-bb4b-b486b21b76aa"
      unitRef="usd">3182000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMS01LTEtMS0yMzk0MTE_d54d3efb-2c35-451f-8ba7-db58c233e4c4"
      unitRef="usd">5855000000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i81a9117e94ff40d2bd8130cb4f715ba9_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMy0xLTEtMS0yMzk0MTE_8254f815-016e-481b-8257-45cfabcbd2e9"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMy0zLTEtMS0yMzk0MTE_6a9d46a7-a962-4978-8dc9-3c8202a7ae2c"
      unitRef="usd">-6000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfMy01LTEtMS0yMzk0MTE_7b6b974a-a509-4135-b9e3-bbcc836c3506"
      unitRef="usd">-6000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i81a9117e94ff40d2bd8130cb4f715ba9_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNC0xLTEtMS0yMzk0MTE_c4d3ec98-9aa4-4aca-9000-3251ba416713"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNC0zLTEtMS0yMzk0MTE_ad68f552-efab-4e10-94e1-8e98bbb4ed24"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNC01LTEtMS0yMzk0MTE_9860b10d-af68-4d1b-b5c8-44ec1a7e374e"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i4f6d35fed34747f8a4556dea55894e83_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNS0xLTEtMS0yMzk0MTE_0dd54616-d05a-4c50-8a7e-86f290bb7a66"
      unitRef="usd">2673000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie79455390cc9409c9303f326b67ebbc3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNS0zLTEtMS0yMzk0MTE_7137286f-2fe7-4373-920d-d92a8bb67ff8"
      unitRef="usd">2313000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjQ5OGMyNDVjMDc0ODQwZmNhMzk4MzBkYjUxMWU5ZjE0L3RhYmxlcmFuZ2U6NDk4YzI0NWMwNzQ4NDBmY2EzOTgzMGRiNTExZTlmMTRfNS01LTEtMS0yMzk0MTE_19150c8b-d3b7-45da-bf8f-11a5d126182a"
      unitRef="usd">4986000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ie79455390cc9409c9303f326b67ebbc3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMzI5ODUzNDg5ODA0OA_7bdc2808-8240-4599-a5e0-110ecaed554a"
      unitRef="usd">4400000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ia1a10ebe6fcd4445a59847a469e7153a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMzM4_37c4c6b7-40ae-46ea-a892-f7cf9302c328"
      unitRef="usd">3500000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id0a29845f22449af9631745d9999727d_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg1Mw_ee3267cb-d58b-4062-989b-16c20725d338"
      unitRef="usd">709000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8beab44640464040a492325d59503158_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg3MA_005372ac-ce8a-48b7-963e-1e9bef1fbdbc"
      unitRef="usd">154000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id4f9a42e1935451e96323fbc875dff5b_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjE1Mg_ad68f552-efab-4e10-94e1-8e98bbb4ed24"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="ide09dd2c95024e149104c6f4bcda4a02_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg4MQ_1b24d02a-4734-4d69-8995-c984d721705d"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="ifccdd71418e045be8ce53738fb5ba2d9_D20221001-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNzY5NjU4MTQxMjg4MQ_c939d8e5-f481-4a70-8296-45874c16306c"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="ifccdd71418e045be8ce53738fb5ba2d9_D20221001-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjc0ODc3OTA5MDY1OQ_73ee467f-aaec-43a2-b7a0-cb338acd3e55"
      unitRef="number">0.105</cah:DiscountRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="ide09dd2c95024e149104c6f4bcda4a02_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjc0ODc3OTA5MDY1OQ_f9c3e149-d32b-4f26-a5b1-246371c54805"
      unitRef="number">0.105</cah:DiscountRateFairValueInput>
    <us-gaap:AssetsNet
      contextRef="iad984dddf58244a2a17c059113ad4369_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNTQ5NzU1ODIyOTQ5_a894f7b6-bcba-4d1d-9474-8e805ec956bb"
      unitRef="usd">6200000000</us-gaap:AssetsNet>
    <us-gaap:Goodwill
      contextRef="iad984dddf58244a2a17c059113ad4369_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfNTQ5NzU1ODIyOTYw_9e36c2e5-d69f-4689-9687-8b7a71ff2cb6"
      unitRef="usd">1100000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id6147059e6e0467e9b1f3c9a0643b5d0_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjc0ODc3OTA4NDA3MQ_2e8374fb-6a52-4e7c-bfce-d1e8a1a51824"
      unitRef="usd">1300000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI3OQ_cb3a8143-a0c6-4bb3-b257-12fb9addaad7">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;429&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,817&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,621&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,828&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9c55cf57cc3e400ba40a7f5c2c90d462_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMy0xLTEtMS0yMzk0MTE_9ca6ef26-c597-4b06-9762-d5cabbd9b704"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9c55cf57cc3e400ba40a7f5c2c90d462_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMy01LTEtMS0yMzk0MTE_5f60d205-e9af-447a-ad66-f2bee7f46f84"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNC0xLTEtMS0yMzk0MTE_36a4a21e-61df-42ae-8cf5-e6370184f993"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNC01LTEtMS0yMzk0MTE_84278d84-7444-4d31-bc97-f3c294b449af"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5e03b79450bc414da77871d9a0b3342a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy0xLTEtMS0yMzk0MTE_10a0913c-2e28-4987-b850-8eebfc4a45a6"
      unitRef="usd">3234000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5e03b79450bc414da77871d9a0b3342a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy0zLTEtMS0yMzk0MTE_c3d23d64-62c0-4bfe-88b4-6ee5d64393b3"
      unitRef="usd">2220000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5e03b79450bc414da77871d9a0b3342a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy01LTEtMS0yMzk0MTE_32765eb5-adb2-4751-b228-9862398914e5"
      unitRef="usd">1014000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i853d1ecaadc74fa8866bcbc54f79d535_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfNy03LTEtMS0yMzk0MTE_7280f25e-2731-4dcb-807e-95a141e827e2">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i99f6c43c451644d383f95dc9f5e104b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC0xLTEtMS0yMzk0MTE_b24b624b-cb4d-4e59-afd2-104285333208"
      unitRef="usd">547000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i99f6c43c451644d383f95dc9f5e104b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC0zLTEtMS0yMzk0MTE_4486dfaf-41fe-4ebb-be05-64fe026e7311"
      unitRef="usd">369000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i99f6c43c451644d383f95dc9f5e104b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC01LTEtMS0yMzk0MTE_89c4d58f-e218-443d-8e57-fcd7cdbded17"
      unitRef="usd">178000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="icec642004b7b430895d25f293ecb4289_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOC03LTEtMS0yMzk0MTE_3f6443bc-c503-4981-b486-ca927071a373">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1971f99a0cc54e75a27067d61f454662_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS0xLTEtMS0yMzk0MTE_34bf560c-3126-4d57-88cf-5acdf730c3be"
      unitRef="usd">1036000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1971f99a0cc54e75a27067d61f454662_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS0zLTEtMS0yMzk0MTE_918e3e94-5b9d-452c-ad92-3793a3e3b4b1"
      unitRef="usd">607000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1971f99a0cc54e75a27067d61f454662_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS01LTEtMS0yMzk0MTE_75516f76-f15a-436c-9551-5dcbbd52a45f"
      unitRef="usd">429000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i77c92c96b759468d918e57bbb8cd0fa2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfOS03LTEtMS0yMzk0MTE_e84205c1-60b6-4295-b462-1e6e5602464d">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtMS0xLTEtMjM5NDEx_605e26a3-58ff-4a07-9eb5-b7ae0874c10c"
      unitRef="usd">4817000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtMy0xLTEtMjM5NDEx_3392a25a-d783-4bae-b502-75aedc0e2ba1"
      unitRef="usd">3196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtNS0xLTEtMjM5NDEx_440e104e-1bc7-4942-a159-d46512e5e2de"
      unitRef="usd">1621000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTAtNy0xLTEtMjM5NDEx_c3719ea1-d3dc-44d5-8357-df644078569f">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTEtMS0xLTEtMjM5NDEx_309f513f-ef10-4177-9a32-8f20dfff6313"
      unitRef="usd">4828000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTEtMy0xLTEtMjM5NDEx_d66afd1e-34f4-418b-b12b-ada94bc9f942"
      unitRef="usd">3196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjE3M2MyMmY4ZjZiMTRhNGY4NjI3YjI3NmE4MWI4OTMyL3RhYmxlcmFuZ2U6MTczYzIyZjhmNmIxNGE0Zjg2MjdiMjc2YTgxYjg5MzJfMTEtNS0xLTEtMjM5NDEx_94bedb0a-e59f-4338-b1f4-51a937f6f2bf"
      unitRef="usd">1632000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7840a9e9f47f44cf9155eef621b95d6e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMy0xLTEtMS0yMzk0MTE_be56e0c6-29ba-4ccd-9c92-70d69d47d496"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7840a9e9f47f44cf9155eef621b95d6e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMy01LTEtMS0yMzk0MTE_6cb93e39-57c4-4826-8ec4-a66f027d7835"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNC0xLTEtMS0yMzk0MTE_0b3e88af-6278-421e-aeb2-83fa20f28d79"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNC01LTEtMS0yMzk0MTE_f816f17f-26ad-4071-b903-87e49abe45ad"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNy0xLTEtMS0yMzk0MTE_4a1d8bf4-15cb-4bc9-9110-4811721cbf4a"
      unitRef="usd">3272000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNy0zLTEtMS0yMzk0MTE_65ef54d9-41ec-4b18-8e06-b2befa18f8cc"
      unitRef="usd">2165000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8f0ff02f5b7e4fe2af7af1b00ce36845_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfNy01LTEtMS0yMzk0MTE_0074c2ed-6887-4e73-8872-e6b61acc24a9"
      unitRef="usd">1107000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i08bfa4932993472cbbd06d16e11a6bc3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOC0xLTEtMS0yMzk0MTE_f0a16f4d-bc6e-4573-9526-13745ce1d76b"
      unitRef="usd">552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i08bfa4932993472cbbd06d16e11a6bc3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOC0zLTEtMS0yMzk0MTE_12070f74-6b31-41fa-8c1a-d1cad2181b2d"
      unitRef="usd">360000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i08bfa4932993472cbbd06d16e11a6bc3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOC01LTEtMS0yMzk0MTE_8fc2029f-810c-4843-8459-d1f516b128db"
      unitRef="usd">192000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iff33151f7630485aa41a66d9a893641d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOS0xLTEtMS0yMzk0MTE_ea8d00e9-c248-4047-8202-62dad08d91d7"
      unitRef="usd">1038000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iff33151f7630485aa41a66d9a893641d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOS0zLTEtMS0yMzk0MTE_eac44a41-a4df-40d7-bb2c-82b37c653ef8"
      unitRef="usd">574000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iff33151f7630485aa41a66d9a893641d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfOS01LTEtMS0yMzk0MTE_ead8b15f-fb9e-4389-974b-af0249e53292"
      unitRef="usd">464000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTAtMS0xLTEtMjM5NDEx_1bfbeb1a-758b-41d9-a19d-4a772d99b637"
      unitRef="usd">4862000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTAtMy0xLTEtMjM5NDEx_4ff77423-35cf-415c-9c4d-9b0078e4e77c"
      unitRef="usd">3099000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTAtNS0xLTEtMjM5NDEx_eea5182e-d73e-4191-ab89-ee78ca416479"
      unitRef="usd">1763000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTEtMS0xLTEtMjM5NDEx_05952cf2-22fa-45b0-89fc-2cfffe8258c0"
      unitRef="usd">4873000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTEtMy0xLTEtMjM5NDEx_619a0329-7a86-4607-b660-9a8563b1e2c8"
      unitRef="usd">3099000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RhYmxlOjhhOGVlZjM2N2MxYjQwZWFiNzYwZTcxZjQyY2JlNzE5L3RhYmxlcmFuZ2U6OGE4ZWVmMzY3YzFiNDBlYWI3NjBlNzFmNDJjYmU3MTlfMTEtNS0xLTEtMjM5NDEx_95012950-0820-4beb-86cc-70865c901cbe"
      unitRef="usd">1774000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjAxMA_860695c2-b48b-404f-b660-6f0f329262f4"
      unitRef="usd">71000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjAxNw_62ef59e7-6820-4743-816d-2476a91335c2"
      unitRef="usd">79000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjA3Ng_0055c6be-b3a7-49b3-a7cd-fffc131e988d"
      unitRef="usd">142000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjA4Mw_4940fc5b-6236-494c-bec6-dafcdffb0581"
      unitRef="usd">157000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjIzMA_82527b48-5835-43f6-a056-95beb5d7e9af"
      unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjIzNA_525f6910-504f-41f3-b5a0-4cd8b61c2b5a"
      unitRef="usd">260000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjIzOA_afabacec-db33-4e65-ac4b-c9721bd504f9"
      unitRef="usd">235000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI0Mg_9efcd5b7-ae05-4e75-8f31-2534cea72cf5"
      unitRef="usd">208000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl85MS9mcmFnOjY0NTVjYWJlY2I3NDQyZDE4NjMxMDcwODFiYmFmOGE0L3RleHRyZWdpb246NjQ1NWNhYmVjYjc0NDJkMTg2MzEwNzA4MWJiYWY4YTRfMjI1MA_5b535414-0340-4af0-bdfb-69abf7b9301e"
      unitRef="usd">176000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzI1MDg_7a3aaeee-8b20-4292-a413-e8e119d1d277">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Long-Term Obligations and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both December&#160;31, 2022 and June&#160;30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $30.1 billion and $27.1 billion at December&#160;31, 2022 and June&#160;30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2021, we redeemed all outstanding $572&#160;million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2025. CHF was organized for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. &lt;/span&gt;&lt;/div&gt;Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2022, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <cah:TotalLongTermandShortTermObligations
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1Nw_8fc7d3c1-5e40-4d2a-904a-8245a754801c"
      unitRef="usd">5300000000</cah:TotalLongTermandShortTermObligations>
    <cah:TotalLongTermandShortTermObligations
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1Nw_9ef417a3-b3a0-46cc-baa6-93c8048e0045"
      unitRef="usd">5300000000</cah:TotalLongTermandShortTermObligations>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzU1MA_a2d78eba-ba6f-4f27-a908-a03fcfcfa7e9"
      unitRef="usd">30100000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzU1Nw_aac92ce6-ec9e-4cb2-a60f-d11adf57c7c2"
      unitRef="usd">27100000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i9eaa1547e5534d768ea3ed534ba2e362_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzQzOTgwNDY1MTM4ODU_c96d3e43-80e5-46de-ad00-786162e9030a"
      unitRef="usd">572000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9eaa1547e5534d768ea3ed534ba2e362_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzg4MA_0e542875-de6d-499f-a577-7abc3a26fea5"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i04d33ee800e348859d151250d6109ee0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE0MTU_82352518-5840-4d07-9370-c5bed4131887"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0293a455c0be418f9e6ccdf022c16c57_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE0NTU_d8dd7fc7-c384-4c71-bb24-bcea46916122"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6f7465ce88c1440a986aade3262014dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1MDA_8fab217d-2197-4461-87a4-09f65049e68e"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i91b17012c22f40f393b25ec61b1315d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDAvZnJhZzpkYjI5ZmQ2YmE0ZTY0MjUyYWQwZmU0NjY0NzI2MWI0Yy90ZXh0cmVnaW9uOmRiMjlmZDZiYTRlNjQyNTJhZDBmZTQ2NjQ3MjYxYjRjXzE1NTU_d1820557-bd8f-495b-ae2f-761c1d2ab07a"
      unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMjk_c0a88e7f-3a09-4e78-8597-fbf7ba23b5a9">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. In the second quarter of fiscal year 2022, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. At June 30, 2022, we had an accrual of $20&#160;million, which represented our estimate of our portion of the assessment for calendar year 2018. Du&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ring the three and six months ended December&#160;31, 2022, we recorded $6&#160;million of income to reduce this accrual to the invoiced amount for the calendar year 2018 assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;National Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;claims brought by states and political subdivisions. This Settlement Agreement became effective on April 2, 2022. In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160&#160;million to the State of Washington and its participating subdivisions and approximately $95&#160;million to the State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. Each of Washington and Oklahoma is now subject to the Settlement Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Distributors, parties to the Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Settlement Agreement, we agreed to pay up to approximately $6.3&#160;billion. The Settlement Agreement also includes injunctive relief terms related to distributors&#x2019; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions, including the Attorney General for the State of Alabama, and we intend to defend ourselves vigorously against all remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December 31, 2022, we made our second annual payment of $372&#160;million under the Settlement Agreement. In total, we have $5.89&#160;billion accrued at December&#160;31, 2022, of which $480&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Settlements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgement in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 468 lawsuits as of January 31, 2023. Of these, 88 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial began in January 2023. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. In the three months ended December 31, 2022, we received approximately $10&#160;million in insurance recoveries related to these matters; however, we &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have not recorded a receivable for any additional recoveries as of&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis IVC Filter Matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January 31, 2023, we are named as a defendant in approximately 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,161 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 3 lawsuits involving similar claims by approximately 3 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These lawsuits seek a variety of remedies, including unspecified monetary damages. Since July 2021, we have entered into agreements to settle approximately 2,885 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized net income of $46&#160;million and $25&#160;million during the three and six months ended December&#160;31, 2022, respectively, to reduce the reserve for the estimated settlement and defense costs for these matters due to certain claim settlements and to reflect insurance recoveries received in the quarter. At December&#160;31, 2022, we had a total of $471&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $826&#160;million. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the intended complaint. We are vigorously defending ourselves in this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust Litigation Proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we received net cash proceeds resulting from the settlement of a lawsuit in which we were a class member or plaintiff of $66&#160;million, which was recognized in litigation (recoveries)/charges, net, during the three months ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;In December 2021, the parties reached an agreement in principle to settle this matter. In October 2022, a court entered an order approving the settlement and dismissing the case. The settlement does not include any admission of liability. Under this settlement, in December 2022, Cardinal's director and officer's liability insurance carriers, on behalf of the defendants, paid Cardinal Health $124&#160;million, less approximately $31&#160;million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal received net cash proceeds resulting from this settlement of $93&#160;million, which was recognized in litigation (recoveries)/charges, net, during the three months ended December 31, 2022.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i4d3712b011c34b738780dc9362b76df4_D20140731-20140731"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI1NA_4ae429d7-e79f-47f7-ab9b-b893ded255b5">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:AggregateAnnualAssessment
      contextRef="if66c1d6e3cbf4381a0bd67de03e24ce5_I20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzcwOQ_6521d980-fd53-4efb-99db-55f0a49d31e3"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i4e6c3fc3e6e2445aa4d9200c41eef841_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIxMjY_4268e126-2ee6-4138-ab89-606c4e067319"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ibf33963c011d47cea39c41f3cb3e98cf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIyNDA_a65b3cd2-8b9b-49e8-8543-e2fb74966694"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
      contextRef="if5c45c8e827040f492eecfcaf9019804_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0MjM_688369ee-e3bb-40f3-8952-add46d009360"
      unitRef="usd">-6000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <cah:JudgmentForLostProfits
      contextRef="i993e4902e3144a5bb0fd1d2340dcc042_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzU5Mzg_8924e588-482e-42a8-aaa4-604a56666781"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i81b5f38455cd438ea15b1ba793e7d1e9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUxNDU_6d6b13af-fa69-4d99-922a-14c8ca3fe117"
      unitRef="usd">160000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ib5158c69b2f141aba7524064bfe8f0df_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUxNTk_f3f689d6-55f2-4788-95a0-74528bf0a35a"
      unitRef="usd">95000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <cah:SettlingStates
      contextRef="ic809c76f51ee4ec1a6f716add527ca16_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIyMzY5_db63aee8-a9c6-4e5e-a9cb-09259837dc6d"
      unitRef="states">48</cah:SettlingStates>
    <cah:SettlingUSTerritories
      contextRef="ic809c76f51ee4ec1a6f716add527ca16_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzIyMzY1_4f4001c9-7aa6-46ca-9a3b-5e8438c65e45"
      unitRef="numberofusterritories">5</cah:SettlingUSTerritories>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i18fb106b5e6f449d8ae9790879d1da5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMDI_bf44c349-6dbc-443a-894d-8c6d1a16faf8"
      unitRef="usd">6300000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i139081ab99184a1f8b7e1b9c76f62c72_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMTY_bcb121ac-3fd8-4bf8-9abb-d85d4cd2d17c"
      unitRef="usd">372000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationReserve
      contextRef="i18fb106b5e6f449d8ae9790879d1da5d_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxMzk3OTY_364b5997-5b11-4a78-b0f9-20ea38ad990f"
      unitRef="usd">5890000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserveCurrent
      contextRef="i18fb106b5e6f449d8ae9790879d1da5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxMzk4MjU_5e74104c-30fc-4a95-8af6-b8500c8ecbf5"
      unitRef="usd">480000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i40b411ebb5184bb1a9dfd35919f25b3e_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyMzM_c7c69680-b23d-47e8-ae8f-fb9388f5ea8c"
      unitRef="usd">124000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i361a1cbfafd442128bda3c3659c07e1c_I20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyNDc_911494e6-3794-4b92-b9a0-0d9b63905ccc"
      unitRef="usd">136000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i4e839715483343b29b2118fba97d1b13_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzQzOTgwNDY1ODMxODU_a08f05c9-92f3-48b2-8a16-eb80e23734ba"
      unitRef="lawsuit">468</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="ia8e0dc33321a4c17baac9c92c4b2a3cb_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE0OTc3_094516c8-c145-472c-a004-6a2cddfda952"
      unitRef="lawsuit">88</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i68386e21f9e742fb969736106a1cbf00_D20220701-20220731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE1MTQw_4fe49892-341e-47fb-b9a3-a4b93c293f98"
      unitRef="plaintiff">21</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i962de220c39d41c99fd21cc23e3bda11_D20230131-20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0OTA_01628af8-ebba-45a4-8255-302578640f8c"
      unitRef="plaintiff">8</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:InsuranceRecoveries
      contextRef="iabd7dc7bfc674ee0ae21b5962987f975_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0NzY_2927da29-9298-4aa3-b19e-f5cdef54d024"
      unitRef="usd">10000000</us-gaap:InsuranceRecoveries>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ifd8168246fc242c59a3f7bb52d90228b_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2Mzk0_dfa5eaf8-4cc1-4a8d-92cc-a726066a41c1"
      unitRef="lawsuit">450</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i0a59fc36d30d420c8aa97be0a9b2a640_D20230131-20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2NTE3_4dae9ea4-3d72-4f9b-990f-0db4b0086757"
      unitRef="plaintiff">5161</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i525578e0fcdf4038a90e4f5d3e79ded2_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2NjY4_4bdeaf78-98f4-434c-bd3b-8575ded7314b"
      unitRef="lawsuit">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ic9944beac48f4f9980659c2177de1820_D20230131-20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE2NzIy_f1d07c9f-623f-4471-8c9b-d8967125309f"
      unitRef="plaintiff">3</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i581bdde63b994b5da0099ea58092e0c5_D20210701-20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzQzOTgwNDY1ODMwNzc_5ab0898e-69c7-49d9-9f89-db8c899d6f1d"
      unitRef="lawsuit">2885</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:ProductLiabilityAccrualPeriodExpense
      contextRef="i7b5c5c45933b48ec82b48e22389cf840_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0NTA_ffbb6e19-2991-4be1-94ac-30b74004fdba"
      unitRef="usd">-46000000</us-gaap:ProductLiabilityAccrualPeriodExpense>
    <us-gaap:ProductLiabilityAccrualPeriodExpense
      contextRef="i527029a879204a469f1592c5d337a7a1_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0NjM_b51d23a7-f6a1-448a-9b7e-53c7b68a2128"
      unitRef="usd">-25000000</us-gaap:ProductLiabilityAccrualPeriodExpense>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0c141cd1d64f4c09ad35c5e008a7f485_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE3MDk0_980b462c-7ac3-420d-8203-48b235346f7e"
      unitRef="usd">471000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="icdf7ff2e260e4c10b571e6c980ad3111_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzE3NTUw_4aca3243-37ef-4cff-8c08-e32a096f49c7"
      unitRef="usd">826000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <cah:IncomefromSettlementsofClassActionLawsuits
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyNjE_e9a36b3d-0832-4f5c-8f68-3462a9de8791"
      unitRef="usd">66000000</cah:IncomefromSettlementsofClassActionLawsuits>
    <cah:GrossInsuranceSettlementBeforeAttorneyFees
      contextRef="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzI3NDg3NzkxNDE0MzY_86264aaf-37eb-4a9d-a88c-057f56fede5b"
      unitRef="usd">124000000</cah:GrossInsuranceSettlementBeforeAttorneyFees>
    <us-gaap:LegalFees
      contextRef="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyNzU_7670cc77-5a3d-4e19-a71e-87effbf14dcf"
      unitRef="usd">31000000</us-gaap:LegalFees>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i71c14d4d7fb6446ead492be19210b310_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDMvZnJhZzoyNTc3NTQyNDgwYTg0ZDJkODZlNTFlMDE1NzI3ODAzMy90ZXh0cmVnaW9uOjI1Nzc1NDI0ODBhODRkMmQ4NmU1MWUwMTU3Mjc4MDMzXzMyOTg1MzQ5NTUyODg_904b919e-ccc3-4ec3-8958-4e87731b47cd"
      unitRef="usd">93000000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzkwODA_c7ec0864-9470-4e95-ba1b-1c68fa7bf516">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax earnings/(loss) (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended&#160;December&#160;31, 2022, the effective tax rate was&#160;5.4 percent and&#160;30.0 percent, respectively, and reflects the impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended&#160;December&#160;31, 2021, the effective tax rate was 105.0 percent and 153.1 percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charge recognized during the three and six months ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Goodwill Impairment Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2022, we recognized pre-tax goodwill impairment charges of $863&#160;million related to the Medical Unit. The net tax benefit related to this charge is $68&#160;million for fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effect of the goodwill impairment charges during the six months ended December 31, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax loss for the six months ended December&#160;31, 2022 resulted in recognizing an incremental interim tax benefit of approximately $140&#160;million, which impacted &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the six months ended December&#160;31, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheet at December&#160;31, 2022. This incremental interim tax benefit will reverse in the future quarters of fiscal 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $1.0 billion and $943 million of unrecognized tax benefits, at December&#160;31, 2022 and June&#160;30, 2022, respectively. The December&#160;31, 2022 and June&#160;30, 2022 balances include $889 million and $858 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and June&#160;30, 2022, we had $56 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $120 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $78 million and $75&#160;million at &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;December&#160;31, 2022 and June&#160;30, 2022, respectively, and is included in other assets in the condensed consolidated balance sheets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzMzMw_77a09c5d-f82a-4269-9623-ed43fa8e19be"
      unitRef="number">0.054</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzM0MA_36b43e92-ab42-4b3b-8a8f-fadf2d61fe2e"
      unitRef="number">0.30</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzU0OA_0f35be0e-5905-46ce-8b29-4f6ae4968804"
      unitRef="number">1.05</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzU1NQ_317d6d59-1b7d-4bd6-bc17-6bd817635f6e"
      unitRef="number">1.531</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2c0539d106574706b4942868128b486d_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzExMTQ_2cfe9942-9863-402b-989d-f480e49dc794"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i350fbf1a37334d5289dc88528245bdb4_D20220701-20230630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzEyMTk_9070ac86-3be3-4dd6-9765-f10bdeba319f"
      unitRef="usd">68000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i95fe2ba8ed3a44abadfb859ec9e251e4_D20230101-20230630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzIyOTQ_d176074a-17aa-4692-ac2c-d8d650a03a1d"
      unitRef="usd">140000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYxNjU_552397f6-2fec-4ecb-8f08-136c5c16bcb8"
      unitRef="usd">1000000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYxNzI_ba962f52-d079-4391-8727-176f859d580e"
      unitRef="usd">943000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYyNjM_b6fe8b24-0fc7-457a-86b9-1c4ae758ce56"
      unitRef="usd">889000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzYyNzA_2a57434e-ae39-4647-95b2-bb9a55a9c13d"
      unitRef="usd">858000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzY0MDc_283cc47c-b951-41d4-a01a-75547b1b416e"
      unitRef="usd">56000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzY0MTQ_8c473609-cf88-4bec-a66f-f8237514fca8"
      unitRef="usd">48000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="icd31a13676b345b183f5ced501f7ae50_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzcyNjM_47a81377-f7f2-44d6-ba1d-adefd66e516a"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="id9b861e2d5ac4b82a144a3b79ab22e81_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzcyOTQ_82008ead-e619-48ac-880f-b98e952dcfa0"
      unitRef="usd">120000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <cah:IndemnificationReceivable
      contextRef="i3459c970df844cf2a1ee3095599f0255_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzg2MDA_6b9b32cb-b753-4b33-b94a-f52dd8b07a49"
      unitRef="usd">78000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i4ced27bfe4894fc6803e626c517f05b7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDYvZnJhZzphMjFlZTNlMDE4ZjY0NjdmYTA2MmUwN2JjMzQwZGY2ZS90ZXh0cmVnaW9uOmEyMWVlM2UwMThmNjQ2N2ZhMDYyZTA3YmMzNDBkZjZlXzI3NDg3NzkwODQxMzk_53d10ec0-d93a-4827-b785-55db4f66c8bb"
      unitRef="usd">75000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90ZXh0cmVnaW9uOmM5NjhiYjA0ODAzMDRiYWZhOThkMzg3ZjRlYjEwMzBmXzEyMzA_f02e4cac-9403-412f-a229-d18cc827013b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90ZXh0cmVnaW9uOmM5NjhiYjA0ODAzMDRiYWZhOThkMzg3ZjRlYjEwMzBmXzEyMjQ_ab050594-01c2-4f9a-bc78-fa34c0fb410f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iac76a749b153465ab4af13b1df78d72a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtMS0xLTEtMjM5NDEx_e1decc22-21b4-411f-a874-86e702a00641"
      unitRef="usd">1146000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtMy0xLTEtMjM5NDEx_550ef176-9bc9-447a-b5cb-3a1dc71f0af4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5c199cfd03a3434fb2252f5f91cf4519_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtNS0xLTEtMjM5NDEx_13d3c073-2553-4e26-9e69-7f0fa3532a16"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzMtNy0xLTEtMjM5NDEx_8d098450-ed69-4af7-8d57-681c0a94d3fb"
      unitRef="usd">1146000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iac76a749b153465ab4af13b1df78d72a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtMS0xLTEtMjM5NDEx_4a75e96d-c250-4f13-98e5-b54cb19de3a0"
      unitRef="usd">94000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtMy0xLTEtMjM5NDEx_8a8cc1d0-db9a-442d-95de-7f8b2429fb9d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5c199cfd03a3434fb2252f5f91cf4519_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtNS0xLTEtMjM5NDEx_a9a6397f-a85c-4dac-bd97-f57a81c2ec94"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzUtNy0xLTEtMjM5NDEx_02b2c574-8943-400c-8256-ef4af1a49df7"
      unitRef="usd">94000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="iac76a749b153465ab4af13b1df78d72a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtMS0xLTEtMjM5NDEx_ee0ea07c-ae90-422f-ab65-48693dc2a34c"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i6da373f7d01f4c34b35d5d1e2f40db0a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtMy0xLTEtMjM5NDEx_6fb7b9a9-116a-4200-984a-4af0700a0b69"
      unitRef="usd">-48000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i5c199cfd03a3434fb2252f5f91cf4519_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtNS0xLTEtMjM5NDEx_c714a56d-3e65-4346-883f-b2c1d661d352"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i47e19d8b09ce4d819512bc1e56ff8edd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTphZTJiYWM0ODc4YTY0OGQ3YWYwZGE2NTE3NDY3MWRmYS90YWJsZXJhbmdlOmFlMmJhYzQ4NzhhNjQ4ZDdhZjBkYTY1MTc0NjcxZGZhXzgtNy0xLTEtMjM5NDEx_3ab779a3-e33d-4264-b613-44b3e4bfcf5d"
      unitRef="usd">-48000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia9bf45fc47f34b519bcb944cf300f764_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtMS0xLTEtMjM5NDEx_95bb8cb5-509f-4b7e-82e2-1a46cd05e41d"
      unitRef="usd">2425000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i28968af686284bf28e66c81f371858ae_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtMy0xLTEtMjM5NDEx_5719a57b-1633-4f11-b0f4-2201b6e8bb32"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7e3e9a1753b947c98746cbb0141dc97f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtNS0xLTEtMjM5NDEx_9ff26152-ad8d-4d3f-9510-f21d32b1ebc1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1f983f7d518449f5badd677106e20d44_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzMtNy0xLTEtMjM5NDEx_42c2db75-32a9-4889-b2aa-39e9c17b5fb8"
      unitRef="usd">2425000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia9bf45fc47f34b519bcb944cf300f764_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtMS0xLTEtMjM5NDEx_f28ece0a-6798-4e57-9833-436e3fc8f2f8"
      unitRef="usd">97000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i28968af686284bf28e66c81f371858ae_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtMy0xLTEtMjM5NDEx_600fa85d-a63d-4d09-be5b-2f4710f0d2dc"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7e3e9a1753b947c98746cbb0141dc97f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtNS0xLTEtMjM5NDEx_3905fbbe-1b4a-4fcf-afac-63828c64ecd0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1f983f7d518449f5badd677106e20d44_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzUtNy0xLTEtMjM5NDEx_4482ec8e-ba03-4714-80b4-f17013f1e431"
      unitRef="usd">97000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ia9bf45fc47f34b519bcb944cf300f764_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtMS0xLTEtMjM5NDEx_bc379888-c565-45f7-8985-e72b04d176d4"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i28968af686284bf28e66c81f371858ae_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtMy0xLTEtMjM5NDEx_f59d9b71-d6b1-4a44-9039-49a45abfa1b1"
      unitRef="usd">15000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i7e3e9a1753b947c98746cbb0141dc97f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtNS0xLTEtMjM5NDEx_5afcffe6-e5ea-4687-a4fa-9589f449709e"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i1f983f7d518449f5badd677106e20d44_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMDkvZnJhZzpjOTY4YmIwNDgwMzA0YmFmYTk4ZDM4N2Y0ZWIxMDMwZi90YWJsZTo0M2JkY2RlNWNlOTI0OTc0YjMxNzZiZmFiMTkzNjQ1YS90YWJsZXJhbmdlOjQzYmRjZGU1Y2U5MjQ5NzRiMzE3NmJmYWIxOTM2NDVhXzYtNy0xLTEtMjM5NDEx_2ed2eba1-f2ec-414e-ba81-26c69a8019d9"
      unitRef="usd">15000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzgzNDU_8a81eab7-0df0-49c8-a2d3-855ea1f28503">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December&#160;31, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the six months ended December 31, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $300 million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains and losses recognized in other comprehensive income/(loss) were a $2&#160;million loss and a $1&#160;million gain for the three months ended December&#160;31, 2022 and 2021, respectively, and a $2&#160;million gain and a $3&#160;million gain for the six months ended December&#160;31, 2022 and 2021, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $43&#160;million loss and a $17&#160;million gain during the three months ended December&#160;31, 2022 and 2021, respectively, and a $21&#160;million loss and a $22&#160;million gain during the six months ended December&#160;31, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4&#160;million and $5&#160;million during the three months ended December&#160;31, 2022 and 2021, respectively, and $8&#160;million and $11&#160;million during the six months ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $3 million gain and a $2 million gain during the three months ended December 31, 2022 and 2021, respectively, and a $3 million loss and a $4 million gain during the six months ended December&#160;31, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht..&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at December&#160;31, 2022 and June&#160;30, 2022 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_11ae3cd9-4955-4def-9e9f-aa8927573202"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_182dbdc0-54ea-4bb9-a38c-aa523d99968d"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_c1063776-cd52-478e-bb43-25c24dd00da9"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzMyODA_ec7adbb3-24d8-4b7a-83d2-848b08f7a695"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic401427aa03a473ea0f233823ee9d726_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzM1Mzc_6003826d-3788-4b5d-a6f8-d6d2298621fe"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib98f9a1c857544358cc749c370824d31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzM1NDQ_54b579c8-777b-429f-9223-072b76da430b"
      unitRef="usd">300000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i419db69ec18d45b5973c1365d849e94d_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0MDA_705cb7bf-3bdf-4b82-85ba-fa6e2e226cb3"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i62912f01f9244e47ae336b38973b6b79_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0MDc_1dce4b0e-c122-41de-8a81-66d6efaa5764"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3a13dfbd6e0e47b49bff1d69a1465152_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0Njg_bcbfed9d-0b3b-406a-ab2d-84194f6a1926"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i80c83599bf12444b8d0eaf98c4ced505_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzQ0NzU_d5676761-9d60-4a46-9bf4-2645f1c67382"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2af00a4f8742447cba317049f64150b3_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYyMTQ_c8c4b52d-7adb-45de-8515-50ce02a93bea"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3c17db4a988b439d8092bcb59165e33a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYyMjg_a141f0b3-8ed3-4c72-964c-4e26cc49c9ee"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5bfe8b32e9774993b62940687e315b97_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYyOTc_17a8ab4c-9b54-4789-b519-779972436971"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie1537e0b026743748253259f1422c1d7_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzYzMTE_c421ef05-0d86-44d4-b3ed-c2691d18c4f0"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i2af00a4f8742447cba317049f64150b3_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzU0OTc1NTgyMjQxOA_b76bb71f-ec46-433f-a782-a572246fda0f"
      unitRef="usd">4000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3c17db4a988b439d8092bcb59165e33a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzY1NjI_c8a3a5ae-fa1f-4efa-897a-ee4db6e6147d"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i5bfe8b32e9774993b62940687e315b97_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzY2MTQ_7f3dcfe6-d5e1-4a87-9c60-d12ca99a7e2b"
      unitRef="usd">8000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ie1537e0b026743748253259f1422c1d7_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzY2MjE_96924bca-46a4-44a8-b6ba-bb3d21318c3b"
      unitRef="usd">11000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i1336136219d3457ba4c78496738f3cfa_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc0NDI_efabc36d-b545-4264-9f61-6aed4020c0e2"
      unitRef="usd">3000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i850b0b51db214c4c979fd9e1de993132_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc0NTY_f0a268b7-9625-436e-9e52-e362c5a3dedd"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic5688d1966bc4586b43f1bd3b0319696_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc1MjY_387c22e7-c6df-4f77-b184-3bae0bc3c3e2"
      unitRef="usd">-3000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8508310d7f6f400da86433e5bf10f0c7_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzc1Mzg_ca6638e2-0ceb-4fb6-85d0-607b3303da4f"
      unitRef="usd">4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90ZXh0cmVnaW9uOmMyZGM3N2ZjYjBjNTRmMjBhNjBiNzdhNjgwOGM3NjdhXzgzNDY_6ee72a68-be23-4f6b-9261-a5594622e1ea">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic296f663b9444e33b5f5d47197bb2a3a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzEtMS0xLTEtMjM5NDEx_5fdfb07d-159d-4143-a4d6-39f541133555"
      unitRef="usd">4912000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i4fc93964635640fe8eb7402e598ad33e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzEtMy0xLTEtMjM5NDEx_1e4792a3-123a-4af8-930a-cfae229f1d61"
      unitRef="usd">5049000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzItMS0xLTEtMjM5NDEx_e6839047-7740-4a57-9098-e76c60455d01"
      unitRef="usd">5262000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTIvZnJhZzpjMmRjNzdmY2IwYzU0ZjIwYTYwYjc3YTY4MDhjNzY3YS90YWJsZTpkZTM1NWUzOWRhYmU0MzQyYWMzZjc2NTU4Y2E5ZGIwMy90YWJsZXJhbmdlOmRlMzU1ZTM5ZGFiZTQzNDJhYzNmNzY1NThjYTlkYjAzXzItMy0xLTEtMjM5NDEx_94c8d1e3-b507-46a0-9a78-2b317179df8c"
      unitRef="usd">5315000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzE4OTQ_abda4781-eab3-477a-8131-eff2c0e9daa4">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Shareholders' Equity/(Deficit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We repurchased $1.3&#160;billion and $800 million of our common shares, in the aggregate, through share repurchase programs during the six months ended December&#160;31, 2022 and 2021, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0&#160;billion. We received an initial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8&#160;million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3&#160;million common shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8&#160;million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax expense of $7&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1cb40a75a8d94359be82ce9a0611c2ea_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzI3NDg3NzkwNzM5MDM_320fe856-1e0b-4e86-821a-bf6516575b9a"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8f9b17d6de06426c9fe2255e6b5b96d1_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODYwODg_f311c78b-0d24-474f-95fc-6b61e4b15130"
      unitRef="usd">800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i44235a75341c4ea98c8f81b1b8a2af14_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzQzNg_bfc188f9-5879-4f22-84d9-1974bab924c2"
      unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzQ3NQ_51c17e3b-a699-4252-b9f8-212ccea03e55"
      unitRef="shares">2600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i3a327f6ce7df44cfbdbfb9de369656fb_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzUxOQ_7431b749-07c1-4321-9a86-7ace13f8ee40"
      unitRef="usdPerShare">76.58</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i9e78550aaf464e52892c197636bb7e4a_D20221001-20230113"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzYwNg_49279dc6-3103-4367-9388-54d07bbfc60b"
      unitRef="usdPerShare">77.50</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4d2749e174ce4d1bb8fced961a9f1965_D20230113-20230113"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzY0Mg_379d2bb8-9c15-4d93-99b8-4bc0167ab8d1"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iec9ecab01856488cb08eb92f6ceefb4f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzExNzE_d43bb862-fa06-44e2-9ab2-c9c352f0c482"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i67242a94677a43a29bdc3644189fb216_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzEyMTA_ce2a6b3a-0dac-45d1-a973-2a109b2669e8"
      unitRef="shares">12000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i67242a94677a43a29bdc3644189fb216_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzEyNTQ_528f5831-7109-4954-ab11-5bbffec1e56f"
      unitRef="usdPerShare">66.74</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if015bf8d31b6432ca4059c2c62023d4c_D20220701-20221223"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc4Mjg_05239456-5c6e-400b-8a39-5cec4a54e92a"
      unitRef="usdPerShare">73.36</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie003cab2aff1438eb31ba142971e023f_D20221223-20221223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc4MzQ_9450f794-8d5a-4f6f-8ad6-c208fb6c0b6e"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib025910e07224dc6bc0dd03aba8e140d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5MjE_e5be466c-a4e0-401e-8552-bfe4f48b27c9"
      unitRef="usd">300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i35bfa7c5d2e64b76a42e9f20bacb3144_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5MzU_14bef42b-bdfc-4bc8-aaf3-0f8f488a3df2"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i35bfa7c5d2e64b76a42e9f20bacb3144_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5NDg_4120c1e4-9d9d-4d59-a116-fc938cc37fcb"
      unitRef="usdPerShare">50.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ifc0a6ac4d1f041e7a3c39bd92acde20c_D20211001-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5NTg_e612e633-39bd-4cae-9ab1-37118a9cacb9"
      unitRef="usdPerShare">49.39</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0aa6850535854b1a86ffcec853e058c2_D20220131-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5NjY_af4c606c-dd65-4d8b-a56b-b39ab58d3a63"
      unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if3e0f4813dc547caa13b2dd18cb5794a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5Nzk_7bc5a97c-b9ed-4d1a-ad74-a71f57fe7a64"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i96adc00f02ea4124a797b7def5d4b482_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODc5OTM_fc6bbaed-1559-4474-9633-d8642ec998c7"
      unitRef="shares">7800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i96adc00f02ea4124a797b7def5d4b482_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODgwMDY_132f0195-cf08-459e-97e9-7c6572ec738a"
      unitRef="usdPerShare">51.53</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i9ab163bd44f34212a39494050f17884b_D20210701-20211004"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODgwMTQ_de4aed3a-f13b-4c06-a14f-2cd64acab1c2"
      unitRef="usdPerShare">51.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i51514bc1c1804e3e8e046c79f210825c_D20211004-20211004"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzMyOTg1MzQ4ODgwMjI_3bc9f1b6-e89c-4623-8f66-a84ddd4b5422"
      unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90ZXh0cmVnaW9uOjI0NWYyOWEwMjQ3ZjQzYzU5OTY0NWQ5MjYxYWIxNzNmXzE5MDI_c5c926c8-aa44-43c7-9234-e2adf6210086">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax expense of $7&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb3ff1d4324243c5b9dab7c4b4e6aaac_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzEtMS0xLTEtMjM5NDEx_b2ed1786-ac94-4c3b-b46e-d01c11291d6f"
      unitRef="usd">-102000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i927dad673ba5420a852bc6b2ae6b2c64_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzEtMy0xLTEtMjM5NDEx_63ad23ed-84ed-416f-81fb-93e0f9146359"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d24c5647c19422b8430fcfe245a94f7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzEtNS0xLTEtMjM5NDEx_5da4e430-5036-4d94-bd1c-10279ab9161f"
      unitRef="usd">-114000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzItMS0xLTEtMjM5NDEx_b0ba47c6-02c9-4026-bbe9-a3f1b75a4f9a"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzItMy0xLTEtMjM5NDEx_86585f7c-d3a7-4968-83f6-d28b0f973a79"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzItNS0xLTEtMjM5NDEx_d19f2c56-58dc-4319-b1bf-f0926672d32f"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzMtMS0xLTEtMjM5NDEx_d9844629-e3dc-4e00-a48d-2ae497737199"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzMtMy0xLTEtMjM5NDEx_c3f54754-a6f0-4f44-849c-57d6c677dd96"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1fc69f1727ce4e7284bae7c1b48be821_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzMtNS0xLTEtMjM5NDEx_0214f979-e5ab-4933-9d1d-df5740770ff4"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtMC0xLTEtMjgyNzc1L3RleHRyZWdpb246NDlhZTY4MzkyZTg2NDlmOGJhN2Q0ZTU0NDA5YWMyNDJfNDM5ODA0NjUxMTIwOQ_7134eba6-40b0-41af-9949-7158161a5d08"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5445439fd87e4a3a8d6b1a94b5883e83_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtMS0xLTEtMjM5NDEx_53b8a58b-7f82-44f3-bd29-0b9269ac86a8"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifa8747ae32aa45da9732a08715ab2d0c_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtMy0xLTEtMjM5NDEx_93fc0811-9b95-4cc7-a70b-10eddf4e4b38"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib1f2ad28443449a3918666f8d0ca9088_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzQtNS0xLTEtMjM5NDEx_a7e03c03-a8b8-4ec5-a95b-ffbffb2727f9"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if89a2915b7ed4a078a678477329b0507_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzUtMS0xLTEtMjM5NDEx_4c26b312-b7ad-4231-871f-faa4e9bbef02"
      unitRef="usd">-140000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib230b5c311ef47d68a27beaea8522ed6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzUtMy0xLTEtMjM5NDEx_c99f135e-e70a-4bc4-9865-cfb8f283c1b7"
      unitRef="usd">-6000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59555a0f0c174b9491efe42bf0cc4203_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpkNGNlYWZhY2I0Mjk0OGNjOWRhZTIzNWRhMzYxYmY2Yi90YWJsZXJhbmdlOmQ0Y2VhZmFjYjQyOTQ4Y2M5ZGFlMjM1ZGEzNjFiZjZiXzUtNS0xLTEtMjM5NDEx_e505ffe4-eeb5-435a-8884-c40570dfad69"
      unitRef="usd">-146000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafbe269331e44497b6736f5de1e2161b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzEtMS0xLTEtMjUzNDIw_85b6bf2a-daeb-43d2-b620-b400d2c677d6"
      unitRef="usd">-46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i234657f026ec4322af8ba2a7554081dc_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzEtMy0xLTEtMjUzNDIw_863e0492-e5ae-48e6-82b8-c56061cb5673"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d0098e44a8448c6988637fda4f53d74_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzEtNS0xLTEtMjUzNDIw_601a404f-9d21-45e3-a424-6ffd55f88116"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9f837aa398974931b78133ce25f15c52_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzItMS0xLTEtMjUzNDIw_38ce61f2-c3c7-4919-b5fa-3e6b21540453"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzItMy0xLTEtMjUzNDIw_edad6d51-3a9e-4ec1-91bf-bed16325a402"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzItNS0xLTEtMjUzNDIw_a5623369-c650-4c7f-88cd-fe2612acfc68"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9f837aa398974931b78133ce25f15c52_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzMtMS0xLTEtMjUzNDIw_f4b7b486-2de9-4f9e-876c-a82ebb1a555e"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzMtMy0xLTEtMjUzNDIw_69c545cf-4afc-4eda-90ef-32e7ae6241bd"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4e529e06cf044a6fa25e10b01c0b26d5_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzMtNS0xLTEtMjUzNDIw_9e447b16-4ac2-4355-94f3-db5eabdde0bf"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtMC0xLTEtMjgzMzEwL3RleHRyZWdpb246MjQyNDU1Mzc3N2E5NGQ5YmJkZjU2OGUxZjNiNzJiMTlfNDM5ODA0NjUxMTIwOQ_7e311931-3310-4558-b0bb-a27a9a31b3b8"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9f837aa398974931b78133ce25f15c52_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtMS0xLTEtMjUzNDIw_fec26c97-6055-4c1d-b200-e0e00ce74225"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id20d97a2ea8b4c31be41ba438ac5fb84_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtMy0xLTEtMjUzNDIw_b37731f8-0f2f-4b2e-bdf2-55e75bd74bd3"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5ea96e756f1646cdbbb7691cf0597a61_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzQtNS0xLTEtMjUzNDIw_779d7105-043f-48b6-a6d6-a2daa4906280"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4260860fbed64ec0a99b94ee41089695_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzUtMS0xLTEtMjUzNDIw_a4fbf289-0903-4d06-b1bd-7405bc80481f"
      unitRef="usd">-89000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i079ed1cf2c02433cb1306b1192fe722a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzUtMy0xLTEtMjUzNDIw_cd0bd1d0-8fd2-48e2-9604-3882ec4f896e"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3668ad01dd604937a1f5a2dbff8c26ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTUvZnJhZzoyNDVmMjlhMDI0N2Y0M2M1OTk2NDVkOTI2MWFiMTczZi90YWJsZTpjOTdlYWNmYjAwZjY0ODExYTE3ZjdhZDcyMWVhYmU3YS90YWJsZXJhbmdlOmM5N2VhY2ZiMDBmNjQ4MTFhMTdmN2FkNzIxZWFiZTdhXzUtNS0xLTEtMjUzNDIw_5ea3b7a8-993c-4129-a70a-e0422fb2fc7a"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzkyOQ_ad03dcfa-31b9-4a24-90cf-eda980df4bf3">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 3 million and 5 million for the three and six months ended December&#160;31, 2022, respectively. For both the three and six months ended December 31, 2022, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzkyNA_a938fdbe-a388-4a95-93bb-b9941597ee20">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;261&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzItMS0xLTEtMjM5NDEx_16b0d5fc-0c83-49bb-bc77-615554e124b0"
      unitRef="shares">261000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzItMy0xLTEtMjM5NDEx_3a53ecb7-5149-405d-84ee-76f38615d511"
      unitRef="shares">279000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzQtMS0xLTEtMjM5NDEx_8af48c26-9574-4079-bbe3-09be571c4a90"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzQtMy0xLTEtMjM5NDEx_7c1a1dec-6ac5-4b76-bc95-c94f8741f407"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzUtMS0xLTEtMjM5NDEx_fe75aef9-281f-4f3d-88c2-b70c7982782e"
      unitRef="shares">261000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTo1NjNkMmEzNmYxNTI0NWQ5YTg1MjU4YWVkZmIwNDE0MC90YWJsZXJhbmdlOjU2M2QyYTM2ZjE1MjQ1ZDlhODUyNThhZWRmYjA0MTQwXzUtMy0xLTEtMjM5NDEx_15fff8ab-d0c2-4053-a2e2-14802686cf69"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzItMS0xLTEtMjM5NDEx_b0be3b42-733a-4a72-8c67-5824c25ef9d2"
      unitRef="shares">266000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzItMy0xLTEtMjM5NDEx_3a922cec-4ec0-4f6a-b026-65611997b365"
      unitRef="shares">283000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzQtMS0xLTEtMjM5NDEx_b449d003-5e3c-4937-9a8f-41261bf524f4"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzQtMy0xLTEtMjM5NDEx_59fc93b5-2616-4019-bd16-6787fbd3261f"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzUtMS0xLTEtMjM5NDEx_1e3c6c79-bd25-4a8d-990e-bcea25d2b223"
      unitRef="shares">266000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90YWJsZTowMDhiYjYwNWFkNzI0YWRlOTI0MTc4YmFmNzk0ZDlhYy90YWJsZXJhbmdlOjAwOGJiNjA1YWQ3MjRhZGU5MjQxNzhiYWY3OTRkOWFjXzUtMy0xLTEtMjM5NDEx_ded199e2-0501-4bb5-a72e-96dbc882091b"
      unitRef="shares">285000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzI4Nw_23b41238-587a-4881-a88e-2471a5a6dfce"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzI4Nw_b49bdd05-af61-4f17-a8ca-8671eacda52b"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE2NzQ_1e9d199e-5f36-4bb2-8545-599dd70fe763"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE2ODg_88c0d400-1ae6-42dc-8c6e-3171a40eebba"
      unitRef="shares">2000000</cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss>
    <cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE2ODg_c70b77c5-3af9-4026-8d13-e538dcdf437e"
      unitRef="shares">2000000</cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzI3NDg3NzkwNzExOTY_4c4d561d-1974-4a00-bd6a-bf320a71992d"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMTgvZnJhZzo4MzU5ZThjNmYzYzA0OGU4OTMwZGQzNGRlYWIxNGM5OC90ZXh0cmVnaW9uOjgzNTllOGM2ZjNjMDQ4ZTg5MzBkZDM0ZGVhYjE0Yzk4XzgyNDYzMzcyMTE3MDI_5a113570-dcd9-42e4-b010-8b40c4277b2f"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYxMDI_0a398e73-f908-4ea0-901e-21fce2ace8dc">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;93,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;last-in first-out, or ("LIFO"), inventory charges/(credits); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;surgical gown recall costs/(income);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;shareholder cooperation agreement costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;state opioid assessment related to prior fiscal years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;restructuring and employee severance;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;amortization and other acquisition-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i495abb9913e04abfaa8f722b6757199b_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized goodwill impairment charges of $709 million and $863&#160;million during the three and six months ended December&#160;31, 2022, respectively;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;litigation (recoveries)/charges, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;other (income)/expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;interest expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;loss on early extinguishment of debt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;(gain)/loss on sale of equity interest in naviHealth; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;provision for/(benefit from) income taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $5 million and $11 million for the three months ended December&#160;31, 2022 and 2021, and $11 million and $18 million for the six months ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;464&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;895&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt"&gt;Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the three and six months ended December 31, 2022, respectively.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzEwMQ_7c8ef6da-8d6e-4e86-921d-dfbdd9bfa76b"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzEwMQ_d8331263-d2f0-48c2-afa6-a83d969edace"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzE4NDc_7c8ef6da-8d6e-4e86-921d-dfbdd9bfa76b"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzE4NDc_d8331263-d2f0-48c2-afa6-a83d969edace"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwOTk_825fe913-102e-4c3b-9e0f-0a8d9f656871">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;93,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i5de1192dba4d40dea7d63dad70307f94_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzItMS0xLTEtMjM5NDEx_a4f9c46d-6924-4a2f-8e09-fbbe3514f4e5"
      unitRef="usd">47391000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d191632a75148da81cbf62a95aacda0_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzItMy0xLTEtMjM5NDEx_f1bfcd19-653d-4e36-8e30-4e17f6671acc"
      unitRef="usd">41164000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac761a14f9bd4458a4a199cf1a930ab0_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzMtMS0xLTEtMjM5NDEx_c69103d0-61a5-475d-92d4-d4bc3c7de1ee"
      unitRef="usd">282000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id14071c1bf65402a88b667c00185bad9_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzMtMy0xLTEtMjM5NDEx_ccd26df5-f792-4f16-b48f-b851a781f83f"
      unitRef="usd">211000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ideb7ebd0dccf4880b310bb4ffe79ba9c_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzQtMS0xLTEtMjM5NDEx_30f8ee65-1417-45b0-b6bb-5e8a857ed090"
      unitRef="usd">47673000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i372f1adca9c14668a399c6ffc8407155_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzQtMy0xLTEtMjM5NDEx_405648a4-2cc6-4135-800f-7e0557b17fc5"
      unitRef="usd">41375000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9327356d31264aeda31dc4ff0d2c87fc_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzUtMS0xLTEtMjM5NDEx_a8bc9efe-a29b-4b9a-a68c-a088debc9b3a"
      unitRef="usd">3099000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i071f8fbaf46941a48f5d41fde9668d9b_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzUtMy0xLTEtMjM5NDEx_f6b4361e-7969-4084-90cb-7c9629f9aa24"
      unitRef="usd">3446000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9a7a93a200d473ab5c358f7df672a72_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzYtMS0xLTEtMjM5NDEx_a7596175-1ce9-4e25-9540-6f9d98c51599"
      unitRef="usd">698000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74408378be5a448e98f4a8a12fb3666f_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzYtMy0xLTEtMjM5NDEx_0fe8437f-2da5-492d-967f-b9d6ef6a3b3e"
      unitRef="usd">639000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd4c69b8bfea43cc82c3f371ef88ebf8_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzctMS0xLTEtMjM5NDEx_f6f67e03-66b3-4033-8b00-6fb7c787f57a"
      unitRef="usd">3797000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6df290f36db4d3d90865e0e99c3d0b8_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzctMy0xLTEtMjM5NDEx_25772d8d-bea4-4a47-97cd-b782d51b32cd"
      unitRef="usd">4085000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzgtMS0xLTEtMjM5NDEx_a59e96f2-90f4-491b-a32f-ef04e05a602d"
      unitRef="usd">51470000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzgtMy0xLTEtMjM5NDEx_c06ad083-b566-474f-befb-fc601fdd4b8e"
      unitRef="usd">45460000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzktMS0xLTEtMjM5NDEx_8994b226-a7a5-40b6-8a5b-7506fa767193"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzktMy0xLTEtMjM5NDEx_180e70c3-a0e2-488a-a629-89e47d077a20"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzEwLTEtMS0xLTIzOTQxMQ_b1610068-b0cd-4b65-b8bf-1b5dca6b6ebe"
      unitRef="usd">51469000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTowZjEyMmRhMGIzOTk0YTQ5YmNkMjE4YTcyZjAxZWQ5YS90YWJsZXJhbmdlOjBmMTIyZGEwYjM5OTRhNDliY2QyMThhNzJmMDFlZDlhXzEwLTMtMS0xLTIzOTQxMQ_c7b38a43-b499-4a65-a530-548b146f8909"
      unitRef="usd">45457000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia39b5639f5fa48fc97157c8446d8e414_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzItMS0xLTEtMjM5NDEx_7d036b8f-fe2e-449c-a346-96b72e94bf7a"
      unitRef="usd">92938000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib59cd6366c894bc7b2baebc2cd23823b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzItMy0xLTEtMjM5NDEx_84242d33-8ac3-46cf-b81d-6f96e49783e3"
      unitRef="usd">80778000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38e7f4cacb374f3c9209b0378d7b463c_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzMtMS0xLTEtMjM5NDEx_d4b708ef-6703-4bc2-9416-be462c1ea28f"
      unitRef="usd">563000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c827171183b49d9b5eac5515ab8dc44_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzMtMy0xLTEtMjM5NDEx_21680c6f-f486-455d-82c2-6a6ea20c696e"
      unitRef="usd">419000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i847b85afccb1427c9843ef38bfb3b4ef_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzQtMS0xLTEtMjM5NDEx_4656af6e-dc8b-4e2b-a3cd-aee4d7bdab98"
      unitRef="usd">93501000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e0e3bfc4cf14a36a1e7f71d2910082d_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzQtMy0xLTEtMjM5NDEx_4831a1dd-5fc6-4bad-8918-2e17dd744c08"
      unitRef="usd">81197000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5840a89e1f24c089cf3dc78fab83e52_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzUtMS0xLTEtMjM5NDEx_baf58957-8675-4b2e-be02-a45e9410488b"
      unitRef="usd">6239000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i991f809891464521b1f29e8e3fa6c4db_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzUtMy0xLTEtMjM5NDEx_4011a520-cec0-47aa-803e-081d75d5f8b9"
      unitRef="usd">7013000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7759d1263204160a70574351e4794da_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzYtMS0xLTEtMjM5NDEx_1c369ef0-27e2-49e6-a44f-8be1c563caba"
      unitRef="usd">1336000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2cadd91b2c54bc6b8874b00950fde1d_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzYtMy0xLTEtMjM5NDEx_16b67981-3959-418c-a47f-4a48d04b72f6"
      unitRef="usd">1221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0748902d2bc42b1aa2187c657d51169_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzctMS0xLTEtMjM5NDEx_2ded3584-330d-4183-ae0f-94dc4ff874b1"
      unitRef="usd">7575000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcc20395d8d04d49bb7875d92c1c581f_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzctMy0xLTEtMjM5NDEx_5764b6b4-ae0e-4c0d-b531-afa736e1ce08"
      unitRef="usd">8234000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzgtMS0xLTEtMjM5NDEx_a6914b68-6efc-4cad-b7b0-501650db7f03"
      unitRef="usd">101076000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzgtMy0xLTEtMjM5NDEx_ecab96e4-a74e-4780-92fe-f15ddfdb41e1"
      unitRef="usd">89431000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzktMS0xLTEtMjM5NDEx_34546a85-a2e1-4ded-929a-3a6e91e52d7a"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8f31a92ecac49d98787199739713426_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzktMy0xLTEtMjM5NDEx_a59253ad-def3-463f-85bd-48c0a66c194a"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzEwLTEtMS0xLTIzOTQxMQ_ce87c657-fd86-48d2-8dee-b4a85ad2de19"
      unitRef="usd">101072000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2NDY4Njg4NzYxYjc0OGFkYmFiZWNkNTdhZjgwNTkyMy90YWJsZXJhbmdlOjY0Njg2ODg3NjFiNzQ4YWRiYWJlY2Q1N2FmODA1OTIzXzEwLTMtMS0xLTIzOTQxMQ_08e553e0-4f12-4773-84ed-adf774a4f426"
      unitRef="usd">89425000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwOTA_dc5ff445-7d82-4618-9c87-767f6899dfeb">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="iaf2a6bafa71e46f6bff513c85997576c_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzItMS0xLTEtMjM5NDEx_db361ed5-db95-4b82-ab05-549f7e62d1fc"
      unitRef="usd">50333000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b72d75aa77747f688bde3fedede66d3_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzItMy0xLTEtMjM5NDEx_917ce6a6-cbcb-4091-8eed-55745be0ba05"
      unitRef="usd">44382000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29d8fab8a7154b2ca8fca6ab14961db8_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzMtMS0xLTEtMjM5NDEx_6b8f3144-1bd2-4504-a858-a72519aec10a"
      unitRef="usd">1137000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ea3c4ca236646ceaff7d1d7d0910e14_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzMtMy0xLTEtMjM5NDEx_66e99d25-556d-435d-819c-39e52ab367cb"
      unitRef="usd">1078000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzQtMS0xLTEtMjM5NDEx_c3841851-a620-481c-9ec3-ed3fe4c1e571"
      unitRef="usd">51470000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzQtMy0xLTEtMjM5NDEx_b6cb700c-6efe-4eeb-b89d-90157f00ff36"
      unitRef="usd">45460000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzUtMS0xLTEtMjM5NDEx_f12766b5-2a64-4fd5-ac46-bf8599172f59"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzUtMy0xLTEtMjM5NDEx_40be71e8-c2f6-4e8b-902c-a6153e067687"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzYtMS0xLTEtMjM5NDEx_539dd775-7aa3-45e0-824b-ceec51d3be4d"
      unitRef="usd">51469000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYWJjNjNkNzU0MTc0MTg0OTI3ODc1ZTJlY2Y0ZDJjNy90YWJsZXJhbmdlOjJhYmM2M2Q3NTQxNzQxODQ5Mjc4NzVlMmVjZjRkMmM3XzYtMy0xLTEtMjM5NDEx_65d6c78f-f1a3-4c5f-ba33-3acb1551113c"
      unitRef="usd">45457000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20401e15a48a4142ab492d9ed551560b_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzItMS0xLTEtMjM5NDEx_c83e35ad-544f-4a4e-8cd0-2baa32dbf928"
      unitRef="usd">98810000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fd024933b8a4c7dbd94a2ee45b24ed2_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzItMy0xLTEtMjM5NDEx_9da00331-e11c-4f5b-87f7-8412d3b8ad64"
      unitRef="usd">87223000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf4d295eb2c84b83a1b9930b69ca5b06_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzMtMS0xLTEtMjM5NDEx_a609191e-3f06-40d5-9d23-8b856a7e8170"
      unitRef="usd">2266000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07757b56850843c5b966cdae4070ece5_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzMtMy0xLTEtMjM5NDEx_c7f9aa62-a593-492d-8958-97d71a3581ca"
      unitRef="usd">2208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzQtMS0xLTEtMjM5NDEx_1941d61f-feed-438f-8978-a571939e2cb5"
      unitRef="usd">101076000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzQtMy0xLTEtMjM5NDEx_bc9ba292-84d5-4ca8-9eb9-56b2e2da4f1e"
      unitRef="usd">89431000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzUtMS0xLTEtMjM5NDEx_ab5c7aa2-7fe5-4438-aa9b-2c228a603128"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8f31a92ecac49d98787199739713426_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzUtMy0xLTEtMjM5NDEx_cdf0e334-0e3f-4bbf-8f25-36b99c03a133"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzYtMS0xLTEtMjM5NDEx_ef44c001-3f69-4bca-b65f-24685cddf1cb"
      unitRef="usd">101072000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo1ZjNkOGYwMDBhOTc0ZjMzYTY0ZWNhODZlYzlmNzhjNi90YWJsZXJhbmdlOjVmM2Q4ZjAwMGE5NzRmMzNhNjRlY2E4NmVjOWY3OGM2XzYtMy0xLTEtMjM5NDEx_4ec64a86-4697-401e-b534-1ba2149de6b0"
      unitRef="usd">89425000000</us-gaap:Revenues>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id0a29845f22449af9631745d9999727d_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzI3NDg3NzkwODQ0NTA_ee3267cb-d58b-4062-989b-16c20725d338"
      unitRef="usd">709000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2c0539d106574706b4942868128b486d_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzI3NDg3NzkwODQ2OTU_2cfe9942-9863-402b-989d-f480e49dc794"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQzODE_951bb6ea-5e98-4f28-b2cb-22414640762c"
      unitRef="usd">5000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQzODg_5992799d-7865-4405-8029-a57130cd45d9"
      unitRef="usd">11000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQ0MzM_a4d3e5a4-3b6b-446a-b28b-8322ef14e4c1"
      unitRef="usd">11000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzQ0NDA_4e21743f-5542-4485-a470-e5e780defa7a"
      unitRef="usd">18000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwODg_43a09551-c8fb-4e8f-b75b-808cc1d985cc">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;464&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;895&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt"&gt;Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="ideb7ebd0dccf4880b310bb4ffe79ba9c_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzItMS0xLTEtMjM5NDEx_21c79d64-4c4a-494c-8431-651c108f59f6"
      unitRef="usd">464000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i372f1adca9c14668a399c6ffc8407155_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzItMy0xLTEtMjM5NDEx_f04b6a20-6695-4bbd-b005-aa5ee6664341"
      unitRef="usd">426000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifd4c69b8bfea43cc82c3f371ef88ebf8_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzMtMS0xLTEtMjM5NDEx_92a23c01-1944-4706-af2c-107d3858ba72"
      unitRef="usd">17000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia6df290f36db4d3d90865e0e99c3d0b8_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzMtMy0xLTEtMjM5NDEx_2c672d17-5acb-4822-8cea-a1759383ba1d"
      unitRef="usd">50000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzQtMS0xLTEtMjM5NDEx_de078f8d-f39a-4f24-82df-e9c2078b1a01"
      unitRef="usd">481000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8541459f8a3b4c708dcef7ae4b515945_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzQtMy0xLTEtMjM5NDEx_606577a0-6fb7-49d9-9678-b440f263308a"
      unitRef="usd">476000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d501cdd14a246b89935dd3a42d9740f_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzUtMS0xLTEtMjM5NDEx_ec642310-9174-4076-a098-70489987e5a3"
      unitRef="usd">-600000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i662c96bb709f4d83bc9fea9be02df93d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzUtMy0xLTEtMjM5NDEx_a6edbab9-b3eb-4785-8fdd-094462b210fb"
      unitRef="usd">-1426000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzYtMS0xLTEtMjM5NDEx_fca83e6b-4c73-4591-85aa-64e9e8332bae"
      unitRef="usd">-119000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTo2MzYxMmFjYzQ1NTQ0NTAyYjgwYzdjMTk2ODZjNTUzOS90YWJsZXJhbmdlOjYzNjEyYWNjNDU1NDQ1MDJiODBjN2MxOTY4NmM1NTM5XzYtMy0xLTEtMjM5NDEx_8e23c95a-5013-4163-abb8-7809a9e3e8ad"
      unitRef="usd">-950000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i847b85afccb1427c9843ef38bfb3b4ef_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzItMS0xLTEtMjM5NDEx_9270dfa9-bc08-474f-9724-00c49aa321cb"
      unitRef="usd">895000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2e0e3bfc4cf14a36a1e7f71d2910082d_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzItMy0xLTEtMjM5NDEx_44d7a8e8-c0ac-4919-8f43-ade86b6d894d"
      unitRef="usd">832000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia0748902d2bc42b1aa2187c657d51169_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzMtMS0xLTEtMjM5NDEx_a827b2b5-6ddc-4061-9500-a69352947d92"
      unitRef="usd">9000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idcc20395d8d04d49bb7875d92c1c581f_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzMtMy0xLTEtMjM5NDEx_05752084-b789-436f-9b5d-c796bfe69d89"
      unitRef="usd">173000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia20e39513a084820904d5bd79ed39c0e_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzQtMS0xLTEtMjM5NDEx_ccc9f2d4-3e7e-445a-b2a5-079eae91c203"
      unitRef="usd">904000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9f945373bdfc44b7a75909465f76f2ba_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzQtMy0xLTEtMjM5NDEx_359d455c-9a18-43fc-8b95-5375b59c207e"
      unitRef="usd">1005000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7e089e0100034688a4a1cf924a86a1ec_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzUtMS0xLTEtMjM5NDEx_478394e4-4206-4ebc-8528-849c90e85714"
      unitRef="usd">-886000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie8f31a92ecac49d98787199739713426_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzUtMy0xLTEtMjM5NDEx_33dffda4-fb3e-4220-8966-e174b5729f92"
      unitRef="usd">-1540000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzYtMS0xLTEtMjM5NDEx_74837fac-bd35-4f0d-8ba7-2c646976a1f1"
      unitRef="usd">18000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZTphYmVjZWU5MGYyOGY0NzFkYjhlODQ2NTliYzQ4ZTUzYS90YWJsZXJhbmdlOmFiZWNlZTkwZjI4ZjQ3MWRiOGU4NDY1OWJjNDhlNTNhXzYtMy0xLTEtMjM5NDEx_000871a0-f380-4339-bea2-54892c0a1401"
      unitRef="usd">-535000000</us-gaap:OperatingIncomeLoss>
    <cah:JudgmentForLostProfits
      contextRef="i993e4902e3144a5bb0fd1d2340dcc042_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzU1OTg_8924e588-482e-42a8-aaa4-604a56666781"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzYwODU_9756ae88-ae91-46c3-ab06-4539ded87f1f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the three and six months ended December 31, 2022, respectively.</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="idb971d5ee0074937ab22b8a564419c1a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzEtMS0xLTEtMjM5NDEx_af05e903-d452-44dd-9f39-4fe5417a4ba3"
      unitRef="usd">28992000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2f93e137bed843d5bbce9e33653971d9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzEtMy0xLTEtMjM5NDEx_e24602a4-a71b-43dc-beb6-b93ea2cb1833"
      unitRef="usd">26409000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i314103e38f99480eb96ce0c421f83746_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzItMS0xLTEtMjM5NDEx_cf04588b-071e-4e81-b18b-6cd3919f1cc9"
      unitRef="usd">10757000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie88445aacaa14c91a809313e59ddaf22_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzItMy0xLTEtMjM5NDEx_f786933c-567b-4a2d-9d98-86395631786b"
      unitRef="usd">11632000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i16af340395d846e2827ed3fc620c2fad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzMtMS0xLTEtMjM5NDEx_bf46d7be-b649-416b-b713-69235db53d79"
      unitRef="usd">4733000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iba6f162e7cb341e5a022eee6d2ce58ad_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzMtMy0xLTEtMjM5NDEx_6063b5b2-94da-4ab8-a00a-dc1b90a6f582"
      unitRef="usd">5837000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9510233b4906437c8abfc1fb414285bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzQtMS0xLTEtMjM5NDEx_c4a1a910-a255-4728-9c37-bc79433a9542"
      unitRef="usd">44482000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i67172f4a4b5744899699d8c0d3f2b040_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90YWJsZToyYjU0YzAyZDg1ZTk0YjcyYmIwZjUwNTM1ZDI2NmI5OS90YWJsZXJhbmdlOjJiNTRjMDJkODVlOTRiNzJiYjBmNTA1MzVkMjY2Yjk5XzQtMy0xLTEtMjM5NDEx_df37af81-036e-4b77-9494-89c0534209d8"
      unitRef="usd">43878000000</us-gaap:Assets>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2c0539d106574706b4942868128b486d_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjEvZnJhZzo1N2U4YjUwODNlOGI0MTViYWMxMjVlOGJjYjBlZTcxYi90ZXh0cmVnaW9uOjU3ZThiNTA4M2U4YjQxNWJhYzEyNWU4YmNiMGVlNzFiXzI3NDg3NzkwODQxNDY_2cfe9942-9863-402b-989d-f480e49dc794"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0NDk_f8326496-43cc-4f4b-87d4-76604a31d4fe">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $3 million and $2 million for the three months ended December&#160;31, 2022 and 2021, respectively, and $6 million for both the six months ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56.86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $108 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76.49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $41 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0NTg_afaba51f-14e1-4f09-8943-31c1fb80e0e7">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i724588d9b5744663ab373f331e1884cc_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzItMS0xLTEtMjM5NDEx_9d17558a-9784-4cef-9704-27f454be3c4d"
      unitRef="usd">15000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d56087f747e42769e4b2bcea6e62a75_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzItMy0xLTEtMjM5NDEx_c5707031-628d-4f59-ad46-eea71358c60c"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd307c58e2c24994829573b1f3f8a6a7_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzQtMS0xLTEtMjM5NDEx_94fa52e5-ef55-424a-92b3-f1b61d172cb8"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebc2a7c414ff419388ee2bf7c1a9ffdf_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzQtMy0xLTEtMjM5NDEx_cef8426c-a515-46f5-846d-e23e63949590"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzUtMS0xLTEtMjM5NDEx_01dbd233-233e-4a63-bfa6-21f73217ee98"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpkYmZiNmJhZDVkYWE0YWE2OTA4N2VjNzBjYjg5NjY3My90YWJsZXJhbmdlOmRiZmI2YmFkNWRhYTRhYTY5MDg3ZWM3MGNiODk2NjczXzUtMy0xLTEtMjM5NDEx_73146ec8-1f1d-4187-bba4-0c19447d6c22"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzItMS0xLTEtMjM5NDEx_fc1455ab-11b5-4cf2-9da4-e7f3ed37f92f"
      unitRef="usd">32000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i78decb5962f2469ba0f935238a752f02_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzItMy0xLTEtMjM5NDEx_0f7089b7-e00b-4be0-97bf-da8b19e89ed8"
      unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzQtMS0xLTEtMjM5NDEx_109c5a49-d943-4ae6-83e7-d899b6d8a6f3"
      unitRef="usd">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38a85160188a49a1a63acb55c053b255_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzQtMy0xLTEtMjM5NDEx_0d2189f2-f079-4f1c-804e-e4acab10601d"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzUtMS0xLTEtMjM5NDEx_6c0b192f-5f0c-4099-a5ed-b111c4351549"
      unitRef="usd">48000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i392074a1226d4b82bb41d7f30b359497_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTpiODBhNDFhMDI4Njk0YzkyYWZlZmE2NWE3NDkyMGJkNy90YWJsZXJhbmdlOmI4MGE0MWEwMjg2OTRjOTJhZmVmYTY1YTc0OTIwYmQ3XzUtMy0xLTEtMjM5NDEx_dc02e7ec-8f39-4bf7-9800-7289d8c7ebd3"
      unitRef="usd">42000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI5Mw_85320fbe-5505-437f-bf65-43a951e6a54b"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="icc75351148f9471193785633b036daec_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzMwMA_7dca1607-bd48-4aa5-bdd9-d55a08a2ea59"
      unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzM1OQ_d0c3b8fb-964d-4e09-bd6e-11cd82afdea8"
      unitRef="usd">6000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzUwMQ_0a38b31c-e8ad-4c94-8e10-78aa4153c861">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0NTk_18a61811-f237-4e69-9237-04f1b2a37689">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56.86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i503ea8a68f26416685bd1508d35865c3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzEtMS0xLTEtMjM5NDEx_d33ace62-f63c-4cfb-b37f-1395af0e7cf5"
      unitRef="shares">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i503ea8a68f26416685bd1508d35865c3_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzEtMy0xLTEtMjM5NDEx_71a9aa68-b895-4eaa-803d-fbae0407b363"
      unitRef="usdPerShare">46.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzItMS0xLTEtMjM5NDEx_2fe26a6d-b4e3-4dd2-9ef5-16f96d9ec987"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzItMy0xLTEtMjM5NDEx_80d79e13-2de7-4b25-8b0e-c1613b7f7e82"
      unitRef="usdPerShare">70.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzMtMS0xLTEtMjM5NDEx_6f20d7e0-4d4c-4ce5-bc6d-ee6cd5d16585"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzMtMy0xLTEtMjM5NDEx_702dffaa-0ef3-4e61-adca-e40d8c023686"
      unitRef="usdPerShare">49.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzQtMS0xLTEtMjM5NDEx_7e22662c-b0cd-4bbb-928f-9c6fe1b67c3e"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzQtMy0xLTEtMjM5NDEx_aa7f6dec-f554-44f1-b01a-881837d9d130"
      unitRef="usdPerShare">57.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5f2f86523a374ec7bcf6bf98d477b026_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzUtMS0xLTEtMjM5NDEx_8b67d704-cf4e-4ac7-8b79-bace9b9b1d47"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5f2f86523a374ec7bcf6bf98d477b026_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTplNGM5YTIxNWQyYzc0OTIxOWUwYmMwMmE3MWRiNDI0MC90YWJsZXJhbmdlOmU0YzlhMjE1ZDJjNzQ5MjE5ZTBiYzAyYTcxZGI0MjQwXzUtMy0xLTEtMjM5NDEx_76bcdd35-6a45-4bc9-a813-bea8a2dc3c30"
      unitRef="usdPerShare">56.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5f2f86523a374ec7bcf6bf98d477b026_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzg0OA_f196bc78-02be-4d9f-88a9-f60d88b46d90"
      unitRef="usd">108000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzkyMQ_48bcdc4b-f911-41a2-b26a-efc39849b3c8">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE2NDc_a6d848d7-8e3f-4c83-b770-12cc731487e4"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i5143d217945b451bb550ec1284ff9356_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTA_24f91f61-2a9e-4ef0-8791-582c169ea148"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i52092b4628a84f24953a6d6e5f6106ee_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTA_6ca42b74-79d7-479d-a51e-861534863fb7"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ifbae0f89cc2e464880a6f49f34d3015f_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTY_8c4c987b-cdbe-401a-a260-91aa1fc04586"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8077e88c3a2248e0b130f3f465521df1_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4MTY_97403093-87bb-49d9-9c37-16317776724a"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i52092b4628a84f24953a6d6e5f6106ee_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4ODY_44128b11-3123-4ac8-9615-0c8f24607fbf"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8bf7d991e3e1433e91f8172e38de1cf0_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzE4OTI_1b464551-61c3-4654-a771-82d275778c69"
      unitRef="number">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzI0OTE_2f10e63c-8bb2-4db6-bfa6-20dbeee5694a">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76.49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzEtMS0xLTEtMjM5NDEx_66f7477f-14f6-4395-937f-2953fe91996b"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzEtMy0xLTEtMjM5NDEx_471fa84a-4d64-4146-8be4-382c924aca1a"
      unitRef="usdPerShare">54.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzItMS0xLTEtMjM5NDEx_1932c111-54e1-4663-87f9-80ceecfcf7f9"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzItMy0xLTEtMjM5NDEx_0ed8fe6a-25d4-407b-9ce3-f6b502bd92b9"
      unitRef="usdPerShare">76.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzMtMS0xLTEtMjM5NDEx_51753727-4ee9-41bb-bd0b-8840c8ad198c"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzMtMy0xLTEtMjM5NDEx_c61b7f9e-9390-404b-9bc2-adfbd022d75c"
      unitRef="usdPerShare">59.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzQtMS0xLTEtMjM5NDEx_983564b4-fb2f-41d3-ae7d-cce2823741b8"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzQtMy0xLTEtMjM5NDEx_d3ba5c72-5e1f-493e-8cbe-e8954dc2ea98"
      unitRef="usdPerShare">64.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idc9a8d5ad3844888a89cd82186360d79_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzUtMS0xLTEtMjM5NDEx_1117bb9e-5cb6-45cf-a0a8-5fd278da4a66"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idc9a8d5ad3844888a89cd82186360d79_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90YWJsZTo5MGY0OTExYzAxYjI0ZTM0YjVjMDNiOWNhZTMzYWRmYS90YWJsZXJhbmdlOjkwZjQ5MTFjMDFiMjRlMzRiNWMwM2I5Y2FlMzNhZGZhXzUtMy0xLTEtMjM5NDEx_41dd1b3a-f817-41a1-9fe3-d97514cd65fd"
      unitRef="usdPerShare">76.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="idc9a8d5ad3844888a89cd82186360d79_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzIzMDA_66c869a0-3041-47cf-8492-159a75829c86"
      unitRef="usd">41000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2a8016fc5e4543eeb7f42433f7e0826c_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWFiYjk5MTNlMDRhYmZhYThmNzIyYjY3NTcxOTliL3NlYzo0OTVhYmI5OTEzZTA0YWJmYWE4ZjcyMmI2NzU3MTk5Yl8xMjQvZnJhZzo0YjQwNmU0OTg4ZmQ0MjMxYjViZmZlMjYyMmZlYjI5ZC90ZXh0cmVnaW9uOjRiNDA2ZTQ5ODhmZDQyMzFiNWJmZmUyNjIyZmViMjlkXzIzNzM_83489766-162d-41d9-bf37-4c1b33cfd6da">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !G@D)6$!Q^NL$%  #!'@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+69:V_;-A2&_PKA 4,+Q+%(Q7;2.08<)VFS]>+&V89NV =:HBVADNA1E)W\
M^QU*MN2NU+$@U/D0ZW9>\=$A>5Z)HZU47]- "$V>XRA)KSN!UNLWO5[J!2+F
MZ;E<BP3.+*6*N89=M>JE:R6XGP?%48\YSJ 7\S#IC$?YL9D:CV2FHS 1,T72
M+(ZY>KD1D=Q>=VAG?^ Q7 7:'.B-1VN^$G.A?U_/%.SU2A4_C$62AC(A2BRO
M.Q/Z9NHR$Y!?\4<HMNG!-C$H"RF_FIT'_[KCF!:)2'C:2'#XV8BIB"*C!.WX
M=R?:*>]I @^W]^KW.3S +'@JIC+Z,_1U<-VY[!!?+'D6Z4>Y?2=V0'VCY\DH
MS?^3;7'MQ46'>%FJ9;P+AA;$85+\\N?=@S@(<.L"V"Z _2^ U@6XNP W!RU:
MEF/=<LW'(R6W1)FK0<ULY,\FCP::,#%IG&L%9T.(T^.IW A%9I QTB5IP)5(
M1ST-PN9TS]N)W!0BK$9D0#[(1 <IN4M\X7\;WX,&E:UB^U;=,%3P5GCGQ*5G
MA#F,6=HSQ<-_Y4D9[B+-<<N'Y.9Z+OJ0_IXL4JV@W_UC>T*%PH5=P0S&-^F:
M>^*Z Z,M%6HC.N.??Z(#YQ<;W@\2^P;VHH2]P-3'M]++8)QJ\O2R%C92/)PZ
MW<\V)#2J)5*_1.HW0_J<<:6%BE[(HUA+I6UXN)16F>VA3-&HEGB#$F_0#&\F
M5"A],PH)3 ;6Y!U1VH^[VH&'QK?D'):<PX8]4W&H(WD9J,\CKK7D46I-)!K6
M$O"R!+Q$&W67Z%"_D/LP$N1C%B^$LH'A&K1+J3MT;6AH8$NTJQ+MJ@G:HUB%
M9A*%)'[DL;6'XCI3KOPPX1%Y)WBD@S/RD'CG-EA4IB4L=:JJZC3!G4)O5=#8
M!ZB+S^0W\6*MK;B4 W]#!CFE-DP\N"WG@7N@>#HRI<R(O ]3#SB_"*[0Z>>(
M7+?K#+JN8P5%(]N"L@J4-9M[#DGOX:#=+N%BW]N2'2,:UI:Q<CD4]17?,>[*
M23TE+O?96D#PH+:,E;FAN#V9 *!?0$9\9:7"!6H+!Q[7%JRR.!0W)KL9!Z9#
MJ: D<E,=S\A<PT D4I&IS& J@AE)^O:!B:M_>F=%/H7KH97MH;A;V2$_\6?R
MX$-*PV7HY=Q(\3PBZ=*N<]6_' P&5MY3N!]:V1^*>Y8=[\3W03T]VV^0]W =
M^938\XI+#J&XD+*FSB)HO!7\%*Z(5K:(-O)%)?C4[$&G?I+;Q J-R]UF"SAD
MY3R%1:*51Z*-3%+)68[>F9*;,+'FYN:(9LW(/84]8I4]8HWL40DZDZF&_O=7
MN*Z=H(XH7K@.'5J_%)S"(+'*(+$C!BGG5(+7@^$" WIAQ3J%'6*5'6*X@WDO
M<X,0R 1[4SDB,NP/NWV8@*Q\I[!"K+)"#/<N3Z&&=S"Y))2]6KPF<^%E"C)I
MA<25IC*.H2(5G];(JVVH YEIL@;[N.%1)EY;Z4]ADEAEDACN<>#]&@K"BLQ?
MXH6,K-"XP'1BG77PJ+98E45BN(G99Y'</7L!3U:B]AWTB-#'+_,[*]\I_!"K
M_!!KY(?V[V3%IY$\CU!'[!;^B.(7Z]?@*1[5EK/R0:R1#WI(M%#%,H!YW^1[
M<"LGKEC'>0K;PRK;PQI_#@(##U9@)95]"L)UWG,%?7WB>0*$0,8O)*W$IS!
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M5?MUP[.<-QH OZ^$4&\7NH/#&R6S_P!02P,$%     @ 9X)"5KS!E0X'!
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MK;[\Z=5/Q(BK HDM7WR&KZJ$LX7P]\U*:0E?_#^NW!?L73>[V0;':HL3,O6
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MR@;@]Y649M>Q)WEW<2?_ %!+ P04    " !G@D)66TAN7$80  #&O0  &
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M"F4@_[]D3+S_4!7L;^;._@]02P,$%     @ 9X)"5BI_D>$P!@  ;!   !@
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M?#K;IIOH:CE/SEW$Z50N5QAC\KP [Q<.$]C><(#^'PPG?P-02P,$%     @
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MTC !WJ^T=NT-"^@^*=[\#5!+ P04    " !G@D)6=5XJ(K,%  "3#0  &0
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M?6VDUFOX)!P/$S:IY;IBS)6"*KSE9[9Q@FZ5#^PV6\^; +H=7GZ(NP:N,F'
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M2VP,QX^Z#<XH'I!N_S_0<GFL7G<JZ1&\ES',2F_O('>&'N+Y !S,:@:.1?#
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M>C['LG@N,A3AR:P(L1!]4/:FZ=:R!>085_90%-P9/_;>H:BT74G,J/3&=S:
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MU\I_+@&^34,WX/K<N39^H W23S6]_%]02P,$%     @ 9X)"5H7:@VCR!P
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MR7OKU6RN_4HA.C+_ @@+%P7=>[&4VHI+63:J,ZJ2M@9QG/&L( 5S0#=*9H6
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MU#="XCRA<O'H'C%9O'Z53897)\B>]V3/3Z$?)?L)GP(LM94/1^F>!LRR >Q
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MY06F\8XX59.ZIJHMT^I'Y<F'MOT;!-^J,UNXC='5>L,X=NPOZ:Z^ Z6X:XQ
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M\\>1T"9C; DO^5<+:@1)(A*%V\RK/>H3L<8C@IL'2-'&=&#'=>8)5+Y]+$4
MN.(0X,GZTL.5A'MP7OJ@0X8Q?N.C2+>1E,&PHF%1#:<^XKG5MSE*(8S@M*F-
M0TG4_'+0PN=;U)V*,'!')J];<]!;U6X+P,\42<6^)MQ4:<5&ZN(<9PO+Z\E;
M^' MJ)PV2EVF6^C9(S<O)@_3*4F:^Y#./I4^G4),3&UC](B-OY\_8OMT7G:8
M=A/TB:[^(0Q1<W_FS.FO/S:BYA1=]W1,G\-I4PB3&>: H[:X%F\\3\0877&G
M'9[&,?7V:'>;AKB-*4[V"[Q.%K17?S'!XK_DU,0+/U],Z',T;(1?0/S1:>$7
M\9B&EWC2%7\^G[+XDW'\6'RD'OW&!? E16C#A$Y>^I-1?4AT9BRO-_QS!3[A
M2 ?$Y3Z &%M2YP\B)()SV@3G;U7F-Z0H+:C#]CO;+J2C4=0\_E+K@=[%*BZV
M!?UL7_ES""B,$FSH]W4KTD+FVY-1&X*6NB RE$??)T]+6VM+]^+(OP^4_WM5
M*C&*HV.S7HCA/%HL:*X:3J-QW![[D0^2.)IA;$R2:(HX:#<;1S.,LI-HCIGU
MYZZ\/-V.Y\1N/(KF&&9/_:@\Z/SDCT9\S7]LL(*;6?_K?_.T^>_$&_^7@7:Y
M_^/%]P#@'-A2J!5(X^O9I.>-'6Z<WO$?");:H>OG2VJ<E:$%>+_2:#_J&]J@
M^4?)Z_\ 4$L#!!0    ( &>"0E8B(9#I< 4  &H/   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;,U7VV[;.!#]E8$;% G@R+K9<=+$0)+N%>@B:'IY
M6.P#+8TMHI*HDK0=]^MWAI15N['3]*&+?;!,23-G9LY<*%ZNE/YD"D0+#U59
MFZM>86US,1B8K,!*F$ U6-.;F=*5L'2KYP/3:!2Y4ZK*01R&HT$E9-V;7+IG
M=WIRJ1:VE#7>:3"+JA)Z?8.E6EWUHM[FP5LY+RP_&$PN&S''>[3OFSM-=X,.
M)9<5UD:J&C3.KGK7T<5-RO).X(/$E=E: T<R5>H3W_R17_5"=@A+S"PC"/I;
MXBV6)0.1&Y];S%YGDA6WUQOT7UWL%,M4&+Q5Y4>9V^*J-^Y!CC.Q*.U;M?H=
MVWB&C)>ITK@KK+QLFO0@6QBKJE:9/*AD[?_%0\O#EL(X/* 0MPJQ\]L;<EZ^
M%E9,+K5:@69I0N.%"]5IDW.RYJ3<6TUO)>G9R7TA-)[>4%PYW*J*<FT$TW4Y
ML(3.,H.L1;KQ2/$!I 3>J-H6!GZI<\QW]0?D5>=:O''M)GX2\#5F 211'^(P
MCI[ 2[I0$X>7/"/4.[&FRK)PK;6HY^C6?U]/C=54)O_L"]YCI_NQN74N3",R
MO.I1;QC42^Q-7KZ(1N&K)SQ/.\_3I]!_*$E/(T5) (?0X","M[&E'U#A99]
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M3>E7 94]0.\74IK=PCJH?SX&OP%02P,$%     @ 9X)"5MYF]*5\!   A0L
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M&7X<;]2_^M@IEB4S.%7BF:<V'P97 :28L4K8![6^Q2:>"Z>7*&'\+ZR;LYT
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MJ2P]!7Z8T]N+VAV@_4PINYDX!^UK/OH%4$L#!!0    ( &>"0E:DP*-X708
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M?1*U [+JLZJ%%J7M;=9"4Z=DISMJ35$: _J^$4*?%B9 T^S._@%02P,$%
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M")H6EUN"(\+R"O+W-:7B[29W4)_J6?P+4$L#!!0    ( &>"0E9?[0YQ/P4
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MVJ":/9IM)P_O)Q^\,'D_^%C->%,$8C6W\Y;QPC]^^-IXZ1\_>6V\>F7[3SS
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M4:T.MI"4FEO:(37;TW=4;%@L40AKG>-=37011;KCFYXHODLV39^X4CQ*#K=
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M06S!F?S^&QYT_FB*L4TPWR988 FLE(U>GHU>&_IDNB)L"6:]/3#])8CH?[!
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M&:AFHIJ%:C:J.:CFHIJ':CZJ!:@64IJ8474_M=+>3_U3\RVTJ1K5-%334<U
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M^+H8:MB?CGM2.K^YW=[(D[OBW*HG729YGBPWG][&T56<EG<HOGZ=)/G3C7*
MAR3]NGDXYW\#4$L#!!0    ( &>"0E:=!;-"9P8  +TM   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0U+GAM;+V:;7.C-A#'OXK&O6F3F>1  C\D=3R3&-K>
M3*^72>[:%YV^D+%LTP/D SG.]=-7/ 0,"-G<[=V;Q,:KG[2[0MH_:+KG\<=D
MPYA SV$0)3>#C1#;:\-(O T+:?*:;UDD?UGQ.*1"?HW71K*-&5UFC<+ (*8Y
M,D+J1X/9-+MV'\^F?"<"/V+W,4IV84CCSW<LX/N; 1Z\7'CPUQN17C!FTRU=
MLT<F/FSO8_G-*"E+/V11XO,(Q6QU,[C%UZY%T@:9Q9\^VR<'GU'JRH+SC^F7
M-\N;@9F.B 7,$RF"RG]/;,Z"("7)<7PJH(.RS[3AX><7^B^9\]*9!4W8G =_
M^4NQN1E,!FC)5G07B >^_XT5#@U3GL>#)/N+]H6M.4#>+A$\+!K+$81^E/^G
MST4@#AI(CKH!*1J09@.[HX%5-+!.[<$N&MBG]C L&F2N&[GO6> <*NAL&O,]
MBE-K24L_9-'/6LMX^5$Z41Y%+'_U93LQ>]S0F&UXL&1Q\A-R/^U\\1F=S3<T
M6K,$^1$2&X9N/6\7[@(JV!*]DQ=B-.>AG)>;=,(\,?0F\GC(T-GO/$G.S]&9
MPP3U@^0<7:(/CPXZ>W6.7J6LMWX0R-F13 TAAYX.P/"*8=[EPR0=P[306QZ)
M38+<:,F6BO:.OOU(T]Z0(2OC1E[B=D>T0(=YKY&%+Q Q"5&,9WYZ<ZQRY^MZ
M=[^X]UHPK'(261G/ZN#=OIN_N4!_R&6-K]![^HS^?N!!@.2=O*?Q\A]5NG.@
MK0:FJ^-ULJ4>NQG(:9:P^(D-9C_^@$?FSZI80\(<2)@+!*MEQ2ZS8NOHLSL:
MT,ACB JT8&L_BOQHG29HRV*?J^ZANYPWRGCI#O,TN\3CB3DUG@ZCW;;"UM6H
M;N0H4&.S8>0J2.,KNS2J>3TLO1YJO3ZZ/EVD,U3EO9;;=TI"PIP<-CR(T[ 1
MR;;%6!W&41G&D3:,[[F@ >)9,+U:,/TLF,99D <SRN]ZH8[IJ#4NJSF=VB:7
MQ&[,)H6-11HA4-@,L3H(XS((XU/O(!8M]??.6.$&P8U!SMM6V#0;1LY)*/<(
MJN;PI'1XHG58KMBRLHK0?!?'+/(^H_<QC1*Y\:<UW>WR7UF/R")1*#=P+;GO
M[0,)<R!A+A"LEIZK,CU7T/OL%616(&$.),P%@M6R@LVJAC:!=UH]L&]>0&E.
M0:NM/[BY2+DJ*WND7G[P@1K!7[M[+YB4QPP],"^@2>*O?"];GI+#&T,9<FW/
MO4,.27,*6GV#FS0CKC"RK8Z(DRKB1!OQ9AS1*N;AB8KOHM@H!+K/9OK1%&B'
MTCL%D#2GH!U&UVPF0&=2#W^EG+!6 D#56?I>>D<65% 5M".36V'4.;DK!81/
MED!'"[@"55_V[&:UJK*:7#4*N)-0[A%4W>5*_F"]_OD0Q8P&_G_RQOV5^I&1
M+YM(WMB.=/V)IL_EDJ/3"50+@=(<4)H+1:MGJU)9> 1=T6&M<.N=&TB: TIS
MH6CUW%3B#Y^L_DZMZK3 WJF!I#E8H2I;FE)AA#LD):XT)=:+RF]9TX&*3E":
M4]!JL<3->+=M+H<=\:Y$(M:JG>];T8'J2U":4] Z@ELD0&'347602@X2O1P$
MJNGTO?2-+2C-(6WUUWRXJS"YG'2$MM*'1*\/^Q1T1*&7&H.<*VR:SQY/P+A:
M3-W52I@1O3 [=L.F2Z?2;5"1!4IS0&DN%*V>H$JZ$?"W7@14IH'2'%":"T6K
MYZ82?@3ZW9<>V#LUD#2'J/0DMIN+D,+*ZEJ&*CU)]'H2:C,#592@-(>TWYZU
M7R^IC+K>+Y%*_Q']:[9>^YGB#1>V6SN:PFHR;.YIIZ#<(ZBZRY6L(GI9E2Z;
MZ%:(V%_L!%T$# F.[FE:="J]!M54H#0'E.9"T>IYJ60:F8!O9Z#R"Y3F@-)<
M*%H]-Y6D(WI)]P7;F4+8X'%KL5!8C7!SL5"AVKN/2DEU[#Y6):4LO93ZAL\.
M]#WW/H($*J\LA78BXT;$549VA\*R*H5EZ176]WQZH!]*[Q2 OI*S%+*O^?1
M9=/Q],"J=)^EUWU]2H("-=*7!"JK5DEP$LH]@LI=-@Z.HX8L7F?G@!-9/>XB
MD1\J+*^69XUOLQ.VC>MW^'J.%=<=?.WF)XDK?'ZP^2V-Y?*8H("M9%?FZ[',
M39R?%<Z_"+[-#L,NN! \S#YN&%VR.#60OZ\X%R]?T@[*$]NS_P%02P,$%
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MAAV45<#UM91F/[$&VK\ T0]02P,$%     @ 9X)"5D:N36:G!   ]1X  !D
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M7A\9K"]$OJW.Q*UR(?*T>KMA0<1X*9"?W^>Y>+HH&V@/;B[^!U!+ P04
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M.!+=DXBM4OH/45_<)&R;RK8 R%T8U%Z%KG-Y\$(UNME5U\M7[]Y7 P:0 X9
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MDV2!2;+0$%FCB*[S>R1Q# M(2=AXN7!:"J*S:2F(SF38DA"-S:@E(79M',N
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M)D:8ACFNTCQ/\Y4)I@W*5"1P1QOHG'(/?U6ZQQGAE@E= )M#9C<*F]' WU7
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MOBQ>F*2S3@'')8D&S2ZY5[IBW76TV-@">2XTE=NVN:8/')1F KU?"J&/';-
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M(1;Q-F9.62CGWH0;PMP7SN('$ 5EH8+90D.8^V!>NSAO%I2%"F8+#4;SW'O
M)+]XCI]S%Y2%"F8+'5ZG=^,HQJ0L5+R&A08QYWCV*L:D+%2\AH4.8?;?&R!?
M''B-S;B#F+&%"LI"16>AT?YMH J6RD#U%?_"8WDI=3ESHOW8/;3,B_89P[+1
M^@++[LRME=7^Y:+]BU&?_@902P,$%     @ :()"5@P_D/SE 0  ?R$  !H
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M"[(M!&X+PBT$<@O2+01V"^(M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&]%O95
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !G@D)6O$P>$^\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !G@D)6
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( &>"0E80''ZZP04  ,$>   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !G@D)6
M1)3G=4X'  !=(@  &               @($%#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ 9X)"5KS!E0X'!   KP\  !@
M     ("!B14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M &>"0E;<VW-Q8@8  -,;   8              " @<89  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !G@D)6M^>*>*0"  #$!P  &
M            @(%>(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ 9X)"5EM(;EQ&$   QKT  !@              ("!.",  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &>"0E:X7&U!^0@  *4[
M   8              " @;0S  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !G@D)6*G^1X3 &  !L$   &               @('C/
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 9X)"5D?8:C4Y
M P  Q 8  !@              ("!24,  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( &>"0E:\L_'B1 0  !4+   9              "
M@;A&  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 9X)"
M5II2K<%$!P  7A0  !D              ("!,TL  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !G@D)6=5XJ(K,%  "3#0  &0
M        @(&N4@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( &>"0E8,[9B],!D  +9)   9              " @9A8  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 9X)"5H7:@VCR!P  CA8
M !D              ("!_W$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !G@D)6PM7H!Z@$   ;"P  &0              @($H>@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &>"0E:)^1UH
MDPL  $DF   9              " @0=_  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ 9X)"5B=?SLX@!0  +!   !D
M ("!T8H  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !G
M@D)6TX<O8*0#   @"@  &0              @($HD   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &>"0E;GS0N'' P  %TB   9
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M970R,RYX;6Q02P$"% ,4    " !G@D)60$>@7[@$   Q"P  &0
M    @(&/M   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M &>"0E:HCC-7VP(  %P&   9              " @7ZY  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ 9X)"5M=4#ZE; P  2P@  !D
M             ("!D+P  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !G@D)6N_G9X@H#  #9!P  &0              @($BP   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &>"0E:DP*-X708
M *@2   9              " @6/#  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ 9X)"5O!J[,?/ P  ^ H  !D              ("!
M]\D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !G@D)6
MJ4NRRQ8#  "("P  &0              @(']S0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( &>"0E:]!"OG!0,  .T)   9
M      " @4K1  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ 9X)"5BS)MREF P  !0T  !D              ("!AM0  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !G@D)6\EIV6LP"  #("
M&0              @($CV   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( &>"0E;IWZ*1!P4  .$C   9              " @2;;  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 9X)"5E_M#G$_
M!0  I1P  !D              ("!9.   'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !G@D)6_/JR(^\%  !-+P  &0
M@(':Y0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &>"
M0E8U.("&:04  !TI   9              " @0#L  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ 9X)"5M]Q[;"* @  JP8  !D
M         ("!H/$  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " !G@D)601_HC5$1  !$$ $ &0              @(%A]   >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &>"0E9AG5G(\@8  #M!
M   9              " @>D% 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ 9X)"5DA;C?@@!   @Q<  !D              ("!$@T!
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !G@D)66)'Q
M/]$$  "?&@  &0              @(%I$0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( &>"0E9Z0E)HW@(  'T(   9
M  " @7$6 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M9X)"5I.4BG]3"P  @;<  !D              ("!AAD! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !G@D)6G06S0F<&  "]+0  &0
M            @($0)0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( &>"0E80I\\($P,  *X)   9              " @:XK 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 9X)"5A=*L,QR P
M#@P  !D              ("!^"X! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " !G@D)61JY-9J<$  #U'@  &0              @(&A
M,@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &>"0E:^
MK\KFN 4  ,0I   9              " @7\W 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ 9X)"5J'6-;:2!   GQX  !D
M     ("!;CT! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B"0E8H(IRK P0   4.   9              "
M@?]4 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ :()"
M5CMF8^K< P  /@T  !D              ("!.5D! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " !H@D)6H\K<PC0#  #.$P  #0
M        @ %,70$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &B"0E:7BKL<
MP    !,"   +              "  :M@ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( &B"0E85_[6_C@0  )PE   /              "  91A 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !H@D)6##^0_.4!  !_(0  &@
M    @ %/9@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !H@D)6C^&W:=,!   V(0  $P              @ %L: $ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     0 !  '<1  !P:@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>251</ContextCount>
  <ElementCount>242</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Discontinued Operations and Disposal Groups (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Restructuring and Employee Severance Narative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Shareholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails</Role>
      <ShortName>Segment Information Revenue From External Customers By Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20221231.htm">cah-20221231.htm</File>
    <File>a23q2_10qx123122xex3111.htm</File>
    <File>a23q2_10qx123122xex3121.htm</File>
    <File>a23q2_10qx123122xex3211.htm</File>
    <File>a23q2_10qx123122xex9911.htm</File>
    <File>a23q2_10qx123122xexhibit101.htm</File>
    <File>a23q2_10qx123122xexhibit102.htm</File>
    <File>cah-20221231.xsd</File>
    <File>cah-20221231_cal.xml</File>
    <File>cah-20221231_def.xml</File>
    <File>cah-20221231_lab.xml</File>
    <File>cah-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20221231_g1.jpg</File>
    <File>cah-20221231_g2.jpg</File>
    <File>cah-20221231_g3.jpg</File>
    <File>cah-20221231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="795">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20221231.htm": {
   "axisCustom": 6,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 795,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 251,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 469,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 21,
   "keyStandard": 221,
   "memberCustom": 30,
   "memberStandard": 40,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Restructuring and Employee Severance",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Goodwill and Other Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i392074a1226d4b82bb41d7f30b359497_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i392074a1226d4b82bb41d7f30b359497_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Segment Information",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Statements of Earnings",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "icc75351148f9471193785633b036daec_D20211001-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "icc75351148f9471193785633b036daec_D20211001-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Restructuring and Employee Severance (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Segment Information (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Discontinued Operations and Disposal Groups (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
     "shortName": "Discontinued Operations and Disposal Groups (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "ia13be735cc2443ad8517d5f01b6bfd7e_D20210701-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i67172f4a4b5744899699d8c0d3f2b040_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i67172f4a4b5744899699d8c0d3f2b040_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Restructuring and Employee Severance Narative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails",
     "shortName": "Restructuring and Employee Severance Narative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i67172f4a4b5744899699d8c0d3f2b040_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i67172f4a4b5744899699d8c0d3f2b040_I20220630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:IncomefromSettlementsofClassActionLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:IncomefromSettlementsofClassActionLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i47e19d8b09ce4d819512bc1e56ff8edd_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i47e19d8b09ce4d819512bc1e56ff8edd_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Financial Instruments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Shareholders' Equity (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i44235a75341c4ea98c8f81b1b8a2af14_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i62a5991ceefb4f3fbff0ab7d3de1ef49_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segment Information (Narrative) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "ideb7ebd0dccf4880b310bb4ffe79ba9c_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i1a8525d995764ce5b450cdac8555b3bf_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
     "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "iaf2a6bafa71e46f6bff513c85997576c_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i9510233b4906437c8abfc1fb414285bc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i2f93e137bed843d5bbce9e33653971d9_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i251b6a00e95740f8ba3c9461da70c1cd_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i503ea8a68f26416685bd1508d35865c3_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i1d2b5b3720054ef4a6ef09c345dd28cc_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i2aca8e52a290406d97f8faa6c40af51d_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "ib39a861394a24af5ae49b541f0fd87ca_D20210701-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i41b4b1daca6f463c9802c03ddd9f2754_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Divestitures",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cardinal.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20221231.htm",
      "contextRef": "i4c667c90d90b4282901ffcfe38b894c2_D20220701-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "cah_A1BillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$1 billion share repurchase program",
        "label": "$1 billion share repurchase program [Member]",
        "terseLabel": "$1 billion share repurchase program"
       }
      }
     },
     "localname": "A1BillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A250MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$250 million share repurchase program",
        "label": "$250 million share repurchase program [Member]",
        "terseLabel": "$250 million share repurchase program [Member]"
       }
      }
     },
     "localname": "A250MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A300MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$300 million share repurchase program",
        "label": "$300 million share repurchase program [Member]",
        "terseLabel": "$300 million share repurchase program"
       }
      }
     },
     "localname": "A300MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A500MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$500 million share repurchase program [Domain]",
        "label": "$500 million share repurchase program [Member]",
        "terseLabel": "$500 million share repurchase program [Domain]"
       }
      }
     },
     "localname": "A500MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CARESActDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act",
        "label": "CARES Act [Domain]",
        "terseLabel": "Net Operating Loss Carryback [Domain]"
       }
      }
     },
     "localname": "CARESActDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home [Member]",
        "label": "Cardinal Health At Home [Member]",
        "terseLabel": "Cardinal Health At Home [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CashReclassifiedToAssetHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Reclassified to Asset Held for Sale",
        "label": "Cash Reclassified to Asset Held for Sale",
        "terseLabel": "Cash and equivalents reclassified from/(to) assets held for sale"
       }
      }
     },
     "localname": "CashReclassifiedToAssetHeldForSale",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Axis]",
        "terseLabel": "Cordis Divestiture [Axis]"
       }
      }
     },
     "localname": "CordisDivestitureAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_CordisDivestitureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture [Domain]",
        "label": "Cordis Divestiture [Domain]",
        "terseLabel": "Cordis Divestiture [Domain]"
       }
      }
     },
     "localname": "CordisDivestitureDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Member]",
        "terseLabel": "Cordis Divestiture"
       }
      }
     },
     "localname": "CordisDivestitureMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DiscountRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount Rate, Fair Value Input",
        "label": "Discount Rate, Fair Value Input",
        "terseLabel": "Discount Rate, Fair Value Input"
       }
      }
     },
     "localname": "DiscountRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_GoodwillImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment",
        "label": "Goodwill Impairment [Axis]",
        "terseLabel": "Goodwill Impairment [Axis]"
       }
      }
     },
     "localname": "GoodwillImpairmentAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_GoodwillImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment [Domain]",
        "label": "Goodwill Impairment [Domain]",
        "terseLabel": "Goodwill Impairment [Domain]"
       }
      }
     },
     "localname": "GoodwillImpairmentDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_GrossInsuranceSettlementBeforeAttorneyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Insurance Settlement Before Attorney Fees",
        "label": "Gross Insurance Settlement Before Attorney Fees",
        "terseLabel": "Gross Insurance Settlement Before Attorney Fees"
       }
      }
     },
     "localname": "GrossInsuranceSettlementBeforeAttorneyFees",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "Trademarks and patents"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IncomefromSettlementsofClassActionLawsuits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from Settlements of Class Action Lawsuits",
        "label": "Income from Settlements of Class Action Lawsuits",
        "terseLabel": "Income from Settlements of Class Action Lawsuits"
       }
      }
     },
     "localname": "IncomefromSettlementsofClassActionLawsuits",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification Receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_JudgmentForLostProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment for lost profits",
        "label": "Judgment for lost profits",
        "terseLabel": "Judgment for lost profits"
       }
      }
     },
     "localname": "JudgmentForLostProfits",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LawsuitTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Domain]",
        "terseLabel": "Lawsuit Type [Domain]"
       }
      }
     },
     "localname": "LawsuitTypeDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]"
       }
      }
     },
     "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract",
     "nsuri": "http://www.cardinal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "verboseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_MaturityDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date",
        "label": "Maturity Date [Axis]",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "MaturityDateAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_MaturityDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date [Domain]",
        "label": "Maturity Date [Domain]",
        "terseLabel": "Maturity Date [Domain]"
       }
      }
     },
     "localname": "MaturityDateDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitGoodwillImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit Goodwill Impairment",
        "label": "Medical Unit Goodwill Impairment [Member]",
        "terseLabel": "Medical Unit Goodwill Impairment [Member]"
       }
      }
     },
     "localname": "MedicalUnitGoodwillImpairmentMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit",
        "label": "Medical Unit [Member]",
        "terseLabel": "Medical Unit"
       }
      }
     },
     "localname": "MedicalUnitMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NarativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Narative [Abstract]",
        "label": "Narative [Abstract]",
        "terseLabel": "Narative [Abstract]"
       }
      }
     },
     "localname": "NarativeAbstract",
     "nsuri": "http://www.cardinal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cah_NativeAmericanTribesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Native American tribes",
        "label": "Native American tribes [Member]",
        "terseLabel": "Native American tribes"
       }
      }
     },
     "localname": "NativeAmericanTribesMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NetOperatingLossCarrybackAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Axis]",
        "terseLabel": "Net Operating Loss Carryback [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net tax proceeds/(withholdings) from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NuclearPrecisionHealthSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Solutions",
        "label": "Nuclear Precision Health Solutions [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthSolutionsMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation [Axis]"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project costs on investment and other spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Line Items]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Table]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SettlingStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling States",
        "label": "Settling States",
        "terseLabel": "Settling States"
       }
      }
     },
     "localname": "SettlingStates",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_SettlingUSTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling U.S Territories",
        "label": "Settling U.S Territories",
        "terseLabel": "Settling U.S Territories"
       }
      }
     },
     "localname": "SettlingUSTerritories",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_ShareholderDerivativeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Derivative Litigation",
        "label": "Shareholder Derivative Litigation [Member]",
        "terseLabel": "Shareholder Derivative Litigation [Member]"
       }
      }
     },
     "localname": "ShareholderDerivativeLitigationMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares that would be antidilutive as a result of net loss",
        "label": "Shares that would be antidilutive as a result of net loss",
        "terseLabel": "Shares that would be antidilutive as a result of net loss"
       }
      }
     },
     "localname": "SharesThatWouldBeAntidilutiveAsAResultOfNetLoss",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMattersAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Axis]",
        "terseLabel": "Tax Matters Agreement [Axis]"
       }
      }
     },
     "localname": "TaxMattersAgreementAxis",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMattersAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Domain]",
        "terseLabel": "Tax Matters Agreement [Domain]"
       }
      }
     },
     "localname": "TaxMattersAgreementDomain",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TerminalGrowthRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminal Growth Rate, Fair Value Input",
        "label": "Terminal Growth Rate, Fair Value Input",
        "terseLabel": "Terminal Growth Rate, Fair Value Input"
       }
      }
     },
     "localname": "TerminalGrowthRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_TotalLongTermandShortTermObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Long-Term and Short-Term Obligations",
        "label": "Total Long-Term and Short-Term Obligations",
        "terseLabel": "Total Long-Term and Short-Term Obligations"
       }
      }
     },
     "localname": "TotalLongTermandShortTermObligations",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20221231",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r238",
      "r269",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r291",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r352",
      "r354",
      "r355",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r238",
      "r269",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r291",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r352",
      "r354",
      "r355",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r297",
      "r561",
      "r621",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r408",
      "r511",
      "r528",
      "r546",
      "r547",
      "r559",
      "r567",
      "r575",
      "r620",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r408",
      "r511",
      "r528",
      "r546",
      "r547",
      "r559",
      "r567",
      "r575",
      "r620",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r297",
      "r561",
      "r621",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r401",
      "r408",
      "r435",
      "r436",
      "r437",
      "r510",
      "r511",
      "r528",
      "r546",
      "r547",
      "r559",
      "r567",
      "r575",
      "r612",
      "r620",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r401",
      "r408",
      "r435",
      "r436",
      "r437",
      "r510",
      "r511",
      "r528",
      "r546",
      "r547",
      "r559",
      "r567",
      "r575",
      "r612",
      "r620",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r409",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r251",
      "r409",
      "r583",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r294",
      "r295",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r560",
      "r574",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r560",
      "r574",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r251",
      "r409",
      "r583",
      "r584",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_AL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ALABAMA",
        "terseLabel": "ALABAMA"
       }
      }
     },
     "localname": "AL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "GEORGIA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OKLAHOMA",
        "terseLabel": "OKLAHOMA"
       }
      }
     },
     "localname": "OK",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEST VIRGINIA",
        "terseLabel": "WEST VIRGINIA"
       }
      }
     },
     "localname": "WV",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r170",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r33",
      "r39",
      "r137",
      "r220",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r34",
      "r39",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r36",
      "r38",
      "r39",
      "r209",
      "r522",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r35",
      "r39",
      "r137",
      "r505",
      "r529",
      "r530",
      "r585",
      "r586",
      "r587",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r59",
      "r77",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r35",
      "r39",
      "r137",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r165",
      "r179",
      "r205",
      "r235",
      "r277",
      "r283",
      "r289",
      "r299",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r355",
      "r356",
      "r470",
      "r474",
      "r493",
      "r573",
      "r618",
      "r619",
      "r631"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r199",
      "r212",
      "r235",
      "r299",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r355",
      "r356",
      "r470",
      "r474",
      "r493",
      "r573",
      "r618",
      "r619",
      "r631"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNet": {
     "auth_ref": [
      "r12",
      "r190",
      "r191",
      "r193",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net assets (liabilities).",
        "label": "Net Assets",
        "terseLabel": "Net Assets"
       }
      }
     },
     "localname": "AssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r468",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r468",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r61",
      "r201",
      "r548"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r55",
      "r61",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r55",
      "r159"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r336",
      "r337",
      "r536",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r593",
      "r594",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at December\u00a031, 2022 and June 30, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r40",
      "r217",
      "r219",
      "r227",
      "r518",
      "r525"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r131",
      "r140",
      "r217",
      "r219",
      "r226",
      "r517",
      "r524"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r72",
      "r282",
      "r283",
      "r284",
      "r285",
      "r291",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r46",
      "r512"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r233",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r373",
      "r380",
      "r381",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r166",
      "r167",
      "r178",
      "r238",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r504",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r371",
      "r492",
      "r555",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r27",
      "r238",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r504",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r27",
      "r109",
      "r112",
      "r113",
      "r114",
      "r160",
      "r161",
      "r163",
      "r177",
      "r238",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r504",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r59",
      "r272"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Forward Contract"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r153",
      "r154",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r147",
      "r149",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r152",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative Liability, Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r151",
      "r153",
      "r155",
      "r156",
      "r158",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r412",
      "r440",
      "r441",
      "r443",
      "r447",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r11",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r115",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r108",
      "r195",
      "r220",
      "r221",
      "r222",
      "r239",
      "r240",
      "r241",
      "r243",
      "r248",
      "r250",
      "r263",
      "r300",
      "r400",
      "r444",
      "r445",
      "r446",
      "r457",
      "r458",
      "r483",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r505",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r485",
      "r486",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r371",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r486",
      "r507",
      "r508",
      "r509",
      "r555",
      "r556",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r371",
      "r402",
      "r407",
      "r486",
      "r507",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r371",
      "r402",
      "r407",
      "r486",
      "r508",
      "r555",
      "r556",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r371",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r486",
      "r509",
      "r555",
      "r556",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r371",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r507",
      "r508",
      "r509",
      "r555",
      "r556",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r489",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r203",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization of intangible assets - Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r315",
      "r317",
      "r318",
      "r320",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r82",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r82",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r550",
      "r562",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "(Gain)/loss on sale of equity interest in naviHealth"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r614"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Loss Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r59",
      "r102",
      "r103"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r202",
      "r302",
      "r515",
      "r553",
      "r573",
      "r601",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r304",
      "r311",
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r59",
      "r303",
      "r308",
      "r314",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r45",
      "r235",
      "r277",
      "r282",
      "r288",
      "r291",
      "r299",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r355",
      "r356",
      "r493",
      "r552",
      "r618"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r147",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r164",
      "r172",
      "r189",
      "r277",
      "r282",
      "r288",
      "r291",
      "r520",
      "r552"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r42",
      "r171",
      "r173",
      "r186",
      "r228",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r254",
      "r256",
      "r257",
      "r484",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r42",
      "r186",
      "r188",
      "r228",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r254",
      "r256",
      "r257",
      "r258",
      "r484",
      "r519",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Schedule of Assets and Liabilities Held for Sale [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r321",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r236",
      "r451",
      "r455",
      "r456",
      "r459",
      "r461",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r237",
      "r249",
      "r250",
      "r275",
      "r449",
      "r460",
      "r463",
      "r527"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r316",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r79",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InsuranceRecoveries": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.",
        "label": "Insurance Recoveries",
        "terseLabel": "Insurance Recoveries"
       }
      }
     },
     "localname": "InsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r76",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r162",
      "r175",
      "r223",
      "r271",
      "r503"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r210",
      "r549",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r169",
      "r182",
      "r573",
      "r592",
      "r600",
      "r628"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r200",
      "r235",
      "r299",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r355",
      "r356",
      "r471",
      "r474",
      "r475",
      "r493",
      "r573",
      "r618",
      "r631",
      "r632"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r28",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r28",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Estimated Litigation Liability, Current"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion",
        "verboseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings",
        "verboseLabel": "Long-term Debt and Lease Obligation, Current"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r27",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r98",
      "r99",
      "r338",
      "r339",
      "r340",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r338",
      "r339",
      "r340",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r338",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "negatedTerseLabel": "Loss Contingency Accrual, Period Increase (Decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss Contingency Accrual, Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r339",
      "r340",
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r98",
      "r99",
      "r338",
      "r339",
      "r340",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss Contingency, Number of Plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss Contingency, Pending Claims, Number"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r31",
      "r168",
      "r181",
      "r235",
      "r299",
      "r344",
      "r347",
      "r348",
      "r349",
      "r355",
      "r356",
      "r493"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r115",
      "r133",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r57",
      "r60"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r44",
      "r60",
      "r174",
      "r187",
      "r198",
      "r215",
      "r218",
      "r222",
      "r235",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r255",
      "r277",
      "r282",
      "r288",
      "r291",
      "r299",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r355",
      "r356",
      "r484",
      "r493",
      "r552",
      "r618"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r135",
      "r139",
      "r215",
      "r218",
      "r249",
      "r250",
      "r587"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r129",
      "r400",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r277",
      "r282",
      "r288",
      "r291",
      "r552"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings/(loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r211",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r221",
      "r495",
      "r497",
      "r501",
      "r585"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r213",
      "r214",
      "r476",
      "r477",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r108",
      "r216",
      "r219",
      "r225",
      "r495",
      "r500",
      "r501",
      "r516",
      "r523",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r131",
      "r132",
      "r136",
      "r216",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r37",
      "r220",
      "r225",
      "r449",
      "r462",
      "r464",
      "r495",
      "r498",
      "r501",
      "r516",
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-Term Borrowings",
        "terseLabel": "Other Short-term Borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for Legal Settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r325",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestitures, net of cash sold"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r231",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Proceeds from Insurance Settlement, Operating Activities"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from disposal of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityAccrualPeriodExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loss reported during the period pertaining to product liability.",
        "label": "Product Liability Accrual, Period Expense",
        "terseLabel": "Product Liability Accrual, Period Expense"
       }
      }
     },
     "localname": "ProductLiabilityAccrualPeriodExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r198",
      "r215",
      "r218",
      "r230",
      "r235",
      "r242",
      "r249",
      "r250",
      "r277",
      "r282",
      "r288",
      "r291",
      "r299",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r355",
      "r356",
      "r469",
      "r472",
      "r473",
      "r484",
      "r493",
      "r520",
      "r552",
      "r569",
      "r570",
      "r587",
      "r618"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r88",
      "r184",
      "r521",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r229",
      "r301"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r183",
      "r192",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r221",
      "r495",
      "r499",
      "r501",
      "r585"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r68",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r68",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r67",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r313",
      "r314",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r313",
      "r314",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r323",
      "r325",
      "r328",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r59",
      "r329",
      "r331",
      "r613"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring and employee severance",
        "totalLabel": "Total restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r325",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r115",
      "r180",
      "r532",
      "r534",
      "r573"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r195",
      "r239",
      "r240",
      "r241",
      "r243",
      "r248",
      "r250",
      "r300",
      "r444",
      "r445",
      "r446",
      "r457",
      "r458",
      "r483",
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r224",
      "r235",
      "r268",
      "r269",
      "r281",
      "r286",
      "r287",
      "r293",
      "r294",
      "r297",
      "r299",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r351",
      "r353",
      "r355",
      "r356",
      "r493",
      "r520",
      "r618"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r39",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r78",
      "r81",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r553",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r92",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r70",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r206",
      "r207",
      "r208",
      "r264",
      "r384",
      "r385",
      "r386",
      "r388",
      "r392",
      "r397",
      "r399",
      "r559",
      "r582",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r297",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r327",
      "r333",
      "r553",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r277",
      "r280",
      "r285",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r197",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r297",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r322",
      "r327",
      "r333",
      "r553",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r30",
      "r108",
      "r195",
      "r220",
      "r221",
      "r222",
      "r239",
      "r240",
      "r241",
      "r243",
      "r248",
      "r250",
      "r263",
      "r300",
      "r400",
      "r444",
      "r445",
      "r446",
      "r457",
      "r458",
      "r483",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r505",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r263",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r108",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r115",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r19",
      "r20",
      "r74",
      "r573",
      "r592",
      "r600",
      "r628"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r129",
      "r130",
      "r138",
      "r195",
      "r196",
      "r221",
      "r239",
      "r240",
      "r241",
      "r243",
      "r248",
      "r300",
      "r400",
      "r444",
      "r445",
      "r446",
      "r457",
      "r458",
      "r483",
      "r495",
      "r496",
      "r501",
      "r505",
      "r530",
      "r531",
      "r592",
      "r600",
      "r628"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r234",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r400",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Stockholders' Equity, Other Shares"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r502",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r502",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r502",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r29",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r29",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Common shares in treasury"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r17",
      "r108",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Treasury shares acquired (in shares)",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r29",
      "r116",
      "r117"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common shares in treasury, at cost: 68 million shares and 54 million shares at December\u00a031, 2022 and June 30, 2022, respectively",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r108",
      "r115",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r324",
      "r325",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r448",
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r253",
      "r258"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r252",
      "r258"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r577": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r578": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r579": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r581": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0000721371-23-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-23-000007-xbrl.zip
M4$L#!!0    ( &B"0E8!#]FE_ <  #4G   ;    83(S<3)?,3!Q>#$R,S$R
M,GAE>#,Q,3$N:'1M[5I=;QLW%GW?7\'*V-0!]#62',NR8\"U7<1%FK2I%\$^
M+:@9CH9KSG!*<B1K?_V>2XYLR983N6X=K;$%JGB&EY>7Y.&YAQP>?7?V\?3R
MG[^<L\SEBOWRCQ_>7YRR1JO3^=P_[73.+L_8N\N?W[-!NQNQ2\,+*YW4!5>=
MSOF'!FMDSI6C3F<VF[5G_;8VD\[EIPZY&G24UE:T$Y<TCH_H#7X%3X[_=O1=
MJ\7.=%SEHG L-H([D;#*RF+"/B?"7K%6J[8ZU>7<R$GF6*_;Z[//VES)*0_E
M3CHECA=^CCKA^:CC&SD:ZV1^?)3(*9/)VX8<#F*1BB@>]+N]06\_.G@3#P<B
M.N#)<)BF!_&_(@39@7FH8]U<B;>-7!:M3%#[HT&OO;]7NL.93%PVBKK=OS=6
M3)VX=BVNY*08Q0A'&!0[/E9B83#6)A&F%6NE>&G%:/''82)MJ?A\) LE"]'R
ME0YS;B9H?*R=T_F(&IX*XV3,5=V(;R\4US$='+0'T1Z%Y0S^3Q8-UQ&W?<0=
ME]POZT?M@^'PP>)N.WJP[(MN>^W>L/=7N,4L;N2VXT<BC ;&VY:\>-OH-Q85
M2IXD -VHRZ+2+?G[<TQ[Y349'RXAPT/Y[DR&283/5&,YU$[@5YO13M?_=T@E
MK93G4LU'WY\8R17[P(W1L^^;%BNR9861:;"R\C\"\$2[_G$6T+L/)QY=-9H#
M?L^O,SF6CF'^HZ,.V2^/6\<C<6E5A BQM*BPMO:O[Z^;%?2^61V$?U?6R73^
MUW9X<+?#/>KP19/]Q*TNV,]M]H[6GVFRF&8CG3.7<?=J9V]XN-JW+_:JGNJ6
M$JD;]=?W,[R210)6&+6BH8?/L_<\:B^Z]<Q-KXY1!*2]H1&X8!F?"F;$5(H9
MV-]ETK(?M<E9U&W]RG3*3KE!/<3P3G#ELB:[*.(V)NC@94Y0;\LFZ =N,2U8
M*OF<715ZID0R$<TP3T:4VCB6:&%9H9'"T027!>/%G%6%,Q4E/21UG]\QE9SE
M>/+QICS&*\-T#MYQ.MC=,RA$+*SE9DXF.;\2:'?)I\6[!,&@2>7% =H@@U@:
MB &8%:B.2)!OV2R3<<9L13^W]6?"B-H)=2"75D$UD "929>A@[84L0^0_)8(
M31/7@[DQ*./Y\C"\7$CV_U<@*5@*IBAB:OUVDIO (\Q1;);*99&"93AI6/P=
MJRJ!3P!I:4:; *$T:LY*X( @3-!6ZA:C-3SLG::Q#!(OCIMD42D8 )@:Z/'-
M61]/S&W&4J5G=H%:(R;2.BAKQSB]#'$CRN82^.PBF'O1OES\#;8,?Y<KD_5J
M9]B+]@]MC;!:1A"%Z#25>-RUK_U,7C!NA,<,,"!I1X"Y9<*2O)(VHQIDEH-!
MB47I&5N"6&E;H1YQJX'(]#:ET;%(\-JR76 E$0!? ,3Y=9SQ8B+8"6CK4Z5@
M$?5Y*]K;%2&*:"\)3^%1TA:E"* E_XRX;0G+ 5L4R\8-I2L-I6B(^GD7X;"@
MS/\DI;7?VV+4[O+76P%;W_TS83% F#F? +\.JR;EYIA7=O,JE"3' A"I6PII
M5U<&#L!=4VD](\)*%-X/">U;+EWF8R,4]YBK\^XM;IHU5U.A!*\B%JN53/S)
M@:W&5B:2&TD=D$$=^ Q1D*?*4L;VJ]3Z].[Y4UN!@!SXFBJ5G+9D%38$H'UT
MRP=QF_E1(^B(9?F#O\:"#,',J"^2)S'Q=F-ZO+68WIC([D%[<PK<&.%8%5.9
M$'!IE^E/?[@%Z$F0$IK]EF928UM)/I9*NCD)@77-TCKS(/3X"DMDQ71)T/J4
M<EUWJ*Q,"7Q;+USB6)O$!^"E[404T",*,$>)*&G]D ED>X RUIDLP>HO&,SQ
MEH"Y/?"RXGS*5>6)C"9;I"FDI9QBFNP:B7BC.C8@YO"X7C5Z^*(B2-4&;3K6
ME7LX@DU2![^Q%B2\TZ_OG=AX(>G]BA1A)!"/1Q\U\#(1F&P) CV=AIF]CQ#:
MS==:SY>LA>$C2)32OH[CRA .EG+L&J^YM@[OZ2 =OFP,1[]72-%PO?M E12
M!KW=L:X#QZ9+^(,(.J,HJINX7H>H,FYO! D1HU\ (O$9PX]'S>9SIN254/6I
MQ!W[YI.'Z,F@W^K=W-Y+V<WY@\MDL6J:MQQ&E+J,W%LZ(^P]0JC<D[\WT7%(
M8*>-O=$&_@5<YKET3H@O)(RQAOJ@\D0B/N]D%_@&/UOB?_Q+0GRQ*,7OE43X
M?@%61>S/+U[_?]/V+(Q\HB#M,$02P*,],^V^8RD DSJIWVR>9H)?498.4L_G
M:2]2_0GKXMSI4>"K]SGAQ&(-[?$$%:VX8;T'@5I+6U0!VJ! FT$J6.@$6^7
M"D;(=Z;.-FM/Z%ZX#-BF7=4)LGUJ0"=-0$!X$@2(_.%XC;9F2):RF&HU%90Q
M"SZIS_A-S9LB+Y6>"Y3.,AV8DJ]@&=C[4^1$^VN(<+H<'7R;>3W#@'FJ9#^*
ML8$2F;_:B=YT#WO-<(MAD]#W?.C/>X%@L-]M]^J&U]\@6/GTO5HXV%_4?>B#
M_A\L[$<'[>ZFE>L/_@N+Q;34G7KLYWI:'=_B:_T]6/FO]:]V!E@B_I?]=/+;
MQP_^*_;']^]//JU\O'_$!88_,%PU"@FC<,3\*1Q;]/R18YG+)%'B6XSEG5L
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M/9'19$.:HK248YPFNT$BSE7'%L0<'C>K1@]?K(BD:H,VC77I[H]@F]3!Y]9
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M"#D<"3F!P'=^AU1(F\_W4R*QGH%B^!(XH#&=C*@LT]8(ZF:N"?%?)->$Y68
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M#\Z!<,U!\$AXSVIWRW#O:G^-J()V(C==!7)- OT+F;>(_T!<7<6H4>@2J3;
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M&SZL<!*BP9/P,AD J.C4CNT(X&*$*G5KO3H,7X?+8!6;[*ET,0Z,&U+#@<\
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M?/]TRG2BRY\L^QR>WX/(3%8!5E]QMLW ^*7T/#H7/>1]HU)6%ZQ:3OAW0G:
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MX#2@3 '6@($E_86[4NE26+HE&#(FJ<<O6N$NF12@'<T_SEXC"REPU.L,A'2
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MJ+]'J/^H"/7W*/3G1*&_?9GR#06A=\MY?CQ.PQ7\;U;,X]?_!U!+ P04
M" !H@D)6*88IIX,(  "A)@  'P   &$R,W$R7S$P<7@Q,C,Q,C)X97AH:6)I
M=#$P,BYH=&W=6FM/XT@6_;Z_HH;>[0$I[V2:)C!((0E+>B @R*@UGT85NQR7
M<%S>JC+I[*_?<\NQ\R+]$@(6)%!BE^N>^SKWWC(GO_2NNZ._;OHLM-.(W?QY
M=CGHLKURM?JYV:U6>Z,>NQA=7;)6I59G(\UC(ZU4,8^JU?YPC^V%UB;M:G4V
MFU5FS8K2D^KHMDI;M:J14D94?.OOG9[0%?P5W#_]Q\DOY3+K*2^=BM@R3PMN
MA<]2(^,)^^P+<\_*Y<6JKDKF6DY"RQJU1I-]5OI>/O#LOI4V$J?Y/B?5[/M)
MU0DY&2M_?GKBRP<F_=_WI%<701"T6MYAK=5J!?6CFJC5CSXT:A\.>2".QG\W
MFT!9Q?KL(6/GD?A];RKC<B@(0/NPD=CCF?1MV*[7:O_:6UMGQ1=;YI&<Q&T'
M%W<#!>46MST5*=U^5W,_QW2G'/"IC.;M7SM:\H@-N=9J]FO)P+YE([0,LE5&
M_E= '"2[K[,%%&P2R5CDT.H-PM/_$LJQM*Q>JS1.JK0^5VA+K16X'FPG]#/C
MK3> ]Z[?O1[V6.>J/^SA=[2.^;6A'5VST47_=6/L=FY[@V'GDEWT.Y>C"];K
MG_=O;_L]UKV^NND/[SJCP?60W5QVAJ]%C]:C>NQW#.L@J7W0 H]]=BN,=1SQ
MB<<IUW-6+Q$?U ZVU,C (OOUZ6M1\3%7'3L,OO"4YL2F[12Z:EJU=WK&O?N)
M5KC"!G&@]-2M^"E-$^[[(-5R) +;;AP"F),K(2RV[3)=>0GW=BHL_^ER#838
M]T+PR(8EJ.Q5V/[[=Q\;C=KQQEUWM7Y\P!(M'J1*331GW%>)782)EVH-Q7!U
MRF5L\6N8#<6F$-83@<!*']5EFHC8. .SFXC';)_6+Z33A4(D'.'V&HM8!"!9
M%3#.C(B$9QEY*Z$K4Q[SB7!5C?"$T!E@O%P*)(II$JFY$(:6;^*B9Z0US*1C
M(WW)M<0ZNLB#0$82&YC*6XJ#LV4<W,&.Y(3#2ITL0Y9V_DBT>I!H"7"%V^7E
M*9_#$XSG'$'VGC,KIP)KX(T)C,EF6EHK8J:%45'JML^C!<[D">V-S^.YV_<<
MGH@]4NULX6*29"A&IK2/**+R_.RFF\=%B<TD/ <1"46"50Z(P^7"@&!C30@8
M?#+18N*BP#U#"Q4DZY7E:N6+64($<H)H<(_YV*'$I(%,;M"'C1%AX@M)QT+(
M#_D## -Q,:@R8D&AEIPF'!"QUV;<P>#__(W!NQ'9"!@B8=Y6I'6+2!N1J^%
MV,D@,V,O2BF"BO!:^L((2UD/^XQ%I&;?[T7C'H4K*$*?SX7D--(C7G'FFW)B
M;]N)8 :IB1U49OZ"(4H,[3YQ"BQ)U.WQ"+>Y9G/!-3E^BN4>#1S$"HYBT0AL
M]!?-$C9^_^ZWC\=LOW[ /-AV(MA*A>BCB4#+'4D[9_U"7@_N7?"#DPV[29 8
M7&D00Q06$"]8]G"$#\N:X++O42B <73LD.XW#G):S,+6=^4,1G;5B%(X$9HZ
M&]0B2$0D0'V-K1"(F@GNA<X*+(U=R&1J%3R8<&VE)Q,>VY^+GE?>7G669!O\
M8'?P0^9X@009Y>41U )&$N/YLD*:;3Y;9@AW[<A&Q/V8]U] W?IV^]#8:!^V
M#2%CUV+!_R .I"V8 RSL#!2H"'8Q+N&?AC=?@B79RL^"IL@J+$?]S("^EHK_
M1J-%O+5*HUT%MJ2%YH4 [YTBK$8%2XN<I1$H!35:07&TK#44:07)LVEJ+-7^
M?7F +K2'./.LTB6B]GU)U^)M[H?, 9$_;).%I"=<8A;SAC/;BLA0S03H'++9
MS9*Q,]DH-(I-A<@Z&BW^DP)#UID@.1:Y8I L#5=0&I4FQ'<>0>6J4:$!,R%'
M+8%FZ)LPH @BR>^PSQ;1T WJ@9";:&ZTLQ89VZP*(]&/0<+&W$,T^>B)1-:#
MV1!YOC6^?;,X'U384%G:P5C8@9H!>AP<*28*WS9["%<Y5_R\K.5F-]0,UU]4
M;]>;CEV%ON1 2"SU:>)#:YA0-#AXANHIJ9UY(E:6&LQH7G)^-"GP;:-X*J_M
M9R.M(>34[WYW#Y0#.%BV4IU$RX@TED$&>\6L&Q&QP["N52D,,T1K,QU3.O1P
M*?NTL&N)G8NQSCX!^1777I@U4]1(==()9<S3(7&:E2 &XCZEL7!"/Z71/)-)
M'- \6/7Y4\EUBI20W1AP,P- UC52"9]=>L^71.%J90>#3'96X;JT?*!9&V79
M;N]22"S<2))R0ZZ$IN7W8A%%H"^+E029NO0%!S1K91^#/+I5J?R-]'"S&&);
M>MPIOA-'91%F/]&MO)I.IK'=R32_V<F0@WQ_05G4N9#ED,Q\HGD2TNW<W#2>
M"A4\86.S-A"^5*>3$] :21=TNSGD[>#;5BF?@]P4/Y-&9'-4-A&M5U>$N]*Y
M9<=B(N/8[1YLANN2]/=)KLU2/#LG<*=4H-3%&19EFPPDO0!S)1[%)XUX5J&E
M,6EQHZLP\.7AT:H==0X>JX68#,$(*0W%=&@^CJ0)E\-=QY_*6!I+O1@,5IQM
M;;019-GZX;'YQFA)]EX;DJ!PG/783M^E%8H:5)R!\.QH]NL"5BP*HV=[/H)R
M!X;==;0 ]A;(H[DDCPZ,G 69.R P+HA6623S YI!3G-0S((47^%&3[@.(B/K
M)S@TJG^L;9!$\T-!$E_?9_5M:Z*RE\UM+2(7L3O?OXZ5M6K:KBT?X6-WZKO]
MR$X0JW]#O=1K(LICS(CW9<<?;1[-^-RLBW^CKXF?RJ?/O\]+OG8ML<&PNYU$
M:S&0E\[Z"T$^!]YA=P#,9_UA_WPP<F^%[^A%\=5@-.IOO^C^[J._YU-MQUNE
M>39GO,83C_?O6BA8[B_[@]HXT.]=2,>-FOV]\?/_ZX&!-0L7;.KT=G3,!MS7
M&F>%@?/!F+5<M]O89??757VKV3]ON7\C._T?4$L#!!0    ( &B"0E:>Z*MQ
M>3P" !=5'  0    8V%H+3(P,C(Q,C,Q+FAT;>R]:7<32;(P_/W^BGH]\\RE
MST$F]X7NX3EN;'H\%QNP37/-ESZYV@62RE,E89OS_/@WLB1YP\8+DE4E1)\&
M2565E1E[1$9&_/9_3WK=[$LHJ[SH_W,%KZ*5[/^^^.W_ZW3^]_>=U]EZX8:]
MT!]D+\M@!L%GQ_G@,/O@0_4YBV71RSX4Y>?\B^ETZF=>%D>G97YP.,@((O3*
MQ?*Y#Q@QHF-'*&L[C!#5T5J@CHN(:1UY\)H^/7@N$%'1>MZA5*L.DPQWE'2N
M(Z.0F!O#16!/_7.FN;%6:TP#8L9&8U24A%@AN<1:V_3:PP&L#E;8KY[G)_]<
M.1P,CIX_>W9\?+QZ8LON:E$>/",(TV=YOYOW0UKRROAV5PS[@_+T[)GZ_BJX
MU8/BR[/Q17B6D)6S\0?7O^!\[&>#TO2K6)0],P!PI\=1!Y$./ALD/93?-$^4
MYED-3-^%LUF:PTMW.U/ZO&^ZJZ[HU;/#A.(+,^S "BX],%G1]R:)>0>ISODX
MPZIS8,S1V3C15+:>XOC");#XD%\/0[APZ49X_^?OK#Q=MJ8Z6WDU."JO'SA=
MN33R2749I,=T,BQ^]K];KW?=8>B9SE70IC']E;F/'Q//1A?/ %L5C&#Y/;R-
M[CB;?#GX%GKPX^5I?P.1\<2!N/6S^NKXUIMO2O1?W_2\:_H'_UP)_<[[W17@
MBV#\B]]Z86"R]&@G_&>8?_GGRLNB/P!N[^R='@$<W.C;/U<&X63PK![JV8O_
M^J__^FV0#[KA!=!>9T)BOST;_?;;L]'(MO"G+W[S^9>L&IQVPS]7?%X==<WI
M\W[1#_#^_.1YNC&4HX^Y]Z%??X3KVR!QRMR-7G\RV GQGRLY<T)(IY'7R#*B
MB$8X1A<#559IYLA?ZVDJ2"+<.2?[ONFE5X?\^48?YG?Z$E93FNYFWX>3_PFG
M*UGN86A/_SRUZ\67UV3GRS[=&OI/&U\^_J$_O?GTCF]_>)7O?_K,M_:VNUOK
M.X?[O8^'^WN'O>VOFZ?[G_;I]IX[>;/7S5_3[>[^UP*]V?L3[MGD;_8VOG[<
M6T/['_[=V_^PP3Y^<J=;O4VR_?4]W=K[S/>["KTF'T_W/SCQ\8^/G[?6W]&/
MZYMXZZNCVW_\^_/6ATWX_OGDXX>=[L?U _ZQM_UI_\.[+_Z/5[G]X[W8_OJ.
M;/WQ9_[QTY]PY=^?M]=?];;7/\/S!W1[?0N]67?T8V__>'MO\LR?\"[>_[A7
MP/7]XX\PK^T/^V2K]PYM?=B'>;__"L^@K:_OV/97W_OX:0UOOU*GK_<V!EN[
MZ.3UWN;7-WOO3K;>_<6BLE);!S)9!!#B0G5LI+:C@V *.^,\ERLO$/R1!%,)
MI'$)K;/$\LMA60**7^65,]W]8,J-OE\'M;5$]&V(_GH-HI4/#C/ L5"<=9C5
M%! =5<<I$D/$1%$I5EYT.DAT*'I$+$]LDG,TOX)?JB62;T,RN@;)(CI&&."7
M>@+<S(D DXSCCK&<..UI!'Y>>9&LN;EA^"V,7_@ECN^$8WP-CG$ T<R5[2CD
M@)$E"&O+(^I80X.4TG%B]<J+=^01,;P&Z/4UBKOF8(G5V[!*KL&J]<"=P+P=
M:JCL, :0U@$865KIL>1,6F)77D33K<(WB'UVV>@J0PR@.%VHKC$5DYWYO*IM
M9$!]5MN=SP=@(/YSI<I[1]UD,->_'9:),BY:A:LG%0B/WYY='F+T^O-WCJ=0
M%<.R_E;[0,_'U#8BC8=0VV2@4)M^DV^Y3]]C'LJLGE"XUAMZN?D_ETV8JP^_
MF/QT>?2C6E1-OH$_40Z2_9'D)^D@V4%G0YU?.YNF/[\5 U;Q^2M&5R;?)R]Y
M=@E0U\*-"!<"X]XS&E@RVZA3AG/#A.;:(/;79I+LX  W 5PC!VQ0*QN U 4(
M3*[<#0+#?CY:?G5H@*S.5M8+IAJ6X<48 ?7%R1"3:Y/O:8SK*9$1RHWDE&''
M@M'*J:BPQ5898B)F(TK$Z!$I<;R><)#DZ>BKAY>=''5SEP^V0L_"*WP.5T<Q
MGK&7_GPW06 G' ';'8)C_;8L#DK36SO) 63 Q<_7"$=;>;<+#UU_ZVCHWYY=
M^\8S4)Y-[/X<@]%C<,P9O0QK:769(,:.^_/WN^OWIA40S$1&8$'I(V,N6F^C
MU3Y0H047T2YIY8Q6[CZ1 2 V37[C/\/DT1>]HZ(/7ZO17":W[94UDDYW!X7[
MO(!T"C9Q#><S>O'Y%\#SQ5MK96\&1?E DO[F^?3C>N@7O;Q_W;!W%:N7AGAV
M>?:W<90.4G&.C(E,L,")TL1A+045ULK S&6. L6&:6,Y:FBK\)]AHN0O\%>*
MN%TFX2LW3(V!EIP\#4ZN+11,IV"C,4\DTP%+Y@+SV%H57?!:8*,C!D51TW1-
MRDN:7M+TO6GZ"J$^#DU'A+F-RE-L!:/$&8:X=L2)]!;/W#?^&FDN3=]&6_CW
MGY2R[NO1DFE05D"(.F/!UP)GBZI@@<0,9D1+'("VXM@" ():4E:+*>L2N3P.
M93%LF<7>."/ NJ1.*T0<HMY['8GD\_#LF^J)7(*;<Y)3CC%343.)L:9@HPM*
M+:+"FS"2]7@"-]Q$N.&[PPU/#6Y4@P)D!B24\,PJ8BW#7D:*+.6::3F"VT1'
M-A1N=]8 TX.;YA@$/;5,([ MI%/&1H<C0(\1Q:VK8YI-8<\+,<TK''>_F.8E
M" B))8G,,,LE8TIKH;57#GD:B44,C2" !$5-@\!XJ_B'(1 "-VD7F@L2&+%4
M.Z>-==(+3JRC8QI >O80>+#ROYO6A=][8 #,1N=>1HV>#FJ )I.-%H@!MS8:
MKJRA8*K)$"P3C/"%0<U.&)B\'_R&*?MY_Z!J"7YHC-)Z[B+8S$Q88Z)T@L.?
M%%D+.BX,?F9LL,X$.0YK08QW-LK O#,Z.NVHQEYSI(3'"X.<->>&O6$WI12_
M&1R&,MU7AL,TVI>PV7=%+[0$91%S#\Z"LRDKV<>T'2V5\\$3(<$&M@N#LNVB
MGQ9>%N"3]@\V 01EJ&X+X34%2\!57&OL0@!#,=)H8T3&2D]]P"$R_7A8FA<$
M#%B&U@H=&..@AJE"V').E&!(@Q'MVK09V2R"G;\+;H,A#%L"+B5E40KEP.0B
M.'@>@XA>+QYN9VH7-P"A6%HGJ%<:.6:=,Q1)03'"!@= -%H\A#9TFV]Z* 5W
M7!AIN$# J\GPIAQA3"(UFH ?BQ</I;-WD.:/54ZQ<PXI)#1H58^581'^$3@@
M0X,VCQ>,:K/ G4V4C"MFN)1::\E<- I+2JT"$TA9Y1%?&-0\<B!B6O@!ZT28
M@'!0K,ZDM#@8I2EXN<2 YD,+@Y_'#$1,"SE,&:ZT0"%HQ#3&RAOC* I*&!?)
MQ%]: .3,/Q Q+91),"MXM(9HK!FGT8!*"AQKXZF,"H6%0=E< A'3PE*4FE$M
M8CK$P#3#REH#.HH!LTGPX$92#R] N.BQ# 8\M0B)BDJ"!VU1Y)P%&T$A60?\
M@CRUUE&^,*AY5(-A>O@)T5FN-2"&"^; 6$#PB1@):LESB</"X.?Q#(;I(0<+
MK[D*C'//F5'$H,"85 $AF\SMQ4'.O V&Z:%,1QR#%9@I)IB6T5!BK*$4>TQY
M"&9A4#8'@V%Z6'(*; ,GP?#&GEE'-/BPD0I$M952*/5X6)J;W$?&>FMCH)@R
M%K#%(G"JO'  &8#-'!+,%H1@YY\$Q[&3F$A$@U L,J>""]X;(82Q.$:V>+B=
MB_Z8/Z*I]UI8%H07D7DAM)3(N>"L,ZEDC%@\1#_>%M5<$(I ]EK@6"P]9LA'
MA2QV0G,I"4^5818/H8^Y1347E ;F.#<IEQ:$L:=@8?A(2%!.4(VQ6T!%^\A;
M5'/!J@*?V7$2* V<Z2@M,&CPQ'(EI;?>CPS(!4#FXT6<IA:RM=SX5$W"(L1H
MLF:QY8$CAC##FJ.%0<TC1YRFA1\O/>+!>0,88<(@ ^ S(!JE ^DHF5T8_#QF
MQ&E:R"$:\*%C(-%R)H,RA$2-$%B8U%I-PL(@9_X1IVFAS 89,-C[U$7'8&!+
MM X$LT@Y(6*!^&DN$:=I8<DIX"2#J /D,"Z36G),.YW.]%G)R>-A:6X0\)II
MP1"/4;&(I4'<*JR](0X'Y<GC';!:$)-I>B>_$!)8(^<E588I:I6RBA+GL5<$
M2RH6!C6/?;QH6B?SM!=*&\8L)RPZKA35'FQ<)"4S7/.%P<^C'B^:$G*\$U$A
MSCD5X.L3$.=1&&Z9!3_0FD@7!CGS-IFFAS*G,-<@V734FE$+?WN+X)< R$-<
M+HZ\F\_QHFEA*76@X!*!=2295TPKBXT!LXD WJ1 <ZA/NB#H^J&*,U.)G^'H
MA 8CD$@76)!$,6N"=-@R90,8'8N'V_EO4<T%T1K<42JIC\Y%%K14C,:@$?=&
M8 0^P.(A^C%/4<V#<YUER$AN%/ASE.O$KBYH RX$=B28Q4-HD\M_36>+BDC$
MF,22,<VX=@;+*+%WZ5"OI]8O'DH?_135/,J4&V=4X,00C1@27LNHHC'" ?M&
MCL=;5 M@Y#YB4O24+-M4"4UYDMS$P&QT&E2A#HIA!AZ]#7AA4//82=%3P@]W
M:7M7*(6M8YXK[3T#A/%@#&,FT(7!SZ,F14\).=CCJ)W4B&)06C[J@+E-RDD+
M).(XCKP(R)EWO&5Z*',1<T5Q- @'E@KO>!()9\9$%+2-:F%0-I^DZ&E)/:(B
M=E[C"%Z:05(9Z2AXYQ$+2QECCX>E>4' 4FV4P%0S0Q@820:HU7*&(XI>26?F
M4#UR00BVFGN%R]390 <D4EM<9D0TA >,+,(.62(\7SS<SC_B-!=$$ZZMU0Z;
M:))]$ Q(,V(BT<(Z8CQ=/$0_9E+T'!"JHK98>N&!>QD1+J4G$<Z#L-SJ5+]O
MX1#ZN$G1<T%IH)9$"?\0QKT!4T,%;SCH7V$<0HN'TD=/BIX#5@VF-DC*G2.,
M4>,5![;E$6$K;/0R7,9J(_=74XN ET7I\VH=E&0%<QJ6X;Q[P#>7FH/&*_NN
M/W)\C%"O/+*<^LBTULKY:+Q/]=2#E<HW?W=\!]!3#AT@"%CM95$-UOH>?@OE
MERNM<S9Z1]WB-(3=\"64J4]]2[;&A<64<(";QH)AZ[137BEJ&15.R;/ZJ(N
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MQ;.:U<[>]@WO7^7HB^3A8,JA;!./:[6JT<V7K^&:R0UC[(]EVK5 'B]\O!0
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M/3T??PR8^A?R-!'5T8B+NJ<W'S1^?"E[-QT-_N,QT%SG=5%\KAL^CL.U=SX
MMU34/[NBWDM2\=W0I'X<H"QVQI*W?^%LZJ25T7]&=XWY:SVXD.I 7*K80+(G
MM9A=.7MZY9?LR7D3Y;P_*I20U /\.K8"1CVBRHE<^&7<=1D$Q$H<4WAW3.'5
M&86O9( $8-\J_1Q.$A>/3O+4JJSF:O@8 +#POK$&K@4G".*DD\;*,HD3'X[2
MFD _#8^203),&BYU5$G*&A;OX6.W.*I?NYIM)1/CYGEEYN@H26+0..<'E<Y*
M8TSKN%+V9&5K_1^F=_3KVLHO3T%[U@U48-9I/?4RJS.==X:+I^-^J#USFOK
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MX';S&>8"$!U5DZD;6Z3:89->1;YPPY'9N7'BPM%@8D+4)>,&YYV&@!& ?[L
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MKZTK_M8*;"6+19DE4R2! 2[Y %JP>Y')KF'%%C+5=[8EOY5Q=]!9V;&IL@A
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M>"A#X/.4'=_2EB9<7$PG0VPPL<7BF8*V]A5/IGC?R%)YKU5BJ!1@8Y9"S@;
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MFRR'+DP$8#>U%WK2G_*/: (OYJF$A=;_H\ %MH(5WAW JMA3D"8(6*9'7:V
M="P@N0![7(;,<9@51IQ*@2Z!>DFV!IKEF/9BDSI.(,1$\G#3I9?<QAK=3=A>
MQ-9:%V2<Q/$>@/[O/2=:4,/DK""*VY]*H>"RL$# /,QM:[Z#F+&\Q<+#?@/P
M>=%(.4^JP<06BV<*VEH1I-;A4P8NR-93\][SX3!>YVK<L63Y'.'^^?.[M'"=
M^##,Q3<3E!6(T!,PR68(45/XXBO@TZ)JFD2D\4;*\0-'=S[R^;^HZ6^*+:9
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MN<;(CZYY)Z-K[C:B:YJ2S% F9(A;XI]6'(62%W+KE^!\-GR3H9&#ZR3>5+.
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M*OO9]^[M0'1M>7GY$W/9U [)CG55J;9L2DJI:K//NMKL5ZR3/IUR^RG6C-6
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M#V,HTX;I/3LDKO>6+J6#8739WK(F55.4U?Y2X<A?-_8J@N5;Z'!$&SAA& N
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MQ(76O:92^KS00FPVQ6?W<#,E^84AO;P. ]D9?>J!;JUX( 0Z S/UCGA5FL2
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M"I2W(4( B?2PMRF\U4I)G-1^Q X YP&U1478\C9@7(FE&IEC#!I&-1BC]W@
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M=VQ2%\TQZ(,HX^-J)A,MBFMRR/K6J0@OTME"H:,%/!O"$I4JXNECE?\/(/
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MC1R^>7UZ?.1:!Z??+@[W#L+!WCX[W'L!#TX_G1_L?;\X?/'5!!L1)RC I%"
M!HR!I$X!I 0UVBA,+=[:Q0S^\\^;&[Y[HRWB[\X]G5$#F%;<P59J5%XT>;OU
MM Q/W,2!(9I@$;CUP@5*;3#.!*.<)UQQQH.Y[\"PR0-SE+HDGO4NBK,QC$U^
M88M&A"Z?E!E."HXGA2&+A"<&:*[B2<$, Z."!''Y(^IH2#QC\:3L\-M/RDV4
M.>L718=3PZD(8L.&6K.@RSO?*[:PVD.#[SPSX],R2K=XV>T/?D]C=$;@4SXC
M1R_.]W]]%90@(Z@"4%@$*,$(*"TY$-IZ1(+TGL)1,$GIE R[)8Z54]S:HM%V
MT8?Q+]TYT[V+(5%.)*FH<: C=6G\[+;.VKXQ5*@)?T;Y,,.CE+)@KA^Z1<^6
M\D(R!K4.E%//L%381H3DA!LC/-4WSQ:!")%\MJH[6Z]^'?SZ2A46RED."((D
MGBTN@")2 D8=%";J,0Y-/%MB9YJNNM&]4Q?]MY914-3A>,H]$M1ZZI Q,ECO
M%$=:!13AIC@/Q3&8>AZR@JKZ@,"#;U])/!XX;@50%C$020P!2L5?J;$0<:&-
M=&AK%\ZLH%;53G4F*Z"P@5;;377)><S13!6Q43-5!%?3374VFZZ"9JKZJAGA
M]9:JFVD!DWI9P!_]C\'(!*9WF,#1QJW(PD4[L&'FL'$0CA^8G^IROB/HD/Q<
MG_L- O3;JS,D/_@AR4^ B)D@7:1V/%(ZJREDRF++DVISU [)#Q17Q!IG\K.<
M;CLZOO@*&2:*,@Z8Y1Y$.3% :A+M=.LMU8QZA?4HJFSE=,=#2*PV6(> *)'>
MQ*.@$<5*(!_/0!C1W[CQ4T] ICL5'(GO]&L\#C (18%T3 ,:>(A'PG%@,93!
M< L-C_0 98*3"4[5!&>>.GSKPW!HO1C.E8]_R&]&O>S_U=6]HAW[7H1'.^CV
M^@V=*C ,^Z1W_*_&_Y"=4=#JF*Z4?/\C5C'N3?TKOJ_ASW\T>_X&O2"H^.9(
M1UX4%T&3+PPI5]$].](C]IL>#9N37<8II4,T^?7]^'-;-XN.W>/NY:DG^7!2
MM[/G7%8ZEY6><[:YK'0N*_T 9:59+BN=RTH_Y%/GLM(;7%::HZW=ARXK71G#
M6:<ZL)'9<EE]'5@&=Q1:K"+I/15;$9R+T,P>%KMI]:NG6;2K*F?]V)6Q[Q'4
M&3&';LWQ7=7HNAG+;M_BM/B]L44A:]U+]F3_SS_^[O:OU09\Q'K;?WSJ%"VT
MO2M/YW8<OEEG^W&L0[0(F#*T0YBJOIHRW,&8KZ3T<_6F;)[L2B=;2?.&>S%<
MK6$1UJ.3GO>-_?B^DW[C52?=$UYWUE51FW8=E^5C\WS&15F1.^1ADT?NND6Y
M7CIWN^'/K8^4I'0GK-N1%0[ZLQ0SOC6EZRZ66+/S<6=EF'D>=6$775W7ZY:R
M4A"C:NM<K]>JY%.TDE.TZ96H/OB?OG/F5U="=(,R2=>R?.KTAYXG)PH9:I#3
M5O- .;%*0FPA<<ZI@ 6;/R=J=.3Z:Q$_@P_&\3.G*4;F_7G\.SFXM'C_Z,/)
M 7Y/CR]?MX[QP??]O>_G\3M;7_:^M/XF:0[GK</VZV8*D=J__ ;W3P_:^Z?O
M\7[[/?MR^@(?'KVX_'+JOG]Y\^KR\/.'YO@S\;O.ON!/_/CS6W1P^O;R<._]
MQ3X^OCC8.[[XLM=J[^\=L_V]@_8!_O#]^&B??7GS5]AOPO._CUX-]C_"^%W?
MX?[1JZ]2$BL8=\!K(P 53 ))% 464>FY04HBN[7+T#;EJA2%LR8)QKDF]>.#
M:JY)O0BHVBB;A*$HBT%1@9 B0C).B(&$.^V'D:IH#*HH@^JC@.KE)*@:0ZUQ
MS -I>0"4$0>T= PX8PCR!%&H]=8N9=N4B1*H9G!;.W#+C'$AQF@Y%U9!IZ"A
M6&(%40@V>"*-5-3B4AA^!K=' #<T"6[8XH @U@ K;2.XV90VC07 TB,:J-%0
MXJU=!-$V%#A3QHRJF3(^)&4D*D(FU0AC[JB1.'(1Y$0@T!"FJ!)#RCA&U4P9
M'P=5R22J0ND9(QX"&A".=K@@0%(?>:,+(FYG!%;,MW:EVJ8I5',]*..F-[A)
MN7U%=:E>UYVE>E=Q"6_O6KO.W1_JYQU,:W\8WG2[KO^BXS[ZWL^F]?V/<0,R
M3E6&4Q=E?Z&RSBML;31H500KH270)A! J764N8",2*:MVI:PG+6W)N0OMY"I
M)[6IW!N60>1!0*3D'V/>>N$=!0Y"%:%#*& "IH %G@HK4>FIB2!"MB5%RY*=
M+,PU9015>W^R,#^(,)?\019'4L<% IPERX4X S1T'FA!:)!8:B'5UJX2VT*5
M+9?,")XRB-3/V9%!Y$% I.3^H)1 18D!5A,)*,<.Q-T,0 5":821$ 3=VI5\
M&_&E;\QJT(!P;M=+;7HG31?9-[UNO]\8)FLLTZ=PD_I@/*9WI-B/=[UN: XR
M;E6%6P<OIX1/*>,#E!(0*SB@3G.@O4'Q5ZYY_(%JHHM.?)RL*_>IZ5783/-9
MII'@>F)1_9PL&8M6@T4EKPI2F%"C*4 LU:JFT@.CK >,!6$P]<P16F 1*GMF
M,R9L,";4SU>3,6$UF%!RSACKA:)8 >=2>+=&"AA"(: &8LJ$#R95^B/;6)3-
MJLQ/,A;5CY]4[O+)6+0:+"KY>+R 3"J) 3;< JJ8 !&: J!!6NH,PC[8 HNF
M]-*H*29,+[N7JFO<7G=O84]O'F.SQMB<G-'I!//P1VK<EDJD^O/48,_WG\V2
M8SQO[&L>HX9C;'KHWUZS/^@US5E23MN-OF_%MWS;;GSSG7CF6T5W!>W:S4YZ
M6U'<]TH&<GS@@WC /PZWY,UP0UYTW(L;V_%JN!N9\%5&^*;$"MI@E,!: *T4
MC\9G_$EIY@!7R$!A#4/!)8<44N4HGS4Q/G-@0#VMQ,J]V!E/'AQ/2@YNRHW%
M$FI@F/" ,HQ2I!$$5F@=.#<AP"&>L!PU6$^YKI\G.LOU@\MUR4D==],*1R6@
M5F) (4D-@;P%&C&C5-QQBM76+MXFLNP8RCSA*>-)_;S)&4\>'$]*CF8=CQ:E
M4 'C @,T,C^@I/; 4*]2ZKK%6"8\P7SI5,H:Q!*NB\OD@X]"<&8'9[VB=63'
M-7S[1ZM[X7VC[U.SQ(XMU9>;YSZLMB!5/^?(C:UX>:)[WU)Z=T:=F5'G<$HH
M("3&.@9MM$[B1L0]TT SSP QG 4>D!(V1.MDW>_9:U3U8B/0H7ZNCHP.RZ-#
MR7?A B76:@>P#28:.B;B!(8>""D0LXXJIR,Z5%4-+ MIW51X];6NLI N*Z0E
M1X14A$9B)8$E%@+*- 7:&0@\1MYBKX53;&N7KFUA@XP.]53A*ZC9E-%A670H
MN1689%)R!($0+J*#2P2?" OB'A&F181T&(:=-&NCPS<]#.-%NQLG<EFT"BE<
M"MW!B>\UM/WO67/8*AD4W95]>OS^'0W4UMD)6A__@M4GSZYO2=R18D.N[<=H
M.XK=R(@T#R)]++L<$*91/\@ I$$>4(4U4(K12%^P0-H[K1R.1D6.KLBW)O5T
M.63 6"E@E+P07E&NK!/ PQ2"KP,!D=((P)6&3%L6+505 :/<Z2$+;AT$MSYN
MB"RX*Q7<<I$EZ CE'@*K4]E%ZF2ZW$3 "A,YFZ386K:UB^C:%MS.B%%/55^9
M:R(CQDH1H^2M4%A@#Q4!/.ATX6 -D(QI0)C5'C$6H)<1,9;/M<LA$#/+W=OV
M#]WL#3M^)V_%']]TL_.//UNI>%(4P]0!N]N/7]4-#=WO^T%_N]'Q@QP4L2*G
M13\^:_RIE! <-R6U8#_L?(P(U#\,+XJ]2+%<Z8??FY@=JPL4?SMZD6!JZ,HX
MW6<'>Z_.ORH8M!+$ @TI 12& +2+&R>8CIMIO.+0)#\&7%=VDR]>ZLEN*G!D
M5 8B.2*T0H2YF$ 83)TM<L\$-2G$W"D@G44@8.BQ82%U94NI(WA*C=HLZW60
M]3KX/C)A>!QQ/I@D#"YNIH<4 8]H-&Z(]-&X@1Q@QF4P&$L)22H7N^Y%%S.(
MU(PP5. .R82AC@@S21@,4EPYRH'DJ86K)C@:)TH PR)=,(I(R/F0,)0Q)L=[
MK$I2_VX.FM^&T1Y_]+SMQGDU??\??]JA3"SN+JF['W<Z^_GC46M,CP#KP]!K
M>]3]O3D?_6#0\@FL,A#-!42ORKX1PJB'@7F@HPD#* L0F,!9)#T",T\\,30"
M4=1*)1CZ1[Y\67.VL7KW1!;>2H5WDD4(R!U'#@/%,0<4(0Z411H(Q)412%.%
MHO 26J,[F"S E6K=RBLG9\%=@>"6' P,2D=5(OV>I-)57@%#"05,$8.XYC1P
M%>F_+-](9*V[[EIW]39^%MY*A7=2ZP8F+%0P "Q(*GIN(="6IT0-[!6B3-IT
MG<C*L5+K%_FP:8VDKM6,U;U._'__SS]2>$0)5>=Q1ZYGI?1:F/RW -G5-KWM
MV&[;)TS+L#47;+V=8NE#2AP6 F"=[BB#I4 %1$$P6D-%.7.I!UZT I?@'(O"
M1FZ64!^,G <"5N=!R!!0 024;AU\"N76''AG%: $!Z"),B!:C5)ICQFE$0(4
M6\;LR!"P3A!0A["'+/A5"W[)WR"=@9AX"R@.4?!EL$ +GS(]+)'0)PH'D[]A
MS>,9,NBL!>@LSSM6YT/)\%,!_$SR#FFE<5Q*P!&,IH=U#FC/)("8>A(4-L*H
MK=W()-> =^2>3'F,W)/I-O]:41_ECV:!G?_X<]24YJFE&3UJW$RQ!0?=3O>F
M(KNJ#)UUV1RZ['W9C884PY!S"PRR!E D%-#8&2"EHR(:/($:-ZW2XMR:+ ?G
MUHUU5EX*-<MJM;(ZR3NMASI9M\!+ZP$EU ,C8 "!2.<8\P:QY/(NA]AF85U_
MQ5JY8RH+:Y7"6O)1$6:9"U #S+D"%!L.M%$!2 $E5U8A;D(T$K.LUDU6:^'.
MR;*Z2EF=5*PP0!JLAJG7(@*4408,LP0(:YFW C'LX=1F!(\BK)N>MO(VBE+/
M]P>-I>WMN@??U:&LQTVD&:]]AI9%H.53V;[&GA&AC0<DN8FI#@@HHA4P6%D!
ML;'4D:EED-?DJBJ'Y=8S++=RXSXCPY+(4,IVH<Y&BRZ5(S8,4,ZC@2"] 0P2
M*1V#VE"_M4N6;G*2);2FNKMJBSY+Z'(26C+A+??&:PX!HJG05H!)0I4 $4JU
MUR&:"4Y'$WYMZVQE9*BG[J[<?Y"184EDF-3=S@FCX@X SU-RN6<!&(LX$(SK
MB.8P\GRQM2OJI+LW_:[^[U%94*][K8M&G&2<]%FS?Y*2Q%*)4.?-4[JT?^Q:
M%_VT'[Y_V'EU8R<.PU[<AYO5>$+SW#MPZ7O=#$QS =-QV=W@J+;(.@RDQPY0
M1!B(6XN "-'<P% '1W3B"3)NX_-UY2WYXJ.>O*5RGT,&D@<#DM*5"&(RVJ(>
MA&CG "H$!<8'#8B57!L4]Y2;VX$D"W0=!+I^+HHLT \ET"5G!J:*4V<\L!9'
MDP5* R0G"&BN76#>&XE\9@892.KJT;BC2,@]B)*18S[D*%$!)12W+ !F2<JT
MQP(8'"1@(?[5!!BH=EN[4]H-Y,J>*XM&>G.C%4H_'O#DX_#_/6L.+AK-<0!%
MLQ.EY6?SWUZW!B<Y@N)!"WT.*Q,?AK>=GW$KBBXVF=Q4 E&V[/8006J-. $2
MDFBM!*&CM1)I#C.FV%6.@UM[<I.O:VH:[[D2O\>M&)*Q8CZLF*0SW'#IK11
M&1\-(00)T!9)8 ."S$,4MRXUA\RE"NLFJ/5T9V1=OUKY+3DR% Y&2<Z!4395
M (D*W[BH\)GF6CN.J1<PZ_H,(6N2VY%U?8584=+U4*NT22 P(Z*NQS(U,J/
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M:Q9-KX!M0(HZZ+=V<:8@&PX@M?"V9 "I/X!,4A *B1510P!.C(H41#*@.)3
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MP&3Y=:Y37Z-J6[-5L#9UT,IK&G27%?%<BOA]V=464/"10>,4-A< 55 "Y:0
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M^V#O/Z?[^!4YCL]^N/<"'9_^%?:/CK\BC2CQU@*H74K<9004JH8[S$*@SN#
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MON^GM3BU\+@=Y[-G+[Z\>?W]RZEK'E_NG\?/T8//QY<'G_\*\?-?12#8&*T
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MHQIA H*X<2QR3FB5XUN[E&Y36::=Z^60JUQ;K-B;5\E\)SGSD]0 TT_1$]<
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M#KP^>%F^_0W!BN!1  &R"->.2:"I<T!&G8U%M&7BOQ&NR3)@/1WI'J*+R=J
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M!"@+/&6+6, 1Y<@B(T4*0Z?+ITG7$3*>DJ@^@->I7#UP+*8ON_W!OA^<=+/
MSBFP)3^3A()!@WQR,463+"15+YB-1\DHH9PS#H4HL+""R@9U%-D\QN9 6"U2
MW3*$K1K"RFXE(5R Q@H0N," 8B: 83[^XQ7$7%!+K=[:Q5/,E1IAV%,,_]MK
M_FPZWW'])$2M2,1G:A"[]H[\IWX9L#S7A)QP+33C4&.:2E43!A'"@6B%/>-H
M;J"^.HD9C>=!XX_EZBN"0V]-($!B0P ET '%201C;!A5C!FJR=8NPJK.B<CK
MCP]YC'J.L<ZX74."G7%[0=PNLV@.E5(".R"-08 B&7\2 @$3N;53$=11\+4'
M[IP7EM_Y!-ZYZ)W_77W1%^XX7JL2QM>:9L_>9WSVMF=+KMP:J//Y+N<807%U
MH(1<,8H=DIJ&^#^./-3$*STLB'R_'L\-M2NH77ST=E"J81&9%N/64\ H9>E"
M#@&I=0!.:NZ8AE9"/[VC]IK$7%6-; ]8AWZ)R2Y8I'X5\%4K^%^T@OVR"[.&
M>%ZVSJH"\US4OH:*8;*X9^!!1T-< B2L 91""XS6&F!%@I>2XT!3@L&V6-]P
MW*P:LFK(JJ&BSB=,4LV$2#XB:H.62!!BI.%*&ND@NUTWY.9X==(#);>?C[J>
M"2@C\#,-*(8*&!'U@$4\_N>Q"<9L[3)>76N3IPK$V=VP?#"P=XQK#Y&7U%*O
ME4%>2T6X0U@3)^&L%#5W7J\ 2DK-Y101#',+(GLD@'*5XG"0B,@2G/&<IJ"<
MK5TN,Y)D2I<IW:-3NI5@:>[R7CG.'DY2-N0H)7&+ "=*I9AM!#0S&###E,3!
M6,CUUB[=QJR"1(L,M1EJ,]0N&_<B-9.*0^\5I HAZ;2V!'K)M0UXW#<T6\]U
MA^+]8;!CA..WEX='[\_WWW]%@1CJ<#2="4Y^5$J A,$#Z90B7BI-BGA'6EUS
M^0S%&8HS%"]XQR4PI2P8C152E)&@N6*>(:4=$4%"_]!W7!F YP3@_4D %BG0
MG#H/B,)^6$M?"D@!QY8B!+4P&$TK=I<OL3+V9^Q?>^R?AX8KAB FD:\IR"D1
M5FH3+ J&(HHE,_;1:'AVEU2I(CY-J@A-'%-42("I)(!"#X'17 +K T<R>,T,
M2;$.<>LWDZ7?&D/\9W$PX_]=\^?N/^,_XT]<^];3L_Z@&2[BYXHW7RW \%'B
MM[7TC[Y_-O[A^?C+FIU"6HL//6_KWK=F9[PJ[$?I,8HO'+[\_%?3#4Z>*;7#
M&$GT;A3I//KBX:MHIV!^$[LR?(W '41O?SF^>NMK=PU+=Z10"XUZ]VN,BB<]
M5[E#.5^3N:[3NJ[37-4.1F1-YKI.YU7M0#$;$MZ34W)O5 -E,QL&<Z>86)^H
M4FU2U8].>MXW]N/[3OJ-5QWG72G9!-V@#9M>H_-:ULU'_V,P6@DX9246BX-9
MLU"7*AHQ!*$H43Q@B155%$ECM(A_DXH+9/#P=A9!1>"3SJRAAV_>PB]'[\F7
MH^^7\;W-8_Q7\\OG+W&<]W$>)R?[G^/\3D].RV;%-WI\^J&5QCT\.F@?O/GK
M]+C]5RM],GXW.WSSZCS.%Q^^.0A76377ZAPP$;Q 4J?"!A!0YP-07C" J':<
M>,J,T-,3:Y9R -7-Q[,2-\YZ>6JF2_NBGIHU<<8L71>X*GS++IC:866IGK#7
MW! -&= (.T!3=&!$1PH<MHX1)36S//E?.%^ZGT5&RXR6&XB6,DA!5&0:@3'J
M33#(&XLP@8X88PG+:+FV:%FNH 4A-A(S0+0E@ 9D(L>4%E@F=#!4*Z<C6J)M
M0EA&RVQ6SIM!$:QA2D4(89Q:KR6,/V$M"/2.">1G19(-SJ!X*,DO54_'!BNE
MK0728 NH%@%H250$ HH-A3B5:M[:I:2R2ZKUEOC,CS:;'\V5S+ *6'LZR0P/
M!7FE^O.&>B*$AB":B %0Q>-/4J><,:FLI@3*U&H&;[,I90@RZF74>]JHA[A3
M3'K*F&-42ZRAIU1(#Z%):?EWH%[.*Z@1*IZ7RG89Z#T*P@%E(0546@R,,AY@
M[(D)"J(0(A/DY:C6C(D9$S</$^>)\0PH>,,1E913)8(F6!M-"'*(,._U0WO*
M,A+.AX23106H,XAZIX!5T  *%072!P:PA5!X%3=3T*W=LDG\A#UA&0TS&H[0
MT$H:[2@AN4:.&HL5,3(0#HDR0G I\[W!^D)EN;UVB,:RH@Q(XU-= .6 0<0
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M*=;S:D!Q>Y)9=3EN0(JD/2PA2II@Q DGR,K@$#':&64Q5Q%(+^%+J E=H+A
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MXNF<7!OQI8TQ:P%\K>W)]8[13U(D$_X 48DO3_=/C^"][-)[KH4R]^"^?^O
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M2G2&-, UKJ6CQ"EI[<86>T%T_?R[0-K*05JI\?.4-7X*I#T I-7.?H/@@46
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M]:=S4&!__B5:[2C.[>*J#XHA"H^.7+J[K9X?UD</"(SSO<*C8[X7/4%1ZRP
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M4^3!)$9SI^XP:YJ5?I25MDHHE_N$!)DS(G5&2<Y59(?/I&6IH*E=WMYG_K@
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MYJ:S>>2'C41^X1R^B[]X1UK[,"1][EO_^*YN8UU#:UHZ6W_'O+;63Z=>#^:
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M!G LI3+($^&8MUH[F\F@\SQ-C34VD2%3+A')&E0&MX#$N)AH6NLH2XG8#'K
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MJ"*7FIJRRH:KPB9PBZM1[66.2?[HMMAKO;L K?PZ/D)/7ZTC7 *X83YO*"W
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M8P5_6:L:66W;W2MMA_<A!U)*>*DH]X))J1-C:$!&?"&ILY9*OG9D$W-)_JP
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M!W$,@B)2:1*E,I(8QHC464X,#0KVJM<BUTXI&D#!W\O5[0?\N,LV:-^KV$
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MG<K6'4VO8M ,O>G]GC:=F]853&KTO=><;(-8$@@'M(E4EB5M=S4K5<N5VQ2
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MU1$DG?-0'>$(5V'[N.)(-"Y<;OA"Y C"0N)H* SQ_OB[<F\)- $2")#P[L&
MAKUS9ZY\\EDK5SY+DL $K=A*!4^O#D_+L)7'AZ4KMO+2@#3-5IAU2AG+4&0L
M %N1'#E)&.+ .2-WR2<1-H2M5*'DUPDEKU^#-^635<<^9\=.*OW.%^FO%/DV
M5S>N:FRER/?BKE!6M:Z-!*TK-;Y[';&WH>E5J?%5:GQKT'N5&E^EQE>I\56-
M?/5&OIW$LI]+C6_^TVZ^HL#\YUHF&<BXQ$7R7"7&G2#&>6=RW6*&<5*2/U3
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ME[U\KUX3N%2VDOS=;K/WO;#Y3NOO&+:'TRZ_"X"(+F*W\*SSA,R?+!M8VA@
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M5[M!J_S8Q: +_9&7NV^GS5:YB)W;LTXWWP@>(O?$'5?-2Q$P7[""HMMLK^
M^1YCGX)U"^AFJ]>I%>)/^:D[=UVP?VK[8U<MAZ+@%; \Y<>MN4'Y@?R\#]YZ
M1)OO:;X-V7[+&Y5]WQ]?D4>#&FVW#1>'[_1+MIT7+UC;+2S(8!W-3B@&(E^Q
M,*_A!3/MB-T+VX6N]+ "-OOE4^3E%JCWO;V[4WOO?:>;AZQU573BJ85/@+T
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M_%:'9_PC-7;K8F_W/6Z<?87G_WR9R]$1QJ.S$G'L@$@0FY QW" @BII(8D7
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MT$XB*P/\0X.UW&!)-=YZ)V:K0ZX.#]9(^I'LB,FF+==H@A]V=LZ;(;3BZY[
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MX125!+]JEF#<F QT="$=V2]DZ+(!]9H_:N=EAF:<R- L2<FP"A(MEKV+Z/-
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M_P\:?A[ON$7_% C@R6D19IX>+]M'_PW?K/UYTPDY"MN#W]9YQLW?</P2_XY
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M0-UCEL#0\T0P-H+AS8>:E] N787\Z-IBPI/Y2R <*^)A-92"8VJU=GG?!#!
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MUDDD9+722ROHFW5 ^">'ICAQW)%@O96)2^:-QM1C%D(PB2I123.M ^A_N"P
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MNPD4%GB@1D1'O>9.,TN<,0P[:;P5#LN*Y"T '(U)OK,2&V)(1"QAB3@. IE
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MM3MGA3^$OH_=%S_Y3@R-7O?G7ZMA>K1AZIY AV;;X*!]FKV(\&.S=-#">#0
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MVDLIU+@P0HQ5G=Q5!]"':R$JFH@-'K"2<"FU9<9XF9+7'"LBQ,2G A6 SA!
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MS*O$GMI.^.5'(+(XB:)58>*J,/$<C\Y*LEV5)JY*$\_F::O2Q"M;FO@=V._
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MPTZ%,<N.,?+'&#.-0W ^/K_*K7?3K;==*\K2RY5/K_+I/?F-3 $V9FWCCW@
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M'0>:+UP[G,$_A[VCYL;_!U!+ P04    " !H@D)6W#-Q T,1  "RO@  $
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M3V9X_MY1A^7G1RD<$2HAN%AC^L_-O_OQ%_@IS-)RMM+6*WI]=H>*=1Q)\-.
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M<L@F9WJ8*6 .VD7@$D60Q6%AK1^@^X0>#Y>W&IU?WPQ7[F*B7:8SE& UC5T
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M93&!-UG7CD9%!Q<E-D]C;0!KG]SZ7<V C8TU"HO6YYC>/C=C0,THU@49+<7
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MF^S\*6ON(X=Q)ZRX^S!?46&#.Q^\Q(<,IW=BE[D01'"94>, WQQ*M<.\7-8
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M<6OJLM!I]GD%>9G@HLEK@R$LRW.KG3SX@"A=F76A\8-0N?H<B<U0^LHJUU6
M&G)]*NGBVQOURYYGRXAQV21=&^V9IZ66&[4X<PZ>BU+=RFU4WJ7@:G<0WPGH
M^.GC%HQOFS#16O)=;!W+O,%RQD$#,!TEBN\!.?)$B?9$/3B+;BOESJG/EC-"
MG )&R^1C+1TZZLZ@ABM.#"=)L-K#IWN@O.GDB(X9WT>XE;L/O#]WDTL7TO5L
M&-S%3:]S$AQA')2/:!01!:Z,&LC4$X\N<PCK1] ;RPXV/?L(,\,.%_6XHIPJ
MUXS\EN(=(%IJ'TBIXF-*8)CF,(RFS$-F@>2D*.66-"#LWD.?*U.'2Z:?IDR,
M:L&]1(?3,-PULL/8.A*PEEB2%=5\?:CKTV_*5-,MJB.YOIHH-8!T0DV4]B&@
M21.E Z374Q.E**TCD@:03!,0:.;!>!LA\2AUED(ZSY\:H?LW4:K,YSY"ZZF)
M4N3!4_3%<$U48GA/+%CI)"2&EB4'I9)X[$CZR3=1VDOL#9HH[2.S?IHH-3_[
M7O^;/BH1MKVSU_*#1@M?JSF@,87DJ9':,$$9-913]*R2<RX)ZLP>-0?;7M^V
M#_=2<.D-:FE<?\F+[[^Y_QQ/7EZXZ9VFZ(IS=/JD "E8!.&L &LL@VAI-!1=
M>.5KYZH.P=F^1_G.=_[\;=GD\O:\(S$7A1:@B"^SZE3 8$5BL!*,)"9;2E/M
MD\]],1YC1$7'&O:P_7>'M'50*''KVC^"?'D+G:!YL-Q!3M1BN%7Z[N82 #A)
M<R16J.J=<?9#V-\8B)X5JT.BGLH9Q1XRG?NWBAIF."/ E"SSUX(!0X@"+:3V
MW@C'8OU)1GM!/'[ 7E]9]MOP6I'60=;[$;BW8.\T_FX"N:-CD0/@'FM@08=J
ML)_*5>/PB:A?UO@)!AT!302&\39(C->HAL $!G+9!&9[=GC[4[M'IPT\;:W;
MA[K*&9/7[S^\^C1Q,5VZR1_3582WZJ.<<W)2:3"AU.9IX<#Q2(#;*%4I4]>I
M2?IKUSN>G*_?GJ!Q!]+MHCG&=AG<NJ*EG9053 'ZGQAV>$[!2ZZ!:<]2R$*H
M6/O.>1-<':[]U\F\5$LKBHOC0&3&=9<)$(Y: E8[*:3)D:XG#+M<]QQ3_U]*
M=0UYT#FD)@W]?B)WJOS.+L>3V?"_YF7- \.%H=HK_)XU!V%0,#91B;"5S1BC
MVR1Z_&"VH/QSJ5(-JCKP\78@?IMF Y)(8&@/()A<+AM[#+;*ET!-IC9%B@^L
MW;)L-Z(_E]+L2T$'5Q-VH/N0B@#+C?4["OT^38;C2 =,^)PLJK36/H&@@H"/
MT0/!^)VZQ 3-/6Y!NZ#^N52J&FD=7(>XS03M6, B"Y2,3B9GB^98H"],G0.?
M$@4F,Z?1:,%9[71:<W1]Y74[UZ.."-FT31TCA[MC40^B\21E9EH+8-&B&"71
M8*.V9;0>X8E);EWMNUA[P#M^[K:N@C3?SUH1U:]#M3&H;P*WHWSMGE"/DZOM
MC/KF*E:-MR>@;C(G09S.0+)P(*P1X$AB("5ACAD=&:F=GWT2:O9(;O:I:MD^
M='6@72^OI[/Q99K,^U&5>:3GPZOIJJMNB-0JS2!X%D"(S,$XC6&*#3I'%Y10
MM;MW[8#SI)SX]E2.N^&A<MW_;5+Y;!3?NUFYC;)$%;(4QJ<" VV\4$F#,52!
MSY*3()W*Z^[2QJ3]]C><)N$5I=K%&/+T)5V,KU+\E,+Y:'PQ_OS]P_#S^0T\
M[;.UVAC@A)0N"BZ XQA-<J%M1MS*I=I!V2.03E-+NN!C:^JHU^+9MV[2MOOU
MWJ_HH31V][+6*V&#-S[[P(6W0FGA&<]"1XSBE534Q4<K81^\K7:'+:V,8PFM
MC:(:MR$=,W@$!SEE#.:\)<[4OJO?68>M 351:<U9N93%\0/$+\5[FH 0QYUT
MTEI3N[_@\9LN'<;EUI9+^\BPPP9::YTNDHUH)P,%;2FBT@27YE(&2Z5+D@O)
M5>W934^M?4Y=GEO(MW+!R*OA-(RO1[,/Z![]@IC^[BZNT^O1U?5L8*TT00@-
M,1'TAW568)D@P)7B$4,V;F5HX'EN?\-S9;.BW"K?:/R4)I?%H/XZ&7^=G6_"
M)C2+Z.-B9%-:DWJ'+J^7"92A(J*WC$%.HVCBD?<\9V:KRK"#LYT[!YK:>B,Q
M:N'.:306S($WRH)42B>5L@VR=E7+$8^/Z^[$ATGQ(9VBJS9.FLK(#=4@$R$@
M$C>H9<2!R5QD*]%]S;6S0D^NC5,;@FO(]:E<D5AT_!V./O^.DI^G3J4V4=A(
M07E7QC$1"UY["=29G*RQT8CZ'?_70!S_J*P%LP]:>;>1<"=-W.\ 6F4X&D#J
MK*/_ SC'ZN;?BJA=M+>0<D\*0!1W66L'SI2.@YP'L,H:H#H8IJ2EC-4>(M,;
M\8]V[^^:]WV$6SD(6S:W*6"6"4>N7(S6!HB9&+1\SI8>*QZHS+D,<2/$T 9^
M^H,''V,T5$M1/VP"=*"<NKA'N[.5F"#"9L(),&%T 9=00W&9UCNNRL$GB;7]
M\V?57[&-P:XG^0Y*/>^WO&H"YL_:7W$OHG9VVSM$RIWW5]312LZ] $/+A8?L
M#9C *>1H-4]6&*NJ]^)]XOT5ZS&^CW"[,=A+(Y1,M(0'#LP$5ZZU2' I,> <
MEQ.YX)8\NSY]>PEW:Y^^?213N:3B8:I]KGZE&8YUF:##$#*Z'EHA(FJ ES8Y
M*?$D&I53;'[Z*1C82K*KF/C<C&BIITTP[=&K;]M[^F_65X.#G92V$&#EW70K
M-F)<(,)XT+%<J<6]!PS/N(=HZ@TW45MOGQRI.QKV]<7I/G+K/)0U++/H<74V
ME#&;:$_ 1<Y NM+KU2GF0Y-IQT<,9>O)>F<LNX^@^NG0]V8\^ER.P][YB^'G
M1;WDJE3FXSE&]>7O7HPGD_%7C.];=.4[[#T5RHTJ+'"MYLAI3;(-01#JA:7$
M,.Y\&?@7,B,AJ<%AKVQ;;NAGKT=E6.6\Y.#V1E,FSMA,0:=RG:0,S#">"@A2
M!8%KP(VG=EW'%BBM#KW',W>Q$BO*\D:,=T0\2)39[*4"DWPH_FP"(TP$QVD4
M2:E(U[M&;3[X;O"N_EWW&OS>.P*O+=$.4F]EE>_RRPENH[/5A/C?W+?AY?7M
MY_/27>'?S+X/9% D:DI!165 N!*',#2S7&=MLK',VMIW:/?!][PUIG-&NI@M
MB$*:EMJK-'TW^OE;R4]?#Z?G11CO<A'. '7;6L$X)(\V6.A$T2Y;"I'8Y"-/
M4?K:HS$>!74:>E)7]AVD;\_"O+1K^MY]+V'T8MSA[&P4WXY'8?&;@=2.9N4%
M"B#F<A-3@\N2 (V:A92#15M?N_;F<5BGH2"UY=]!$=:'=.6^SY.:[_+;\2RM
ML);1BE1'IT'E5,*!,OJ2DH0!G?">9!%]JC]D?3.6TU"&*I+NH&YKF\<^X-9%
M08P$&DK2S9;%9H<[&/>)<1-,$+6G2V_#<AH:4$72#S5 MK_$=7>MRYZJU#!J
MC(&$RP-41 ;6)0]9\R"L(P0#^DXCJEXK]KI@NZU4GTK-WOUUS/-\SEIT;AD%
M+N8-1"0N(UL'A@N?C=%$=JP<QSRC:,WK3CW96[Z=7.J\B^C.S<0FN#HJ -B&
MZ3BU &TYVZD"+07>IT)HXIW/U(*;]T'4"7\JLUV$HDHZJHT5M8=4]ZL(CU0(
M]*4'^\BY\CG(&?L+OF3NL,;K5.A89OE%2)I':0 W-T1BN01O/6Z!.@D:+7?1
M-:GLV_;\8[M\ATI_7%ETE:L)7HXO+X>S68H?4DC#+\5Z33\Z_&65Z'H_&7^>
MN,L54D1">2ET()Z45A(9_'P(-<F1J7+W..<&)._WUA.@OD,Q=]'4Y5ZJ<[Z-
M,>M#)J6E!"LS%3+#;2PHC%%ETE[ZS(VN/8[G(8I3<?%:RK>#S.!]1$ME;X*I
M(_=N$Y[CN'9MN=I)?0M!=_[9+[$%I:2G%+<BIC6(9 ,8@SM3QA^%XIHF4[N_
M;W_D/^+.]<']/O+M@G,T3+@1#MW%>W=UT_(_&$4LFC2(PN!2>13@$^YPCGA.
MF)7$5N\!MQ%(_Y:_/4?KI+<6< =GS!_2E_'%EW)L>?]0<P&.65?\M=*'$P,5
M06@&:ZV&:)203,@R1[QZJG\'H!/0@GH"KQS.W:2?[P$;IE6#J,2RH*5M'(FQ
MX.,*O$0W)Q%N<K12VM DJGOD-<^8X=I"K#X*?*_ @^-2=2Q= KTO(_VD!8-K
M!V4EIY([:1H.('[:\5U5]CL4\=8#WB-60WZ\OKQTD^_C>45#7Z61&U_:>YWD
MXTM?*YKD)*I0VG!82T5.T>+6S@U^\2[C!D_-GD63&]_?306E=LD8[CF&MZ5?
MEPAHDCRJJK*:<:EP0_.UW?YC55#:F U^VP0HDVA]O='@>3(0N46^*%="-<EI
M/:\*RGWXW;N"<A^)=E%!N817UGXVBB_=U;" 3FZ:[J!<5M\,3,8 KNSX6CN"
M$1U)8(@HEQ08BY9%0ZIW]]L+X//6F>XYZ2 H;@9VP *Z[>B<0PQE.E,F$:Q&
ME-8(IY6E/IG:<5(S9'\FE=F+A0XRIQMSPRY%%IT#&HPL'3P\V'GOWL H6GTF
M1:@]">0)%LNTX;ZM5)]*L4S1X=E2AS_A?S//(8;D*5,H$^]#.=W!+0[C#@%&
M*B(9Y=Z&VF<IFW \J=.4?;C=L$^TDG%'%N0NIE6(V0!51R<JFQ$=YTRE/6./
MJ$ +<?>G#(($HDQ40$(0("@Q8#2QP"A1G.; I>QZ&SCBV4I?.K"/E#LOE5I,
M[1:1\T UN#3ON:]*NRAI("2BHG*,A-QMD=0I;?XMY=NY0WBG=J0)KC]KM>1>
MG#6MDCM$X'U62T9K&14^@'2>E<&^H6QT&H1DGN%.)[VKW4;MJ5=+=J('^\BY
MKVK)1,O4)>Y!^H@[W3Q@1300<LEP^$2U6[M,\URK)?>2?I-JR7U$UT\[B<4)
MT/PNUTN,(X>CS_- V/GE,: ;Q3?XPR)C<?B1R4&OJ7!(TGYYZ[TDB*64(6F4
M,V%%M$27:3:.TZ04TVIPT!O;.NG3VW<%?,=M(L.5QJM>2##>H\(95#V?>83"
MC366&5W]ZN-V-+6"D??7DW#NINE6U(L1SP.NC95,9V 2W60AC %?^K8H)GE.
MDE.::$=AR39,_>]FE;1A6XQ21?B5*\'//G^>)/RBTMEH=.TNRAR!Z;1 &U T
MP=X("BJ94)K=&7!14M"&E5KHF!7E36S5MA<\>WKKB:^3[,/=M7X_"V%R78K1
M%G>/!TD:$@3"(:*,(HA.(3K/@:"W15G.A*QWL:J\N:TC>O;:T('@.PA3-Z,[
MF[UTD\EW_,/Y7)@!\X;(8#086M:O%0>+$H&4K(GXEVC#:W>#: 3LQ)6D#0T=
M-(78#/(>Q(7]>CT*DW(^]RHM_G>0#*=HQ#(HZ04(9@4XGCD$SE-6Y=*3JYWK
M.ACLB>M4;;HJMIXH]O-_7\?YB=LOXPGBG[V?C/,0=\G,$O79>8B92Q!!J')]
M4H)/063)K%%,-? ]-C_]V3->27 =])!8T\&?I[/A)3I'[_)[_(LRB'0^'S!B
M^!=)IJ6-LD=]PU#>Y2R QYQ4*8Q5MMO(:@NP9Z\8W='P4%=46UU9N41%@]&%
MOOB89K/%.?QT0#2GD<@$G@K<D52V8$F.4,Z"DJ24ZEB[M<0..">C%[5$_E ;
M=/O^AZO$SH<T39,O:1"LI=38A!N8+)=N10 354)/.1*&/R3"JQ^4KH,X&>;;
MB?<AWZ8ZWZLB0.9ECBE%,$*A!:.6@E-4HS)BK,23T[:^[[@%R^FR?XBP'RJ!
M;>/YK=FH-^[K]!H]F+?7\VR_=1I-D"G T(415A,P03@(,GHCN8B)-9EKL/,E
MSY[>NF+<D(2J4)-]#]T"%;HA%RBMV3#GZ4!Q0QS#S4?,FYZAI0%+HT,K1"B3
M#*,/WG&JX2&H9Z\8W8A_@X+43E.^1&27TX5;$I<ZK+G/R@<*B<92RE,F[-#2
M@4&2K#/!_V?J%TP]ANI45:0M 1MTI';.\GT:Q7*E=HYT!9$HF;5E0%TVY8I=
M!N>#+8V7 F61$,<[3F=O0'6J.M*6@ TZTFJ8SEQ;$=!\4-=T( 35^+J$$6W$
M?4U&"589 318+GT(J+]-6N/??^JSY[*EH#9PUBKOMX+R^\=/:3(9XC_$%0Y2
M3@B=>0BZ7.HHU\@LNJ*0HLCHB1*20Y-[R!L??E(,'BZV#40>G/4KB%Z/PO@R
ME<7?22:,,VX.T^E9F%>=+%W20:9*E$[XD$@9+4,# <NXAF1MT)([ZT63\4?-
MWW@2E'<DX UZT#JC]WHTO9ZX44@?4AA_27/=I)SYK%V )!PKUX$8."8-<)FY
MR8P(96MG\C; >/::4$O$&VAOG;I[/QG'ZW!3J'5SY#T_;/KYVU4:3=. >$68
MC 0\"ZHTSJ/@T7F$'%42R<?,:.V;Y4UPG8QB5"=A@Z8<G/2;3QR;X,)OU/=V
M+WN1\GB2SF;X7X[2]U]246AA4_;.@[+SQBD"Y6"<!.*YLE;&E-8SOYOGY#5^
MX[/7@@X%O$$/#L[[W:R^'#[,D3AKN# T0$@TE^)@]$&%-:"(DRHF):6L?6?V
MYN7/GO5VXMQ07=0ZWX>[4$@I3G_!I6]0Q7=7:>+*ZHOC\F5>TSO /<<(@?&B
MBKAF468->F\"ZB+S@7!<?/4N\ONC/!E5Z9B@#3I5.46(B!;7QPQ-N&^%! @
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M]W\&B5LV[X82;$G><\K!>&& ,A^D28%+[]ONF._^SW-F[Q!)54RISE]_]F;
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M%OYY/9P.;QRO*#RUFB3(!+TOH7R9V&H-9"&S<TEEK==:N;?.%FR!<B)&L*;
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M?Z:K>Q'2&YEC CW/J9:=PT>-^U/.(EF>&#6-BHSZ)'2'2]0/G_L(K6L>EQ:
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M*J\IE[758@><4]"'6M+NP&FY!VT%ZNP+VN-2%#.=O2^Y-P0\H(YS*K. 8-"
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MZ$..%:A&:L,N*S 9B6^24C%BS-H,BD@^DV;_\--?@5W6B?6=RVV^I.BF:_(
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MRX2B12@>R+%=:,AX7G&(H&J5B2PIKWJ[LI8=^QJ%T\#8UQ@FSQK[RIBDR)3
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M,;&F09GNPNF56I99R,YHJRR#">EMJ3)GNNM]+7PLG"?KN3("@"^%0E+5"/9
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MIC^DU6!BN;K/W*_DEA=!F,Y;N8$/BUQ:EI5#Y/R4;3>>.A)9D_[AX*N7VIF
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MII24>T+GC2>#.<?>9Y:>T+[AII D]A(D*V"\^ZBN]#ZN+()E4IQ=7$?>4XN
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M1;SL8 >J!U]":)R':\\-<KM"7&?2;*3J>DC5*U5IW"Z\J\_+SJXDR:$&<VR
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M0U.]A'L@V0 S.7B:WZ76]T,=B%#_5S^(/<"# N!.]A,!<$$;43TN[,]M%$4
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M7PFNA_W/2+%VA0]?E([P79;MW9MX++6G\>FOR-@=Z_*U(_V38!ITFB]I"PF
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MD'[@2.?J<")7"Y \2E!YG;F5<_1&WJHE^_)FNX9;V<U=42KAY.<#!U'HV'=
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M^0:2[5$\Z@&,![ULGB*=#::8'6@)>X0OC53@[M$F]:UJ>9BO(=J#81^_ZR=
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MN-/)@.>H";:<$A:>_<5A>+94RR:@(89WW8<(%-@=:X[5/SBV5)E\-0SNH9_
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M&V/M.*0?-'!Y".4PU)6C>:+YS37EK(64^*YH&.!!+-,7AI=SK$6F B=T#F@
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M^^SB^Z7CO)SN__=F\?]__-]["*^-_PM02P,$%     @ :()"5KF$$>7U70
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MTYZ1=<>5&%:KHLHL5LD[_M\;YWA':U[7PP%,%=M#:JY>'W]\VEKH]'[NW"5
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M)?NK=PC'=_-.TMZ U.!YARMO77Y7S=&@8!I/7H5S%5X#Z=,Q[:4A'$/8BRT
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M7#OMKEA;FSGO1K%.R[5M4H@U8H_^6:C=1QHO>;O-5ZZ+$C@=FB$--D\* *$
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MDL@OVNS*6L?<QA_;;7]P0GK7PM"[]%WUO549HQ6(N"T3/U+<@8><,P""+:1
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MD4\!AKW)R';D;57CZYVGWG&4OM$V.+5YR%_>O?++=:WKJ HI2 ?MUTG*PL0
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MQ9Z(X>>45 V1.&Y^9.-=MT=K/F0$G?ZF.>V^2@!(V*!S)KDL7TS-0WN(+U2
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M22IFYH]P:]G;.MM0%BNRZD?$P>!%G&X^*N9N%LE4O5CCNM*P>]D?#!R$@ )
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M"ZJQZ+2(L&B<;DIV<'GFW5P-U\! _2T.$L\AYDTBBJZ$:=&Z==]U6^"/??,
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M_N\,U\H%R63-4^_G?M:L@3?&HP$;]SNY.@%\_'S 2?@'X"T!4O9!F%/!0#
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MCK4N/Q#]JU!_8BYB@DQ+(H,NN10J\RBGK,T8W^Y,II5=&DE5ZJ9F29Z7YZJ
M7VI<I4HD^Z>G)EL'1):P;_1R-M9T^7AHOHDQWAN/9LM*V!4P*V$Y"_"1R(E+
MGVR'[L=I^+5[69:&[#;N&F'JOYY4W?BC3@J9<G1/-X#K]W"4!_[%@^\-%@OI
MT4PH;K3<3'PH#\CP#9VPL9Y!2I_X07DGD=@S-:V;WB<K-<I',KCH!>0XQ@VP
M90.9!A"<XH(,3EJK)0O!/@)U!LP4@9=_K5Z2:@E\^.8TON[ABX2TLCRUS\O9
M#_+L1?CX^0;;"NXGBNO_?P\S;"!FNH0L.M?8)CQL9&31=&%\R+F%?.V-H*73
M3AF;M I%.Y8;$&6GV;9.4*WQ[:;F5$BG:.'Q>1#MR5C ;6>DIK$]$J81:G'=
MD2J(1;_9L6W7G[WK2Q??]\(PBAO(:,WXT_RO6]3\G_$_X_]F&*1P'K #IY&I
M5(#M,X,6/8T,&E[M5_%9>(:]4?#V^@7KXPK(O:+/OK4.,/MX0($/8Y23.<0#
M-.P0_/A.N(R>(?PQ1*]APJGL7&>V#9KYA@?<A]\N9-[E :]_31\Y)-+( _[E
M)Z+/<E_Q $6N!O8T)-QF 95,2R_N.3!ON5V54.LHO304\K%1^^B,WIT0LE'$
M:@E7#"8-NK4$YO8IO/X/@1]S_P8%NU"97#.&23+Q:=F'!A.-D'2*_9?RH*0=
MOZ\\L^8J?N]"_MF$_'D8P=4DX9"P+&X'>< S6?R/O:U_$JU0D!]A(P_X<9('
MO''!0QE(^EDLW#>77>4!.AH\8-J@Y/Y_\:3"SNG>W&]M*<H7V55]3SH7:J)@
M\AW5=)K@Q@.NWR1S8E$<T4,B'\W_,SV0MQ8C88;<04BDN#]L8J"[T>->I%%A
M"1]<IPWKB_BQK+TYSL"=ZT+G$" #/S;!S53B^E%R>8#6!Y'&C_XZ/$!:B9--
M_E&#__H2)HL_]_SK3SNZFNW5>6(P\F+_-OS.D9^3>HU% 2<8S2F>27S*@ILW
M2AXKY<_0AX>!A"=TDU:MSCUA=GBDM8D>6:LW7K%KSZ5DS43+L&<8V(N= W]Y
M$</5S(4-+8W\R\ZN9"@#F-7_OS_A::32M#3<R^&:0W*KUH9J"X^P;#*O[[:I
MO>)G_E?M\[[-'4?_C+"UX@$UE_!?#(8,WL&13%RS(*CAQUXB?\KSK9GX[V#T
M,EF<(AX0FIM>C.K I^-E3C9^:E#N\-?6>G="=V=ZA>O9#![PQ%OCB)3?[XPN
MP;>YH<0W1(K  2@!]&8N,&S36<%LTZ:"CBE#QM>E9VU&+-4#(8/&YO-C6BFR
M\J2EH*8K=<J?LX7/[=<!<'?9CA 5S*2;)'I/%W6ATR[YWZ2O*9H)5^WYL.-X
M_-4+IXR:3 O1MP0%KXMM%K?=B,5 ;HR5#C)8S%9C?$U-,^^^U:G3G77M5@4@
MFY,EX#2VA9ZX:\NJ9FM@+[*6L$!@(&G.G50EB4GT"5"D4\W8/;2S>4_RW)3O
M'+-*_$7.A=L^SP 7YA/% V>#;&0-8)"AY1O140K8(&B2X4E?NAE!=Q?P'C4*
M&&I#"+LL7?B:VV][862V^\6I!05G8"UCE_UUZ5I;;?9!Z#*8T*'D;PL1IEEJ
MTLYUO1237V))FOGGGEC7R;TZ)*97:G$;#&4F0F8LAS@<1AZK!*560DE]%+SN
M[,*=U"N,Z[5.-*N@*$N^O"&+?NXG9)U2QP#%T_[#0/=\M:^[7H=5QWRJ:\UM
M096K^RIW'-?24M[X\%?'S5TQWXO74KEBL?$TM#IW#*F,,\9N S^1KK3NC@T/
M#@T$Y_;E4)9DJ]3G*^NS%I-C#?)(VU3H-]1-[6Q_$@<QD$XEN[@//]89SRXG
M]A>O[XY(\L6_>5K)R;(D]%D!?ZS^BFO]4NGM$ ^ @=?(FOO"%<8,<89T#E4=
MMQ'WCBS^"Y--5F/'!M/)$C^N/RTNK+[\XFG"+<UM3X3CU6[?/"KC<_L6(+:+
MB/F[&2 WKO@B6#Z]W(6XTB8 705CZ5BN=0ODP\BU9_00:6ZFY#"&%.%4B)QO
M1_7/-_HKA<$.=_M% ;, %Q$42WJ]?4(&42?^1(8Z0,HSJB_8]J5OSU&*DG]-
MFD88K-;GS+E=:#WV]>B*1E1&5,6M=QGY@OC"!@MI:"MZ0;F"^]& I3>';$!>
M*X.21CMZN3+?R=:%"W<D/'?:W+S3J/3&6/OSWL7);FPOS/ARH$Z6"/>3^BX>
M<&UT7\:*.\2@N:-ZQ<[3%W&JU69>0_61WMV6HU-'1KZD/=L;SQ!1ON'7]XYL
ML!$E /<!SJ#)P@Q+#I872>6*==),4G&Z+4T,9D/D)8*BC<_#JP_"BI.7ZKXU
MUE3-;Y75]I:I?7' Y)9'(+JE'\ ]&$V-^\X5]V8)8\VA-9&%]ID!"J'#%YWS
MO2F#RN*?@U(RXG=\[30LC3_T>J)(YO5<;Q1C90/+*2/%2'UPYS"7XD79CC%%
MXG_F3IWO[1_-]66/K??7D"?<GU_%GT2DH6LK4]ND(6+WI=2>:@?/X0;$YOGF
M72^&5B>]/=H$3S?W/,HSC*G":#_YD/^ .5&J;'TO$7E@VV43[EXO'O!K$KFJ
M<;RRO7KG"56Z2+)Y.ANME.8_U.FUO8V\H6/?<,;$_9*;YP[2=2U3WKP^,^K]
M *Y;^ZG<EDKN-7V!'\7_/[SX[X<MW.@DM<)(MQ6$8],4_R.%.)"[<?Z/<_(%
MB67YN*0UHZ?F$[O/$I\%O1\KRY9HN1,C+L8V6$5PQ5=X@'9E!UQMURNY"MFJ
M33M.MW,:W?D23W]?=8[A"UUU;!XZ&YR%?;,9K#_0^5E8-]%V%P2S;:&\(9L
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M'+U3CIV_0CC(22:?F:=29CIM#0=M\&#A/)T'="%2<?H%G5Q;\,141=']CL5
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MJO.G^YCO+Q:JIIUPT$Z;V]]<>]V!WUY0!KV="QL-]$- .KT+F0R"#^<>.6R
M\MT9)&>U(IGXQ6SQ>>?AX/R) 5+&-\/ZG>]3+YCM8^^@O]JU&Q"8NV3P=3F%
M#/HB(%V3;AX@.3ME"L6R?,)54O*>0--OVYF7R@8M1"/?DV*RF",H[<:Y&IN,
MIT?O/,%6?J.-MK$#(#(X0!/I6$R8\>Y!*_M ^(ZI34,ZPQ:3(9RTC,&I'851
M\HJ!8]N2WKD<%;PN*N+J&*?4.P!M0RX(L8S8)F!1CPE%CEGRH56G+&[Y8 8<
MI495G5%%E^X^S:O(-(\YI17]W#"O4'='W:64]BW>\7"/0.EDAC%^+T#(TSQ
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M#8)2,>6GU9$,<W\$&',O\N&]R]X>>6Z&.WK%K4\";BYV^S9]?IM'*,)/:YM
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M?65E7$-F3D"YJCS@=/BASV?MX_G$L=V[E?5R+V5RQ3[1,)*X7@)X#$-)8.I
MNQ\X5&!W,:23;:P9)G;@@R31A7JCO?/]=<.*%)VU4ZY3^E_&2K>E?3HB=,@
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M0D4X'^NEFDI!C5/?KY_<.[2&2B\DX4R3)PL&G2HXS%)TWV@E]*4?2/@:38%
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M_T6DWB(/F&=YHS"&&<2&;1<RIH+DJ?1G<8(F!(U"R!,T@7)ULS>M*;<=D4D
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MUM>59#F* $Y#C'X#QGS-\=L\=""?1U,1;*TOSAG<0 #-<$Y=?MEJT"LT*O_
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M-Q <!9:=#3TS=2?B!7 DV=5I(6_WCCL]>SZ]L-I"5M"%L-J2;W[&?XJK^(5
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M4!:],3E=JO#8E=K"Z@5EE;&^(N_)X>I+3U6X(+5OJO/-A]S/MLI,BK(/8>Y
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M"DUZ.Y)@LGT*1%" CF(IW"2%SK%DJQGB[ +.P2\8NI5[ZQ0BGFXQN PJ=IA
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M-U!ZVONT=#;J[L=-\</]C^-;W1CDK>*K#XMBE9=K1QE"J2,5) $6,*%,&-9
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M30D,,8DABB,.:2(E5"KF2<"CB 9>88-G^IG:.O.N6&7W9;H@;5W&CU;&2V*
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MU645CXD,$B@9%Q IKB%-!8(LC@(B%=+"C2_\NYX:@6RE!WOBE[$6!=@HL+M
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MLHWH>Z'FGFDF.HR+FUDU+-HC>*X:8L^W2NS%G@^23*([B,.&HS<),(6P= >
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M4J2",$1AK/U234_W$Q@G.?5GE=O:ALRPRG^;K\#-'IWNR Y]5GAI3.P5J"
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MY[N8&G=M_<@[,;V.V1O ;-^X7 [1P#PS(#KN&X_+41IICW$"K7YLPV8$&LS
M,R^.9O$U"[YOW+4\V<V..Y$@^Q>U^J1OV/<N9U SK4)*(BE@$ AC[RF=0HII
M!#F)@I H@:D6/I'F/<OGQ:VCI=,6SS+95Z'E=;RYG]'7]VBZ&8<O.$9#^U+/
MEQBX O96L3$3C997W=T)_=F6 XU"3S9HW]*-:JL.!.VA33M4-]U6AJ;Z"4:L
M7>FS/REYJS:5T:IP]B]*S%E19#JK4Q$NI%%B)A3A 0XX% S93*-FA>"2:DA"
M&\HJ,.)QZ',8T+^(4[.]6RN=5#2TTQ24JEZ!O=J!5YL;+H<JEX=U1FF_-6:
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MPY &6,*(ACJEJ:$7OSKU#7U-C5:VI5CS?5D]4SHW0.M&(CT!-C"!;+%Z)N8
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M9U55Y*\KEJ^F.H*'(@XWCJ^9^5$HP%: J]ML459>7NJZ=/2+#&(24YQ@@6!
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M_0ZP/&!J.LIR:6:\0RT/I9X=;_F\U]$-NLR-^<)6ZI?EHC9?ZC-I3G601H)
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MK#S,^<.EZ?3/#J!K(,00PS)X#,3)!/N[L.-:]%Y+?G1';+"L^V<[?N'T^VV
MM.?A;VVA_[.,O2W#N^_V[%;]EV+YC1D\->,<::63&&J61! I&D)"K9>241G@
ME*<4>14$Z2C'U)CQG6&Q^W)?S1:+M9EOK"V9#8# :@-*=?H[_&@:N\M/0'H:
MD9<\!KD"5G)Q> 1RY3(:O1Z'.& YPIE(DQ23.1AQ@,KG=,2EN:YE3E9F_Z#D
M.Y8O;)VF>EN:RC!DG"E(8J8ADI&MYQ<+0YK26.FQQ 'VNE]PNINI<>)&2K 1
MT[>XQTDLW4CL<H0&YJ@C< 8(DV\&H;?"("<[&;E,2).BQT5#&I_N&#]6W9:L
MLK:85C\L]#*_+SGFH^GLPTK=%S,1*!6G 8>"(P018AA2C35,*)<A%3R(E?:*
M[G+H=&JLL+G<NQ4:[$D-_F;E!J7@GM'Q3@/@1AY]PSHPE?2 J'\4D0=$?<7X
MN'0Y;@2.!PA'\3$^[_I14K%ZR&<_7\\B'"LJPL#8&G:KQCF!1 @)DPA;_N$B
M=2M$5+<W-2+Y^=VG+S]_N'9CB0TFS0300=.!YW:;DLX3]T"UAH 0^V0U'^V_
M=O-PT\(H4^Q W,WL.?SU!>6^?EDNMH>853V(>B]0VYD8:RT9H5 %*88(*V0C
M-Q(HI4@8260H9.Q=QJNETZE-L<I'MR_TMLI3+?>/GAX\KR%P6ZW[!G;@&=T+
MIMWJ8#F"U&=]J[8NQZ];Y0C"R7I4KN]VHZ5-):LOJHS<N%E^S#;>W:]JM9J7
MOL]9*&44!R* -+39[>*(01+3!(:8B(3;XH)I,ENHV[()=WIRZMQI&M%J&AV)
M,-R4VHD*?LB5L"GV,U7\^$K<L?RV]D7YT9/;4(@X5,J:52PB,?S_N?O6)K=Q
M[=J_PJK<2CQ5C1R"!$@@YU/[-<<I']O7]B25F@\J/+N5R)(CJ3WC_/H+D)1$
M/4@!$,CF355R9L8FB;T7A(77WFLC2LU2*S.=PD2N82Y3S(3<=<7S]L+0'6"U
M;1J;[25ZJT,.9@_1 VXS1#Q41UKT'2HEAJ/J/45XH11ICG!K<]1)P@N&TUG"
M[V7_,+P/3V*AV/J38;GYQGRTSM7]LEH\57?J^W@\G<F2$) IK !2A %*90&T
M1B0K2JEP 5WC\9Q:G-JZM3$ZV5O=)#6;<5/%.SD<M@9"WT](@P Z,!EU8[DS
M>3 PW:/YHH,Z4EC?=7#C1(]YX=,31N;VG='BR;S<:@>6^;T8*H'Z[9NA_;9&
M%J.:2<6!AM+PLM1FZ6X7C2B3A5 %51A[5>$X:V%J/%P;&"(Q=@Z>VU+O)D@&
M9M(V&H-HFW:X'DW3]/3[(VN9=KAWKF':]> -IX4=E:@_J.U'_97]^<D>XJ^6
M;0&0KZM:_F/&RZPDN4Z!9*4&"$H"J,K-5K&0HH1""I%ZA8_>:,_4.,*AE/R'
M.I34^'67-)[Y:JT,TK,>YY/C]-<H1Y=#=U78V>;M ,<\]KS!FO%/1&^'[N)A
M:83/WB#J]6ZS>5+R]=-ZOGSX5-7(K 0!+LL2S%"N=)YB"G*8";,R4Q*0#&*
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M!R\&D1(,!S'2(B; @%&7-.$ G2YP;OC2C5>][^=+]<[\ZV96""A2CC0H)68
M248 95D&"LZQSLM2H@S/?J@U7WG?\.X;\1EE[:8&O);8EZ1>Z5J(ZG&U,#AN
M_JFI8AIXPWO U?-:-PBKH>]N#G6[K7E)9=\0-[EGSL>^OCTT\#QWMF<.=E[4
MGC\9-M)_9?.ES5?ZN/S"%FKS4=?Q(C:3S?[+(1KWU2-;/ZC-C%'!#'[$;',$
M!8AI"7A*-4AED2I68%)R'J#JYVN'T\]_?*F_@YVU5OB+!^/7+W]9&,^2U=+6
M]:C35 V;L$;NU[O6G'>7N5',(#TP#@%9TY,7UOA?+,K6?HMP$\1F^Z'ZUW9^
M1.-$/)(*A2\2A7DW/RK!A8)S2G_!WPE<!@U6CWE?\?/#4W5]BZDHN(8ID"G/
M (*L )1"#DJ24O-'@G)%9M^KXLUF"EAO'5=88]GOPP6G7@RX4]J7W67;A*N'
M^=+J?5AFJ&T(E[T=[X<A&..8$ 3RDID?!H%FV5UR"#*H*$,9%4JGS0_CS=)1
MLWC"/XN=#R/]*)29&OZ_^CDX[A:FV,%#;T*L0TU-[;;72<MM>U+2?JYQ/:E\
MOVMV=$G+_2:]?VL 2!H$[@[5O,V_5BA$W.F,W7&Q-E"CV3WNOFSL[CC;[HUN
MP" *SB]__IW]YVK]:F'V/(>3CRS#N<I4 0II=Y)<Y&9J8RG(N2!40II*XB5K
M&F+$U$[16]K#BZZ<')<SEGB]Y'K1/RSV@U_\7Y5\'N9HZQ;<QI%[OFS"E"2?
M>T'RE'WN_Y9_"OI]GJ9_GR\6AG(KHOZLOIO?[*.AZT]KJW3ZK0G?+3BR!;\@
MX%@0L\RW6GY(Y@"G1&DH2TDSX9J;[MCFU*CO_QBSDV^UW?4R/%GO+;<%<*WI
M[GG<KLCW\]M > Y,9TY0!DB$N&+JGC0_ +8C9=/?]G/URK'W!*DG^=[U2Z-E
MY7NZUD[7]WWUQN26ES_W__JWN5J;#SW^?*]^&&1L<B9"4-NX#Z"8L,6<60&(
MI"G@*=="IBPE&@:EM_0V.S4*/^1K)'MCJ^/W#_?_%I01ZXB^VQHU/J8#T_@M
M<(;GP#BA$SL+IK_1Y\F#<0*B,Q/&[>U 4NI>P/ZZ7FT,'3%*"I8+4.",V[P8
M"AA.&<!9K@0B"'._K?6U!J=&1)51P261KL+KR#<101N::7KWOG=)96]$KG%$
M)A;+7&MN7'YQ=/Z,65S?"[SK5)46YJ]J:<AJ42D9?S,MVG"RK6FSB:J?X1P2
M5A(%4,92@"1) 8-0 <*EA%(*+CW%BIR:G1J_O+8&6CE1L_B\2S:U#W?)0^U%
M-4>S(S\253OBJ0OLV"F.MT+1H1[Z2F>'ZZ\M7(^-3AJK(U[!>*$4Z_[$K=%Q
M+S^\@#B[N?![.XRS;"C(JTH_W8P\,5>-=A<6B*9022!985<_F *N( ,I1(BE
M/$6D0#X<=;F9J7&2M3(Y,M./:SK =..6VR$:F$O.T8DO;M8/0B2JZ&AD5&KH
M=_24"JX\'5C@X*#!7UUM'BGPUXF S6&D2A$GC)9 (6B+Q68,D(*;M4M&!=:%
M1$@YI>EYMSPU@KA6MJ"V_2]U'*5G_0+GWB!E6:+27O6J' ,$4PV(0B4PFU7.
MI=)ESDJ_-()!^F.<[(*JD,%IV8)/;-VG-'TC_FYT/@BF S-\#YA#E'SP12A6
M=0?G=L<MY. +QUG-!N\/^%_&5A_^UZ?U?"/GHHJ":0:%9@+E98X 9#0'B!?2
MT),H@<QTB?-2%5BGKK>O78U,;3:H9X C0P-N!#LAO7ZM&@.H@2EE8(S<KTEC
M8#72O6@09E[7H=? Z+G_['QUM O/:\:W;SBO/NM/@:_8>OW39HQ^6STMMRO]
M?K5\^*K6W]A2KFQK7QY7ZZW]@Y>K]7KUARV/.1-"%0J7"G"BH*U!3@'%10$D
MP:Q )689=:Z;$-#^U(ASYT)2^V#CQZT7P%I=G5!5CB25)_4?'GQQ)XV0CKK.
MN0/#/S =3Q=Y=R8?N =&(OE!>L)K$K@!QY[Y(>2KHTT=-[C<GE5N^8S_A/.>
M_;%YFF];(H-I*=-4JQRP0B(SG6 .",T*H+%*B[S@I5F,NTXG9U^?VF31&)A8
M"SV5&B^C=YWC;\)DZ%/8V'"X$^]-L(Q$JSM$$KU:)\=818KVZ46BAQC/WQF-
M]CK-;9-:]T-AQ\OV0Q_U9V7S9\3VR:K8-K^X7&*"RU0!F2(-$"\%X#Q# *I,
ME#C+,1%>D7Z=+4V-RJK?H9GHCTSU',37X74[GXP"VL!<%XB7]TGD52PBG3QV
MMS/J2>-5=T]/%J^_$"X)^77-EINJWO=G]=TLFV8":I)F!0%FA6.5:3,".&4:
MJ#(C.560I:E3'D=?(U,CAKWHX<'0I+;47Q3R#-!^/H@%T\!4$(!0D"QD%P0W
MZ4*>?71T8<@NMRXI0W8^ZS_(WQO,%Y\>5TO5)-]K(IB5.:MS55&>V_(5B@.9
MIR1C9<ZH=+HFN/3QJ0WJRKZD,O!:EOMUX*X/XEO@&'K/XHZ$UZ#M<CEHL)Y]
M;+1!VN5&>W!V/A-PA_=]OIK+@_A\LVRDF,)2BA1(5"H[[U+ -+6YY-C\,=40
MI4X![]U-3&V UE8FK6H'_OOI#C =[NYNAFCHF[OAT/&XM;L9I;'N[/S1\KNQ
MZP6B[[[N\HOCW=;U&GYT5]?_9-@IQ%[@M0Z L(%9,\4RD>5F<Y&:O89=A!!;
MQ1P!0C3269HCF>/9=K5E"[?SAPMM>%'=OJ4A?YX[26/%UE;":_.7%PO_(+5+
M:'*(,BY*#F">F7E#I!K0C!8 ZS*'-B1-Y<3G-.=6-,<XQ[$]UI+GWF%Z.YAN
M9S<W0C3XQ+'#95<#I#\<TONXIL?]2 <UEUH8]8BFQ\73PYF^1T.EB,1:L8UZ
MK>I_OEN^6_XP4^AJ/5>;6<EL->(" Y(C"E!1&.+D10G27.=<\T(C&J)>V]NH
MTZ_[&:1J&YN3^=+\W]Y:7TFA/K3=".%V\,82"6H >[&S]!>+W3L'[ )T@1PP
MB28 U-?6R$H_#FZ?2_JXO!2@W8/=U$[2DA.4PP)HQ:PROC#LPGD*H&:E+*#!
M&^?.VCUN;4YM3?%_L)/@C/<6S+4+KN]8!P!V8+IQQ-1?Q,<14P\1G_C8CB7B
M$^=WZZ?FXX=6GYJ/XY?&4_/Q<^U(S<?SU=!*3W_<"V'CGLR2TWQX:?Y5U-5J
M/ZT6<_&S_M^OZL_M2^/4?\V(E@5)I0UVY;96/:& <@R!IAIQP33%PBMYS->
MJ1']9R7J\F9+MA1SLX\\>)-\V;*E9&OIN83T[A.W5>602 _,_,;T-J['QM\E
MM>')[\T_K0=)Y4+4XDYAZ$4K[>39_,B%G<+ .2_K%/B=H+A_]?9I8]BUF=V1
M@*6$ALX0M@7LN): IJP .9=*F*VPT-*I@-VECT^-M [V!2R7SI"[OM:\!8^!
MJ24N%%YA[\&0C!?3[@R-;ZCZ1=_[X]"/7QDSR/RBL2<1Y)>?"5N4_;N:/SQN
ME;S_H=;LH;DB?CU?/)D_J]:"FX]/VXU=7-BH=?F?3YMMI7.^J_E8%%!D*9)
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M[Y:_+6W9^X>E_>A7]F=3#G#S;O/9_/UJ:58Q/S^M-AM;I76F(2<L1Q 4NA0
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MZKJ_D,ZIF[$D=/;?'5<\Y]2=,]F<LP<"<PGL<'_)-DI: 0BUW%1G9_?KM;U
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M":CA#9 5LI02H10IY%<#\^C[4Z.&VL2DLC'9&>E;W?(8P7X6B(#+P"/?#Y*
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MBY8X_LN?YC^^KS9L\>MZ]?1]8SZQ>)*-&$]];JSDX=BXSM3BO" LTP1H33.
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MXW4[%3X;?=M]1]33S\]?>?FW]=.]^N7!/AWE&V.T6ZFZ$BZ?JJIU'!58I#G
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MW$@$*&-9)GDFN/':E.OL96Z\V4H7N W?C60WQ47#9V3F\H?&FXR\5._B&-O
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M_NOR[S-RIH0O8%R,H(1PX+UAD I3WA>-V<O_Y^3O#1.NQ*Q!2N] 6<7!V93
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M%?FLS!4(9'.!B29GIFW.S6MNF[4$&[[@K0V*F@OBA8#K0:O_O#YG4C>EBC?
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MK^;Y=?@RK9O$L,(;N[IX4)FXXE/M$PK6DNVO"L,Z^:"VEZL:5&3'FK=.VHG
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M8$;>;_V%RRR4SZQP$"Y%@K@B"[(4!>3_HLE>:^/'#1(\0%AG6>2C:*(&(ND
M9S>68]TMI,JNWN)Z?85;8Y)9R3/3")$K4J"F>/"L9. R>M2<<YM;WW$\0DYG
MB89M,-6*_1T@Z7-7U#<DFN5O>)F\Y]SY.OA'QSH+/-7D."1G)#-!'Y -2V4_
M1#O=)Z*SK(Y&FN@D5O>(E9OANB+JDA$S.&7HE.:>0S#<$O#)E948K&]O;C]
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M00FLCBEUKL@1=\1(JYHV>#3JKN@!!SWLC$6:G;#:$&PTH3C@#F.=9%ASVV,
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MY2LRMN-H"T<OI;&0@ZQ7:3I \$J!8['8DB3I M.8(4T(GS@%J@6^OKJ9/+M
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MC+!6MQ[.\C U$]\NC:VD&HFA(T"]^H@UXWG^[G8AB0DGF"Q@E:AIZ=Y#M+8
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M3%#:T=+X_<Y@CV4J/?JNB4-%S8#2G*]3E^;<:8IZL?ZOSR-G0T M<JYQ]A!
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M4$L! A0#%     @ :()"5@$/V:7\!P  -2<  !L              ( !
M &$R,W$R7S$P<7@Q,C,Q,C)X97@S,3$Q+FAT;5!+ 0(4 Q0    ( &B"0E;:
M*@C\  @  #XG   ;              "  34(  !A,C-Q,E\Q,'%X,3(S,3(R
M>&5X,S$R,2YH=&U02P$"% ,4    " !H@D)6IA!1K/L$  !V%P  &P
M        @ %N$   83(S<3)?,3!Q>#$R,S$R,GAE>#,R,3$N:'1M4$L! A0#
M%     @ :()"5GA]H,GR&P  ::X  !L              ( !HA4  &$R,W$R
M7S$P<7@Q,C,Q,C)X97@Y.3$Q+FAT;5!+ 0(4 Q0    ( &B"0E;*+X(R B,
M 'BM   ?              "  <TQ  !A,C-Q,E\Q,'%X,3(S,3(R>&5X:&EB
M:70Q,#$N:'1M4$L! A0#%     @ :()"5BF&*:>#"   H28  !\
M     ( !#%4  &$R,W$R7S$P<7@Q,C,Q,C)X97AH:6)I=#$P,BYH=&U02P$"
M% ,4    " !H@D)6GNBK<7D\ @ 751P $               @ ',70  8V%H
M+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( &B"0E;<,W$#0Q$  +*^   0
M          "  7.: @!C86@M,C R,C$R,S$N>'-D4$L! A0#%     @ :()"
M5BY\$0C-%@  X=0  !0              ( !Y*L" &-A:"TR,#(R,3(S,5]C
M86PN>&UL4$L! A0#%     @ :()"5JMBB7WM9P  ":4$ !0
M ( !X\(" &-A:"TR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ :()"5OIL
MG!^7:0  ,WT  !,              ( ! BL# &-A:"TR,#(R,3(S,5]G,2YJ
M<&=02P$"% ,4    " !H@D)6N801Y?5=  !3<   $P              @ '*
ME , 8V%H+3(P,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( &B"0E:[)'<6XTP
M .Y<   3              "  ?#R P!C86@M,C R,C$R,S%?9S,N:G!G4$L!
M A0#%     @ :()"5NB1/M"Y=   RH,  !,              ( !!$ $ &-A
M:"TR,#(R,3(S,5]G-"YJ<&=02P$"% ,4    " !H@D)64IU(.Y#;  !-\@@
M%               @ 'NM 0 8V%H+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4
M    " !H@D)6X-#RR<25  !DT08 %               @ &PD 4 8V%H+3(P
D,C(Q,C,Q7W!R92YX;6Q02P4&     !  $ !&!   IB8&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
